<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>R Notebook</title>

<script>// Pandoc 2.9 adds attributes on both header and div. We remove the former (to
// be compatible with the behavior of Pandoc < 2.8).
document.addEventListener('DOMContentLoaded', function(e) {
  var hs = document.querySelectorAll("div.section[class*='level'] > :first-child");
  var i, h, a;
  for (i = 0; i < hs.length; i++) {
    h = hs[i];
    if (!/^h[1-6]$/i.test(h.tagName)) continue;  // it should be a header h1-h6
    a = h.attributes;
    while (a.length > 0) h.removeAttribute(a[0].name);
  }
});
</script>
<script>/*! jQuery v3.6.0 | (c) OpenJS Foundation and other contributors | jquery.org/license */
!function(e,t){"use strict";"object"==typeof module&&"object"==typeof module.exports?module.exports=e.document?t(e,!0):function(e){if(!e.document)throw new Error("jQuery requires a window with a document");return t(e)}:t(e)}("undefined"!=typeof window?window:this,function(C,e){"use strict";var t=[],r=Object.getPrototypeOf,s=t.slice,g=t.flat?function(e){return t.flat.call(e)}:function(e){return t.concat.apply([],e)},u=t.push,i=t.indexOf,n={},o=n.toString,v=n.hasOwnProperty,a=v.toString,l=a.call(Object),y={},m=function(e){return"function"==typeof e&&"number"!=typeof e.nodeType&&"function"!=typeof e.item},x=function(e){return null!=e&&e===e.window},E=C.document,c={type:!0,src:!0,nonce:!0,noModule:!0};function b(e,t,n){var r,i,o=(n=n||E).createElement("script");if(o.text=e,t)for(r in c)(i=t[r]||t.getAttribute&&t.getAttribute(r))&&o.setAttribute(r,i);n.head.appendChild(o).parentNode.removeChild(o)}function w(e){return null==e?e+"":"object"==typeof e||"function"==typeof e?n[o.call(e)]||"object":typeof e}var f="3.6.0",S=function(e,t){return new S.fn.init(e,t)};function p(e){var t=!!e&&"length"in e&&e.length,n=w(e);return!m(e)&&!x(e)&&("array"===n||0===t||"number"==typeof t&&0<t&&t-1 in e)}S.fn=S.prototype={jquery:f,constructor:S,length:0,toArray:function(){return s.call(this)},get:function(e){return null==e?s.call(this):e<0?this[e+this.length]:this[e]},pushStack:function(e){var t=S.merge(this.constructor(),e);return t.prevObject=this,t},each:function(e){return S.each(this,e)},map:function(n){return this.pushStack(S.map(this,function(e,t){return n.call(e,t,e)}))},slice:function(){return this.pushStack(s.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},even:function(){return this.pushStack(S.grep(this,function(e,t){return(t+1)%2}))},odd:function(){return this.pushStack(S.grep(this,function(e,t){return t%2}))},eq:function(e){var t=this.length,n=+e+(e<0?t:0);return this.pushStack(0<=n&&n<t?[this[n]]:[])},end:function(){return this.prevObject||this.constructor()},push:u,sort:t.sort,splice:t.splice},S.extend=S.fn.extend=function(){var e,t,n,r,i,o,a=arguments[0]||{},s=1,u=arguments.length,l=!1;for("boolean"==typeof a&&(l=a,a=arguments[s]||{},s++),"object"==typeof a||m(a)||(a={}),s===u&&(a=this,s--);s<u;s++)if(null!=(e=arguments[s]))for(t in e)r=e[t],"__proto__"!==t&&a!==r&&(l&&r&&(S.isPlainObject(r)||(i=Array.isArray(r)))?(n=a[t],o=i&&!Array.isArray(n)?[]:i||S.isPlainObject(n)?n:{},i=!1,a[t]=S.extend(l,o,r)):void 0!==r&&(a[t]=r));return a},S.extend({expando:"jQuery"+(f+Math.random()).replace(/\D/g,""),isReady:!0,error:function(e){throw new Error(e)},noop:function(){},isPlainObject:function(e){var t,n;return!(!e||"[object Object]"!==o.call(e))&&(!(t=r(e))||"function"==typeof(n=v.call(t,"constructor")&&t.constructor)&&a.call(n)===l)},isEmptyObject:function(e){var t;for(t in e)return!1;return!0},globalEval:function(e,t,n){b(e,{nonce:t&&t.nonce},n)},each:function(e,t){var n,r=0;if(p(e)){for(n=e.length;r<n;r++)if(!1===t.call(e[r],r,e[r]))break}else for(r in e)if(!1===t.call(e[r],r,e[r]))break;return e},makeArray:function(e,t){var n=t||[];return null!=e&&(p(Object(e))?S.merge(n,"string"==typeof e?[e]:e):u.call(n,e)),n},inArray:function(e,t,n){return null==t?-1:i.call(t,e,n)},merge:function(e,t){for(var n=+t.length,r=0,i=e.length;r<n;r++)e[i++]=t[r];return e.length=i,e},grep:function(e,t,n){for(var r=[],i=0,o=e.length,a=!n;i<o;i++)!t(e[i],i)!==a&&r.push(e[i]);return r},map:function(e,t,n){var r,i,o=0,a=[];if(p(e))for(r=e.length;o<r;o++)null!=(i=t(e[o],o,n))&&a.push(i);else for(o in e)null!=(i=t(e[o],o,n))&&a.push(i);return g(a)},guid:1,support:y}),"function"==typeof Symbol&&(S.fn[Symbol.iterator]=t[Symbol.iterator]),S.each("Boolean Number String Function Array Date RegExp Object Error Symbol".split(" "),function(e,t){n["[object "+t+"]"]=t.toLowerCase()});var d=function(n){var e,d,b,o,i,h,f,g,w,u,l,T,C,a,E,v,s,c,y,S="sizzle"+1*new Date,p=n.document,k=0,r=0,m=ue(),x=ue(),A=ue(),N=ue(),j=function(e,t){return e===t&&(l=!0),0},D={}.hasOwnProperty,t=[],q=t.pop,L=t.push,H=t.push,O=t.slice,P=function(e,t){for(var n=0,r=e.length;n<r;n++)if(e[n]===t)return n;return-1},R="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",M="[\\x20\\t\\r\\n\\f]",I="(?:\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\[^\\r\\n\\f]|[\\w-]|[^\0-\\x7f])+",W="\\["+M+"*("+I+")(?:"+M+"*([*^$|!~]?=)"+M+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+I+"))|)"+M+"*\\]",F=":("+I+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+W+")*)|.*)\\)|)",B=new RegExp(M+"+","g"),$=new RegExp("^"+M+"+|((?:^|[^\\\\])(?:\\\\.)*)"+M+"+$","g"),_=new RegExp("^"+M+"*,"+M+"*"),z=new RegExp("^"+M+"*([>+~]|"+M+")"+M+"*"),U=new RegExp(M+"|>"),X=new RegExp(F),V=new RegExp("^"+I+"$"),G={ID:new RegExp("^#("+I+")"),CLASS:new RegExp("^\\.("+I+")"),TAG:new RegExp("^("+I+"|[*])"),ATTR:new RegExp("^"+W),PSEUDO:new RegExp("^"+F),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+M+"*(even|odd|(([+-]|)(\\d*)n|)"+M+"*(?:([+-]|)"+M+"*(\\d+)|))"+M+"*\\)|)","i"),bool:new RegExp("^(?:"+R+")$","i"),needsContext:new RegExp("^"+M+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+M+"*((?:-\\d)?\\d*)"+M+"*\\)|)(?=[^-]|$)","i")},Y=/HTML$/i,Q=/^(?:input|select|textarea|button)$/i,J=/^h\d$/i,K=/^[^{]+\{\s*\[native \w/,Z=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,ee=/[+~]/,te=new RegExp("\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\([^\\r\\n\\f])","g"),ne=function(e,t){var n="0x"+e.slice(1)-65536;return t||(n<0?String.fromCharCode(n+65536):String.fromCharCode(n>>10|55296,1023&n|56320))},re=/([\0-\x1f\x7f]|^-?\d)|^-$|[^\0-\x1f\x7f-\uFFFF\w-]/g,ie=function(e,t){return t?"\0"===e?"\ufffd":e.slice(0,-1)+"\\"+e.charCodeAt(e.length-1).toString(16)+" ":"\\"+e},oe=function(){T()},ae=be(function(e){return!0===e.disabled&&"fieldset"===e.nodeName.toLowerCase()},{dir:"parentNode",next:"legend"});try{H.apply(t=O.call(p.childNodes),p.childNodes),t[p.childNodes.length].nodeType}catch(e){H={apply:t.length?function(e,t){L.apply(e,O.call(t))}:function(e,t){var n=e.length,r=0;while(e[n++]=t[r++]);e.length=n-1}}}function se(t,e,n,r){var i,o,a,s,u,l,c,f=e&&e.ownerDocument,p=e?e.nodeType:9;if(n=n||[],"string"!=typeof t||!t||1!==p&&9!==p&&11!==p)return n;if(!r&&(T(e),e=e||C,E)){if(11!==p&&(u=Z.exec(t)))if(i=u[1]){if(9===p){if(!(a=e.getElementById(i)))return n;if(a.id===i)return n.push(a),n}else if(f&&(a=f.getElementById(i))&&y(e,a)&&a.id===i)return n.push(a),n}else{if(u[2])return H.apply(n,e.getElementsByTagName(t)),n;if((i=u[3])&&d.getElementsByClassName&&e.getElementsByClassName)return H.apply(n,e.getElementsByClassName(i)),n}if(d.qsa&&!N[t+" "]&&(!v||!v.test(t))&&(1!==p||"object"!==e.nodeName.toLowerCase())){if(c=t,f=e,1===p&&(U.test(t)||z.test(t))){(f=ee.test(t)&&ye(e.parentNode)||e)===e&&d.scope||((s=e.getAttribute("id"))?s=s.replace(re,ie):e.setAttribute("id",s=S)),o=(l=h(t)).length;while(o--)l[o]=(s?"#"+s:":scope")+" "+xe(l[o]);c=l.join(",")}try{return H.apply(n,f.querySelectorAll(c)),n}catch(e){N(t,!0)}finally{s===S&&e.removeAttribute("id")}}}return g(t.replace($,"$1"),e,n,r)}function ue(){var r=[];return function e(t,n){return r.push(t+" ")>b.cacheLength&&delete e[r.shift()],e[t+" "]=n}}function le(e){return e[S]=!0,e}function ce(e){var t=C.createElement("fieldset");try{return!!e(t)}catch(e){return!1}finally{t.parentNode&&t.parentNode.removeChild(t),t=null}}function fe(e,t){var n=e.split("|"),r=n.length;while(r--)b.attrHandle[n[r]]=t}function pe(e,t){var n=t&&e,r=n&&1===e.nodeType&&1===t.nodeType&&e.sourceIndex-t.sourceIndex;if(r)return r;if(n)while(n=n.nextSibling)if(n===t)return-1;return e?1:-1}function de(t){return function(e){return"input"===e.nodeName.toLowerCase()&&e.type===t}}function he(n){return function(e){var t=e.nodeName.toLowerCase();return("input"===t||"button"===t)&&e.type===n}}function ge(t){return function(e){return"form"in e?e.parentNode&&!1===e.disabled?"label"in e?"label"in e.parentNode?e.parentNode.disabled===t:e.disabled===t:e.isDisabled===t||e.isDisabled!==!t&&ae(e)===t:e.disabled===t:"label"in e&&e.disabled===t}}function ve(a){return le(function(o){return o=+o,le(function(e,t){var n,r=a([],e.length,o),i=r.length;while(i--)e[n=r[i]]&&(e[n]=!(t[n]=e[n]))})})}function ye(e){return e&&"undefined"!=typeof e.getElementsByTagName&&e}for(e in d=se.support={},i=se.isXML=function(e){var t=e&&e.namespaceURI,n=e&&(e.ownerDocument||e).documentElement;return!Y.test(t||n&&n.nodeName||"HTML")},T=se.setDocument=function(e){var t,n,r=e?e.ownerDocument||e:p;return r!=C&&9===r.nodeType&&r.documentElement&&(a=(C=r).documentElement,E=!i(C),p!=C&&(n=C.defaultView)&&n.top!==n&&(n.addEventListener?n.addEventListener("unload",oe,!1):n.attachEvent&&n.attachEvent("onunload",oe)),d.scope=ce(function(e){return a.appendChild(e).appendChild(C.createElement("div")),"undefined"!=typeof e.querySelectorAll&&!e.querySelectorAll(":scope fieldset div").length}),d.attributes=ce(function(e){return e.className="i",!e.getAttribute("className")}),d.getElementsByTagName=ce(function(e){return e.appendChild(C.createComment("")),!e.getElementsByTagName("*").length}),d.getElementsByClassName=K.test(C.getElementsByClassName),d.getById=ce(function(e){return a.appendChild(e).id=S,!C.getElementsByName||!C.getElementsByName(S).length}),d.getById?(b.filter.ID=function(e){var t=e.replace(te,ne);return function(e){return e.getAttribute("id")===t}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n=t.getElementById(e);return n?[n]:[]}}):(b.filter.ID=function(e){var n=e.replace(te,ne);return function(e){var t="undefined"!=typeof e.getAttributeNode&&e.getAttributeNode("id");return t&&t.value===n}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n,r,i,o=t.getElementById(e);if(o){if((n=o.getAttributeNode("id"))&&n.value===e)return[o];i=t.getElementsByName(e),r=0;while(o=i[r++])if((n=o.getAttributeNode("id"))&&n.value===e)return[o]}return[]}}),b.find.TAG=d.getElementsByTagName?function(e,t){return"undefined"!=typeof t.getElementsByTagName?t.getElementsByTagName(e):d.qsa?t.querySelectorAll(e):void 0}:function(e,t){var n,r=[],i=0,o=t.getElementsByTagName(e);if("*"===e){while(n=o[i++])1===n.nodeType&&r.push(n);return r}return o},b.find.CLASS=d.getElementsByClassName&&function(e,t){if("undefined"!=typeof t.getElementsByClassName&&E)return t.getElementsByClassName(e)},s=[],v=[],(d.qsa=K.test(C.querySelectorAll))&&(ce(function(e){var t;a.appendChild(e).innerHTML="<a id='"+S+"'></a><select id='"+S+"-\r\\' msallowcapture=''><option selected=''></option></select>",e.querySelectorAll("[msallowcapture^='']").length&&v.push("[*^$]="+M+"*(?:''|\"\")"),e.querySelectorAll("[selected]").length||v.push("\\["+M+"*(?:value|"+R+")"),e.querySelectorAll("[id~="+S+"-]").length||v.push("~="),(t=C.createElement("input")).setAttribute("name",""),e.appendChild(t),e.querySelectorAll("[name='']").length||v.push("\\["+M+"*name"+M+"*="+M+"*(?:''|\"\")"),e.querySelectorAll(":checked").length||v.push(":checked"),e.querySelectorAll("a#"+S+"+*").length||v.push(".#.+[+~]"),e.querySelectorAll("\\\f"),v.push("[\\r\\n\\f]")}),ce(function(e){e.innerHTML="<a href='' disabled='disabled'></a><select disabled='disabled'><option/></select>";var t=C.createElement("input");t.setAttribute("type","hidden"),e.appendChild(t).setAttribute("name","D"),e.querySelectorAll("[name=d]").length&&v.push("name"+M+"*[*^$|!~]?="),2!==e.querySelectorAll(":enabled").length&&v.push(":enabled",":disabled"),a.appendChild(e).disabled=!0,2!==e.querySelectorAll(":disabled").length&&v.push(":enabled",":disabled"),e.querySelectorAll("*,:x"),v.push(",.*:")})),(d.matchesSelector=K.test(c=a.matches||a.webkitMatchesSelector||a.mozMatchesSelector||a.oMatchesSelector||a.msMatchesSelector))&&ce(function(e){d.disconnectedMatch=c.call(e,"*"),c.call(e,"[s!='']:x"),s.push("!=",F)}),v=v.length&&new RegExp(v.join("|")),s=s.length&&new RegExp(s.join("|")),t=K.test(a.compareDocumentPosition),y=t||K.test(a.contains)?function(e,t){var n=9===e.nodeType?e.documentElement:e,r=t&&t.parentNode;return e===r||!(!r||1!==r.nodeType||!(n.contains?n.contains(r):e.compareDocumentPosition&&16&e.compareDocumentPosition(r)))}:function(e,t){if(t)while(t=t.parentNode)if(t===e)return!0;return!1},j=t?function(e,t){if(e===t)return l=!0,0;var n=!e.compareDocumentPosition-!t.compareDocumentPosition;return n||(1&(n=(e.ownerDocument||e)==(t.ownerDocument||t)?e.compareDocumentPosition(t):1)||!d.sortDetached&&t.compareDocumentPosition(e)===n?e==C||e.ownerDocument==p&&y(p,e)?-1:t==C||t.ownerDocument==p&&y(p,t)?1:u?P(u,e)-P(u,t):0:4&n?-1:1)}:function(e,t){if(e===t)return l=!0,0;var n,r=0,i=e.parentNode,o=t.parentNode,a=[e],s=[t];if(!i||!o)return e==C?-1:t==C?1:i?-1:o?1:u?P(u,e)-P(u,t):0;if(i===o)return pe(e,t);n=e;while(n=n.parentNode)a.unshift(n);n=t;while(n=n.parentNode)s.unshift(n);while(a[r]===s[r])r++;return r?pe(a[r],s[r]):a[r]==p?-1:s[r]==p?1:0}),C},se.matches=function(e,t){return se(e,null,null,t)},se.matchesSelector=function(e,t){if(T(e),d.matchesSelector&&E&&!N[t+" "]&&(!s||!s.test(t))&&(!v||!v.test(t)))try{var n=c.call(e,t);if(n||d.disconnectedMatch||e.document&&11!==e.document.nodeType)return n}catch(e){N(t,!0)}return 0<se(t,C,null,[e]).length},se.contains=function(e,t){return(e.ownerDocument||e)!=C&&T(e),y(e,t)},se.attr=function(e,t){(e.ownerDocument||e)!=C&&T(e);var n=b.attrHandle[t.toLowerCase()],r=n&&D.call(b.attrHandle,t.toLowerCase())?n(e,t,!E):void 0;return void 0!==r?r:d.attributes||!E?e.getAttribute(t):(r=e.getAttributeNode(t))&&r.specified?r.value:null},se.escape=function(e){return(e+"").replace(re,ie)},se.error=function(e){throw new Error("Syntax error, unrecognized expression: "+e)},se.uniqueSort=function(e){var t,n=[],r=0,i=0;if(l=!d.detectDuplicates,u=!d.sortStable&&e.slice(0),e.sort(j),l){while(t=e[i++])t===e[i]&&(r=n.push(i));while(r--)e.splice(n[r],1)}return u=null,e},o=se.getText=function(e){var t,n="",r=0,i=e.nodeType;if(i){if(1===i||9===i||11===i){if("string"==typeof e.textContent)return e.textContent;for(e=e.firstChild;e;e=e.nextSibling)n+=o(e)}else if(3===i||4===i)return e.nodeValue}else while(t=e[r++])n+=o(t);return n},(b=se.selectors={cacheLength:50,createPseudo:le,match:G,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(e){return e[1]=e[1].replace(te,ne),e[3]=(e[3]||e[4]||e[5]||"").replace(te,ne),"~="===e[2]&&(e[3]=" "+e[3]+" "),e.slice(0,4)},CHILD:function(e){return e[1]=e[1].toLowerCase(),"nth"===e[1].slice(0,3)?(e[3]||se.error(e[0]),e[4]=+(e[4]?e[5]+(e[6]||1):2*("even"===e[3]||"odd"===e[3])),e[5]=+(e[7]+e[8]||"odd"===e[3])):e[3]&&se.error(e[0]),e},PSEUDO:function(e){var t,n=!e[6]&&e[2];return G.CHILD.test(e[0])?null:(e[3]?e[2]=e[4]||e[5]||"":n&&X.test(n)&&(t=h(n,!0))&&(t=n.indexOf(")",n.length-t)-n.length)&&(e[0]=e[0].slice(0,t),e[2]=n.slice(0,t)),e.slice(0,3))}},filter:{TAG:function(e){var t=e.replace(te,ne).toLowerCase();return"*"===e?function(){return!0}:function(e){return e.nodeName&&e.nodeName.toLowerCase()===t}},CLASS:function(e){var t=m[e+" "];return t||(t=new RegExp("(^|"+M+")"+e+"("+M+"|$)"))&&m(e,function(e){return t.test("string"==typeof e.className&&e.className||"undefined"!=typeof e.getAttribute&&e.getAttribute("class")||"")})},ATTR:function(n,r,i){return function(e){var t=se.attr(e,n);return null==t?"!="===r:!r||(t+="","="===r?t===i:"!="===r?t!==i:"^="===r?i&&0===t.indexOf(i):"*="===r?i&&-1<t.indexOf(i):"$="===r?i&&t.slice(-i.length)===i:"~="===r?-1<(" "+t.replace(B," ")+" ").indexOf(i):"|="===r&&(t===i||t.slice(0,i.length+1)===i+"-"))}},CHILD:function(h,e,t,g,v){var y="nth"!==h.slice(0,3),m="last"!==h.slice(-4),x="of-type"===e;return 1===g&&0===v?function(e){return!!e.parentNode}:function(e,t,n){var r,i,o,a,s,u,l=y!==m?"nextSibling":"previousSibling",c=e.parentNode,f=x&&e.nodeName.toLowerCase(),p=!n&&!x,d=!1;if(c){if(y){while(l){a=e;while(a=a[l])if(x?a.nodeName.toLowerCase()===f:1===a.nodeType)return!1;u=l="only"===h&&!u&&"nextSibling"}return!0}if(u=[m?c.firstChild:c.lastChild],m&&p){d=(s=(r=(i=(o=(a=c)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1])&&r[2],a=s&&c.childNodes[s];while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if(1===a.nodeType&&++d&&a===e){i[h]=[k,s,d];break}}else if(p&&(d=s=(r=(i=(o=(a=e)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1]),!1===d)while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if((x?a.nodeName.toLowerCase()===f:1===a.nodeType)&&++d&&(p&&((i=(o=a[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]=[k,d]),a===e))break;return(d-=v)===g||d%g==0&&0<=d/g}}},PSEUDO:function(e,o){var t,a=b.pseudos[e]||b.setFilters[e.toLowerCase()]||se.error("unsupported pseudo: "+e);return a[S]?a(o):1<a.length?(t=[e,e,"",o],b.setFilters.hasOwnProperty(e.toLowerCase())?le(function(e,t){var n,r=a(e,o),i=r.length;while(i--)e[n=P(e,r[i])]=!(t[n]=r[i])}):function(e){return a(e,0,t)}):a}},pseudos:{not:le(function(e){var r=[],i=[],s=f(e.replace($,"$1"));return s[S]?le(function(e,t,n,r){var i,o=s(e,null,r,[]),a=e.length;while(a--)(i=o[a])&&(e[a]=!(t[a]=i))}):function(e,t,n){return r[0]=e,s(r,null,n,i),r[0]=null,!i.pop()}}),has:le(function(t){return function(e){return 0<se(t,e).length}}),contains:le(function(t){return t=t.replace(te,ne),function(e){return-1<(e.textContent||o(e)).indexOf(t)}}),lang:le(function(n){return V.test(n||"")||se.error("unsupported lang: "+n),n=n.replace(te,ne).toLowerCase(),function(e){var t;do{if(t=E?e.lang:e.getAttribute("xml:lang")||e.getAttribute("lang"))return(t=t.toLowerCase())===n||0===t.indexOf(n+"-")}while((e=e.parentNode)&&1===e.nodeType);return!1}}),target:function(e){var t=n.location&&n.location.hash;return t&&t.slice(1)===e.id},root:function(e){return e===a},focus:function(e){return e===C.activeElement&&(!C.hasFocus||C.hasFocus())&&!!(e.type||e.href||~e.tabIndex)},enabled:ge(!1),disabled:ge(!0),checked:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&!!e.checked||"option"===t&&!!e.selected},selected:function(e){return e.parentNode&&e.parentNode.selectedIndex,!0===e.selected},empty:function(e){for(e=e.firstChild;e;e=e.nextSibling)if(e.nodeType<6)return!1;return!0},parent:function(e){return!b.pseudos.empty(e)},header:function(e){return J.test(e.nodeName)},input:function(e){return Q.test(e.nodeName)},button:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&"button"===e.type||"button"===t},text:function(e){var t;return"input"===e.nodeName.toLowerCase()&&"text"===e.type&&(null==(t=e.getAttribute("type"))||"text"===t.toLowerCase())},first:ve(function(){return[0]}),last:ve(function(e,t){return[t-1]}),eq:ve(function(e,t,n){return[n<0?n+t:n]}),even:ve(function(e,t){for(var n=0;n<t;n+=2)e.push(n);return e}),odd:ve(function(e,t){for(var n=1;n<t;n+=2)e.push(n);return e}),lt:ve(function(e,t,n){for(var r=n<0?n+t:t<n?t:n;0<=--r;)e.push(r);return e}),gt:ve(function(e,t,n){for(var r=n<0?n+t:n;++r<t;)e.push(r);return e})}}).pseudos.nth=b.pseudos.eq,{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})b.pseudos[e]=de(e);for(e in{submit:!0,reset:!0})b.pseudos[e]=he(e);function me(){}function xe(e){for(var t=0,n=e.length,r="";t<n;t++)r+=e[t].value;return r}function be(s,e,t){var u=e.dir,l=e.next,c=l||u,f=t&&"parentNode"===c,p=r++;return e.first?function(e,t,n){while(e=e[u])if(1===e.nodeType||f)return s(e,t,n);return!1}:function(e,t,n){var r,i,o,a=[k,p];if(n){while(e=e[u])if((1===e.nodeType||f)&&s(e,t,n))return!0}else while(e=e[u])if(1===e.nodeType||f)if(i=(o=e[S]||(e[S]={}))[e.uniqueID]||(o[e.uniqueID]={}),l&&l===e.nodeName.toLowerCase())e=e[u]||e;else{if((r=i[c])&&r[0]===k&&r[1]===p)return a[2]=r[2];if((i[c]=a)[2]=s(e,t,n))return!0}return!1}}function we(i){return 1<i.length?function(e,t,n){var r=i.length;while(r--)if(!i[r](e,t,n))return!1;return!0}:i[0]}function Te(e,t,n,r,i){for(var o,a=[],s=0,u=e.length,l=null!=t;s<u;s++)(o=e[s])&&(n&&!n(o,r,i)||(a.push(o),l&&t.push(s)));return a}function Ce(d,h,g,v,y,e){return v&&!v[S]&&(v=Ce(v)),y&&!y[S]&&(y=Ce(y,e)),le(function(e,t,n,r){var i,o,a,s=[],u=[],l=t.length,c=e||function(e,t,n){for(var r=0,i=t.length;r<i;r++)se(e,t[r],n);return n}(h||"*",n.nodeType?[n]:n,[]),f=!d||!e&&h?c:Te(c,s,d,n,r),p=g?y||(e?d:l||v)?[]:t:f;if(g&&g(f,p,n,r),v){i=Te(p,u),v(i,[],n,r),o=i.length;while(o--)(a=i[o])&&(p[u[o]]=!(f[u[o]]=a))}if(e){if(y||d){if(y){i=[],o=p.length;while(o--)(a=p[o])&&i.push(f[o]=a);y(null,p=[],i,r)}o=p.length;while(o--)(a=p[o])&&-1<(i=y?P(e,a):s[o])&&(e[i]=!(t[i]=a))}}else p=Te(p===t?p.splice(l,p.length):p),y?y(null,t,p,r):H.apply(t,p)})}function Ee(e){for(var i,t,n,r=e.length,o=b.relative[e[0].type],a=o||b.relative[" "],s=o?1:0,u=be(function(e){return e===i},a,!0),l=be(function(e){return-1<P(i,e)},a,!0),c=[function(e,t,n){var r=!o&&(n||t!==w)||((i=t).nodeType?u(e,t,n):l(e,t,n));return i=null,r}];s<r;s++)if(t=b.relative[e[s].type])c=[be(we(c),t)];else{if((t=b.filter[e[s].type].apply(null,e[s].matches))[S]){for(n=++s;n<r;n++)if(b.relative[e[n].type])break;return Ce(1<s&&we(c),1<s&&xe(e.slice(0,s-1).concat({value:" "===e[s-2].type?"*":""})).replace($,"$1"),t,s<n&&Ee(e.slice(s,n)),n<r&&Ee(e=e.slice(n)),n<r&&xe(e))}c.push(t)}return we(c)}return me.prototype=b.filters=b.pseudos,b.setFilters=new me,h=se.tokenize=function(e,t){var n,r,i,o,a,s,u,l=x[e+" "];if(l)return t?0:l.slice(0);a=e,s=[],u=b.preFilter;while(a){for(o in n&&!(r=_.exec(a))||(r&&(a=a.slice(r[0].length)||a),s.push(i=[])),n=!1,(r=z.exec(a))&&(n=r.shift(),i.push({value:n,type:r[0].replace($," ")}),a=a.slice(n.length)),b.filter)!(r=G[o].exec(a))||u[o]&&!(r=u[o](r))||(n=r.shift(),i.push({value:n,type:o,matches:r}),a=a.slice(n.length));if(!n)break}return t?a.length:a?se.error(e):x(e,s).slice(0)},f=se.compile=function(e,t){var n,v,y,m,x,r,i=[],o=[],a=A[e+" "];if(!a){t||(t=h(e)),n=t.length;while(n--)(a=Ee(t[n]))[S]?i.push(a):o.push(a);(a=A(e,(v=o,m=0<(y=i).length,x=0<v.length,r=function(e,t,n,r,i){var o,a,s,u=0,l="0",c=e&&[],f=[],p=w,d=e||x&&b.find.TAG("*",i),h=k+=null==p?1:Math.random()||.1,g=d.length;for(i&&(w=t==C||t||i);l!==g&&null!=(o=d[l]);l++){if(x&&o){a=0,t||o.ownerDocument==C||(T(o),n=!E);while(s=v[a++])if(s(o,t||C,n)){r.push(o);break}i&&(k=h)}m&&((o=!s&&o)&&u--,e&&c.push(o))}if(u+=l,m&&l!==u){a=0;while(s=y[a++])s(c,f,t,n);if(e){if(0<u)while(l--)c[l]||f[l]||(f[l]=q.call(r));f=Te(f)}H.apply(r,f),i&&!e&&0<f.length&&1<u+y.length&&se.uniqueSort(r)}return i&&(k=h,w=p),c},m?le(r):r))).selector=e}return a},g=se.select=function(e,t,n,r){var i,o,a,s,u,l="function"==typeof e&&e,c=!r&&h(e=l.selector||e);if(n=n||[],1===c.length){if(2<(o=c[0]=c[0].slice(0)).length&&"ID"===(a=o[0]).type&&9===t.nodeType&&E&&b.relative[o[1].type]){if(!(t=(b.find.ID(a.matches[0].replace(te,ne),t)||[])[0]))return n;l&&(t=t.parentNode),e=e.slice(o.shift().value.length)}i=G.needsContext.test(e)?0:o.length;while(i--){if(a=o[i],b.relative[s=a.type])break;if((u=b.find[s])&&(r=u(a.matches[0].replace(te,ne),ee.test(o[0].type)&&ye(t.parentNode)||t))){if(o.splice(i,1),!(e=r.length&&xe(o)))return H.apply(n,r),n;break}}}return(l||f(e,c))(r,t,!E,n,!t||ee.test(e)&&ye(t.parentNode)||t),n},d.sortStable=S.split("").sort(j).join("")===S,d.detectDuplicates=!!l,T(),d.sortDetached=ce(function(e){return 1&e.compareDocumentPosition(C.createElement("fieldset"))}),ce(function(e){return e.innerHTML="<a href='#'></a>","#"===e.firstChild.getAttribute("href")})||fe("type|href|height|width",function(e,t,n){if(!n)return e.getAttribute(t,"type"===t.toLowerCase()?1:2)}),d.attributes&&ce(function(e){return e.innerHTML="<input/>",e.firstChild.setAttribute("value",""),""===e.firstChild.getAttribute("value")})||fe("value",function(e,t,n){if(!n&&"input"===e.nodeName.toLowerCase())return e.defaultValue}),ce(function(e){return null==e.getAttribute("disabled")})||fe(R,function(e,t,n){var r;if(!n)return!0===e[t]?t.toLowerCase():(r=e.getAttributeNode(t))&&r.specified?r.value:null}),se}(C);S.find=d,S.expr=d.selectors,S.expr[":"]=S.expr.pseudos,S.uniqueSort=S.unique=d.uniqueSort,S.text=d.getText,S.isXMLDoc=d.isXML,S.contains=d.contains,S.escapeSelector=d.escape;var h=function(e,t,n){var r=[],i=void 0!==n;while((e=e[t])&&9!==e.nodeType)if(1===e.nodeType){if(i&&S(e).is(n))break;r.push(e)}return r},T=function(e,t){for(var n=[];e;e=e.nextSibling)1===e.nodeType&&e!==t&&n.push(e);return n},k=S.expr.match.needsContext;function A(e,t){return e.nodeName&&e.nodeName.toLowerCase()===t.toLowerCase()}var N=/^<([a-z][^\/\0>:\x20\t\r\n\f]*)[\x20\t\r\n\f]*\/?>(?:<\/\1>|)$/i;function j(e,n,r){return m(n)?S.grep(e,function(e,t){return!!n.call(e,t,e)!==r}):n.nodeType?S.grep(e,function(e){return e===n!==r}):"string"!=typeof n?S.grep(e,function(e){return-1<i.call(n,e)!==r}):S.filter(n,e,r)}S.filter=function(e,t,n){var r=t[0];return n&&(e=":not("+e+")"),1===t.length&&1===r.nodeType?S.find.matchesSelector(r,e)?[r]:[]:S.find.matches(e,S.grep(t,function(e){return 1===e.nodeType}))},S.fn.extend({find:function(e){var t,n,r=this.length,i=this;if("string"!=typeof e)return this.pushStack(S(e).filter(function(){for(t=0;t<r;t++)if(S.contains(i[t],this))return!0}));for(n=this.pushStack([]),t=0;t<r;t++)S.find(e,i[t],n);return 1<r?S.uniqueSort(n):n},filter:function(e){return this.pushStack(j(this,e||[],!1))},not:function(e){return this.pushStack(j(this,e||[],!0))},is:function(e){return!!j(this,"string"==typeof e&&k.test(e)?S(e):e||[],!1).length}});var D,q=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]+))$/;(S.fn.init=function(e,t,n){var r,i;if(!e)return this;if(n=n||D,"string"==typeof e){if(!(r="<"===e[0]&&">"===e[e.length-1]&&3<=e.length?[null,e,null]:q.exec(e))||!r[1]&&t)return!t||t.jquery?(t||n).find(e):this.constructor(t).find(e);if(r[1]){if(t=t instanceof S?t[0]:t,S.merge(this,S.parseHTML(r[1],t&&t.nodeType?t.ownerDocument||t:E,!0)),N.test(r[1])&&S.isPlainObject(t))for(r in t)m(this[r])?this[r](t[r]):this.attr(r,t[r]);return this}return(i=E.getElementById(r[2]))&&(this[0]=i,this.length=1),this}return e.nodeType?(this[0]=e,this.length=1,this):m(e)?void 0!==n.ready?n.ready(e):e(S):S.makeArray(e,this)}).prototype=S.fn,D=S(E);var L=/^(?:parents|prev(?:Until|All))/,H={children:!0,contents:!0,next:!0,prev:!0};function O(e,t){while((e=e[t])&&1!==e.nodeType);return e}S.fn.extend({has:function(e){var t=S(e,this),n=t.length;return this.filter(function(){for(var e=0;e<n;e++)if(S.contains(this,t[e]))return!0})},closest:function(e,t){var n,r=0,i=this.length,o=[],a="string"!=typeof e&&S(e);if(!k.test(e))for(;r<i;r++)for(n=this[r];n&&n!==t;n=n.parentNode)if(n.nodeType<11&&(a?-1<a.index(n):1===n.nodeType&&S.find.matchesSelector(n,e))){o.push(n);break}return this.pushStack(1<o.length?S.uniqueSort(o):o)},index:function(e){return e?"string"==typeof e?i.call(S(e),this[0]):i.call(this,e.jquery?e[0]:e):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(e,t){return this.pushStack(S.uniqueSort(S.merge(this.get(),S(e,t))))},addBack:function(e){return this.add(null==e?this.prevObject:this.prevObject.filter(e))}}),S.each({parent:function(e){var t=e.parentNode;return t&&11!==t.nodeType?t:null},parents:function(e){return h(e,"parentNode")},parentsUntil:function(e,t,n){return h(e,"parentNode",n)},next:function(e){return O(e,"nextSibling")},prev:function(e){return O(e,"previousSibling")},nextAll:function(e){return h(e,"nextSibling")},prevAll:function(e){return h(e,"previousSibling")},nextUntil:function(e,t,n){return h(e,"nextSibling",n)},prevUntil:function(e,t,n){return h(e,"previousSibling",n)},siblings:function(e){return T((e.parentNode||{}).firstChild,e)},children:function(e){return T(e.firstChild)},contents:function(e){return null!=e.contentDocument&&r(e.contentDocument)?e.contentDocument:(A(e,"template")&&(e=e.content||e),S.merge([],e.childNodes))}},function(r,i){S.fn[r]=function(e,t){var n=S.map(this,i,e);return"Until"!==r.slice(-5)&&(t=e),t&&"string"==typeof t&&(n=S.filter(t,n)),1<this.length&&(H[r]||S.uniqueSort(n),L.test(r)&&n.reverse()),this.pushStack(n)}});var P=/[^\x20\t\r\n\f]+/g;function R(e){return e}function M(e){throw e}function I(e,t,n,r){var i;try{e&&m(i=e.promise)?i.call(e).done(t).fail(n):e&&m(i=e.then)?i.call(e,t,n):t.apply(void 0,[e].slice(r))}catch(e){n.apply(void 0,[e])}}S.Callbacks=function(r){var e,n;r="string"==typeof r?(e=r,n={},S.each(e.match(P)||[],function(e,t){n[t]=!0}),n):S.extend({},r);var i,t,o,a,s=[],u=[],l=-1,c=function(){for(a=a||r.once,o=i=!0;u.length;l=-1){t=u.shift();while(++l<s.length)!1===s[l].apply(t[0],t[1])&&r.stopOnFalse&&(l=s.length,t=!1)}r.memory||(t=!1),i=!1,a&&(s=t?[]:"")},f={add:function(){return s&&(t&&!i&&(l=s.length-1,u.push(t)),function n(e){S.each(e,function(e,t){m(t)?r.unique&&f.has(t)||s.push(t):t&&t.length&&"string"!==w(t)&&n(t)})}(arguments),t&&!i&&c()),this},remove:function(){return S.each(arguments,function(e,t){var n;while(-1<(n=S.inArray(t,s,n)))s.splice(n,1),n<=l&&l--}),this},has:function(e){return e?-1<S.inArray(e,s):0<s.length},empty:function(){return s&&(s=[]),this},disable:function(){return a=u=[],s=t="",this},disabled:function(){return!s},lock:function(){return a=u=[],t||i||(s=t=""),this},locked:function(){return!!a},fireWith:function(e,t){return a||(t=[e,(t=t||[]).slice?t.slice():t],u.push(t),i||c()),this},fire:function(){return f.fireWith(this,arguments),this},fired:function(){return!!o}};return f},S.extend({Deferred:function(e){var o=[["notify","progress",S.Callbacks("memory"),S.Callbacks("memory"),2],["resolve","done",S.Callbacks("once memory"),S.Callbacks("once memory"),0,"resolved"],["reject","fail",S.Callbacks("once memory"),S.Callbacks("once memory"),1,"rejected"]],i="pending",a={state:function(){return i},always:function(){return s.done(arguments).fail(arguments),this},"catch":function(e){return a.then(null,e)},pipe:function(){var i=arguments;return S.Deferred(function(r){S.each(o,function(e,t){var n=m(i[t[4]])&&i[t[4]];s[t[1]](function(){var e=n&&n.apply(this,arguments);e&&m(e.promise)?e.promise().progress(r.notify).done(r.resolve).fail(r.reject):r[t[0]+"With"](this,n?[e]:arguments)})}),i=null}).promise()},then:function(t,n,r){var u=0;function l(i,o,a,s){return function(){var n=this,r=arguments,e=function(){var e,t;if(!(i<u)){if((e=a.apply(n,r))===o.promise())throw new TypeError("Thenable self-resolution");t=e&&("object"==typeof e||"function"==typeof e)&&e.then,m(t)?s?t.call(e,l(u,o,R,s),l(u,o,M,s)):(u++,t.call(e,l(u,o,R,s),l(u,o,M,s),l(u,o,R,o.notifyWith))):(a!==R&&(n=void 0,r=[e]),(s||o.resolveWith)(n,r))}},t=s?e:function(){try{e()}catch(e){S.Deferred.exceptionHook&&S.Deferred.exceptionHook(e,t.stackTrace),u<=i+1&&(a!==M&&(n=void 0,r=[e]),o.rejectWith(n,r))}};i?t():(S.Deferred.getStackHook&&(t.stackTrace=S.Deferred.getStackHook()),C.setTimeout(t))}}return S.Deferred(function(e){o[0][3].add(l(0,e,m(r)?r:R,e.notifyWith)),o[1][3].add(l(0,e,m(t)?t:R)),o[2][3].add(l(0,e,m(n)?n:M))}).promise()},promise:function(e){return null!=e?S.extend(e,a):a}},s={};return S.each(o,function(e,t){var n=t[2],r=t[5];a[t[1]]=n.add,r&&n.add(function(){i=r},o[3-e][2].disable,o[3-e][3].disable,o[0][2].lock,o[0][3].lock),n.add(t[3].fire),s[t[0]]=function(){return s[t[0]+"With"](this===s?void 0:this,arguments),this},s[t[0]+"With"]=n.fireWith}),a.promise(s),e&&e.call(s,s),s},when:function(e){var n=arguments.length,t=n,r=Array(t),i=s.call(arguments),o=S.Deferred(),a=function(t){return function(e){r[t]=this,i[t]=1<arguments.length?s.call(arguments):e,--n||o.resolveWith(r,i)}};if(n<=1&&(I(e,o.done(a(t)).resolve,o.reject,!n),"pending"===o.state()||m(i[t]&&i[t].then)))return o.then();while(t--)I(i[t],a(t),o.reject);return o.promise()}});var W=/^(Eval|Internal|Range|Reference|Syntax|Type|URI)Error$/;S.Deferred.exceptionHook=function(e,t){C.console&&C.console.warn&&e&&W.test(e.name)&&C.console.warn("jQuery.Deferred exception: "+e.message,e.stack,t)},S.readyException=function(e){C.setTimeout(function(){throw e})};var F=S.Deferred();function B(){E.removeEventListener("DOMContentLoaded",B),C.removeEventListener("load",B),S.ready()}S.fn.ready=function(e){return F.then(e)["catch"](function(e){S.readyException(e)}),this},S.extend({isReady:!1,readyWait:1,ready:function(e){(!0===e?--S.readyWait:S.isReady)||(S.isReady=!0)!==e&&0<--S.readyWait||F.resolveWith(E,[S])}}),S.ready.then=F.then,"complete"===E.readyState||"loading"!==E.readyState&&!E.documentElement.doScroll?C.setTimeout(S.ready):(E.addEventListener("DOMContentLoaded",B),C.addEventListener("load",B));var $=function(e,t,n,r,i,o,a){var s=0,u=e.length,l=null==n;if("object"===w(n))for(s in i=!0,n)$(e,t,s,n[s],!0,o,a);else if(void 0!==r&&(i=!0,m(r)||(a=!0),l&&(a?(t.call(e,r),t=null):(l=t,t=function(e,t,n){return l.call(S(e),n)})),t))for(;s<u;s++)t(e[s],n,a?r:r.call(e[s],s,t(e[s],n)));return i?e:l?t.call(e):u?t(e[0],n):o},_=/^-ms-/,z=/-([a-z])/g;function U(e,t){return t.toUpperCase()}function X(e){return e.replace(_,"ms-").replace(z,U)}var V=function(e){return 1===e.nodeType||9===e.nodeType||!+e.nodeType};function G(){this.expando=S.expando+G.uid++}G.uid=1,G.prototype={cache:function(e){var t=e[this.expando];return t||(t={},V(e)&&(e.nodeType?e[this.expando]=t:Object.defineProperty(e,this.expando,{value:t,configurable:!0}))),t},set:function(e,t,n){var r,i=this.cache(e);if("string"==typeof t)i[X(t)]=n;else for(r in t)i[X(r)]=t[r];return i},get:function(e,t){return void 0===t?this.cache(e):e[this.expando]&&e[this.expando][X(t)]},access:function(e,t,n){return void 0===t||t&&"string"==typeof t&&void 0===n?this.get(e,t):(this.set(e,t,n),void 0!==n?n:t)},remove:function(e,t){var n,r=e[this.expando];if(void 0!==r){if(void 0!==t){n=(t=Array.isArray(t)?t.map(X):(t=X(t))in r?[t]:t.match(P)||[]).length;while(n--)delete r[t[n]]}(void 0===t||S.isEmptyObject(r))&&(e.nodeType?e[this.expando]=void 0:delete e[this.expando])}},hasData:function(e){var t=e[this.expando];return void 0!==t&&!S.isEmptyObject(t)}};var Y=new G,Q=new G,J=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,K=/[A-Z]/g;function Z(e,t,n){var r,i;if(void 0===n&&1===e.nodeType)if(r="data-"+t.replace(K,"-$&").toLowerCase(),"string"==typeof(n=e.getAttribute(r))){try{n="true"===(i=n)||"false"!==i&&("null"===i?null:i===+i+""?+i:J.test(i)?JSON.parse(i):i)}catch(e){}Q.set(e,t,n)}else n=void 0;return n}S.extend({hasData:function(e){return Q.hasData(e)||Y.hasData(e)},data:function(e,t,n){return Q.access(e,t,n)},removeData:function(e,t){Q.remove(e,t)},_data:function(e,t,n){return Y.access(e,t,n)},_removeData:function(e,t){Y.remove(e,t)}}),S.fn.extend({data:function(n,e){var t,r,i,o=this[0],a=o&&o.attributes;if(void 0===n){if(this.length&&(i=Q.get(o),1===o.nodeType&&!Y.get(o,"hasDataAttrs"))){t=a.length;while(t--)a[t]&&0===(r=a[t].name).indexOf("data-")&&(r=X(r.slice(5)),Z(o,r,i[r]));Y.set(o,"hasDataAttrs",!0)}return i}return"object"==typeof n?this.each(function(){Q.set(this,n)}):$(this,function(e){var t;if(o&&void 0===e)return void 0!==(t=Q.get(o,n))?t:void 0!==(t=Z(o,n))?t:void 0;this.each(function(){Q.set(this,n,e)})},null,e,1<arguments.length,null,!0)},removeData:function(e){return this.each(function(){Q.remove(this,e)})}}),S.extend({queue:function(e,t,n){var r;if(e)return t=(t||"fx")+"queue",r=Y.get(e,t),n&&(!r||Array.isArray(n)?r=Y.access(e,t,S.makeArray(n)):r.push(n)),r||[]},dequeue:function(e,t){t=t||"fx";var n=S.queue(e,t),r=n.length,i=n.shift(),o=S._queueHooks(e,t);"inprogress"===i&&(i=n.shift(),r--),i&&("fx"===t&&n.unshift("inprogress"),delete o.stop,i.call(e,function(){S.dequeue(e,t)},o)),!r&&o&&o.empty.fire()},_queueHooks:function(e,t){var n=t+"queueHooks";return Y.get(e,n)||Y.access(e,n,{empty:S.Callbacks("once memory").add(function(){Y.remove(e,[t+"queue",n])})})}}),S.fn.extend({queue:function(t,n){var e=2;return"string"!=typeof t&&(n=t,t="fx",e--),arguments.length<e?S.queue(this[0],t):void 0===n?this:this.each(function(){var e=S.queue(this,t,n);S._queueHooks(this,t),"fx"===t&&"inprogress"!==e[0]&&S.dequeue(this,t)})},dequeue:function(e){return this.each(function(){S.dequeue(this,e)})},clearQueue:function(e){return this.queue(e||"fx",[])},promise:function(e,t){var n,r=1,i=S.Deferred(),o=this,a=this.length,s=function(){--r||i.resolveWith(o,[o])};"string"!=typeof e&&(t=e,e=void 0),e=e||"fx";while(a--)(n=Y.get(o[a],e+"queueHooks"))&&n.empty&&(r++,n.empty.add(s));return s(),i.promise(t)}});var ee=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,te=new RegExp("^(?:([+-])=|)("+ee+")([a-z%]*)$","i"),ne=["Top","Right","Bottom","Left"],re=E.documentElement,ie=function(e){return S.contains(e.ownerDocument,e)},oe={composed:!0};re.getRootNode&&(ie=function(e){return S.contains(e.ownerDocument,e)||e.getRootNode(oe)===e.ownerDocument});var ae=function(e,t){return"none"===(e=t||e).style.display||""===e.style.display&&ie(e)&&"none"===S.css(e,"display")};function se(e,t,n,r){var i,o,a=20,s=r?function(){return r.cur()}:function(){return S.css(e,t,"")},u=s(),l=n&&n[3]||(S.cssNumber[t]?"":"px"),c=e.nodeType&&(S.cssNumber[t]||"px"!==l&&+u)&&te.exec(S.css(e,t));if(c&&c[3]!==l){u/=2,l=l||c[3],c=+u||1;while(a--)S.style(e,t,c+l),(1-o)*(1-(o=s()/u||.5))<=0&&(a=0),c/=o;c*=2,S.style(e,t,c+l),n=n||[]}return n&&(c=+c||+u||0,i=n[1]?c+(n[1]+1)*n[2]:+n[2],r&&(r.unit=l,r.start=c,r.end=i)),i}var ue={};function le(e,t){for(var n,r,i,o,a,s,u,l=[],c=0,f=e.length;c<f;c++)(r=e[c]).style&&(n=r.style.display,t?("none"===n&&(l[c]=Y.get(r,"display")||null,l[c]||(r.style.display="")),""===r.style.display&&ae(r)&&(l[c]=(u=a=o=void 0,a=(i=r).ownerDocument,s=i.nodeName,(u=ue[s])||(o=a.body.appendChild(a.createElement(s)),u=S.css(o,"display"),o.parentNode.removeChild(o),"none"===u&&(u="block"),ue[s]=u)))):"none"!==n&&(l[c]="none",Y.set(r,"display",n)));for(c=0;c<f;c++)null!=l[c]&&(e[c].style.display=l[c]);return e}S.fn.extend({show:function(){return le(this,!0)},hide:function(){return le(this)},toggle:function(e){return"boolean"==typeof e?e?this.show():this.hide():this.each(function(){ae(this)?S(this).show():S(this).hide()})}});var ce,fe,pe=/^(?:checkbox|radio)$/i,de=/<([a-z][^\/\0>\x20\t\r\n\f]*)/i,he=/^$|^module$|\/(?:java|ecma)script/i;ce=E.createDocumentFragment().appendChild(E.createElement("div")),(fe=E.createElement("input")).setAttribute("type","radio"),fe.setAttribute("checked","checked"),fe.setAttribute("name","t"),ce.appendChild(fe),y.checkClone=ce.cloneNode(!0).cloneNode(!0).lastChild.checked,ce.innerHTML="<textarea>x</textarea>",y.noCloneChecked=!!ce.cloneNode(!0).lastChild.defaultValue,ce.innerHTML="<option></option>",y.option=!!ce.lastChild;var ge={thead:[1,"<table>","</table>"],col:[2,"<table><colgroup>","</colgroup></table>"],tr:[2,"<table><tbody>","</tbody></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:[0,"",""]};function ve(e,t){var n;return n="undefined"!=typeof e.getElementsByTagName?e.getElementsByTagName(t||"*"):"undefined"!=typeof e.querySelectorAll?e.querySelectorAll(t||"*"):[],void 0===t||t&&A(e,t)?S.merge([e],n):n}function ye(e,t){for(var n=0,r=e.length;n<r;n++)Y.set(e[n],"globalEval",!t||Y.get(t[n],"globalEval"))}ge.tbody=ge.tfoot=ge.colgroup=ge.caption=ge.thead,ge.th=ge.td,y.option||(ge.optgroup=ge.option=[1,"<select multiple='multiple'>","</select>"]);var me=/<|&#?\w+;/;function xe(e,t,n,r,i){for(var o,a,s,u,l,c,f=t.createDocumentFragment(),p=[],d=0,h=e.length;d<h;d++)if((o=e[d])||0===o)if("object"===w(o))S.merge(p,o.nodeType?[o]:o);else if(me.test(o)){a=a||f.appendChild(t.createElement("div")),s=(de.exec(o)||["",""])[1].toLowerCase(),u=ge[s]||ge._default,a.innerHTML=u[1]+S.htmlPrefilter(o)+u[2],c=u[0];while(c--)a=a.lastChild;S.merge(p,a.childNodes),(a=f.firstChild).textContent=""}else p.push(t.createTextNode(o));f.textContent="",d=0;while(o=p[d++])if(r&&-1<S.inArray(o,r))i&&i.push(o);else if(l=ie(o),a=ve(f.appendChild(o),"script"),l&&ye(a),n){c=0;while(o=a[c++])he.test(o.type||"")&&n.push(o)}return f}var be=/^([^.]*)(?:\.(.+)|)/;function we(){return!0}function Te(){return!1}function Ce(e,t){return e===function(){try{return E.activeElement}catch(e){}}()==("focus"===t)}function Ee(e,t,n,r,i,o){var a,s;if("object"==typeof t){for(s in"string"!=typeof n&&(r=r||n,n=void 0),t)Ee(e,s,n,r,t[s],o);return e}if(null==r&&null==i?(i=n,r=n=void 0):null==i&&("string"==typeof n?(i=r,r=void 0):(i=r,r=n,n=void 0)),!1===i)i=Te;else if(!i)return e;return 1===o&&(a=i,(i=function(e){return S().off(e),a.apply(this,arguments)}).guid=a.guid||(a.guid=S.guid++)),e.each(function(){S.event.add(this,t,i,r,n)})}function Se(e,i,o){o?(Y.set(e,i,!1),S.event.add(e,i,{namespace:!1,handler:function(e){var t,n,r=Y.get(this,i);if(1&e.isTrigger&&this[i]){if(r.length)(S.event.special[i]||{}).delegateType&&e.stopPropagation();else if(r=s.call(arguments),Y.set(this,i,r),t=o(this,i),this[i](),r!==(n=Y.get(this,i))||t?Y.set(this,i,!1):n={},r!==n)return e.stopImmediatePropagation(),e.preventDefault(),n&&n.value}else r.length&&(Y.set(this,i,{value:S.event.trigger(S.extend(r[0],S.Event.prototype),r.slice(1),this)}),e.stopImmediatePropagation())}})):void 0===Y.get(e,i)&&S.event.add(e,i,we)}S.event={global:{},add:function(t,e,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.get(t);if(V(t)){n.handler&&(n=(o=n).handler,i=o.selector),i&&S.find.matchesSelector(re,i),n.guid||(n.guid=S.guid++),(u=v.events)||(u=v.events=Object.create(null)),(a=v.handle)||(a=v.handle=function(e){return"undefined"!=typeof S&&S.event.triggered!==e.type?S.event.dispatch.apply(t,arguments):void 0}),l=(e=(e||"").match(P)||[""]).length;while(l--)d=g=(s=be.exec(e[l])||[])[1],h=(s[2]||"").split(".").sort(),d&&(f=S.event.special[d]||{},d=(i?f.delegateType:f.bindType)||d,f=S.event.special[d]||{},c=S.extend({type:d,origType:g,data:r,handler:n,guid:n.guid,selector:i,needsContext:i&&S.expr.match.needsContext.test(i),namespace:h.join(".")},o),(p=u[d])||((p=u[d]=[]).delegateCount=0,f.setup&&!1!==f.setup.call(t,r,h,a)||t.addEventListener&&t.addEventListener(d,a)),f.add&&(f.add.call(t,c),c.handler.guid||(c.handler.guid=n.guid)),i?p.splice(p.delegateCount++,0,c):p.push(c),S.event.global[d]=!0)}},remove:function(e,t,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.hasData(e)&&Y.get(e);if(v&&(u=v.events)){l=(t=(t||"").match(P)||[""]).length;while(l--)if(d=g=(s=be.exec(t[l])||[])[1],h=(s[2]||"").split(".").sort(),d){f=S.event.special[d]||{},p=u[d=(r?f.delegateType:f.bindType)||d]||[],s=s[2]&&new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"),a=o=p.length;while(o--)c=p[o],!i&&g!==c.origType||n&&n.guid!==c.guid||s&&!s.test(c.namespace)||r&&r!==c.selector&&("**"!==r||!c.selector)||(p.splice(o,1),c.selector&&p.delegateCount--,f.remove&&f.remove.call(e,c));a&&!p.length&&(f.teardown&&!1!==f.teardown.call(e,h,v.handle)||S.removeEvent(e,d,v.handle),delete u[d])}else for(d in u)S.event.remove(e,d+t[l],n,r,!0);S.isEmptyObject(u)&&Y.remove(e,"handle events")}},dispatch:function(e){var t,n,r,i,o,a,s=new Array(arguments.length),u=S.event.fix(e),l=(Y.get(this,"events")||Object.create(null))[u.type]||[],c=S.event.special[u.type]||{};for(s[0]=u,t=1;t<arguments.length;t++)s[t]=arguments[t];if(u.delegateTarget=this,!c.preDispatch||!1!==c.preDispatch.call(this,u)){a=S.event.handlers.call(this,u,l),t=0;while((i=a[t++])&&!u.isPropagationStopped()){u.currentTarget=i.elem,n=0;while((o=i.handlers[n++])&&!u.isImmediatePropagationStopped())u.rnamespace&&!1!==o.namespace&&!u.rnamespace.test(o.namespace)||(u.handleObj=o,u.data=o.data,void 0!==(r=((S.event.special[o.origType]||{}).handle||o.handler).apply(i.elem,s))&&!1===(u.result=r)&&(u.preventDefault(),u.stopPropagation()))}return c.postDispatch&&c.postDispatch.call(this,u),u.result}},handlers:function(e,t){var n,r,i,o,a,s=[],u=t.delegateCount,l=e.target;if(u&&l.nodeType&&!("click"===e.type&&1<=e.button))for(;l!==this;l=l.parentNode||this)if(1===l.nodeType&&("click"!==e.type||!0!==l.disabled)){for(o=[],a={},n=0;n<u;n++)void 0===a[i=(r=t[n]).selector+" "]&&(a[i]=r.needsContext?-1<S(i,this).index(l):S.find(i,this,null,[l]).length),a[i]&&o.push(r);o.length&&s.push({elem:l,handlers:o})}return l=this,u<t.length&&s.push({elem:l,handlers:t.slice(u)}),s},addProp:function(t,e){Object.defineProperty(S.Event.prototype,t,{enumerable:!0,configurable:!0,get:m(e)?function(){if(this.originalEvent)return e(this.originalEvent)}:function(){if(this.originalEvent)return this.originalEvent[t]},set:function(e){Object.defineProperty(this,t,{enumerable:!0,configurable:!0,writable:!0,value:e})}})},fix:function(e){return e[S.expando]?e:new S.Event(e)},special:{load:{noBubble:!0},click:{setup:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click",we),!1},trigger:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click"),!0},_default:function(e){var t=e.target;return pe.test(t.type)&&t.click&&A(t,"input")&&Y.get(t,"click")||A(t,"a")}},beforeunload:{postDispatch:function(e){void 0!==e.result&&e.originalEvent&&(e.originalEvent.returnValue=e.result)}}}},S.removeEvent=function(e,t,n){e.removeEventListener&&e.removeEventListener(t,n)},S.Event=function(e,t){if(!(this instanceof S.Event))return new S.Event(e,t);e&&e.type?(this.originalEvent=e,this.type=e.type,this.isDefaultPrevented=e.defaultPrevented||void 0===e.defaultPrevented&&!1===e.returnValue?we:Te,this.target=e.target&&3===e.target.nodeType?e.target.parentNode:e.target,this.currentTarget=e.currentTarget,this.relatedTarget=e.relatedTarget):this.type=e,t&&S.extend(this,t),this.timeStamp=e&&e.timeStamp||Date.now(),this[S.expando]=!0},S.Event.prototype={constructor:S.Event,isDefaultPrevented:Te,isPropagationStopped:Te,isImmediatePropagationStopped:Te,isSimulated:!1,preventDefault:function(){var e=this.originalEvent;this.isDefaultPrevented=we,e&&!this.isSimulated&&e.preventDefault()},stopPropagation:function(){var e=this.originalEvent;this.isPropagationStopped=we,e&&!this.isSimulated&&e.stopPropagation()},stopImmediatePropagation:function(){var e=this.originalEvent;this.isImmediatePropagationStopped=we,e&&!this.isSimulated&&e.stopImmediatePropagation(),this.stopPropagation()}},S.each({altKey:!0,bubbles:!0,cancelable:!0,changedTouches:!0,ctrlKey:!0,detail:!0,eventPhase:!0,metaKey:!0,pageX:!0,pageY:!0,shiftKey:!0,view:!0,"char":!0,code:!0,charCode:!0,key:!0,keyCode:!0,button:!0,buttons:!0,clientX:!0,clientY:!0,offsetX:!0,offsetY:!0,pointerId:!0,pointerType:!0,screenX:!0,screenY:!0,targetTouches:!0,toElement:!0,touches:!0,which:!0},S.event.addProp),S.each({focus:"focusin",blur:"focusout"},function(e,t){S.event.special[e]={setup:function(){return Se(this,e,Ce),!1},trigger:function(){return Se(this,e),!0},_default:function(){return!0},delegateType:t}}),S.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(e,i){S.event.special[e]={delegateType:i,bindType:i,handle:function(e){var t,n=e.relatedTarget,r=e.handleObj;return n&&(n===this||S.contains(this,n))||(e.type=r.origType,t=r.handler.apply(this,arguments),e.type=i),t}}}),S.fn.extend({on:function(e,t,n,r){return Ee(this,e,t,n,r)},one:function(e,t,n,r){return Ee(this,e,t,n,r,1)},off:function(e,t,n){var r,i;if(e&&e.preventDefault&&e.handleObj)return r=e.handleObj,S(e.delegateTarget).off(r.namespace?r.origType+"."+r.namespace:r.origType,r.selector,r.handler),this;if("object"==typeof e){for(i in e)this.off(i,t,e[i]);return this}return!1!==t&&"function"!=typeof t||(n=t,t=void 0),!1===n&&(n=Te),this.each(function(){S.event.remove(this,e,n,t)})}});var ke=/<script|<style|<link/i,Ae=/checked\s*(?:[^=]|=\s*.checked.)/i,Ne=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g;function je(e,t){return A(e,"table")&&A(11!==t.nodeType?t:t.firstChild,"tr")&&S(e).children("tbody")[0]||e}function De(e){return e.type=(null!==e.getAttribute("type"))+"/"+e.type,e}function qe(e){return"true/"===(e.type||"").slice(0,5)?e.type=e.type.slice(5):e.removeAttribute("type"),e}function Le(e,t){var n,r,i,o,a,s;if(1===t.nodeType){if(Y.hasData(e)&&(s=Y.get(e).events))for(i in Y.remove(t,"handle events"),s)for(n=0,r=s[i].length;n<r;n++)S.event.add(t,i,s[i][n]);Q.hasData(e)&&(o=Q.access(e),a=S.extend({},o),Q.set(t,a))}}function He(n,r,i,o){r=g(r);var e,t,a,s,u,l,c=0,f=n.length,p=f-1,d=r[0],h=m(d);if(h||1<f&&"string"==typeof d&&!y.checkClone&&Ae.test(d))return n.each(function(e){var t=n.eq(e);h&&(r[0]=d.call(this,e,t.html())),He(t,r,i,o)});if(f&&(t=(e=xe(r,n[0].ownerDocument,!1,n,o)).firstChild,1===e.childNodes.length&&(e=t),t||o)){for(s=(a=S.map(ve(e,"script"),De)).length;c<f;c++)u=e,c!==p&&(u=S.clone(u,!0,!0),s&&S.merge(a,ve(u,"script"))),i.call(n[c],u,c);if(s)for(l=a[a.length-1].ownerDocument,S.map(a,qe),c=0;c<s;c++)u=a[c],he.test(u.type||"")&&!Y.access(u,"globalEval")&&S.contains(l,u)&&(u.src&&"module"!==(u.type||"").toLowerCase()?S._evalUrl&&!u.noModule&&S._evalUrl(u.src,{nonce:u.nonce||u.getAttribute("nonce")},l):b(u.textContent.replace(Ne,""),u,l))}return n}function Oe(e,t,n){for(var r,i=t?S.filter(t,e):e,o=0;null!=(r=i[o]);o++)n||1!==r.nodeType||S.cleanData(ve(r)),r.parentNode&&(n&&ie(r)&&ye(ve(r,"script")),r.parentNode.removeChild(r));return e}S.extend({htmlPrefilter:function(e){return e},clone:function(e,t,n){var r,i,o,a,s,u,l,c=e.cloneNode(!0),f=ie(e);if(!(y.noCloneChecked||1!==e.nodeType&&11!==e.nodeType||S.isXMLDoc(e)))for(a=ve(c),r=0,i=(o=ve(e)).length;r<i;r++)s=o[r],u=a[r],void 0,"input"===(l=u.nodeName.toLowerCase())&&pe.test(s.type)?u.checked=s.checked:"input"!==l&&"textarea"!==l||(u.defaultValue=s.defaultValue);if(t)if(n)for(o=o||ve(e),a=a||ve(c),r=0,i=o.length;r<i;r++)Le(o[r],a[r]);else Le(e,c);return 0<(a=ve(c,"script")).length&&ye(a,!f&&ve(e,"script")),c},cleanData:function(e){for(var t,n,r,i=S.event.special,o=0;void 0!==(n=e[o]);o++)if(V(n)){if(t=n[Y.expando]){if(t.events)for(r in t.events)i[r]?S.event.remove(n,r):S.removeEvent(n,r,t.handle);n[Y.expando]=void 0}n[Q.expando]&&(n[Q.expando]=void 0)}}}),S.fn.extend({detach:function(e){return Oe(this,e,!0)},remove:function(e){return Oe(this,e)},text:function(e){return $(this,function(e){return void 0===e?S.text(this):this.empty().each(function(){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||(this.textContent=e)})},null,e,arguments.length)},append:function(){return He(this,arguments,function(e){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||je(this,e).appendChild(e)})},prepend:function(){return He(this,arguments,function(e){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var t=je(this,e);t.insertBefore(e,t.firstChild)}})},before:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this)})},after:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this.nextSibling)})},empty:function(){for(var e,t=0;null!=(e=this[t]);t++)1===e.nodeType&&(S.cleanData(ve(e,!1)),e.textContent="");return this},clone:function(e,t){return e=null!=e&&e,t=null==t?e:t,this.map(function(){return S.clone(this,e,t)})},html:function(e){return $(this,function(e){var t=this[0]||{},n=0,r=this.length;if(void 0===e&&1===t.nodeType)return t.innerHTML;if("string"==typeof e&&!ke.test(e)&&!ge[(de.exec(e)||["",""])[1].toLowerCase()]){e=S.htmlPrefilter(e);try{for(;n<r;n++)1===(t=this[n]||{}).nodeType&&(S.cleanData(ve(t,!1)),t.innerHTML=e);t=0}catch(e){}}t&&this.empty().append(e)},null,e,arguments.length)},replaceWith:function(){var n=[];return He(this,arguments,function(e){var t=this.parentNode;S.inArray(this,n)<0&&(S.cleanData(ve(this)),t&&t.replaceChild(e,this))},n)}}),S.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(e,a){S.fn[e]=function(e){for(var t,n=[],r=S(e),i=r.length-1,o=0;o<=i;o++)t=o===i?this:this.clone(!0),S(r[o])[a](t),u.apply(n,t.get());return this.pushStack(n)}});var Pe=new RegExp("^("+ee+")(?!px)[a-z%]+$","i"),Re=function(e){var t=e.ownerDocument.defaultView;return t&&t.opener||(t=C),t.getComputedStyle(e)},Me=function(e,t,n){var r,i,o={};for(i in t)o[i]=e.style[i],e.style[i]=t[i];for(i in r=n.call(e),t)e.style[i]=o[i];return r},Ie=new RegExp(ne.join("|"),"i");function We(e,t,n){var r,i,o,a,s=e.style;return(n=n||Re(e))&&(""!==(a=n.getPropertyValue(t)||n[t])||ie(e)||(a=S.style(e,t)),!y.pixelBoxStyles()&&Pe.test(a)&&Ie.test(t)&&(r=s.width,i=s.minWidth,o=s.maxWidth,s.minWidth=s.maxWidth=s.width=a,a=n.width,s.width=r,s.minWidth=i,s.maxWidth=o)),void 0!==a?a+"":a}function Fe(e,t){return{get:function(){if(!e())return(this.get=t).apply(this,arguments);delete this.get}}}!function(){function e(){if(l){u.style.cssText="position:absolute;left:-11111px;width:60px;margin-top:1px;padding:0;border:0",l.style.cssText="position:relative;display:block;box-sizing:border-box;overflow:scroll;margin:auto;border:1px;padding:1px;width:60%;top:1%",re.appendChild(u).appendChild(l);var e=C.getComputedStyle(l);n="1%"!==e.top,s=12===t(e.marginLeft),l.style.right="60%",o=36===t(e.right),r=36===t(e.width),l.style.position="absolute",i=12===t(l.offsetWidth/3),re.removeChild(u),l=null}}function t(e){return Math.round(parseFloat(e))}var n,r,i,o,a,s,u=E.createElement("div"),l=E.createElement("div");l.style&&(l.style.backgroundClip="content-box",l.cloneNode(!0).style.backgroundClip="",y.clearCloneStyle="content-box"===l.style.backgroundClip,S.extend(y,{boxSizingReliable:function(){return e(),r},pixelBoxStyles:function(){return e(),o},pixelPosition:function(){return e(),n},reliableMarginLeft:function(){return e(),s},scrollboxSize:function(){return e(),i},reliableTrDimensions:function(){var e,t,n,r;return null==a&&(e=E.createElement("table"),t=E.createElement("tr"),n=E.createElement("div"),e.style.cssText="position:absolute;left:-11111px;border-collapse:separate",t.style.cssText="border:1px solid",t.style.height="1px",n.style.height="9px",n.style.display="block",re.appendChild(e).appendChild(t).appendChild(n),r=C.getComputedStyle(t),a=parseInt(r.height,10)+parseInt(r.borderTopWidth,10)+parseInt(r.borderBottomWidth,10)===t.offsetHeight,re.removeChild(e)),a}}))}();var Be=["Webkit","Moz","ms"],$e=E.createElement("div").style,_e={};function ze(e){var t=S.cssProps[e]||_e[e];return t||(e in $e?e:_e[e]=function(e){var t=e[0].toUpperCase()+e.slice(1),n=Be.length;while(n--)if((e=Be[n]+t)in $e)return e}(e)||e)}var Ue=/^(none|table(?!-c[ea]).+)/,Xe=/^--/,Ve={position:"absolute",visibility:"hidden",display:"block"},Ge={letterSpacing:"0",fontWeight:"400"};function Ye(e,t,n){var r=te.exec(t);return r?Math.max(0,r[2]-(n||0))+(r[3]||"px"):t}function Qe(e,t,n,r,i,o){var a="width"===t?1:0,s=0,u=0;if(n===(r?"border":"content"))return 0;for(;a<4;a+=2)"margin"===n&&(u+=S.css(e,n+ne[a],!0,i)),r?("content"===n&&(u-=S.css(e,"padding"+ne[a],!0,i)),"margin"!==n&&(u-=S.css(e,"border"+ne[a]+"Width",!0,i))):(u+=S.css(e,"padding"+ne[a],!0,i),"padding"!==n?u+=S.css(e,"border"+ne[a]+"Width",!0,i):s+=S.css(e,"border"+ne[a]+"Width",!0,i));return!r&&0<=o&&(u+=Math.max(0,Math.ceil(e["offset"+t[0].toUpperCase()+t.slice(1)]-o-u-s-.5))||0),u}function Je(e,t,n){var r=Re(e),i=(!y.boxSizingReliable()||n)&&"border-box"===S.css(e,"boxSizing",!1,r),o=i,a=We(e,t,r),s="offset"+t[0].toUpperCase()+t.slice(1);if(Pe.test(a)){if(!n)return a;a="auto"}return(!y.boxSizingReliable()&&i||!y.reliableTrDimensions()&&A(e,"tr")||"auto"===a||!parseFloat(a)&&"inline"===S.css(e,"display",!1,r))&&e.getClientRects().length&&(i="border-box"===S.css(e,"boxSizing",!1,r),(o=s in e)&&(a=e[s])),(a=parseFloat(a)||0)+Qe(e,t,n||(i?"border":"content"),o,r,a)+"px"}function Ke(e,t,n,r,i){return new Ke.prototype.init(e,t,n,r,i)}S.extend({cssHooks:{opacity:{get:function(e,t){if(t){var n=We(e,"opacity");return""===n?"1":n}}}},cssNumber:{animationIterationCount:!0,columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,gridArea:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnStart:!0,gridRow:!0,gridRowEnd:!0,gridRowStart:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{},style:function(e,t,n,r){if(e&&3!==e.nodeType&&8!==e.nodeType&&e.style){var i,o,a,s=X(t),u=Xe.test(t),l=e.style;if(u||(t=ze(s)),a=S.cssHooks[t]||S.cssHooks[s],void 0===n)return a&&"get"in a&&void 0!==(i=a.get(e,!1,r))?i:l[t];"string"===(o=typeof n)&&(i=te.exec(n))&&i[1]&&(n=se(e,t,i),o="number"),null!=n&&n==n&&("number"!==o||u||(n+=i&&i[3]||(S.cssNumber[s]?"":"px")),y.clearCloneStyle||""!==n||0!==t.indexOf("background")||(l[t]="inherit"),a&&"set"in a&&void 0===(n=a.set(e,n,r))||(u?l.setProperty(t,n):l[t]=n))}},css:function(e,t,n,r){var i,o,a,s=X(t);return Xe.test(t)||(t=ze(s)),(a=S.cssHooks[t]||S.cssHooks[s])&&"get"in a&&(i=a.get(e,!0,n)),void 0===i&&(i=We(e,t,r)),"normal"===i&&t in Ge&&(i=Ge[t]),""===n||n?(o=parseFloat(i),!0===n||isFinite(o)?o||0:i):i}}),S.each(["height","width"],function(e,u){S.cssHooks[u]={get:function(e,t,n){if(t)return!Ue.test(S.css(e,"display"))||e.getClientRects().length&&e.getBoundingClientRect().width?Je(e,u,n):Me(e,Ve,function(){return Je(e,u,n)})},set:function(e,t,n){var r,i=Re(e),o=!y.scrollboxSize()&&"absolute"===i.position,a=(o||n)&&"border-box"===S.css(e,"boxSizing",!1,i),s=n?Qe(e,u,n,a,i):0;return a&&o&&(s-=Math.ceil(e["offset"+u[0].toUpperCase()+u.slice(1)]-parseFloat(i[u])-Qe(e,u,"border",!1,i)-.5)),s&&(r=te.exec(t))&&"px"!==(r[3]||"px")&&(e.style[u]=t,t=S.css(e,u)),Ye(0,t,s)}}}),S.cssHooks.marginLeft=Fe(y.reliableMarginLeft,function(e,t){if(t)return(parseFloat(We(e,"marginLeft"))||e.getBoundingClientRect().left-Me(e,{marginLeft:0},function(){return e.getBoundingClientRect().left}))+"px"}),S.each({margin:"",padding:"",border:"Width"},function(i,o){S.cssHooks[i+o]={expand:function(e){for(var t=0,n={},r="string"==typeof e?e.split(" "):[e];t<4;t++)n[i+ne[t]+o]=r[t]||r[t-2]||r[0];return n}},"margin"!==i&&(S.cssHooks[i+o].set=Ye)}),S.fn.extend({css:function(e,t){return $(this,function(e,t,n){var r,i,o={},a=0;if(Array.isArray(t)){for(r=Re(e),i=t.length;a<i;a++)o[t[a]]=S.css(e,t[a],!1,r);return o}return void 0!==n?S.style(e,t,n):S.css(e,t)},e,t,1<arguments.length)}}),((S.Tween=Ke).prototype={constructor:Ke,init:function(e,t,n,r,i,o){this.elem=e,this.prop=n,this.easing=i||S.easing._default,this.options=t,this.start=this.now=this.cur(),this.end=r,this.unit=o||(S.cssNumber[n]?"":"px")},cur:function(){var e=Ke.propHooks[this.prop];return e&&e.get?e.get(this):Ke.propHooks._default.get(this)},run:function(e){var t,n=Ke.propHooks[this.prop];return this.options.duration?this.pos=t=S.easing[this.easing](e,this.options.duration*e,0,1,this.options.duration):this.pos=t=e,this.now=(this.end-this.start)*t+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),n&&n.set?n.set(this):Ke.propHooks._default.set(this),this}}).init.prototype=Ke.prototype,(Ke.propHooks={_default:{get:function(e){var t;return 1!==e.elem.nodeType||null!=e.elem[e.prop]&&null==e.elem.style[e.prop]?e.elem[e.prop]:(t=S.css(e.elem,e.prop,""))&&"auto"!==t?t:0},set:function(e){S.fx.step[e.prop]?S.fx.step[e.prop](e):1!==e.elem.nodeType||!S.cssHooks[e.prop]&&null==e.elem.style[ze(e.prop)]?e.elem[e.prop]=e.now:S.style(e.elem,e.prop,e.now+e.unit)}}}).scrollTop=Ke.propHooks.scrollLeft={set:function(e){e.elem.nodeType&&e.elem.parentNode&&(e.elem[e.prop]=e.now)}},S.easing={linear:function(e){return e},swing:function(e){return.5-Math.cos(e*Math.PI)/2},_default:"swing"},S.fx=Ke.prototype.init,S.fx.step={};var Ze,et,tt,nt,rt=/^(?:toggle|show|hide)$/,it=/queueHooks$/;function ot(){et&&(!1===E.hidden&&C.requestAnimationFrame?C.requestAnimationFrame(ot):C.setTimeout(ot,S.fx.interval),S.fx.tick())}function at(){return C.setTimeout(function(){Ze=void 0}),Ze=Date.now()}function st(e,t){var n,r=0,i={height:e};for(t=t?1:0;r<4;r+=2-t)i["margin"+(n=ne[r])]=i["padding"+n]=e;return t&&(i.opacity=i.width=e),i}function ut(e,t,n){for(var r,i=(lt.tweeners[t]||[]).concat(lt.tweeners["*"]),o=0,a=i.length;o<a;o++)if(r=i[o].call(n,t,e))return r}function lt(o,e,t){var n,a,r=0,i=lt.prefilters.length,s=S.Deferred().always(function(){delete u.elem}),u=function(){if(a)return!1;for(var e=Ze||at(),t=Math.max(0,l.startTime+l.duration-e),n=1-(t/l.duration||0),r=0,i=l.tweens.length;r<i;r++)l.tweens[r].run(n);return s.notifyWith(o,[l,n,t]),n<1&&i?t:(i||s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l]),!1)},l=s.promise({elem:o,props:S.extend({},e),opts:S.extend(!0,{specialEasing:{},easing:S.easing._default},t),originalProperties:e,originalOptions:t,startTime:Ze||at(),duration:t.duration,tweens:[],createTween:function(e,t){var n=S.Tween(o,l.opts,e,t,l.opts.specialEasing[e]||l.opts.easing);return l.tweens.push(n),n},stop:function(e){var t=0,n=e?l.tweens.length:0;if(a)return this;for(a=!0;t<n;t++)l.tweens[t].run(1);return e?(s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l,e])):s.rejectWith(o,[l,e]),this}}),c=l.props;for(!function(e,t){var n,r,i,o,a;for(n in e)if(i=t[r=X(n)],o=e[n],Array.isArray(o)&&(i=o[1],o=e[n]=o[0]),n!==r&&(e[r]=o,delete e[n]),(a=S.cssHooks[r])&&"expand"in a)for(n in o=a.expand(o),delete e[r],o)n in e||(e[n]=o[n],t[n]=i);else t[r]=i}(c,l.opts.specialEasing);r<i;r++)if(n=lt.prefilters[r].call(l,o,c,l.opts))return m(n.stop)&&(S._queueHooks(l.elem,l.opts.queue).stop=n.stop.bind(n)),n;return S.map(c,ut,l),m(l.opts.start)&&l.opts.start.call(o,l),l.progress(l.opts.progress).done(l.opts.done,l.opts.complete).fail(l.opts.fail).always(l.opts.always),S.fx.timer(S.extend(u,{elem:o,anim:l,queue:l.opts.queue})),l}S.Animation=S.extend(lt,{tweeners:{"*":[function(e,t){var n=this.createTween(e,t);return se(n.elem,e,te.exec(t),n),n}]},tweener:function(e,t){m(e)?(t=e,e=["*"]):e=e.match(P);for(var n,r=0,i=e.length;r<i;r++)n=e[r],lt.tweeners[n]=lt.tweeners[n]||[],lt.tweeners[n].unshift(t)},prefilters:[function(e,t,n){var r,i,o,a,s,u,l,c,f="width"in t||"height"in t,p=this,d={},h=e.style,g=e.nodeType&&ae(e),v=Y.get(e,"fxshow");for(r in n.queue||(null==(a=S._queueHooks(e,"fx")).unqueued&&(a.unqueued=0,s=a.empty.fire,a.empty.fire=function(){a.unqueued||s()}),a.unqueued++,p.always(function(){p.always(function(){a.unqueued--,S.queue(e,"fx").length||a.empty.fire()})})),t)if(i=t[r],rt.test(i)){if(delete t[r],o=o||"toggle"===i,i===(g?"hide":"show")){if("show"!==i||!v||void 0===v[r])continue;g=!0}d[r]=v&&v[r]||S.style(e,r)}if((u=!S.isEmptyObject(t))||!S.isEmptyObject(d))for(r in f&&1===e.nodeType&&(n.overflow=[h.overflow,h.overflowX,h.overflowY],null==(l=v&&v.display)&&(l=Y.get(e,"display")),"none"===(c=S.css(e,"display"))&&(l?c=l:(le([e],!0),l=e.style.display||l,c=S.css(e,"display"),le([e]))),("inline"===c||"inline-block"===c&&null!=l)&&"none"===S.css(e,"float")&&(u||(p.done(function(){h.display=l}),null==l&&(c=h.display,l="none"===c?"":c)),h.display="inline-block")),n.overflow&&(h.overflow="hidden",p.always(function(){h.overflow=n.overflow[0],h.overflowX=n.overflow[1],h.overflowY=n.overflow[2]})),u=!1,d)u||(v?"hidden"in v&&(g=v.hidden):v=Y.access(e,"fxshow",{display:l}),o&&(v.hidden=!g),g&&le([e],!0),p.done(function(){for(r in g||le([e]),Y.remove(e,"fxshow"),d)S.style(e,r,d[r])})),u=ut(g?v[r]:0,r,p),r in v||(v[r]=u.start,g&&(u.end=u.start,u.start=0))}],prefilter:function(e,t){t?lt.prefilters.unshift(e):lt.prefilters.push(e)}}),S.speed=function(e,t,n){var r=e&&"object"==typeof e?S.extend({},e):{complete:n||!n&&t||m(e)&&e,duration:e,easing:n&&t||t&&!m(t)&&t};return S.fx.off?r.duration=0:"number"!=typeof r.duration&&(r.duration in S.fx.speeds?r.duration=S.fx.speeds[r.duration]:r.duration=S.fx.speeds._default),null!=r.queue&&!0!==r.queue||(r.queue="fx"),r.old=r.complete,r.complete=function(){m(r.old)&&r.old.call(this),r.queue&&S.dequeue(this,r.queue)},r},S.fn.extend({fadeTo:function(e,t,n,r){return this.filter(ae).css("opacity",0).show().end().animate({opacity:t},e,n,r)},animate:function(t,e,n,r){var i=S.isEmptyObject(t),o=S.speed(e,n,r),a=function(){var e=lt(this,S.extend({},t),o);(i||Y.get(this,"finish"))&&e.stop(!0)};return a.finish=a,i||!1===o.queue?this.each(a):this.queue(o.queue,a)},stop:function(i,e,o){var a=function(e){var t=e.stop;delete e.stop,t(o)};return"string"!=typeof i&&(o=e,e=i,i=void 0),e&&this.queue(i||"fx",[]),this.each(function(){var e=!0,t=null!=i&&i+"queueHooks",n=S.timers,r=Y.get(this);if(t)r[t]&&r[t].stop&&a(r[t]);else for(t in r)r[t]&&r[t].stop&&it.test(t)&&a(r[t]);for(t=n.length;t--;)n[t].elem!==this||null!=i&&n[t].queue!==i||(n[t].anim.stop(o),e=!1,n.splice(t,1));!e&&o||S.dequeue(this,i)})},finish:function(a){return!1!==a&&(a=a||"fx"),this.each(function(){var e,t=Y.get(this),n=t[a+"queue"],r=t[a+"queueHooks"],i=S.timers,o=n?n.length:0;for(t.finish=!0,S.queue(this,a,[]),r&&r.stop&&r.stop.call(this,!0),e=i.length;e--;)i[e].elem===this&&i[e].queue===a&&(i[e].anim.stop(!0),i.splice(e,1));for(e=0;e<o;e++)n[e]&&n[e].finish&&n[e].finish.call(this);delete t.finish})}}),S.each(["toggle","show","hide"],function(e,r){var i=S.fn[r];S.fn[r]=function(e,t,n){return null==e||"boolean"==typeof e?i.apply(this,arguments):this.animate(st(r,!0),e,t,n)}}),S.each({slideDown:st("show"),slideUp:st("hide"),slideToggle:st("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(e,r){S.fn[e]=function(e,t,n){return this.animate(r,e,t,n)}}),S.timers=[],S.fx.tick=function(){var e,t=0,n=S.timers;for(Ze=Date.now();t<n.length;t++)(e=n[t])()||n[t]!==e||n.splice(t--,1);n.length||S.fx.stop(),Ze=void 0},S.fx.timer=function(e){S.timers.push(e),S.fx.start()},S.fx.interval=13,S.fx.start=function(){et||(et=!0,ot())},S.fx.stop=function(){et=null},S.fx.speeds={slow:600,fast:200,_default:400},S.fn.delay=function(r,e){return r=S.fx&&S.fx.speeds[r]||r,e=e||"fx",this.queue(e,function(e,t){var n=C.setTimeout(e,r);t.stop=function(){C.clearTimeout(n)}})},tt=E.createElement("input"),nt=E.createElement("select").appendChild(E.createElement("option")),tt.type="checkbox",y.checkOn=""!==tt.value,y.optSelected=nt.selected,(tt=E.createElement("input")).value="t",tt.type="radio",y.radioValue="t"===tt.value;var ct,ft=S.expr.attrHandle;S.fn.extend({attr:function(e,t){return $(this,S.attr,e,t,1<arguments.length)},removeAttr:function(e){return this.each(function(){S.removeAttr(this,e)})}}),S.extend({attr:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return"undefined"==typeof e.getAttribute?S.prop(e,t,n):(1===o&&S.isXMLDoc(e)||(i=S.attrHooks[t.toLowerCase()]||(S.expr.match.bool.test(t)?ct:void 0)),void 0!==n?null===n?void S.removeAttr(e,t):i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:(e.setAttribute(t,n+""),n):i&&"get"in i&&null!==(r=i.get(e,t))?r:null==(r=S.find.attr(e,t))?void 0:r)},attrHooks:{type:{set:function(e,t){if(!y.radioValue&&"radio"===t&&A(e,"input")){var n=e.value;return e.setAttribute("type",t),n&&(e.value=n),t}}}},removeAttr:function(e,t){var n,r=0,i=t&&t.match(P);if(i&&1===e.nodeType)while(n=i[r++])e.removeAttribute(n)}}),ct={set:function(e,t,n){return!1===t?S.removeAttr(e,n):e.setAttribute(n,n),n}},S.each(S.expr.match.bool.source.match(/\w+/g),function(e,t){var a=ft[t]||S.find.attr;ft[t]=function(e,t,n){var r,i,o=t.toLowerCase();return n||(i=ft[o],ft[o]=r,r=null!=a(e,t,n)?o:null,ft[o]=i),r}});var pt=/^(?:input|select|textarea|button)$/i,dt=/^(?:a|area)$/i;function ht(e){return(e.match(P)||[]).join(" ")}function gt(e){return e.getAttribute&&e.getAttribute("class")||""}function vt(e){return Array.isArray(e)?e:"string"==typeof e&&e.match(P)||[]}S.fn.extend({prop:function(e,t){return $(this,S.prop,e,t,1<arguments.length)},removeProp:function(e){return this.each(function(){delete this[S.propFix[e]||e]})}}),S.extend({prop:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return 1===o&&S.isXMLDoc(e)||(t=S.propFix[t]||t,i=S.propHooks[t]),void 0!==n?i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:e[t]=n:i&&"get"in i&&null!==(r=i.get(e,t))?r:e[t]},propHooks:{tabIndex:{get:function(e){var t=S.find.attr(e,"tabindex");return t?parseInt(t,10):pt.test(e.nodeName)||dt.test(e.nodeName)&&e.href?0:-1}}},propFix:{"for":"htmlFor","class":"className"}}),y.optSelected||(S.propHooks.selected={get:function(e){var t=e.parentNode;return t&&t.parentNode&&t.parentNode.selectedIndex,null},set:function(e){var t=e.parentNode;t&&(t.selectedIndex,t.parentNode&&t.parentNode.selectedIndex)}}),S.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){S.propFix[this.toLowerCase()]=this}),S.fn.extend({addClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).addClass(t.call(this,e,gt(this)))});if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])r.indexOf(" "+o+" ")<0&&(r+=o+" ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},removeClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).removeClass(t.call(this,e,gt(this)))});if(!arguments.length)return this.attr("class","");if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])while(-1<r.indexOf(" "+o+" "))r=r.replace(" "+o+" "," ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},toggleClass:function(i,t){var o=typeof i,a="string"===o||Array.isArray(i);return"boolean"==typeof t&&a?t?this.addClass(i):this.removeClass(i):m(i)?this.each(function(e){S(this).toggleClass(i.call(this,e,gt(this),t),t)}):this.each(function(){var e,t,n,r;if(a){t=0,n=S(this),r=vt(i);while(e=r[t++])n.hasClass(e)?n.removeClass(e):n.addClass(e)}else void 0!==i&&"boolean"!==o||((e=gt(this))&&Y.set(this,"__className__",e),this.setAttribute&&this.setAttribute("class",e||!1===i?"":Y.get(this,"__className__")||""))})},hasClass:function(e){var t,n,r=0;t=" "+e+" ";while(n=this[r++])if(1===n.nodeType&&-1<(" "+ht(gt(n))+" ").indexOf(t))return!0;return!1}});var yt=/\r/g;S.fn.extend({val:function(n){var r,e,i,t=this[0];return arguments.length?(i=m(n),this.each(function(e){var t;1===this.nodeType&&(null==(t=i?n.call(this,e,S(this).val()):n)?t="":"number"==typeof t?t+="":Array.isArray(t)&&(t=S.map(t,function(e){return null==e?"":e+""})),(r=S.valHooks[this.type]||S.valHooks[this.nodeName.toLowerCase()])&&"set"in r&&void 0!==r.set(this,t,"value")||(this.value=t))})):t?(r=S.valHooks[t.type]||S.valHooks[t.nodeName.toLowerCase()])&&"get"in r&&void 0!==(e=r.get(t,"value"))?e:"string"==typeof(e=t.value)?e.replace(yt,""):null==e?"":e:void 0}}),S.extend({valHooks:{option:{get:function(e){var t=S.find.attr(e,"value");return null!=t?t:ht(S.text(e))}},select:{get:function(e){var t,n,r,i=e.options,o=e.selectedIndex,a="select-one"===e.type,s=a?null:[],u=a?o+1:i.length;for(r=o<0?u:a?o:0;r<u;r++)if(((n=i[r]).selected||r===o)&&!n.disabled&&(!n.parentNode.disabled||!A(n.parentNode,"optgroup"))){if(t=S(n).val(),a)return t;s.push(t)}return s},set:function(e,t){var n,r,i=e.options,o=S.makeArray(t),a=i.length;while(a--)((r=i[a]).selected=-1<S.inArray(S.valHooks.option.get(r),o))&&(n=!0);return n||(e.selectedIndex=-1),o}}}}),S.each(["radio","checkbox"],function(){S.valHooks[this]={set:function(e,t){if(Array.isArray(t))return e.checked=-1<S.inArray(S(e).val(),t)}},y.checkOn||(S.valHooks[this].get=function(e){return null===e.getAttribute("value")?"on":e.value})}),y.focusin="onfocusin"in C;var mt=/^(?:focusinfocus|focusoutblur)$/,xt=function(e){e.stopPropagation()};S.extend(S.event,{trigger:function(e,t,n,r){var i,o,a,s,u,l,c,f,p=[n||E],d=v.call(e,"type")?e.type:e,h=v.call(e,"namespace")?e.namespace.split("."):[];if(o=f=a=n=n||E,3!==n.nodeType&&8!==n.nodeType&&!mt.test(d+S.event.triggered)&&(-1<d.indexOf(".")&&(d=(h=d.split(".")).shift(),h.sort()),u=d.indexOf(":")<0&&"on"+d,(e=e[S.expando]?e:new S.Event(d,"object"==typeof e&&e)).isTrigger=r?2:3,e.namespace=h.join("."),e.rnamespace=e.namespace?new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,e.result=void 0,e.target||(e.target=n),t=null==t?[e]:S.makeArray(t,[e]),c=S.event.special[d]||{},r||!c.trigger||!1!==c.trigger.apply(n,t))){if(!r&&!c.noBubble&&!x(n)){for(s=c.delegateType||d,mt.test(s+d)||(o=o.parentNode);o;o=o.parentNode)p.push(o),a=o;a===(n.ownerDocument||E)&&p.push(a.defaultView||a.parentWindow||C)}i=0;while((o=p[i++])&&!e.isPropagationStopped())f=o,e.type=1<i?s:c.bindType||d,(l=(Y.get(o,"events")||Object.create(null))[e.type]&&Y.get(o,"handle"))&&l.apply(o,t),(l=u&&o[u])&&l.apply&&V(o)&&(e.result=l.apply(o,t),!1===e.result&&e.preventDefault());return e.type=d,r||e.isDefaultPrevented()||c._default&&!1!==c._default.apply(p.pop(),t)||!V(n)||u&&m(n[d])&&!x(n)&&((a=n[u])&&(n[u]=null),S.event.triggered=d,e.isPropagationStopped()&&f.addEventListener(d,xt),n[d](),e.isPropagationStopped()&&f.removeEventListener(d,xt),S.event.triggered=void 0,a&&(n[u]=a)),e.result}},simulate:function(e,t,n){var r=S.extend(new S.Event,n,{type:e,isSimulated:!0});S.event.trigger(r,null,t)}}),S.fn.extend({trigger:function(e,t){return this.each(function(){S.event.trigger(e,t,this)})},triggerHandler:function(e,t){var n=this[0];if(n)return S.event.trigger(e,t,n,!0)}}),y.focusin||S.each({focus:"focusin",blur:"focusout"},function(n,r){var i=function(e){S.event.simulate(r,e.target,S.event.fix(e))};S.event.special[r]={setup:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r);t||e.addEventListener(n,i,!0),Y.access(e,r,(t||0)+1)},teardown:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r)-1;t?Y.access(e,r,t):(e.removeEventListener(n,i,!0),Y.remove(e,r))}}});var bt=C.location,wt={guid:Date.now()},Tt=/\?/;S.parseXML=function(e){var t,n;if(!e||"string"!=typeof e)return null;try{t=(new C.DOMParser).parseFromString(e,"text/xml")}catch(e){}return n=t&&t.getElementsByTagName("parsererror")[0],t&&!n||S.error("Invalid XML: "+(n?S.map(n.childNodes,function(e){return e.textContent}).join("\n"):e)),t};var Ct=/\[\]$/,Et=/\r?\n/g,St=/^(?:submit|button|image|reset|file)$/i,kt=/^(?:input|select|textarea|keygen)/i;function At(n,e,r,i){var t;if(Array.isArray(e))S.each(e,function(e,t){r||Ct.test(n)?i(n,t):At(n+"["+("object"==typeof t&&null!=t?e:"")+"]",t,r,i)});else if(r||"object"!==w(e))i(n,e);else for(t in e)At(n+"["+t+"]",e[t],r,i)}S.param=function(e,t){var n,r=[],i=function(e,t){var n=m(t)?t():t;r[r.length]=encodeURIComponent(e)+"="+encodeURIComponent(null==n?"":n)};if(null==e)return"";if(Array.isArray(e)||e.jquery&&!S.isPlainObject(e))S.each(e,function(){i(this.name,this.value)});else for(n in e)At(n,e[n],t,i);return r.join("&")},S.fn.extend({serialize:function(){return S.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var e=S.prop(this,"elements");return e?S.makeArray(e):this}).filter(function(){var e=this.type;return this.name&&!S(this).is(":disabled")&&kt.test(this.nodeName)&&!St.test(e)&&(this.checked||!pe.test(e))}).map(function(e,t){var n=S(this).val();return null==n?null:Array.isArray(n)?S.map(n,function(e){return{name:t.name,value:e.replace(Et,"\r\n")}}):{name:t.name,value:n.replace(Et,"\r\n")}}).get()}});var Nt=/%20/g,jt=/#.*$/,Dt=/([?&])_=[^&]*/,qt=/^(.*?):[ \t]*([^\r\n]*)$/gm,Lt=/^(?:GET|HEAD)$/,Ht=/^\/\//,Ot={},Pt={},Rt="*/".concat("*"),Mt=E.createElement("a");function It(o){return function(e,t){"string"!=typeof e&&(t=e,e="*");var n,r=0,i=e.toLowerCase().match(P)||[];if(m(t))while(n=i[r++])"+"===n[0]?(n=n.slice(1)||"*",(o[n]=o[n]||[]).unshift(t)):(o[n]=o[n]||[]).push(t)}}function Wt(t,i,o,a){var s={},u=t===Pt;function l(e){var r;return s[e]=!0,S.each(t[e]||[],function(e,t){var n=t(i,o,a);return"string"!=typeof n||u||s[n]?u?!(r=n):void 0:(i.dataTypes.unshift(n),l(n),!1)}),r}return l(i.dataTypes[0])||!s["*"]&&l("*")}function Ft(e,t){var n,r,i=S.ajaxSettings.flatOptions||{};for(n in t)void 0!==t[n]&&((i[n]?e:r||(r={}))[n]=t[n]);return r&&S.extend(!0,e,r),e}Mt.href=bt.href,S.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:bt.href,type:"GET",isLocal:/^(?:about|app|app-storage|.+-extension|file|res|widget):$/.test(bt.protocol),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Rt,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/\bxml\b/,html:/\bhtml/,json:/\bjson\b/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":JSON.parse,"text xml":S.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(e,t){return t?Ft(Ft(e,S.ajaxSettings),t):Ft(S.ajaxSettings,e)},ajaxPrefilter:It(Ot),ajaxTransport:It(Pt),ajax:function(e,t){"object"==typeof e&&(t=e,e=void 0),t=t||{};var c,f,p,n,d,r,h,g,i,o,v=S.ajaxSetup({},t),y=v.context||v,m=v.context&&(y.nodeType||y.jquery)?S(y):S.event,x=S.Deferred(),b=S.Callbacks("once memory"),w=v.statusCode||{},a={},s={},u="canceled",T={readyState:0,getResponseHeader:function(e){var t;if(h){if(!n){n={};while(t=qt.exec(p))n[t[1].toLowerCase()+" "]=(n[t[1].toLowerCase()+" "]||[]).concat(t[2])}t=n[e.toLowerCase()+" "]}return null==t?null:t.join(", ")},getAllResponseHeaders:function(){return h?p:null},setRequestHeader:function(e,t){return null==h&&(e=s[e.toLowerCase()]=s[e.toLowerCase()]||e,a[e]=t),this},overrideMimeType:function(e){return null==h&&(v.mimeType=e),this},statusCode:function(e){var t;if(e)if(h)T.always(e[T.status]);else for(t in e)w[t]=[w[t],e[t]];return this},abort:function(e){var t=e||u;return c&&c.abort(t),l(0,t),this}};if(x.promise(T),v.url=((e||v.url||bt.href)+"").replace(Ht,bt.protocol+"//"),v.type=t.method||t.type||v.method||v.type,v.dataTypes=(v.dataType||"*").toLowerCase().match(P)||[""],null==v.crossDomain){r=E.createElement("a");try{r.href=v.url,r.href=r.href,v.crossDomain=Mt.protocol+"//"+Mt.host!=r.protocol+"//"+r.host}catch(e){v.crossDomain=!0}}if(v.data&&v.processData&&"string"!=typeof v.data&&(v.data=S.param(v.data,v.traditional)),Wt(Ot,v,t,T),h)return T;for(i in(g=S.event&&v.global)&&0==S.active++&&S.event.trigger("ajaxStart"),v.type=v.type.toUpperCase(),v.hasContent=!Lt.test(v.type),f=v.url.replace(jt,""),v.hasContent?v.data&&v.processData&&0===(v.contentType||"").indexOf("application/x-www-form-urlencoded")&&(v.data=v.data.replace(Nt,"+")):(o=v.url.slice(f.length),v.data&&(v.processData||"string"==typeof v.data)&&(f+=(Tt.test(f)?"&":"?")+v.data,delete v.data),!1===v.cache&&(f=f.replace(Dt,"$1"),o=(Tt.test(f)?"&":"?")+"_="+wt.guid+++o),v.url=f+o),v.ifModified&&(S.lastModified[f]&&T.setRequestHeader("If-Modified-Since",S.lastModified[f]),S.etag[f]&&T.setRequestHeader("If-None-Match",S.etag[f])),(v.data&&v.hasContent&&!1!==v.contentType||t.contentType)&&T.setRequestHeader("Content-Type",v.contentType),T.setRequestHeader("Accept",v.dataTypes[0]&&v.accepts[v.dataTypes[0]]?v.accepts[v.dataTypes[0]]+("*"!==v.dataTypes[0]?", "+Rt+"; q=0.01":""):v.accepts["*"]),v.headers)T.setRequestHeader(i,v.headers[i]);if(v.beforeSend&&(!1===v.beforeSend.call(y,T,v)||h))return T.abort();if(u="abort",b.add(v.complete),T.done(v.success),T.fail(v.error),c=Wt(Pt,v,t,T)){if(T.readyState=1,g&&m.trigger("ajaxSend",[T,v]),h)return T;v.async&&0<v.timeout&&(d=C.setTimeout(function(){T.abort("timeout")},v.timeout));try{h=!1,c.send(a,l)}catch(e){if(h)throw e;l(-1,e)}}else l(-1,"No Transport");function l(e,t,n,r){var i,o,a,s,u,l=t;h||(h=!0,d&&C.clearTimeout(d),c=void 0,p=r||"",T.readyState=0<e?4:0,i=200<=e&&e<300||304===e,n&&(s=function(e,t,n){var r,i,o,a,s=e.contents,u=e.dataTypes;while("*"===u[0])u.shift(),void 0===r&&(r=e.mimeType||t.getResponseHeader("Content-Type"));if(r)for(i in s)if(s[i]&&s[i].test(r)){u.unshift(i);break}if(u[0]in n)o=u[0];else{for(i in n){if(!u[0]||e.converters[i+" "+u[0]]){o=i;break}a||(a=i)}o=o||a}if(o)return o!==u[0]&&u.unshift(o),n[o]}(v,T,n)),!i&&-1<S.inArray("script",v.dataTypes)&&S.inArray("json",v.dataTypes)<0&&(v.converters["text script"]=function(){}),s=function(e,t,n,r){var i,o,a,s,u,l={},c=e.dataTypes.slice();if(c[1])for(a in e.converters)l[a.toLowerCase()]=e.converters[a];o=c.shift();while(o)if(e.responseFields[o]&&(n[e.responseFields[o]]=t),!u&&r&&e.dataFilter&&(t=e.dataFilter(t,e.dataType)),u=o,o=c.shift())if("*"===o)o=u;else if("*"!==u&&u!==o){if(!(a=l[u+" "+o]||l["* "+o]))for(i in l)if((s=i.split(" "))[1]===o&&(a=l[u+" "+s[0]]||l["* "+s[0]])){!0===a?a=l[i]:!0!==l[i]&&(o=s[0],c.unshift(s[1]));break}if(!0!==a)if(a&&e["throws"])t=a(t);else try{t=a(t)}catch(e){return{state:"parsererror",error:a?e:"No conversion from "+u+" to "+o}}}return{state:"success",data:t}}(v,s,T,i),i?(v.ifModified&&((u=T.getResponseHeader("Last-Modified"))&&(S.lastModified[f]=u),(u=T.getResponseHeader("etag"))&&(S.etag[f]=u)),204===e||"HEAD"===v.type?l="nocontent":304===e?l="notmodified":(l=s.state,o=s.data,i=!(a=s.error))):(a=l,!e&&l||(l="error",e<0&&(e=0))),T.status=e,T.statusText=(t||l)+"",i?x.resolveWith(y,[o,l,T]):x.rejectWith(y,[T,l,a]),T.statusCode(w),w=void 0,g&&m.trigger(i?"ajaxSuccess":"ajaxError",[T,v,i?o:a]),b.fireWith(y,[T,l]),g&&(m.trigger("ajaxComplete",[T,v]),--S.active||S.event.trigger("ajaxStop")))}return T},getJSON:function(e,t,n){return S.get(e,t,n,"json")},getScript:function(e,t){return S.get(e,void 0,t,"script")}}),S.each(["get","post"],function(e,i){S[i]=function(e,t,n,r){return m(t)&&(r=r||n,n=t,t=void 0),S.ajax(S.extend({url:e,type:i,dataType:r,data:t,success:n},S.isPlainObject(e)&&e))}}),S.ajaxPrefilter(function(e){var t;for(t in e.headers)"content-type"===t.toLowerCase()&&(e.contentType=e.headers[t]||"")}),S._evalUrl=function(e,t,n){return S.ajax({url:e,type:"GET",dataType:"script",cache:!0,async:!1,global:!1,converters:{"text script":function(){}},dataFilter:function(e){S.globalEval(e,t,n)}})},S.fn.extend({wrapAll:function(e){var t;return this[0]&&(m(e)&&(e=e.call(this[0])),t=S(e,this[0].ownerDocument).eq(0).clone(!0),this[0].parentNode&&t.insertBefore(this[0]),t.map(function(){var e=this;while(e.firstElementChild)e=e.firstElementChild;return e}).append(this)),this},wrapInner:function(n){return m(n)?this.each(function(e){S(this).wrapInner(n.call(this,e))}):this.each(function(){var e=S(this),t=e.contents();t.length?t.wrapAll(n):e.append(n)})},wrap:function(t){var n=m(t);return this.each(function(e){S(this).wrapAll(n?t.call(this,e):t)})},unwrap:function(e){return this.parent(e).not("body").each(function(){S(this).replaceWith(this.childNodes)}),this}}),S.expr.pseudos.hidden=function(e){return!S.expr.pseudos.visible(e)},S.expr.pseudos.visible=function(e){return!!(e.offsetWidth||e.offsetHeight||e.getClientRects().length)},S.ajaxSettings.xhr=function(){try{return new C.XMLHttpRequest}catch(e){}};var Bt={0:200,1223:204},$t=S.ajaxSettings.xhr();y.cors=!!$t&&"withCredentials"in $t,y.ajax=$t=!!$t,S.ajaxTransport(function(i){var o,a;if(y.cors||$t&&!i.crossDomain)return{send:function(e,t){var n,r=i.xhr();if(r.open(i.type,i.url,i.async,i.username,i.password),i.xhrFields)for(n in i.xhrFields)r[n]=i.xhrFields[n];for(n in i.mimeType&&r.overrideMimeType&&r.overrideMimeType(i.mimeType),i.crossDomain||e["X-Requested-With"]||(e["X-Requested-With"]="XMLHttpRequest"),e)r.setRequestHeader(n,e[n]);o=function(e){return function(){o&&(o=a=r.onload=r.onerror=r.onabort=r.ontimeout=r.onreadystatechange=null,"abort"===e?r.abort():"error"===e?"number"!=typeof r.status?t(0,"error"):t(r.status,r.statusText):t(Bt[r.status]||r.status,r.statusText,"text"!==(r.responseType||"text")||"string"!=typeof r.responseText?{binary:r.response}:{text:r.responseText},r.getAllResponseHeaders()))}},r.onload=o(),a=r.onerror=r.ontimeout=o("error"),void 0!==r.onabort?r.onabort=a:r.onreadystatechange=function(){4===r.readyState&&C.setTimeout(function(){o&&a()})},o=o("abort");try{r.send(i.hasContent&&i.data||null)}catch(e){if(o)throw e}},abort:function(){o&&o()}}}),S.ajaxPrefilter(function(e){e.crossDomain&&(e.contents.script=!1)}),S.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/\b(?:java|ecma)script\b/},converters:{"text script":function(e){return S.globalEval(e),e}}}),S.ajaxPrefilter("script",function(e){void 0===e.cache&&(e.cache=!1),e.crossDomain&&(e.type="GET")}),S.ajaxTransport("script",function(n){var r,i;if(n.crossDomain||n.scriptAttrs)return{send:function(e,t){r=S("<script>").attr(n.scriptAttrs||{}).prop({charset:n.scriptCharset,src:n.url}).on("load error",i=function(e){r.remove(),i=null,e&&t("error"===e.type?404:200,e.type)}),E.head.appendChild(r[0])},abort:function(){i&&i()}}});var _t,zt=[],Ut=/(=)\?(?=&|$)|\?\?/;S.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var e=zt.pop()||S.expando+"_"+wt.guid++;return this[e]=!0,e}}),S.ajaxPrefilter("json jsonp",function(e,t,n){var r,i,o,a=!1!==e.jsonp&&(Ut.test(e.url)?"url":"string"==typeof e.data&&0===(e.contentType||"").indexOf("application/x-www-form-urlencoded")&&Ut.test(e.data)&&"data");if(a||"jsonp"===e.dataTypes[0])return r=e.jsonpCallback=m(e.jsonpCallback)?e.jsonpCallback():e.jsonpCallback,a?e[a]=e[a].replace(Ut,"$1"+r):!1!==e.jsonp&&(e.url+=(Tt.test(e.url)?"&":"?")+e.jsonp+"="+r),e.converters["script json"]=function(){return o||S.error(r+" was not called"),o[0]},e.dataTypes[0]="json",i=C[r],C[r]=function(){o=arguments},n.always(function(){void 0===i?S(C).removeProp(r):C[r]=i,e[r]&&(e.jsonpCallback=t.jsonpCallback,zt.push(r)),o&&m(i)&&i(o[0]),o=i=void 0}),"script"}),y.createHTMLDocument=((_t=E.implementation.createHTMLDocument("").body).innerHTML="<form></form><form></form>",2===_t.childNodes.length),S.parseHTML=function(e,t,n){return"string"!=typeof e?[]:("boolean"==typeof t&&(n=t,t=!1),t||(y.createHTMLDocument?((r=(t=E.implementation.createHTMLDocument("")).createElement("base")).href=E.location.href,t.head.appendChild(r)):t=E),o=!n&&[],(i=N.exec(e))?[t.createElement(i[1])]:(i=xe([e],t,o),o&&o.length&&S(o).remove(),S.merge([],i.childNodes)));var r,i,o},S.fn.load=function(e,t,n){var r,i,o,a=this,s=e.indexOf(" ");return-1<s&&(r=ht(e.slice(s)),e=e.slice(0,s)),m(t)?(n=t,t=void 0):t&&"object"==typeof t&&(i="POST"),0<a.length&&S.ajax({url:e,type:i||"GET",dataType:"html",data:t}).done(function(e){o=arguments,a.html(r?S("<div>").append(S.parseHTML(e)).find(r):e)}).always(n&&function(e,t){a.each(function(){n.apply(this,o||[e.responseText,t,e])})}),this},S.expr.pseudos.animated=function(t){return S.grep(S.timers,function(e){return t===e.elem}).length},S.offset={setOffset:function(e,t,n){var r,i,o,a,s,u,l=S.css(e,"position"),c=S(e),f={};"static"===l&&(e.style.position="relative"),s=c.offset(),o=S.css(e,"top"),u=S.css(e,"left"),("absolute"===l||"fixed"===l)&&-1<(o+u).indexOf("auto")?(a=(r=c.position()).top,i=r.left):(a=parseFloat(o)||0,i=parseFloat(u)||0),m(t)&&(t=t.call(e,n,S.extend({},s))),null!=t.top&&(f.top=t.top-s.top+a),null!=t.left&&(f.left=t.left-s.left+i),"using"in t?t.using.call(e,f):c.css(f)}},S.fn.extend({offset:function(t){if(arguments.length)return void 0===t?this:this.each(function(e){S.offset.setOffset(this,t,e)});var e,n,r=this[0];return r?r.getClientRects().length?(e=r.getBoundingClientRect(),n=r.ownerDocument.defaultView,{top:e.top+n.pageYOffset,left:e.left+n.pageXOffset}):{top:0,left:0}:void 0},position:function(){if(this[0]){var e,t,n,r=this[0],i={top:0,left:0};if("fixed"===S.css(r,"position"))t=r.getBoundingClientRect();else{t=this.offset(),n=r.ownerDocument,e=r.offsetParent||n.documentElement;while(e&&(e===n.body||e===n.documentElement)&&"static"===S.css(e,"position"))e=e.parentNode;e&&e!==r&&1===e.nodeType&&((i=S(e).offset()).top+=S.css(e,"borderTopWidth",!0),i.left+=S.css(e,"borderLeftWidth",!0))}return{top:t.top-i.top-S.css(r,"marginTop",!0),left:t.left-i.left-S.css(r,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var e=this.offsetParent;while(e&&"static"===S.css(e,"position"))e=e.offsetParent;return e||re})}}),S.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(t,i){var o="pageYOffset"===i;S.fn[t]=function(e){return $(this,function(e,t,n){var r;if(x(e)?r=e:9===e.nodeType&&(r=e.defaultView),void 0===n)return r?r[i]:e[t];r?r.scrollTo(o?r.pageXOffset:n,o?n:r.pageYOffset):e[t]=n},t,e,arguments.length)}}),S.each(["top","left"],function(e,n){S.cssHooks[n]=Fe(y.pixelPosition,function(e,t){if(t)return t=We(e,n),Pe.test(t)?S(e).position()[n]+"px":t})}),S.each({Height:"height",Width:"width"},function(a,s){S.each({padding:"inner"+a,content:s,"":"outer"+a},function(r,o){S.fn[o]=function(e,t){var n=arguments.length&&(r||"boolean"!=typeof e),i=r||(!0===e||!0===t?"margin":"border");return $(this,function(e,t,n){var r;return x(e)?0===o.indexOf("outer")?e["inner"+a]:e.document.documentElement["client"+a]:9===e.nodeType?(r=e.documentElement,Math.max(e.body["scroll"+a],r["scroll"+a],e.body["offset"+a],r["offset"+a],r["client"+a])):void 0===n?S.css(e,t,i):S.style(e,t,n,i)},s,n?e:void 0,n)}})}),S.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(e,t){S.fn[t]=function(e){return this.on(t,e)}}),S.fn.extend({bind:function(e,t,n){return this.on(e,null,t,n)},unbind:function(e,t){return this.off(e,null,t)},delegate:function(e,t,n,r){return this.on(t,e,n,r)},undelegate:function(e,t,n){return 1===arguments.length?this.off(e,"**"):this.off(t,e||"**",n)},hover:function(e,t){return this.mouseenter(e).mouseleave(t||e)}}),S.each("blur focus focusin focusout resize scroll click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup contextmenu".split(" "),function(e,n){S.fn[n]=function(e,t){return 0<arguments.length?this.on(n,null,e,t):this.trigger(n)}});var Xt=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g;S.proxy=function(e,t){var n,r,i;if("string"==typeof t&&(n=e[t],t=e,e=n),m(e))return r=s.call(arguments,2),(i=function(){return e.apply(t||this,r.concat(s.call(arguments)))}).guid=e.guid=e.guid||S.guid++,i},S.holdReady=function(e){e?S.readyWait++:S.ready(!0)},S.isArray=Array.isArray,S.parseJSON=JSON.parse,S.nodeName=A,S.isFunction=m,S.isWindow=x,S.camelCase=X,S.type=w,S.now=Date.now,S.isNumeric=function(e){var t=S.type(e);return("number"===t||"string"===t)&&!isNaN(e-parseFloat(e))},S.trim=function(e){return null==e?"":(e+"").replace(Xt,"")},"function"==typeof define&&define.amd&&define("jquery",[],function(){return S});var Vt=C.jQuery,Gt=C.$;return S.noConflict=function(e){return C.$===S&&(C.$=Gt),e&&C.jQuery===S&&(C.jQuery=Vt),S},"undefined"==typeof e&&(C.jQuery=C.$=S),S});
</script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<style type="text/css">html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}article,aside,details,figcaption,figure,footer,header,hgroup,main,menu,nav,section,summary{display:block}audio,canvas,progress,video{display:inline-block;vertical-align:baseline}audio:not([controls]){display:none;height:0}[hidden],template{display:none}a{background-color:transparent}a:active,a:hover{outline:0}abbr[title]{border-bottom:1px dotted}b,strong{font-weight:700}dfn{font-style:italic}h1{margin:.67em 0;font-size:2em}mark{color:#000;background:#ff0}small{font-size:80%}sub,sup{position:relative;font-size:75%;line-height:0;vertical-align:baseline}sup{top:-.5em}sub{bottom:-.25em}img{border:0}svg:not(:root){overflow:hidden}figure{margin:1em 40px}hr{height:0;-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box}pre{overflow:auto}code,kbd,pre,samp{font-family:monospace,monospace;font-size:1em}button,input,optgroup,select,textarea{margin:0;font:inherit;color:inherit}button{overflow:visible}button,select{text-transform:none}button,html input[type=button],input[type=reset],input[type=submit]{-webkit-appearance:button;cursor:pointer}button[disabled],html input[disabled]{cursor:default}button::-moz-focus-inner,input::-moz-focus-inner{padding:0;border:0}input{line-height:normal}input[type=checkbox],input[type=radio]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;padding:0}input[type=number]::-webkit-inner-spin-button,input[type=number]::-webkit-outer-spin-button{height:auto}input[type=search]{-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;-webkit-appearance:textfield}input[type=search]::-webkit-search-cancel-button,input[type=search]::-webkit-search-decoration{-webkit-appearance:none}fieldset{padding:.35em .625em .75em;margin:0 2px;border:1px solid silver}legend{padding:0;border:0}textarea{overflow:auto}optgroup{font-weight:700}table{border-spacing:0;border-collapse:collapse}td,th{padding:0}@media print{*,:after,:before{color:#000!important;text-shadow:none!important;background:0 0!important;-webkit-box-shadow:none!important;box-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}abbr[title]:after{content:" (" attr(title) ")"}a[href^="javascript:"]:after,a[href^="#"]:after{content:""}blockquote,pre{border:1px solid #999;page-break-inside:avoid}thead{display:table-header-group}img,tr{page-break-inside:avoid}img{max-width:100%!important}h2,h3,p{orphans:3;widows:3}h2,h3{page-break-after:avoid}.navbar{display:none}.btn>.caret,.dropup>.btn>.caret{border-top-color:#000!important}.label{border:1px solid #000}.table{border-collapse:collapse!important}.table td,.table th{background-color:#fff!important}.table-bordered td,.table-bordered th{border:1px solid #ddd!important}}@font-face{font-family:'Glyphicons Halflings';src:url(data:application/vnd.ms-fontobject;base64,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);src:url(data:application/vnd.ms-fontobject;base64,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) format('embedded-opentype'),url(data:application/font-woff;base64,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) format('woff'),url(data:application/font-sfnt;base64,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) format('truetype'),url(data:image/svg+xml;base64,<?xml version="1.0" standalone="no"?>
<!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd" >
<svg xmlns="http://www.w3.org/2000/svg">
<metadata></metadata>
<defs>
<font id="glyphicons_halflingsregular" horiz-adv-x="1200" >
<font-face units-per-em="1200" ascent="960" descent="-240" />
<missing-glyph horiz-adv-x="500" />
<glyph horiz-adv-x="0" />
<glyph horiz-adv-x="400" />
<glyph unicode=" " />
<glyph unicode="*" d="M600 1100q15 0 34 -1.5t30 -3.5l11 -1q10 -2 17.5 -10.5t7.5 -18.5v-224l158 158q7 7 18 8t19 -6l106 -106q7 -8 6 -19t-8 -18l-158 -158h224q10 0 18.5 -7.5t10.5 -17.5q6 -41 6 -75q0 -15 -1.5 -34t-3.5 -30l-1 -11q-2 -10 -10.5 -17.5t-18.5 -7.5h-224l158 -158 q7 -7 8 -18t-6 -19l-106 -106q-8 -7 -19 -6t-18 8l-158 158v-224q0 -10 -7.5 -18.5t-17.5 -10.5q-41 -6 -75 -6q-15 0 -34 1.5t-30 3.5l-11 1q-10 2 -17.5 10.5t-7.5 18.5v224l-158 -158q-7 -7 -18 -8t-19 6l-106 106q-7 8 -6 19t8 18l158 158h-224q-10 0 -18.5 7.5 t-10.5 17.5q-6 41 -6 75q0 15 1.5 34t3.5 30l1 11q2 10 10.5 17.5t18.5 7.5h224l-158 158q-7 7 -8 18t6 19l106 106q8 7 19 6t18 -8l158 -158v224q0 10 7.5 18.5t17.5 10.5q41 6 75 6z" />
<glyph unicode="+" d="M450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-350h350q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-350v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v350h-350q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5 h350v350q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xa0;" />
<glyph unicode="&#xa5;" d="M825 1100h250q10 0 12.5 -5t-5.5 -13l-364 -364q-6 -6 -11 -18h268q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-100h275q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-174q0 -11 -7.5 -18.5t-18.5 -7.5h-148q-11 0 -18.5 7.5t-7.5 18.5v174 h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h125v100h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h118q-5 12 -11 18l-364 364q-8 8 -5.5 13t12.5 5h250q25 0 43 -18l164 -164q8 -8 18 -8t18 8l164 164q18 18 43 18z" />
<glyph unicode="&#x2000;" horiz-adv-x="650" />
<glyph unicode="&#x2001;" horiz-adv-x="1300" />
<glyph unicode="&#x2002;" horiz-adv-x="650" />
<glyph unicode="&#x2003;" horiz-adv-x="1300" />
<glyph unicode="&#x2004;" horiz-adv-x="433" />
<glyph unicode="&#x2005;" horiz-adv-x="325" />
<glyph unicode="&#x2006;" horiz-adv-x="216" />
<glyph unicode="&#x2007;" horiz-adv-x="216" />
<glyph unicode="&#x2008;" horiz-adv-x="162" />
<glyph unicode="&#x2009;" horiz-adv-x="260" />
<glyph unicode="&#x200a;" horiz-adv-x="72" />
<glyph unicode="&#x202f;" horiz-adv-x="260" />
<glyph unicode="&#x205f;" horiz-adv-x="325" />
<glyph unicode="&#x20ac;" d="M744 1198q242 0 354 -189q60 -104 66 -209h-181q0 45 -17.5 82.5t-43.5 61.5t-58 40.5t-60.5 24t-51.5 7.5q-19 0 -40.5 -5.5t-49.5 -20.5t-53 -38t-49 -62.5t-39 -89.5h379l-100 -100h-300q-6 -50 -6 -100h406l-100 -100h-300q9 -74 33 -132t52.5 -91t61.5 -54.5t59 -29 t47 -7.5q22 0 50.5 7.5t60.5 24.5t58 41t43.5 61t17.5 80h174q-30 -171 -128 -278q-107 -117 -274 -117q-206 0 -324 158q-36 48 -69 133t-45 204h-217l100 100h112q1 47 6 100h-218l100 100h134q20 87 51 153.5t62 103.5q117 141 297 141z" />
<glyph unicode="&#x20bd;" d="M428 1200h350q67 0 120 -13t86 -31t57 -49.5t35 -56.5t17 -64.5t6.5 -60.5t0.5 -57v-16.5v-16.5q0 -36 -0.5 -57t-6.5 -61t-17 -65t-35 -57t-57 -50.5t-86 -31.5t-120 -13h-178l-2 -100h288q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-138v-175q0 -11 -5.5 -18 t-15.5 -7h-149q-10 0 -17.5 7.5t-7.5 17.5v175h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v100h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v475q0 10 7.5 17.5t17.5 7.5zM600 1000v-300h203q64 0 86.5 33t22.5 119q0 84 -22.5 116t-86.5 32h-203z" />
<glyph unicode="&#x2212;" d="M250 700h800q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#x231b;" d="M1000 1200v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-50v-100q0 -91 -49.5 -165.5t-130.5 -109.5q81 -35 130.5 -109.5t49.5 -165.5v-150h50q21 0 35.5 -14.5t14.5 -35.5v-150h-800v150q0 21 14.5 35.5t35.5 14.5h50v150q0 91 49.5 165.5t130.5 109.5q-81 35 -130.5 109.5 t-49.5 165.5v100h-50q-21 0 -35.5 14.5t-14.5 35.5v150h800zM400 1000v-100q0 -60 32.5 -109.5t87.5 -73.5q28 -12 44 -37t16 -55t-16 -55t-44 -37q-55 -24 -87.5 -73.5t-32.5 -109.5v-150h400v150q0 60 -32.5 109.5t-87.5 73.5q-28 12 -44 37t-16 55t16 55t44 37 q55 24 87.5 73.5t32.5 109.5v100h-400z" />
<glyph unicode="&#x25fc;" horiz-adv-x="500" d="M0 0z" />
<glyph unicode="&#x2601;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -206.5q0 -121 -85 -207.5t-205 -86.5h-750q-79 0 -135.5 57t-56.5 137q0 69 42.5 122.5t108.5 67.5q-2 12 -2 37q0 153 108 260.5t260 107.5z" />
<glyph unicode="&#x26fa;" d="M774 1193.5q16 -9.5 20.5 -27t-5.5 -33.5l-136 -187l467 -746h30q20 0 35 -18.5t15 -39.5v-42h-1200v42q0 21 15 39.5t35 18.5h30l468 746l-135 183q-10 16 -5.5 34t20.5 28t34 5.5t28 -20.5l111 -148l112 150q9 16 27 20.5t34 -5zM600 200h377l-182 112l-195 534v-646z " />
<glyph unicode="&#x2709;" d="M25 1100h1150q10 0 12.5 -5t-5.5 -13l-564 -567q-8 -8 -18 -8t-18 8l-564 567q-8 8 -5.5 13t12.5 5zM18 882l264 -264q8 -8 8 -18t-8 -18l-264 -264q-8 -8 -13 -5.5t-5 12.5v550q0 10 5 12.5t13 -5.5zM918 618l264 264q8 8 13 5.5t5 -12.5v-550q0 -10 -5 -12.5t-13 5.5 l-264 264q-8 8 -8 18t8 18zM818 482l364 -364q8 -8 5.5 -13t-12.5 -5h-1150q-10 0 -12.5 5t5.5 13l364 364q8 8 18 8t18 -8l164 -164q8 -8 18 -8t18 8l164 164q8 8 18 8t18 -8z" />
<glyph unicode="&#x270f;" d="M1011 1210q19 0 33 -13l153 -153q13 -14 13 -33t-13 -33l-99 -92l-214 214l95 96q13 14 32 14zM1013 800l-615 -614l-214 214l614 614zM317 96l-333 -112l110 335z" />
<glyph unicode="&#xe001;" d="M700 650v-550h250q21 0 35.5 -14.5t14.5 -35.5v-50h-800v50q0 21 14.5 35.5t35.5 14.5h250v550l-500 550h1200z" />
<glyph unicode="&#xe002;" d="M368 1017l645 163q39 15 63 0t24 -49v-831q0 -55 -41.5 -95.5t-111.5 -63.5q-79 -25 -147 -4.5t-86 75t25.5 111.5t122.5 82q72 24 138 8v521l-600 -155v-606q0 -42 -44 -90t-109 -69q-79 -26 -147 -5.5t-86 75.5t25.5 111.5t122.5 82.5q72 24 138 7v639q0 38 14.5 59 t53.5 34z" />
<glyph unicode="&#xe003;" d="M500 1191q100 0 191 -39t156.5 -104.5t104.5 -156.5t39 -191l-1 -2l1 -5q0 -141 -78 -262l275 -274q23 -26 22.5 -44.5t-22.5 -42.5l-59 -58q-26 -20 -46.5 -20t-39.5 20l-275 274q-119 -77 -261 -77l-5 1l-2 -1q-100 0 -191 39t-156.5 104.5t-104.5 156.5t-39 191 t39 191t104.5 156.5t156.5 104.5t191 39zM500 1022q-88 0 -162 -43t-117 -117t-43 -162t43 -162t117 -117t162 -43t162 43t117 117t43 162t-43 162t-117 117t-162 43z" />
<glyph unicode="&#xe005;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104z" />
<glyph unicode="&#xe006;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429z" />
<glyph unicode="&#xe007;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429zM477 700h-240l197 -142l-74 -226 l193 139l195 -140l-74 229l192 140h-234l-78 211z" />
<glyph unicode="&#xe008;" d="M600 1200q124 0 212 -88t88 -212v-250q0 -46 -31 -98t-69 -52v-75q0 -10 6 -21.5t15 -17.5l358 -230q9 -5 15 -16.5t6 -21.5v-93q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v93q0 10 6 21.5t15 16.5l358 230q9 6 15 17.5t6 21.5v75q-38 0 -69 52 t-31 98v250q0 124 88 212t212 88z" />
<glyph unicode="&#xe009;" d="M25 1100h1150q10 0 17.5 -7.5t7.5 -17.5v-1050q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v1050q0 10 7.5 17.5t17.5 7.5zM100 1000v-100h100v100h-100zM875 1000h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5t17.5 -7.5h550 q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM1000 1000v-100h100v100h-100zM100 800v-100h100v100h-100zM1000 800v-100h100v100h-100zM100 600v-100h100v100h-100zM1000 600v-100h100v100h-100zM875 500h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5 t17.5 -7.5h550q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM100 400v-100h100v100h-100zM1000 400v-100h100v100h-100zM100 200v-100h100v100h-100zM1000 200v-100h100v100h-100z" />
<glyph unicode="&#xe010;" d="M50 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM50 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe011;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM850 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 700h200q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h200 q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5 t35.5 14.5z" />
<glyph unicode="&#xe012;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h700q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe013;" d="M465 477l571 571q8 8 18 8t17 -8l177 -177q8 -7 8 -17t-8 -18l-783 -784q-7 -8 -17.5 -8t-17.5 8l-384 384q-8 8 -8 18t8 17l177 177q7 8 17 8t18 -8l171 -171q7 -7 18 -7t18 7z" />
<glyph unicode="&#xe014;" d="M904 1083l178 -179q8 -8 8 -18.5t-8 -17.5l-267 -268l267 -268q8 -7 8 -17.5t-8 -18.5l-178 -178q-8 -8 -18.5 -8t-17.5 8l-268 267l-268 -267q-7 -8 -17.5 -8t-18.5 8l-178 178q-8 8 -8 18.5t8 17.5l267 268l-267 268q-8 7 -8 17.5t8 18.5l178 178q8 8 18.5 8t17.5 -8 l268 -267l268 268q7 7 17.5 7t18.5 -7z" />
<glyph unicode="&#xe015;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM425 900h150q10 0 17.5 -7.5t7.5 -17.5v-75h75q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5 t-17.5 -7.5h-75v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-75q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v75q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe016;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM325 800h350q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-350q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe017;" d="M550 1200h100q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM800 975v166q167 -62 272 -209.5t105 -331.5q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5 t-184.5 123t-123 184.5t-45.5 224q0 184 105 331.5t272 209.5v-166q-103 -55 -165 -155t-62 -220q0 -116 57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5q0 120 -62 220t-165 155z" />
<glyph unicode="&#xe018;" d="M1025 1200h150q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM725 800h150q10 0 17.5 -7.5t7.5 -17.5v-750q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v750 q0 10 7.5 17.5t17.5 7.5zM425 500h150q10 0 17.5 -7.5t7.5 -17.5v-450q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v450q0 10 7.5 17.5t17.5 7.5zM125 300h150q10 0 17.5 -7.5t7.5 -17.5v-250q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5 v250q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe019;" d="M600 1174q33 0 74 -5l38 -152l5 -1q49 -14 94 -39l5 -2l134 80q61 -48 104 -105l-80 -134l3 -5q25 -44 39 -93l1 -6l152 -38q5 -43 5 -73q0 -34 -5 -74l-152 -38l-1 -6q-15 -49 -39 -93l-3 -5l80 -134q-48 -61 -104 -105l-134 81l-5 -3q-44 -25 -94 -39l-5 -2l-38 -151 q-43 -5 -74 -5q-33 0 -74 5l-38 151l-5 2q-49 14 -94 39l-5 3l-134 -81q-60 48 -104 105l80 134l-3 5q-25 45 -38 93l-2 6l-151 38q-6 42 -6 74q0 33 6 73l151 38l2 6q13 48 38 93l3 5l-80 134q47 61 105 105l133 -80l5 2q45 25 94 39l5 1l38 152q43 5 74 5zM600 815 q-89 0 -152 -63t-63 -151.5t63 -151.5t152 -63t152 63t63 151.5t-63 151.5t-152 63z" />
<glyph unicode="&#xe020;" d="M500 1300h300q41 0 70.5 -29.5t29.5 -70.5v-100h275q10 0 17.5 -7.5t7.5 -17.5v-75h-1100v75q0 10 7.5 17.5t17.5 7.5h275v100q0 41 29.5 70.5t70.5 29.5zM500 1200v-100h300v100h-300zM1100 900v-800q0 -41 -29.5 -70.5t-70.5 -29.5h-700q-41 0 -70.5 29.5t-29.5 70.5 v800h900zM300 800v-700h100v700h-100zM500 800v-700h100v700h-100zM700 800v-700h100v700h-100zM900 800v-700h100v700h-100z" />
<glyph unicode="&#xe021;" d="M18 618l620 608q8 7 18.5 7t17.5 -7l608 -608q8 -8 5.5 -13t-12.5 -5h-175v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v375h-300v-375q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v575h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe022;" d="M600 1200v-400q0 -41 29.5 -70.5t70.5 -29.5h300v-650q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5h450zM1000 800h-250q-21 0 -35.5 14.5t-14.5 35.5v250z" />
<glyph unicode="&#xe023;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h50q10 0 17.5 -7.5t7.5 -17.5v-275h175q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe024;" d="M1300 0h-538l-41 400h-242l-41 -400h-538l431 1200h209l-21 -300h162l-20 300h208zM515 800l-27 -300h224l-27 300h-170z" />
<glyph unicode="&#xe025;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-450h191q20 0 25.5 -11.5t-7.5 -27.5l-327 -400q-13 -16 -32 -16t-32 16l-327 400q-13 16 -7.5 27.5t25.5 11.5h191v450q0 21 14.5 35.5t35.5 14.5zM1125 400h50q10 0 17.5 -7.5t7.5 -17.5v-350q0 -10 -7.5 -17.5t-17.5 -7.5 h-1050q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h50q10 0 17.5 -7.5t7.5 -17.5v-175h900v175q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe026;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -275q-13 -16 -32 -16t-32 16l-223 275q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z " />
<glyph unicode="&#xe027;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM632 914l223 -275q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5l223 275q13 16 32 16 t32 -16z" />
<glyph unicode="&#xe028;" d="M225 1200h750q10 0 19.5 -7t12.5 -17l186 -652q7 -24 7 -49v-425q0 -12 -4 -27t-9 -17q-12 -6 -37 -6h-1100q-12 0 -27 4t-17 8q-6 13 -6 38l1 425q0 25 7 49l185 652q3 10 12.5 17t19.5 7zM878 1000h-556q-10 0 -19 -7t-11 -18l-87 -450q-2 -11 4 -18t16 -7h150 q10 0 19.5 -7t11.5 -17l38 -152q2 -10 11.5 -17t19.5 -7h250q10 0 19.5 7t11.5 17l38 152q2 10 11.5 17t19.5 7h150q10 0 16 7t4 18l-87 450q-2 11 -11 18t-19 7z" />
<glyph unicode="&#xe029;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM540 820l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe030;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-362q0 -10 -7.5 -17.5t-17.5 -7.5h-362q-11 0 -13 5.5t5 12.5l133 133q-109 76 -238 76q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5h150q0 -117 -45.5 -224 t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117z" />
<glyph unicode="&#xe031;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-361q0 -11 -7.5 -18.5t-18.5 -7.5h-361q-11 0 -13 5.5t5 12.5l134 134q-110 75 -239 75q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5h-150q0 117 45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117zM1027 600h150 q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5q-192 0 -348 118l-134 -134q-7 -8 -12.5 -5.5t-5.5 12.5v360q0 11 7.5 18.5t18.5 7.5h360q10 0 12.5 -5.5t-5.5 -12.5l-133 -133q110 -76 240 -76q116 0 214.5 57t155.5 155.5t57 214.5z" />
<glyph unicode="&#xe032;" d="M125 1200h1050q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-1050q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM1075 1000h-850q-10 0 -17.5 -7.5t-7.5 -17.5v-850q0 -10 7.5 -17.5t17.5 -7.5h850q10 0 17.5 7.5t7.5 17.5v850 q0 10 -7.5 17.5t-17.5 7.5zM325 900h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 900h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 700h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 700h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 500h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 500h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 300h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 300h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe033;" d="M900 800v200q0 83 -58.5 141.5t-141.5 58.5h-300q-82 0 -141 -59t-59 -141v-200h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h900q41 0 70.5 29.5t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5h-100zM400 800v150q0 21 15 35.5t35 14.5h200 q20 0 35 -14.5t15 -35.5v-150h-300z" />
<glyph unicode="&#xe034;" d="M125 1100h50q10 0 17.5 -7.5t7.5 -17.5v-1075h-100v1075q0 10 7.5 17.5t17.5 7.5zM1075 1052q4 0 9 -2q16 -6 16 -23v-421q0 -6 -3 -12q-33 -59 -66.5 -99t-65.5 -58t-56.5 -24.5t-52.5 -6.5q-26 0 -57.5 6.5t-52.5 13.5t-60 21q-41 15 -63 22.5t-57.5 15t-65.5 7.5 q-85 0 -160 -57q-7 -5 -15 -5q-6 0 -11 3q-14 7 -14 22v438q22 55 82 98.5t119 46.5q23 2 43 0.5t43 -7t32.5 -8.5t38 -13t32.5 -11q41 -14 63.5 -21t57 -14t63.5 -7q103 0 183 87q7 8 18 8z" />
<glyph unicode="&#xe035;" d="M600 1175q116 0 227 -49.5t192.5 -131t131 -192.5t49.5 -227v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v300q0 127 -70.5 231.5t-184.5 161.5t-245 57t-245 -57t-184.5 -161.5t-70.5 -231.5v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50 q-10 0 -17.5 7.5t-7.5 17.5v300q0 116 49.5 227t131 192.5t192.5 131t227 49.5zM220 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460q0 8 6 14t14 6zM820 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460 q0 8 6 14t14 6z" />
<glyph unicode="&#xe036;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM900 668l120 120q7 7 17 7t17 -7l34 -34q7 -7 7 -17t-7 -17l-120 -120l120 -120q7 -7 7 -17 t-7 -17l-34 -34q-7 -7 -17 -7t-17 7l-120 119l-120 -119q-7 -7 -17 -7t-17 7l-34 34q-7 7 -7 17t7 17l119 120l-119 120q-7 7 -7 17t7 17l34 34q7 8 17 8t17 -8z" />
<glyph unicode="&#xe037;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6 l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238q-6 8 -4.5 18t9.5 17l29 22q7 5 15 5z" />
<glyph unicode="&#xe038;" d="M967 1004h3q11 -1 17 -10q135 -179 135 -396q0 -105 -34 -206.5t-98 -185.5q-7 -9 -17 -10h-3q-9 0 -16 6l-42 34q-8 6 -9 16t5 18q111 150 111 328q0 90 -29.5 176t-84.5 157q-6 9 -5 19t10 16l42 33q7 5 15 5zM321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5 t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238 q-6 8 -4.5 18.5t9.5 16.5l29 22q7 5 15 5z" />
<glyph unicode="&#xe039;" d="M500 900h100v-100h-100v-100h-400v-100h-100v600h500v-300zM1200 700h-200v-100h200v-200h-300v300h-200v300h-100v200h600v-500zM100 1100v-300h300v300h-300zM800 1100v-300h300v300h-300zM300 900h-100v100h100v-100zM1000 900h-100v100h100v-100zM300 500h200v-500 h-500v500h200v100h100v-100zM800 300h200v-100h-100v-100h-200v100h-100v100h100v200h-200v100h300v-300zM100 400v-300h300v300h-300zM300 200h-100v100h100v-100zM1200 200h-100v100h100v-100zM700 0h-100v100h100v-100zM1200 0h-300v100h300v-100z" />
<glyph unicode="&#xe040;" d="M100 200h-100v1000h100v-1000zM300 200h-100v1000h100v-1000zM700 200h-200v1000h200v-1000zM900 200h-100v1000h100v-1000zM1200 200h-200v1000h200v-1000zM400 0h-300v100h300v-100zM600 0h-100v91h100v-91zM800 0h-100v91h100v-91zM1100 0h-200v91h200v-91z" />
<glyph unicode="&#xe041;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe042;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM800 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-56 56l424 426l-700 700h150zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5 t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe043;" d="M300 1200h825q75 0 75 -75v-900q0 -25 -18 -43l-64 -64q-8 -8 -13 -5.5t-5 12.5v950q0 10 -7.5 17.5t-17.5 7.5h-700q-25 0 -43 -18l-64 -64q-8 -8 -5.5 -13t12.5 -5h700q10 0 17.5 -7.5t7.5 -17.5v-950q0 -10 -7.5 -17.5t-17.5 -7.5h-850q-10 0 -17.5 7.5t-7.5 17.5v975 q0 25 18 43l139 139q18 18 43 18z" />
<glyph unicode="&#xe044;" d="M250 1200h800q21 0 35.5 -14.5t14.5 -35.5v-1150l-450 444l-450 -445v1151q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe045;" d="M822 1200h-444q-11 0 -19 -7.5t-9 -17.5l-78 -301q-7 -24 7 -45l57 -108q6 -9 17.5 -15t21.5 -6h450q10 0 21.5 6t17.5 15l62 108q14 21 7 45l-83 301q-1 10 -9 17.5t-19 7.5zM1175 800h-150q-10 0 -21 -6.5t-15 -15.5l-78 -156q-4 -9 -15 -15.5t-21 -6.5h-550 q-10 0 -21 6.5t-15 15.5l-78 156q-4 9 -15 15.5t-21 6.5h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-650q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h750q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5 t7.5 17.5v650q0 10 -7.5 17.5t-17.5 7.5zM850 200h-500q-10 0 -19.5 -7t-11.5 -17l-38 -152q-2 -10 3.5 -17t15.5 -7h600q10 0 15.5 7t3.5 17l-38 152q-2 10 -11.5 17t-19.5 7z" />
<glyph unicode="&#xe046;" d="M500 1100h200q56 0 102.5 -20.5t72.5 -50t44 -59t25 -50.5l6 -20h150q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5h150q2 8 6.5 21.5t24 48t45 61t72 48t102.5 21.5zM900 800v-100 h100v100h-100zM600 730q-95 0 -162.5 -67.5t-67.5 -162.5t67.5 -162.5t162.5 -67.5t162.5 67.5t67.5 162.5t-67.5 162.5t-162.5 67.5zM600 603q43 0 73 -30t30 -73t-30 -73t-73 -30t-73 30t-30 73t30 73t73 30z" />
<glyph unicode="&#xe047;" d="M681 1199l385 -998q20 -50 60 -92q18 -19 36.5 -29.5t27.5 -11.5l10 -2v-66h-417v66q53 0 75 43.5t5 88.5l-82 222h-391q-58 -145 -92 -234q-11 -34 -6.5 -57t25.5 -37t46 -20t55 -6v-66h-365v66q56 24 84 52q12 12 25 30.5t20 31.5l7 13l399 1006h93zM416 521h340 l-162 457z" />
<glyph unicode="&#xe048;" d="M753 641q5 -1 14.5 -4.5t36 -15.5t50.5 -26.5t53.5 -40t50.5 -54.5t35.5 -70t14.5 -87q0 -67 -27.5 -125.5t-71.5 -97.5t-98.5 -66.5t-108.5 -40.5t-102 -13h-500v89q41 7 70.5 32.5t29.5 65.5v827q0 24 -0.5 34t-3.5 24t-8.5 19.5t-17 13.5t-28 12.5t-42.5 11.5v71 l471 -1q57 0 115.5 -20.5t108 -57t80.5 -94t31 -124.5q0 -51 -15.5 -96.5t-38 -74.5t-45 -50.5t-38.5 -30.5zM400 700h139q78 0 130.5 48.5t52.5 122.5q0 41 -8.5 70.5t-29.5 55.5t-62.5 39.5t-103.5 13.5h-118v-350zM400 200h216q80 0 121 50.5t41 130.5q0 90 -62.5 154.5 t-156.5 64.5h-159v-400z" />
<glyph unicode="&#xe049;" d="M877 1200l2 -57q-83 -19 -116 -45.5t-40 -66.5l-132 -839q-9 -49 13 -69t96 -26v-97h-500v97q186 16 200 98l173 832q3 17 3 30t-1.5 22.5t-9 17.5t-13.5 12.5t-21.5 10t-26 8.5t-33.5 10q-13 3 -19 5v57h425z" />
<glyph unicode="&#xe050;" d="M1300 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM175 1000h-75v-800h75l-125 -167l-125 167h75v800h-75l125 167z" />
<glyph unicode="&#xe051;" d="M1100 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-650q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v650h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM1167 50l-167 -125v75h-800v-75l-167 125l167 125v-75h800v75z" />
<glyph unicode="&#xe052;" d="M50 1100h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe053;" d="M250 1100h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM250 500h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe054;" d="M500 950v100q0 21 14.5 35.5t35.5 14.5h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5zM100 650v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000 q-21 0 -35.5 14.5t-14.5 35.5zM300 350v100q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5zM0 50v100q0 21 14.5 35.5t35.5 14.5h1100q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5z" />
<glyph unicode="&#xe055;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe056;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 1100h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 800h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 500h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 500h800q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 200h800 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe057;" d="M400 0h-100v1100h100v-1100zM550 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM267 550l-167 -125v75h-200v100h200v75zM550 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe058;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM900 0h-100v1100h100v-1100zM50 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM1100 600h200v-100h-200v-75l-167 125l167 125v-75zM50 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe059;" d="M75 1000h750q31 0 53 -22t22 -53v-650q0 -31 -22 -53t-53 -22h-750q-31 0 -53 22t-22 53v650q0 31 22 53t53 22zM1200 300l-300 300l300 300v-600z" />
<glyph unicode="&#xe060;" d="M44 1100h1112q18 0 31 -13t13 -31v-1012q0 -18 -13 -31t-31 -13h-1112q-18 0 -31 13t-13 31v1012q0 18 13 31t31 13zM100 1000v-737l247 182l298 -131l-74 156l293 318l236 -288v500h-1000zM342 884q56 0 95 -39t39 -94.5t-39 -95t-95 -39.5t-95 39.5t-39 95t39 94.5 t95 39z" />
<glyph unicode="&#xe062;" d="M648 1169q117 0 216 -60t156.5 -161t57.5 -218q0 -115 -70 -258q-69 -109 -158 -225.5t-143 -179.5l-54 -62q-9 8 -25.5 24.5t-63.5 67.5t-91 103t-98.5 128t-95.5 148q-60 132 -60 249q0 88 34 169.5t91.5 142t137 96.5t166.5 36zM652.5 974q-91.5 0 -156.5 -65 t-65 -157t65 -156.5t156.5 -64.5t156.5 64.5t65 156.5t-65 157t-156.5 65z" />
<glyph unicode="&#xe063;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 173v854q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57z" />
<glyph unicode="&#xe064;" d="M554 1295q21 -72 57.5 -143.5t76 -130t83 -118t82.5 -117t70 -116t49.5 -126t18.5 -136.5q0 -71 -25.5 -135t-68.5 -111t-99 -82t-118.5 -54t-125.5 -23q-84 5 -161.5 34t-139.5 78.5t-99 125t-37 164.5q0 69 18 136.5t49.5 126.5t69.5 116.5t81.5 117.5t83.5 119 t76.5 131t58.5 143zM344 710q-23 -33 -43.5 -70.5t-40.5 -102.5t-17 -123q1 -37 14.5 -69.5t30 -52t41 -37t38.5 -24.5t33 -15q21 -7 32 -1t13 22l6 34q2 10 -2.5 22t-13.5 19q-5 4 -14 12t-29.5 40.5t-32.5 73.5q-26 89 6 271q2 11 -6 11q-8 1 -15 -10z" />
<glyph unicode="&#xe065;" d="M1000 1013l108 115q2 1 5 2t13 2t20.5 -1t25 -9.5t28.5 -21.5q22 -22 27 -43t0 -32l-6 -10l-108 -115zM350 1100h400q50 0 105 -13l-187 -187h-368q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v182l200 200v-332 q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM1009 803l-362 -362l-161 -50l55 170l355 355z" />
<glyph unicode="&#xe066;" d="M350 1100h361q-164 -146 -216 -200h-195q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5l200 153v-103q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M824 1073l339 -301q8 -7 8 -17.5t-8 -17.5l-340 -306q-7 -6 -12.5 -4t-6.5 11v203q-26 1 -54.5 0t-78.5 -7.5t-92 -17.5t-86 -35t-70 -57q10 59 33 108t51.5 81.5t65 58.5t68.5 40.5t67 24.5t56 13.5t40 4.5v210q1 10 6.5 12.5t13.5 -4.5z" />
<glyph unicode="&#xe067;" d="M350 1100h350q60 0 127 -23l-178 -177h-349q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v69l200 200v-219q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M643 639l395 395q7 7 17.5 7t17.5 -7l101 -101q7 -7 7 -17.5t-7 -17.5l-531 -532q-7 -7 -17.5 -7t-17.5 7l-248 248q-7 7 -7 17.5t7 17.5l101 101q7 7 17.5 7t17.5 -7l111 -111q8 -7 18 -7t18 7z" />
<glyph unicode="&#xe068;" d="M318 918l264 264q8 8 18 8t18 -8l260 -264q7 -8 4.5 -13t-12.5 -5h-170v-200h200v173q0 10 5 12t13 -5l264 -260q8 -7 8 -17.5t-8 -17.5l-264 -265q-8 -7 -13 -5t-5 12v173h-200v-200h170q10 0 12.5 -5t-4.5 -13l-260 -264q-8 -8 -18 -8t-18 8l-264 264q-8 8 -5.5 13 t12.5 5h175v200h-200v-173q0 -10 -5 -12t-13 5l-264 265q-8 7 -8 17.5t8 17.5l264 260q8 7 13 5t5 -12v-173h200v200h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe069;" d="M250 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe070;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5 t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe071;" d="M1200 1050v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-492 480q-15 14 -15 35t15 35l492 480q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25z" />
<glyph unicode="&#xe072;" d="M243 1074l814 -498q18 -11 18 -26t-18 -26l-814 -498q-18 -11 -30.5 -4t-12.5 28v1000q0 21 12.5 28t30.5 -4z" />
<glyph unicode="&#xe073;" d="M250 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM650 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe074;" d="M1100 950v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe075;" d="M500 612v438q0 21 10.5 25t25.5 -10l492 -480q15 -14 15 -35t-15 -35l-492 -480q-15 -14 -25.5 -10t-10.5 25v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10z" />
<glyph unicode="&#xe076;" d="M1048 1102l100 1q20 0 35 -14.5t15 -35.5l5 -1000q0 -21 -14.5 -35.5t-35.5 -14.5l-100 -1q-21 0 -35.5 14.5t-14.5 35.5l-2 437l-463 -454q-14 -15 -24.5 -10.5t-10.5 25.5l-2 437l-462 -455q-15 -14 -25.5 -9.5t-10.5 24.5l-5 1000q0 21 10.5 25.5t25.5 -10.5l466 -450 l-2 438q0 20 10.5 24.5t25.5 -9.5l466 -451l-2 438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe077;" d="M850 1100h100q21 0 35.5 -14.5t14.5 -35.5v-1000q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10l464 -453v438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe078;" d="M686 1081l501 -540q15 -15 10.5 -26t-26.5 -11h-1042q-22 0 -26.5 11t10.5 26l501 540q15 15 36 15t36 -15zM150 400h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe079;" d="M885 900l-352 -353l352 -353l-197 -198l-552 552l552 550z" />
<glyph unicode="&#xe080;" d="M1064 547l-551 -551l-198 198l353 353l-353 353l198 198z" />
<glyph unicode="&#xe081;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM650 900h-100q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-150 q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5h150v-150q0 -21 14.5 -35.5t35.5 -14.5h100q21 0 35.5 14.5t14.5 35.5v150h150q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-150v150q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe082;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM850 700h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5 t35.5 -14.5h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe083;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM741.5 913q-12.5 0 -21.5 -9l-120 -120l-120 120q-9 9 -21.5 9 t-21.5 -9l-141 -141q-9 -9 -9 -21.5t9 -21.5l120 -120l-120 -120q-9 -9 -9 -21.5t9 -21.5l141 -141q9 -9 21.5 -9t21.5 9l120 120l120 -120q9 -9 21.5 -9t21.5 9l141 141q9 9 9 21.5t-9 21.5l-120 120l120 120q9 9 9 21.5t-9 21.5l-141 141q-9 9 -21.5 9z" />
<glyph unicode="&#xe084;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM546 623l-84 85q-7 7 -17.5 7t-18.5 -7l-139 -139q-7 -8 -7 -18t7 -18 l242 -241q7 -8 17.5 -8t17.5 8l375 375q7 7 7 17.5t-7 18.5l-139 139q-7 7 -17.5 7t-17.5 -7z" />
<glyph unicode="&#xe085;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM588 941q-29 0 -59 -5.5t-63 -20.5t-58 -38.5t-41.5 -63t-16.5 -89.5 q0 -25 20 -25h131q30 -5 35 11q6 20 20.5 28t45.5 8q20 0 31.5 -10.5t11.5 -28.5q0 -23 -7 -34t-26 -18q-1 0 -13.5 -4t-19.5 -7.5t-20 -10.5t-22 -17t-18.5 -24t-15.5 -35t-8 -46q-1 -8 5.5 -16.5t20.5 -8.5h173q7 0 22 8t35 28t37.5 48t29.5 74t12 100q0 47 -17 83 t-42.5 57t-59.5 34.5t-64 18t-59 4.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe086;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM675 1000h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5 t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5zM675 700h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h75v-200h-75q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h350q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5 t-17.5 7.5h-75v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe087;" d="M525 1200h150q10 0 17.5 -7.5t7.5 -17.5v-194q103 -27 178.5 -102.5t102.5 -178.5h194q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-194q-27 -103 -102.5 -178.5t-178.5 -102.5v-194q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v194 q-103 27 -178.5 102.5t-102.5 178.5h-194q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h194q27 103 102.5 178.5t178.5 102.5v194q0 10 7.5 17.5t17.5 7.5zM700 893v-168q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v168q-68 -23 -119 -74 t-74 -119h168q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-168q23 -68 74 -119t119 -74v168q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-168q68 23 119 74t74 119h-168q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h168 q-23 68 -74 119t-119 74z" />
<glyph unicode="&#xe088;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM759 823l64 -64q7 -7 7 -17.5t-7 -17.5l-124 -124l124 -124q7 -7 7 -17.5t-7 -17.5l-64 -64q-7 -7 -17.5 -7t-17.5 7l-124 124l-124 -124q-7 -7 -17.5 -7t-17.5 7l-64 64 q-7 7 -7 17.5t7 17.5l124 124l-124 124q-7 7 -7 17.5t7 17.5l64 64q7 7 17.5 7t17.5 -7l124 -124l124 124q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe089;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM782 788l106 -106q7 -7 7 -17.5t-7 -17.5l-320 -321q-8 -7 -18 -7t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l197 197q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe090;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5q0 -120 65 -225 l587 587q-105 65 -225 65zM965 819l-584 -584q104 -62 219 -62q116 0 214.5 57t155.5 155.5t57 214.5q0 115 -62 219z" />
<glyph unicode="&#xe091;" d="M39 582l522 427q16 13 27.5 8t11.5 -26v-291h550q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-550v-291q0 -21 -11.5 -26t-27.5 8l-522 427q-16 13 -16 32t16 32z" />
<glyph unicode="&#xe092;" d="M639 1009l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291h-550q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h550v291q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe093;" d="M682 1161l427 -522q13 -16 8 -27.5t-26 -11.5h-291v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v550h-291q-21 0 -26 11.5t8 27.5l427 522q13 16 32 16t32 -16z" />
<glyph unicode="&#xe094;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-550h291q21 0 26 -11.5t-8 -27.5l-427 -522q-13 -16 -32 -16t-32 16l-427 522q-13 16 -8 27.5t26 11.5h291v550q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe095;" d="M639 1109l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291q-94 -2 -182 -20t-170.5 -52t-147 -92.5t-100.5 -135.5q5 105 27 193.5t67.5 167t113 135t167 91.5t225.5 42v262q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe096;" d="M850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5zM350 0h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249 q8 7 18 7t18 -7l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5z" />
<glyph unicode="&#xe097;" d="M1014 1120l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249q8 7 18 7t18 -7zM250 600h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5z" />
<glyph unicode="&#xe101;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM704 900h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5 t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe102;" d="M260 1200q9 0 19 -2t15 -4l5 -2q22 -10 44 -23l196 -118q21 -13 36 -24q29 -21 37 -12q11 13 49 35l196 118q22 13 45 23q17 7 38 7q23 0 47 -16.5t37 -33.5l13 -16q14 -21 18 -45l25 -123l8 -44q1 -9 8.5 -14.5t17.5 -5.5h61q10 0 17.5 -7.5t7.5 -17.5v-50 q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 -7.5t-7.5 -17.5v-175h-400v300h-200v-300h-400v175q0 10 -7.5 17.5t-17.5 7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5h61q11 0 18 3t7 8q0 4 9 52l25 128q5 25 19 45q2 3 5 7t13.5 15t21.5 19.5t26.5 15.5 t29.5 7zM915 1079l-166 -162q-7 -7 -5 -12t12 -5h219q10 0 15 7t2 17l-51 149q-3 10 -11 12t-15 -6zM463 917l-177 157q-8 7 -16 5t-11 -12l-51 -143q-3 -10 2 -17t15 -7h231q11 0 12.5 5t-5.5 12zM500 0h-375q-10 0 -17.5 7.5t-7.5 17.5v375h400v-400zM1100 400v-375 q0 -10 -7.5 -17.5t-17.5 -7.5h-375v400h400z" />
<glyph unicode="&#xe103;" d="M1165 1190q8 3 21 -6.5t13 -17.5q-2 -178 -24.5 -323.5t-55.5 -245.5t-87 -174.5t-102.5 -118.5t-118 -68.5t-118.5 -33t-120 -4.5t-105 9.5t-90 16.5q-61 12 -78 11q-4 1 -12.5 0t-34 -14.5t-52.5 -40.5l-153 -153q-26 -24 -37 -14.5t-11 43.5q0 64 42 102q8 8 50.5 45 t66.5 58q19 17 35 47t13 61q-9 55 -10 102.5t7 111t37 130t78 129.5q39 51 80 88t89.5 63.5t94.5 45t113.5 36t129 31t157.5 37t182 47.5zM1116 1098q-8 9 -22.5 -3t-45.5 -50q-38 -47 -119 -103.5t-142 -89.5l-62 -33q-56 -30 -102 -57t-104 -68t-102.5 -80.5t-85.5 -91 t-64 -104.5q-24 -56 -31 -86t2 -32t31.5 17.5t55.5 59.5q25 30 94 75.5t125.5 77.5t147.5 81q70 37 118.5 69t102 79.5t99 111t86.5 148.5q22 50 24 60t-6 19z" />
<glyph unicode="&#xe104;" d="M653 1231q-39 -67 -54.5 -131t-10.5 -114.5t24.5 -96.5t47.5 -80t63.5 -62.5t68.5 -46.5t65 -30q-4 7 -17.5 35t-18.5 39.5t-17 39.5t-17 43t-13 42t-9.5 44.5t-2 42t4 43t13.5 39t23 38.5q96 -42 165 -107.5t105 -138t52 -156t13 -159t-19 -149.5q-13 -55 -44 -106.5 t-68 -87t-78.5 -64.5t-72.5 -45t-53 -22q-72 -22 -127 -11q-31 6 -13 19q6 3 17 7q13 5 32.5 21t41 44t38.5 63.5t21.5 81.5t-6.5 94.5t-50 107t-104 115.5q10 -104 -0.5 -189t-37 -140.5t-65 -93t-84 -52t-93.5 -11t-95 24.5q-80 36 -131.5 114t-53.5 171q-2 23 0 49.5 t4.5 52.5t13.5 56t27.5 60t46 64.5t69.5 68.5q-8 -53 -5 -102.5t17.5 -90t34 -68.5t44.5 -39t49 -2q31 13 38.5 36t-4.5 55t-29 64.5t-36 75t-26 75.5q-15 85 2 161.5t53.5 128.5t85.5 92.5t93.5 61t81.5 25.5z" />
<glyph unicode="&#xe105;" d="M600 1094q82 0 160.5 -22.5t140 -59t116.5 -82.5t94.5 -95t68 -95t42.5 -82.5t14 -57.5t-14 -57.5t-43 -82.5t-68.5 -95t-94.5 -95t-116.5 -82.5t-140 -59t-159.5 -22.5t-159.5 22.5t-140 59t-116.5 82.5t-94.5 95t-68.5 95t-43 82.5t-14 57.5t14 57.5t42.5 82.5t68 95 t94.5 95t116.5 82.5t140 59t160.5 22.5zM888 829q-15 15 -18 12t5 -22q25 -57 25 -119q0 -124 -88 -212t-212 -88t-212 88t-88 212q0 59 23 114q8 19 4.5 22t-17.5 -12q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q22 -36 47 -71t70 -82t92.5 -81t113 -58.5t133.5 -24.5 t133.5 24t113 58.5t92.5 81.5t70 81.5t47 70.5q11 18 9 42.5t-14 41.5q-90 117 -163 189zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l35 34q14 15 12.5 33.5t-16.5 33.5q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe106;" d="M592 0h-148l31 120q-91 20 -175.5 68.5t-143.5 106.5t-103.5 119t-66.5 110t-22 76q0 21 14 57.5t42.5 82.5t68 95t94.5 95t116.5 82.5t140 59t160.5 22.5q61 0 126 -15l32 121h148zM944 770l47 181q108 -85 176.5 -192t68.5 -159q0 -26 -19.5 -71t-59.5 -102t-93 -112 t-129 -104.5t-158 -75.5l46 173q77 49 136 117t97 131q11 18 9 42.5t-14 41.5q-54 70 -107 130zM310 824q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q18 -30 39 -60t57 -70.5t74 -73t90 -61t105 -41.5l41 154q-107 18 -178.5 101.5t-71.5 193.5q0 59 23 114q8 19 4.5 22 t-17.5 -12zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l12 11l22 86l-3 4q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe107;" d="M-90 100l642 1066q20 31 48 28.5t48 -35.5l642 -1056q21 -32 7.5 -67.5t-50.5 -35.5h-1294q-37 0 -50.5 34t7.5 66zM155 200h345v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h345l-445 723zM496 700h208q20 0 32 -14.5t8 -34.5l-58 -252 q-4 -20 -21.5 -34.5t-37.5 -14.5h-54q-20 0 -37.5 14.5t-21.5 34.5l-58 252q-4 20 8 34.5t32 14.5z" />
<glyph unicode="&#xe108;" d="M650 1200q62 0 106 -44t44 -106v-339l363 -325q15 -14 26 -38.5t11 -44.5v-41q0 -20 -12 -26.5t-29 5.5l-359 249v-263q100 -93 100 -113v-64q0 -21 -13 -29t-32 1l-205 128l-205 -128q-19 -9 -32 -1t-13 29v64q0 20 100 113v263l-359 -249q-17 -12 -29 -5.5t-12 26.5v41 q0 20 11 44.5t26 38.5l363 325v339q0 62 44 106t106 44z" />
<glyph unicode="&#xe109;" d="M850 1200h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-150h-1100v150q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5h100q21 0 35.5 -14.5t14.5 -35.5v-50h500v50q0 21 14.5 35.5t35.5 14.5zM1100 800v-750q0 -21 -14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v750h1100zM100 600v-100h100v100h-100zM300 600v-100h100v100h-100zM500 600v-100h100v100h-100zM700 600v-100h100v100h-100zM900 600v-100h100v100h-100zM100 400v-100h100v100h-100zM300 400v-100h100v100h-100zM500 400 v-100h100v100h-100zM700 400v-100h100v100h-100zM900 400v-100h100v100h-100zM100 200v-100h100v100h-100zM300 200v-100h100v100h-100zM500 200v-100h100v100h-100zM700 200v-100h100v100h-100zM900 200v-100h100v100h-100z" />
<glyph unicode="&#xe110;" d="M1135 1165l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-159l-600 -600h-291q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h209l600 600h241v150q0 21 10.5 25t24.5 -10zM522 819l-141 -141l-122 122h-209q-21 0 -35.5 14.5 t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h291zM1135 565l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-241l-181 181l141 141l122 -122h159v150q0 21 10.5 25t24.5 -10z" />
<glyph unicode="&#xe111;" d="M100 1100h1000q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-596l-304 -300v300h-100q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5z" />
<glyph unicode="&#xe112;" d="M150 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM850 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM1100 800v-300q0 -41 -3 -77.5t-15 -89.5t-32 -96t-58 -89t-89 -77t-129 -51t-174 -20t-174 20 t-129 51t-89 77t-58 89t-32 96t-15 89.5t-3 77.5v300h300v-250v-27v-42.5t1.5 -41t5 -38t10 -35t16.5 -30t25.5 -24.5t35 -19t46.5 -12t60 -4t60 4.5t46.5 12.5t35 19.5t25 25.5t17 30.5t10 35t5 38t2 40.5t-0.5 42v25v250h300z" />
<glyph unicode="&#xe113;" d="M1100 411l-198 -199l-353 353l-353 -353l-197 199l551 551z" />
<glyph unicode="&#xe114;" d="M1101 789l-550 -551l-551 551l198 199l353 -353l353 353z" />
<glyph unicode="&#xe115;" d="M404 1000h746q21 0 35.5 -14.5t14.5 -35.5v-551h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v401h-381zM135 984l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-400h385l215 -200h-750q-21 0 -35.5 14.5 t-14.5 35.5v550h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe116;" d="M56 1200h94q17 0 31 -11t18 -27l38 -162h896q24 0 39 -18.5t10 -42.5l-100 -475q-5 -21 -27 -42.5t-55 -21.5h-633l48 -200h535q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-50q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-300v-50 q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-31q-18 0 -32.5 10t-20.5 19l-5 10l-201 961h-54q-20 0 -35 14.5t-15 35.5t15 35.5t35 14.5z" />
<glyph unicode="&#xe117;" d="M1200 1000v-100h-1200v100h200q0 41 29.5 70.5t70.5 29.5h300q41 0 70.5 -29.5t29.5 -70.5h500zM0 800h1200v-800h-1200v800z" />
<glyph unicode="&#xe118;" d="M200 800l-200 -400v600h200q0 41 29.5 70.5t70.5 29.5h300q42 0 71 -29.5t29 -70.5h500v-200h-1000zM1500 700l-300 -700h-1200l300 700h1200z" />
<glyph unicode="&#xe119;" d="M635 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-601h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v601h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe120;" d="M936 864l249 -229q14 -15 14 -35.5t-14 -35.5l-249 -229q-15 -15 -25.5 -10.5t-10.5 24.5v151h-600v-151q0 -20 -10.5 -24.5t-25.5 10.5l-249 229q-14 15 -14 35.5t14 35.5l249 229q15 15 25.5 10.5t10.5 -25.5v-149h600v149q0 21 10.5 25.5t25.5 -10.5z" />
<glyph unicode="&#xe121;" d="M1169 400l-172 732q-5 23 -23 45.5t-38 22.5h-672q-20 0 -38 -20t-23 -41l-172 -739h1138zM1100 300h-1000q-41 0 -70.5 -29.5t-29.5 -70.5v-100q0 -41 29.5 -70.5t70.5 -29.5h1000q41 0 70.5 29.5t29.5 70.5v100q0 41 -29.5 70.5t-70.5 29.5zM800 100v100h100v-100h-100 zM1000 100v100h100v-100h-100z" />
<glyph unicode="&#xe122;" d="M1150 1100q21 0 35.5 -14.5t14.5 -35.5v-850q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v850q0 21 14.5 35.5t35.5 14.5zM1000 200l-675 200h-38l47 -276q3 -16 -5.5 -20t-29.5 -4h-7h-84q-20 0 -34.5 14t-18.5 35q-55 337 -55 351v250v6q0 16 1 23.5t6.5 14 t17.5 6.5h200l675 250v-850zM0 750v-250q-4 0 -11 0.5t-24 6t-30 15t-24 30t-11 48.5v50q0 26 10.5 46t25 30t29 16t25.5 7z" />
<glyph unicode="&#xe123;" d="M553 1200h94q20 0 29 -10.5t3 -29.5l-18 -37q83 -19 144 -82.5t76 -140.5l63 -327l118 -173h17q19 0 33 -14.5t14 -35t-13 -40.5t-31 -27q-8 -4 -23 -9.5t-65 -19.5t-103 -25t-132.5 -20t-158.5 -9q-57 0 -115 5t-104 12t-88.5 15.5t-73.5 17.5t-54.5 16t-35.5 12l-11 4 q-18 8 -31 28t-13 40.5t14 35t33 14.5h17l118 173l63 327q15 77 76 140t144 83l-18 32q-6 19 3.5 32t28.5 13zM498 110q50 -6 102 -6q53 0 102 6q-12 -49 -39.5 -79.5t-62.5 -30.5t-63 30.5t-39 79.5z" />
<glyph unicode="&#xe124;" d="M800 946l224 78l-78 -224l234 -45l-180 -155l180 -155l-234 -45l78 -224l-224 78l-45 -234l-155 180l-155 -180l-45 234l-224 -78l78 224l-234 45l180 155l-180 155l234 45l-78 224l224 -78l45 234l155 -180l155 180z" />
<glyph unicode="&#xe125;" d="M650 1200h50q40 0 70 -40.5t30 -84.5v-150l-28 -125h328q40 0 70 -40.5t30 -84.5v-100q0 -45 -29 -74l-238 -344q-16 -24 -38 -40.5t-45 -16.5h-250q-7 0 -42 25t-66 50l-31 25h-61q-45 0 -72.5 18t-27.5 57v400q0 36 20 63l145 196l96 198q13 28 37.5 48t51.5 20z M650 1100l-100 -212l-150 -213v-375h100l136 -100h214l250 375v125h-450l50 225v175h-50zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe126;" d="M600 1100h250q23 0 45 -16.5t38 -40.5l238 -344q29 -29 29 -74v-100q0 -44 -30 -84.5t-70 -40.5h-328q28 -118 28 -125v-150q0 -44 -30 -84.5t-70 -40.5h-50q-27 0 -51.5 20t-37.5 48l-96 198l-145 196q-20 27 -20 63v400q0 39 27.5 57t72.5 18h61q124 100 139 100z M50 1000h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM636 1000l-136 -100h-100v-375l150 -213l100 -212h50v175l-50 225h450v125l-250 375h-214z" />
<glyph unicode="&#xe127;" d="M356 873l363 230q31 16 53 -6l110 -112q13 -13 13.5 -32t-11.5 -34l-84 -121h302q84 0 138 -38t54 -110t-55 -111t-139 -39h-106l-131 -339q-6 -21 -19.5 -41t-28.5 -20h-342q-7 0 -90 81t-83 94v525q0 17 14 35.5t28 28.5zM400 792v-503l100 -89h293l131 339 q6 21 19.5 41t28.5 20h203q21 0 30.5 25t0.5 50t-31 25h-456h-7h-6h-5.5t-6 0.5t-5 1.5t-5 2t-4 2.5t-4 4t-2.5 4.5q-12 25 5 47l146 183l-86 83zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe128;" d="M475 1103l366 -230q2 -1 6 -3.5t14 -10.5t18 -16.5t14.5 -20t6.5 -22.5v-525q0 -13 -86 -94t-93 -81h-342q-15 0 -28.5 20t-19.5 41l-131 339h-106q-85 0 -139.5 39t-54.5 111t54 110t138 38h302l-85 121q-11 15 -10.5 34t13.5 32l110 112q22 22 53 6zM370 945l146 -183 q17 -22 5 -47q-2 -2 -3.5 -4.5t-4 -4t-4 -2.5t-5 -2t-5 -1.5t-6 -0.5h-6h-6.5h-6h-475v-100h221q15 0 29 -20t20 -41l130 -339h294l106 89v503l-342 236zM1050 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5 v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe129;" d="M550 1294q72 0 111 -55t39 -139v-106l339 -131q21 -6 41 -19.5t20 -28.5v-342q0 -7 -81 -90t-94 -83h-525q-17 0 -35.5 14t-28.5 28l-9 14l-230 363q-16 31 6 53l112 110q13 13 32 13.5t34 -11.5l121 -84v302q0 84 38 138t110 54zM600 972v203q0 21 -25 30.5t-50 0.5 t-25 -31v-456v-7v-6v-5.5t-0.5 -6t-1.5 -5t-2 -5t-2.5 -4t-4 -4t-4.5 -2.5q-25 -12 -47 5l-183 146l-83 -86l236 -339h503l89 100v293l-339 131q-21 6 -41 19.5t-20 28.5zM450 200h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe130;" d="M350 1100h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5zM600 306v-106q0 -84 -39 -139t-111 -55t-110 54t-38 138v302l-121 -84q-15 -12 -34 -11.5t-32 13.5l-112 110 q-22 22 -6 53l230 363q1 2 3.5 6t10.5 13.5t16.5 17t20 13.5t22.5 6h525q13 0 94 -83t81 -90v-342q0 -15 -20 -28.5t-41 -19.5zM308 900l-236 -339l83 -86l183 146q22 17 47 5q2 -1 4.5 -2.5t4 -4t2.5 -4t2 -5t1.5 -5t0.5 -6v-5.5v-6v-7v-456q0 -22 25 -31t50 0.5t25 30.5 v203q0 15 20 28.5t41 19.5l339 131v293l-89 100h-503z" />
<glyph unicode="&#xe131;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM914 632l-275 223q-16 13 -27.5 8t-11.5 -26v-137h-275 q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h275v-137q0 -21 11.5 -26t27.5 8l275 223q16 13 16 32t-16 32z" />
<glyph unicode="&#xe132;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM561 855l-275 -223q-16 -13 -16 -32t16 -32l275 -223q16 -13 27.5 -8 t11.5 26v137h275q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5h-275v137q0 21 -11.5 26t-27.5 -8z" />
<glyph unicode="&#xe133;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM855 639l-223 275q-13 16 -32 16t-32 -16l-223 -275q-13 -16 -8 -27.5 t26 -11.5h137v-275q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v275h137q21 0 26 11.5t-8 27.5z" />
<glyph unicode="&#xe134;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM675 900h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-275h-137q-21 0 -26 -11.5 t8 -27.5l223 -275q13 -16 32 -16t32 16l223 275q13 16 8 27.5t-26 11.5h-137v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe135;" d="M600 1176q116 0 222.5 -46t184 -123.5t123.5 -184t46 -222.5t-46 -222.5t-123.5 -184t-184 -123.5t-222.5 -46t-222.5 46t-184 123.5t-123.5 184t-46 222.5t46 222.5t123.5 184t184 123.5t222.5 46zM627 1101q-15 -12 -36.5 -20.5t-35.5 -12t-43 -8t-39 -6.5 q-15 -3 -45.5 0t-45.5 -2q-20 -7 -51.5 -26.5t-34.5 -34.5q-3 -11 6.5 -22.5t8.5 -18.5q-3 -34 -27.5 -91t-29.5 -79q-9 -34 5 -93t8 -87q0 -9 17 -44.5t16 -59.5q12 0 23 -5t23.5 -15t19.5 -14q16 -8 33 -15t40.5 -15t34.5 -12q21 -9 52.5 -32t60 -38t57.5 -11 q7 -15 -3 -34t-22.5 -40t-9.5 -38q13 -21 23 -34.5t27.5 -27.5t36.5 -18q0 -7 -3.5 -16t-3.5 -14t5 -17q104 -2 221 112q30 29 46.5 47t34.5 49t21 63q-13 8 -37 8.5t-36 7.5q-15 7 -49.5 15t-51.5 19q-18 0 -41 -0.5t-43 -1.5t-42 -6.5t-38 -16.5q-51 -35 -66 -12 q-4 1 -3.5 25.5t0.5 25.5q-6 13 -26.5 17.5t-24.5 6.5q1 15 -0.5 30.5t-7 28t-18.5 11.5t-31 -21q-23 -25 -42 4q-19 28 -8 58q6 16 22 22q6 -1 26 -1.5t33.5 -4t19.5 -13.5q7 -12 18 -24t21.5 -20.5t20 -15t15.5 -10.5l5 -3q2 12 7.5 30.5t8 34.5t-0.5 32q-3 18 3.5 29 t18 22.5t15.5 24.5q6 14 10.5 35t8 31t15.5 22.5t34 22.5q-6 18 10 36q8 0 24 -1.5t24.5 -1.5t20 4.5t20.5 15.5q-10 23 -31 42.5t-37.5 29.5t-49 27t-43.5 23q0 1 2 8t3 11.5t1.5 10.5t-1 9.5t-4.5 4.5q31 -13 58.5 -14.5t38.5 2.5l12 5q5 28 -9.5 46t-36.5 24t-50 15 t-41 20q-18 -4 -37 0zM613 994q0 -17 8 -42t17 -45t9 -23q-8 1 -39.5 5.5t-52.5 10t-37 16.5q3 11 16 29.5t16 25.5q10 -10 19 -10t14 6t13.5 14.5t16.5 12.5z" />
<glyph unicode="&#xe136;" d="M756 1157q164 92 306 -9l-259 -138l145 -232l251 126q6 -89 -34 -156.5t-117 -110.5q-60 -34 -127 -39.5t-126 16.5l-596 -596q-15 -16 -36.5 -16t-36.5 16l-111 110q-15 15 -15 36.5t15 37.5l600 599q-34 101 5.5 201.5t135.5 154.5z" />
<glyph unicode="&#xe137;" horiz-adv-x="1220" d="M100 1196h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 1096h-200v-100h200v100zM100 796h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 696h-500v-100h500v100zM100 396h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 296h-300v-100h300v100z " />
<glyph unicode="&#xe138;" d="M150 1200h900q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM700 500v-300l-200 -200v500l-350 500h900z" />
<glyph unicode="&#xe139;" d="M500 1200h200q41 0 70.5 -29.5t29.5 -70.5v-100h300q41 0 70.5 -29.5t29.5 -70.5v-400h-500v100h-200v-100h-500v400q0 41 29.5 70.5t70.5 29.5h300v100q0 41 29.5 70.5t70.5 29.5zM500 1100v-100h200v100h-200zM1200 400v-200q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v200h1200z" />
<glyph unicode="&#xe140;" d="M50 1200h300q21 0 25 -10.5t-10 -24.5l-94 -94l199 -199q7 -8 7 -18t-7 -18l-106 -106q-8 -7 -18 -7t-18 7l-199 199l-94 -94q-14 -14 -24.5 -10t-10.5 25v300q0 21 14.5 35.5t35.5 14.5zM850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-199 -199q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l199 199l-94 94q-14 14 -10 24.5t25 10.5zM364 470l106 -106q7 -8 7 -18t-7 -18l-199 -199l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l199 199 q8 7 18 7t18 -7zM1071 271l94 94q14 14 24.5 10t10.5 -25v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -25 10.5t10 24.5l94 94l-199 199q-7 8 -7 18t7 18l106 106q8 7 18 7t18 -7z" />
<glyph unicode="&#xe141;" d="M596 1192q121 0 231.5 -47.5t190 -127t127 -190t47.5 -231.5t-47.5 -231.5t-127 -190.5t-190 -127t-231.5 -47t-231.5 47t-190.5 127t-127 190.5t-47 231.5t47 231.5t127 190t190.5 127t231.5 47.5zM596 1010q-112 0 -207.5 -55.5t-151 -151t-55.5 -207.5t55.5 -207.5 t151 -151t207.5 -55.5t207.5 55.5t151 151t55.5 207.5t-55.5 207.5t-151 151t-207.5 55.5zM454.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38.5 -16.5t-38.5 16.5t-16 39t16 38.5t38.5 16zM754.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38 -16.5q-14 0 -29 10l-55 -145 q17 -23 17 -51q0 -36 -25.5 -61.5t-61.5 -25.5t-61.5 25.5t-25.5 61.5q0 32 20.5 56.5t51.5 29.5l122 126l1 1q-9 14 -9 28q0 23 16 39t38.5 16zM345.5 709q22.5 0 38.5 -16t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16zM854.5 709q22.5 0 38.5 -16 t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16z" />
<glyph unicode="&#xe142;" d="M546 173l469 470q91 91 99 192q7 98 -52 175.5t-154 94.5q-22 4 -47 4q-34 0 -66.5 -10t-56.5 -23t-55.5 -38t-48 -41.5t-48.5 -47.5q-376 -375 -391 -390q-30 -27 -45 -41.5t-37.5 -41t-32 -46.5t-16 -47.5t-1.5 -56.5q9 -62 53.5 -95t99.5 -33q74 0 125 51l548 548 q36 36 20 75q-7 16 -21.5 26t-32.5 10q-26 0 -50 -23q-13 -12 -39 -38l-341 -338q-15 -15 -35.5 -15.5t-34.5 13.5t-14 34.5t14 34.5q327 333 361 367q35 35 67.5 51.5t78.5 16.5q14 0 29 -1q44 -8 74.5 -35.5t43.5 -68.5q14 -47 2 -96.5t-47 -84.5q-12 -11 -32 -32 t-79.5 -81t-114.5 -115t-124.5 -123.5t-123 -119.5t-96.5 -89t-57 -45q-56 -27 -120 -27q-70 0 -129 32t-93 89q-48 78 -35 173t81 163l511 511q71 72 111 96q91 55 198 55q80 0 152 -33q78 -36 129.5 -103t66.5 -154q17 -93 -11 -183.5t-94 -156.5l-482 -476 q-15 -15 -36 -16t-37 14t-17.5 34t14.5 35z" />
<glyph unicode="&#xe143;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104zM896 972q-33 0 -64.5 -19t-56.5 -46t-47.5 -53.5t-43.5 -45.5t-37.5 -19t-36 19t-40 45.5t-43 53.5t-54 46t-65.5 19q-67 0 -122.5 -55.5t-55.5 -132.5q0 -23 13.5 -51t46 -65t57.5 -63t76 -75l22 -22q15 -14 44 -44t50.5 -51t46 -44t41 -35t23 -12 t23.5 12t42.5 36t46 44t52.5 52t44 43q4 4 12 13q43 41 63.5 62t52 55t46 55t26 46t11.5 44q0 79 -53 133.5t-120 54.5z" />
<glyph unicode="&#xe144;" d="M776.5 1214q93.5 0 159.5 -66l141 -141q66 -66 66 -160q0 -42 -28 -95.5t-62 -87.5l-29 -29q-31 53 -77 99l-18 18l95 95l-247 248l-389 -389l212 -212l-105 -106l-19 18l-141 141q-66 66 -66 159t66 159l283 283q65 66 158.5 66zM600 706l105 105q10 -8 19 -17l141 -141 q66 -66 66 -159t-66 -159l-283 -283q-66 -66 -159 -66t-159 66l-141 141q-66 66 -66 159.5t66 159.5l55 55q29 -55 75 -102l18 -17l-95 -95l247 -248l389 389z" />
<glyph unicode="&#xe145;" d="M603 1200q85 0 162 -15t127 -38t79 -48t29 -46v-953q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-41 0 -70.5 29.5t-29.5 70.5v953q0 21 30 46.5t81 48t129 37.5t163 15zM300 1000v-700h600v700h-600zM600 254q-43 0 -73.5 -30.5t-30.5 -73.5t30.5 -73.5t73.5 -30.5t73.5 30.5 t30.5 73.5t-30.5 73.5t-73.5 30.5z" />
<glyph unicode="&#xe146;" d="M902 1185l283 -282q15 -15 15 -36t-14.5 -35.5t-35.5 -14.5t-35 15l-36 35l-279 -267v-300l-212 210l-308 -307l-280 -203l203 280l307 308l-210 212h300l267 279l-35 36q-15 14 -15 35t14.5 35.5t35.5 14.5t35 -15z" />
<glyph unicode="&#xe148;" d="M700 1248v-78q38 -5 72.5 -14.5t75.5 -31.5t71 -53.5t52 -84t24 -118.5h-159q-4 36 -10.5 59t-21 45t-40 35.5t-64.5 20.5v-307l64 -13q34 -7 64 -16.5t70 -32t67.5 -52.5t47.5 -80t20 -112q0 -139 -89 -224t-244 -97v-77h-100v79q-150 16 -237 103q-40 40 -52.5 93.5 t-15.5 139.5h139q5 -77 48.5 -126t117.5 -65v335l-27 8q-46 14 -79 26.5t-72 36t-63 52t-40 72.5t-16 98q0 70 25 126t67.5 92t94.5 57t110 27v77h100zM600 754v274q-29 -4 -50 -11t-42 -21.5t-31.5 -41.5t-10.5 -65q0 -29 7 -50.5t16.5 -34t28.5 -22.5t31.5 -14t37.5 -10 q9 -3 13 -4zM700 547v-310q22 2 42.5 6.5t45 15.5t41.5 27t29 42t12 59.5t-12.5 59.5t-38 44.5t-53 31t-66.5 24.5z" />
<glyph unicode="&#xe149;" d="M561 1197q84 0 160.5 -40t123.5 -109.5t47 -147.5h-153q0 40 -19.5 71.5t-49.5 48.5t-59.5 26t-55.5 9q-37 0 -79 -14.5t-62 -35.5q-41 -44 -41 -101q0 -26 13.5 -63t26.5 -61t37 -66q6 -9 9 -14h241v-100h-197q8 -50 -2.5 -115t-31.5 -95q-45 -62 -99 -112 q34 10 83 17.5t71 7.5q32 1 102 -16t104 -17q83 0 136 30l50 -147q-31 -19 -58 -30.5t-55 -15.5t-42 -4.5t-46 -0.5q-23 0 -76 17t-111 32.5t-96 11.5q-39 -3 -82 -16t-67 -25l-23 -11l-55 145q4 3 16 11t15.5 10.5t13 9t15.5 12t14.5 14t17.5 18.5q48 55 54 126.5 t-30 142.5h-221v100h166q-23 47 -44 104q-7 20 -12 41.5t-6 55.5t6 66.5t29.5 70.5t58.5 71q97 88 263 88z" />
<glyph unicode="&#xe150;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM935 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-900h-200v900h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe151;" d="M1000 700h-100v100h-100v-100h-100v500h300v-500zM400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM801 1100v-200h100v200h-100zM1000 350l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150z " />
<glyph unicode="&#xe152;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 1050l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150zM1000 0h-100v100h-100v-100h-100v500h300v-500zM801 400v-200h100v200h-100z " />
<glyph unicode="&#xe153;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 700h-100v400h-100v100h200v-500zM1100 0h-100v100h-200v400h300v-500zM901 400v-200h100v200h-100z" />
<glyph unicode="&#xe154;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1100 700h-100v100h-200v400h300v-500zM901 1100v-200h100v200h-100zM1000 0h-100v400h-100v100h200v-500z" />
<glyph unicode="&#xe155;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM900 1000h-200v200h200v-200zM1000 700h-300v200h300v-200zM1100 400h-400v200h400v-200zM1200 100h-500v200h500v-200z" />
<glyph unicode="&#xe156;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1200 1000h-500v200h500v-200zM1100 700h-400v200h400v-200zM1000 400h-300v200h300v-200zM900 100h-200v200h200v-200z" />
<glyph unicode="&#xe157;" d="M350 1100h400q162 0 256 -93.5t94 -256.5v-400q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5z" />
<glyph unicode="&#xe158;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-163 0 -256.5 92.5t-93.5 257.5v400q0 163 94 256.5t256 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM440 770l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe159;" d="M350 1100h400q163 0 256.5 -94t93.5 -256v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 163 92.5 256.5t257.5 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM350 700h400q21 0 26.5 -12t-6.5 -28l-190 -253q-12 -17 -30 -17t-30 17l-190 253q-12 16 -6.5 28t26.5 12z" />
<glyph unicode="&#xe160;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -163 -92.5 -256.5t-257.5 -93.5h-400q-163 0 -256.5 94t-93.5 256v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM580 693l190 -253q12 -16 6.5 -28t-26.5 -12h-400q-21 0 -26.5 12t6.5 28l190 253q12 17 30 17t30 -17z" />
<glyph unicode="&#xe161;" d="M550 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h450q41 0 70.5 29.5t29.5 70.5v500q0 41 -29.5 70.5t-70.5 29.5h-450q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM338 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe162;" d="M793 1182l9 -9q8 -10 5 -27q-3 -11 -79 -225.5t-78 -221.5l300 1q24 0 32.5 -17.5t-5.5 -35.5q-1 0 -133.5 -155t-267 -312.5t-138.5 -162.5q-12 -15 -26 -15h-9l-9 8q-9 11 -4 32q2 9 42 123.5t79 224.5l39 110h-302q-23 0 -31 19q-10 21 6 41q75 86 209.5 237.5 t228 257t98.5 111.5q9 16 25 16h9z" />
<glyph unicode="&#xe163;" d="M350 1100h400q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-450q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h450q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400 q0 165 92.5 257.5t257.5 92.5zM938 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe164;" d="M750 1200h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -10.5 -25t-24.5 10l-109 109l-312 -312q-15 -15 -35.5 -15t-35.5 15l-141 141q-15 15 -15 35.5t15 35.5l312 312l-109 109q-14 14 -10 24.5t25 10.5zM456 900h-156q-41 0 -70.5 -29.5t-29.5 -70.5v-500 q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v148l200 200v-298q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5h300z" />
<glyph unicode="&#xe165;" d="M600 1186q119 0 227.5 -46.5t187 -125t125 -187t46.5 -227.5t-46.5 -227.5t-125 -187t-187 -125t-227.5 -46.5t-227.5 46.5t-187 125t-125 187t-46.5 227.5t46.5 227.5t125 187t187 125t227.5 46.5zM600 1022q-115 0 -212 -56.5t-153.5 -153.5t-56.5 -212t56.5 -212 t153.5 -153.5t212 -56.5t212 56.5t153.5 153.5t56.5 212t-56.5 212t-153.5 153.5t-212 56.5zM600 794q80 0 137 -57t57 -137t-57 -137t-137 -57t-137 57t-57 137t57 137t137 57z" />
<glyph unicode="&#xe166;" d="M450 1200h200q21 0 35.5 -14.5t14.5 -35.5v-350h245q20 0 25 -11t-9 -26l-383 -426q-14 -15 -33.5 -15t-32.5 15l-379 426q-13 15 -8.5 26t25.5 11h250v350q0 21 14.5 35.5t35.5 14.5zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe167;" d="M583 1182l378 -435q14 -15 9 -31t-26 -16h-244v-250q0 -20 -17 -35t-39 -15h-200q-20 0 -32 14.5t-12 35.5v250h-250q-20 0 -25.5 16.5t8.5 31.5l383 431q14 16 33.5 17t33.5 -14zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe168;" d="M396 723l369 369q7 7 17.5 7t17.5 -7l139 -139q7 -8 7 -18.5t-7 -17.5l-525 -525q-7 -8 -17.5 -8t-17.5 8l-292 291q-7 8 -7 18t7 18l139 139q8 7 18.5 7t17.5 -7zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50 h-100z" />
<glyph unicode="&#xe169;" d="M135 1023l142 142q14 14 35 14t35 -14l77 -77l-212 -212l-77 76q-14 15 -14 36t14 35zM655 855l210 210q14 14 24.5 10t10.5 -25l-2 -599q-1 -20 -15.5 -35t-35.5 -15l-597 -1q-21 0 -25 10.5t10 24.5l208 208l-154 155l212 212zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5 v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe170;" d="M350 1200l599 -2q20 -1 35 -15.5t15 -35.5l1 -597q0 -21 -10.5 -25t-24.5 10l-208 208l-155 -154l-212 212l155 154l-210 210q-14 14 -10 24.5t25 10.5zM524 512l-76 -77q-15 -14 -36 -14t-35 14l-142 142q-14 14 -14 35t14 35l77 77zM50 300h1000q21 0 35.5 -14.5 t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe171;" d="M1200 103l-483 276l-314 -399v423h-399l1196 796v-1096zM483 424v-230l683 953z" />
<glyph unicode="&#xe172;" d="M1100 1000v-850q0 -21 -14.5 -35.5t-35.5 -14.5h-150v400h-700v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200z" />
<glyph unicode="&#xe173;" d="M1100 1000l-2 -149l-299 -299l-95 95q-9 9 -21.5 9t-21.5 -9l-149 -147h-312v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1132 638l106 -106q7 -7 7 -17.5t-7 -17.5l-420 -421q-8 -7 -18 -7 t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l297 297q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe174;" d="M1100 1000v-269l-103 -103l-134 134q-15 15 -33.5 16.5t-34.5 -12.5l-266 -266h-329v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1202 572l70 -70q15 -15 15 -35.5t-15 -35.5l-131 -131 l131 -131q15 -15 15 -35.5t-15 -35.5l-70 -70q-15 -15 -35.5 -15t-35.5 15l-131 131l-131 -131q-15 -15 -35.5 -15t-35.5 15l-70 70q-15 15 -15 35.5t15 35.5l131 131l-131 131q-15 15 -15 35.5t15 35.5l70 70q15 15 35.5 15t35.5 -15l131 -131l131 131q15 15 35.5 15 t35.5 -15z" />
<glyph unicode="&#xe175;" d="M1100 1000v-300h-350q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-500v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM850 600h100q21 0 35.5 -14.5t14.5 -35.5v-250h150q21 0 25 -10.5t-10 -24.5 l-230 -230q-14 -14 -35 -14t-35 14l-230 230q-14 14 -10 24.5t25 10.5h150v250q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe176;" d="M1100 1000v-400l-165 165q-14 15 -35 15t-35 -15l-263 -265h-402v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM935 565l230 -229q14 -15 10 -25.5t-25 -10.5h-150v-250q0 -20 -14.5 -35 t-35.5 -15h-100q-21 0 -35.5 15t-14.5 35v250h-150q-21 0 -25 10.5t10 25.5l230 229q14 15 35 15t35 -15z" />
<glyph unicode="&#xe177;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-150h-1200v150q0 21 14.5 35.5t35.5 14.5zM1200 800v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v550h1200zM100 500v-200h400v200h-400z" />
<glyph unicode="&#xe178;" d="M935 1165l248 -230q14 -14 14 -35t-14 -35l-248 -230q-14 -14 -24.5 -10t-10.5 25v150h-400v200h400v150q0 21 10.5 25t24.5 -10zM200 800h-50q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v-200zM400 800h-100v200h100v-200zM18 435l247 230 q14 14 24.5 10t10.5 -25v-150h400v-200h-400v-150q0 -21 -10.5 -25t-24.5 10l-247 230q-15 14 -15 35t15 35zM900 300h-100v200h100v-200zM1000 500h51q20 0 34.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-34.5 -14.5h-51v200z" />
<glyph unicode="&#xe179;" d="M862 1073l276 116q25 18 43.5 8t18.5 -41v-1106q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v397q-4 1 -11 5t-24 17.5t-30 29t-24 42t-11 56.5v359q0 31 18.5 65t43.5 52zM550 1200q22 0 34.5 -12.5t14.5 -24.5l1 -13v-450q0 -28 -10.5 -59.5 t-25 -56t-29 -45t-25.5 -31.5l-10 -11v-447q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v447q-4 4 -11 11.5t-24 30.5t-30 46t-24 55t-11 60v450q0 2 0.5 5.5t4 12t8.5 15t14.5 12t22.5 5.5q20 0 32.5 -12.5t14.5 -24.5l3 -13v-350h100v350v5.5t2.5 12 t7 15t15 12t25.5 5.5q23 0 35.5 -12.5t13.5 -24.5l1 -13v-350h100v350q0 2 0.5 5.5t3 12t7 15t15 12t24.5 5.5z" />
<glyph unicode="&#xe180;" d="M1200 1100v-56q-4 0 -11 -0.5t-24 -3t-30 -7.5t-24 -15t-11 -24v-888q0 -22 25 -34.5t50 -13.5l25 -2v-56h-400v56q75 0 87.5 6.5t12.5 43.5v394h-500v-394q0 -37 12.5 -43.5t87.5 -6.5v-56h-400v56q4 0 11 0.5t24 3t30 7.5t24 15t11 24v888q0 22 -25 34.5t-50 13.5 l-25 2v56h400v-56q-75 0 -87.5 -6.5t-12.5 -43.5v-394h500v394q0 37 -12.5 43.5t-87.5 6.5v56h400z" />
<glyph unicode="&#xe181;" d="M675 1000h375q21 0 35.5 -14.5t14.5 -35.5v-150h-105l-295 -98v98l-200 200h-400l100 100h375zM100 900h300q41 0 70.5 -29.5t29.5 -70.5v-500q0 -41 -29.5 -70.5t-70.5 -29.5h-300q-41 0 -70.5 29.5t-29.5 70.5v500q0 41 29.5 70.5t70.5 29.5zM100 800v-200h300v200 h-300zM1100 535l-400 -133v163l400 133v-163zM100 500v-200h300v200h-300zM1100 398v-248q0 -21 -14.5 -35.5t-35.5 -14.5h-375l-100 -100h-375l-100 100h400l200 200h105z" />
<glyph unicode="&#xe182;" d="M17 1007l162 162q17 17 40 14t37 -22l139 -194q14 -20 11 -44.5t-20 -41.5l-119 -118q102 -142 228 -268t267 -227l119 118q17 17 42.5 19t44.5 -12l192 -136q19 -14 22.5 -37.5t-13.5 -40.5l-163 -162q-3 -1 -9.5 -1t-29.5 2t-47.5 6t-62.5 14.5t-77.5 26.5t-90 42.5 t-101.5 60t-111 83t-119 108.5q-74 74 -133.5 150.5t-94.5 138.5t-60 119.5t-34.5 100t-15 74.5t-4.5 48z" />
<glyph unicode="&#xe183;" d="M600 1100q92 0 175 -10.5t141.5 -27t108.5 -36.5t81.5 -40t53.5 -37t31 -27l9 -10v-200q0 -21 -14.5 -33t-34.5 -9l-202 34q-20 3 -34.5 20t-14.5 38v146q-141 24 -300 24t-300 -24v-146q0 -21 -14.5 -38t-34.5 -20l-202 -34q-20 -3 -34.5 9t-14.5 33v200q3 4 9.5 10.5 t31 26t54 37.5t80.5 39.5t109 37.5t141 26.5t175 10.5zM600 795q56 0 97 -9.5t60 -23.5t30 -28t12 -24l1 -10v-50l365 -303q14 -15 24.5 -40t10.5 -45v-212q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v212q0 20 10.5 45t24.5 40l365 303v50 q0 4 1 10.5t12 23t30 29t60 22.5t97 10z" />
<glyph unicode="&#xe184;" d="M1100 700l-200 -200h-600l-200 200v500h200v-200h200v200h200v-200h200v200h200v-500zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5 t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe185;" d="M700 1100h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-1000h300v1000q0 41 -29.5 70.5t-70.5 29.5zM1100 800h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-700h300v700q0 41 -29.5 70.5t-70.5 29.5zM400 0h-300v400q0 41 29.5 70.5t70.5 29.5h100q41 0 70.5 -29.5t29.5 -70.5v-400z " />
<glyph unicode="&#xe186;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe187;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 300h-100v200h-100v-200h-100v500h100v-200h100v200h100v-500zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe188;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-300h200v-100h-300v500h300v-100zM900 700h-200v-300h200v-100h-300v500h300v-100z" />
<glyph unicode="&#xe189;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 400l-300 150l300 150v-300zM900 550l-300 -150v300z" />
<glyph unicode="&#xe190;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM900 300h-700v500h700v-500zM800 700h-130q-38 0 -66.5 -43t-28.5 -108t27 -107t68 -42h130v300zM300 700v-300 h130q41 0 68 42t27 107t-28.5 108t-66.5 43h-130z" />
<glyph unicode="&#xe191;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 300h-100v400h-100v100h200v-500z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe192;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM300 700h200v-400h-300v500h100v-100zM900 300h-100v400h-100v100h200v-500zM300 600v-200h100v200h-100z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe193;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 500l-199 -200h-100v50l199 200v150h-200v100h300v-300zM900 300h-100v400h-100v100h200v-500zM701 300h-100 v100h100v-100z" />
<glyph unicode="&#xe194;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700h-300v-200h300v-100h-300l-100 100v200l100 100h300v-100z" />
<glyph unicode="&#xe195;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700v-100l-50 -50l100 -100v-50h-100l-100 100h-150v-100h-100v400h300zM500 700v-100h200v100h-200z" />
<glyph unicode="&#xe197;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -207t-85 -207t-205 -86.5h-128v250q0 21 -14.5 35.5t-35.5 14.5h-300q-21 0 -35.5 -14.5t-14.5 -35.5v-250h-222q-80 0 -136 57.5t-56 136.5q0 69 43 122.5t108 67.5q-2 19 -2 37q0 100 49 185 t134 134t185 49zM525 500h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -244q-13 -16 -32 -16t-32 16l-223 244q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe198;" d="M502 1089q110 0 201 -59.5t135 -156.5q43 15 89 15q121 0 206 -86.5t86 -206.5q0 -99 -60 -181t-150 -110l-378 360q-13 16 -31.5 16t-31.5 -16l-381 -365h-9q-79 0 -135.5 57.5t-56.5 136.5q0 69 43 122.5t108 67.5q-2 19 -2 38q0 100 49 184.5t133.5 134t184.5 49.5z M632 467l223 -228q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5q199 204 223 228q19 19 31.5 19t32.5 -19z" />
<glyph unicode="&#xe199;" d="M700 100v100h400l-270 300h170l-270 300h170l-300 333l-300 -333h170l-270 -300h170l-270 -300h400v-100h-50q-21 0 -35.5 -14.5t-14.5 -35.5v-50h400v50q0 21 -14.5 35.5t-35.5 14.5h-50z" />
<glyph unicode="&#xe200;" d="M600 1179q94 0 167.5 -56.5t99.5 -145.5q89 -6 150.5 -71.5t61.5 -155.5q0 -61 -29.5 -112.5t-79.5 -82.5q9 -29 9 -55q0 -74 -52.5 -126.5t-126.5 -52.5q-55 0 -100 30v-251q21 0 35.5 -14.5t14.5 -35.5v-50h-300v50q0 21 14.5 35.5t35.5 14.5v251q-45 -30 -100 -30 q-74 0 -126.5 52.5t-52.5 126.5q0 18 4 38q-47 21 -75.5 65t-28.5 97q0 74 52.5 126.5t126.5 52.5q5 0 23 -2q0 2 -1 10t-1 13q0 116 81.5 197.5t197.5 81.5z" />
<glyph unicode="&#xe201;" d="M1010 1010q111 -111 150.5 -260.5t0 -299t-150.5 -260.5q-83 -83 -191.5 -126.5t-218.5 -43.5t-218.5 43.5t-191.5 126.5q-111 111 -150.5 260.5t0 299t150.5 260.5q83 83 191.5 126.5t218.5 43.5t218.5 -43.5t191.5 -126.5zM476 1065q-4 0 -8 -1q-121 -34 -209.5 -122.5 t-122.5 -209.5q-4 -12 2.5 -23t18.5 -14l36 -9q3 -1 7 -1q23 0 29 22q27 96 98 166q70 71 166 98q11 3 17.5 13.5t3.5 22.5l-9 35q-3 13 -14 19q-7 4 -15 4zM512 920q-4 0 -9 -2q-80 -24 -138.5 -82.5t-82.5 -138.5q-4 -13 2 -24t19 -14l34 -9q4 -1 8 -1q22 0 28 21 q18 58 58.5 98.5t97.5 58.5q12 3 18 13.5t3 21.5l-9 35q-3 12 -14 19q-7 4 -15 4zM719.5 719.5q-49.5 49.5 -119.5 49.5t-119.5 -49.5t-49.5 -119.5t49.5 -119.5t119.5 -49.5t119.5 49.5t49.5 119.5t-49.5 119.5zM855 551q-22 0 -28 -21q-18 -58 -58.5 -98.5t-98.5 -57.5 q-11 -4 -17 -14.5t-3 -21.5l9 -35q3 -12 14 -19q7 -4 15 -4q4 0 9 2q80 24 138.5 82.5t82.5 138.5q4 13 -2.5 24t-18.5 14l-34 9q-4 1 -8 1zM1000 515q-23 0 -29 -22q-27 -96 -98 -166q-70 -71 -166 -98q-11 -3 -17.5 -13.5t-3.5 -22.5l9 -35q3 -13 14 -19q7 -4 15 -4 q4 0 8 1q121 34 209.5 122.5t122.5 209.5q4 12 -2.5 23t-18.5 14l-36 9q-3 1 -7 1z" />
<glyph unicode="&#xe202;" d="M700 800h300v-380h-180v200h-340v-200h-380v755q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM700 300h162l-212 -212l-212 212h162v200h100v-200zM520 0h-395q-10 0 -17.5 7.5t-7.5 17.5v395zM1000 220v-195q0 -10 -7.5 -17.5t-17.5 -7.5h-195z" />
<glyph unicode="&#xe203;" d="M700 800h300v-520l-350 350l-550 -550v1095q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM862 200h-162v-200h-100v200h-162l212 212zM480 0h-355q-10 0 -17.5 7.5t-7.5 17.5v55h380v-80zM1000 80v-55q0 -10 -7.5 -17.5t-17.5 -7.5h-155v80h180z" />
<glyph unicode="&#xe204;" d="M1162 800h-162v-200h100l100 -100h-300v300h-162l212 212zM200 800h200q27 0 40 -2t29.5 -10.5t23.5 -30t7 -57.5h300v-100h-600l-200 -350v450h100q0 36 7 57.5t23.5 30t29.5 10.5t40 2zM800 400h240l-240 -400h-800l300 500h500v-100z" />
<glyph unicode="&#xe205;" d="M650 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM1000 850v150q41 0 70.5 -29.5t29.5 -70.5v-800 q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-1 0 -20 4l246 246l-326 326v324q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM412 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe206;" d="M450 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM800 850v150q41 0 70.5 -29.5t29.5 -70.5v-500 h-200v-300h200q0 -36 -7 -57.5t-23.5 -30t-29.5 -10.5t-40 -2h-600q-41 0 -70.5 29.5t-29.5 70.5v800q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM1212 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe209;" d="M658 1197l637 -1104q23 -38 7 -65.5t-60 -27.5h-1276q-44 0 -60 27.5t7 65.5l637 1104q22 39 54 39t54 -39zM704 800h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM500 300v-100h200 v100h-200z" />
<glyph unicode="&#xe210;" d="M425 1100h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM825 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM25 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5zM425 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5 v150q0 10 7.5 17.5t17.5 7.5zM25 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe211;" d="M700 1200h100v-200h-100v-100h350q62 0 86.5 -39.5t-3.5 -94.5l-66 -132q-41 -83 -81 -134h-772q-40 51 -81 134l-66 132q-28 55 -3.5 94.5t86.5 39.5h350v100h-100v200h100v100h200v-100zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100 h-950l138 100h-13q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe212;" d="M600 1300q40 0 68.5 -29.5t28.5 -70.5h-194q0 41 28.5 70.5t68.5 29.5zM443 1100h314q18 -37 18 -75q0 -8 -3 -25h328q41 0 44.5 -16.5t-30.5 -38.5l-175 -145h-678l-178 145q-34 22 -29 38.5t46 16.5h328q-3 17 -3 25q0 38 18 75zM250 700h700q21 0 35.5 -14.5 t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-150v-200l275 -200h-950l275 200v200h-150q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe213;" d="M600 1181q75 0 128 -53t53 -128t-53 -128t-128 -53t-128 53t-53 128t53 128t128 53zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13 l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe214;" d="M600 1300q47 0 92.5 -53.5t71 -123t25.5 -123.5q0 -78 -55.5 -133.5t-133.5 -55.5t-133.5 55.5t-55.5 133.5q0 62 34 143l144 -143l111 111l-163 163q34 26 63 26zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45 zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe215;" d="M600 1200l300 -161v-139h-300q0 -57 18.5 -108t50 -91.5t63 -72t70 -67.5t57.5 -61h-530q-60 83 -90.5 177.5t-30.5 178.5t33 164.5t87.5 139.5t126 96.5t145.5 41.5v-98zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100 h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe216;" d="M600 1300q41 0 70.5 -29.5t29.5 -70.5v-78q46 -26 73 -72t27 -100v-50h-400v50q0 54 27 100t73 72v78q0 41 29.5 70.5t70.5 29.5zM400 800h400q54 0 100 -27t72 -73h-172v-100h200v-100h-200v-100h200v-100h-200v-100h200q0 -83 -58.5 -141.5t-141.5 -58.5h-400 q-83 0 -141.5 58.5t-58.5 141.5v400q0 83 58.5 141.5t141.5 58.5z" />
<glyph unicode="&#xe218;" d="M150 1100h900q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM125 400h950q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-283l224 -224q13 -13 13 -31.5t-13 -32 t-31.5 -13.5t-31.5 13l-88 88h-524l-87 -88q-13 -13 -32 -13t-32 13.5t-13 32t13 31.5l224 224h-289q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM541 300l-100 -100h324l-100 100h-124z" />
<glyph unicode="&#xe219;" d="M200 1100h800q83 0 141.5 -58.5t58.5 -141.5v-200h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100v200q0 83 58.5 141.5t141.5 58.5zM100 600h1000q41 0 70.5 -29.5 t29.5 -70.5v-300h-1200v300q0 41 29.5 70.5t70.5 29.5zM300 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200zM1100 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200z" />
<glyph unicode="&#xe221;" d="M480 1165l682 -683q31 -31 31 -75.5t-31 -75.5l-131 -131h-481l-517 518q-32 31 -32 75.5t32 75.5l295 296q31 31 75.5 31t76.5 -31zM108 794l342 -342l303 304l-341 341zM250 100h800q21 0 35.5 -14.5t14.5 -35.5v-50h-900v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe223;" d="M1057 647l-189 506q-8 19 -27.5 33t-40.5 14h-400q-21 0 -40.5 -14t-27.5 -33l-189 -506q-8 -19 1.5 -33t30.5 -14h625v-150q0 -21 14.5 -35.5t35.5 -14.5t35.5 14.5t14.5 35.5v150h125q21 0 30.5 14t1.5 33zM897 0h-595v50q0 21 14.5 35.5t35.5 14.5h50v50 q0 21 14.5 35.5t35.5 14.5h48v300h200v-300h47q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-50z" />
<glyph unicode="&#xe224;" d="M900 800h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-375v591l-300 300v84q0 10 7.5 17.5t17.5 7.5h375v-400zM1200 900h-200v200zM400 600h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-650q-10 0 -17.5 7.5t-7.5 17.5v950q0 10 7.5 17.5t17.5 7.5h375v-400zM700 700h-200v200z " />
<glyph unicode="&#xe225;" d="M484 1095h195q75 0 146 -32.5t124 -86t89.5 -122.5t48.5 -142q18 -14 35 -20q31 -10 64.5 6.5t43.5 48.5q10 34 -15 71q-19 27 -9 43q5 8 12.5 11t19 -1t23.5 -16q41 -44 39 -105q-3 -63 -46 -106.5t-104 -43.5h-62q-7 -55 -35 -117t-56 -100l-39 -234q-3 -20 -20 -34.5 t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l12 70q-49 -14 -91 -14h-195q-24 0 -65 8l-11 -64q-3 -20 -20 -34.5t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l26 157q-84 74 -128 175l-159 53q-19 7 -33 26t-14 40v50q0 21 14.5 35.5t35.5 14.5h124q11 87 56 166l-111 95 q-16 14 -12.5 23.5t24.5 9.5h203q116 101 250 101zM675 1000h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h250q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe226;" d="M641 900l423 247q19 8 42 2.5t37 -21.5l32 -38q14 -15 12.5 -36t-17.5 -34l-139 -120h-390zM50 1100h106q67 0 103 -17t66 -71l102 -212h823q21 0 35.5 -14.5t14.5 -35.5v-50q0 -21 -14 -40t-33 -26l-737 -132q-23 -4 -40 6t-26 25q-42 67 -100 67h-300q-62 0 -106 44 t-44 106v200q0 62 44 106t106 44zM173 928h-80q-19 0 -28 -14t-9 -35v-56q0 -51 42 -51h134q16 0 21.5 8t5.5 24q0 11 -16 45t-27 51q-18 28 -43 28zM550 727q-32 0 -54.5 -22.5t-22.5 -54.5t22.5 -54.5t54.5 -22.5t54.5 22.5t22.5 54.5t-22.5 54.5t-54.5 22.5zM130 389 l152 130q18 19 34 24t31 -3.5t24.5 -17.5t25.5 -28q28 -35 50.5 -51t48.5 -13l63 5l48 -179q13 -61 -3.5 -97.5t-67.5 -79.5l-80 -69q-47 -40 -109 -35.5t-103 51.5l-130 151q-40 47 -35.5 109.5t51.5 102.5zM380 377l-102 -88q-31 -27 2 -65l37 -43q13 -15 27.5 -19.5 t31.5 6.5l61 53q19 16 14 49q-2 20 -12 56t-17 45q-11 12 -19 14t-23 -8z" />
<glyph unicode="&#xe227;" d="M625 1200h150q10 0 17.5 -7.5t7.5 -17.5v-109q79 -33 131 -87.5t53 -128.5q1 -46 -15 -84.5t-39 -61t-46 -38t-39 -21.5l-17 -6q6 0 15 -1.5t35 -9t50 -17.5t53 -30t50 -45t35.5 -64t14.5 -84q0 -59 -11.5 -105.5t-28.5 -76.5t-44 -51t-49.5 -31.5t-54.5 -16t-49.5 -6.5 t-43.5 -1v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-100v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-175q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v600h-75q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5h175v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h100v75q0 10 7.5 17.5t17.5 7.5zM400 900v-200h263q28 0 48.5 10.5t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-263zM400 500v-200h363q28 0 48.5 10.5 t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-363z" />
<glyph unicode="&#xe230;" d="M212 1198h780q86 0 147 -61t61 -147v-416q0 -51 -18 -142.5t-36 -157.5l-18 -66q-29 -87 -93.5 -146.5t-146.5 -59.5h-572q-82 0 -147 59t-93 147q-8 28 -20 73t-32 143.5t-20 149.5v416q0 86 61 147t147 61zM600 1045q-70 0 -132.5 -11.5t-105.5 -30.5t-78.5 -41.5 t-57 -45t-36 -41t-20.5 -30.5l-6 -12l156 -243h560l156 243q-2 5 -6 12.5t-20 29.5t-36.5 42t-57 44.5t-79 42t-105 29.5t-132.5 12zM762 703h-157l195 261z" />
<glyph unicode="&#xe231;" d="M475 1300h150q103 0 189 -86t86 -189v-500q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe232;" d="M475 1300h96q0 -150 89.5 -239.5t239.5 -89.5v-446q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe233;" d="M1294 767l-638 -283l-378 170l-78 -60v-224l100 -150v-199l-150 148l-150 -149v200l100 150v250q0 4 -0.5 10.5t0 9.5t1 8t3 8t6.5 6l47 40l-147 65l642 283zM1000 380l-350 -166l-350 166v147l350 -165l350 165v-147z" />
<glyph unicode="&#xe234;" d="M250 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM650 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM1050 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe235;" d="M550 1100q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 700q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 300q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe236;" d="M125 1100h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM125 700h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM125 300h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe237;" d="M350 1200h500q162 0 256 -93.5t94 -256.5v-500q0 -165 -93.5 -257.5t-256.5 -92.5h-500q-165 0 -257.5 92.5t-92.5 257.5v500q0 165 92.5 257.5t257.5 92.5zM900 1000h-600q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h600q41 0 70.5 29.5 t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5zM350 900h500q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-500q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 14.5 35.5t35.5 14.5zM400 800v-200h400v200h-400z" />
<glyph unicode="&#xe238;" d="M150 1100h1000q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe239;" d="M650 1187q87 -67 118.5 -156t0 -178t-118.5 -155q-87 66 -118.5 155t0 178t118.5 156zM300 800q124 0 212 -88t88 -212q-124 0 -212 88t-88 212zM1000 800q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM300 500q124 0 212 -88t88 -212q-124 0 -212 88t-88 212z M1000 500q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM700 199v-144q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v142q40 -4 43 -4q17 0 57 6z" />
<glyph unicode="&#xe240;" d="M745 878l69 19q25 6 45 -12l298 -295q11 -11 15 -26.5t-2 -30.5q-5 -14 -18 -23.5t-28 -9.5h-8q1 0 1 -13q0 -29 -2 -56t-8.5 -62t-20 -63t-33 -53t-51 -39t-72.5 -14h-146q-184 0 -184 288q0 24 10 47q-20 4 -62 4t-63 -4q11 -24 11 -47q0 -288 -184 -288h-142 q-48 0 -84.5 21t-56 51t-32 71.5t-16 75t-3.5 68.5q0 13 2 13h-7q-15 0 -27.5 9.5t-18.5 23.5q-6 15 -2 30.5t15 25.5l298 296q20 18 46 11l76 -19q20 -5 30.5 -22.5t5.5 -37.5t-22.5 -31t-37.5 -5l-51 12l-182 -193h891l-182 193l-44 -12q-20 -5 -37.5 6t-22.5 31t6 37.5 t31 22.5z" />
<glyph unicode="&#xe241;" d="M1200 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM500 450h-25q0 15 -4 24.5t-9 14.5t-17 7.5t-20 3t-25 0.5h-100v-425q0 -11 12.5 -17.5t25.5 -7.5h12v-50h-200v50q50 0 50 25v425h-100q-17 0 -25 -0.5t-20 -3t-17 -7.5t-9 -14.5t-4 -24.5h-25v150h500v-150z" />
<glyph unicode="&#xe242;" d="M1000 300v50q-25 0 -55 32q-14 14 -25 31t-16 27l-4 11l-289 747h-69l-300 -754q-18 -35 -39 -56q-9 -9 -24.5 -18.5t-26.5 -14.5l-11 -5v-50h273v50q-49 0 -78.5 21.5t-11.5 67.5l69 176h293l61 -166q13 -34 -3.5 -66.5t-55.5 -32.5v-50h312zM412 691l134 342l121 -342 h-255zM1100 150v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe243;" d="M50 1200h1100q21 0 35.5 -14.5t14.5 -35.5v-1100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5zM611 1118h-70q-13 0 -18 -12l-299 -753q-17 -32 -35 -51q-18 -18 -56 -34q-12 -5 -12 -18v-50q0 -8 5.5 -14t14.5 -6 h273q8 0 14 6t6 14v50q0 8 -6 14t-14 6q-55 0 -71 23q-10 14 0 39l63 163h266l57 -153q11 -31 -6 -55q-12 -17 -36 -17q-8 0 -14 -6t-6 -14v-50q0 -8 6 -14t14 -6h313q8 0 14 6t6 14v50q0 7 -5.5 13t-13.5 7q-17 0 -42 25q-25 27 -40 63h-1l-288 748q-5 12 -19 12zM639 611 h-197l103 264z" />
<glyph unicode="&#xe244;" d="M1200 1100h-1200v100h1200v-100zM50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 1000h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM700 900v-300h300v300h-300z" />
<glyph unicode="&#xe245;" d="M50 1200h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 700h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM700 600v-300h300v300h-300zM1200 0h-1200v100h1200v-100z" />
<glyph unicode="&#xe246;" d="M50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-350h100v150q0 21 14.5 35.5t35.5 14.5h400q21 0 35.5 -14.5t14.5 -35.5v-150h100v-100h-100v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v150h-100v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM700 700v-300h300v300h-300z" />
<glyph unicode="&#xe247;" d="M100 0h-100v1200h100v-1200zM250 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM300 1000v-300h300v300h-300zM250 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe248;" d="M600 1100h150q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-100h450q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h350v100h-150q-21 0 -35.5 14.5 t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h150v100h100v-100zM400 1000v-300h300v300h-300z" />
<glyph unicode="&#xe249;" d="M1200 0h-100v1200h100v-1200zM550 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM600 1000v-300h300v300h-300zM50 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe250;" d="M865 565l-494 -494q-23 -23 -41 -23q-14 0 -22 13.5t-8 38.5v1000q0 25 8 38.5t22 13.5q18 0 41 -23l494 -494q14 -14 14 -35t-14 -35z" />
<glyph unicode="&#xe251;" d="M335 635l494 494q29 29 50 20.5t21 -49.5v-1000q0 -41 -21 -49.5t-50 20.5l-494 494q-14 14 -14 35t14 35z" />
<glyph unicode="&#xe252;" d="M100 900h1000q41 0 49.5 -21t-20.5 -50l-494 -494q-14 -14 -35 -14t-35 14l-494 494q-29 29 -20.5 50t49.5 21z" />
<glyph unicode="&#xe253;" d="M635 865l494 -494q29 -29 20.5 -50t-49.5 -21h-1000q-41 0 -49.5 21t20.5 50l494 494q14 14 35 14t35 -14z" />
<glyph unicode="&#xe254;" d="M700 741v-182l-692 -323v221l413 193l-413 193v221zM1200 0h-800v200h800v-200z" />
<glyph unicode="&#xe255;" d="M1200 900h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300zM0 700h50q0 21 4 37t9.5 26.5t18 17.5t22 11t28.5 5.5t31 2t37 0.5h100v-550q0 -22 -25 -34.5t-50 -13.5l-25 -2v-100h400v100q-4 0 -11 0.5t-24 3t-30 7t-24 15t-11 24.5v550h100q25 0 37 -0.5t31 -2 t28.5 -5.5t22 -11t18 -17.5t9.5 -26.5t4 -37h50v300h-800v-300z" />
<glyph unicode="&#xe256;" d="M800 700h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-100v-550q0 -22 25 -34.5t50 -14.5l25 -1v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v550h-100q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h800v-300zM1100 200h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300z" />
<glyph unicode="&#xe257;" d="M701 1098h160q16 0 21 -11t-7 -23l-464 -464l464 -464q12 -12 7 -23t-21 -11h-160q-13 0 -23 9l-471 471q-7 8 -7 18t7 18l471 471q10 9 23 9z" />
<glyph unicode="&#xe258;" d="M339 1098h160q13 0 23 -9l471 -471q7 -8 7 -18t-7 -18l-471 -471q-10 -9 -23 -9h-160q-16 0 -21 11t7 23l464 464l-464 464q-12 12 -7 23t21 11z" />
<glyph unicode="&#xe259;" d="M1087 882q11 -5 11 -21v-160q0 -13 -9 -23l-471 -471q-8 -7 -18 -7t-18 7l-471 471q-9 10 -9 23v160q0 16 11 21t23 -7l464 -464l464 464q12 12 23 7z" />
<glyph unicode="&#xe260;" d="M618 993l471 -471q9 -10 9 -23v-160q0 -16 -11 -21t-23 7l-464 464l-464 -464q-12 -12 -23 -7t-11 21v160q0 13 9 23l471 471q8 7 18 7t18 -7z" />
<glyph unicode="&#xf8ff;" d="M1000 1200q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM450 1000h100q21 0 40 -14t26 -33l79 -194q5 1 16 3q34 6 54 9.5t60 7t65.5 1t61 -10t56.5 -23t42.5 -42t29 -64t5 -92t-19.5 -121.5q-1 -7 -3 -19.5t-11 -50t-20.5 -73t-32.5 -81.5t-46.5 -83t-64 -70 t-82.5 -50q-13 -5 -42 -5t-65.5 2.5t-47.5 2.5q-14 0 -49.5 -3.5t-63 -3.5t-43.5 7q-57 25 -104.5 78.5t-75 111.5t-46.5 112t-26 90l-7 35q-15 63 -18 115t4.5 88.5t26 64t39.5 43.5t52 25.5t58.5 13t62.5 2t59.5 -4.5t55.5 -8l-147 192q-12 18 -5.5 30t27.5 12z" />
<glyph unicode="&#x1f511;" d="M250 1200h600q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-500l-255 -178q-19 -9 -32 -1t-13 29v650h-150q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM400 1100v-100h300v100h-300z" />
<glyph unicode="&#x1f6aa;" d="M250 1200h750q39 0 69.5 -40.5t30.5 -84.5v-933l-700 -117v950l600 125h-700v-1000h-100v1025q0 23 15.5 49t34.5 26zM500 525v-100l100 20v100z" />
</font>
</defs></svg> ) format('svg')}.glyphicon{position:relative;top:1px;display:inline-block;font-family:'Glyphicons Halflings';font-style:normal;font-weight:400;line-height:1;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.glyphicon-asterisk:before{content:"\2a"}.glyphicon-plus:before{content:"\2b"}.glyphicon-eur:before,.glyphicon-euro:before{content:"\20ac"}.glyphicon-minus:before{content:"\2212"}.glyphicon-cloud:before{content:"\2601"}.glyphicon-envelope:before{content:"\2709"}.glyphicon-pencil:before{content:"\270f"}.glyphicon-glass:before{content:"\e001"}.glyphicon-music:before{content:"\e002"}.glyphicon-search:before{content:"\e003"}.glyphicon-heart:before{content:"\e005"}.glyphicon-star:before{content:"\e006"}.glyphicon-star-empty:before{content:"\e007"}.glyphicon-user:before{content:"\e008"}.glyphicon-film:before{content:"\e009"}.glyphicon-th-large:before{content:"\e010"}.glyphicon-th:before{content:"\e011"}.glyphicon-th-list:before{content:"\e012"}.glyphicon-ok:before{content:"\e013"}.glyphicon-remove:before{content:"\e014"}.glyphicon-zoom-in:before{content:"\e015"}.glyphicon-zoom-out:before{content:"\e016"}.glyphicon-off:before{content:"\e017"}.glyphicon-signal:before{content:"\e018"}.glyphicon-cog:before{content:"\e019"}.glyphicon-trash:before{content:"\e020"}.glyphicon-home:before{content:"\e021"}.glyphicon-file:before{content:"\e022"}.glyphicon-time:before{content:"\e023"}.glyphicon-road:before{content:"\e024"}.glyphicon-download-alt:before{content:"\e025"}.glyphicon-download:before{content:"\e026"}.glyphicon-upload:before{content:"\e027"}.glyphicon-inbox:before{content:"\e028"}.glyphicon-play-circle:before{content:"\e029"}.glyphicon-repeat:before{content:"\e030"}.glyphicon-refresh:before{content:"\e031"}.glyphicon-list-alt:before{content:"\e032"}.glyphicon-lock:before{content:"\e033"}.glyphicon-flag:before{content:"\e034"}.glyphicon-headphones:before{content:"\e035"}.glyphicon-volume-off:before{content:"\e036"}.glyphicon-volume-down:before{content:"\e037"}.glyphicon-volume-up:before{content:"\e038"}.glyphicon-qrcode:before{content:"\e039"}.glyphicon-barcode:before{content:"\e040"}.glyphicon-tag:before{content:"\e041"}.glyphicon-tags:before{content:"\e042"}.glyphicon-book:before{content:"\e043"}.glyphicon-bookmark:before{content:"\e044"}.glyphicon-print:before{content:"\e045"}.glyphicon-camera:before{content:"\e046"}.glyphicon-font:before{content:"\e047"}.glyphicon-bold:before{content:"\e048"}.glyphicon-italic:before{content:"\e049"}.glyphicon-text-height:before{content:"\e050"}.glyphicon-text-width:before{content:"\e051"}.glyphicon-align-left:before{content:"\e052"}.glyphicon-align-center:before{content:"\e053"}.glyphicon-align-right:before{content:"\e054"}.glyphicon-align-justify:before{content:"\e055"}.glyphicon-list:before{content:"\e056"}.glyphicon-indent-left:before{content:"\e057"}.glyphicon-indent-right:before{content:"\e058"}.glyphicon-facetime-video:before{content:"\e059"}.glyphicon-picture:before{content:"\e060"}.glyphicon-map-marker:before{content:"\e062"}.glyphicon-adjust:before{content:"\e063"}.glyphicon-tint:before{content:"\e064"}.glyphicon-edit:before{content:"\e065"}.glyphicon-share:before{content:"\e066"}.glyphicon-check:before{content:"\e067"}.glyphicon-move:before{content:"\e068"}.glyphicon-step-backward:before{content:"\e069"}.glyphicon-fast-backward:before{content:"\e070"}.glyphicon-backward:before{content:"\e071"}.glyphicon-play:before{content:"\e072"}.glyphicon-pause:before{content:"\e073"}.glyphicon-stop:before{content:"\e074"}.glyphicon-forward:before{content:"\e075"}.glyphicon-fast-forward:before{content:"\e076"}.glyphicon-step-forward:before{content:"\e077"}.glyphicon-eject:before{content:"\e078"}.glyphicon-chevron-left:before{content:"\e079"}.glyphicon-chevron-right:before{content:"\e080"}.glyphicon-plus-sign:before{content:"\e081"}.glyphicon-minus-sign:before{content:"\e082"}.glyphicon-remove-sign:before{content:"\e083"}.glyphicon-ok-sign:before{content:"\e084"}.glyphicon-question-sign:before{content:"\e085"}.glyphicon-info-sign:before{content:"\e086"}.glyphicon-screenshot:before{content:"\e087"}.glyphicon-remove-circle:before{content:"\e088"}.glyphicon-ok-circle:before{content:"\e089"}.glyphicon-ban-circle:before{content:"\e090"}.glyphicon-arrow-left:before{content:"\e091"}.glyphicon-arrow-right:before{content:"\e092"}.glyphicon-arrow-up:before{content:"\e093"}.glyphicon-arrow-down:before{content:"\e094"}.glyphicon-share-alt:before{content:"\e095"}.glyphicon-resize-full:before{content:"\e096"}.glyphicon-resize-small:before{content:"\e097"}.glyphicon-exclamation-sign:before{content:"\e101"}.glyphicon-gift:before{content:"\e102"}.glyphicon-leaf:before{content:"\e103"}.glyphicon-fire:before{content:"\e104"}.glyphicon-eye-open:before{content:"\e105"}.glyphicon-eye-close:before{content:"\e106"}.glyphicon-warning-sign:before{content:"\e107"}.glyphicon-plane:before{content:"\e108"}.glyphicon-calendar:before{content:"\e109"}.glyphicon-random:before{content:"\e110"}.glyphicon-comment:before{content:"\e111"}.glyphicon-magnet:before{content:"\e112"}.glyphicon-chevron-up:before{content:"\e113"}.glyphicon-chevron-down:before{content:"\e114"}.glyphicon-retweet:before{content:"\e115"}.glyphicon-shopping-cart:before{content:"\e116"}.glyphicon-folder-close:before{content:"\e117"}.glyphicon-folder-open:before{content:"\e118"}.glyphicon-resize-vertical:before{content:"\e119"}.glyphicon-resize-horizontal:before{content:"\e120"}.glyphicon-hdd:before{content:"\e121"}.glyphicon-bullhorn:before{content:"\e122"}.glyphicon-bell:before{content:"\e123"}.glyphicon-certificate:before{content:"\e124"}.glyphicon-thumbs-up:before{content:"\e125"}.glyphicon-thumbs-down:before{content:"\e126"}.glyphicon-hand-right:before{content:"\e127"}.glyphicon-hand-left:before{content:"\e128"}.glyphicon-hand-up:before{content:"\e129"}.glyphicon-hand-down:before{content:"\e130"}.glyphicon-circle-arrow-right:before{content:"\e131"}.glyphicon-circle-arrow-left:before{content:"\e132"}.glyphicon-circle-arrow-up:before{content:"\e133"}.glyphicon-circle-arrow-down:before{content:"\e134"}.glyphicon-globe:before{content:"\e135"}.glyphicon-wrench:before{content:"\e136"}.glyphicon-tasks:before{content:"\e137"}.glyphicon-filter:before{content:"\e138"}.glyphicon-briefcase:before{content:"\e139"}.glyphicon-fullscreen:before{content:"\e140"}.glyphicon-dashboard:before{content:"\e141"}.glyphicon-paperclip:before{content:"\e142"}.glyphicon-heart-empty:before{content:"\e143"}.glyphicon-link:before{content:"\e144"}.glyphicon-phone:before{content:"\e145"}.glyphicon-pushpin:before{content:"\e146"}.glyphicon-usd:before{content:"\e148"}.glyphicon-gbp:before{content:"\e149"}.glyphicon-sort:before{content:"\e150"}.glyphicon-sort-by-alphabet:before{content:"\e151"}.glyphicon-sort-by-alphabet-alt:before{content:"\e152"}.glyphicon-sort-by-order:before{content:"\e153"}.glyphicon-sort-by-order-alt:before{content:"\e154"}.glyphicon-sort-by-attributes:before{content:"\e155"}.glyphicon-sort-by-attributes-alt:before{content:"\e156"}.glyphicon-unchecked:before{content:"\e157"}.glyphicon-expand:before{content:"\e158"}.glyphicon-collapse-down:before{content:"\e159"}.glyphicon-collapse-up:before{content:"\e160"}.glyphicon-log-in:before{content:"\e161"}.glyphicon-flash:before{content:"\e162"}.glyphicon-log-out:before{content:"\e163"}.glyphicon-new-window:before{content:"\e164"}.glyphicon-record:before{content:"\e165"}.glyphicon-save:before{content:"\e166"}.glyphicon-open:before{content:"\e167"}.glyphicon-saved:before{content:"\e168"}.glyphicon-import:before{content:"\e169"}.glyphicon-export:before{content:"\e170"}.glyphicon-send:before{content:"\e171"}.glyphicon-floppy-disk:before{content:"\e172"}.glyphicon-floppy-saved:before{content:"\e173"}.glyphicon-floppy-remove:before{content:"\e174"}.glyphicon-floppy-save:before{content:"\e175"}.glyphicon-floppy-open:before{content:"\e176"}.glyphicon-credit-card:before{content:"\e177"}.glyphicon-transfer:before{content:"\e178"}.glyphicon-cutlery:before{content:"\e179"}.glyphicon-header:before{content:"\e180"}.glyphicon-compressed:before{content:"\e181"}.glyphicon-earphone:before{content:"\e182"}.glyphicon-phone-alt:before{content:"\e183"}.glyphicon-tower:before{content:"\e184"}.glyphicon-stats:before{content:"\e185"}.glyphicon-sd-video:before{content:"\e186"}.glyphicon-hd-video:before{content:"\e187"}.glyphicon-subtitles:before{content:"\e188"}.glyphicon-sound-stereo:before{content:"\e189"}.glyphicon-sound-dolby:before{content:"\e190"}.glyphicon-sound-5-1:before{content:"\e191"}.glyphicon-sound-6-1:before{content:"\e192"}.glyphicon-sound-7-1:before{content:"\e193"}.glyphicon-copyright-mark:before{content:"\e194"}.glyphicon-registration-mark:before{content:"\e195"}.glyphicon-cloud-download:before{content:"\e197"}.glyphicon-cloud-upload:before{content:"\e198"}.glyphicon-tree-conifer:before{content:"\e199"}.glyphicon-tree-deciduous:before{content:"\e200"}.glyphicon-cd:before{content:"\e201"}.glyphicon-save-file:before{content:"\e202"}.glyphicon-open-file:before{content:"\e203"}.glyphicon-level-up:before{content:"\e204"}.glyphicon-copy:before{content:"\e205"}.glyphicon-paste:before{content:"\e206"}.glyphicon-alert:before{content:"\e209"}.glyphicon-equalizer:before{content:"\e210"}.glyphicon-king:before{content:"\e211"}.glyphicon-queen:before{content:"\e212"}.glyphicon-pawn:before{content:"\e213"}.glyphicon-bishop:before{content:"\e214"}.glyphicon-knight:before{content:"\e215"}.glyphicon-baby-formula:before{content:"\e216"}.glyphicon-tent:before{content:"\26fa"}.glyphicon-blackboard:before{content:"\e218"}.glyphicon-bed:before{content:"\e219"}.glyphicon-apple:before{content:"\f8ff"}.glyphicon-erase:before{content:"\e221"}.glyphicon-hourglass:before{content:"\231b"}.glyphicon-lamp:before{content:"\e223"}.glyphicon-duplicate:before{content:"\e224"}.glyphicon-piggy-bank:before{content:"\e225"}.glyphicon-scissors:before{content:"\e226"}.glyphicon-bitcoin:before{content:"\e227"}.glyphicon-btc:before{content:"\e227"}.glyphicon-xbt:before{content:"\e227"}.glyphicon-yen:before{content:"\00a5"}.glyphicon-jpy:before{content:"\00a5"}.glyphicon-ruble:before{content:"\20bd"}.glyphicon-rub:before{content:"\20bd"}.glyphicon-scale:before{content:"\e230"}.glyphicon-ice-lolly:before{content:"\e231"}.glyphicon-ice-lolly-tasted:before{content:"\e232"}.glyphicon-education:before{content:"\e233"}.glyphicon-option-horizontal:before{content:"\e234"}.glyphicon-option-vertical:before{content:"\e235"}.glyphicon-menu-hamburger:before{content:"\e236"}.glyphicon-modal-window:before{content:"\e237"}.glyphicon-oil:before{content:"\e238"}.glyphicon-grain:before{content:"\e239"}.glyphicon-sunglasses:before{content:"\e240"}.glyphicon-text-size:before{content:"\e241"}.glyphicon-text-color:before{content:"\e242"}.glyphicon-text-background:before{content:"\e243"}.glyphicon-object-align-top:before{content:"\e244"}.glyphicon-object-align-bottom:before{content:"\e245"}.glyphicon-object-align-horizontal:before{content:"\e246"}.glyphicon-object-align-left:before{content:"\e247"}.glyphicon-object-align-vertical:before{content:"\e248"}.glyphicon-object-align-right:before{content:"\e249"}.glyphicon-triangle-right:before{content:"\e250"}.glyphicon-triangle-left:before{content:"\e251"}.glyphicon-triangle-bottom:before{content:"\e252"}.glyphicon-triangle-top:before{content:"\e253"}.glyphicon-console:before{content:"\e254"}.glyphicon-superscript:before{content:"\e255"}.glyphicon-subscript:before{content:"\e256"}.glyphicon-menu-left:before{content:"\e257"}.glyphicon-menu-right:before{content:"\e258"}.glyphicon-menu-down:before{content:"\e259"}.glyphicon-menu-up:before{content:"\e260"}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:rgba(0,0,0,0)}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}button,input,select,textarea{font-family:inherit;font-size:inherit;line-height:inherit}a{color:#337ab7;text-decoration:none}a:focus,a:hover{color:#23527c;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}figure{margin:0}img{vertical-align:middle}.carousel-inner>.item>a>img,.carousel-inner>.item>img,.img-responsive,.thumbnail a>img,.thumbnail>img{display:block;max-width:100%;height:auto}.img-rounded{border-radius:6px}.img-thumbnail{display:inline-block;max-width:100%;height:auto;padding:4px;line-height:1.42857143;background-color:#fff;border:1px solid #ddd;border-radius:4px;-webkit-transition:all .2s ease-in-out;-o-transition:all .2s ease-in-out;transition:all .2s ease-in-out}.img-circle{border-radius:50%}hr{margin-top:20px;margin-bottom:20px;border:0;border-top:1px solid #eee}.sr-only{position:absolute;width:1px;height:1px;padding:0;margin:-1px;overflow:hidden;clip:rect(0,0,0,0);border:0}.sr-only-focusable:active,.sr-only-focusable:focus{position:static;width:auto;height:auto;margin:0;overflow:visible;clip:auto}[role=button]{cursor:pointer}.h1,.h2,.h3,.h4,.h5,.h6,h1,h2,h3,h4,h5,h6{font-family:inherit;font-weight:500;line-height:1.1;color:inherit}.h1 .small,.h1 small,.h2 .small,.h2 small,.h3 .small,.h3 small,.h4 .small,.h4 small,.h5 .small,.h5 small,.h6 .small,.h6 small,h1 .small,h1 small,h2 .small,h2 small,h3 .small,h3 small,h4 .small,h4 small,h5 .small,h5 small,h6 .small,h6 small{font-weight:400;line-height:1;color:#777}.h1,.h2,.h3,h1,h2,h3{margin-top:20px;margin-bottom:10px}.h1 .small,.h1 small,.h2 .small,.h2 small,.h3 .small,.h3 small,h1 .small,h1 small,h2 .small,h2 small,h3 .small,h3 small{font-size:65%}.h4,.h5,.h6,h4,h5,h6{margin-top:10px;margin-bottom:10px}.h4 .small,.h4 small,.h5 .small,.h5 small,.h6 .small,.h6 small,h4 .small,h4 small,h5 .small,h5 small,h6 .small,h6 small{font-size:75%}.h1,h1{font-size:36px}.h2,h2{font-size:30px}.h3,h3{font-size:24px}.h4,h4{font-size:18px}.h5,h5{font-size:14px}.h6,h6{font-size:12px}p{margin:0 0 10px}.lead{margin-bottom:20px;font-size:16px;font-weight:300;line-height:1.4}@media (min-width:768px){.lead{font-size:21px}}.small,small{font-size:85%}.mark,mark{padding:.2em;background-color:#fcf8e3}.text-left{text-align:left}.text-right{text-align:right}.text-center{text-align:center}.text-justify{text-align:justify}.text-nowrap{white-space:nowrap}.text-lowercase{text-transform:lowercase}.text-uppercase{text-transform:uppercase}.text-capitalize{text-transform:capitalize}.text-muted{color:#777}.text-primary{color:#337ab7}a.text-primary:focus,a.text-primary:hover{color:#286090}.text-success{color:#3c763d}a.text-success:focus,a.text-success:hover{color:#2b542c}.text-info{color:#31708f}a.text-info:focus,a.text-info:hover{color:#245269}.text-warning{color:#8a6d3b}a.text-warning:focus,a.text-warning:hover{color:#66512c}.text-danger{color:#a94442}a.text-danger:focus,a.text-danger:hover{color:#843534}.bg-primary{color:#fff;background-color:#337ab7}a.bg-primary:focus,a.bg-primary:hover{background-color:#286090}.bg-success{background-color:#dff0d8}a.bg-success:focus,a.bg-success:hover{background-color:#c1e2b3}.bg-info{background-color:#d9edf7}a.bg-info:focus,a.bg-info:hover{background-color:#afd9ee}.bg-warning{background-color:#fcf8e3}a.bg-warning:focus,a.bg-warning:hover{background-color:#f7ecb5}.bg-danger{background-color:#f2dede}a.bg-danger:focus,a.bg-danger:hover{background-color:#e4b9b9}.page-header{padding-bottom:9px;margin:40px 0 20px;border-bottom:1px solid #eee}ol,ul{margin-top:0;margin-bottom:10px}ol ol,ol ul,ul ol,ul ul{margin-bottom:0}.list-unstyled{padding-left:0;list-style:none}.list-inline{padding-left:0;margin-left:-5px;list-style:none}.list-inline>li{display:inline-block;padding-right:5px;padding-left:5px}dl{margin-top:0;margin-bottom:20px}dd,dt{line-height:1.42857143}dt{font-weight:700}dd{margin-left:0}@media (min-width:768px){.dl-horizontal dt{float:left;width:160px;overflow:hidden;clear:left;text-align:right;text-overflow:ellipsis;white-space:nowrap}.dl-horizontal dd{margin-left:180px}}abbr[data-original-title],abbr[title]{cursor:help;border-bottom:1px dotted #777}.initialism{font-size:90%;text-transform:uppercase}blockquote{padding:10px 20px;margin:0 0 20px;font-size:17.5px;border-left:5px solid #eee}blockquote ol:last-child,blockquote p:last-child,blockquote ul:last-child{margin-bottom:0}blockquote .small,blockquote footer,blockquote small{display:block;font-size:80%;line-height:1.42857143;color:#777}blockquote .small:before,blockquote footer:before,blockquote small:before{content:'\2014 \00A0'}.blockquote-reverse,blockquote.pull-right{padding-right:15px;padding-left:0;text-align:right;border-right:5px solid #eee;border-left:0}.blockquote-reverse .small:before,.blockquote-reverse footer:before,.blockquote-reverse small:before,blockquote.pull-right .small:before,blockquote.pull-right footer:before,blockquote.pull-right small:before{content:''}.blockquote-reverse .small:after,.blockquote-reverse footer:after,.blockquote-reverse small:after,blockquote.pull-right .small:after,blockquote.pull-right footer:after,blockquote.pull-right small:after{content:'\00A0 \2014'}address{margin-bottom:20px;font-style:normal;line-height:1.42857143}code,kbd,pre,samp{font-family:monospace}code{padding:2px 4px;font-size:90%;color:#c7254e;background-color:#f9f2f4;border-radius:4px}kbd{padding:2px 4px;font-size:90%;color:#fff;background-color:#333;border-radius:3px;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,.25);box-shadow:inset 0 -1px 0 rgba(0,0,0,.25)}kbd kbd{padding:0;font-size:100%;font-weight:700;-webkit-box-shadow:none;box-shadow:none}pre{display:block;padding:9.5px;margin:0 0 10px;font-size:13px;line-height:1.42857143;color:#333;word-break:break-all;word-wrap:break-word;background-color:#f5f5f5;border:1px solid #ccc;border-radius:4px}pre code{padding:0;font-size:inherit;color:inherit;white-space:pre-wrap;background-color:transparent;border-radius:0}.pre-scrollable{max-height:340px;overflow-y:scroll}.container{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}.row{margin-right:-15px;margin-left:-15px}.col-lg-1,.col-lg-10,.col-lg-11,.col-lg-12,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9,.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9,.col-sm-1,.col-sm-10,.col-sm-11,.col-sm-12,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9,.col-xs-1,.col-xs-10,.col-xs-11,.col-xs-12,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9{position:relative;min-height:1px;padding-right:15px;padding-left:15px}.col-xs-1,.col-xs-10,.col-xs-11,.col-xs-12,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9{float:left}.col-xs-12{width:100%}.col-xs-11{width:91.66666667%}.col-xs-10{width:83.33333333%}.col-xs-9{width:75%}.col-xs-8{width:66.66666667%}.col-xs-7{width:58.33333333%}.col-xs-6{width:50%}.col-xs-5{width:41.66666667%}.col-xs-4{width:33.33333333%}.col-xs-3{width:25%}.col-xs-2{width:16.66666667%}.col-xs-1{width:8.33333333%}.col-xs-pull-12{right:100%}.col-xs-pull-11{right:91.66666667%}.col-xs-pull-10{right:83.33333333%}.col-xs-pull-9{right:75%}.col-xs-pull-8{right:66.66666667%}.col-xs-pull-7{right:58.33333333%}.col-xs-pull-6{right:50%}.col-xs-pull-5{right:41.66666667%}.col-xs-pull-4{right:33.33333333%}.col-xs-pull-3{right:25%}.col-xs-pull-2{right:16.66666667%}.col-xs-pull-1{right:8.33333333%}.col-xs-pull-0{right:auto}.col-xs-push-12{left:100%}.col-xs-push-11{left:91.66666667%}.col-xs-push-10{left:83.33333333%}.col-xs-push-9{left:75%}.col-xs-push-8{left:66.66666667%}.col-xs-push-7{left:58.33333333%}.col-xs-push-6{left:50%}.col-xs-push-5{left:41.66666667%}.col-xs-push-4{left:33.33333333%}.col-xs-push-3{left:25%}.col-xs-push-2{left:16.66666667%}.col-xs-push-1{left:8.33333333%}.col-xs-push-0{left:auto}.col-xs-offset-12{margin-left:100%}.col-xs-offset-11{margin-left:91.66666667%}.col-xs-offset-10{margin-left:83.33333333%}.col-xs-offset-9{margin-left:75%}.col-xs-offset-8{margin-left:66.66666667%}.col-xs-offset-7{margin-left:58.33333333%}.col-xs-offset-6{margin-left:50%}.col-xs-offset-5{margin-left:41.66666667%}.col-xs-offset-4{margin-left:33.33333333%}.col-xs-offset-3{margin-left:25%}.col-xs-offset-2{margin-left:16.66666667%}.col-xs-offset-1{margin-left:8.33333333%}.col-xs-offset-0{margin-left:0}@media (min-width:768px){.col-sm-1,.col-sm-10,.col-sm-11,.col-sm-12,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9{float:left}.col-sm-12{width:100%}.col-sm-11{width:91.66666667%}.col-sm-10{width:83.33333333%}.col-sm-9{width:75%}.col-sm-8{width:66.66666667%}.col-sm-7{width:58.33333333%}.col-sm-6{width:50%}.col-sm-5{width:41.66666667%}.col-sm-4{width:33.33333333%}.col-sm-3{width:25%}.col-sm-2{width:16.66666667%}.col-sm-1{width:8.33333333%}.col-sm-pull-12{right:100%}.col-sm-pull-11{right:91.66666667%}.col-sm-pull-10{right:83.33333333%}.col-sm-pull-9{right:75%}.col-sm-pull-8{right:66.66666667%}.col-sm-pull-7{right:58.33333333%}.col-sm-pull-6{right:50%}.col-sm-pull-5{right:41.66666667%}.col-sm-pull-4{right:33.33333333%}.col-sm-pull-3{right:25%}.col-sm-pull-2{right:16.66666667%}.col-sm-pull-1{right:8.33333333%}.col-sm-pull-0{right:auto}.col-sm-push-12{left:100%}.col-sm-push-11{left:91.66666667%}.col-sm-push-10{left:83.33333333%}.col-sm-push-9{left:75%}.col-sm-push-8{left:66.66666667%}.col-sm-push-7{left:58.33333333%}.col-sm-push-6{left:50%}.col-sm-push-5{left:41.66666667%}.col-sm-push-4{left:33.33333333%}.col-sm-push-3{left:25%}.col-sm-push-2{left:16.66666667%}.col-sm-push-1{left:8.33333333%}.col-sm-push-0{left:auto}.col-sm-offset-12{margin-left:100%}.col-sm-offset-11{margin-left:91.66666667%}.col-sm-offset-10{margin-left:83.33333333%}.col-sm-offset-9{margin-left:75%}.col-sm-offset-8{margin-left:66.66666667%}.col-sm-offset-7{margin-left:58.33333333%}.col-sm-offset-6{margin-left:50%}.col-sm-offset-5{margin-left:41.66666667%}.col-sm-offset-4{margin-left:33.33333333%}.col-sm-offset-3{margin-left:25%}.col-sm-offset-2{margin-left:16.66666667%}.col-sm-offset-1{margin-left:8.33333333%}.col-sm-offset-0{margin-left:0}}@media (min-width:992px){.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9{float:left}.col-md-12{width:100%}.col-md-11{width:91.66666667%}.col-md-10{width:83.33333333%}.col-md-9{width:75%}.col-md-8{width:66.66666667%}.col-md-7{width:58.33333333%}.col-md-6{width:50%}.col-md-5{width:41.66666667%}.col-md-4{width:33.33333333%}.col-md-3{width:25%}.col-md-2{width:16.66666667%}.col-md-1{width:8.33333333%}.col-md-pull-12{right:100%}.col-md-pull-11{right:91.66666667%}.col-md-pull-10{right:83.33333333%}.col-md-pull-9{right:75%}.col-md-pull-8{right:66.66666667%}.col-md-pull-7{right:58.33333333%}.col-md-pull-6{right:50%}.col-md-pull-5{right:41.66666667%}.col-md-pull-4{right:33.33333333%}.col-md-pull-3{right:25%}.col-md-pull-2{right:16.66666667%}.col-md-pull-1{right:8.33333333%}.col-md-pull-0{right:auto}.col-md-push-12{left:100%}.col-md-push-11{left:91.66666667%}.col-md-push-10{left:83.33333333%}.col-md-push-9{left:75%}.col-md-push-8{left:66.66666667%}.col-md-push-7{left:58.33333333%}.col-md-push-6{left:50%}.col-md-push-5{left:41.66666667%}.col-md-push-4{left:33.33333333%}.col-md-push-3{left:25%}.col-md-push-2{left:16.66666667%}.col-md-push-1{left:8.33333333%}.col-md-push-0{left:auto}.col-md-offset-12{margin-left:100%}.col-md-offset-11{margin-left:91.66666667%}.col-md-offset-10{margin-left:83.33333333%}.col-md-offset-9{margin-left:75%}.col-md-offset-8{margin-left:66.66666667%}.col-md-offset-7{margin-left:58.33333333%}.col-md-offset-6{margin-left:50%}.col-md-offset-5{margin-left:41.66666667%}.col-md-offset-4{margin-left:33.33333333%}.col-md-offset-3{margin-left:25%}.col-md-offset-2{margin-left:16.66666667%}.col-md-offset-1{margin-left:8.33333333%}.col-md-offset-0{margin-left:0}}@media (min-width:1200px){.col-lg-1,.col-lg-10,.col-lg-11,.col-lg-12,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9{float:left}.col-lg-12{width:100%}.col-lg-11{width:91.66666667%}.col-lg-10{width:83.33333333%}.col-lg-9{width:75%}.col-lg-8{width:66.66666667%}.col-lg-7{width:58.33333333%}.col-lg-6{width:50%}.col-lg-5{width:41.66666667%}.col-lg-4{width:33.33333333%}.col-lg-3{width:25%}.col-lg-2{width:16.66666667%}.col-lg-1{width:8.33333333%}.col-lg-pull-12{right:100%}.col-lg-pull-11{right:91.66666667%}.col-lg-pull-10{right:83.33333333%}.col-lg-pull-9{right:75%}.col-lg-pull-8{right:66.66666667%}.col-lg-pull-7{right:58.33333333%}.col-lg-pull-6{right:50%}.col-lg-pull-5{right:41.66666667%}.col-lg-pull-4{right:33.33333333%}.col-lg-pull-3{right:25%}.col-lg-pull-2{right:16.66666667%}.col-lg-pull-1{right:8.33333333%}.col-lg-pull-0{right:auto}.col-lg-push-12{left:100%}.col-lg-push-11{left:91.66666667%}.col-lg-push-10{left:83.33333333%}.col-lg-push-9{left:75%}.col-lg-push-8{left:66.66666667%}.col-lg-push-7{left:58.33333333%}.col-lg-push-6{left:50%}.col-lg-push-5{left:41.66666667%}.col-lg-push-4{left:33.33333333%}.col-lg-push-3{left:25%}.col-lg-push-2{left:16.66666667%}.col-lg-push-1{left:8.33333333%}.col-lg-push-0{left:auto}.col-lg-offset-12{margin-left:100%}.col-lg-offset-11{margin-left:91.66666667%}.col-lg-offset-10{margin-left:83.33333333%}.col-lg-offset-9{margin-left:75%}.col-lg-offset-8{margin-left:66.66666667%}.col-lg-offset-7{margin-left:58.33333333%}.col-lg-offset-6{margin-left:50%}.col-lg-offset-5{margin-left:41.66666667%}.col-lg-offset-4{margin-left:33.33333333%}.col-lg-offset-3{margin-left:25%}.col-lg-offset-2{margin-left:16.66666667%}.col-lg-offset-1{margin-left:8.33333333%}.col-lg-offset-0{margin-left:0}}table{background-color:transparent}caption{padding-top:8px;padding-bottom:8px;color:#777;text-align:left}th{}.table{width:100%;max-width:100%;margin-bottom:20px}.table>tbody>tr>td,.table>tbody>tr>th,.table>tfoot>tr>td,.table>tfoot>tr>th,.table>thead>tr>td,.table>thead>tr>th{padding:8px;line-height:1.42857143;vertical-align:top;border-top:1px solid #ddd}.table>thead>tr>th{vertical-align:bottom;border-bottom:2px solid #ddd}.table>caption+thead>tr:first-child>td,.table>caption+thead>tr:first-child>th,.table>colgroup+thead>tr:first-child>td,.table>colgroup+thead>tr:first-child>th,.table>thead:first-child>tr:first-child>td,.table>thead:first-child>tr:first-child>th{border-top:0}.table>tbody+tbody{border-top:2px solid #ddd}.table .table{background-color:#fff}.table-condensed>tbody>tr>td,.table-condensed>tbody>tr>th,.table-condensed>tfoot>tr>td,.table-condensed>tfoot>tr>th,.table-condensed>thead>tr>td,.table-condensed>thead>tr>th{padding:5px}.table-bordered{border:1px solid #ddd}.table-bordered>tbody>tr>td,.table-bordered>tbody>tr>th,.table-bordered>tfoot>tr>td,.table-bordered>tfoot>tr>th,.table-bordered>thead>tr>td,.table-bordered>thead>tr>th{border:1px solid #ddd}.table-bordered>thead>tr>td,.table-bordered>thead>tr>th{border-bottom-width:2px}.table-striped>tbody>tr:nth-of-type(odd){background-color:#f9f9f9}.table-hover>tbody>tr:hover{background-color:#f5f5f5}table col[class*=col-]{position:static;display:table-column;float:none}table td[class*=col-],table th[class*=col-]{position:static;display:table-cell;float:none}.table>tbody>tr.active>td,.table>tbody>tr.active>th,.table>tbody>tr>td.active,.table>tbody>tr>th.active,.table>tfoot>tr.active>td,.table>tfoot>tr.active>th,.table>tfoot>tr>td.active,.table>tfoot>tr>th.active,.table>thead>tr.active>td,.table>thead>tr.active>th,.table>thead>tr>td.active,.table>thead>tr>th.active{background-color:#f5f5f5}.table-hover>tbody>tr.active:hover>td,.table-hover>tbody>tr.active:hover>th,.table-hover>tbody>tr:hover>.active,.table-hover>tbody>tr>td.active:hover,.table-hover>tbody>tr>th.active:hover{background-color:#e8e8e8}.table>tbody>tr.success>td,.table>tbody>tr.success>th,.table>tbody>tr>td.success,.table>tbody>tr>th.success,.table>tfoot>tr.success>td,.table>tfoot>tr.success>th,.table>tfoot>tr>td.success,.table>tfoot>tr>th.success,.table>thead>tr.success>td,.table>thead>tr.success>th,.table>thead>tr>td.success,.table>thead>tr>th.success{background-color:#dff0d8}.table-hover>tbody>tr.success:hover>td,.table-hover>tbody>tr.success:hover>th,.table-hover>tbody>tr:hover>.success,.table-hover>tbody>tr>td.success:hover,.table-hover>tbody>tr>th.success:hover{background-color:#d0e9c6}.table>tbody>tr.info>td,.table>tbody>tr.info>th,.table>tbody>tr>td.info,.table>tbody>tr>th.info,.table>tfoot>tr.info>td,.table>tfoot>tr.info>th,.table>tfoot>tr>td.info,.table>tfoot>tr>th.info,.table>thead>tr.info>td,.table>thead>tr.info>th,.table>thead>tr>td.info,.table>thead>tr>th.info{background-color:#d9edf7}.table-hover>tbody>tr.info:hover>td,.table-hover>tbody>tr.info:hover>th,.table-hover>tbody>tr:hover>.info,.table-hover>tbody>tr>td.info:hover,.table-hover>tbody>tr>th.info:hover{background-color:#c4e3f3}.table>tbody>tr.warning>td,.table>tbody>tr.warning>th,.table>tbody>tr>td.warning,.table>tbody>tr>th.warning,.table>tfoot>tr.warning>td,.table>tfoot>tr.warning>th,.table>tfoot>tr>td.warning,.table>tfoot>tr>th.warning,.table>thead>tr.warning>td,.table>thead>tr.warning>th,.table>thead>tr>td.warning,.table>thead>tr>th.warning{background-color:#fcf8e3}.table-hover>tbody>tr.warning:hover>td,.table-hover>tbody>tr.warning:hover>th,.table-hover>tbody>tr:hover>.warning,.table-hover>tbody>tr>td.warning:hover,.table-hover>tbody>tr>th.warning:hover{background-color:#faf2cc}.table>tbody>tr.danger>td,.table>tbody>tr.danger>th,.table>tbody>tr>td.danger,.table>tbody>tr>th.danger,.table>tfoot>tr.danger>td,.table>tfoot>tr.danger>th,.table>tfoot>tr>td.danger,.table>tfoot>tr>th.danger,.table>thead>tr.danger>td,.table>thead>tr.danger>th,.table>thead>tr>td.danger,.table>thead>tr>th.danger{background-color:#f2dede}.table-hover>tbody>tr.danger:hover>td,.table-hover>tbody>tr.danger:hover>th,.table-hover>tbody>tr:hover>.danger,.table-hover>tbody>tr>td.danger:hover,.table-hover>tbody>tr>th.danger:hover{background-color:#ebcccc}.table-responsive{min-height:.01%;overflow-x:auto}@media screen and (max-width:767px){.table-responsive{width:100%;margin-bottom:15px;overflow-y:hidden;-ms-overflow-style:-ms-autohiding-scrollbar;border:1px solid #ddd}.table-responsive>.table{margin-bottom:0}.table-responsive>.table>tbody>tr>td,.table-responsive>.table>tbody>tr>th,.table-responsive>.table>tfoot>tr>td,.table-responsive>.table>tfoot>tr>th,.table-responsive>.table>thead>tr>td,.table-responsive>.table>thead>tr>th{white-space:nowrap}.table-responsive>.table-bordered{border:0}.table-responsive>.table-bordered>tbody>tr>td:first-child,.table-responsive>.table-bordered>tbody>tr>th:first-child,.table-responsive>.table-bordered>tfoot>tr>td:first-child,.table-responsive>.table-bordered>tfoot>tr>th:first-child,.table-responsive>.table-bordered>thead>tr>td:first-child,.table-responsive>.table-bordered>thead>tr>th:first-child{border-left:0}.table-responsive>.table-bordered>tbody>tr>td:last-child,.table-responsive>.table-bordered>tbody>tr>th:last-child,.table-responsive>.table-bordered>tfoot>tr>td:last-child,.table-responsive>.table-bordered>tfoot>tr>th:last-child,.table-responsive>.table-bordered>thead>tr>td:last-child,.table-responsive>.table-bordered>thead>tr>th:last-child{border-right:0}.table-responsive>.table-bordered>tbody>tr:last-child>td,.table-responsive>.table-bordered>tbody>tr:last-child>th,.table-responsive>.table-bordered>tfoot>tr:last-child>td,.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}}fieldset{min-width:0;padding:0;margin:0;border:0}legend{display:block;width:100%;padding:0;margin-bottom:20px;font-size:21px;line-height:inherit;color:#333;border:0;border-bottom:1px solid #e5e5e5}label{display:inline-block;max-width:100%;margin-bottom:5px;font-weight:700}input[type=search]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}input[type=checkbox],input[type=radio]{margin:4px 0 0;margin-top:1px\9;line-height:normal}input[type=file]{display:block}input[type=range]{display:block;width:100%}select[multiple],select[size]{height:auto}input[type=file]:focus,input[type=checkbox]:focus,input[type=radio]:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}output{display:block;padding-top:7px;font-size:14px;line-height:1.42857143;color:#555}.form-control{display:block;width:100%;height:34px;padding:6px 12px;font-size:14px;line-height:1.42857143;color:#555;background-color:#fff;background-image:none;border:1px solid #ccc;border-radius:4px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075);-webkit-transition:border-color ease-in-out .15s,-webkit-box-shadow ease-in-out .15s;-o-transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s;transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s}.form-control:focus{border-color:#66afe9;outline:0;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 8px rgba(102,175,233,.6);box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 8px rgba(102,175,233,.6)}.form-control::-moz-placeholder{color:#999;opacity:1}.form-control:-ms-input-placeholder{color:#999}.form-control::-webkit-input-placeholder{color:#999}.form-control[disabled],.form-control[readonly],fieldset[disabled] .form-control{background-color:#eee;opacity:1}.form-control[disabled],fieldset[disabled] .form-control{cursor:not-allowed}textarea.form-control{height:auto}input[type=search]{-webkit-appearance:none}@media screen and (-webkit-min-device-pixel-ratio:0){input[type=date].form-control,input[type=time].form-control,input[type=datetime-local].form-control,input[type=month].form-control{line-height:34px}.input-group-sm input[type=date],.input-group-sm input[type=time],.input-group-sm input[type=datetime-local],.input-group-sm input[type=month],input[type=date].input-sm,input[type=time].input-sm,input[type=datetime-local].input-sm,input[type=month].input-sm{line-height:30px}.input-group-lg input[type=date],.input-group-lg input[type=time],.input-group-lg input[type=datetime-local],.input-group-lg input[type=month],input[type=date].input-lg,input[type=time].input-lg,input[type=datetime-local].input-lg,input[type=month].input-lg{line-height:46px}}.form-group{margin-bottom:15px}.checkbox,.radio{position:relative;display:block;margin-top:10px;margin-bottom:10px}.checkbox label,.radio label{min-height:20px;padding-left:20px;margin-bottom:0;font-weight:400;cursor:pointer}.checkbox input[type=checkbox],.checkbox-inline input[type=checkbox],.radio input[type=radio],.radio-inline input[type=radio]{position:absolute;margin-top:4px\9;margin-left:-20px}.checkbox+.checkbox,.radio+.radio{margin-top:-5px}.checkbox-inline,.radio-inline{position:relative;display:inline-block;padding-left:20px;margin-bottom:0;font-weight:400;vertical-align:middle;cursor:pointer}.checkbox-inline+.checkbox-inline,.radio-inline+.radio-inline{margin-top:0;margin-left:10px}fieldset[disabled] input[type=checkbox],fieldset[disabled] input[type=radio],input[type=checkbox].disabled,input[type=checkbox][disabled],input[type=radio].disabled,input[type=radio][disabled]{cursor:not-allowed}.checkbox-inline.disabled,.radio-inline.disabled,fieldset[disabled] .checkbox-inline,fieldset[disabled] .radio-inline{cursor:not-allowed}.checkbox.disabled label,.radio.disabled label,fieldset[disabled] .checkbox label,fieldset[disabled] .radio label{cursor:not-allowed}.form-control-static{min-height:34px;padding-top:7px;padding-bottom:7px;margin-bottom:0}.form-control-static.input-lg,.form-control-static.input-sm{padding-right:0;padding-left:0}.input-sm{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-sm{height:30px;line-height:30px}select[multiple].input-sm,textarea.input-sm{height:auto}.form-group-sm .form-control{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.form-group-sm select.form-control{height:30px;line-height:30px}.form-group-sm select[multiple].form-control,.form-group-sm textarea.form-control{height:auto}.form-group-sm .form-control-static{height:30px;min-height:32px;padding:6px 10px;font-size:12px;line-height:1.5}.input-lg{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}select.input-lg{height:46px;line-height:46px}select[multiple].input-lg,textarea.input-lg{height:auto}.form-group-lg .form-control{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}.form-group-lg select.form-control{height:46px;line-height:46px}.form-group-lg select[multiple].form-control,.form-group-lg textarea.form-control{height:auto}.form-group-lg .form-control-static{height:46px;min-height:38px;padding:11px 16px;font-size:18px;line-height:1.3333333}.has-feedback{position:relative}.has-feedback .form-control{padding-right:42.5px}.form-control-feedback{position:absolute;top:0;right:0;z-index:2;display:block;width:34px;height:34px;line-height:34px;text-align:center;pointer-events:none}.form-group-lg .form-control+.form-control-feedback,.input-group-lg+.form-control-feedback,.input-lg+.form-control-feedback{width:46px;height:46px;line-height:46px}.form-group-sm .form-control+.form-control-feedback,.input-group-sm+.form-control-feedback,.input-sm+.form-control-feedback{width:30px;height:30px;line-height:30px}.has-success .checkbox,.has-success .checkbox-inline,.has-success .control-label,.has-success .help-block,.has-success .radio,.has-success .radio-inline,.has-success.checkbox label,.has-success.checkbox-inline label,.has-success.radio label,.has-success.radio-inline label{color:#3c763d}.has-success .form-control{border-color:#3c763d;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-success .form-control:focus{border-color:#2b542c;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #67b168;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #67b168}.has-success .input-group-addon{color:#3c763d;background-color:#dff0d8;border-color:#3c763d}.has-success .form-control-feedback{color:#3c763d}.has-warning .checkbox,.has-warning .checkbox-inline,.has-warning .control-label,.has-warning .help-block,.has-warning .radio,.has-warning .radio-inline,.has-warning.checkbox label,.has-warning.checkbox-inline label,.has-warning.radio label,.has-warning.radio-inline label{color:#8a6d3b}.has-warning .form-control{border-color:#8a6d3b;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-warning .form-control:focus{border-color:#66512c;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #c0a16b;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #c0a16b}.has-warning .input-group-addon{color:#8a6d3b;background-color:#fcf8e3;border-color:#8a6d3b}.has-warning .form-control-feedback{color:#8a6d3b}.has-error .checkbox,.has-error .checkbox-inline,.has-error .control-label,.has-error .help-block,.has-error .radio,.has-error .radio-inline,.has-error.checkbox label,.has-error.checkbox-inline label,.has-error.radio label,.has-error.radio-inline label{color:#a94442}.has-error .form-control{border-color:#a94442;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-error .form-control:focus{border-color:#843534;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #ce8483;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #ce8483}.has-error .input-group-addon{color:#a94442;background-color:#f2dede;border-color:#a94442}.has-error .form-control-feedback{color:#a94442}.has-feedback label~.form-control-feedback{top:25px}.has-feedback label.sr-only~.form-control-feedback{top:0}.help-block{display:block;margin-top:5px;margin-bottom:10px;color:#737373}@media (min-width:768px){.form-inline .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.form-inline .form-control{display:inline-block;width:auto;vertical-align:middle}.form-inline .form-control-static{display:inline-block}.form-inline .input-group{display:inline-table;vertical-align:middle}.form-inline .input-group .form-control,.form-inline .input-group .input-group-addon,.form-inline .input-group .input-group-btn{width:auto}.form-inline .input-group>.form-control{width:100%}.form-inline .control-label{margin-bottom:0;vertical-align:middle}.form-inline .checkbox,.form-inline .radio{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.form-inline .checkbox label,.form-inline .radio label{padding-left:0}.form-inline .checkbox input[type=checkbox],.form-inline .radio input[type=radio]{position:relative;margin-left:0}.form-inline .has-feedback .form-control-feedback{top:0}}.form-horizontal .checkbox,.form-horizontal .checkbox-inline,.form-horizontal .radio,.form-horizontal .radio-inline{padding-top:7px;margin-top:0;margin-bottom:0}.form-horizontal .checkbox,.form-horizontal .radio{min-height:27px}.form-horizontal .form-group{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.form-horizontal .control-label{padding-top:7px;margin-bottom:0;text-align:right}}.form-horizontal .has-feedback .form-control-feedback{right:15px}@media (min-width:768px){.form-horizontal .form-group-lg .control-label{padding-top:14.33px;font-size:18px}}@media (min-width:768px){.form-horizontal .form-group-sm .control-label{padding-top:6px;font-size:12px}}.btn{display:inline-block;padding:6px 12px;margin-bottom:0;font-size:14px;font-weight:400;line-height:1.42857143;text-align:center;white-space:nowrap;vertical-align:middle;-ms-touch-action:manipulation;touch-action:manipulation;cursor:pointer;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;background-image:none;border:1px solid transparent;border-radius:4px}.btn.active.focus,.btn.active:focus,.btn.focus,.btn:active.focus,.btn:active:focus,.btn:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}.btn.focus,.btn:focus,.btn:hover{color:#333;text-decoration:none}.btn.active,.btn:active{background-image:none;outline:0;-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,.125);box-shadow:inset 0 3px 5px rgba(0,0,0,.125)}.btn.disabled,.btn[disabled],fieldset[disabled] .btn{cursor:not-allowed;filter:alpha(opacity=65);-webkit-box-shadow:none;box-shadow:none;opacity:.65}a.btn.disabled,fieldset[disabled] a.btn{pointer-events:none}.btn-default{color:#333;background-color:#fff;border-color:#ccc}.btn-default.focus,.btn-default:focus{color:#333;background-color:#e6e6e6;border-color:#8c8c8c}.btn-default:hover{color:#333;background-color:#e6e6e6;border-color:#adadad}.btn-default.active,.btn-default:active,.open>.dropdown-toggle.btn-default{color:#333;background-color:#e6e6e6;border-color:#adadad}.btn-default.active.focus,.btn-default.active:focus,.btn-default.active:hover,.btn-default:active.focus,.btn-default:active:focus,.btn-default:active:hover,.open>.dropdown-toggle.btn-default.focus,.open>.dropdown-toggle.btn-default:focus,.open>.dropdown-toggle.btn-default:hover{color:#333;background-color:#d4d4d4;border-color:#8c8c8c}.btn-default.active,.btn-default:active,.open>.dropdown-toggle.btn-default{background-image:none}.btn-default.disabled,.btn-default.disabled.active,.btn-default.disabled.focus,.btn-default.disabled:active,.btn-default.disabled:focus,.btn-default.disabled:hover,.btn-default[disabled],.btn-default[disabled].active,.btn-default[disabled].focus,.btn-default[disabled]:active,.btn-default[disabled]:focus,.btn-default[disabled]:hover,fieldset[disabled] .btn-default,fieldset[disabled] .btn-default.active,fieldset[disabled] .btn-default.focus,fieldset[disabled] .btn-default:active,fieldset[disabled] .btn-default:focus,fieldset[disabled] .btn-default:hover{background-color:#fff;border-color:#ccc}.btn-default .badge{color:#fff;background-color:#333}.btn-primary{color:#fff;background-color:#337ab7;border-color:#2e6da4}.btn-primary.focus,.btn-primary:focus{color:#fff;background-color:#286090;border-color:#122b40}.btn-primary:hover{color:#fff;background-color:#286090;border-color:#204d74}.btn-primary.active,.btn-primary:active,.open>.dropdown-toggle.btn-primary{color:#fff;background-color:#286090;border-color:#204d74}.btn-primary.active.focus,.btn-primary.active:focus,.btn-primary.active:hover,.btn-primary:active.focus,.btn-primary:active:focus,.btn-primary:active:hover,.open>.dropdown-toggle.btn-primary.focus,.open>.dropdown-toggle.btn-primary:focus,.open>.dropdown-toggle.btn-primary:hover{color:#fff;background-color:#204d74;border-color:#122b40}.btn-primary.active,.btn-primary:active,.open>.dropdown-toggle.btn-primary{background-image:none}.btn-primary.disabled,.btn-primary.disabled.active,.btn-primary.disabled.focus,.btn-primary.disabled:active,.btn-primary.disabled:focus,.btn-primary.disabled:hover,.btn-primary[disabled],.btn-primary[disabled].active,.btn-primary[disabled].focus,.btn-primary[disabled]:active,.btn-primary[disabled]:focus,.btn-primary[disabled]:hover,fieldset[disabled] .btn-primary,fieldset[disabled] .btn-primary.active,fieldset[disabled] .btn-primary.focus,fieldset[disabled] .btn-primary:active,fieldset[disabled] .btn-primary:focus,fieldset[disabled] .btn-primary:hover{background-color:#337ab7;border-color:#2e6da4}.btn-primary .badge{color:#337ab7;background-color:#fff}.btn-success{color:#fff;background-color:#5cb85c;border-color:#4cae4c}.btn-success.focus,.btn-success:focus{color:#fff;background-color:#449d44;border-color:#255625}.btn-success:hover{color:#fff;background-color:#449d44;border-color:#398439}.btn-success.active,.btn-success:active,.open>.dropdown-toggle.btn-success{color:#fff;background-color:#449d44;border-color:#398439}.btn-success.active.focus,.btn-success.active:focus,.btn-success.active:hover,.btn-success:active.focus,.btn-success:active:focus,.btn-success:active:hover,.open>.dropdown-toggle.btn-success.focus,.open>.dropdown-toggle.btn-success:focus,.open>.dropdown-toggle.btn-success:hover{color:#fff;background-color:#398439;border-color:#255625}.btn-success.active,.btn-success:active,.open>.dropdown-toggle.btn-success{background-image:none}.btn-success.disabled,.btn-success.disabled.active,.btn-success.disabled.focus,.btn-success.disabled:active,.btn-success.disabled:focus,.btn-success.disabled:hover,.btn-success[disabled],.btn-success[disabled].active,.btn-success[disabled].focus,.btn-success[disabled]:active,.btn-success[disabled]:focus,.btn-success[disabled]:hover,fieldset[disabled] .btn-success,fieldset[disabled] .btn-success.active,fieldset[disabled] .btn-success.focus,fieldset[disabled] .btn-success:active,fieldset[disabled] .btn-success:focus,fieldset[disabled] .btn-success:hover{background-color:#5cb85c;border-color:#4cae4c}.btn-success .badge{color:#5cb85c;background-color:#fff}.btn-info{color:#fff;background-color:#5bc0de;border-color:#46b8da}.btn-info.focus,.btn-info:focus{color:#fff;background-color:#31b0d5;border-color:#1b6d85}.btn-info:hover{color:#fff;background-color:#31b0d5;border-color:#269abc}.btn-info.active,.btn-info:active,.open>.dropdown-toggle.btn-info{color:#fff;background-color:#31b0d5;border-color:#269abc}.btn-info.active.focus,.btn-info.active:focus,.btn-info.active:hover,.btn-info:active.focus,.btn-info:active:focus,.btn-info:active:hover,.open>.dropdown-toggle.btn-info.focus,.open>.dropdown-toggle.btn-info:focus,.open>.dropdown-toggle.btn-info:hover{color:#fff;background-color:#269abc;border-color:#1b6d85}.btn-info.active,.btn-info:active,.open>.dropdown-toggle.btn-info{background-image:none}.btn-info.disabled,.btn-info.disabled.active,.btn-info.disabled.focus,.btn-info.disabled:active,.btn-info.disabled:focus,.btn-info.disabled:hover,.btn-info[disabled],.btn-info[disabled].active,.btn-info[disabled].focus,.btn-info[disabled]:active,.btn-info[disabled]:focus,.btn-info[disabled]:hover,fieldset[disabled] .btn-info,fieldset[disabled] .btn-info.active,fieldset[disabled] .btn-info.focus,fieldset[disabled] .btn-info:active,fieldset[disabled] .btn-info:focus,fieldset[disabled] .btn-info:hover{background-color:#5bc0de;border-color:#46b8da}.btn-info .badge{color:#5bc0de;background-color:#fff}.btn-warning{color:#fff;background-color:#f0ad4e;border-color:#eea236}.btn-warning.focus,.btn-warning:focus{color:#fff;background-color:#ec971f;border-color:#985f0d}.btn-warning:hover{color:#fff;background-color:#ec971f;border-color:#d58512}.btn-warning.active,.btn-warning:active,.open>.dropdown-toggle.btn-warning{color:#fff;background-color:#ec971f;border-color:#d58512}.btn-warning.active.focus,.btn-warning.active:focus,.btn-warning.active:hover,.btn-warning:active.focus,.btn-warning:active:focus,.btn-warning:active:hover,.open>.dropdown-toggle.btn-warning.focus,.open>.dropdown-toggle.btn-warning:focus,.open>.dropdown-toggle.btn-warning:hover{color:#fff;background-color:#d58512;border-color:#985f0d}.btn-warning.active,.btn-warning:active,.open>.dropdown-toggle.btn-warning{background-image:none}.btn-warning.disabled,.btn-warning.disabled.active,.btn-warning.disabled.focus,.btn-warning.disabled:active,.btn-warning.disabled:focus,.btn-warning.disabled:hover,.btn-warning[disabled],.btn-warning[disabled].active,.btn-warning[disabled].focus,.btn-warning[disabled]:active,.btn-warning[disabled]:focus,.btn-warning[disabled]:hover,fieldset[disabled] .btn-warning,fieldset[disabled] .btn-warning.active,fieldset[disabled] .btn-warning.focus,fieldset[disabled] .btn-warning:active,fieldset[disabled] .btn-warning:focus,fieldset[disabled] .btn-warning:hover{background-color:#f0ad4e;border-color:#eea236}.btn-warning .badge{color:#f0ad4e;background-color:#fff}.btn-danger{color:#fff;background-color:#d9534f;border-color:#d43f3a}.btn-danger.focus,.btn-danger:focus{color:#fff;background-color:#c9302c;border-color:#761c19}.btn-danger:hover{color:#fff;background-color:#c9302c;border-color:#ac2925}.btn-danger.active,.btn-danger:active,.open>.dropdown-toggle.btn-danger{color:#fff;background-color:#c9302c;border-color:#ac2925}.btn-danger.active.focus,.btn-danger.active:focus,.btn-danger.active:hover,.btn-danger:active.focus,.btn-danger:active:focus,.btn-danger:active:hover,.open>.dropdown-toggle.btn-danger.focus,.open>.dropdown-toggle.btn-danger:focus,.open>.dropdown-toggle.btn-danger:hover{color:#fff;background-color:#ac2925;border-color:#761c19}.btn-danger.active,.btn-danger:active,.open>.dropdown-toggle.btn-danger{background-image:none}.btn-danger.disabled,.btn-danger.disabled.active,.btn-danger.disabled.focus,.btn-danger.disabled:active,.btn-danger.disabled:focus,.btn-danger.disabled:hover,.btn-danger[disabled],.btn-danger[disabled].active,.btn-danger[disabled].focus,.btn-danger[disabled]:active,.btn-danger[disabled]:focus,.btn-danger[disabled]:hover,fieldset[disabled] .btn-danger,fieldset[disabled] .btn-danger.active,fieldset[disabled] .btn-danger.focus,fieldset[disabled] .btn-danger:active,fieldset[disabled] .btn-danger:focus,fieldset[disabled] .btn-danger:hover{background-color:#d9534f;border-color:#d43f3a}.btn-danger .badge{color:#d9534f;background-color:#fff}.btn-link{font-weight:400;color:#337ab7;border-radius:0}.btn-link,.btn-link.active,.btn-link:active,.btn-link[disabled],fieldset[disabled] .btn-link{background-color:transparent;-webkit-box-shadow:none;box-shadow:none}.btn-link,.btn-link:active,.btn-link:focus,.btn-link:hover{border-color:transparent}.btn-link:focus,.btn-link:hover{color:#23527c;text-decoration:underline;background-color:transparent}.btn-link[disabled]:focus,.btn-link[disabled]:hover,fieldset[disabled] .btn-link:focus,fieldset[disabled] .btn-link:hover{color:#777;text-decoration:none}.btn-group-lg>.btn,.btn-lg{padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}.btn-group-sm>.btn,.btn-sm{padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.btn-group-xs>.btn,.btn-xs{padding:1px 5px;font-size:12px;line-height:1.5;border-radius:3px}.btn-block{display:block;width:100%}.btn-block+.btn-block{margin-top:5px}input[type=button].btn-block,input[type=reset].btn-block,input[type=submit].btn-block{width:100%}.fade{opacity:0;-webkit-transition:opacity .15s linear;-o-transition:opacity .15s linear;transition:opacity .15s linear}.fade.in{opacity:1}.collapse{display:none}.collapse.in{display:block}tr.collapse.in{display:table-row}tbody.collapse.in{display:table-row-group}.collapsing{position:relative;height:0;overflow:hidden;-webkit-transition-timing-function:ease;-o-transition-timing-function:ease;transition-timing-function:ease;-webkit-transition-duration:.35s;-o-transition-duration:.35s;transition-duration:.35s;-webkit-transition-property:height,visibility;-o-transition-property:height,visibility;transition-property:height,visibility}.caret{display:inline-block;width:0;height:0;margin-left:2px;vertical-align:middle;border-top:4px dashed;border-top:4px solid\9;border-right:4px solid transparent;border-left:4px solid transparent}.dropdown,.dropup{position:relative}.dropdown-toggle:focus{outline:0}.dropdown-menu{position:absolute;top:100%;left:0;z-index:1000;display:none;float:left;min-width:160px;padding:5px 0;margin:2px 0 0;font-size:14px;text-align:left;list-style:none;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #ccc;border:1px solid rgba(0,0,0,.15);border-radius:4px;-webkit-box-shadow:0 6px 12px rgba(0,0,0,.175);box-shadow:0 6px 12px rgba(0,0,0,.175)}.dropdown-menu.pull-right{right:0;left:auto}.dropdown-menu .divider{height:1px;margin:9px 0;overflow:hidden;background-color:#e5e5e5}.dropdown-menu>li>a{display:block;padding:3px 20px;clear:both;font-weight:400;line-height:1.42857143;color:#333;white-space:nowrap}.dropdown-menu>li>a:focus,.dropdown-menu>li>a:hover{color:#262626;text-decoration:none;background-color:#f5f5f5}.dropdown-menu>.active>a,.dropdown-menu>.active>a:focus,.dropdown-menu>.active>a:hover{color:#fff;text-decoration:none;background-color:#337ab7;outline:0}.dropdown-menu>.disabled>a,.dropdown-menu>.disabled>a:focus,.dropdown-menu>.disabled>a:hover{color:#777}.dropdown-menu>.disabled>a:focus,.dropdown-menu>.disabled>a:hover{text-decoration:none;cursor:not-allowed;background-color:transparent;background-image:none;filter:progid:DXImageTransform.Microsoft.gradient(enabled=false)}.open>.dropdown-menu{display:block}.open>a{outline:0}.dropdown-menu-right{right:0;left:auto}.dropdown-menu-left{right:auto;left:0}.dropdown-header{display:block;padding:3px 20px;font-size:12px;line-height:1.42857143;color:#777;white-space:nowrap}.dropdown-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:990}.pull-right>.dropdown-menu{right:0;left:auto}.dropup .caret,.navbar-fixed-bottom .dropdown .caret{content:"";border-top:0;border-bottom:4px dashed;border-bottom:4px solid\9}.dropup .dropdown-menu,.navbar-fixed-bottom .dropdown .dropdown-menu{top:auto;bottom:100%;margin-bottom:2px}@media (min-width:768px){.navbar-right .dropdown-menu{right:0;left:auto}.navbar-right .dropdown-menu-left{right:auto;left:0}}.btn-group,.btn-group-vertical{position:relative;display:inline-block;vertical-align:middle}.btn-group-vertical>.btn,.btn-group>.btn{position:relative;float:left}.btn-group-vertical>.btn.active,.btn-group-vertical>.btn:active,.btn-group-vertical>.btn:focus,.btn-group-vertical>.btn:hover,.btn-group>.btn.active,.btn-group>.btn:active,.btn-group>.btn:focus,.btn-group>.btn:hover{z-index:2}.btn-group .btn+.btn,.btn-group .btn+.btn-group,.btn-group .btn-group+.btn,.btn-group .btn-group+.btn-group{margin-left:-1px}.btn-toolbar{margin-left:-5px}.btn-toolbar .btn,.btn-toolbar .btn-group,.btn-toolbar .input-group{float:left}.btn-toolbar>.btn,.btn-toolbar>.btn-group,.btn-toolbar>.input-group{margin-left:5px}.btn-group>.btn:not(:first-child):not(:last-child):not(.dropdown-toggle){border-radius:0}.btn-group>.btn:first-child{margin-left:0}.btn-group>.btn:first-child:not(:last-child):not(.dropdown-toggle){border-top-right-radius:0;border-bottom-right-radius:0}.btn-group>.btn:last-child:not(:first-child),.btn-group>.dropdown-toggle:not(:first-child){border-top-left-radius:0;border-bottom-left-radius:0}.btn-group>.btn-group{float:left}.btn-group>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-top-right-radius:0;border-bottom-right-radius:0}.btn-group>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-left-radius:0;border-bottom-left-radius:0}.btn-group .dropdown-toggle:active,.btn-group.open .dropdown-toggle{outline:0}.btn-group>.btn+.dropdown-toggle{padding-right:8px;padding-left:8px}.btn-group>.btn-lg+.dropdown-toggle{padding-right:12px;padding-left:12px}.btn-group.open .dropdown-toggle{-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,.125);box-shadow:inset 0 3px 5px rgba(0,0,0,.125)}.btn-group.open .dropdown-toggle.btn-link{-webkit-box-shadow:none;box-shadow:none}.btn .caret{margin-left:0}.btn-lg .caret{border-width:5px 5px 0;border-bottom-width:0}.dropup .btn-lg .caret{border-width:0 5px 5px}.btn-group-vertical>.btn,.btn-group-vertical>.btn-group,.btn-group-vertical>.btn-group>.btn{display:block;float:none;width:100%;max-width:100%}.btn-group-vertical>.btn-group>.btn{float:none}.btn-group-vertical>.btn+.btn,.btn-group-vertical>.btn+.btn-group,.btn-group-vertical>.btn-group+.btn,.btn-group-vertical>.btn-group+.btn-group{margin-top:-1px;margin-left:0}.btn-group-vertical>.btn:not(:first-child):not(:last-child){border-radius:0}.btn-group-vertical>.btn:first-child:not(:last-child){border-top-right-radius:4px;border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn:last-child:not(:first-child){border-top-left-radius:0;border-top-right-radius:0;border-bottom-left-radius:4px}.btn-group-vertical>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group-vertical>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group-vertical>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-left-radius:0;border-top-right-radius:0}.btn-group-justified{display:table;width:100%;table-layout:fixed;border-collapse:separate}.btn-group-justified>.btn,.btn-group-justified>.btn-group{display:table-cell;float:none;width:1%}.btn-group-justified>.btn-group .btn{width:100%}.btn-group-justified>.btn-group .dropdown-menu{left:auto}[data-toggle=buttons]>.btn input[type=checkbox],[data-toggle=buttons]>.btn input[type=radio],[data-toggle=buttons]>.btn-group>.btn input[type=checkbox],[data-toggle=buttons]>.btn-group>.btn input[type=radio]{position:absolute;clip:rect(0,0,0,0);pointer-events:none}.input-group{position:relative;display:table;border-collapse:separate}.input-group[class*=col-]{float:none;padding-right:0;padding-left:0}.input-group .form-control{position:relative;z-index:2;float:left;width:100%;margin-bottom:0}.input-group-lg>.form-control,.input-group-lg>.input-group-addon,.input-group-lg>.input-group-btn>.btn{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}select.input-group-lg>.form-control,select.input-group-lg>.input-group-addon,select.input-group-lg>.input-group-btn>.btn{height:46px;line-height:46px}select[multiple].input-group-lg>.form-control,select[multiple].input-group-lg>.input-group-addon,select[multiple].input-group-lg>.input-group-btn>.btn,textarea.input-group-lg>.form-control,textarea.input-group-lg>.input-group-addon,textarea.input-group-lg>.input-group-btn>.btn{height:auto}.input-group-sm>.form-control,.input-group-sm>.input-group-addon,.input-group-sm>.input-group-btn>.btn{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-group-sm>.form-control,select.input-group-sm>.input-group-addon,select.input-group-sm>.input-group-btn>.btn{height:30px;line-height:30px}select[multiple].input-group-sm>.form-control,select[multiple].input-group-sm>.input-group-addon,select[multiple].input-group-sm>.input-group-btn>.btn,textarea.input-group-sm>.form-control,textarea.input-group-sm>.input-group-addon,textarea.input-group-sm>.input-group-btn>.btn{height:auto}.input-group .form-control,.input-group-addon,.input-group-btn{display:table-cell}.input-group .form-control:not(:first-child):not(:last-child),.input-group-addon:not(:first-child):not(:last-child),.input-group-btn:not(:first-child):not(:last-child){border-radius:0}.input-group-addon,.input-group-btn{width:1%;white-space:nowrap;vertical-align:middle}.input-group-addon{padding:6px 12px;font-size:14px;font-weight:400;line-height:1;color:#555;text-align:center;background-color:#eee;border:1px solid #ccc;border-radius:4px}.input-group-addon.input-sm{padding:5px 10px;font-size:12px;border-radius:3px}.input-group-addon.input-lg{padding:10px 16px;font-size:18px;border-radius:6px}.input-group-addon input[type=checkbox],.input-group-addon input[type=radio]{margin-top:0}.input-group .form-control:first-child,.input-group-addon:first-child,.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group>.btn,.input-group-btn:first-child>.dropdown-toggle,.input-group-btn:last-child>.btn-group:not(:last-child)>.btn,.input-group-btn:last-child>.btn:not(:last-child):not(.dropdown-toggle){border-top-right-radius:0;border-bottom-right-radius:0}.input-group-addon:first-child{border-right:0}.input-group .form-control:last-child,.input-group-addon:last-child,.input-group-btn:first-child>.btn-group:not(:first-child)>.btn,.input-group-btn:first-child>.btn:not(:first-child),.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group>.btn,.input-group-btn:last-child>.dropdown-toggle{border-top-left-radius:0;border-bottom-left-radius:0}.input-group-addon:last-child{border-left:0}.input-group-btn{position:relative;font-size:0;white-space:nowrap}.input-group-btn>.btn{position:relative}.input-group-btn>.btn+.btn{margin-left:-1px}.input-group-btn>.btn:active,.input-group-btn>.btn:focus,.input-group-btn>.btn:hover{z-index:2}.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group{margin-right:-1px}.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group{z-index:2;margin-left:-1px}.nav{padding-left:0;margin-bottom:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.nav>li.disabled>a{color:#777}.nav>li.disabled>a:focus,.nav>li.disabled>a:hover{color:#777;text-decoration:none;cursor:not-allowed;background-color:transparent}.nav .open>a,.nav .open>a:focus,.nav .open>a:hover{background-color:#eee;border-color:#337ab7}.nav .nav-divider{height:1px;margin:9px 0;overflow:hidden;background-color:#e5e5e5}.nav>li>a>img{max-width:none}.nav-tabs{border-bottom:1px solid #ddd}.nav-tabs>li{float:left;margin-bottom:-1px}.nav-tabs>li>a{margin-right:2px;line-height:1.42857143;border:1px solid transparent;border-radius:4px 4px 0 0}.nav-tabs>li>a:hover{border-color:#eee #eee #ddd}.nav-tabs>li.active>a,.nav-tabs>li.active>a:focus,.nav-tabs>li.active>a:hover{color:#555;cursor:default;background-color:#fff;border:1px solid #ddd;border-bottom-color:transparent}.nav-tabs.nav-justified{width:100%;border-bottom:0}.nav-tabs.nav-justified>li{float:none}.nav-tabs.nav-justified>li>a{margin-bottom:5px;text-align:center}.nav-tabs.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-tabs.nav-justified>li{display:table-cell;width:1%}.nav-tabs.nav-justified>li>a{margin-bottom:0}}.nav-tabs.nav-justified>li>a{margin-right:0;border-radius:4px}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:focus,.nav-tabs.nav-justified>.active>a:hover{border:1px solid #ddd}@media (min-width:768px){.nav-tabs.nav-justified>li>a{border-bottom:1px solid #ddd;border-radius:4px 4px 0 0}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:focus,.nav-tabs.nav-justified>.active>a:hover{border-bottom-color:#fff}}.nav-pills>li{float:left}.nav-pills>li>a{border-radius:4px}.nav-pills>li+li{margin-left:2px}.nav-pills>li.active>a,.nav-pills>li.active>a:focus,.nav-pills>li.active>a:hover{color:#fff;background-color:#337ab7}.nav-stacked>li{float:none}.nav-stacked>li+li{margin-top:2px;margin-left:0}.nav-justified{width:100%}.nav-justified>li{float:none}.nav-justified>li>a{margin-bottom:5px;text-align:center}.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-justified>li{display:table-cell;width:1%}.nav-justified>li>a{margin-bottom:0}}.nav-tabs-justified{border-bottom:0}.nav-tabs-justified>li>a{margin-right:0;border-radius:4px}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:focus,.nav-tabs-justified>.active>a:hover{border:1px solid #ddd}@media (min-width:768px){.nav-tabs-justified>li>a{border-bottom:1px solid #ddd;border-radius:4px 4px 0 0}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:focus,.nav-tabs-justified>.active>a:hover{border-bottom-color:#fff}}.tab-content>.tab-pane{display:none}.tab-content>.active{display:block}.nav-tabs .dropdown-menu{margin-top:-1px;border-top-left-radius:0;border-top-right-radius:0}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.navbar-collapse{padding-right:15px;padding-left:15px;overflow-x:visible;-webkit-overflow-scrolling:touch;border-top:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,.1);box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}.navbar-collapse.in{overflow-y:auto}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;-webkit-box-shadow:none;box-shadow:none}.navbar-collapse.collapse{display:block!important;height:auto!important;padding-bottom:0;overflow:visible!important}.navbar-collapse.in{overflow-y:visible}.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse,.navbar-static-top .navbar-collapse{padding-right:0;padding-left:0}}.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse{max-height:340px}@media (max-device-width:480px) and (orientation:landscape){.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse{max-height:200px}}.container-fluid>.navbar-collapse,.container-fluid>.navbar-header,.container>.navbar-collapse,.container>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container-fluid>.navbar-collapse,.container-fluid>.navbar-header,.container>.navbar-collapse,.container>.navbar-header{margin-right:0;margin-left:0}}.navbar-static-top{z-index:1000;border-width:0 0 1px}@media (min-width:768px){.navbar-static-top{border-radius:0}}.navbar-fixed-bottom,.navbar-fixed-top{position:fixed;right:0;left:0;z-index:1030}@media (min-width:768px){.navbar-fixed-bottom,.navbar-fixed-top{border-radius:0}}.navbar-fixed-top{top:0;border-width:0 0 1px}.navbar-fixed-bottom{bottom:0;margin-bottom:0;border-width:1px 0 0}.navbar-brand{float:left;height:50px;padding:15px 15px;font-size:18px;line-height:20px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}.navbar-brand>img{display:block}@media (min-width:768px){.navbar>.container .navbar-brand,.navbar>.container-fluid .navbar-brand{margin-left:-15px}}.navbar-toggle{position:relative;float:right;padding:9px 10px;margin-top:8px;margin-right:15px;margin-bottom:8px;background-color:transparent;background-image:none;border:1px solid transparent;border-radius:4px}.navbar-toggle:focus{outline:0}.navbar-toggle .icon-bar{display:block;width:22px;height:2px;border-radius:1px}.navbar-toggle .icon-bar+.icon-bar{margin-top:4px}@media (min-width:768px){.navbar-toggle{display:none}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (max-width:767px){.navbar-nav .open .dropdown-menu{position:static;float:none;width:auto;margin-top:0;background-color:transparent;border:0;-webkit-box-shadow:none;box-shadow:none}.navbar-nav .open .dropdown-menu .dropdown-header,.navbar-nav .open .dropdown-menu>li>a{padding:5px 15px 5px 25px}.navbar-nav .open .dropdown-menu>li>a{line-height:20px}.navbar-nav .open .dropdown-menu>li>a:focus,.navbar-nav .open .dropdown-menu>li>a:hover{background-image:none}}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}}.navbar-form{padding:10px 15px;margin-top:8px;margin-right:-15px;margin-bottom:8px;margin-left:-15px;border-top:1px solid transparent;border-bottom:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,.1),0 1px 0 rgba(255,255,255,.1);box-shadow:inset 0 1px 0 rgba(255,255,255,.1),0 1px 0 rgba(255,255,255,.1)}@media (min-width:768px){.navbar-form .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.navbar-form .form-control{display:inline-block;width:auto;vertical-align:middle}.navbar-form .form-control-static{display:inline-block}.navbar-form .input-group{display:inline-table;vertical-align:middle}.navbar-form .input-group .form-control,.navbar-form .input-group .input-group-addon,.navbar-form .input-group .input-group-btn{width:auto}.navbar-form .input-group>.form-control{width:100%}.navbar-form .control-label{margin-bottom:0;vertical-align:middle}.navbar-form .checkbox,.navbar-form .radio{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.navbar-form .checkbox label,.navbar-form .radio label{padding-left:0}.navbar-form .checkbox input[type=checkbox],.navbar-form .radio input[type=radio]{position:relative;margin-left:0}.navbar-form .has-feedback .form-control-feedback{top:0}}@media (max-width:767px){.navbar-form .form-group{margin-bottom:5px}.navbar-form .form-group:last-child{margin-bottom:0}}@media (min-width:768px){.navbar-form{width:auto;padding-top:0;padding-bottom:0;margin-right:0;margin-left:0;border:0;-webkit-box-shadow:none;box-shadow:none}}.navbar-nav>li>.dropdown-menu{margin-top:0;border-top-left-radius:0;border-top-right-radius:0}.navbar-fixed-bottom .navbar-nav>li>.dropdown-menu{margin-bottom:0;border-top-left-radius:4px;border-top-right-radius:4px;border-bottom-right-radius:0;border-bottom-left-radius:0}.navbar-btn{margin-top:8px;margin-bottom:8px}.navbar-btn.btn-sm{margin-top:10px;margin-bottom:10px}.navbar-btn.btn-xs{margin-top:14px;margin-bottom:14px}.navbar-text{margin-top:15px;margin-bottom:15px}@media (min-width:768px){.navbar-text{float:left;margin-right:15px;margin-left:15px}}@media (min-width:768px){.navbar-left{float:left!important}.navbar-right{float:right!important;margin-right:-15px}.navbar-right~.navbar-right{margin-right:0}}.navbar-default{background-color:#f8f8f8;border-color:#e7e7e7}.navbar-default .navbar-brand{color:#777}.navbar-default .navbar-brand:focus,.navbar-default .navbar-brand:hover{color:#5e5e5e;background-color:transparent}.navbar-default .navbar-text{color:#777}.navbar-default .navbar-nav>li>a{color:#777}.navbar-default .navbar-nav>li>a:focus,.navbar-default .navbar-nav>li>a:hover{color:#333;background-color:transparent}.navbar-default .navbar-nav>.active>a,.navbar-default .navbar-nav>.active>a:focus,.navbar-default .navbar-nav>.active>a:hover{color:#555;background-color:#e7e7e7}.navbar-default .navbar-nav>.disabled>a,.navbar-default .navbar-nav>.disabled>a:focus,.navbar-default .navbar-nav>.disabled>a:hover{color:#ccc;background-color:transparent}.navbar-default .navbar-toggle{border-color:#ddd}.navbar-default .navbar-toggle:focus,.navbar-default .navbar-toggle:hover{background-color:#ddd}.navbar-default .navbar-toggle .icon-bar{background-color:#888}.navbar-default .navbar-collapse,.navbar-default .navbar-form{border-color:#e7e7e7}.navbar-default .navbar-nav>.open>a,.navbar-default .navbar-nav>.open>a:focus,.navbar-default .navbar-nav>.open>a:hover{color:#555;background-color:#e7e7e7}@media (max-width:767px){.navbar-default .navbar-nav .open .dropdown-menu>li>a{color:#777}.navbar-default .navbar-nav .open .dropdown-menu>li>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>li>a:hover{color:#333;background-color:transparent}.navbar-default .navbar-nav .open .dropdown-menu>.active>a,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:hover{color:#555;background-color:#e7e7e7}.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:hover{color:#ccc;background-color:transparent}}.navbar-default .navbar-link{color:#777}.navbar-default .navbar-link:hover{color:#333}.navbar-default .btn-link{color:#777}.navbar-default .btn-link:focus,.navbar-default .btn-link:hover{color:#333}.navbar-default .btn-link[disabled]:focus,.navbar-default .btn-link[disabled]:hover,fieldset[disabled] .navbar-default .btn-link:focus,fieldset[disabled] .navbar-default .btn-link:hover{color:#ccc}.navbar-inverse{background-color:#222;border-color:#080808}.navbar-inverse .navbar-brand{color:#9d9d9d}.navbar-inverse .navbar-brand:focus,.navbar-inverse .navbar-brand:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-text{color:#9d9d9d}.navbar-inverse .navbar-nav>li>a{color:#9d9d9d}.navbar-inverse .navbar-nav>li>a:focus,.navbar-inverse .navbar-nav>li>a:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-nav>.active>a,.navbar-inverse .navbar-nav>.active>a:focus,.navbar-inverse .navbar-nav>.active>a:hover{color:#fff;background-color:#080808}.navbar-inverse .navbar-nav>.disabled>a,.navbar-inverse .navbar-nav>.disabled>a:focus,.navbar-inverse .navbar-nav>.disabled>a:hover{color:#444;background-color:transparent}.navbar-inverse .navbar-toggle{border-color:#333}.navbar-inverse .navbar-toggle:focus,.navbar-inverse .navbar-toggle:hover{background-color:#333}.navbar-inverse .navbar-toggle .icon-bar{background-color:#fff}.navbar-inverse .navbar-collapse,.navbar-inverse .navbar-form{border-color:#101010}.navbar-inverse .navbar-nav>.open>a,.navbar-inverse .navbar-nav>.open>a:focus,.navbar-inverse .navbar-nav>.open>a:hover{color:#fff;background-color:#080808}@media (max-width:767px){.navbar-inverse .navbar-nav .open .dropdown-menu>.dropdown-header{border-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu .divider{background-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a{color:#9d9d9d}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:hover{color:#fff;background-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:hover{color:#444;background-color:transparent}}.navbar-inverse .navbar-link{color:#9d9d9d}.navbar-inverse .navbar-link:hover{color:#fff}.navbar-inverse .btn-link{color:#9d9d9d}.navbar-inverse .btn-link:focus,.navbar-inverse .btn-link:hover{color:#fff}.navbar-inverse .btn-link[disabled]:focus,.navbar-inverse .btn-link[disabled]:hover,fieldset[disabled] .navbar-inverse .btn-link:focus,fieldset[disabled] .navbar-inverse .btn-link:hover{color:#444}.breadcrumb{padding:8px 15px;margin-bottom:20px;list-style:none;background-color:#f5f5f5;border-radius:4px}.breadcrumb>li{display:inline-block}.breadcrumb>li+li:before{padding:0 5px;color:#ccc;content:"/\00a0"}.breadcrumb>.active{color:#777}.pagination{display:inline-block;padding-left:0;margin:20px 0;border-radius:4px}.pagination>li{display:inline}.pagination>li>a,.pagination>li>span{position:relative;float:left;padding:6px 12px;margin-left:-1px;line-height:1.42857143;color:#337ab7;text-decoration:none;background-color:#fff;border:1px solid #ddd}.pagination>li:first-child>a,.pagination>li:first-child>span{margin-left:0;border-top-left-radius:4px;border-bottom-left-radius:4px}.pagination>li:last-child>a,.pagination>li:last-child>span{border-top-right-radius:4px;border-bottom-right-radius:4px}.pagination>li>a:focus,.pagination>li>a:hover,.pagination>li>span:focus,.pagination>li>span:hover{z-index:3;color:#23527c;background-color:#eee;border-color:#ddd}.pagination>.active>a,.pagination>.active>a:focus,.pagination>.active>a:hover,.pagination>.active>span,.pagination>.active>span:focus,.pagination>.active>span:hover{z-index:2;color:#fff;cursor:default;background-color:#337ab7;border-color:#337ab7}.pagination>.disabled>a,.pagination>.disabled>a:focus,.pagination>.disabled>a:hover,.pagination>.disabled>span,.pagination>.disabled>span:focus,.pagination>.disabled>span:hover{color:#777;cursor:not-allowed;background-color:#fff;border-color:#ddd}.pagination-lg>li>a,.pagination-lg>li>span{padding:10px 16px;font-size:18px;line-height:1.3333333}.pagination-lg>li:first-child>a,.pagination-lg>li:first-child>span{border-top-left-radius:6px;border-bottom-left-radius:6px}.pagination-lg>li:last-child>a,.pagination-lg>li:last-child>span{border-top-right-radius:6px;border-bottom-right-radius:6px}.pagination-sm>li>a,.pagination-sm>li>span{padding:5px 10px;font-size:12px;line-height:1.5}.pagination-sm>li:first-child>a,.pagination-sm>li:first-child>span{border-top-left-radius:3px;border-bottom-left-radius:3px}.pagination-sm>li:last-child>a,.pagination-sm>li:last-child>span{border-top-right-radius:3px;border-bottom-right-radius:3px}.pager{padding-left:0;margin:20px 0;text-align:center;list-style:none}.pager li{display:inline}.pager li>a,.pager li>span{display:inline-block;padding:5px 14px;background-color:#fff;border:1px solid #ddd;border-radius:15px}.pager li>a:focus,.pager li>a:hover{text-decoration:none;background-color:#eee}.pager .next>a,.pager .next>span{float:right}.pager .previous>a,.pager .previous>span{float:left}.pager .disabled>a,.pager .disabled>a:focus,.pager .disabled>a:hover,.pager .disabled>span{color:#777;cursor:not-allowed;background-color:#fff}.label{display:inline;padding:.2em .6em .3em;font-size:75%;font-weight:700;line-height:1;color:#fff;text-align:center;white-space:nowrap;vertical-align:baseline;border-radius:.25em}a.label:focus,a.label:hover{color:#fff;text-decoration:none;cursor:pointer}.label:empty{display:none}.btn .label{position:relative;top:-1px}.label-default{background-color:#777}.label-default[href]:focus,.label-default[href]:hover{background-color:#5e5e5e}.label-primary{background-color:#337ab7}.label-primary[href]:focus,.label-primary[href]:hover{background-color:#286090}.label-success{background-color:#5cb85c}.label-success[href]:focus,.label-success[href]:hover{background-color:#449d44}.label-info{background-color:#5bc0de}.label-info[href]:focus,.label-info[href]:hover{background-color:#31b0d5}.label-warning{background-color:#f0ad4e}.label-warning[href]:focus,.label-warning[href]:hover{background-color:#ec971f}.label-danger{background-color:#d9534f}.label-danger[href]:focus,.label-danger[href]:hover{background-color:#c9302c}.badge{display:inline-block;min-width:10px;padding:3px 7px;font-size:12px;font-weight:700;line-height:1;color:#fff;text-align:center;white-space:nowrap;vertical-align:middle;background-color:#777;border-radius:10px}.badge:empty{display:none}.btn .badge{position:relative;top:-1px}.btn-group-xs>.btn .badge,.btn-xs .badge{top:0;padding:1px 5px}a.badge:focus,a.badge:hover{color:#fff;text-decoration:none;cursor:pointer}.list-group-item.active>.badge,.nav-pills>.active>a>.badge{color:#337ab7;background-color:#fff}.list-group-item>.badge{float:right}.list-group-item>.badge+.badge{margin-right:5px}.nav-pills>li>a>.badge{margin-left:3px}.jumbotron{padding-top:30px;padding-bottom:30px;margin-bottom:30px;color:inherit;background-color:#eee}.jumbotron .h1,.jumbotron h1{color:inherit}.jumbotron p{margin-bottom:15px;font-size:21px;font-weight:200}.jumbotron>hr{border-top-color:#d5d5d5}.container .jumbotron,.container-fluid .jumbotron{border-radius:6px}.jumbotron .container{max-width:100%}@media screen and (min-width:768px){.jumbotron{padding-top:48px;padding-bottom:48px}.container .jumbotron,.container-fluid .jumbotron{padding-right:60px;padding-left:60px}.jumbotron .h1,.jumbotron h1{font-size:63px}}.thumbnail{display:block;padding:4px;margin-bottom:20px;line-height:1.42857143;background-color:#fff;border:1px solid #ddd;border-radius:4px;-webkit-transition:border .2s ease-in-out;-o-transition:border .2s ease-in-out;transition:border .2s ease-in-out}.thumbnail a>img,.thumbnail>img{margin-right:auto;margin-left:auto}a.thumbnail.active,a.thumbnail:focus,a.thumbnail:hover{border-color:#337ab7}.thumbnail .caption{padding:9px;color:#333}.alert{padding:15px;margin-bottom:20px;border:1px solid transparent;border-radius:4px}.alert h4{margin-top:0;color:inherit}.alert .alert-link{font-weight:700}.alert>p,.alert>ul{margin-bottom:0}.alert>p+p{margin-top:5px}.alert-dismissable,.alert-dismissible{padding-right:35px}.alert-dismissable .close,.alert-dismissible .close{position:relative;top:-2px;right:-21px;color:inherit}.alert-success{color:#3c763d;background-color:#dff0d8;border-color:#d6e9c6}.alert-success hr{border-top-color:#c9e2b3}.alert-success .alert-link{color:#2b542c}.alert-info{color:#31708f;background-color:#d9edf7;border-color:#bce8f1}.alert-info hr{border-top-color:#a6e1ec}.alert-info .alert-link{color:#245269}.alert-warning{color:#8a6d3b;background-color:#fcf8e3;border-color:#faebcc}.alert-warning hr{border-top-color:#f7e1b5}.alert-warning .alert-link{color:#66512c}.alert-danger{color:#a94442;background-color:#f2dede;border-color:#ebccd1}.alert-danger hr{border-top-color:#e4b9c0}.alert-danger .alert-link{color:#843534}@-webkit-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@-o-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}.progress{height:20px;margin-bottom:20px;overflow:hidden;background-color:#f5f5f5;border-radius:4px;-webkit-box-shadow:inset 0 1px 2px rgba(0,0,0,.1);box-shadow:inset 0 1px 2px rgba(0,0,0,.1)}.progress-bar{float:left;width:0;height:100%;font-size:12px;line-height:20px;color:#fff;text-align:center;background-color:#337ab7;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,.15);box-shadow:inset 0 -1px 0 rgba(0,0,0,.15);-webkit-transition:width .6s ease;-o-transition:width .6s ease;transition:width .6s ease}.progress-bar-striped,.progress-striped .progress-bar{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);-webkit-background-size:40px 40px;background-size:40px 40px}.progress-bar.active,.progress.active .progress-bar{-webkit-animation:progress-bar-stripes 2s linear infinite;-o-animation:progress-bar-stripes 2s linear infinite;animation:progress-bar-stripes 2s linear infinite}.progress-bar-success{background-color:#5cb85c}.progress-striped .progress-bar-success{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-info{background-color:#5bc0de}.progress-striped .progress-bar-info{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-warning{background-color:#f0ad4e}.progress-striped .progress-bar-warning{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-danger{background-color:#d9534f}.progress-striped .progress-bar-danger{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.media{margin-top:15px}.media:first-child{margin-top:0}.media,.media-body{overflow:hidden;zoom:1}.media-body{width:10000px}.media-object{display:block}.media-object.img-thumbnail{max-width:none}.media-right,.media>.pull-right{padding-left:10px}.media-left,.media>.pull-left{padding-right:10px}.media-body,.media-left,.media-right{display:table-cell;vertical-align:top}.media-middle{vertical-align:middle}.media-bottom{vertical-align:bottom}.media-heading{margin-top:0;margin-bottom:5px}.media-list{padding-left:0;list-style:none}.list-group{padding-left:0;margin-bottom:20px}.list-group-item{position:relative;display:block;padding:10px 15px;margin-bottom:-1px;background-color:#fff;border:1px solid #ddd}.list-group-item:first-child{border-top-left-radius:4px;border-top-right-radius:4px}.list-group-item:last-child{margin-bottom:0;border-bottom-right-radius:4px;border-bottom-left-radius:4px}a.list-group-item,button.list-group-item{color:#555}a.list-group-item .list-group-item-heading,button.list-group-item .list-group-item-heading{color:#333}a.list-group-item:focus,a.list-group-item:hover,button.list-group-item:focus,button.list-group-item:hover{color:#555;text-decoration:none;background-color:#f5f5f5}button.list-group-item{width:100%;text-align:left}.list-group-item.disabled,.list-group-item.disabled:focus,.list-group-item.disabled:hover{color:#777;cursor:not-allowed;background-color:#eee}.list-group-item.disabled .list-group-item-heading,.list-group-item.disabled:focus .list-group-item-heading,.list-group-item.disabled:hover .list-group-item-heading{color:inherit}.list-group-item.disabled .list-group-item-text,.list-group-item.disabled:focus .list-group-item-text,.list-group-item.disabled:hover .list-group-item-text{color:#777}.list-group-item.active,.list-group-item.active:focus,.list-group-item.active:hover{z-index:2;color:#fff;background-color:#337ab7;border-color:#337ab7}.list-group-item.active .list-group-item-heading,.list-group-item.active .list-group-item-heading>.small,.list-group-item.active .list-group-item-heading>small,.list-group-item.active:focus .list-group-item-heading,.list-group-item.active:focus .list-group-item-heading>.small,.list-group-item.active:focus .list-group-item-heading>small,.list-group-item.active:hover .list-group-item-heading,.list-group-item.active:hover .list-group-item-heading>.small,.list-group-item.active:hover .list-group-item-heading>small{color:inherit}.list-group-item.active .list-group-item-text,.list-group-item.active:focus .list-group-item-text,.list-group-item.active:hover .list-group-item-text{color:#c7ddef}.list-group-item-success{color:#3c763d;background-color:#dff0d8}a.list-group-item-success,button.list-group-item-success{color:#3c763d}a.list-group-item-success .list-group-item-heading,button.list-group-item-success .list-group-item-heading{color:inherit}a.list-group-item-success:focus,a.list-group-item-success:hover,button.list-group-item-success:focus,button.list-group-item-success:hover{color:#3c763d;background-color:#d0e9c6}a.list-group-item-success.active,a.list-group-item-success.active:focus,a.list-group-item-success.active:hover,button.list-group-item-success.active,button.list-group-item-success.active:focus,button.list-group-item-success.active:hover{color:#fff;background-color:#3c763d;border-color:#3c763d}.list-group-item-info{color:#31708f;background-color:#d9edf7}a.list-group-item-info,button.list-group-item-info{color:#31708f}a.list-group-item-info .list-group-item-heading,button.list-group-item-info .list-group-item-heading{color:inherit}a.list-group-item-info:focus,a.list-group-item-info:hover,button.list-group-item-info:focus,button.list-group-item-info:hover{color:#31708f;background-color:#c4e3f3}a.list-group-item-info.active,a.list-group-item-info.active:focus,a.list-group-item-info.active:hover,button.list-group-item-info.active,button.list-group-item-info.active:focus,button.list-group-item-info.active:hover{color:#fff;background-color:#31708f;border-color:#31708f}.list-group-item-warning{color:#8a6d3b;background-color:#fcf8e3}a.list-group-item-warning,button.list-group-item-warning{color:#8a6d3b}a.list-group-item-warning .list-group-item-heading,button.list-group-item-warning .list-group-item-heading{color:inherit}a.list-group-item-warning:focus,a.list-group-item-warning:hover,button.list-group-item-warning:focus,button.list-group-item-warning:hover{color:#8a6d3b;background-color:#faf2cc}a.list-group-item-warning.active,a.list-group-item-warning.active:focus,a.list-group-item-warning.active:hover,button.list-group-item-warning.active,button.list-group-item-warning.active:focus,button.list-group-item-warning.active:hover{color:#fff;background-color:#8a6d3b;border-color:#8a6d3b}.list-group-item-danger{color:#a94442;background-color:#f2dede}a.list-group-item-danger,button.list-group-item-danger{color:#a94442}a.list-group-item-danger .list-group-item-heading,button.list-group-item-danger .list-group-item-heading{color:inherit}a.list-group-item-danger:focus,a.list-group-item-danger:hover,button.list-group-item-danger:focus,button.list-group-item-danger:hover{color:#a94442;background-color:#ebcccc}a.list-group-item-danger.active,a.list-group-item-danger.active:focus,a.list-group-item-danger.active:hover,button.list-group-item-danger.active,button.list-group-item-danger.active:focus,button.list-group-item-danger.active:hover{color:#fff;background-color:#a94442;border-color:#a94442}.list-group-item-heading{margin-top:0;margin-bottom:5px}.list-group-item-text{margin-bottom:0;line-height:1.3}.panel{margin-bottom:20px;background-color:#fff;border:1px solid transparent;border-radius:4px;-webkit-box-shadow:0 1px 1px rgba(0,0,0,.05);box-shadow:0 1px 1px rgba(0,0,0,.05)}.panel-body{padding:15px}.panel-heading{padding:10px 15px;border-bottom:1px solid transparent;border-top-left-radius:3px;border-top-right-radius:3px}.panel-heading>.dropdown .dropdown-toggle{color:inherit}.panel-title{margin-top:0;margin-bottom:0;font-size:16px;color:inherit}.panel-title>.small,.panel-title>.small>a,.panel-title>a,.panel-title>small,.panel-title>small>a{color:inherit}.panel-footer{padding:10px 15px;background-color:#f5f5f5;border-top:1px solid #ddd;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.list-group,.panel>.panel-collapse>.list-group{margin-bottom:0}.panel>.list-group .list-group-item,.panel>.panel-collapse>.list-group .list-group-item{border-width:1px 0;border-radius:0}.panel>.list-group:first-child .list-group-item:first-child,.panel>.panel-collapse>.list-group:first-child .list-group-item:first-child{border-top:0;border-top-left-radius:3px;border-top-right-radius:3px}.panel>.list-group:last-child .list-group-item:last-child,.panel>.panel-collapse>.list-group:last-child .list-group-item:last-child{border-bottom:0;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.panel-heading+.panel-collapse>.list-group .list-group-item:first-child{border-top-left-radius:0;border-top-right-radius:0}.panel-heading+.list-group .list-group-item:first-child{border-top-width:0}.list-group+.panel-footer{border-top-width:0}.panel>.panel-collapse>.table,.panel>.table,.panel>.table-responsive>.table{margin-bottom:0}.panel>.panel-collapse>.table caption,.panel>.table caption,.panel>.table-responsive>.table caption{padding-right:15px;padding-left:15px}.panel>.table-responsive:first-child>.table:first-child,.panel>.table:first-child{border-top-left-radius:3px;border-top-right-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child,.panel>.table:first-child>thead:first-child>tr:first-child{border-top-left-radius:3px;border-top-right-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table:first-child>thead:first-child>tr:first-child th:first-child{border-top-left-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table:first-child>thead:first-child>tr:first-child th:last-child{border-top-right-radius:3px}.panel>.table-responsive:last-child>.table:last-child,.panel>.table:last-child{border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child{border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:first-child{border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:last-child{border-bottom-right-radius:3px}.panel>.panel-body+.table,.panel>.panel-body+.table-responsive,.panel>.table+.panel-body,.panel>.table-responsive+.panel-body{border-top:1px solid #ddd}.panel>.table>tbody:first-child>tr:first-child td,.panel>.table>tbody:first-child>tr:first-child th{border-top:0}.panel>.table-bordered,.panel>.table-responsive>.table-bordered{border:0}.panel>.table-bordered>tbody>tr>td:first-child,.panel>.table-bordered>tbody>tr>th:first-child,.panel>.table-bordered>tfoot>tr>td:first-child,.panel>.table-bordered>tfoot>tr>th:first-child,.panel>.table-bordered>thead>tr>td:first-child,.panel>.table-bordered>thead>tr>th:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:first-child,.panel>.table-responsive>.table-bordered>thead>tr>td:first-child,.panel>.table-responsive>.table-bordered>thead>tr>th:first-child{border-left:0}.panel>.table-bordered>tbody>tr>td:last-child,.panel>.table-bordered>tbody>tr>th:last-child,.panel>.table-bordered>tfoot>tr>td:last-child,.panel>.table-bordered>tfoot>tr>th:last-child,.panel>.table-bordered>thead>tr>td:last-child,.panel>.table-bordered>thead>tr>th:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:last-child,.panel>.table-responsive>.table-bordered>thead>tr>td:last-child,.panel>.table-responsive>.table-bordered>thead>tr>th:last-child{border-right:0}.panel>.table-bordered>tbody>tr:first-child>td,.panel>.table-bordered>tbody>tr:first-child>th,.panel>.table-bordered>thead>tr:first-child>td,.panel>.table-bordered>thead>tr:first-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>th,.panel>.table-responsive>.table-bordered>thead>tr:first-child>td,.panel>.table-responsive>.table-bordered>thead>tr:first-child>th{border-bottom:0}.panel>.table-bordered>tbody>tr:last-child>td,.panel>.table-bordered>tbody>tr:last-child>th,.panel>.table-bordered>tfoot>tr:last-child>td,.panel>.table-bordered>tfoot>tr:last-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>th,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>td,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}.panel>.table-responsive{margin-bottom:0;border:0}.panel-group{margin-bottom:20px}.panel-group .panel{margin-bottom:0;border-radius:4px}.panel-group .panel+.panel{margin-top:5px}.panel-group .panel-heading{border-bottom:0}.panel-group .panel-heading+.panel-collapse>.list-group,.panel-group .panel-heading+.panel-collapse>.panel-body{border-top:1px solid #ddd}.panel-group .panel-footer{border-top:0}.panel-group .panel-footer+.panel-collapse .panel-body{border-bottom:1px solid #ddd}.panel-default{border-color:#ddd}.panel-default>.panel-heading{color:#333;background-color:#f5f5f5;border-color:#ddd}.panel-default>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ddd}.panel-default>.panel-heading .badge{color:#f5f5f5;background-color:#333}.panel-default>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ddd}.panel-primary{border-color:#337ab7}.panel-primary>.panel-heading{color:#fff;background-color:#337ab7;border-color:#337ab7}.panel-primary>.panel-heading+.panel-collapse>.panel-body{border-top-color:#337ab7}.panel-primary>.panel-heading .badge{color:#337ab7;background-color:#fff}.panel-primary>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#337ab7}.panel-success{border-color:#d6e9c6}.panel-success>.panel-heading{color:#3c763d;background-color:#dff0d8;border-color:#d6e9c6}.panel-success>.panel-heading+.panel-collapse>.panel-body{border-top-color:#d6e9c6}.panel-success>.panel-heading .badge{color:#dff0d8;background-color:#3c763d}.panel-success>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#d6e9c6}.panel-info{border-color:#bce8f1}.panel-info>.panel-heading{color:#31708f;background-color:#d9edf7;border-color:#bce8f1}.panel-info>.panel-heading+.panel-collapse>.panel-body{border-top-color:#bce8f1}.panel-info>.panel-heading .badge{color:#d9edf7;background-color:#31708f}.panel-info>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#bce8f1}.panel-warning{border-color:#faebcc}.panel-warning>.panel-heading{color:#8a6d3b;background-color:#fcf8e3;border-color:#faebcc}.panel-warning>.panel-heading+.panel-collapse>.panel-body{border-top-color:#faebcc}.panel-warning>.panel-heading .badge{color:#fcf8e3;background-color:#8a6d3b}.panel-warning>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#faebcc}.panel-danger{border-color:#ebccd1}.panel-danger>.panel-heading{color:#a94442;background-color:#f2dede;border-color:#ebccd1}.panel-danger>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ebccd1}.panel-danger>.panel-heading .badge{color:#f2dede;background-color:#a94442}.panel-danger>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ebccd1}.embed-responsive{position:relative;display:block;height:0;padding:0;overflow:hidden}.embed-responsive .embed-responsive-item,.embed-responsive embed,.embed-responsive iframe,.embed-responsive object,.embed-responsive video{position:absolute;top:0;bottom:0;left:0;width:100%;height:100%;border:0}.embed-responsive-16by9{padding-bottom:56.25%}.embed-responsive-4by3{padding-bottom:75%}.well{min-height:20px;padding:19px;margin-bottom:20px;background-color:#f5f5f5;border:1px solid #e3e3e3;border-radius:4px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.05);box-shadow:inset 0 1px 1px rgba(0,0,0,.05)}.well blockquote{border-color:#ddd;border-color:rgba(0,0,0,.15)}.well-lg{padding:24px;border-radius:6px}.well-sm{padding:9px;border-radius:3px}.close{float:right;font-size:21px;font-weight:700;line-height:1;color:#000;text-shadow:0 1px 0 #fff;filter:alpha(opacity=20);opacity:.2}.close:focus,.close:hover{color:#000;text-decoration:none;cursor:pointer;filter:alpha(opacity=50);opacity:.5}button.close{-webkit-appearance:none;padding:0;cursor:pointer;background:0 0;border:0}.modal-open{overflow:hidden}.modal{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1050;display:none;overflow:hidden;-webkit-overflow-scrolling:touch;outline:0}.modal.fade .modal-dialog{-webkit-transition:-webkit-transform .3s ease-out;-o-transition:-o-transform .3s ease-out;transition:transform .3s ease-out;-webkit-transform:translate(0,-25%);-ms-transform:translate(0,-25%);-o-transform:translate(0,-25%);transform:translate(0,-25%)}.modal.in .modal-dialog{-webkit-transform:translate(0,0);-ms-transform:translate(0,0);-o-transform:translate(0,0);transform:translate(0,0)}.modal-open .modal{overflow-x:hidden;overflow-y:auto}.modal-dialog{position:relative;width:auto;margin:10px}.modal-content{position:relative;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #999;border:1px solid rgba(0,0,0,.2);border-radius:6px;outline:0;-webkit-box-shadow:0 3px 9px rgba(0,0,0,.5);box-shadow:0 3px 9px rgba(0,0,0,.5)}.modal-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1040;background-color:#000}.modal-backdrop.fade{filter:alpha(opacity=0);opacity:0}.modal-backdrop.in{filter:alpha(opacity=50);opacity:.5}.modal-header{min-height:16.43px;padding:15px;border-bottom:1px solid #e5e5e5}.modal-header .close{margin-top:-2px}.modal-title{margin:0;line-height:1.42857143}.modal-body{position:relative;padding:15px}.modal-footer{padding:15px;text-align:right;border-top:1px solid #e5e5e5}.modal-footer .btn+.btn{margin-bottom:0;margin-left:5px}.modal-footer .btn-group .btn+.btn{margin-left:-1px}.modal-footer .btn-block+.btn-block{margin-left:0}.modal-scrollbar-measure{position:absolute;top:-9999px;width:50px;height:50px;overflow:scroll}@media (min-width:768px){.modal-dialog{width:600px;margin:30px auto}.modal-content{-webkit-box-shadow:0 5px 15px rgba(0,0,0,.5);box-shadow:0 5px 15px rgba(0,0,0,.5)}.modal-sm{width:300px}}@media (min-width:992px){.modal-lg{width:900px}}.tooltip{position:absolute;z-index:1070;display:block;font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:12px;font-style:normal;font-weight:400;line-height:1.42857143;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;letter-spacing:normal;word-break:normal;word-spacing:normal;word-wrap:normal;white-space:normal;filter:alpha(opacity=0);opacity:0;line-break:auto}.tooltip.in{filter:alpha(opacity=90);opacity:.9}.tooltip.top{padding:5px 0;margin-top:-3px}.tooltip.right{padding:0 5px;margin-left:3px}.tooltip.bottom{padding:5px 0;margin-top:3px}.tooltip.left{padding:0 5px;margin-left:-3px}.tooltip-inner{max-width:200px;padding:3px 8px;color:#fff;text-align:center;background-color:#000;border-radius:4px}.tooltip-arrow{position:absolute;width:0;height:0;border-color:transparent;border-style:solid}.tooltip.top .tooltip-arrow{bottom:0;left:50%;margin-left:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.top-left .tooltip-arrow{right:5px;bottom:0;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.top-right .tooltip-arrow{bottom:0;left:5px;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.right .tooltip-arrow{top:50%;left:0;margin-top:-5px;border-width:5px 5px 5px 0;border-right-color:#000}.tooltip.left .tooltip-arrow{top:50%;right:0;margin-top:-5px;border-width:5px 0 5px 5px;border-left-color:#000}.tooltip.bottom .tooltip-arrow{top:0;left:50%;margin-left:-5px;border-width:0 5px 5px;border-bottom-color:#000}.tooltip.bottom-left .tooltip-arrow{top:0;right:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#000}.tooltip.bottom-right .tooltip-arrow{top:0;left:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#000}.popover{position:absolute;top:0;left:0;z-index:1060;display:none;max-width:276px;padding:1px;font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;font-style:normal;font-weight:400;line-height:1.42857143;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;letter-spacing:normal;word-break:normal;word-spacing:normal;word-wrap:normal;white-space:normal;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #ccc;border:1px solid rgba(0,0,0,.2);border-radius:6px;-webkit-box-shadow:0 5px 10px rgba(0,0,0,.2);box-shadow:0 5px 10px rgba(0,0,0,.2);line-break:auto}.popover.top{margin-top:-10px}.popover.right{margin-left:10px}.popover.bottom{margin-top:10px}.popover.left{margin-left:-10px}.popover-title{padding:8px 14px;margin:0;font-size:14px;background-color:#f7f7f7;border-bottom:1px solid #ebebeb;border-radius:5px 5px 0 0}.popover-content{padding:9px 14px}.popover>.arrow,.popover>.arrow:after{position:absolute;display:block;width:0;height:0;border-color:transparent;border-style:solid}.popover>.arrow{border-width:11px}.popover>.arrow:after{content:"";border-width:10px}.popover.top>.arrow{bottom:-11px;left:50%;margin-left:-11px;border-top-color:#999;border-top-color:rgba(0,0,0,.25);border-bottom-width:0}.popover.top>.arrow:after{bottom:1px;margin-left:-10px;content:" ";border-top-color:#fff;border-bottom-width:0}.popover.right>.arrow{top:50%;left:-11px;margin-top:-11px;border-right-color:#999;border-right-color:rgba(0,0,0,.25);border-left-width:0}.popover.right>.arrow:after{bottom:-10px;left:1px;content:" ";border-right-color:#fff;border-left-width:0}.popover.bottom>.arrow{top:-11px;left:50%;margin-left:-11px;border-top-width:0;border-bottom-color:#999;border-bottom-color:rgba(0,0,0,.25)}.popover.bottom>.arrow:after{top:1px;margin-left:-10px;content:" ";border-top-width:0;border-bottom-color:#fff}.popover.left>.arrow{top:50%;right:-11px;margin-top:-11px;border-right-width:0;border-left-color:#999;border-left-color:rgba(0,0,0,.25)}.popover.left>.arrow:after{right:1px;bottom:-10px;content:" ";border-right-width:0;border-left-color:#fff}.carousel{position:relative}.carousel-inner{position:relative;width:100%;overflow:hidden}.carousel-inner>.item{position:relative;display:none;-webkit-transition:.6s ease-in-out left;-o-transition:.6s ease-in-out left;transition:.6s ease-in-out left}.carousel-inner>.item>a>img,.carousel-inner>.item>img{line-height:1}@media all and (transform-3d),(-webkit-transform-3d){.carousel-inner>.item{-webkit-transition:-webkit-transform .6s ease-in-out;-o-transition:-o-transform .6s ease-in-out;transition:transform .6s ease-in-out;-webkit-backface-visibility:hidden;backface-visibility:hidden;-webkit-perspective:1000px;perspective:1000px}.carousel-inner>.item.active.right,.carousel-inner>.item.next{left:0;-webkit-transform:translate3d(100%,0,0);transform:translate3d(100%,0,0)}.carousel-inner>.item.active.left,.carousel-inner>.item.prev{left:0;-webkit-transform:translate3d(-100%,0,0);transform:translate3d(-100%,0,0)}.carousel-inner>.item.active,.carousel-inner>.item.next.left,.carousel-inner>.item.prev.right{left:0;-webkit-transform:translate3d(0,0,0);transform:translate3d(0,0,0)}}.carousel-inner>.active,.carousel-inner>.next,.carousel-inner>.prev{display:block}.carousel-inner>.active{left:0}.carousel-inner>.next,.carousel-inner>.prev{position:absolute;top:0;width:100%}.carousel-inner>.next{left:100%}.carousel-inner>.prev{left:-100%}.carousel-inner>.next.left,.carousel-inner>.prev.right{left:0}.carousel-inner>.active.left{left:-100%}.carousel-inner>.active.right{left:100%}.carousel-control{position:absolute;top:0;bottom:0;left:0;width:15%;font-size:20px;color:#fff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,.6);filter:alpha(opacity=50);opacity:.5}.carousel-control.left{background-image:-webkit-linear-gradient(left,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);background-image:-o-linear-gradient(left,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);background-image:-webkit-gradient(linear,left top,right top,from(rgba(0,0,0,.5)),to(rgba(0,0,0,.0001)));background-image:linear-gradient(to right,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#80000000', endColorstr='#00000000', GradientType=1);background-repeat:repeat-x}.carousel-control.right{right:0;left:auto;background-image:-webkit-linear-gradient(left,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);background-image:-o-linear-gradient(left,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);background-image:-webkit-gradient(linear,left top,right top,from(rgba(0,0,0,.0001)),to(rgba(0,0,0,.5)));background-image:linear-gradient(to right,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#00000000', endColorstr='#80000000', GradientType=1);background-repeat:repeat-x}.carousel-control:focus,.carousel-control:hover{color:#fff;text-decoration:none;filter:alpha(opacity=90);outline:0;opacity:.9}.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next,.carousel-control .icon-prev{position:absolute;top:50%;z-index:5;display:inline-block;margin-top:-10px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{left:50%;margin-left:-10px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{right:50%;margin-right:-10px}.carousel-control .icon-next,.carousel-control .icon-prev{width:20px;height:20px;font-family:serif;line-height:1}.carousel-control .icon-prev:before{content:'\2039'}.carousel-control .icon-next:before{content:'\203a'}.carousel-indicators{position:absolute;bottom:10px;left:50%;z-index:15;width:60%;padding-left:0;margin-left:-30%;text-align:center;list-style:none}.carousel-indicators li{display:inline-block;width:10px;height:10px;margin:1px;text-indent:-999px;cursor:pointer;background-color:#000\9;background-color:rgba(0,0,0,0);border:1px solid #fff;border-radius:10px}.carousel-indicators .active{width:12px;height:12px;margin:0;background-color:#fff}.carousel-caption{position:absolute;right:15%;bottom:20px;left:15%;z-index:10;padding-top:20px;padding-bottom:20px;color:#fff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,.6)}.carousel-caption .btn{text-shadow:none}@media screen and (min-width:768px){.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next,.carousel-control .icon-prev{width:30px;height:30px;margin-top:-15px;font-size:30px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{margin-left:-15px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{margin-right:-15px}.carousel-caption{right:20%;left:20%;padding-bottom:30px}.carousel-indicators{bottom:20px}}.btn-group-vertical>.btn-group:after,.btn-group-vertical>.btn-group:before,.btn-toolbar:after,.btn-toolbar:before,.clearfix:after,.clearfix:before,.container-fluid:after,.container-fluid:before,.container:after,.container:before,.dl-horizontal dd:after,.dl-horizontal dd:before,.form-horizontal .form-group:after,.form-horizontal .form-group:before,.modal-footer:after,.modal-footer:before,.nav:after,.nav:before,.navbar-collapse:after,.navbar-collapse:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.pager:after,.pager:before,.panel-body:after,.panel-body:before,.row:after,.row:before{display:table;content:" "}.btn-group-vertical>.btn-group:after,.btn-toolbar:after,.clearfix:after,.container-fluid:after,.container:after,.dl-horizontal dd:after,.form-horizontal .form-group:after,.modal-footer:after,.nav:after,.navbar-collapse:after,.navbar-header:after,.navbar:after,.pager:after,.panel-body:after,.row:after{clear:both}.center-block{display:block;margin-right:auto;margin-left:auto}.pull-right{float:right!important}.pull-left{float:left!important}.hide{display:none!important}.show{display:block!important}.invisible{visibility:hidden}.text-hide{font:0/0 a;color:transparent;text-shadow:none;background-color:transparent;border:0}.hidden{display:none!important}.affix{position:fixed}@-ms-viewport{width:device-width}.visible-lg,.visible-md,.visible-sm,.visible-xs{display:none!important}.visible-lg-block,.visible-lg-inline,.visible-lg-inline-block,.visible-md-block,.visible-md-inline,.visible-md-inline-block,.visible-sm-block,.visible-sm-inline,.visible-sm-inline-block,.visible-xs-block,.visible-xs-inline,.visible-xs-inline-block{display:none!important}@media (max-width:767px){.visible-xs{display:block!important}table.visible-xs{display:table!important}tr.visible-xs{display:table-row!important}td.visible-xs,th.visible-xs{display:table-cell!important}}@media (max-width:767px){.visible-xs-block{display:block!important}}@media (max-width:767px){.visible-xs-inline{display:inline!important}}@media (max-width:767px){.visible-xs-inline-block{display:inline-block!important}}@media (min-width:768px) and (max-width:991px){.visible-sm{display:block!important}table.visible-sm{display:table!important}tr.visible-sm{display:table-row!important}td.visible-sm,th.visible-sm{display:table-cell!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-block{display:block!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline{display:inline!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline-block{display:inline-block!important}}@media (min-width:992px) and (max-width:1199px){.visible-md{display:block!important}table.visible-md{display:table!important}tr.visible-md{display:table-row!important}td.visible-md,th.visible-md{display:table-cell!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-block{display:block!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline{display:inline!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline-block{display:inline-block!important}}@media (min-width:1200px){.visible-lg{display:block!important}table.visible-lg{display:table!important}tr.visible-lg{display:table-row!important}td.visible-lg,th.visible-lg{display:table-cell!important}}@media (min-width:1200px){.visible-lg-block{display:block!important}}@media (min-width:1200px){.visible-lg-inline{display:inline!important}}@media (min-width:1200px){.visible-lg-inline-block{display:inline-block!important}}@media (max-width:767px){.hidden-xs{display:none!important}}@media (min-width:768px) and (max-width:991px){.hidden-sm{display:none!important}}@media (min-width:992px) and (max-width:1199px){.hidden-md{display:none!important}}@media (min-width:1200px){.hidden-lg{display:none!important}}.visible-print{display:none!important}@media print{.visible-print{display:block!important}table.visible-print{display:table!important}tr.visible-print{display:table-row!important}td.visible-print,th.visible-print{display:table-cell!important}}.visible-print-block{display:none!important}@media print{.visible-print-block{display:block!important}}.visible-print-inline{display:none!important}@media print{.visible-print-inline{display:inline!important}}.visible-print-inline-block{display:none!important}@media print{.visible-print-inline-block{display:inline-block!important}}@media print{.hidden-print{display:none!important}}
</style>
<script>/*!
 * Bootstrap v3.3.5 (http://getbootstrap.com)
 * Copyright 2011-2015 Twitter, Inc.
 * Licensed under the MIT license
 */
if("undefined"==typeof jQuery)throw new Error("Bootstrap's JavaScript requires jQuery");+function(a){"use strict";var b=a.fn.jquery.split(" ")[0].split(".");if(b[0]<2&&b[1]<9||1==b[0]&&9==b[1]&&b[2]<1)throw new Error("Bootstrap's JavaScript requires jQuery version 1.9.1 or higher")}(jQuery),+function(a){"use strict";function b(){var a=document.createElement("bootstrap"),b={WebkitTransition:"webkitTransitionEnd",MozTransition:"transitionend",OTransition:"oTransitionEnd otransitionend",transition:"transitionend"};for(var c in b)if(void 0!==a.style[c])return{end:b[c]};return!1}a.fn.emulateTransitionEnd=function(b){var c=!1,d=this;a(this).one("bsTransitionEnd",function(){c=!0});var e=function(){c||a(d).trigger(a.support.transition.end)};return setTimeout(e,b),this},a(function(){a.support.transition=b(),a.support.transition&&(a.event.special.bsTransitionEnd={bindType:a.support.transition.end,delegateType:a.support.transition.end,handle:function(b){return a(b.target).is(this)?b.handleObj.handler.apply(this,arguments):void 0}})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var c=a(this),e=c.data("bs.alert");e||c.data("bs.alert",e=new d(this)),"string"==typeof b&&e[b].call(c)})}var c='[data-dismiss="alert"]',d=function(b){a(b).on("click",c,this.close)};d.VERSION="3.3.5",d.TRANSITION_DURATION=150,d.prototype.close=function(b){function c(){g.detach().trigger("closed.bs.alert").remove()}var e=a(this),f=e.attr("data-target");f||(f=e.attr("href"),f=f&&f.replace(/.*(?=#[^\s]*$)/,""));var g=a(f);b&&b.preventDefault(),g.length||(g=e.closest(".alert")),g.trigger(b=a.Event("close.bs.alert")),b.isDefaultPrevented()||(g.removeClass("in"),a.support.transition&&g.hasClass("fade")?g.one("bsTransitionEnd",c).emulateTransitionEnd(d.TRANSITION_DURATION):c())};var e=a.fn.alert;a.fn.alert=b,a.fn.alert.Constructor=d,a.fn.alert.noConflict=function(){return a.fn.alert=e,this},a(document).on("click.bs.alert.data-api",c,d.prototype.close)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.button"),f="object"==typeof b&&b;e||d.data("bs.button",e=new c(this,f)),"toggle"==b?e.toggle():b&&e.setState(b)})}var c=function(b,d){this.$element=a(b),this.options=a.extend({},c.DEFAULTS,d),this.isLoading=!1};c.VERSION="3.3.5",c.DEFAULTS={loadingText:"loading..."},c.prototype.setState=function(b){var c="disabled",d=this.$element,e=d.is("input")?"val":"html",f=d.data();b+="Text",null==f.resetText&&d.data("resetText",d[e]()),setTimeout(a.proxy(function(){d[e](null==f[b]?this.options[b]:f[b]),"loadingText"==b?(this.isLoading=!0,d.addClass(c).attr(c,c)):this.isLoading&&(this.isLoading=!1,d.removeClass(c).removeAttr(c))},this),0)},c.prototype.toggle=function(){var a=!0,b=this.$element.closest('[data-toggle="buttons"]');if(b.length){var c=this.$element.find("input");"radio"==c.prop("type")?(c.prop("checked")&&(a=!1),b.find(".active").removeClass("active"),this.$element.addClass("active")):"checkbox"==c.prop("type")&&(c.prop("checked")!==this.$element.hasClass("active")&&(a=!1),this.$element.toggleClass("active")),c.prop("checked",this.$element.hasClass("active")),a&&c.trigger("change")}else this.$element.attr("aria-pressed",!this.$element.hasClass("active")),this.$element.toggleClass("active")};var d=a.fn.button;a.fn.button=b,a.fn.button.Constructor=c,a.fn.button.noConflict=function(){return a.fn.button=d,this},a(document).on("click.bs.button.data-api",'[data-toggle^="button"]',function(c){var d=a(c.target);d.hasClass("btn")||(d=d.closest(".btn")),b.call(d,"toggle"),a(c.target).is('input[type="radio"]')||a(c.target).is('input[type="checkbox"]')||c.preventDefault()}).on("focus.bs.button.data-api blur.bs.button.data-api",'[data-toggle^="button"]',function(b){a(b.target).closest(".btn").toggleClass("focus",/^focus(in)?$/.test(b.type))})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.carousel"),f=a.extend({},c.DEFAULTS,d.data(),"object"==typeof b&&b),g="string"==typeof b?b:f.slide;e||d.data("bs.carousel",e=new c(this,f)),"number"==typeof b?e.to(b):g?e[g]():f.interval&&e.pause().cycle()})}var c=function(b,c){this.$element=a(b),this.$indicators=this.$element.find(".carousel-indicators"),this.options=c,this.paused=null,this.sliding=null,this.interval=null,this.$active=null,this.$items=null,this.options.keyboard&&this.$element.on("keydown.bs.carousel",a.proxy(this.keydown,this)),"hover"==this.options.pause&&!("ontouchstart"in document.documentElement)&&this.$element.on("mouseenter.bs.carousel",a.proxy(this.pause,this)).on("mouseleave.bs.carousel",a.proxy(this.cycle,this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=600,c.DEFAULTS={interval:5e3,pause:"hover",wrap:!0,keyboard:!0},c.prototype.keydown=function(a){if(!/input|textarea/i.test(a.target.tagName)){switch(a.which){case 37:this.prev();break;case 39:this.next();break;default:return}a.preventDefault()}},c.prototype.cycle=function(b){return b||(this.paused=!1),this.interval&&clearInterval(this.interval),this.options.interval&&!this.paused&&(this.interval=setInterval(a.proxy(this.next,this),this.options.interval)),this},c.prototype.getItemIndex=function(a){return this.$items=a.parent().children(".item"),this.$items.index(a||this.$active)},c.prototype.getItemForDirection=function(a,b){var c=this.getItemIndex(b),d="prev"==a&&0===c||"next"==a&&c==this.$items.length-1;if(d&&!this.options.wrap)return b;var e="prev"==a?-1:1,f=(c+e)%this.$items.length;return this.$items.eq(f)},c.prototype.to=function(a){var b=this,c=this.getItemIndex(this.$active=this.$element.find(".item.active"));return a>this.$items.length-1||0>a?void 0:this.sliding?this.$element.one("slid.bs.carousel",function(){b.to(a)}):c==a?this.pause().cycle():this.slide(a>c?"next":"prev",this.$items.eq(a))},c.prototype.pause=function(b){return b||(this.paused=!0),this.$element.find(".next, .prev").length&&a.support.transition&&(this.$element.trigger(a.support.transition.end),this.cycle(!0)),this.interval=clearInterval(this.interval),this},c.prototype.next=function(){return this.sliding?void 0:this.slide("next")},c.prototype.prev=function(){return this.sliding?void 0:this.slide("prev")},c.prototype.slide=function(b,d){var e=this.$element.find(".item.active"),f=d||this.getItemForDirection(b,e),g=this.interval,h="next"==b?"left":"right",i=this;if(f.hasClass("active"))return this.sliding=!1;var j=f[0],k=a.Event("slide.bs.carousel",{relatedTarget:j,direction:h});if(this.$element.trigger(k),!k.isDefaultPrevented()){if(this.sliding=!0,g&&this.pause(),this.$indicators.length){this.$indicators.find(".active").removeClass("active");var l=a(this.$indicators.children()[this.getItemIndex(f)]);l&&l.addClass("active")}var m=a.Event("slid.bs.carousel",{relatedTarget:j,direction:h});return a.support.transition&&this.$element.hasClass("slide")?(f.addClass(b),f[0].offsetWidth,e.addClass(h),f.addClass(h),e.one("bsTransitionEnd",function(){f.removeClass([b,h].join(" ")).addClass("active"),e.removeClass(["active",h].join(" ")),i.sliding=!1,setTimeout(function(){i.$element.trigger(m)},0)}).emulateTransitionEnd(c.TRANSITION_DURATION)):(e.removeClass("active"),f.addClass("active"),this.sliding=!1,this.$element.trigger(m)),g&&this.cycle(),this}};var d=a.fn.carousel;a.fn.carousel=b,a.fn.carousel.Constructor=c,a.fn.carousel.noConflict=function(){return a.fn.carousel=d,this};var e=function(c){var d,e=a(this),f=a(e.attr("data-target")||(d=e.attr("href"))&&d.replace(/.*(?=#[^\s]+$)/,""));if(f.hasClass("carousel")){var g=a.extend({},f.data(),e.data()),h=e.attr("data-slide-to");h&&(g.interval=!1),b.call(f,g),h&&f.data("bs.carousel").to(h),c.preventDefault()}};a(document).on("click.bs.carousel.data-api","[data-slide]",e).on("click.bs.carousel.data-api","[data-slide-to]",e),a(window).on("load",function(){a('[data-ride="carousel"]').each(function(){var c=a(this);b.call(c,c.data())})})}(jQuery),+function(a){"use strict";function b(b){var c,d=b.attr("data-target")||(c=b.attr("href"))&&c.replace(/.*(?=#[^\s]+$)/,"");return a(d)}function c(b){return this.each(function(){var c=a(this),e=c.data("bs.collapse"),f=a.extend({},d.DEFAULTS,c.data(),"object"==typeof b&&b);!e&&f.toggle&&/show|hide/.test(b)&&(f.toggle=!1),e||c.data("bs.collapse",e=new d(this,f)),"string"==typeof b&&e[b]()})}var d=function(b,c){this.$element=a(b),this.options=a.extend({},d.DEFAULTS,c),this.$trigger=a('[data-toggle="collapse"][href="#'+b.id+'"],[data-toggle="collapse"][data-target="#'+b.id+'"]'),this.transitioning=null,this.options.parent?this.$parent=this.getParent():this.addAriaAndCollapsedClass(this.$element,this.$trigger),this.options.toggle&&this.toggle()};d.VERSION="3.3.5",d.TRANSITION_DURATION=350,d.DEFAULTS={toggle:!0},d.prototype.dimension=function(){var a=this.$element.hasClass("width");return a?"width":"height"},d.prototype.show=function(){if(!this.transitioning&&!this.$element.hasClass("in")){var b,e=this.$parent&&this.$parent.children(".panel").children(".in, .collapsing");if(!(e&&e.length&&(b=e.data("bs.collapse"),b&&b.transitioning))){var f=a.Event("show.bs.collapse");if(this.$element.trigger(f),!f.isDefaultPrevented()){e&&e.length&&(c.call(e,"hide"),b||e.data("bs.collapse",null));var g=this.dimension();this.$element.removeClass("collapse").addClass("collapsing")[g](0).attr("aria-expanded",!0),this.$trigger.removeClass("collapsed").attr("aria-expanded",!0),this.transitioning=1;var h=function(){this.$element.removeClass("collapsing").addClass("collapse in")[g](""),this.transitioning=0,this.$element.trigger("shown.bs.collapse")};if(!a.support.transition)return h.call(this);var i=a.camelCase(["scroll",g].join("-"));this.$element.one("bsTransitionEnd",a.proxy(h,this)).emulateTransitionEnd(d.TRANSITION_DURATION)[g](this.$element[0][i])}}}},d.prototype.hide=function(){if(!this.transitioning&&this.$element.hasClass("in")){var b=a.Event("hide.bs.collapse");if(this.$element.trigger(b),!b.isDefaultPrevented()){var c=this.dimension();this.$element[c](this.$element[c]())[0].offsetHeight,this.$element.addClass("collapsing").removeClass("collapse in").attr("aria-expanded",!1),this.$trigger.addClass("collapsed").attr("aria-expanded",!1),this.transitioning=1;var e=function(){this.transitioning=0,this.$element.removeClass("collapsing").addClass("collapse").trigger("hidden.bs.collapse")};return a.support.transition?void this.$element[c](0).one("bsTransitionEnd",a.proxy(e,this)).emulateTransitionEnd(d.TRANSITION_DURATION):e.call(this)}}},d.prototype.toggle=function(){this[this.$element.hasClass("in")?"hide":"show"]()},d.prototype.getParent=function(){return a(this.options.parent).find('[data-toggle="collapse"][data-parent="'+this.options.parent+'"]').each(a.proxy(function(c,d){var e=a(d);this.addAriaAndCollapsedClass(b(e),e)},this)).end()},d.prototype.addAriaAndCollapsedClass=function(a,b){var c=a.hasClass("in");a.attr("aria-expanded",c),b.toggleClass("collapsed",!c).attr("aria-expanded",c)};var e=a.fn.collapse;a.fn.collapse=c,a.fn.collapse.Constructor=d,a.fn.collapse.noConflict=function(){return a.fn.collapse=e,this},a(document).on("click.bs.collapse.data-api",'[data-toggle="collapse"]',function(d){var e=a(this);e.attr("data-target")||d.preventDefault();var f=b(e),g=f.data("bs.collapse"),h=g?"toggle":e.data();c.call(f,h)})}(jQuery),+function(a){"use strict";function b(b){var c=b.attr("data-target");c||(c=b.attr("href"),c=c&&/#[A-Za-z]/.test(c)&&c.replace(/.*(?=#[^\s]*$)/,""));var d=c&&a(c);return d&&d.length?d:b.parent()}function c(c){c&&3===c.which||(a(e).remove(),a(f).each(function(){var d=a(this),e=b(d),f={relatedTarget:this};e.hasClass("open")&&(c&&"click"==c.type&&/input|textarea/i.test(c.target.tagName)&&a.contains(e[0],c.target)||(e.trigger(c=a.Event("hide.bs.dropdown",f)),c.isDefaultPrevented()||(d.attr("aria-expanded","false"),e.removeClass("open").trigger("hidden.bs.dropdown",f))))}))}function d(b){return this.each(function(){var c=a(this),d=c.data("bs.dropdown");d||c.data("bs.dropdown",d=new g(this)),"string"==typeof b&&d[b].call(c)})}var e=".dropdown-backdrop",f='[data-toggle="dropdown"]',g=function(b){a(b).on("click.bs.dropdown",this.toggle)};g.VERSION="3.3.5",g.prototype.toggle=function(d){var e=a(this);if(!e.is(".disabled, :disabled")){var f=b(e),g=f.hasClass("open");if(c(),!g){"ontouchstart"in document.documentElement&&!f.closest(".navbar-nav").length&&a(document.createElement("div")).addClass("dropdown-backdrop").insertAfter(a(this)).on("click",c);var h={relatedTarget:this};if(f.trigger(d=a.Event("show.bs.dropdown",h)),d.isDefaultPrevented())return;e.trigger("focus").attr("aria-expanded","true"),f.toggleClass("open").trigger("shown.bs.dropdown",h)}return!1}},g.prototype.keydown=function(c){if(/(38|40|27|32)/.test(c.which)&&!/input|textarea/i.test(c.target.tagName)){var d=a(this);if(c.preventDefault(),c.stopPropagation(),!d.is(".disabled, :disabled")){var e=b(d),g=e.hasClass("open");if(!g&&27!=c.which||g&&27==c.which)return 27==c.which&&e.find(f).trigger("focus"),d.trigger("click");var h=" li:not(.disabled):visible a",i=e.find(".dropdown-menu"+h);if(i.length){var j=i.index(c.target);38==c.which&&j>0&&j--,40==c.which&&j<i.length-1&&j++,~j||(j=0),i.eq(j).trigger("focus")}}}};var h=a.fn.dropdown;a.fn.dropdown=d,a.fn.dropdown.Constructor=g,a.fn.dropdown.noConflict=function(){return a.fn.dropdown=h,this},a(document).on("click.bs.dropdown.data-api",c).on("click.bs.dropdown.data-api",".dropdown form",function(a){a.stopPropagation()}).on("click.bs.dropdown.data-api",f,g.prototype.toggle).on("keydown.bs.dropdown.data-api",f,g.prototype.keydown).on("keydown.bs.dropdown.data-api",".dropdown-menu",g.prototype.keydown)}(jQuery),+function(a){"use strict";function b(b,d){return this.each(function(){var e=a(this),f=e.data("bs.modal"),g=a.extend({},c.DEFAULTS,e.data(),"object"==typeof b&&b);f||e.data("bs.modal",f=new c(this,g)),"string"==typeof b?f[b](d):g.show&&f.show(d)})}var c=function(b,c){this.options=c,this.$body=a(document.body),this.$element=a(b),this.$dialog=this.$element.find(".modal-dialog"),this.$backdrop=null,this.isShown=null,this.originalBodyPad=null,this.scrollbarWidth=0,this.ignoreBackdropClick=!1,this.options.remote&&this.$element.find(".modal-content").load(this.options.remote,a.proxy(function(){this.$element.trigger("loaded.bs.modal")},this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=300,c.BACKDROP_TRANSITION_DURATION=150,c.DEFAULTS={backdrop:!0,keyboard:!0,show:!0},c.prototype.toggle=function(a){return this.isShown?this.hide():this.show(a)},c.prototype.show=function(b){var d=this,e=a.Event("show.bs.modal",{relatedTarget:b});this.$element.trigger(e),this.isShown||e.isDefaultPrevented()||(this.isShown=!0,this.checkScrollbar(),this.setScrollbar(),this.$body.addClass("modal-open"),this.escape(),this.resize(),this.$element.on("click.dismiss.bs.modal",'[data-dismiss="modal"]',a.proxy(this.hide,this)),this.$dialog.on("mousedown.dismiss.bs.modal",function(){d.$element.one("mouseup.dismiss.bs.modal",function(b){a(b.target).is(d.$element)&&(d.ignoreBackdropClick=!0)})}),this.backdrop(function(){var e=a.support.transition&&d.$element.hasClass("fade");d.$element.parent().length||d.$element.appendTo(d.$body),d.$element.show().scrollTop(0),d.adjustDialog(),e&&d.$element[0].offsetWidth,d.$element.addClass("in"),d.enforceFocus();var f=a.Event("shown.bs.modal",{relatedTarget:b});e?d.$dialog.one("bsTransitionEnd",function(){d.$element.trigger("focus").trigger(f)}).emulateTransitionEnd(c.TRANSITION_DURATION):d.$element.trigger("focus").trigger(f)}))},c.prototype.hide=function(b){b&&b.preventDefault(),b=a.Event("hide.bs.modal"),this.$element.trigger(b),this.isShown&&!b.isDefaultPrevented()&&(this.isShown=!1,this.escape(),this.resize(),a(document).off("focusin.bs.modal"),this.$element.removeClass("in").off("click.dismiss.bs.modal").off("mouseup.dismiss.bs.modal"),this.$dialog.off("mousedown.dismiss.bs.modal"),a.support.transition&&this.$element.hasClass("fade")?this.$element.one("bsTransitionEnd",a.proxy(this.hideModal,this)).emulateTransitionEnd(c.TRANSITION_DURATION):this.hideModal())},c.prototype.enforceFocus=function(){a(document).off("focusin.bs.modal").on("focusin.bs.modal",a.proxy(function(a){this.$element[0]===a.target||this.$element.has(a.target).length||this.$element.trigger("focus")},this))},c.prototype.escape=function(){this.isShown&&this.options.keyboard?this.$element.on("keydown.dismiss.bs.modal",a.proxy(function(a){27==a.which&&this.hide()},this)):this.isShown||this.$element.off("keydown.dismiss.bs.modal")},c.prototype.resize=function(){this.isShown?a(window).on("resize.bs.modal",a.proxy(this.handleUpdate,this)):a(window).off("resize.bs.modal")},c.prototype.hideModal=function(){var a=this;this.$element.hide(),this.backdrop(function(){a.$body.removeClass("modal-open"),a.resetAdjustments(),a.resetScrollbar(),a.$element.trigger("hidden.bs.modal")})},c.prototype.removeBackdrop=function(){this.$backdrop&&this.$backdrop.remove(),this.$backdrop=null},c.prototype.backdrop=function(b){var d=this,e=this.$element.hasClass("fade")?"fade":"";if(this.isShown&&this.options.backdrop){var f=a.support.transition&&e;if(this.$backdrop=a(document.createElement("div")).addClass("modal-backdrop "+e).appendTo(this.$body),this.$element.on("click.dismiss.bs.modal",a.proxy(function(a){return this.ignoreBackdropClick?void(this.ignoreBackdropClick=!1):void(a.target===a.currentTarget&&("static"==this.options.backdrop?this.$element[0].focus():this.hide()))},this)),f&&this.$backdrop[0].offsetWidth,this.$backdrop.addClass("in"),!b)return;f?this.$backdrop.one("bsTransitionEnd",b).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):b()}else if(!this.isShown&&this.$backdrop){this.$backdrop.removeClass("in");var g=function(){d.removeBackdrop(),b&&b()};a.support.transition&&this.$element.hasClass("fade")?this.$backdrop.one("bsTransitionEnd",g).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):g()}else b&&b()},c.prototype.handleUpdate=function(){this.adjustDialog()},c.prototype.adjustDialog=function(){var a=this.$element[0].scrollHeight>document.documentElement.clientHeight;this.$element.css({paddingLeft:!this.bodyIsOverflowing&&a?this.scrollbarWidth:"",paddingRight:this.bodyIsOverflowing&&!a?this.scrollbarWidth:""})},c.prototype.resetAdjustments=function(){this.$element.css({paddingLeft:"",paddingRight:""})},c.prototype.checkScrollbar=function(){var a=window.innerWidth;if(!a){var b=document.documentElement.getBoundingClientRect();a=b.right-Math.abs(b.left)}this.bodyIsOverflowing=document.body.clientWidth<a,this.scrollbarWidth=this.measureScrollbar()},c.prototype.setScrollbar=function(){var a=parseInt(this.$body.css("padding-right")||0,10);this.originalBodyPad=document.body.style.paddingRight||"",this.bodyIsOverflowing&&this.$body.css("padding-right",a+this.scrollbarWidth)},c.prototype.resetScrollbar=function(){this.$body.css("padding-right",this.originalBodyPad)},c.prototype.measureScrollbar=function(){var a=document.createElement("div");a.className="modal-scrollbar-measure",this.$body.append(a);var b=a.offsetWidth-a.clientWidth;return this.$body[0].removeChild(a),b};var d=a.fn.modal;a.fn.modal=b,a.fn.modal.Constructor=c,a.fn.modal.noConflict=function(){return a.fn.modal=d,this},a(document).on("click.bs.modal.data-api",'[data-toggle="modal"]',function(c){var d=a(this),e=d.attr("href"),f=a(d.attr("data-target")||e&&e.replace(/.*(?=#[^\s]+$)/,"")),g=f.data("bs.modal")?"toggle":a.extend({remote:!/#/.test(e)&&e},f.data(),d.data());d.is("a")&&c.preventDefault(),f.one("show.bs.modal",function(a){a.isDefaultPrevented()||f.one("hidden.bs.modal",function(){d.is(":visible")&&d.trigger("focus")})}),b.call(f,g,this)})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tooltip"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.tooltip",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.type=null,this.options=null,this.enabled=null,this.timeout=null,this.hoverState=null,this.$element=null,this.inState=null,this.init("tooltip",a,b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.DEFAULTS={animation:!0,placement:"top",selector:!1,template:'<div class="tooltip" role="tooltip"><div class="tooltip-arrow"></div><div class="tooltip-inner"></div></div>',trigger:"hover focus",title:"",delay:0,html:!1,container:!1,viewport:{selector:"body",padding:0}},c.prototype.init=function(b,c,d){if(this.enabled=!0,this.type=b,this.$element=a(c),this.options=this.getOptions(d),this.$viewport=this.options.viewport&&a(a.isFunction(this.options.viewport)?this.options.viewport.call(this,this.$element):this.options.viewport.selector||this.options.viewport),this.inState={click:!1,hover:!1,focus:!1},this.$element[0]instanceof document.constructor&&!this.options.selector)throw new Error("`selector` option must be specified when initializing "+this.type+" on the window.document object!");for(var e=this.options.trigger.split(" "),f=e.length;f--;){var g=e[f];if("click"==g)this.$element.on("click."+this.type,this.options.selector,a.proxy(this.toggle,this));else if("manual"!=g){var h="hover"==g?"mouseenter":"focusin",i="hover"==g?"mouseleave":"focusout";this.$element.on(h+"."+this.type,this.options.selector,a.proxy(this.enter,this)),this.$element.on(i+"."+this.type,this.options.selector,a.proxy(this.leave,this))}}this.options.selector?this._options=a.extend({},this.options,{trigger:"manual",selector:""}):this.fixTitle()},c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.getOptions=function(b){return b=a.extend({},this.getDefaults(),this.$element.data(),b),b.delay&&"number"==typeof b.delay&&(b.delay={show:b.delay,hide:b.delay}),b},c.prototype.getDelegateOptions=function(){var b={},c=this.getDefaults();return this._options&&a.each(this._options,function(a,d){c[a]!=d&&(b[a]=d)}),b},c.prototype.enter=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusin"==b.type?"focus":"hover"]=!0),c.tip().hasClass("in")||"in"==c.hoverState?void(c.hoverState="in"):(clearTimeout(c.timeout),c.hoverState="in",c.options.delay&&c.options.delay.show?void(c.timeout=setTimeout(function(){"in"==c.hoverState&&c.show()},c.options.delay.show)):c.show())},c.prototype.isInStateTrue=function(){for(var a in this.inState)if(this.inState[a])return!0;return!1},c.prototype.leave=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusout"==b.type?"focus":"hover"]=!1),c.isInStateTrue()?void 0:(clearTimeout(c.timeout),c.hoverState="out",c.options.delay&&c.options.delay.hide?void(c.timeout=setTimeout(function(){"out"==c.hoverState&&c.hide()},c.options.delay.hide)):c.hide())},c.prototype.show=function(){var b=a.Event("show.bs."+this.type);if(this.hasContent()&&this.enabled){this.$element.trigger(b);var d=a.contains(this.$element[0].ownerDocument.documentElement,this.$element[0]);if(b.isDefaultPrevented()||!d)return;var e=this,f=this.tip(),g=this.getUID(this.type);this.setContent(),f.attr("id",g),this.$element.attr("aria-describedby",g),this.options.animation&&f.addClass("fade");var h="function"==typeof this.options.placement?this.options.placement.call(this,f[0],this.$element[0]):this.options.placement,i=/\s?auto?\s?/i,j=i.test(h);j&&(h=h.replace(i,"")||"top"),f.detach().css({top:0,left:0,display:"block"}).addClass(h).data("bs."+this.type,this),this.options.container?f.appendTo(this.options.container):f.insertAfter(this.$element),this.$element.trigger("inserted.bs."+this.type);var k=this.getPosition(),l=f[0].offsetWidth,m=f[0].offsetHeight;if(j){var n=h,o=this.getPosition(this.$viewport);h="bottom"==h&&k.bottom+m>o.bottom?"top":"top"==h&&k.top-m<o.top?"bottom":"right"==h&&k.right+l>o.width?"left":"left"==h&&k.left-l<o.left?"right":h,f.removeClass(n).addClass(h)}var p=this.getCalculatedOffset(h,k,l,m);this.applyPlacement(p,h);var q=function(){var a=e.hoverState;e.$element.trigger("shown.bs."+e.type),e.hoverState=null,"out"==a&&e.leave(e)};a.support.transition&&this.$tip.hasClass("fade")?f.one("bsTransitionEnd",q).emulateTransitionEnd(c.TRANSITION_DURATION):q()}},c.prototype.applyPlacement=function(b,c){var d=this.tip(),e=d[0].offsetWidth,f=d[0].offsetHeight,g=parseInt(d.css("margin-top"),10),h=parseInt(d.css("margin-left"),10);isNaN(g)&&(g=0),isNaN(h)&&(h=0),b.top+=g,b.left+=h,a.offset.setOffset(d[0],a.extend({using:function(a){d.css({top:Math.round(a.top),left:Math.round(a.left)})}},b),0),d.addClass("in");var i=d[0].offsetWidth,j=d[0].offsetHeight;"top"==c&&j!=f&&(b.top=b.top+f-j);var k=this.getViewportAdjustedDelta(c,b,i,j);k.left?b.left+=k.left:b.top+=k.top;var l=/top|bottom/.test(c),m=l?2*k.left-e+i:2*k.top-f+j,n=l?"offsetWidth":"offsetHeight";d.offset(b),this.replaceArrow(m,d[0][n],l)},c.prototype.replaceArrow=function(a,b,c){this.arrow().css(c?"left":"top",50*(1-a/b)+"%").css(c?"top":"left","")},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle();a.find(".tooltip-inner")[this.options.html?"html":"text"](b),a.removeClass("fade in top bottom left right")},c.prototype.hide=function(b){function d(){"in"!=e.hoverState&&f.detach(),e.$element.removeAttr("aria-describedby").trigger("hidden.bs."+e.type),b&&b()}var e=this,f=a(this.$tip),g=a.Event("hide.bs."+this.type);return this.$element.trigger(g),g.isDefaultPrevented()?void 0:(f.removeClass("in"),a.support.transition&&f.hasClass("fade")?f.one("bsTransitionEnd",d).emulateTransitionEnd(c.TRANSITION_DURATION):d(),this.hoverState=null,this)},c.prototype.fixTitle=function(){var a=this.$element;(a.attr("title")||"string"!=typeof a.attr("data-original-title"))&&a.attr("data-original-title",a.attr("title")||"").attr("title","")},c.prototype.hasContent=function(){return this.getTitle()},c.prototype.getPosition=function(b){b=b||this.$element;var c=b[0],d="BODY"==c.tagName,e=c.getBoundingClientRect();null==e.width&&(e=a.extend({},e,{width:e.right-e.left,height:e.bottom-e.top}));var f=d?{top:0,left:0}:b.offset(),g={scroll:d?document.documentElement.scrollTop||document.body.scrollTop:b.scrollTop()},h=d?{width:a(window).width(),height:a(window).height()}:null;return a.extend({},e,g,h,f)},c.prototype.getCalculatedOffset=function(a,b,c,d){return"bottom"==a?{top:b.top+b.height,left:b.left+b.width/2-c/2}:"top"==a?{top:b.top-d,left:b.left+b.width/2-c/2}:"left"==a?{top:b.top+b.height/2-d/2,left:b.left-c}:{top:b.top+b.height/2-d/2,left:b.left+b.width}},c.prototype.getViewportAdjustedDelta=function(a,b,c,d){var e={top:0,left:0};if(!this.$viewport)return e;var f=this.options.viewport&&this.options.viewport.padding||0,g=this.getPosition(this.$viewport);if(/right|left/.test(a)){var h=b.top-f-g.scroll,i=b.top+f-g.scroll+d;h<g.top?e.top=g.top-h:i>g.top+g.height&&(e.top=g.top+g.height-i)}else{var j=b.left-f,k=b.left+f+c;j<g.left?e.left=g.left-j:k>g.right&&(e.left=g.left+g.width-k)}return e},c.prototype.getTitle=function(){var a,b=this.$element,c=this.options;return a=b.attr("data-original-title")||("function"==typeof c.title?c.title.call(b[0]):c.title)},c.prototype.getUID=function(a){do a+=~~(1e6*Math.random());while(document.getElementById(a));return a},c.prototype.tip=function(){if(!this.$tip&&(this.$tip=a(this.options.template),1!=this.$tip.length))throw new Error(this.type+" `template` option must consist of exactly 1 top-level element!");return this.$tip},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".tooltip-arrow")},c.prototype.enable=function(){this.enabled=!0},c.prototype.disable=function(){this.enabled=!1},c.prototype.toggleEnabled=function(){this.enabled=!this.enabled},c.prototype.toggle=function(b){var c=this;b&&(c=a(b.currentTarget).data("bs."+this.type),c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c))),b?(c.inState.click=!c.inState.click,c.isInStateTrue()?c.enter(c):c.leave(c)):c.tip().hasClass("in")?c.leave(c):c.enter(c)},c.prototype.destroy=function(){var a=this;clearTimeout(this.timeout),this.hide(function(){a.$element.off("."+a.type).removeData("bs."+a.type),a.$tip&&a.$tip.detach(),a.$tip=null,a.$arrow=null,a.$viewport=null})};var d=a.fn.tooltip;a.fn.tooltip=b,a.fn.tooltip.Constructor=c,a.fn.tooltip.noConflict=function(){return a.fn.tooltip=d,this}}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.popover"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.popover",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.init("popover",a,b)};if(!a.fn.tooltip)throw new Error("Popover requires tooltip.js");c.VERSION="3.3.5",c.DEFAULTS=a.extend({},a.fn.tooltip.Constructor.DEFAULTS,{placement:"right",trigger:"click",content:"",template:'<div class="popover" role="tooltip"><div class="arrow"></div><h3 class="popover-title"></h3><div class="popover-content"></div></div>'}),c.prototype=a.extend({},a.fn.tooltip.Constructor.prototype),c.prototype.constructor=c,c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle(),c=this.getContent();a.find(".popover-title")[this.options.html?"html":"text"](b),a.find(".popover-content").children().detach().end()[this.options.html?"string"==typeof c?"html":"append":"text"](c),a.removeClass("fade top bottom left right in"),a.find(".popover-title").html()||a.find(".popover-title").hide()},c.prototype.hasContent=function(){return this.getTitle()||this.getContent()},c.prototype.getContent=function(){var a=this.$element,b=this.options;return a.attr("data-content")||("function"==typeof b.content?b.content.call(a[0]):b.content)},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".arrow")};var d=a.fn.popover;a.fn.popover=b,a.fn.popover.Constructor=c,a.fn.popover.noConflict=function(){return a.fn.popover=d,this}}(jQuery),+function(a){"use strict";function b(c,d){this.$body=a(document.body),this.$scrollElement=a(a(c).is(document.body)?window:c),this.options=a.extend({},b.DEFAULTS,d),this.selector=(this.options.target||"")+" .nav li > a",this.offsets=[],this.targets=[],this.activeTarget=null,this.scrollHeight=0,this.$scrollElement.on("scroll.bs.scrollspy",a.proxy(this.process,this)),this.refresh(),this.process()}function c(c){return this.each(function(){var d=a(this),e=d.data("bs.scrollspy"),f="object"==typeof c&&c;e||d.data("bs.scrollspy",e=new b(this,f)),"string"==typeof c&&e[c]()})}b.VERSION="3.3.5",b.DEFAULTS={offset:10},b.prototype.getScrollHeight=function(){return this.$scrollElement[0].scrollHeight||Math.max(this.$body[0].scrollHeight,document.documentElement.scrollHeight)},b.prototype.refresh=function(){var b=this,c="offset",d=0;this.offsets=[],this.targets=[],this.scrollHeight=this.getScrollHeight(),a.isWindow(this.$scrollElement[0])||(c="position",d=this.$scrollElement.scrollTop()),this.$body.find(this.selector).map(function(){var b=a(this),e=b.data("target")||b.attr("href"),f=/^#./.test(e)&&a(e);return f&&f.length&&f.is(":visible")&&[[f[c]().top+d,e]]||null}).sort(function(a,b){return a[0]-b[0]}).each(function(){b.offsets.push(this[0]),b.targets.push(this[1])})},b.prototype.process=function(){var a,b=this.$scrollElement.scrollTop()+this.options.offset,c=this.getScrollHeight(),d=this.options.offset+c-this.$scrollElement.height(),e=this.offsets,f=this.targets,g=this.activeTarget;if(this.scrollHeight!=c&&this.refresh(),b>=d)return g!=(a=f[f.length-1])&&this.activate(a);if(g&&b<e[0])return this.activeTarget=null,this.clear();for(a=e.length;a--;)g!=f[a]&&b>=e[a]&&(void 0===e[a+1]||b<e[a+1])&&this.activate(f[a])},b.prototype.activate=function(b){this.activeTarget=b,this.clear();var c=this.selector+'[data-target="'+b+'"],'+this.selector+'[href="'+b+'"]',d=a(c).parents("li").addClass("active");d.parent(".dropdown-menu").length&&(d=d.closest("li.dropdown").addClass("active")),
d.trigger("activate.bs.scrollspy")},b.prototype.clear=function(){a(this.selector).parentsUntil(this.options.target,".active").removeClass("active")};var d=a.fn.scrollspy;a.fn.scrollspy=c,a.fn.scrollspy.Constructor=b,a.fn.scrollspy.noConflict=function(){return a.fn.scrollspy=d,this},a(window).on("load.bs.scrollspy.data-api",function(){a('[data-spy="scroll"]').each(function(){var b=a(this);c.call(b,b.data())})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tab");e||d.data("bs.tab",e=new c(this)),"string"==typeof b&&e[b]()})}var c=function(b){this.element=a(b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.prototype.show=function(){var b=this.element,c=b.closest("ul:not(.dropdown-menu)"),d=b.data("target");if(d||(d=b.attr("href"),d=d&&d.replace(/.*(?=#[^\s]*$)/,"")),!b.parent("li").hasClass("active")){var e=c.find(".active:last a"),f=a.Event("hide.bs.tab",{relatedTarget:b[0]}),g=a.Event("show.bs.tab",{relatedTarget:e[0]});if(e.trigger(f),b.trigger(g),!g.isDefaultPrevented()&&!f.isDefaultPrevented()){var h=a(d);this.activate(b.closest("li"),c),this.activate(h,h.parent(),function(){e.trigger({type:"hidden.bs.tab",relatedTarget:b[0]}),b.trigger({type:"shown.bs.tab",relatedTarget:e[0]})})}}},c.prototype.activate=function(b,d,e){function f(){g.removeClass("active").find("> .dropdown-menu > .active").removeClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!1),b.addClass("active").find('[data-toggle="tab"]').attr("aria-expanded",!0),h?(b[0].offsetWidth,b.addClass("in")):b.removeClass("fade"),b.parent(".dropdown-menu").length&&b.closest("li.dropdown").addClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!0),e&&e()}var g=d.find("> .active"),h=e&&a.support.transition&&(g.length&&g.hasClass("fade")||!!d.find("> .fade").length);g.length&&h?g.one("bsTransitionEnd",f).emulateTransitionEnd(c.TRANSITION_DURATION):f(),g.removeClass("in")};var d=a.fn.tab;a.fn.tab=b,a.fn.tab.Constructor=c,a.fn.tab.noConflict=function(){return a.fn.tab=d,this};var e=function(c){c.preventDefault(),b.call(a(this),"show")};a(document).on("click.bs.tab.data-api",'[data-toggle="tab"]',e).on("click.bs.tab.data-api",'[data-toggle="pill"]',e)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.affix"),f="object"==typeof b&&b;e||d.data("bs.affix",e=new c(this,f)),"string"==typeof b&&e[b]()})}var c=function(b,d){this.options=a.extend({},c.DEFAULTS,d),this.$target=a(this.options.target).on("scroll.bs.affix.data-api",a.proxy(this.checkPosition,this)).on("click.bs.affix.data-api",a.proxy(this.checkPositionWithEventLoop,this)),this.$element=a(b),this.affixed=null,this.unpin=null,this.pinnedOffset=null,this.checkPosition()};c.VERSION="3.3.5",c.RESET="affix affix-top affix-bottom",c.DEFAULTS={offset:0,target:window},c.prototype.getState=function(a,b,c,d){var e=this.$target.scrollTop(),f=this.$element.offset(),g=this.$target.height();if(null!=c&&"top"==this.affixed)return c>e?"top":!1;if("bottom"==this.affixed)return null!=c?e+this.unpin<=f.top?!1:"bottom":a-d>=e+g?!1:"bottom";var h=null==this.affixed,i=h?e:f.top,j=h?g:b;return null!=c&&c>=e?"top":null!=d&&i+j>=a-d?"bottom":!1},c.prototype.getPinnedOffset=function(){if(this.pinnedOffset)return this.pinnedOffset;this.$element.removeClass(c.RESET).addClass("affix");var a=this.$target.scrollTop(),b=this.$element.offset();return this.pinnedOffset=b.top-a},c.prototype.checkPositionWithEventLoop=function(){setTimeout(a.proxy(this.checkPosition,this),1)},c.prototype.checkPosition=function(){if(this.$element.is(":visible")){var b=this.$element.height(),d=this.options.offset,e=d.top,f=d.bottom,g=Math.max(a(document).height(),a(document.body).height());"object"!=typeof d&&(f=e=d),"function"==typeof e&&(e=d.top(this.$element)),"function"==typeof f&&(f=d.bottom(this.$element));var h=this.getState(g,b,e,f);if(this.affixed!=h){null!=this.unpin&&this.$element.css("top","");var i="affix"+(h?"-"+h:""),j=a.Event(i+".bs.affix");if(this.$element.trigger(j),j.isDefaultPrevented())return;this.affixed=h,this.unpin="bottom"==h?this.getPinnedOffset():null,this.$element.removeClass(c.RESET).addClass(i).trigger(i.replace("affix","affixed")+".bs.affix")}"bottom"==h&&this.$element.offset({top:g-b-f})}};var d=a.fn.affix;a.fn.affix=b,a.fn.affix.Constructor=c,a.fn.affix.noConflict=function(){return a.fn.affix=d,this},a(window).on("load",function(){a('[data-spy="affix"]').each(function(){var c=a(this),d=c.data();d.offset=d.offset||{},null!=d.offsetBottom&&(d.offset.bottom=d.offsetBottom),null!=d.offsetTop&&(d.offset.top=d.offsetTop),b.call(c,d)})})}(jQuery);</script>
<script>/**
* @preserve HTML5 Shiv 3.7.2 | @afarkas @jdalton @jon_neal @rem | MIT/GPL2 Licensed
*/
// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a,b){function c(a,b){var c=a.createElement("p"),d=a.getElementsByTagName("head")[0]||a.documentElement;return c.innerHTML="x<style>"+b+"</style>",d.insertBefore(c.lastChild,d.firstChild)}function d(){var a=t.elements;return"string"==typeof a?a.split(" "):a}function e(a,b){var c=t.elements;"string"!=typeof c&&(c=c.join(" ")),"string"!=typeof a&&(a=a.join(" ")),t.elements=c+" "+a,j(b)}function f(a){var b=s[a[q]];return b||(b={},r++,a[q]=r,s[r]=b),b}function g(a,c,d){if(c||(c=b),l)return c.createElement(a);d||(d=f(c));var e;return e=d.cache[a]?d.cache[a].cloneNode():p.test(a)?(d.cache[a]=d.createElem(a)).cloneNode():d.createElem(a),!e.canHaveChildren||o.test(a)||e.tagUrn?e:d.frag.appendChild(e)}function h(a,c){if(a||(a=b),l)return a.createDocumentFragment();c=c||f(a);for(var e=c.frag.cloneNode(),g=0,h=d(),i=h.length;i>g;g++)e.createElement(h[g]);return e}function i(a,b){b.cache||(b.cache={},b.createElem=a.createElement,b.createFrag=a.createDocumentFragment,b.frag=b.createFrag()),a.createElement=function(c){return t.shivMethods?g(c,a,b):b.createElem(c)},a.createDocumentFragment=Function("h,f","return function(){var n=f.cloneNode(),c=n.createElement;h.shivMethods&&("+d().join().replace(/[\w\-:]+/g,function(a){return b.createElem(a),b.frag.createElement(a),'c("'+a+'")'})+");return n}")(t,b.frag)}function j(a){a||(a=b);var d=f(a);return!t.shivCSS||k||d.hasCSS||(d.hasCSS=!!c(a,"article,aside,dialog,figcaption,figure,footer,header,hgroup,main,nav,section{display:block}mark{background:#FF0;color:#000}template{display:none}")),l||i(a,d),a}var k,l,m="3.7.2",n=a.html5||{},o=/^<|^(?:button|map|select|textarea|object|iframe|option|optgroup)$/i,p=/^(?:a|b|code|div|fieldset|h1|h2|h3|h4|h5|h6|i|label|li|ol|p|q|span|strong|style|table|tbody|td|th|tr|ul)$/i,q="_html5shiv",r=0,s={};!function(){try{var a=b.createElement("a");a.innerHTML="<xyz></xyz>",k="hidden"in a,l=1==a.childNodes.length||function(){b.createElement("a");var a=b.createDocumentFragment();return"undefined"==typeof a.cloneNode||"undefined"==typeof a.createDocumentFragment||"undefined"==typeof a.createElement}()}catch(c){k=!0,l=!0}}();var t={elements:n.elements||"abbr article aside audio bdi canvas data datalist details dialog figcaption figure footer header hgroup main mark meter nav output picture progress section summary template time video",version:m,shivCSS:n.shivCSS!==!1,supportsUnknownElements:l,shivMethods:n.shivMethods!==!1,type:"default",shivDocument:j,createElement:g,createDocumentFragment:h,addElements:e};a.html5=t,j(b)}(this,document);
};
</script>
<script>/*! Respond.js v1.4.2: min/max-width media query polyfill * Copyright 2013 Scott Jehl
 * Licensed under https://github.com/scottjehl/Respond/blob/master/LICENSE-MIT
 *  */

// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a){"use strict";a.matchMedia=a.matchMedia||function(a){var b,c=a.documentElement,d=c.firstElementChild||c.firstChild,e=a.createElement("body"),f=a.createElement("div");return f.id="mq-test-1",f.style.cssText="position:absolute;top:-100em",e.style.background="none",e.appendChild(f),function(a){return f.innerHTML='&shy;<style media="'+a+'"> #mq-test-1 { width: 42px; }</style>',c.insertBefore(e,d),b=42===f.offsetWidth,c.removeChild(e),{matches:b,media:a}}}(a.document)}(this),function(a){"use strict";function b(){u(!0)}var c={};a.respond=c,c.update=function(){};var d=[],e=function(){var b=!1;try{b=new a.XMLHttpRequest}catch(c){b=new a.ActiveXObject("Microsoft.XMLHTTP")}return function(){return b}}(),f=function(a,b){var c=e();c&&(c.open("GET",a,!0),c.onreadystatechange=function(){4!==c.readyState||200!==c.status&&304!==c.status||b(c.responseText)},4!==c.readyState&&c.send(null))};if(c.ajax=f,c.queue=d,c.regex={media:/@media[^\{]+\{([^\{\}]*\{[^\}\{]*\})+/gi,keyframes:/@(?:\-(?:o|moz|webkit)\-)?keyframes[^\{]+\{(?:[^\{\}]*\{[^\}\{]*\})+[^\}]*\}/gi,urls:/(url\()['"]?([^\/\)'"][^:\)'"]+)['"]?(\))/g,findStyles:/@media *([^\{]+)\{([\S\s]+?)$/,only:/(only\s+)?([a-zA-Z]+)\s?/,minw:/\([\s]*min\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/,maxw:/\([\s]*max\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/},c.mediaQueriesSupported=a.matchMedia&&null!==a.matchMedia("only all")&&a.matchMedia("only all").matches,!c.mediaQueriesSupported){var g,h,i,j=a.document,k=j.documentElement,l=[],m=[],n=[],o={},p=30,q=j.getElementsByTagName("head")[0]||k,r=j.getElementsByTagName("base")[0],s=q.getElementsByTagName("link"),t=function(){var a,b=j.createElement("div"),c=j.body,d=k.style.fontSize,e=c&&c.style.fontSize,f=!1;return b.style.cssText="position:absolute;font-size:1em;width:1em",c||(c=f=j.createElement("body"),c.style.background="none"),k.style.fontSize="100%",c.style.fontSize="100%",c.appendChild(b),f&&k.insertBefore(c,k.firstChild),a=b.offsetWidth,f?k.removeChild(c):c.removeChild(b),k.style.fontSize=d,e&&(c.style.fontSize=e),a=i=parseFloat(a)},u=function(b){var c="clientWidth",d=k[c],e="CSS1Compat"===j.compatMode&&d||j.body[c]||d,f={},o=s[s.length-1],r=(new Date).getTime();if(b&&g&&p>r-g)return a.clearTimeout(h),h=a.setTimeout(u,p),void 0;g=r;for(var v in l)if(l.hasOwnProperty(v)){var w=l[v],x=w.minw,y=w.maxw,z=null===x,A=null===y,B="em";x&&(x=parseFloat(x)*(x.indexOf(B)>-1?i||t():1)),y&&(y=parseFloat(y)*(y.indexOf(B)>-1?i||t():1)),w.hasquery&&(z&&A||!(z||e>=x)||!(A||y>=e))||(f[w.media]||(f[w.media]=[]),f[w.media].push(m[w.rules]))}for(var C in n)n.hasOwnProperty(C)&&n[C]&&n[C].parentNode===q&&q.removeChild(n[C]);n.length=0;for(var D in f)if(f.hasOwnProperty(D)){var E=j.createElement("style"),F=f[D].join("\n");E.type="text/css",E.media=D,q.insertBefore(E,o.nextSibling),E.styleSheet?E.styleSheet.cssText=F:E.appendChild(j.createTextNode(F)),n.push(E)}},v=function(a,b,d){var e=a.replace(c.regex.keyframes,"").match(c.regex.media),f=e&&e.length||0;b=b.substring(0,b.lastIndexOf("/"));var g=function(a){return a.replace(c.regex.urls,"$1"+b+"$2$3")},h=!f&&d;b.length&&(b+="/"),h&&(f=1);for(var i=0;f>i;i++){var j,k,n,o;h?(j=d,m.push(g(a))):(j=e[i].match(c.regex.findStyles)&&RegExp.$1,m.push(RegExp.$2&&g(RegExp.$2))),n=j.split(","),o=n.length;for(var p=0;o>p;p++)k=n[p],l.push({media:k.split("(")[0].match(c.regex.only)&&RegExp.$2||"all",rules:m.length-1,hasquery:k.indexOf("(")>-1,minw:k.match(c.regex.minw)&&parseFloat(RegExp.$1)+(RegExp.$2||""),maxw:k.match(c.regex.maxw)&&parseFloat(RegExp.$1)+(RegExp.$2||"")})}u()},w=function(){if(d.length){var b=d.shift();f(b.href,function(c){v(c,b.href,b.media),o[b.href]=!0,a.setTimeout(function(){w()},0)})}},x=function(){for(var b=0;b<s.length;b++){var c=s[b],e=c.href,f=c.media,g=c.rel&&"stylesheet"===c.rel.toLowerCase();e&&g&&!o[e]&&(c.styleSheet&&c.styleSheet.rawCssText?(v(c.styleSheet.rawCssText,e,f),o[e]=!0):(!/^([a-zA-Z:]*\/\/)/.test(e)&&!r||e.replace(RegExp.$1,"").split("/")[0]===a.location.host)&&("//"===e.substring(0,2)&&(e=a.location.protocol+e),d.push({href:e,media:f})))}w()};x(),c.update=x,c.getEmValue=t,a.addEventListener?a.addEventListener("resize",b,!1):a.attachEvent&&a.attachEvent("onresize",b)}}(this);
};
</script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<style type="text/css">.pagedtable {
overflow: auto;
padding-left: 8px;
padding-right: 8px;
}
.pagedtable-wrapper {
border: 1px solid #ccc;
border-radius: 4px;
margin-bottom: 10px;
}
.pagedtable table {
width: 100%;
max-width: 100%;
margin: 0;
}
.pagedtable th {
padding: 0 5px 0 5px;
border: none;
border-bottom: 2px solid #dddddd;
min-width: 45px;
}
.pagedtable-empty th {
display: none;
}
.pagedtable td {
padding: 0 4px 0 4px;
}
.pagedtable .even {
background-color: rgba(140, 140, 140, 0.1);
}
.pagedtable-padding-col {
display: none;
}
.pagedtable a {
-webkit-touch-callout: none;
-webkit-user-select: none;
-khtml-user-select: none;
-moz-user-select: none;
-ms-user-select: none;
user-select: none;
}
.pagedtable-index-nav {
cursor: pointer;
padding: 0 5px 0 5px;
float: right;
border: 0;
}
.pagedtable-index-nav-disabled {
cursor: default;
text-decoration: none;
color: #999;
}
a.pagedtable-index-nav-disabled:hover {
text-decoration: none;
color: #999;
}
.pagedtable-indexes {
cursor: pointer;
float: right;
border: 0;
}
.pagedtable-index-current {
cursor: default;
text-decoration: none;
font-weight: bold;
color: #333;
border: 0;
}
a.pagedtable-index-current:hover {
text-decoration: none;
font-weight: bold;
color: #333;
}
.pagedtable-index {
width: 30px;
display: inline-block;
text-align: center;
border: 0;
}
.pagedtable-index-separator-left {
display: inline-block;
color: #333;
font-size: 9px;
padding: 0 0 0 0;
cursor: default;
}
.pagedtable-index-separator-right {
display: inline-block;
color: #333;
font-size: 9px;
padding: 0 4px 0 0;
cursor: default;
}
.pagedtable-footer {
padding-top: 4px;
padding-bottom: 5px;
}
.pagedtable-not-empty .pagedtable-footer {
border-top: 2px solid #dddddd;
}
.pagedtable-info {
overflow: hidden;
color: #999;
white-space: nowrap;
text-overflow: ellipsis;
}
.pagedtable-header-name {
overflow: hidden;
text-overflow: ellipsis;
}
.pagedtable-header-type {
color: #999;
font-weight: 400;
}
.pagedtable-na-cell {
font-style: italic;
opacity: 0.3;
}
</style>
<script>// Production steps of ECMA-262, Edition 5, 15.4.4.18
// Reference: http://es5.github.io/#x15.4.4.18
if (!Array.prototype.forEach) {

  Array.prototype.forEach = function(callback, thisArg) {

    var T, k;

    if (this === null) {
      throw new TypeError(' this is null or not defined');
    }

    // 1. Let O be the result of calling toObject() passing the
    // |this| value as the argument.
    var O = Object(this);

    // 2. Let lenValue be the result of calling the Get() internal
    // method of O with the argument "length".
    // 3. Let len be toUint32(lenValue).
    var len = O.length >>> 0;

    // 4. If isCallable(callback) is false, throw a TypeError exception.
    // See: http://es5.github.com/#x9.11
    if (typeof callback !== "function") {
      throw new TypeError(callback + ' is not a function');
    }

    // 5. If thisArg was supplied, let T be thisArg; else let
    // T be undefined.
    if (arguments.length > 1) {
      T = thisArg;
    }

    // 6. Let k be 0
    k = 0;

    // 7. Repeat, while k < len
    while (k < len) {

      var kValue;

      // a. Let Pk be ToString(k).
      //    This is implicit for LHS operands of the in operator
      // b. Let kPresent be the result of calling the HasProperty
      //    internal method of O with argument Pk.
      //    This step can be combined with c
      // c. If kPresent is true, then
      if (k in O) {

        // i. Let kValue be the result of calling the Get internal
        // method of O with argument Pk.
        kValue = O[k];

        // ii. Call the Call internal method of callback with T as
        // the this value and argument list containing kValue, k, and O.
        callback.call(T, kValue, k, O);
      }
      // d. Increase k by 1.
      k++;
    }
    // 8. return undefined
  };
}

// Production steps of ECMA-262, Edition 5, 15.4.4.19
// Reference: http://es5.github.io/#x15.4.4.19
if (!Array.prototype.map) {

  Array.prototype.map = function(callback, thisArg) {

    var T, A, k;

    if (this == null) {
      throw new TypeError(' this is null or not defined');
    }

    // 1. Let O be the result of calling ToObject passing the |this|
    //    value as the argument.
    var O = Object(this);

    // 2. Let lenValue be the result of calling the Get internal
    //    method of O with the argument "length".
    // 3. Let len be ToUint32(lenValue).
    var len = O.length >>> 0;

    // 4. If IsCallable(callback) is false, throw a TypeError exception.
    // See: http://es5.github.com/#x9.11
    if (typeof callback !== 'function') {
      throw new TypeError(callback + ' is not a function');
    }

    // 5. If thisArg was supplied, let T be thisArg; else let T be undefined.
    if (arguments.length > 1) {
      T = thisArg;
    }

    // 6. Let A be a new array created as if by the expression new Array(len)
    //    where Array is the standard built-in constructor with that name and
    //    len is the value of len.
    A = new Array(len);

    // 7. Let k be 0
    k = 0;

    // 8. Repeat, while k < len
    while (k < len) {

      var kValue, mappedValue;

      // a. Let Pk be ToString(k).
      //   This is implicit for LHS operands of the in operator
      // b. Let kPresent be the result of calling the HasProperty internal
      //    method of O with argument Pk.
      //   This step can be combined with c
      // c. If kPresent is true, then
      if (k in O) {

        // i. Let kValue be the result of calling the Get internal
        //    method of O with argument Pk.
        kValue = O[k];

        // ii. Let mappedValue be the result of calling the Call internal
        //     method of callback with T as the this value and argument
        //     list containing kValue, k, and O.
        mappedValue = callback.call(T, kValue, k, O);

        // iii. Call the DefineOwnProperty internal method of A with arguments
        // Pk, Property Descriptor
        // { Value: mappedValue,
        //   Writable: true,
        //   Enumerable: true,
        //   Configurable: true },
        // and false.

        // In browsers that support Object.defineProperty, use the following:
        // Object.defineProperty(A, k, {
        //   value: mappedValue,
        //   writable: true,
        //   enumerable: true,
        //   configurable: true
        // });

        // For best browser support, use the following:
        A[k] = mappedValue;
      }
      // d. Increase k by 1.
      k++;
    }

    // 9. return A
    return A;
  };
}

var PagedTable = function (pagedTable) {
  var me = this;

  var source = function(pagedTable) {
    var sourceElems = [].slice.call(pagedTable.children).filter(function(e) {
      return e.hasAttribute("data-pagedtable-source");
    });

    if (sourceElems === null || sourceElems.length !== 1) {
      throw("A single data-pagedtable-source was not found");
    }

    return JSON.parse(sourceElems[0].innerHTML);
  }(pagedTable);

  var options = function(source) {
    var options = typeof(source.options) !== "undefined" &&
      source.options !== null ? source.options : {};

    var columns = typeof(options.columns) !== "undefined" ? options.columns : {};
    var rows = typeof(options.rows) !== "undefined" ? options.rows : {};

    var positiveIntOrNull = function(value) {
      return parseInt(value) >= 0 ? parseInt(value) : null;
    };

    return {
      pages: positiveIntOrNull(options.pages),
      rows: {
        min: positiveIntOrNull(rows.min),
        max: positiveIntOrNull(rows.max),
        total: positiveIntOrNull(rows.total)
      },
      columns: {
        min: positiveIntOrNull(columns.min),
        max: positiveIntOrNull(columns.max),
        total: positiveIntOrNull(columns.total)
      }
    };
  }(source);

  var Measurer = function() {

    // set some default initial values that will get adjusted in runtime
    me.measures = {
      padding: 12,
      character: 8,
      height: 15,
      defaults: true
    };

    me.calculate = function(measuresCell) {
      if (!me.measures.defaults)
        return;

      var measuresCellStyle = window.getComputedStyle(measuresCell, null);

      var newPadding = parsePadding(measuresCellStyle.paddingLeft) +
            parsePadding(measuresCellStyle.paddingRight);

      var sampleString = "ABCDEFGHIJ0123456789";
      var newCharacter = Math.ceil(measuresCell.clientWidth / sampleString.length);

      if (newPadding <= 0 || newCharacter <= 0)
        return;

      me.measures.padding = newPadding;
      me.measures.character = newCharacter;
      me.measures.height = measuresCell.clientHeight;
      me.measures.defaults = false;
    };

    return me;
  };

  var Page = function(data, options) {
    var me = this;

    var defaults = {
      max: 7,
      rows: 10
    };

    var totalPages = function() {
      return Math.ceil(data.length / me.rows);
    };

    me.number = 0;
    me.max = options.pages !== null ? options.pages : defaults.max;
    me.visible = me.max;
    me.rows = options.rows.min !== null ? options.rows.min : defaults.rows;
    me.total = totalPages();

    me.setRows = function(newRows) {
      me.rows = newRows;
      me.total = totalPages();
    };

    me.setPageNumber = function(newPageNumber) {
      if (newPageNumber < 0) newPageNumber = 0;
      if (newPageNumber >= me.total) newPageNumber = me.total - 1;

      me.number = newPageNumber;
    };

    me.setVisiblePages = function(visiblePages) {
      me.visible = Math.min(me.max, visiblePages);
      me.setPageNumber(me.number);
    };

    me.getVisiblePageRange = function() {
      var start = me.number - Math.max(Math.floor((me.visible - 1) / 2), 0);
      var end = me.number + Math.floor(me.visible / 2) + 1;
      var pageCount = me.total;

      if (start < 0) {
        var diffToStart = 0 - start;
        start += diffToStart;
        end += diffToStart;
      }

      if (end > pageCount) {
        var diffToEnd = end - pageCount;
        start -= diffToEnd;
        end -= diffToEnd;
      }

      start = start < 0 ? 0 : start;
      end = end >= pageCount ? pageCount : end;

      var first = false;
      var last = false;

      if (start > 0 && me.visible > 1) {
        start = start + 1;
        first = true;
      }

      if (end < pageCount && me.visible > 2) {
        end = end - 1;
        last = true;
      }

      return {
        first: first,
        start: start,
        end: end,
        last: last
      };
    };

    me.getRowStart = function() {
      var rowStart = page.number * page.rows;
      if (rowStart < 0)
        rowStart = 0;

      return rowStart;
    };

    me.getRowEnd = function() {
      var rowStart = me.getRowStart();
      return Math.min(rowStart + me.rows, data.length);
    };

    me.getPaddingRows = function() {
      var rowStart = me.getRowStart();
      var rowEnd = me.getRowEnd();
      return data.length > me.rows ? me.rows - (rowEnd - rowStart) : 0;
    };
  };

  var Columns = function(data, columns, options) {
    var me = this;

    me.defaults = {
      min: 5
    };

    me.number = 0;
    me.visible = 0;
    me.total = columns.length;
    me.subset = [];
    me.padding = 0;
    me.min = options.columns.min !== null ? options.columns.min : me.defaults.min;
    me.max = options.columns.max !== null ? options.columns.max : null;
    me.widths = {};

    var widthsLookAhead = Math.max(100, options.rows.min);
    var paddingColChars = 10;

    me.emptyNames = function() {
      columns.forEach(function(column) {
        if (columns.label !== null && columns.label !== "")
          return false;
      });

      return true;
    };

    var parsePadding = function(value) {
      return parseInt(value) >= 0 ? parseInt(value) : 0;
    };

    me.calculateWidths = function(measures) {
      columns.forEach(function(column) {
        var maxChars = Math.max(
          column.label.toString().length,
          column.type.toString().length
        );

        for (var idxRow = 0; idxRow < Math.min(widthsLookAhead, data.length); idxRow++) {
          maxChars = Math.max(maxChars, data[idxRow][column.name.toString()].length);
        }

        me.widths[column.name] = {
          // width in characters
          chars: maxChars,
          // width for the inner html columns
          inner: maxChars * measures.character,
          // width adding outer styles like padding
          outer: maxChars * measures.character + measures.padding
        };
      });
    };

    me.getWidth = function() {
      var widthOuter = 0;
      for (var idxCol = 0; idxCol < me.subset.length; idxCol++) {
        var columnName = me.subset[idxCol].name;
        widthOuter = widthOuter + me.widths[columnName].outer;
      }

      widthOuter = widthOuter + me.padding * paddingColChars * measurer.measures.character;

      if (me.hasMoreLeftColumns()) {
        widthOuter = widthOuter + columnNavigationWidthPX + measurer.measures.padding;
      }

      if (me.hasMoreRightColumns()) {
        widthOuter = widthOuter + columnNavigationWidthPX + measurer.measures.padding;
      }

      return widthOuter;
    };

    me.updateSlice = function() {
      if (me.number + me.visible >= me.total)
        me.number = me.total - me.visible;

      if (me.number < 0) me.number = 0;

      me.subset = columns.slice(me.number, Math.min(me.number + me.visible, me.total));

      me.subset = me.subset.map(function(column) {
        Object.keys(column).forEach(function(colKey) {
          column[colKey] = column[colKey] === null ? "" : column[colKey].toString();
        });

        column.width = null;
        return column;
      });
    };

    me.setVisibleColumns = function(columnNumber, newVisibleColumns, paddingCount) {
      me.number = columnNumber;
      me.visible = newVisibleColumns;
      me.padding = paddingCount;

      me.updateSlice();
    };

    me.incColumnNumber = function(increment) {
      me.number = me.number + increment;
    };

    me.setColumnNumber = function(newNumber) {
      me.number = newNumber;
    };

    me.setPaddingCount = function(newPadding) {
      me.padding = newPadding;
    };

    me.getPaddingCount = function() {
      return me.padding;
    };

    me.hasMoreLeftColumns = function() {
      return me.number > 0;
    };

    me.hasMoreRightColumns = function() {
      return me.number + me.visible < me.total;
    };

    me.updateSlice(0);
    return me;
  };

  var data = source.data;
  var page = new Page(data, options);
  var measurer = new Measurer(data, options);
  var columns = new Columns(data, source.columns, options);

  var table = null;
  var tableDiv = null;
  var header = null;
  var footer = null;
  var tbody = null;

  // Caches pagedTable.clientWidth, specially for webkit
  var cachedPagedTableClientWidth = null;

  var onChangeCallbacks = [];

  var clearSelection = function() {
    if(document.selection && document.selection.empty) {
      document.selection.empty();
    } else if(window.getSelection) {
      var sel = window.getSelection();
      sel.removeAllRanges();
    }
  };

  var columnNavigationWidthPX = 5;

  var renderColumnNavigation = function(increment, backwards) {
    var arrow = document.createElement("div");
    arrow.setAttribute("style",
      "border-top: " + columnNavigationWidthPX + "px solid transparent;" +
      "border-bottom: " + columnNavigationWidthPX + "px solid transparent;" +
      "border-" + (backwards ? "right" : "left") + ": " + columnNavigationWidthPX + "px solid;");

    var header = document.createElement("th");
    header.appendChild(arrow);
    header.setAttribute("style",
      "cursor: pointer;" +
      "vertical-align: middle;" +
      "min-width: " + columnNavigationWidthPX + "px;" +
      "width: " + columnNavigationWidthPX + "px;");

    header.onclick = function() {
      columns.incColumnNumber(backwards ? -1 : increment);

      me.animateColumns(backwards);
      renderFooter();

      clearSelection();
      triggerOnChange();
    };

    return header;
  };

  var maxColumnWidth = function(width) {
    var padding = 80;
    var columnMax = Math.max(cachedPagedTableClientWidth - padding, 0);

    return parseInt(width) > 0 ?
      Math.min(columnMax, parseInt(width)) + "px" :
      columnMax + "px";
  };

  var clearHeader = function() {
    var thead = pagedTable.querySelectorAll("thead")[0];
    thead.innerHTML = "";
  };

  var renderHeader = function(clear) {
    cachedPagedTableClientWidth = pagedTable.clientWidth;

    var fragment = document.createDocumentFragment();

    header = document.createElement("tr");
    fragment.appendChild(header);

    if (columns.number > 0)
      header.appendChild(renderColumnNavigation(-columns.visible, true));

    columns.subset = columns.subset.map(function(columnData) {
      var column = document.createElement("th");
      column.setAttribute("align", columnData.align);
      column.style.textAlign = columnData.align;

      column.style.maxWidth = maxColumnWidth(null);
      if (columnData.width) {
        column.style.minWidth =
          column.style.maxWidth = maxColumnWidth(columnData.width);
      }

      var columnName = document.createElement("div");
      columnName.setAttribute("class", "pagedtable-header-name");
      if (columnData.label === "") {
        columnName.innerHTML = "&nbsp;";
      }
      else {
        columnName.appendChild(document.createTextNode(columnData.label));
      }
      column.appendChild(columnName);

      var columnType = document.createElement("div");
      columnType.setAttribute("class", "pagedtable-header-type");
      if (columnData.type === "") {
        columnType.innerHTML = "&nbsp;";
      }
      else {
        columnType.appendChild(document.createTextNode("<" + columnData.type + ">"));
      }
      column.appendChild(columnType);

      header.appendChild(column);

      columnData.element = column;

      return columnData;
    });

    for (var idx = 0; idx < columns.getPaddingCount(); idx++) {
      var paddingCol = document.createElement("th");
      paddingCol.setAttribute("class", "pagedtable-padding-col");
      header.appendChild(paddingCol);
    }

    if (columns.number + columns.visible < columns.total)
      header.appendChild(renderColumnNavigation(columns.visible, false));

    if (typeof(clear) == "undefined" || clear) clearHeader();
    var thead = pagedTable.querySelectorAll("thead")[0];
    thead.appendChild(fragment);
  };

  me.animateColumns = function(backwards) {
    var thead = pagedTable.querySelectorAll("thead")[0];

    var headerOld = thead.querySelectorAll("tr")[0];
    var tbodyOld = table.querySelectorAll("tbody")[0];

    me.fitColumns(backwards);

    renderHeader(false);

    header.style.opacity = "0";
    header.style.transform = backwards ? "translateX(-30px)" : "translateX(30px)";
    header.style.transition = "transform 200ms linear, opacity 200ms";
    header.style.transitionDelay = "0";

    renderBody(false);

    if (headerOld) {
      headerOld.style.position = "absolute";
      headerOld.style.transform = "translateX(0px)";
      headerOld.style.opacity = "1";
      headerOld.style.transition = "transform 100ms linear, opacity 100ms";
      headerOld.setAttribute("class", "pagedtable-remove-head");
      if (headerOld.style.transitionEnd) {
        headerOld.addEventListener("transitionend", function() {
          var headerOldByClass = thead.querySelector(".pagedtable-remove-head");
          if (headerOldByClass) thead.removeChild(headerOldByClass);
        });
      }
      else {
        thead.removeChild(headerOld);
      }
    }

    if (tbodyOld) table.removeChild(tbodyOld);

    tbody.style.opacity = "0";
    tbody.style.transition = "transform 200ms linear, opacity 200ms";
    tbody.style.transitionDelay = "0ms";

    // force relayout
    window.getComputedStyle(header).opacity;
    window.getComputedStyle(tbody).opacity;

    if (headerOld) {
      headerOld.style.transform = backwards ? "translateX(20px)" : "translateX(-30px)";
      headerOld.style.opacity = "0";
    }

    header.style.transform = "translateX(0px)";
    header.style.opacity = "1";

    tbody.style.opacity = "1";
  }

  me.onChange = function(callback) {
    onChangeCallbacks.push(callback);
  };

  var triggerOnChange = function() {
    onChangeCallbacks.forEach(function(onChange) {
      onChange();
    });
  };

  var clearBody = function() {
    if (tbody) {
      table.removeChild(tbody);
      tbody = null;
    }
  };

  var renderBody = function(clear) {
    cachedPagedTableClientWidth = pagedTable.clientWidth

    var fragment = document.createDocumentFragment();

    var pageData = data.slice(page.getRowStart(), page.getRowEnd());

    pageData.forEach(function(dataRow, idxRow) {
      var htmlRow = document.createElement("tr");
      htmlRow.setAttribute("class", (idxRow % 2 !==0) ? "even" : "odd");

      if (columns.hasMoreLeftColumns())
        htmlRow.appendChild(document.createElement("td"));

      columns.subset.forEach(function(columnData) {
        var cellName = columnData.name;
        var dataCell = dataRow[cellName];
        var htmlCell = document.createElement("td");

        if (dataCell === "NA") htmlCell.setAttribute("class", "pagedtable-na-cell");
        if (dataCell === "__NA__") dataCell = "NA";

        var cellText = document.createTextNode(dataCell);
        htmlCell.appendChild(cellText);
        if (dataCell.length > 50) {
          htmlCell.setAttribute("title", dataCell);
        }
        htmlCell.setAttribute("align", columnData.align);
        htmlCell.style.textAlign = columnData.align;
        htmlCell.style.maxWidth = maxColumnWidth(null);
        if (columnData.width) {
          htmlCell.style.minWidth = htmlCell.style.maxWidth = maxColumnWidth(columnData.width);
        }
        htmlRow.appendChild(htmlCell);
      });

      for (var idx = 0; idx < columns.getPaddingCount(); idx++) {
        var paddingCol = document.createElement("td");
        paddingCol.setAttribute("class", "pagedtable-padding-col");
        htmlRow.appendChild(paddingCol);
      }

      if (columns.hasMoreRightColumns())
        htmlRow.appendChild(document.createElement("td"));

      fragment.appendChild(htmlRow);
    });

    for (var idxPadding = 0; idxPadding < page.getPaddingRows(); idxPadding++) {
      var paddingRow = document.createElement("tr");

      var paddingCellRow = document.createElement("td");
      paddingCellRow.innerHTML = "&nbsp;";
      paddingCellRow.setAttribute("colspan", "100%");
      paddingRow.appendChild(paddingCellRow);

      fragment.appendChild(paddingRow);
    }

    if (typeof(clear) == "undefined" || clear) clearBody();
    tbody = document.createElement("tbody");
    tbody.appendChild(fragment);

    table.appendChild(tbody);
  };

  var getLabelInfo = function() {
    var pageStart = page.getRowStart();
    var pageEnd = page.getRowEnd();
    var totalRows = data.length;

    var totalRowsLabel = options.rows.total ? options.rows.total : totalRows;
    var totalRowsLabelFormat = totalRowsLabel.toString().replace(/(\d)(?=(\d\d\d)+(?!\d))/g, '$1,');

    var infoText = (pageStart + 1) + "-" + pageEnd + " of " + totalRowsLabelFormat + " rows";
    if (totalRows < page.rows) {
      infoText = totalRowsLabel + " row" + (totalRows != 1 ? "s" : "");
    }
    if (columns.total > columns.visible) {
      var totalColumnsLabel = options.columns.total ? options.columns.total : columns.total;

      infoText = infoText + " | " + (columns.number + 1) + "-" +
        (Math.min(columns.number + columns.visible, columns.total)) +
        " of " + totalColumnsLabel + " columns";
    }

    return infoText;
  };

  var clearFooter = function() {
    footer = pagedTable.querySelectorAll("div.pagedtable-footer")[0];
    footer.innerHTML = "";

    return footer;
  };

  var createPageLink = function(idxPage) {
    var pageLink = document.createElement("a");
    pageLinkClass = idxPage === page.number ? "pagedtable-index pagedtable-index-current" : "pagedtable-index";
    pageLink.setAttribute("class", pageLinkClass);
    pageLink.setAttribute("data-page-index", idxPage);
    pageLink.onclick = function() {
      page.setPageNumber(parseInt(this.getAttribute("data-page-index")));
      renderBody();
      renderFooter();

      triggerOnChange();
    };

    pageLink.appendChild(document.createTextNode(idxPage + 1));

    return pageLink;
  }

  var renderFooter = function() {
    footer = clearFooter();

    var next = document.createElement("a");
    next.appendChild(document.createTextNode("Next"));
    next.onclick = function() {
      page.setPageNumber(page.number + 1);
      renderBody();
      renderFooter();

      triggerOnChange();
    };
    if (data.length > page.rows) footer.appendChild(next);

    var pageNumbers = document.createElement("div");
    pageNumbers.setAttribute("class", "pagedtable-indexes");

    var pageRange = page.getVisiblePageRange();

    if (pageRange.first) {
      var pageLink = createPageLink(0);
      pageNumbers.appendChild(pageLink);

      var pageSeparator = document.createElement("div");
      pageSeparator.setAttribute("class", "pagedtable-index-separator-left");
      pageSeparator.appendChild(document.createTextNode("..."))
      pageNumbers.appendChild(pageSeparator);
    }

    for (var idxPage = pageRange.start; idxPage < pageRange.end; idxPage++) {
      var pageLink = createPageLink(idxPage);

      pageNumbers.appendChild(pageLink);
    }

    if (pageRange.last) {
      var pageSeparator = document.createElement("div");
      pageSeparator.setAttribute("class", "pagedtable-index-separator-right");
      pageSeparator.appendChild(document.createTextNode("..."))
      pageNumbers.appendChild(pageSeparator);

      var pageLink = createPageLink(page.total - 1);
      pageNumbers.appendChild(pageLink);
    }

    if (data.length > page.rows) footer.appendChild(pageNumbers);

    var previous = document.createElement("a");
    previous.appendChild(document.createTextNode("Previous"));
    previous.onclick = function() {
      page.setPageNumber(page.number - 1);
      renderBody();
      renderFooter();

      triggerOnChange();
    };
    if (data.length > page.rows) footer.appendChild(previous);

    var infoLabel = document.createElement("div");
    infoLabel.setAttribute("class", "pagedtable-info");
    infoLabel.setAttribute("title", getLabelInfo());
    infoLabel.appendChild(document.createTextNode(getLabelInfo()));
    footer.appendChild(infoLabel);

    var enabledClass = "pagedtable-index-nav";
    var disabledClass = "pagedtable-index-nav pagedtable-index-nav-disabled";
    previous.setAttribute("class", page.number <= 0 ? disabledClass : enabledClass);
    next.setAttribute("class", (page.number + 1) * page.rows >= data.length ? disabledClass : enabledClass);
  };

  var measuresCell = null;

  var renderMeasures = function() {
    var measuresTable = document.createElement("table");
    measuresTable.style.visibility = "hidden";
    measuresTable.style.position = "absolute";
    measuresTable.style.whiteSpace = "nowrap";
    measuresTable.style.height = "auto";
    measuresTable.style.width = "auto";

    var measuresRow = document.createElement("tr");
    measuresTable.appendChild(measuresRow);

    measuresCell = document.createElement("td");
    var sampleString = "ABCDEFGHIJ0123456789";
    measuresCell.appendChild(document.createTextNode(sampleString));

    measuresRow.appendChild(measuresCell);

    tableDiv.appendChild(measuresTable);
  }

  me.init = function() {
    tableDiv = document.createElement("div");
    pagedTable.appendChild(tableDiv);
    var pagedTableClass = data.length > 0 ?
      "pagedtable pagedtable-not-empty" :
      "pagedtable pagedtable-empty";

    if (columns.total == 0 || (columns.emptyNames() && data.length == 0)) {
      pagedTableClass = pagedTableClass + " pagedtable-empty-columns";
    }

    tableDiv.setAttribute("class", pagedTableClass);

    renderMeasures();
    measurer.calculate(measuresCell);
    columns.calculateWidths(measurer.measures);

    table = document.createElement("table");
    table.setAttribute("cellspacing", "0");
    table.setAttribute("class", "table table-condensed");
    tableDiv.appendChild(table);

    table.appendChild(document.createElement("thead"));

    var footerDiv = document.createElement("div");
    footerDiv.setAttribute("class", "pagedtable-footer");
    tableDiv.appendChild(footerDiv);

    // if the host has not yet provided horizontal space, render hidden
    if (tableDiv.clientWidth <= 0) {
      tableDiv.style.opacity = "0";
    }

    me.render();

    // retry seizing columns later if the host has not provided space
    function retryFit() {
      if (tableDiv.clientWidth <= 0) {
        setTimeout(retryFit, 100);
      } else {
        me.render();
        triggerOnChange();
      }
    }
    if (tableDiv.clientWidth <= 0) {
      retryFit();
    }
  };

  var registerWidths = function() {
    columns.subset = columns.subset.map(function(column) {
      column.width = columns.widths[column.name].inner;
      return column;
    });
  };

  var parsePadding = function(value) {
    return parseInt(value) >= 0 ? parseInt(value) : 0;
  };

  me.fixedHeight = function() {
    return options.rows.max != null;
  }

  me.fitRows = function() {
    if (me.fixedHeight())
      return;

    measurer.calculate(measuresCell);

    var rows = options.rows.min !== null ? options.rows.min : 0;
    var headerHeight = header !== null && header.offsetHeight > 0 ? header.offsetHeight : 0;
    var footerHeight = footer !== null && footer.offsetHeight > 0 ? footer.offsetHeight : 0;

    if (pagedTable.offsetHeight > 0) {
      var availableHeight = pagedTable.offsetHeight - headerHeight - footerHeight;
      rows = Math.floor((availableHeight) / measurer.measures.height);
    }

    rows = options.rows.min !== null ? Math.max(options.rows.min, rows) : rows;

    page.setRows(rows);
  }

  // The goal of this function is to add as many columns as possible
  // starting from left-to-right, when the right most limit is reached
  // it tries to add columns from the left as well.
  //
  // When startBackwards is true columns are added from right-to-left
  me.fitColumns = function(startBackwards) {
    measurer.calculate(measuresCell);
    columns.calculateWidths(measurer.measures);

    if (tableDiv.clientWidth > 0) {
      tableDiv.style.opacity = 1;
    }

    var visibleColumns = tableDiv.clientWidth <= 0 ? Math.max(columns.min, 1) : 1;
    var columnNumber = columns.number;
    var paddingCount = 0;

    // track a list of added columns as we build the visible ones to allow us
    // to remove columns when they don't fit anymore.
    var columnHistory = [];

    var lastTableHeight = 0;
    var backwards = startBackwards;

    var tableDivStyle = window.getComputedStyle(tableDiv, null);
    var tableDivPadding = parsePadding(tableDivStyle.paddingLeft) +
      parsePadding(tableDivStyle.paddingRight);

    var addPaddingCol = false;
    var currentWidth = 0;

    while (true) {
      columns.setVisibleColumns(columnNumber, visibleColumns, paddingCount);
      currentWidth = columns.getWidth();

      if (tableDiv.clientWidth - tableDivPadding < currentWidth) {
        break;
      }

      columnHistory.push({
        columnNumber: columnNumber,
        visibleColumns: visibleColumns,
        paddingCount: paddingCount
      });

      if (columnHistory.length > 100) {
        console.error("More than 100 tries to fit columns, aborting");
        break;
      }

      if (columns.max !== null &&
        columns.visible + columns.getPaddingCount() >= columns.max) {
        break;
      }

      // if we run out of right-columns
      if (!backwards && columnNumber + columns.visible >= columns.total) {
        // if we started adding right-columns, try adding left-columns
        if (!startBackwards && columnNumber > 0) {
          backwards = true;
        }
        else if (columns.min === null || visibleColumns + columns.getPaddingCount() >= columns.min) {
          break;
        }
        else {
          paddingCount = paddingCount + 1;
        }
      }

      // if we run out of left-columns
      if (backwards && columnNumber == 0) {
        // if we started adding left-columns, try adding right-columns
        if (startBackwards && columnNumber + columns.visible < columns.total) {
          backwards = false;
        }
        else if (columns.min === null || visibleColumns + columns.getPaddingCount() >= columns.min) {
          break;
        }
        else {
          paddingCount = paddingCount + 1;
        }
      }

      // when moving backwards try fitting left columns first
      if (backwards && columnNumber > 0) {
        columnNumber = columnNumber - 1;
      }

      if (columnNumber + visibleColumns < columns.total) {
        visibleColumns = visibleColumns + 1;
      }
    }

    var lastRenderableColumn = {
        columnNumber: columnNumber,
        visibleColumns: visibleColumns,
        paddingCount: paddingCount
    };

    if (columnHistory.length > 0) {
      lastRenderableColumn = columnHistory[columnHistory.length - 1];
    }

    columns.setVisibleColumns(
      lastRenderableColumn.columnNumber,
      lastRenderableColumn.visibleColumns,
      lastRenderableColumn.paddingCount);

    if (pagedTable.offsetWidth > 0) {
      page.setVisiblePages(Math.max(Math.ceil(1.0 * (pagedTable.offsetWidth - 250) / 40), 2));
    }

    registerWidths();
  };

  me.fit = function(startBackwards) {
    me.fitRows();
    me.fitColumns(startBackwards);
  }

  me.render = function() {
    me.fitColumns(false);

    // render header/footer to measure height accurately
    renderHeader();
    renderFooter();

    me.fitRows();
    renderBody();

    // re-render footer to match new rows
    renderFooter();
  }

  var resizeLastWidth = -1;
  var resizeLastHeight = -1;
  var resizeNewWidth = -1;
  var resizeNewHeight = -1;
  var resizePending = false;

  me.resize = function(newWidth, newHeight) {

    function resizeDelayed() {
      resizePending = false;

      if (
        (resizeNewWidth !== resizeLastWidth) ||
        (!me.fixedHeight() && resizeNewHeight !== resizeLastHeight)
      ) {
        resizeLastWidth = resizeNewWidth;
        resizeLastHeight = resizeNewHeight;

        setTimeout(resizeDelayed, 200);
        resizePending = true;
      } else {
        me.render();
        triggerOnChange();

        resizeLastWidth = -1;
        resizeLastHeight = -1;
      }
    }

    resizeNewWidth = newWidth;
    resizeNewHeight = newHeight;

    if (!resizePending) resizeDelayed();
  };
};

var PagedTableDoc;
(function (PagedTableDoc) {
  var allPagedTables = [];

  PagedTableDoc.initAll = function() {
    allPagedTables = [];

    var pagedTables = [].slice.call(document.querySelectorAll('[data-pagedtable="false"],[data-pagedtable=""]'));
    pagedTables.forEach(function(pagedTable, idx) {
      pagedTable.setAttribute("data-pagedtable", "true");
      pagedTable.setAttribute("pagedtable-page", 0);
      pagedTable.setAttribute("class", "pagedtable-wrapper");

      var pagedTableInstance = new PagedTable(pagedTable);
      pagedTableInstance.init();

      allPagedTables.push(pagedTableInstance);
    });
  };

  PagedTableDoc.resizeAll = function() {
    allPagedTables.forEach(function(pagedTable) {
      pagedTable.render();
    });
  };

  window.addEventListener("resize", PagedTableDoc.resizeAll);

  return PagedTableDoc;
})(PagedTableDoc || (PagedTableDoc = {}));

window.onload = function() {
  PagedTableDoc.initAll();
};
</script>
<script>

/**
 * jQuery Plugin: Sticky Tabs
 *
 * @author Aidan Lister <aidan@php.net>
 * adapted by Ruben Arslan to activate parent tabs too
 * http://www.aidanlister.com/2014/03/persisting-the-tab-state-in-bootstrap/
 */
(function($) {
  "use strict";
  $.fn.rmarkdownStickyTabs = function() {
    var context = this;
    // Show the tab corresponding with the hash in the URL, or the first tab
    var showStuffFromHash = function() {
      var hash = window.location.hash;
      var selector = hash ? 'a[href="' + hash + '"]' : 'li.active > a';
      var $selector = $(selector, context);
      if($selector.data('toggle') === "tab") {
        $selector.tab('show');
        // walk up the ancestors of this element, show any hidden tabs
        $selector.parents('.section.tabset').each(function(i, elm) {
          var link = $('a[href="#' + $(elm).attr('id') + '"]');
          if(link.data('toggle') === "tab") {
            link.tab("show");
          }
        });
      }
    };


    // Set the correct tab when the page loads
    showStuffFromHash(context);

    // Set the correct tab when a user uses their back/forward button
    $(window).on('hashchange', function() {
      showStuffFromHash(context);
    });

    // Change the URL when tabs are clicked
    $('a', context).on('click', function(e) {
      history.pushState(null, null, this.href);
      showStuffFromHash(context);
    });

    return this;
  };
}(jQuery));

window.buildTabsets = function(tocID) {

  // build a tabset from a section div with the .tabset class
  function buildTabset(tabset) {

    // check for fade and pills options
    var fade = tabset.hasClass("tabset-fade");
    var pills = tabset.hasClass("tabset-pills");
    var navClass = pills ? "nav-pills" : "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    var activeTab = 0;
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // see if this is marked as the active tab
      if (tab.hasClass('active'))
        activeTab = i;

      // remove any table of contents entries associated with
      // this ID (since we'll be removing the heading element)
      $("div#" + tocID + " li a[href='#" + id + "']").parent().remove();

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it, grab it's text, then remove it
      var heading = tab.find('h' + tabLevel + ':first');
      var headingText = heading.html();
      heading.remove();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab">' + headingText + '</a>');
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation"></li>');
      li.append(a);
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      if (fade)
        tab.addClass('fade');

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // set active tab
    $(tabList.children('li')[activeTab]).addClass('active');
    var active = $(tabContent.children('div.section')[activeTab]);
    active.addClass('active');
    if (fade)
      active.addClass('in');

    if (tabset.hasClass("tabset-sticky"))
      tabset.rmarkdownStickyTabs();
  }

  // convert section divs with the .tabset class to tabsets
  var tabsets = $("div.section.tabset");
  tabsets.each(function(i) {
    buildTabset($(tabsets[i]));
  });
};

</script>
<script>
window.initializeCodeFolding = function(show) {

  // handlers for show-all and hide all
  $("#rmd-show-all-code").click(function() {
    $('div.r-code-collapse').each(function() {
      $(this).collapse('show');
    });
  });
  $("#rmd-hide-all-code").click(function() {
    $('div.r-code-collapse').each(function() {
      $(this).collapse('hide');
    });
  });

  // index for unique code element ids
  var currentIndex = 1;

  // select all R code blocks
  var rCodeBlocks = $('pre.r, pre.python, pre.bash, pre.sql, pre.cpp, pre.stan, pre.julia, pre.foldable');
  rCodeBlocks.each(function() {
    // skip if the block has fold-none class
    if ($(this).hasClass('fold-none')) return;

    // create a collapsable div to wrap the code in
    var div = $('<div class="collapse r-code-collapse"></div>');
    var showThis = (show || $(this).hasClass('fold-show')) && !$(this).hasClass('fold-hide');
    var id = 'rcode-643E0F36' + currentIndex++;
    div.attr('id', id);
    $(this).before(div);
    $(this).detach().appendTo(div);

    // add a show code button right above
    var showCodeText = $('<span>' + (showThis ? 'Hide' : 'Code') + '</span>');
    var showCodeButton = $('<button type="button" class="btn btn-default btn-xs btn-secondary btn-sm code-folding-btn pull-right float-right"></button>');
    showCodeButton.append(showCodeText);
    showCodeButton
        .attr('data-toggle', 'collapse')
        .attr('data-bs-toggle', 'collapse') // BS5
        .attr('data-target', '#' + id)
        .attr('data-bs-target', '#' + id)   // BS5
        .attr('aria-expanded', showThis)
        .attr('aria-controls', id);

    var buttonRow = $('<div class="row"></div>');
    var buttonCol = $('<div class="col-md-12"></div>');

    buttonCol.append(showCodeButton);
    buttonRow.append(buttonCol);

    div.before(buttonRow);

    // show the div if necessary
    if (showThis) div.collapse('show');

    // update state of button on show/hide
    //   * Change text
    //   * add a class for intermediate states styling
    div.on('hide.bs.collapse', function () {
      showCodeText.text('Code');
      showCodeButton.addClass('btn-collapsing');
    });
    div.on('hidden.bs.collapse', function () {
      showCodeButton.removeClass('btn-collapsing');
    });
    div.on('show.bs.collapse', function () {
      showCodeText.text('Hide');
      showCodeButton.addClass('btn-expanding');
    });
    div.on('shown.bs.collapse', function () {
      showCodeButton.removeClass('btn-expanding');
    });

  });

}
</script>
<script>
window.initializeSourceEmbed = function(filename) {
  $("#rmd-download-source").click(function() {
    var src = $("#rmd-source-code").html();
    var a = document.createElement('a');
    a.href = "data:text/x-r-markdown;base64," + src;
    a.download = filename;
    document.body.appendChild(a);
    a.click();
    document.body.removeChild(a);
  });
};
</script>
<style type="text/css">.hljs-literal {
color: rgb(88, 72, 246);
}
.hljs-number {
color: rgb(0, 0, 205);
}
.hljs-comment {
color: rgb(76, 136, 107);
}
.hljs-keyword {
color: rgb(0, 0, 255);
}
.hljs-string {
color: rgb(3, 106, 7);
}
</style>
<script src="data:application/javascript;base64,/*! highlight.js v9.12.0 | BSD3 License | git.io/hljslicense */
!function(e){var n="object"==typeof window&&window||"object"==typeof self&&self;"undefined"!=typeof exports?e(exports):n&&(n.hljs=e({}),"function"==typeof define&&define.amd&&define([],function(){return n.hljs}))}(function(e){function n(e){return e.replace(/&/g,"&amp;").replace(/</g,"&lt;").replace(/>/g,"&gt;")}function t(e){return e.nodeName.toLowerCase()}function r(e,n){var t=e&&e.exec(n);return t&&0===t.index}function a(e){return k.test(e)}function i(e){var n,t,r,i,o=e.className+" ";if(o+=e.parentNode?e.parentNode.className:"",t=B.exec(o))return w(t[1])?t[1]:"no-highlight";for(o=o.split(/\s+/),n=0,r=o.length;r>n;n++)if(i=o[n],a(i)||w(i))return i}function o(e){var n,t={},r=Array.prototype.slice.call(arguments,1);for(n in e)t[n]=e[n];return r.forEach(function(e){for(n in e)t[n]=e[n]}),t}function u(e){var n=[];return function r(e,a){for(var i=e.firstChild;i;i=i.nextSibling)3===i.nodeType?a+=i.nodeValue.length:1===i.nodeType&&(n.push({event:"start",offset:a,node:i}),a=r(i,a),t(i).match(/br|hr|img|input/)||n.push({event:"stop",offset:a,node:i}));return a}(e,0),n}function c(e,r,a){function i(){return e.length&&r.length?e[0].offset!==r[0].offset?e[0].offset<r[0].offset?e:r:"start"===r[0].event?e:r:e.length?e:r}function o(e){function r(e){return" "+e.nodeName+'="'+n(e.value).replace('"',"&quot;")+'"'}s+="<"+t(e)+E.map.call(e.attributes,r).join("")+">"}function u(e){s+="</"+t(e)+">"}function c(e){("start"===e.event?o:u)(e.node)}for(var l=0,s="",f=[];e.length||r.length;){var g=i();if(s+=n(a.substring(l,g[0].offset)),l=g[0].offset,g===e){f.reverse().forEach(u);do c(g.splice(0,1)[0]),g=i();while(g===e&&g.length&&g[0].offset===l);f.reverse().forEach(o)}else"start"===g[0].event?f.push(g[0].node):f.pop(),c(g.splice(0,1)[0])}return s+n(a.substr(l))}function l(e){return e.v&&!e.cached_variants&&(e.cached_variants=e.v.map(function(n){return o(e,{v:null},n)})),e.cached_variants||e.eW&&[o(e)]||[e]}function s(e){function n(e){return e&&e.source||e}function t(t,r){return new RegExp(n(t),"m"+(e.cI?"i":"")+(r?"g":""))}function r(a,i){if(!a.compiled){if(a.compiled=!0,a.k=a.k||a.bK,a.k){var o={},u=function(n,t){e.cI&&(t=t.toLowerCase()),t.split(" ").forEach(function(e){var t=e.split("|");o[t[0]]=[n,t[1]?Number(t[1]):1]})};"string"==typeof a.k?u("keyword",a.k):x(a.k).forEach(function(e){u(e,a.k[e])}),a.k=o}a.lR=t(a.l||/\w+/,!0),i&&(a.bK&&(a.b="\\b("+a.bK.split(" ").join("|")+")\\b"),a.b||(a.b=/\B|\b/),a.bR=t(a.b),a.e||a.eW||(a.e=/\B|\b/),a.e&&(a.eR=t(a.e)),a.tE=n(a.e)||"",a.eW&&i.tE&&(a.tE+=(a.e?"|":"")+i.tE)),a.i&&(a.iR=t(a.i)),null==a.r&&(a.r=1),a.c||(a.c=[]),a.c=Array.prototype.concat.apply([],a.c.map(function(e){return l("self"===e?a:e)})),a.c.forEach(function(e){r(e,a)}),a.starts&&r(a.starts,i);var c=a.c.map(function(e){return e.bK?"\\.?("+e.b+")\\.?":e.b}).concat([a.tE,a.i]).map(n).filter(Boolean);a.t=c.length?t(c.join("|"),!0):{exec:function(){return null}}}}r(e)}function f(e,t,a,i){function o(e,n){var t,a;for(t=0,a=n.c.length;a>t;t++)if(r(n.c[t].bR,e))return n.c[t]}function u(e,n){if(r(e.eR,n)){for(;e.endsParent&&e.parent;)e=e.parent;return e}return e.eW?u(e.parent,n):void 0}function c(e,n){return!a&&r(n.iR,e)}function l(e,n){var t=N.cI?n[0].toLowerCase():n[0];return e.k.hasOwnProperty(t)&&e.k[t]}function p(e,n,t,r){var a=r?"":I.classPrefix,i='<span class="'+a,o=t?"":C;return i+=e+'">',i+n+o}function h(){var e,t,r,a;if(!E.k)return n(k);for(a="",t=0,E.lR.lastIndex=0,r=E.lR.exec(k);r;)a+=n(k.substring(t,r.index)),e=l(E,r),e?(B+=e[1],a+=p(e[0],n(r[0]))):a+=n(r[0]),t=E.lR.lastIndex,r=E.lR.exec(k);return a+n(k.substr(t))}function d(){var e="string"==typeof E.sL;if(e&&!y[E.sL])return n(k);var t=e?f(E.sL,k,!0,x[E.sL]):g(k,E.sL.length?E.sL:void 0);return E.r>0&&(B+=t.r),e&&(x[E.sL]=t.top),p(t.language,t.value,!1,!0)}function b(){L+=null!=E.sL?d():h(),k=""}function v(e){L+=e.cN?p(e.cN,"",!0):"",E=Object.create(e,{parent:{value:E}})}function m(e,n){if(k+=e,null==n)return b(),0;var t=o(n,E);if(t)return t.skip?k+=n:(t.eB&&(k+=n),b(),t.rB||t.eB||(k=n)),v(t,n),t.rB?0:n.length;var r=u(E,n);if(r){var a=E;a.skip?k+=n:(a.rE||a.eE||(k+=n),b(),a.eE&&(k=n));do E.cN&&(L+=C),E.skip||(B+=E.r),E=E.parent;while(E!==r.parent);return r.starts&&v(r.starts,""),a.rE?0:n.length}if(c(n,E))throw new Error('Illegal lexeme "'+n+'" for mode "'+(E.cN||"<unnamed>")+'"');return k+=n,n.length||1}var N=w(e);if(!N)throw new Error('Unknown language: "'+e+'"');s(N);var R,E=i||N,x={},L="";for(R=E;R!==N;R=R.parent)R.cN&&(L=p(R.cN,"",!0)+L);var k="",B=0;try{for(var M,j,O=0;;){if(E.t.lastIndex=O,M=E.t.exec(t),!M)break;j=m(t.substring(O,M.index),M[0]),O=M.index+j}for(m(t.substr(O)),R=E;R.parent;R=R.parent)R.cN&&(L+=C);return{r:B,value:L,language:e,top:E}}catch(T){if(T.message&&-1!==T.message.indexOf("Illegal"))return{r:0,value:n(t)};throw T}}function g(e,t){t=t||I.languages||x(y);var r={r:0,value:n(e)},a=r;return t.filter(w).forEach(function(n){var t=f(n,e,!1);t.language=n,t.r>a.r&&(a=t),t.r>r.r&&(a=r,r=t)}),a.language&&(r.second_best=a),r}function p(e){return I.tabReplace||I.useBR?e.replace(M,function(e,n){return I.useBR&&"\n"===e?"<br>":I.tabReplace?n.replace(/\t/g,I.tabReplace):""}):e}function h(e,n,t){var r=n?L[n]:t,a=[e.trim()];return e.match(/\bhljs\b/)||a.push("hljs"),-1===e.indexOf(r)&&a.push(r),a.join(" ").trim()}function d(e){var n,t,r,o,l,s=i(e);a(s)||(I.useBR?(n=document.createElementNS("http://www.w3.org/1999/xhtml","div"),n.innerHTML=e.innerHTML.replace(/\n/g,"").replace(/<br[ \/]*>/g,"\n")):n=e,l=n.textContent,r=s?f(s,l,!0):g(l),t=u(n),t.length&&(o=document.createElementNS("http://www.w3.org/1999/xhtml","div"),o.innerHTML=r.value,r.value=c(t,u(o),l)),r.value=p(r.value),e.innerHTML=r.value,e.className=h(e.className,s,r.language),e.result={language:r.language,re:r.r},r.second_best&&(e.second_best={language:r.second_best.language,re:r.second_best.r}))}function b(e){I=o(I,e)}function v(){if(!v.called){v.called=!0;var e=document.querySelectorAll("pre code");E.forEach.call(e,d)}}function m(){addEventListener("DOMContentLoaded",v,!1),addEventListener("load",v,!1)}function N(n,t){var r=y[n]=t(e);r.aliases&&r.aliases.forEach(function(e){L[e]=n})}function R(){return x(y)}function w(e){return e=(e||"").toLowerCase(),y[e]||y[L[e]]}var E=[],x=Object.keys,y={},L={},k=/^(no-?highlight|plain|text)$/i,B=/\blang(?:uage)?-([\w-]+)\b/i,M=/((^(<[^>]+>|\t|)+|(?:\n)))/gm,C="</span>",I={classPrefix:"hljs-",tabReplace:null,useBR:!1,languages:void 0};return e.highlight=f,e.highlightAuto=g,e.fixMarkup=p,e.highlightBlock=d,e.configure=b,e.initHighlighting=v,e.initHighlightingOnLoad=m,e.registerLanguage=N,e.listLanguages=R,e.getLanguage=w,e.inherit=o,e.IR="[a-zA-Z]\\w*",e.UIR="[a-zA-Z_]\\w*",e.NR="\\b\\d+(\\.\\d+)?",e.CNR="(-?)(\\b0[xX][a-fA-F0-9]+|(\\b\\d+(\\.\\d*)?|\\.\\d+)([eE][-+]?\\d+)?)",e.BNR="\\b(0b[01]+)",e.RSR="!|!=|!==|%|%=|&|&&|&=|\\*|\\*=|\\+|\\+=|,|-|-=|/=|/|:|;|<<|<<=|<=|<|===|==|=|>>>=|>>=|>=|>>>|>>|>|\\?|\\[|\\{|\\(|\\^|\\^=|\\||\\|=|\\|\\||~",e.BE={b:"\\\\[\\s\\S]",r:0},e.ASM={cN:"string",b:"'",e:"'",i:"\\n",c:[e.BE]},e.QSM={cN:"string",b:'"',e:'"',i:"\\n",c:[e.BE]},e.PWM={b:/\b(a|an|the|are|I'm|isn't|don't|doesn't|won't|but|just|should|pretty|simply|enough|gonna|going|wtf|so|such|will|you|your|they|like|more)\b/},e.C=function(n,t,r){var a=e.inherit({cN:"comment",b:n,e:t,c:[]},r||{});return a.c.push(e.PWM),a.c.push({cN:"doctag",b:"(?:TODO|FIXME|NOTE|BUG|XXX):",r:0}),a},e.CLCM=e.C("//","$"),e.CBCM=e.C("/\\*","\\*/"),e.HCM=e.C("#","$"),e.NM={cN:"number",b:e.NR,r:0},e.CNM={cN:"number",b:e.CNR,r:0},e.BNM={cN:"number",b:e.BNR,r:0},e.CSSNM={cN:"number",b:e.NR+"(%|em|ex|ch|rem|vw|vh|vmin|vmax|cm|mm|in|pt|pc|px|deg|grad|rad|turn|s|ms|Hz|kHz|dpi|dpcm|dppx)?",r:0},e.RM={cN:"regexp",b:/\//,e:/\/[gimuy]*/,i:/\n/,c:[e.BE,{b:/\[/,e:/\]/,r:0,c:[e.BE]}]},e.TM={cN:"title",b:e.IR,r:0},e.UTM={cN:"title",b:e.UIR,r:0},e.METHOD_GUARD={b:"\\.\\s*"+e.UIR,r:0},e});hljs.registerLanguage("sql",function(e){var t=e.C("--","$");return{cI:!0,i:/[<>{}*#]/,c:[{bK:"begin end start commit rollback savepoint lock alter create drop rename call delete do handler insert load replace select truncate update set show pragma grant merge describe use explain help declare prepare execute deallocate release unlock purge reset change stop analyze cache flush optimize repair kill install uninstall checksum restore check backup revoke comment",e:/;/,eW:!0,l:/[\w\.]+/,k:{keyword:"abort abs absolute acc acce accep accept access accessed accessible account acos action activate add addtime admin administer advanced advise aes_decrypt aes_encrypt after agent aggregate ali alia alias allocate allow alter always analyze ancillary and any anydata anydataset anyschema anytype apply archive archived archivelog are as asc ascii asin assembly assertion associate asynchronous at atan atn2 attr attri attrib attribu attribut attribute attributes audit authenticated authentication authid authors auto autoallocate autodblink autoextend automatic availability avg backup badfile basicfile before begin beginning benchmark between bfile bfile_base big bigfile bin binary_double binary_float binlog bit_and bit_count bit_length bit_or bit_xor bitmap blob_base block blocksize body both bound buffer_cache buffer_pool build bulk by byte byteordermark bytes cache caching call calling cancel capacity cascade cascaded case cast catalog category ceil ceiling chain change changed char_base char_length character_length characters characterset charindex charset charsetform charsetid check checksum checksum_agg child choose chr chunk class cleanup clear client clob clob_base clone close cluster_id cluster_probability cluster_set clustering coalesce coercibility col collate collation collect colu colum column column_value columns columns_updated comment commit compact compatibility compiled complete composite_limit compound compress compute concat concat_ws concurrent confirm conn connec connect connect_by_iscycle connect_by_isleaf connect_by_root connect_time connection consider consistent constant constraint constraints constructor container content contents context contributors controlfile conv convert convert_tz corr corr_k corr_s corresponding corruption cos cost count count_big counted covar_pop covar_samp cpu_per_call cpu_per_session crc32 create creation critical cross cube cume_dist curdate current current_date current_time current_timestamp current_user cursor curtime customdatum cycle data database databases datafile datafiles datalength date_add date_cache date_format date_sub dateadd datediff datefromparts datename datepart datetime2fromparts day day_to_second dayname dayofmonth dayofweek dayofyear days db_role_change dbtimezone ddl deallocate declare decode decompose decrement decrypt deduplicate def defa defau defaul default defaults deferred defi defin define degrees delayed delegate delete delete_all delimited demand dense_rank depth dequeue des_decrypt des_encrypt des_key_file desc descr descri describ describe descriptor deterministic diagnostics difference dimension direct_load directory disable disable_all disallow disassociate discardfile disconnect diskgroup distinct distinctrow distribute distributed div do document domain dotnet double downgrade drop dumpfile duplicate duration each edition editionable editions element ellipsis else elsif elt empty enable enable_all enclosed encode encoding encrypt end end-exec endian enforced engine engines enqueue enterprise entityescaping eomonth error errors escaped evalname evaluate event eventdata events except exception exceptions exchange exclude excluding execu execut execute exempt exists exit exp expire explain export export_set extended extent external external_1 external_2 externally extract failed failed_login_attempts failover failure far fast feature_set feature_value fetch field fields file file_name_convert filesystem_like_logging final finish first first_value fixed flash_cache flashback floor flush following follows for forall force form forma format found found_rows freelist freelists freepools fresh from from_base64 from_days ftp full function general generated get get_format get_lock getdate getutcdate global global_name globally go goto grant grants greatest group group_concat group_id grouping grouping_id groups gtid_subtract guarantee guard handler hash hashkeys having hea head headi headin heading heap help hex hierarchy high high_priority hosts hour http id ident_current ident_incr ident_seed identified identity idle_time if ifnull ignore iif ilike ilm immediate import in include including increment index indexes indexing indextype indicator indices inet6_aton inet6_ntoa inet_aton inet_ntoa infile initial initialized initially initrans inmemory inner innodb input insert install instance instantiable instr interface interleaved intersect into invalidate invisible is is_free_lock is_ipv4 is_ipv4_compat is_not is_not_null is_used_lock isdate isnull isolation iterate java join json json_exists keep keep_duplicates key keys kill language large last last_day last_insert_id last_value lax lcase lead leading least leaves left len lenght length less level levels library like like2 like4 likec limit lines link list listagg little ln load load_file lob lobs local localtime localtimestamp locate locator lock locked log log10 log2 logfile logfiles logging logical logical_reads_per_call logoff logon logs long loop low low_priority lower lpad lrtrim ltrim main make_set makedate maketime managed management manual map mapping mask master master_pos_wait match matched materialized max maxextents maximize maxinstances maxlen maxlogfiles maxloghistory maxlogmembers maxsize maxtrans md5 measures median medium member memcompress memory merge microsecond mid migration min minextents minimum mining minus minute minvalue missing mod mode model modification modify module monitoring month months mount move movement multiset mutex name name_const names nan national native natural nav nchar nclob nested never new newline next nextval no no_write_to_binlog noarchivelog noaudit nobadfile nocheck nocompress nocopy nocycle nodelay nodiscardfile noentityescaping noguarantee nokeep nologfile nomapping nomaxvalue nominimize nominvalue nomonitoring none noneditionable nonschema noorder nopr nopro noprom nopromp noprompt norely noresetlogs noreverse normal norowdependencies noschemacheck noswitch not nothing notice notrim novalidate now nowait nth_value nullif nulls num numb numbe nvarchar nvarchar2 object ocicoll ocidate ocidatetime ociduration ociinterval ociloblocator ocinumber ociref ocirefcursor ocirowid ocistring ocitype oct octet_length of off offline offset oid oidindex old on online only opaque open operations operator optimal optimize option optionally or oracle oracle_date oradata ord ordaudio orddicom orddoc order ordimage ordinality ordvideo organization orlany orlvary out outer outfile outline output over overflow overriding package pad parallel parallel_enable parameters parent parse partial partition partitions pascal passing password password_grace_time password_lock_time password_reuse_max password_reuse_time password_verify_function patch path patindex pctincrease pctthreshold pctused pctversion percent percent_rank percentile_cont percentile_disc performance period period_add period_diff permanent physical pi pipe pipelined pivot pluggable plugin policy position post_transaction pow power pragma prebuilt precedes preceding precision prediction prediction_cost prediction_details prediction_probability prediction_set prepare present preserve prior priority private private_sga privileges procedural procedure procedure_analyze processlist profiles project prompt protection public publishingservername purge quarter query quick quiesce quota quotename radians raise rand range rank raw read reads readsize rebuild record records recover recovery recursive recycle redo reduced ref reference referenced references referencing refresh regexp_like register regr_avgx regr_avgy regr_count regr_intercept regr_r2 regr_slope regr_sxx regr_sxy reject rekey relational relative relaylog release release_lock relies_on relocate rely rem remainder rename repair repeat replace replicate replication required reset resetlogs resize resource respect restore restricted result result_cache resumable resume retention return returning returns reuse reverse revoke right rlike role roles rollback rolling rollup round row row_count rowdependencies rowid rownum rows rtrim rules safe salt sample save savepoint sb1 sb2 sb4 scan schema schemacheck scn scope scroll sdo_georaster sdo_topo_geometry search sec_to_time second section securefile security seed segment select self sequence sequential serializable server servererror session session_user sessions_per_user set sets settings sha sha1 sha2 share shared shared_pool short show shrink shutdown si_averagecolor si_colorhistogram si_featurelist si_positionalcolor si_stillimage si_texture siblings sid sign sin size size_t sizes skip slave sleep smalldatetimefromparts smallfile snapshot some soname sort soundex source space sparse spfile split sql sql_big_result sql_buffer_result sql_cache sql_calc_found_rows sql_small_result sql_variant_property sqlcode sqldata sqlerror sqlname sqlstate sqrt square standalone standby start starting startup statement static statistics stats_binomial_test stats_crosstab stats_ks_test stats_mode stats_mw_test stats_one_way_anova stats_t_test_ stats_t_test_indep stats_t_test_one stats_t_test_paired stats_wsr_test status std stddev stddev_pop stddev_samp stdev stop storage store stored str str_to_date straight_join strcmp strict string struct stuff style subdate subpartition subpartitions substitutable substr substring subtime subtring_index subtype success sum suspend switch switchoffset switchover sync synchronous synonym sys sys_xmlagg sysasm sysaux sysdate sysdatetimeoffset sysdba sysoper system system_user sysutcdatetime table tables tablespace tan tdo template temporary terminated tertiary_weights test than then thread through tier ties time time_format time_zone timediff timefromparts timeout timestamp timestampadd timestampdiff timezone_abbr timezone_minute timezone_region to to_base64 to_date to_days to_seconds todatetimeoffset trace tracking transaction transactional translate translation treat trigger trigger_nestlevel triggers trim truncate try_cast try_convert try_parse type ub1 ub2 ub4 ucase unarchived unbounded uncompress under undo unhex unicode uniform uninstall union unique unix_timestamp unknown unlimited unlock unpivot unrecoverable unsafe unsigned until untrusted unusable unused update updated upgrade upped upper upsert url urowid usable usage use use_stored_outlines user user_data user_resources users using utc_date utc_timestamp uuid uuid_short validate validate_password_strength validation valist value values var var_samp varcharc vari varia variab variabl variable variables variance varp varraw varrawc varray verify version versions view virtual visible void wait wallet warning warnings week weekday weekofyear wellformed when whene whenev wheneve whenever where while whitespace with within without work wrapped xdb xml xmlagg xmlattributes xmlcast xmlcolattval xmlelement xmlexists xmlforest xmlindex xmlnamespaces xmlpi xmlquery xmlroot xmlschema xmlserialize xmltable xmltype xor year year_to_month years yearweek",literal:"true false null",built_in:"array bigint binary bit blob boolean char character date dec decimal float int int8 integer interval number numeric real record serial serial8 smallint text varchar varying void"},c:[{cN:"string",b:"'",e:"'",c:[e.BE,{b:"''"}]},{cN:"string",b:'"',e:'"',c:[e.BE,{b:'""'}]},{cN:"string",b:"`",e:"`",c:[e.BE]},e.CNM,e.CBCM,t]},e.CBCM,t]}});hljs.registerLanguage("r",function(e){var r="([a-zA-Z]|\\.[a-zA-Z.])[a-zA-Z0-9._]*";return{c:[e.HCM,{b:r,l:r,k:{keyword:"function if in break next repeat else for return switch while try tryCatch stop warning require library attach detach source setMethod setGeneric setGroupGeneric setClass ...",literal:"NULL NA TRUE FALSE T F Inf NaN NA_integer_|10 NA_real_|10 NA_character_|10 NA_complex_|10"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{b:"`",e:"`",r:0},{cN:"string",c:[e.BE],v:[{b:'"',e:'"'},{b:"'",e:"'"}]}]}});hljs.registerLanguage("perl",function(e){var t="getpwent getservent quotemeta msgrcv scalar kill dbmclose undef lc ma syswrite tr send umask sysopen shmwrite vec qx utime local oct semctl localtime readpipe do return format read sprintf dbmopen pop getpgrp not getpwnam rewinddir qqfileno qw endprotoent wait sethostent bless s|0 opendir continue each sleep endgrent shutdown dump chomp connect getsockname die socketpair close flock exists index shmgetsub for endpwent redo lstat msgctl setpgrp abs exit select print ref gethostbyaddr unshift fcntl syscall goto getnetbyaddr join gmtime symlink semget splice x|0 getpeername recv log setsockopt cos last reverse gethostbyname getgrnam study formline endhostent times chop length gethostent getnetent pack getprotoent getservbyname rand mkdir pos chmod y|0 substr endnetent printf next open msgsnd readdir use unlink getsockopt getpriority rindex wantarray hex system getservbyport endservent int chr untie rmdir prototype tell listen fork shmread ucfirst setprotoent else sysseek link getgrgid shmctl waitpid unpack getnetbyname reset chdir grep split require caller lcfirst until warn while values shift telldir getpwuid my getprotobynumber delete and sort uc defined srand accept package seekdir getprotobyname semop our rename seek if q|0 chroot sysread setpwent no crypt getc chown sqrt write setnetent setpriority foreach tie sin msgget map stat getlogin unless elsif truncate exec keys glob tied closedirioctl socket readlink eval xor readline binmode setservent eof ord bind alarm pipe atan2 getgrent exp time push setgrent gt lt or ne m|0 break given say state when",r={cN:"subst",b:"[$@]\\{",e:"\\}",k:t},s={b:"->{",e:"}"},n={v:[{b:/\$\d/},{b:/[\$%@](\^\w\b|#\w+(::\w+)*|{\w+}|\w+(::\w*)*)/},{b:/[\$%@][^\s\w{]/,r:0}]},i=[e.BE,r,n],o=[n,e.HCM,e.C("^\\=\\w","\\=cut",{eW:!0}),s,{cN:"string",c:i,v:[{b:"q[qwxr]?\\s*\\(",e:"\\)",r:5},{b:"q[qwxr]?\\s*\\[",e:"\\]",r:5},{b:"q[qwxr]?\\s*\\{",e:"\\}",r:5},{b:"q[qwxr]?\\s*\\|",e:"\\|",r:5},{b:"q[qwxr]?\\s*\\<",e:"\\>",r:5},{b:"qw\\s+q",e:"q",r:5},{b:"'",e:"'",c:[e.BE]},{b:'"',e:'"'},{b:"`",e:"`",c:[e.BE]},{b:"{\\w+}",c:[],r:0},{b:"-?\\w+\\s*\\=\\>",c:[],r:0}]},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\/\\/|"+e.RSR+"|\\b(split|return|print|reverse|grep)\\b)\\s*",k:"split return print reverse grep",r:0,c:[e.HCM,{cN:"regexp",b:"(s|tr|y)/(\\\\.|[^/])*/(\\\\.|[^/])*/[a-z]*",r:10},{cN:"regexp",b:"(m|qr)?/",e:"/[a-z]*",c:[e.BE],r:0}]},{cN:"function",bK:"sub",e:"(\\s*\\(.*?\\))?[;{]",eE:!0,r:5,c:[e.TM]},{b:"-\\w\\b",r:0},{b:"^__DATA__$",e:"^__END__$",sL:"mojolicious",c:[{b:"^@@.*",e:"$",cN:"comment"}]}];return r.c=o,s.c=o,{aliases:["pl","pm"],l:/[\w\.]+/,k:t,c:o}});hljs.registerLanguage("ini",function(e){var b={cN:"string",c:[e.BE],v:[{b:"'''",e:"'''",r:10},{b:'"""',e:'"""',r:10},{b:'"',e:'"'},{b:"'",e:"'"}]};return{aliases:["toml"],cI:!0,i:/\S/,c:[e.C(";","$"),e.HCM,{cN:"section",b:/^\s*\[+/,e:/\]+/},{b:/^[a-z0-9\[\]_-]+\s*=\s*/,e:"$",rB:!0,c:[{cN:"attr",b:/[a-z0-9\[\]_-]+/},{b:/=/,eW:!0,r:0,c:[{cN:"literal",b:/\bon|off|true|false|yes|no\b/},{cN:"variable",v:[{b:/\$[\w\d"][\w\d_]*/},{b:/\$\{(.*?)}/}]},b,{cN:"number",b:/([\+\-]+)?[\d]+_[\d_]+/},e.NM]}]}]}});hljs.registerLanguage("diff",function(e){return{aliases:["patch"],c:[{cN:"meta",r:10,v:[{b:/^@@ +\-\d+,\d+ +\+\d+,\d+ +@@$/},{b:/^\*\*\* +\d+,\d+ +\*\*\*\*$/},{b:/^\-\-\- +\d+,\d+ +\-\-\-\-$/}]},{cN:"comment",v:[{b:/Index: /,e:/$/},{b:/={3,}/,e:/$/},{b:/^\-{3}/,e:/$/},{b:/^\*{3} /,e:/$/},{b:/^\+{3}/,e:/$/},{b:/\*{5}/,e:/\*{5}$/}]},{cN:"addition",b:"^\\+",e:"$"},{cN:"deletion",b:"^\\-",e:"$"},{cN:"addition",b:"^\\!",e:"$"}]}});hljs.registerLanguage("go",function(e){var t={keyword:"break default func interface select case map struct chan else goto package switch const fallthrough if range type continue for import return var go defer bool byte complex64 complex128 float32 float64 int8 int16 int32 int64 string uint8 uint16 uint32 uint64 int uint uintptr rune",literal:"true false iota nil",built_in:"append cap close complex copy imag len make new panic print println real recover delete"};return{aliases:["golang"],k:t,i:"</",c:[e.CLCM,e.CBCM,{cN:"string",v:[e.QSM,{b:"'",e:"[^\\\\]'"},{b:"`",e:"`"}]},{cN:"number",v:[{b:e.CNR+"[dflsi]",r:1},e.CNM]},{b:/:=/},{cN:"function",bK:"func",e:/\s*\{/,eE:!0,c:[e.TM,{cN:"params",b:/\(/,e:/\)/,k:t,i:/["']/}]}]}});hljs.registerLanguage("bash",function(e){var t={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},s={cN:"string",b:/"/,e:/"/,c:[e.BE,t,{cN:"variable",b:/\$\(/,e:/\)/,c:[e.BE]}]},a={cN:"string",b:/'/,e:/'/};return{aliases:["sh","zsh"],l:/\b-?[a-z\._]+\b/,k:{keyword:"if then else elif fi for while in do done case esac function",literal:"true false",built_in:"break cd continue eval exec exit export getopts hash pwd readonly return shift test times trap umask unset alias bind builtin caller command declare echo enable help let local logout mapfile printf read readarray source type typeset ulimit unalias set shopt autoload bg bindkey bye cap chdir clone comparguments compcall compctl compdescribe compfiles compgroups compquote comptags comptry compvalues dirs disable disown echotc echoti emulate fc fg float functions getcap getln history integer jobs kill limit log noglob popd print pushd pushln rehash sched setcap setopt stat suspend ttyctl unfunction unhash unlimit unsetopt vared wait whence where which zcompile zformat zftp zle zmodload zparseopts zprof zpty zregexparse zsocket zstyle ztcp",_:"-ne -eq -lt -gt -f -d -e -s -l -a"},c:[{cN:"meta",b:/^#![^\n]+sh\s*$/,r:10},{cN:"function",b:/\w[\w\d_]*\s*\(\s*\)\s*\{/,rB:!0,c:[e.inherit(e.TM,{b:/\w[\w\d_]*/})],r:0},e.HCM,s,a,t]}});hljs.registerLanguage("python",function(e){var r={keyword:"and elif is global as in if from raise for except finally print import pass return exec else break not with class assert yield try while continue del or def lambda async await nonlocal|10 None True False",built_in:"Ellipsis NotImplemented"},b={cN:"meta",b:/^(>>>|\.\.\.) /},c={cN:"subst",b:/\{/,e:/\}/,k:r,i:/#/},a={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,c:[b],r:10},{b:/(u|b)?r?"""/,e:/"""/,c:[b],r:10},{b:/(fr|rf|f)'''/,e:/'''/,c:[b,c]},{b:/(fr|rf|f)"""/,e:/"""/,c:[b,c]},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},{b:/(fr|rf|f)'/,e:/'/,c:[c]},{b:/(fr|rf|f)"/,e:/"/,c:[c]},e.ASM,e.QSM]},s={cN:"number",r:0,v:[{b:e.BNR+"[lLjJ]?"},{b:"\\b(0o[0-7]+)[lLjJ]?"},{b:e.CNR+"[lLjJ]?"}]},i={cN:"params",b:/\(/,e:/\)/,c:["self",b,s,a]};return c.c=[a,s,b],{aliases:["py","gyp"],k:r,i:/(<\/|->|\?)|=>/,c:[b,s,a,e.HCM,{v:[{cN:"function",bK:"def"},{cN:"class",bK:"class"}],e:/:/,i:/[${=;\n,]/,c:[e.UTM,i,{b:/->/,eW:!0,k:"None"}]},{cN:"meta",b:/^[\t ]*@/,e:/$/},{b:/\b(print|exec)\(/}]}});hljs.registerLanguage("julia",function(e){var r={keyword:"in isa where baremodule begin break catch ccall const continue do else elseif end export false finally for function global if import importall let local macro module quote return true try using while type immutable abstract bitstype typealias ",literal:"true false ARGS C_NULL DevNull ENDIAN_BOM ENV I Inf Inf16 Inf32 Inf64 InsertionSort JULIA_HOME LOAD_PATH MergeSort NaN NaN16 NaN32 NaN64 PROGRAM_FILE QuickSort RoundDown RoundFromZero RoundNearest RoundNearestTiesAway RoundNearestTiesUp RoundToZero RoundUp STDERR STDIN STDOUT VERSION catalan e|0 eu|0 eulergamma golden im nothing pi γ π φ ",built_in:"ANY AbstractArray AbstractChannel AbstractFloat AbstractMatrix AbstractRNG AbstractSerializer AbstractSet AbstractSparseArray AbstractSparseMatrix AbstractSparseVector AbstractString AbstractUnitRange AbstractVecOrMat AbstractVector Any ArgumentError Array AssertionError Associative Base64DecodePipe Base64EncodePipe Bidiagonal BigFloat BigInt BitArray BitMatrix BitVector Bool BoundsError BufferStream CachingPool CapturedException CartesianIndex CartesianRange Cchar Cdouble Cfloat Channel Char Cint Cintmax_t Clong Clonglong ClusterManager Cmd CodeInfo Colon Complex Complex128 Complex32 Complex64 CompositeException Condition ConjArray ConjMatrix ConjVector Cptrdiff_t Cshort Csize_t Cssize_t Cstring Cuchar Cuint Cuintmax_t Culong Culonglong Cushort Cwchar_t Cwstring DataType Date DateFormat DateTime DenseArray DenseMatrix DenseVecOrMat DenseVector Diagonal Dict DimensionMismatch Dims DirectIndexString Display DivideError DomainError EOFError EachLine Enum Enumerate ErrorException Exception ExponentialBackOff Expr Factorization FileMonitor Float16 Float32 Float64 Function Future GlobalRef GotoNode HTML Hermitian IO IOBuffer IOContext IOStream IPAddr IPv4 IPv6 IndexCartesian IndexLinear IndexStyle InexactError InitError Int Int128 Int16 Int32 Int64 Int8 IntSet Integer InterruptException InvalidStateException Irrational KeyError LabelNode LinSpace LineNumberNode LoadError LowerTriangular MIME Matrix MersenneTwister Method MethodError MethodTable Module NTuple NewvarNode NullException Nullable Number ObjectIdDict OrdinalRange OutOfMemoryError OverflowError Pair ParseError PartialQuickSort PermutedDimsArray Pipe PollingFileWatcher ProcessExitedException Ptr QuoteNode RandomDevice Range RangeIndex Rational RawFD ReadOnlyMemoryError Real ReentrantLock Ref Regex RegexMatch RemoteChannel RemoteException RevString RoundingMode RowVector SSAValue SegmentationFault SerializationState Set SharedArray SharedMatrix SharedVector Signed SimpleVector Slot SlotNumber SparseMatrixCSC SparseVector StackFrame StackOverflowError StackTrace StepRange StepRangeLen StridedArray StridedMatrix StridedVecOrMat StridedVector String SubArray SubString SymTridiagonal Symbol Symmetric SystemError TCPSocket Task Text TextDisplay Timer Tridiagonal Tuple Type TypeError TypeMapEntry TypeMapLevel TypeName TypeVar TypedSlot UDPSocket UInt UInt128 UInt16 UInt32 UInt64 UInt8 UndefRefError UndefVarError UnicodeError UniformScaling Union UnionAll UnitRange Unsigned UpperTriangular Val Vararg VecElement VecOrMat Vector VersionNumber Void WeakKeyDict WeakRef WorkerConfig WorkerPool "},t="[A-Za-z_\\u00A1-\\uFFFF][A-Za-z_0-9\\u00A1-\\uFFFF]*",a={l:t,k:r,i:/<\//},n={cN:"number",b:/(\b0x[\d_]*(\.[\d_]*)?|0x\.\d[\d_]*)p[-+]?\d+|\b0[box][a-fA-F0-9][a-fA-F0-9_]*|(\b\d[\d_]*(\.[\d_]*)?|\.\d[\d_]*)([eEfF][-+]?\d+)?/,r:0},o={cN:"string",b:/'(.|\\[xXuU][a-zA-Z0-9]+)'/},i={cN:"subst",b:/\$\(/,e:/\)/,k:r},l={cN:"variable",b:"\\$"+t},c={cN:"string",c:[e.BE,i,l],v:[{b:/\w*"""/,e:/"""\w*/,r:10},{b:/\w*"/,e:/"\w*/}]},s={cN:"string",c:[e.BE,i,l],b:"`",e:"`"},d={cN:"meta",b:"@"+t},u={cN:"comment",v:[{b:"#=",e:"=#",r:10},{b:"#",e:"$"}]};return a.c=[n,o,c,s,d,u,e.HCM,{cN:"keyword",b:"\\b(((abstract|primitive)\\s+)type|(mutable\\s+)?struct)\\b"},{b:/<:/}],i.c=a.c,a});hljs.registerLanguage("coffeescript",function(e){var c={keyword:"in if for while finally new do return else break catch instanceof throw try this switch continue typeof delete debugger super yield import export from as default await then unless until loop of by when and or is isnt not",literal:"true false null undefined yes no on off",built_in:"npm require console print module global window document"},n="[A-Za-z$_][0-9A-Za-z$_]*",r={cN:"subst",b:/#\{/,e:/}/,k:c},i=[e.BNM,e.inherit(e.CNM,{starts:{e:"(\\s*/)?",r:0}}),{cN:"string",v:[{b:/'''/,e:/'''/,c:[e.BE]},{b:/'/,e:/'/,c:[e.BE]},{b:/"""/,e:/"""/,c:[e.BE,r]},{b:/"/,e:/"/,c:[e.BE,r]}]},{cN:"regexp",v:[{b:"///",e:"///",c:[r,e.HCM]},{b:"//[gim]*",r:0},{b:/\/(?![ *])(\\\/|.)*?\/[gim]*(?=\W|$)/}]},{b:"@"+n},{sL:"javascript",eB:!0,eE:!0,v:[{b:"```",e:"```"},{b:"`",e:"`"}]}];r.c=i;var s=e.inherit(e.TM,{b:n}),t="(\\(.*\\))?\\s*\\B[-=]>",o={cN:"params",b:"\\([^\\(]",rB:!0,c:[{b:/\(/,e:/\)/,k:c,c:["self"].concat(i)}]};return{aliases:["coffee","cson","iced"],k:c,i:/\/\*/,c:i.concat([e.C("###","###"),e.HCM,{cN:"function",b:"^\\s*"+n+"\\s*=\\s*"+t,e:"[-=]>",rB:!0,c:[s,o]},{b:/[:\(,=]\s*/,r:0,c:[{cN:"function",b:t,e:"[-=]>",rB:!0,c:[o]}]},{cN:"class",bK:"class",e:"$",i:/[:="\[\]]/,c:[{bK:"extends",eW:!0,i:/[:="\[\]]/,c:[s]},s]},{b:n+":",e:":",rB:!0,rE:!0,r:0}])}});hljs.registerLanguage("cpp",function(t){var e={cN:"keyword",b:"\\b[a-z\\d_]*_t\\b"},r={cN:"string",v:[{b:'(u8?|U)?L?"',e:'"',i:"\\n",c:[t.BE]},{b:'(u8?|U)?R"',e:'"',c:[t.BE]},{b:"'\\\\?.",e:"'",i:"."}]},s={cN:"number",v:[{b:"\\b(0b[01']+)"},{b:"(-?)\\b([\\d']+(\\.[\\d']*)?|\\.[\\d']+)(u|U|l|L|ul|UL|f|F|b|B)"},{b:"(-?)(\\b0[xX][a-fA-F0-9']+|(\\b[\\d']+(\\.[\\d']*)?|\\.[\\d']+)([eE][-+]?[\\d']+)?)"}],r:0},i={cN:"meta",b:/#\s*[a-z]+\b/,e:/$/,k:{"meta-keyword":"if else elif endif define undef warning error line pragma ifdef ifndef include"},c:[{b:/\\\n/,r:0},t.inherit(r,{cN:"meta-string"}),{cN:"meta-string",b:/<[^\n>]*>/,e:/$/,i:"\\n"},t.CLCM,t.CBCM]},a=t.IR+"\\s*\\(",c={keyword:"int float while private char catch import module export virtual operator sizeof dynamic_cast|10 typedef const_cast|10 const for static_cast|10 union namespace unsigned long volatile static protected bool template mutable if public friend do goto auto void enum else break extern using asm case typeid short reinterpret_cast|10 default double register explicit signed typename try this switch continue inline delete alignof constexpr decltype noexcept static_assert thread_local restrict _Bool complex _Complex _Imaginary atomic_bool atomic_char atomic_schar atomic_uchar atomic_short atomic_ushort atomic_int atomic_uint atomic_long atomic_ulong atomic_llong atomic_ullong new throw return and or not",built_in:"std string cin cout cerr clog stdin stdout stderr stringstream istringstream ostringstream auto_ptr deque list queue stack vector map set bitset multiset multimap unordered_set unordered_map unordered_multiset unordered_multimap array shared_ptr abort abs acos asin atan2 atan calloc ceil cosh cos exit exp fabs floor fmod fprintf fputs free frexp fscanf isalnum isalpha iscntrl isdigit isgraph islower isprint ispunct isspace isupper isxdigit tolower toupper labs ldexp log10 log malloc realloc memchr memcmp memcpy memset modf pow printf putchar puts scanf sinh sin snprintf sprintf sqrt sscanf strcat strchr strcmp strcpy strcspn strlen strncat strncmp strncpy strpbrk strrchr strspn strstr tanh tan vfprintf vprintf vsprintf endl initializer_list unique_ptr",literal:"true false nullptr NULL"},n=[e,t.CLCM,t.CBCM,s,r];return{aliases:["c","cc","h","c++","h++","hpp"],k:c,i:"</",c:n.concat([i,{b:"\\b(deque|list|queue|stack|vector|map|set|bitset|multiset|multimap|unordered_map|unordered_set|unordered_multiset|unordered_multimap|array)\\s*<",e:">",k:c,c:["self",e]},{b:t.IR+"::",k:c},{v:[{b:/=/,e:/;/},{b:/\(/,e:/\)/},{bK:"new throw return else",e:/;/}],k:c,c:n.concat([{b:/\(/,e:/\)/,k:c,c:n.concat(["self"]),r:0}]),r:0},{cN:"function",b:"("+t.IR+"[\\*&\\s]+)+"+a,rB:!0,e:/[{;=]/,eE:!0,k:c,i:/[^\w\s\*&]/,c:[{b:a,rB:!0,c:[t.TM],r:0},{cN:"params",b:/\(/,e:/\)/,k:c,r:0,c:[t.CLCM,t.CBCM,r,s,e]},t.CLCM,t.CBCM,i]},{cN:"class",bK:"class struct",e:/[{;:]/,c:[{b:/</,e:/>/,c:["self"]},t.TM]}]),exports:{preprocessor:i,strings:r,k:c}}});hljs.registerLanguage("ruby",function(e){var b="[a-zA-Z_]\\w*[!?=]?|[-+~]\\@|<<|>>|=~|===?|<=>|[<>]=?|\\*\\*|[-/+%^&*~`|]|\\[\\]=?",r={keyword:"and then defined module in return redo if BEGIN retry end for self when next until do begin unless END rescue else break undef not super class case require yield alias while ensure elsif or include attr_reader attr_writer attr_accessor",literal:"true false nil"},c={cN:"doctag",b:"@[A-Za-z]+"},a={b:"#<",e:">"},s=[e.C("#","$",{c:[c]}),e.C("^\\=begin","^\\=end",{c:[c],r:10}),e.C("^__END__","\\n$")],n={cN:"subst",b:"#\\{",e:"}",k:r},t={cN:"string",c:[e.BE,n],v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/`/,e:/`/},{b:"%[qQwWx]?\\(",e:"\\)"},{b:"%[qQwWx]?\\[",e:"\\]"},{b:"%[qQwWx]?{",e:"}"},{b:"%[qQwWx]?<",e:">"},{b:"%[qQwWx]?/",e:"/"},{b:"%[qQwWx]?%",e:"%"},{b:"%[qQwWx]?-",e:"-"},{b:"%[qQwWx]?\\|",e:"\\|"},{b:/\B\?(\\\d{1,3}|\\x[A-Fa-f0-9]{1,2}|\\u[A-Fa-f0-9]{4}|\\?\S)\b/},{b:/<<(-?)\w+$/,e:/^\s*\w+$/}]},i={cN:"params",b:"\\(",e:"\\)",endsParent:!0,k:r},d=[t,a,{cN:"class",bK:"class module",e:"$|;",i:/=/,c:[e.inherit(e.TM,{b:"[A-Za-z_]\\w*(::\\w+)*(\\?|\\!)?"}),{b:"<\\s*",c:[{b:"("+e.IR+"::)?"+e.IR}]}].concat(s)},{cN:"function",bK:"def",e:"$|;",c:[e.inherit(e.TM,{b:b}),i].concat(s)},{b:e.IR+"::"},{cN:"symbol",b:e.UIR+"(\\!|\\?)?:",r:0},{cN:"symbol",b:":(?!\\s)",c:[t,{b:b}],r:0},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\$\\W)|((\\$|\\@\\@?)(\\w+))"},{cN:"params",b:/\|/,e:/\|/,k:r},{b:"("+e.RSR+"|unless)\\s*",k:"unless",c:[a,{cN:"regexp",c:[e.BE,n],i:/\n/,v:[{b:"/",e:"/[a-z]*"},{b:"%r{",e:"}[a-z]*"},{b:"%r\\(",e:"\\)[a-z]*"},{b:"%r!",e:"![a-z]*"},{b:"%r\\[",e:"\\][a-z]*"}]}].concat(s),r:0}].concat(s);n.c=d,i.c=d;var l="[>?]>",o="[\\w#]+\\(\\w+\\):\\d+:\\d+>",u="(\\w+-)?\\d+\\.\\d+\\.\\d(p\\d+)?[^>]+>",w=[{b:/^\s*=>/,starts:{e:"$",c:d}},{cN:"meta",b:"^("+l+"|"+o+"|"+u+")",starts:{e:"$",c:d}}];return{aliases:["rb","gemspec","podspec","thor","irb"],k:r,i:/\/\*/,c:s.concat(w).concat(d)}});hljs.registerLanguage("yaml",function(e){var b="true false yes no null",a="^[ \\-]*",r="[a-zA-Z_][\\w\\-]*",t={cN:"attr",v:[{b:a+r+":"},{b:a+'"'+r+'":'},{b:a+"'"+r+"':"}]},c={cN:"template-variable",v:[{b:"{{",e:"}}"},{b:"%{",e:"}"}]},l={cN:"string",r:0,v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/\S+/}],c:[e.BE,c]};return{cI:!0,aliases:["yml","YAML","yaml"],c:[t,{cN:"meta",b:"^---s*$",r:10},{cN:"string",b:"[\\|>] *$",rE:!0,c:l.c,e:t.v[0].b},{b:"<%[%=-]?",e:"[%-]?%>",sL:"ruby",eB:!0,eE:!0,r:0},{cN:"type",b:"!!"+e.UIR},{cN:"meta",b:"&"+e.UIR+"$"},{cN:"meta",b:"\\*"+e.UIR+"$"},{cN:"bullet",b:"^ *-",r:0},e.HCM,{bK:b,k:{literal:b}},e.CNM,l]}});hljs.registerLanguage("css",function(e){var c="[a-zA-Z-][a-zA-Z0-9_-]*",t={b:/[A-Z\_\.\-]+\s*:/,rB:!0,e:";",eW:!0,c:[{cN:"attribute",b:/\S/,e:":",eE:!0,starts:{eW:!0,eE:!0,c:[{b:/[\w-]+\(/,rB:!0,c:[{cN:"built_in",b:/[\w-]+/},{b:/\(/,e:/\)/,c:[e.ASM,e.QSM]}]},e.CSSNM,e.QSM,e.ASM,e.CBCM,{cN:"number",b:"#[0-9A-Fa-f]+"},{cN:"meta",b:"!important"}]}}]};return{cI:!0,i:/[=\/|'\$]/,c:[e.CBCM,{cN:"selector-id",b:/#[A-Za-z0-9_-]+/},{cN:"selector-class",b:/\.[A-Za-z0-9_-]+/},{cN:"selector-attr",b:/\[/,e:/\]/,i:"$"},{cN:"selector-pseudo",b:/:(:)?[a-zA-Z0-9\_\-\+\(\)"'.]+/},{b:"@(font-face|page)",l:"[a-z-]+",k:"font-face page"},{b:"@",e:"[{;]",i:/:/,c:[{cN:"keyword",b:/\w+/},{b:/\s/,eW:!0,eE:!0,r:0,c:[e.ASM,e.QSM,e.CSSNM]}]},{cN:"selector-tag",b:c,r:0},{b:"{",e:"}",i:/\S/,c:[e.CBCM,t]}]}});hljs.registerLanguage("fortran",function(e){var t={cN:"params",b:"\\(",e:"\\)"},n={literal:".False. .True.",keyword:"kind do while private call intrinsic where elsewhere type endtype endmodule endselect endinterface end enddo endif if forall endforall only contains default return stop then public subroutine|10 function program .and. .or. .not. .le. .eq. .ge. .gt. .lt. goto save else use module select case access blank direct exist file fmt form formatted iostat name named nextrec number opened rec recl sequential status unformatted unit continue format pause cycle exit c_null_char c_alert c_backspace c_form_feed flush wait decimal round iomsg synchronous nopass non_overridable pass protected volatile abstract extends import non_intrinsic value deferred generic final enumerator class associate bind enum c_int c_short c_long c_long_long c_signed_char c_size_t c_int8_t c_int16_t c_int32_t c_int64_t c_int_least8_t c_int_least16_t c_int_least32_t c_int_least64_t c_int_fast8_t c_int_fast16_t c_int_fast32_t c_int_fast64_t c_intmax_t C_intptr_t c_float c_double c_long_double c_float_complex c_double_complex c_long_double_complex c_bool c_char c_null_ptr c_null_funptr c_new_line c_carriage_return c_horizontal_tab c_vertical_tab iso_c_binding c_loc c_funloc c_associated  c_f_pointer c_ptr c_funptr iso_fortran_env character_storage_size error_unit file_storage_size input_unit iostat_end iostat_eor numeric_storage_size output_unit c_f_procpointer ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode newunit contiguous recursive pad position action delim readwrite eor advance nml interface procedure namelist include sequence elemental pure integer real character complex logical dimension allocatable|10 parameter external implicit|10 none double precision assign intent optional pointer target in out common equivalence data",built_in:"alog alog10 amax0 amax1 amin0 amin1 amod cabs ccos cexp clog csin csqrt dabs dacos dasin datan datan2 dcos dcosh ddim dexp dint dlog dlog10 dmax1 dmin1 dmod dnint dsign dsin dsinh dsqrt dtan dtanh float iabs idim idint idnint ifix isign max0 max1 min0 min1 sngl algama cdabs cdcos cdexp cdlog cdsin cdsqrt cqabs cqcos cqexp cqlog cqsin cqsqrt dcmplx dconjg derf derfc dfloat dgamma dimag dlgama iqint qabs qacos qasin qatan qatan2 qcmplx qconjg qcos qcosh qdim qerf qerfc qexp qgamma qimag qlgama qlog qlog10 qmax1 qmin1 qmod qnint qsign qsin qsinh qsqrt qtan qtanh abs acos aimag aint anint asin atan atan2 char cmplx conjg cos cosh exp ichar index int log log10 max min nint sign sin sinh sqrt tan tanh print write dim lge lgt lle llt mod nullify allocate deallocate adjustl adjustr all allocated any associated bit_size btest ceiling count cshift date_and_time digits dot_product eoshift epsilon exponent floor fraction huge iand ibclr ibits ibset ieor ior ishft ishftc lbound len_trim matmul maxexponent maxloc maxval merge minexponent minloc minval modulo mvbits nearest pack present product radix random_number random_seed range repeat reshape rrspacing scale scan selected_int_kind selected_real_kind set_exponent shape size spacing spread sum system_clock tiny transpose trim ubound unpack verify achar iachar transfer dble entry dprod cpu_time command_argument_count get_command get_command_argument get_environment_variable is_iostat_end ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode is_iostat_eor move_alloc new_line selected_char_kind same_type_as extends_type_ofacosh asinh atanh bessel_j0 bessel_j1 bessel_jn bessel_y0 bessel_y1 bessel_yn erf erfc erfc_scaled gamma log_gamma hypot norm2 atomic_define atomic_ref execute_command_line leadz trailz storage_size merge_bits bge bgt ble blt dshiftl dshiftr findloc iall iany iparity image_index lcobound ucobound maskl maskr num_images parity popcnt poppar shifta shiftl shiftr this_image"};return{cI:!0,aliases:["f90","f95"],k:n,i:/\/\*/,c:[e.inherit(e.ASM,{cN:"string",r:0}),e.inherit(e.QSM,{cN:"string",r:0}),{cN:"function",bK:"subroutine function program",i:"[${=\\n]",c:[e.UTM,t]},e.C("!","$",{r:0}),{cN:"number",b:"(?=\\b|\\+|\\-|\\.)(?=\\.\\d|\\d)(?:\\d+)?(?:\\.?\\d*)(?:[de][+-]?\\d+)?\\b\\.?",r:0}]}});hljs.registerLanguage("awk",function(e){var r={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},b="BEGIN END if else while do for in break continue delete next nextfile function func exit|10",n={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,r:10},{b:/(u|b)?r?"""/,e:/"""/,r:10},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},e.ASM,e.QSM]};return{k:{keyword:b},c:[r,n,e.RM,e.HCM,e.NM]}});hljs.registerLanguage("makefile",function(e){var i={cN:"variable",v:[{b:"\\$\\("+e.UIR+"\\)",c:[e.BE]},{b:/\$[@%<?\^\+\*]/}]},r={cN:"string",b:/"/,e:/"/,c:[e.BE,i]},a={cN:"variable",b:/\$\([\w-]+\s/,e:/\)/,k:{built_in:"subst patsubst strip findstring filter filter-out sort word wordlist firstword lastword dir notdir suffix basename addsuffix addprefix join wildcard realpath abspath error warning shell origin flavor foreach if or and call eval file value"},c:[i]},n={b:"^"+e.UIR+"\\s*[:+?]?=",i:"\\n",rB:!0,c:[{b:"^"+e.UIR,e:"[:+?]?=",eE:!0}]},t={cN:"meta",b:/^\.PHONY:/,e:/$/,k:{"meta-keyword":".PHONY"},l:/[\.\w]+/},l={cN:"section",b:/^[^\s]+:/,e:/$/,c:[i]};return{aliases:["mk","mak"],k:"define endef undefine ifdef ifndef ifeq ifneq else endif include -include sinclude override export unexport private vpath",l:/[\w-]+/,c:[e.HCM,i,r,a,n,t,l]}});hljs.registerLanguage("java",function(e){var a="[À-ʸa-zA-Z_$][À-ʸa-zA-Z_$0-9]*",t=a+"(<"+a+"(\\s*,\\s*"+a+")*>)?",r="false synchronized int abstract float private char boolean static null if const for true while long strictfp finally protected import native final void enum else break transient catch instanceof byte super volatile case assert short package default double public try this switch continue throws protected public private module requires exports do",s="\\b(0[bB]([01]+[01_]+[01]+|[01]+)|0[xX]([a-fA-F0-9]+[a-fA-F0-9_]+[a-fA-F0-9]+|[a-fA-F0-9]+)|(([\\d]+[\\d_]+[\\d]+|[\\d]+)(\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))?|\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))([eE][-+]?\\d+)?)[lLfF]?",c={cN:"number",b:s,r:0};return{aliases:["jsp"],k:r,i:/<\/|#/,c:[e.C("/\\*\\*","\\*/",{r:0,c:[{b:/\w+@/,r:0},{cN:"doctag",b:"@[A-Za-z]+"}]}),e.CLCM,e.CBCM,e.ASM,e.QSM,{cN:"class",bK:"class interface",e:/[{;=]/,eE:!0,k:"class interface",i:/[:"\[\]]/,c:[{bK:"extends implements"},e.UTM]},{bK:"new throw return else",r:0},{cN:"function",b:"("+t+"\\s+)+"+e.UIR+"\\s*\\(",rB:!0,e:/[{;=]/,eE:!0,k:r,c:[{b:e.UIR+"\\s*\\(",rB:!0,r:0,c:[e.UTM]},{cN:"params",b:/\(/,e:/\)/,k:r,r:0,c:[e.ASM,e.QSM,e.CNM,e.CBCM]},e.CLCM,e.CBCM]},c,{cN:"meta",b:"@[A-Za-z]+"}]}});hljs.registerLanguage("stan",function(e){return{c:[e.HCM,e.CLCM,e.CBCM,{b:e.UIR,l:e.UIR,k:{name:"for in while repeat until if then else",symbol:"bernoulli bernoulli_logit binomial binomial_logit beta_binomial hypergeometric categorical categorical_logit ordered_logistic neg_binomial neg_binomial_2 neg_binomial_2_log poisson poisson_log multinomial normal exp_mod_normal skew_normal student_t cauchy double_exponential logistic gumbel lognormal chi_square inv_chi_square scaled_inv_chi_square exponential inv_gamma weibull frechet rayleigh wiener pareto pareto_type_2 von_mises uniform multi_normal multi_normal_prec multi_normal_cholesky multi_gp multi_gp_cholesky multi_student_t gaussian_dlm_obs dirichlet lkj_corr lkj_corr_cholesky wishart inv_wishart","selector-tag":"int real vector simplex unit_vector ordered positive_ordered row_vector matrix cholesky_factor_corr cholesky_factor_cov corr_matrix cov_matrix",title:"functions model data parameters quantities transformed generated",literal:"true false"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0}]}});hljs.registerLanguage("javascript",function(e){var r="[A-Za-z$_][0-9A-Za-z$_]*",t={keyword:"in of if for while finally var new function do return void else break catch instanceof with throw case default try this switch continue typeof delete let yield const export super debugger as async await static import from as",literal:"true false null undefined NaN Infinity",built_in:"eval isFinite isNaN parseFloat parseInt decodeURI decodeURIComponent encodeURI encodeURIComponent escape unescape Object Function Boolean Error EvalError InternalError RangeError ReferenceError StopIteration SyntaxError TypeError URIError Number Math Date String RegExp Array Float32Array Float64Array Int16Array Int32Array Int8Array Uint16Array Uint32Array Uint8Array Uint8ClampedArray ArrayBuffer DataView JSON Intl arguments require module console window document Symbol Set Map WeakSet WeakMap Proxy Reflect Promise"},a={cN:"number",v:[{b:"\\b(0[bB][01]+)"},{b:"\\b(0[oO][0-7]+)"},{b:e.CNR}],r:0},n={cN:"subst",b:"\\$\\{",e:"\\}",k:t,c:[]},c={cN:"string",b:"`",e:"`",c:[e.BE,n]};n.c=[e.ASM,e.QSM,c,a,e.RM];var s=n.c.concat([e.CBCM,e.CLCM]);return{aliases:["js","jsx"],k:t,c:[{cN:"meta",r:10,b:/^\s*['"]use (strict|asm)['"]/},{cN:"meta",b:/^#!/,e:/$/},e.ASM,e.QSM,c,e.CLCM,e.CBCM,a,{b:/[{,]\s*/,r:0,c:[{b:r+"\\s*:",rB:!0,r:0,c:[{cN:"attr",b:r,r:0}]}]},{b:"("+e.RSR+"|\\b(case|return|throw)\\b)\\s*",k:"return throw case",c:[e.CLCM,e.CBCM,e.RM,{cN:"function",b:"(\\(.*?\\)|"+r+")\\s*=>",rB:!0,e:"\\s*=>",c:[{cN:"params",v:[{b:r},{b:/\(\s*\)/},{b:/\(/,e:/\)/,eB:!0,eE:!0,k:t,c:s}]}]},{b:/</,e:/(\/\w+|\w+\/)>/,sL:"xml",c:[{b:/<\w+\s*\/>/,skip:!0},{b:/<\w+/,e:/(\/\w+|\w+\/)>/,skip:!0,c:[{b:/<\w+\s*\/>/,skip:!0},"self"]}]}],r:0},{cN:"function",bK:"function",e:/\{/,eE:!0,c:[e.inherit(e.TM,{b:r}),{cN:"params",b:/\(/,e:/\)/,eB:!0,eE:!0,c:s}],i:/\[|%/},{b:/\$[(.]/},e.METHOD_GUARD,{cN:"class",bK:"class",e:/[{;=]/,eE:!0,i:/[:"\[\]]/,c:[{bK:"extends"},e.UTM]},{bK:"constructor",e:/\{/,eE:!0}],i:/#(?!!)/}});hljs.registerLanguage("tex",function(c){var e={cN:"tag",b:/\\/,r:0,c:[{cN:"name",v:[{b:/[a-zA-Zа-яА-я]+[*]?/},{b:/[^a-zA-Zа-яА-я0-9]/}],starts:{eW:!0,r:0,c:[{cN:"string",v:[{b:/\[/,e:/\]/},{b:/\{/,e:/\}/}]},{b:/\s*=\s*/,eW:!0,r:0,c:[{cN:"number",b:/-?\d*\.?\d+(pt|pc|mm|cm|in|dd|cc|ex|em)?/}]}]}}]};return{c:[e,{cN:"formula",c:[e],r:0,v:[{b:/\$\$/,e:/\$\$/},{b:/\$/,e:/\$/}]},c.C("%","$",{r:0})]}});hljs.registerLanguage("xml",function(s){var e="[A-Za-z0-9\\._:-]+",t={eW:!0,i:/</,r:0,c:[{cN:"attr",b:e,r:0},{b:/=\s*/,r:0,c:[{cN:"string",endsParent:!0,v:[{b:/"/,e:/"/},{b:/'/,e:/'/},{b:/[^\s"'=<>`]+/}]}]}]};return{aliases:["html","xhtml","rss","atom","xjb","xsd","xsl","plist"],cI:!0,c:[{cN:"meta",b:"<!DOCTYPE",e:">",r:10,c:[{b:"\\[",e:"\\]"}]},s.C("<!--","-->",{r:10}),{b:"<\\!\\[CDATA\\[",e:"\\]\\]>",r:10},{b:/<\?(php)?/,e:/\?>/,sL:"php",c:[{b:"/\\*",e:"\\*/",skip:!0}]},{cN:"tag",b:"<style(?=\\s|>|$)",e:">",k:{name:"style"},c:[t],starts:{e:"</style>",rE:!0,sL:["css","xml"]}},{cN:"tag",b:"<script(?=\\s|>|$)",e:">",k:{name:"script"},c:[t],starts:{e:"</script>",rE:!0,sL:["actionscript","javascript","handlebars","xml"]}},{cN:"meta",v:[{b:/<\?xml/,e:/\?>/,r:10},{b:/<\?\w+/,e:/\?>/}]},{cN:"tag",b:"</?",e:"/?>",c:[{cN:"name",b:/[^\/><\s]+/,r:0},t]}]}});hljs.registerLanguage("markdown",function(e){return{aliases:["md","mkdown","mkd"],c:[{cN:"section",v:[{b:"^#{1,6}",e:"$"},{b:"^.+?\\n[=-]{2,}$"}]},{b:"<",e:">",sL:"xml",r:0},{cN:"bullet",b:"^([*+-]|(\\d+\\.))\\s+"},{cN:"strong",b:"[*_]{2}.+?[*_]{2}"},{cN:"emphasis",v:[{b:"\\*.+?\\*"},{b:"_.+?_",r:0}]},{cN:"quote",b:"^>\\s+",e:"$"},{cN:"code",v:[{b:"^```w*s*$",e:"^```s*$"},{b:"`.+?`"},{b:"^( {4}|	)",e:"$",r:0}]},{b:"^[-\\*]{3,}",e:"$"},{b:"\\[.+?\\][\\(\\[].*?[\\)\\]]",rB:!0,c:[{cN:"string",b:"\\[",e:"\\]",eB:!0,rE:!0,r:0},{cN:"link",b:"\\]\\(",e:"\\)",eB:!0,eE:!0},{cN:"symbol",b:"\\]\\[",e:"\\]",eB:!0,eE:!0}],r:10},{b:/^\[[^\n]+\]:/,rB:!0,c:[{cN:"symbol",b:/\[/,e:/\]/,eB:!0,eE:!0},{cN:"link",b:/:\s*/,e:/$/,eB:!0}]}]}});hljs.registerLanguage("json",function(e){var i={literal:"true false null"},n=[e.QSM,e.CNM],r={e:",",eW:!0,eE:!0,c:n,k:i},t={b:"{",e:"}",c:[{cN:"attr",b:/"/,e:/"/,c:[e.BE],i:"\\n"},e.inherit(r,{b:/:/})],i:"\\S"},c={b:"\\[",e:"\\]",c:[e.inherit(r)],i:"\\S"};return n.splice(n.length,0,t,c),{c:n,k:i,i:"\\S"}});"></script>

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>




<style type="text/css">
#rmd-source-code {
  display: none;
}
</style>





<style type="text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>

<style type="text/css">
.kable-table {
  border: 1px solid #ccc;
  border-radius: 4px;
  overflow: auto;
  padding-left: 8px;
  padding-right: 8px;
  margin-bottom: 20px;
  max-height: 350px;
}

.kable-table table {
  margin-bottom: 0px;
}

.kable-table table>thead>tr>th {
  border: none;
  border-bottom: 2px solid #dddddd;
}

.kable-table table>thead {
  background-color: #fff;
}
</style>


<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->
<style type="text/css">
.code-folding-btn { margin-bottom: 4px; }
</style>




</head>

<body>


<div class="container-fluid main-container">




<div id="header">

<div class="btn-group pull-right float-right">
<button type="button" class="btn btn-default btn-xs btn-secondary btn-sm dropdown-toggle" data-toggle="dropdown" data-bs-toggle="dropdown" aria-haspopup="true" aria-expanded="false"><span>Code</span> <span class="caret"></span></button>
<ul class="dropdown-menu dropdown-menu-right" style="min-width: 50px;">
<li><a id="rmd-show-all-code" href="#">Show All Code</a></li>
<li><a id="rmd-hide-all-code" href="#">Hide All Code</a></li>
<li role="separator" class="divider"></li>
<li><a id="rmd-download-source" href="#">Download Rmd</a></li>
</ul>
</div>



<h1 class="title toc-ignore">R Notebook</h1>

</div>


<!-- rnb-text-begin -->
<p>This is an <a href="http://rmarkdown.rstudio.com">R Markdown</a>
Notebook. When you execute code within the notebook, the results appear
beneath the code.</p>
<p>Try executing this chunk by clicking the <em>Run</em> button within
the chunk or by placing your cursor inside it and pressing
<em>Cmd+Shift+Enter</em>.
<!-- "Drug's specificity to its known target" (DSKT score) -->
<!-- Find if DSKT Score can explain the cancer types where the drug is approved -->
<!-- Scripts and data needed --></p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxua25pdHI6OmtuaXQoJy9Vc2Vycy9zaW5oYXM4L1Byb2plY3RfVHJ1ZVRhcmdldC9Ub29sc19naXRodWIvMy5Ub29scy9TdGVwMEJfRGF0YV9hbmRfTGlicmFyaWVzLlJtZCcpXG5rbml0cjo6a25pdCgnL1VzZXJzL3NpbmhhczgvUHJvamVjdF9UcnVlVGFyZ2V0L1Rvb2xzX2dpdGh1Yi8zLlRvb2xzL1N0ZXAwX1dyaXRlX0Z1bmN0aW9ucy5SbWQnKVxuYGBgIn0= -->
<pre class="r"><code>knitr::knit(&#39;/Users/sinhas8/Project_TrueTarget/Tools_github/3.Tools/Step0B_Data_and_Libraries.Rmd&#39;)
knitr::knit(&#39;/Users/sinhas8/Project_TrueTarget/Tools_github/3.Tools/Step0_Write_Functions.Rmd&#39;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Provide query drug -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["drugName"],"name":[1],"type":["chr"],"align":["left"]},{"label":["MaxTargetName"],"name":[2],"type":["chr"],"align":["left"]},{"label":["Maxcorr"],"name":[3],"type":["dbl"],"align":["right"]},{"label":["cellLines_withLOWexp"],"name":[4],"type":["int"],"align":["right"]},{"label":["Maxcorr_Q"],"name":[5],"type":["int"],"align":["right"]},{"label":["drugBroadID"],"name":[6],"type":["chr"],"align":["left"]},{"label":["Whether_interaction"],"name":[7],"type":["lgl"],"align":["right"]},{"label":["PredictedRank"],"name":[8],"type":["dbl"],"align":["right"]},{"label":["interaction_strength"],"name":[9],"type":["dbl"],"align":["right"]},{"label":["interaction_P"],"name":[10],"type":["dbl"],"align":["right"]},{"label":["drugName_stripall"],"name":[11],"type":["chr"],"align":["left"]},{"label":["BestTargetName"],"name":[12],"type":["chr"],"align":["left"]},{"label":["BestTargetCorr"],"name":[13],"type":["dbl"],"align":["right"]},{"label":["BestTargetCorrP"],"name":[14],"type":["dbl"],"align":["right"]},{"label":["KnownTargetCorrP"],"name":[15],"type":["dbl"],"align":["right"]},{"label":["KnownTarget_meanCorr"],"name":[16],"type":["dbl"],"align":["right"]},{"label":["phase"],"name":[17],"type":["chr"],"align":["left"]},{"label":["BestTargetCorrFDR"],"name":[18],"type":["dbl"],"align":["right"]},{"label":["KnownTargetCorrFDR"],"name":[19],"type":["dbl"],"align":["right"]},{"label":["mutation_interaction_strength"],"name":[20],"type":["dbl"],"align":["right"]},{"label":["mutation_interaction_P"],"name":[21],"type":["dbl"],"align":["right"]},{"label":["predicted_resistance_mutation"],"name":[22],"type":["lgl"],"align":["right"]},{"label":["drugCategory"],"name":[23],"type":["fctr"],"align":["left"]}],"data":[{"1":"erlotinib","2":"EGFR","3":"0.426273","4":"40","5":"2","6":"K70401845","7":"FALSE","8":"1","9":"-0.113033","10":"0.3045463","11":"erlotinib","12":"EGFR","13":"0.426273","14":"5.11988e-17","15":"5.11988e-17","16":"4.452544","17":"Launched","18":"8.901424e-13","19":"8.901424e-13","20":"-0.0768605","21":"0.05344208","22":"TRUE","23":"targeted cancer","_rn_":"1218"},{"1":"erlotinib","2":"EGFR","3":"0.426273","4":"40","5":"2","6":"K70401845","7":"FALSE","8":"1","9":"-0.113033","10":"0.3045463","11":"erlotinib","12":"EGFR","13":"0.426273","14":"5.11988e-17","15":"5.11988e-17","16":"4.452544","17":"Launched","18":"8.901424e-13","19":"8.901424e-13","20":"-0.0768605","21":"0.05344208","22":"TRUE","23":"targeted cancer","_rn_":"1219"}],"options":{"columns":{"min":{},"max":[10],"total":[23]},"rows":{"min":[10],"max":[10],"total":[2]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Note 1: Please write a script to provide all the synonyms of a given Query_Drug -->
<!-- Check if the drug is in our screens and if yes, please provide drugID -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuaWYoaXMubmEoUXVlcnlfRHJ1Z0lEX21hdGNoZWQpKXsgcHJpbnQoJ1ByZXNlbnQgaW4gc2hhbGxvdyBzY3JlZW5zIG9ubHkob25lIGRvc2FnZSknKVxufSBlbHNleyBwcmludCgnUHJlc2VudCBpbiBvdXIgZGVlcCBzY3JlZW5zKG11bHRpcGxlIGRvc2FnZXMpJykgfVxuXG5gYGAifQ== -->
<pre class="r"><code>if(is.na(Query_DrugID_matched)){ print(&#39;Present in shallow screens only(one dosage)&#39;)
} else{ print(&#39;Present in our deep screens(multiple dosages)&#39;) }
</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIFwiUHJlc2VudCBpbiBvdXIgZGVlcCBzY3JlZW5zKG11bHRpcGxlIGRvc2FnZXMpXCJcbiJ9 -->
<pre><code>[1] &quot;Present in our deep screens(multiple dosages)&quot;</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Step 0: Find Lineages with greater than 20 cell lines -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxucGFzdGUocHJpbWFyeV9kaXNlYXNlV0RfZ3JlYXRlclRoYW5fMjBfY2VsbExpbmVzLCc7JyxcbiAgICAgIG1hdGNoZWRfcHJpbWFyeV9kaXNlYXNlX2ZyZXFbd2hpY2gobWF0Y2hlZF9wcmltYXJ5X2Rpc2Vhc2VfZnJlcT49MjApXSwgc2VwID0gJycpXG5cbmBgYCJ9 -->
<pre class="r"><code>paste(primary_diseaseWD_greaterThan_20_cellLines,&#39;;&#39;,
      matched_primary_disease_freq[which(matched_primary_disease_freq&gt;=20)], sep = &#39;&#39;)
</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIFwiQnJhaW4gQ2FuY2VyOzMwXCIgICAgICAgICAgICBcIkNvbG9uL0NvbG9yZWN0YWwgQ2FuY2VyOzIyXCIgXCJFc29waGFnZWFsIENhbmNlcjsyMlwiICAgICAgIFwiSGVhZCBhbmQgTmVjayBDYW5jZXI7MjBcIiAgIFxuWzVdIFwiTHVuZyBDYW5jZXI7NzdcIiAgICAgICAgICAgICBcIk92YXJpYW4gQ2FuY2VyOzI5XCIgICAgICAgICAgXCJQYW5jcmVhdGljIENhbmNlcjsyOVwiICAgICAgIFwiU2tpbiBDYW5jZXI7MzBcIiAgICAgICAgICAgIFxuIn0= -->
<pre><code>[1] &quot;Brain Cancer;30&quot;            &quot;Colon/Colorectal Cancer;22&quot; &quot;Esophageal Cancer;22&quot;       &quot;Head and Neck Cancer;20&quot;   
[5] &quot;Lung Cancer;77&quot;             &quot;Ovarian Cancer;29&quot;          &quot;Pancreatic Cancer;29&quot;       &quot;Skin Cancer;30&quot;            </code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Step 1: Function to compute Primary-target profile in lineages with greater than 20 cell lines -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>Find_cancer_specific_targetProfile &lt;- function(
    infunc_cancerType_of_interest=primary_diseaseWD_greaterThan_20_cellLines[1],
    infunc_drugBroadID=Query_DrugID_broadID){
  # Lineage of Interest is denoted with LOI
  cellLines_LOI= matched_cellLines[matched_primary_disease %in% infunc_cancerType_of_interest]
  drug_matched_subsettedLOI=drug_matched[infunc_drugBroadID,cellLines_LOI]
  avana_matched_subsettedLOI=avana_matched[,cellLines_LOI]
  avana_matched_subsettedLOI=avana_matched_subsettedLOI[,!is.na(drug_matched_subsettedLOI)]
  drug_matched_subsettedLOI=na.omit(drug_matched_subsettedLOI)
  Primarytarget_profile=apply(avana_matched_subsettedLOI, 1, function(x)
    unlist(cor.test_trimmed_v0(x, drug_matched_subsettedLOI))
    )
}</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Step 2: Call Function and preprocess results -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuUHJpbWFyeVRhcmdldF9Qcm9maWxlX2luRGlmZl9DYW5UeXBlcz1tY2xhcHBseShwcmltYXJ5X2Rpc2Vhc2VXRF9ncmVhdGVyVGhhbl8yMF9jZWxsTGluZXMsIGZ1bmN0aW9uKHgpXG4gIEZpbmRfY2FuY2VyX3NwZWNpZmljX3RhcmdldFByb2ZpbGUoaW5mdW5jX2NhbmNlclR5cGVfb2ZfaW50ZXJlc3Q9eCxcbiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICBpbmZ1bmNfZHJ1Z0Jyb2FkSUQ9UXVlcnlfRHJ1Z0lEX2Jyb2FkSUQpLFxuICBtYy5jb3JlcyA9IGRldGVjdENvcmVzKClcbiAgKVxuUHJpbWFyeVRhcmdldF9Qcm9maWxlX2luRGlmZl9DYW5UeXBlc19wcmVwPWxhcHBseShQcmltYXJ5VGFyZ2V0X1Byb2ZpbGVfaW5EaWZmX0NhblR5cGVzLCB0KVxubmFtZXMoUHJpbWFyeVRhcmdldF9Qcm9maWxlX2luRGlmZl9DYW5UeXBlc19wcmVwKT1wcmltYXJ5X2Rpc2Vhc2VXRF9ncmVhdGVyVGhhbl8yMF9jZWxsTGluZXNcbmBgYCJ9 -->
<pre class="r"><code>PrimaryTarget_Profile_inDiff_CanTypes=mclapply(primary_diseaseWD_greaterThan_20_cellLines, function(x)
  Find_cancer_specific_targetProfile(infunc_cancerType_of_interest=x,
                                     infunc_drugBroadID=Query_DrugID_broadID),
  mc.cores = detectCores()
  )
PrimaryTarget_Profile_inDiff_CanTypes_prep=lapply(PrimaryTarget_Profile_inDiff_CanTypes, t)
names(PrimaryTarget_Profile_inDiff_CanTypes_prep)=primary_diseaseWD_greaterThan_20_cellLines</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- See if drug specificity to its Target is more in approved cancer types vs non-aproved ones -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuc2FwcGx5KFByaW1hcnlUYXJnZXRfUHJvZmlsZV9pbkRpZmZfQ2FuVHlwZXNfcHJlcCwgZnVuY3Rpb24oeCkgeFtRdWVyeV9UYXJnZXQsMl0pXG5cbmBgYCJ9 -->
<pre class="r"><code>sapply(PrimaryTarget_Profile_inDiff_CanTypes_prep, function(x) x[Query_Target,2])
</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code>           Brain Cancer Colon/Colorectal Cancer       Esophageal Cancer    Head and Neck Cancer             Lung Cancer 
            -0.03264913              0.34417282              0.09426025              0.12524105              0.20010179 
         Ovarian Cancer       Pancreatic Cancer             Skin Cancer 
             0.57439712              0.45360164              0.24636750 </code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Identify all the drugs for our seven cancer types of interest -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-frame-begin {"metadata":{"classes":["data.frame"],"nrow":1509,"ncol":8,"summary":{"Description":["df [1,509 × 8]"]}},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["broad_id"],"name":[1],"type":["chr"],"align":["left"]},{"label":["name"],"name":[2],"type":["chr"],"align":["left"]},{"label":["moa"],"name":[3],"type":["chr"],"align":["left"]},{"label":["target"],"name":[4],"type":["chr"],"align":["left"]},{"label":["disease.area"],"name":[5],"type":["chr"],"align":["left"]},{"label":["indication"],"name":[6],"type":["chr"],"align":["left"]},{"label":["phase"],"name":[7],"type":["chr"],"align":["left"]},{"label":["indication_processed"],"name":[8],"type":["chr"],"align":["left"]}],"data":[{"1":"BRD-K36788280-001-01-2","2":"ribociclib","3":"CDK inhibitor","4":"CDK4, CDK6","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"1"},{"1":"BRD-K88510285-001-50-9","2":"bortezomib","3":"NFkB pathway inhibitor, proteasome inhibitor","4":"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA","5":"hematologic malignancy","6":"multiple myeloma, mantle cell lymphoma (MCL)","7":"Launched","8":"multiple myeloma, mantle cell lymphoma (MCL)","_rn_":"2"},{"1":"BRD-K99749624-001-07-0","2":"linifanib","3":"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3"},{"1":"BRD-K85402309-043-01-9","2":"dovitinib","3":"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"4"},{"1":"BRD-K50168500-001-07-9","2":"canertinib","3":"EGFR inhibitor","4":"AKT1, EGFR, ERBB2, ERBB4","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"5"},{"1":"BRD-K64881305-001-03-7","2":"ispinesib","3":"kinesin inhibitor","4":"KIF11","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"6"},{"1":"","2":"NA","3":"NA","4":"NA","5":"NA","6":"NA","7":"NA","8":"NA","_rn_":"8"},{"1":"BRD-K99113996-001-02-0","2":"AZD2014","3":"mTOR inhibitor","4":"MTOR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"11"},{"1":"BRD-K62391742-001-09-7","2":"venetoclax","3":"BCL inhibitor","4":"BCL2","5":"hematologic malignancy","6":"chronic lymphocytic leukemia (CLL)","7":"Launched","8":"chronic lymphocytic leukemia (CLL)","_rn_":"12"},{"1":"BRD-K87782578-001-01-4","2":"AVL-292","3":"Bruton's tyrosine kinase (BTK) inhibitor","4":"BTK, YES1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"13"},{"1":"BRD-K09951645-001-11-8","2":"dabrafenib","3":"RAF inhibitor","4":"BRAF, LIMK1, NEK11, RAF1, SIK1","5":"oncology","6":"melanoma","7":"Launched","8":"Skin Cancer","_rn_":"15"},{"1":"BRD-K03390685-001-01-7","2":"cobimetinib","3":"MEK inhibitor","4":"NA","5":"oncology","6":"melanoma","7":"Launched","8":"Skin Cancer","_rn_":"16"},{"1":"BRD-K22822991-001-02-3","2":"odanacatib","3":"cathepsin inhibitor","4":"CTSK","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19"},{"1":"BRD-K42828737-001-03-3","2":"sunitinib","3":"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","4":"CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET","5":"oncology","6":"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","7":"Launched","8":"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","_rn_":"20"},{"1":"BRD-K92723993-001-17-4","2":"imatinib","3":"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","4":"ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","5":"hematologic malignancy, oncology","6":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","7":"Launched","8":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","_rn_":"22"},{"1":"BRD-K38527262-300-01-0","2":"atiprimod","3":"JAK inhibitor, STAT inhibitor","4":"JAK2, STAT3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"24"},{"1":"BRD-K42495768-001-01-7","2":"tasisulam","3":"apoptosis stimulant","4":"NA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"26"},{"1":"BRD-K44408410-001-17-6","2":"2-methoxyestradiol","3":"hypoxia inducible factor inhibitor","4":"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"29"},{"1":"BRD-K53414658-001-08-2","2":"tivozanib","3":"VEGFR inhibitor","4":"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"31"},{"1":"BRD-K58529924-001-01-5","2":"ONC201","3":"AKT inhibitor, MAP kinase inhibitor","4":"TNFSF10","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"32"},{"1":"BRD-K81418486-001-44-2","2":"vorinostat","3":"HDAC inhibitor","4":"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9","5":"hematologic malignancy","6":"cutaneous T-cell lymphoma (CTCL)","7":"Launched","8":"cutaneous T-cell lymphoma (CTCL)","_rn_":"35"},{"1":"BRD-K31928526-001-02-1","2":"barasertib","3":"Aurora kinase inhibitor","4":"AURKA, AURKB","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"37"},{"1":"BRD-K43389675-001-02-1","2":"daunorubicin","3":"RNA synthesis inhibitor, topoisomerase inhibitor","4":"TOP2A, TOP2B","5":"hematologic malignancy","6":"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","7":"Launched","8":"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","_rn_":"38"},{"1":"BRD-K76239644-001-02-6","2":"BMS-690514","3":"EGFR inhibitor, VEGFR inhibitor","4":"EGFR, ERBB2, FLT3, KDR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"39"},{"1":"BRD-K08547377-001-04-4","2":"irinotecan","3":"topoisomerase inhibitor","4":"TOP1, TOP1MT","5":"oncology","6":"colorectal cancer","7":"Launched","8":"Colon/Colorectal Cancer","_rn_":"40"},{"1":"BRD-K82135108-001-04-3","2":"elesclomol","3":"oxidative stress inducer","4":"HSPA1A","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"43"},{"1":"BRD-K69001009-001-02-8","2":"golvatinib","3":"VEGFR inhibitor","4":"KDR, MET","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"44"},{"1":"BRD-K62200014-003-10-5","2":"anagrelide","3":"phosphodiesterase inhibitor","4":"PDE3A","5":"hematology, hematologic malignancy","6":"thrombocythemia, myeloproliferative neoplasms","7":"Launched","8":"thrombocythemia, myeloproliferative neoplasms","_rn_":"46"},{"1":"BRD-K05804044-001-18-5","2":"AZ-628","3":"RAF inhibitor","4":"BRAF, RAF1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"48"},{"1":"BRD-K03406345-001-21-1","2":"azacitidine","3":"DNA methyltransferase inhibitor","4":"DNMT1, DNMT3A","5":"hematologic malignancy, hematology","6":"myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","7":"Launched","8":"myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","_rn_":"51"},{"1":"BRD-K08703257-001-13-9","2":"3-amino-benzamide","3":"PARP inhibitor","4":"PARP1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"53"},{"1":"BRD-K46386702-001-02-1","2":"ARRY-334543","3":"EGFR inhibitor","4":"ERBB2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"55"},{"1":"BRD-K54955827-001-02-2","2":"niraparib","3":"PARP inhibitor","4":"PARP1","5":"oncology","6":"primary peritoneal cancer (PPC)","7":"Launched","8":"primary peritoneal cancer (PPC)","_rn_":"59"},{"1":"BRD-K23984367-001-07-5","2":"sorafenib","3":"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","4":"BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET","5":"oncology","6":"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","7":"Launched","8":"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","_rn_":"64"},{"1":"BRD-K29905972-001-06-3","2":"axitinib","3":"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"CSF1, FLT1, FLT4, KDR, PLK4","5":"oncology","6":"renal cell carcinoma (RCC)","7":"Launched","8":"renal cell carcinoma (RCC)","_rn_":"67"},{"1":"BRD-K56981171-001-02-8","2":"brigatinib","3":"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","4":"ALK, EGFR","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"74"},{"1":"BRD-M97302542-001-04-4","2":"dichloroacetate","3":"pyruvate dehydrogenase kinase inhibitor","4":"PDK1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"91"},{"1":"BRD-K76210423-001-01-6","2":"resiquimod","3":"toll-like receptor agonist","4":"TLR7, TLR8","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"102"},{"1":"BRD-K17610631-001-03-3","2":"indisulam","3":"CDK inhibitor","4":"CA1, CA12, CA14, CA2, CA6, CA7, CA9","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"103"},{"1":"BRD-K86118762-001-01-8","2":"linsitinib","3":"IGF-1 inhibitor","4":"IGF1R, INSR, INSRR","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1079"},{"1":"BRD-K06814349-304-02-7","2":"fosbretabulin","3":"tubulin polymerization inhibitor, VE-cadherin antagonist","4":"CDH5","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1081"},{"1":"BRD-K08799216-001-05-3","2":"pelitinib","3":"EGFR inhibitor","4":"EGFR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1082"},{"1":"BRD-K13049116-001-04-0","2":"BMS-754807","3":"IGF-1 inhibitor","4":"AKT1, IGF1R","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1083"},{"1":"BRD-K63504947-001-14-7","2":"semaxanib","3":"VEGFR inhibitor","4":"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1084"},{"1":"BRD-K02130563-001-11-4","2":"panobinostat","3":"HDAC inhibitor","4":"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9","5":"hematologic malignancy","6":"multiple myeloma","7":"Launched","8":"multiple myeloma","_rn_":"1085"},{"1":"BRD-K87909389-003-03-4","2":"alvocidib","3":"CDK inhibitor","4":"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1090"},{"1":"BRD-K08109215-001-06-4","2":"I-BET-762","3":"bromodomain inhibitor","4":"BRD2, BRD3, BRD4","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1091"},{"1":"BRD-K77625799-001-07-7","2":"vandetanib","3":"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","4":"EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA","5":"oncology","6":"medullary thyroid cancer (MTC)","7":"Launched","8":"medullary thyroid cancer (MTC)","_rn_":"1092"},{"1":"BRD-K28822270-001-03-7","2":"resminostat","3":"HDAC inhibitor","4":"HDAC1, HDAC3, HDAC6, HDAC8","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1096"},{"1":"BRD-K54997624-001-06-0","2":"alpelisib","3":"PI3K inhibitor","4":"PIK3CA, PIK3CB, PIK3CD, PIK3CG","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1098"},{"1":"BRD-K82746043-001-19-3","2":"navitoclax","3":"BCL inhibitor","4":"BCL2, BCL2L1, BCL2L2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1100"},{"1":"BRD-K96123349-236-02-8","2":"brequinar","3":"dihydroorotate dehydrogenase inhibitor","4":"DHODH","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1102"},{"1":"BRD-K57080016-001-15-9","2":"selumetinib","3":"MEK inhibitor","4":"MAP2K1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1106"},{"1":"BRD-K33610132-001-02-9","2":"rociletinib","3":"EGFR inhibitor","4":"EGFR","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1108"},{"1":"BRD-K35520305-001-16-9","2":"dacarbazine","3":"DNA alkylating agent","4":"PGD, POLA2","5":"oncology, hematologic malignancy","6":"melanoma, Hodgkin's lymphoma","7":"Launched","8":"Skin Cancer, Hodgkin's lymphoma","_rn_":"1109"},{"1":"BRD-K58435339-001-03-0","2":"AT13387","3":"HSP antagonist","4":"HSP90AA1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1112"},{"1":"BRD-K57169635-001-04-5","2":"dacomitinib","3":"EGFR inhibitor","4":"EGFR, ERBB2, ERBB4","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1113"},{"1":"BRD-K76908866-001-07-6","2":"CP-724714","3":"EGFR inhibitor, protein tyrosine kinase inhibitor","4":"ERBB2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1115"},{"1":"BRD-K17894950-001-14-3","2":"indirubin","3":"CDK inhibitor, glycogen synthase kinase inhibitor","4":"CDK1, CDK5, GSK3A","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"1118"},{"1":"BRD-K87737963-001-06-0","2":"cyt387","3":"NA","4":"JAK1, JAK2, JAK3","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1119"},{"1":"BRD-K18961567-001-01-1","2":"LY2801653","3":"MET inhibitor","4":"MET","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1121"},{"1":"BRD-K64052750-001-22-5","2":"gefitinib","3":"EGFR inhibitor","4":"EGFR","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"1126"},{"1":"BRD-K49350383-001-14-5","2":"thioguanine","3":"purine antagonist","4":"IMPDH1, IMPDH2","5":"hematologic malignancy","6":"acute myeloid leukemia (AML)","7":"Launched","8":"acute myeloid leukemia (AML)","_rn_":"1128"},{"1":"BRD-K03765900-001-01-9","2":"XL-647","3":"EGFR inhibitor, VEGFR inhibitor","4":"EGFR, EPHB4, ERBB2, FLT4, KDR","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1130"},{"1":"BRD-K38332599-001-01-3","2":"uprosertib","3":"AKT inhibitor","4":"AKT1, AKT2, AKT3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1138"},{"1":"BRD-K69694239-001-02-2","2":"bardoxolone-methyl","3":"nuclear factor erythroid derived, like (NRF2) activator","4":"PPARG, STAT3","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1158"},{"1":"BRD-K17555800-003-02-3","2":"talmapimod","3":"p38 MAPK inhibitor","4":"MAPK11, MAPK14","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1169"},{"1":"BRD-K98572433-001-02-9","2":"AZD8931","3":"EGFR inhibitor","4":"EGFR, ERBB2, ERBB3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1170"},{"1":"BRD-K61192372-001-08-9","2":"capecitabine","3":"DNA synthesis inhibitor, thymidylate synthase inhibitor","4":"TYMS","5":"oncology","6":"breast cancer, colorectal cancer","7":"Launched","8":"breast cancer, Colon/Colorectal Cancer","_rn_":"2002"},{"1":"BRD-K76674262-001-03-3","2":"homoharringtonine","3":"protein synthesis inhibitor","4":"RPL3","5":"hematologic malignancy","6":"chronic myeloid leukemia (CML)","7":"Launched","8":"chronic myeloid leukemia (CML)","_rn_":"2004"},{"1":"BRD-K53972329-001-07-0","2":"ruxolitinib","3":"JAK inhibitor","4":"JAK1, JAK2, JAK3, TYK2","5":"hematologic malignancy, hematology","6":"myelofibrosis, polycythemia vera","7":"Launched","8":"myelofibrosis, polycythemia vera","_rn_":"2005"},{"1":"BRD-K42805893-001-04-9","2":"osimertinib","3":"EGFR inhibitor","4":"EGFR","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"2010"},{"1":"BRD-K92441787-001-04-1","2":"bexarotene","3":"retinoid receptor agonist","4":"RXRA, RXRB, RXRG","5":"hematologic malignancy","6":"cutaneous T-cell lymphoma (CTCL)","7":"Launched","8":"cutaneous T-cell lymphoma (CTCL)","_rn_":"2011"},{"1":"BRD-K60866521-001-07-1","2":"idelalisib","3":"PI3K inhibitor","4":"PIK3CA, PIK3CB, PIK3CD, PIK3CG","5":"hematologic malignancy","6":"chronic lymphocytic leukemia (CLL)","7":"Launched","8":"chronic lymphocytic leukemia (CLL)","_rn_":"2012"},{"1":"BRD-K82818427-001-04-8","2":"batimastat","3":"matrix metalloprotease inhibitor","4":"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"2013"},{"1":"BRD-K62627508-001-01-5","2":"idasanutlin","3":"MDM inhibitor","4":"MDM2, TP53","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"2016"},{"1":"BRD-A25234499-001-19-1","2":"aminoglutethimide","3":"glucocorticoid receptor antagonist","4":"CYP11A1, CYP19A1","5":"endocrinology, oncology","6":"Cushing's syndrome, breast cancer","7":"Launched","8":"Cushing's syndrome, breast cancer","_rn_":"2017"},{"1":"BRD-K39974922-001-04-3","2":"lenvatinib","3":"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"FLT4, KDR","5":"oncology","6":"thyroid cancer","7":"Launched","8":"thyroid cancer","_rn_":"2019"},{"1":"BRD-K17743125-001-08-4","2":"belinostat","3":"HDAC inhibitor","4":"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9","5":"hematologic malignancy","6":"peripheral T-cell lymphoma (PTCL)","7":"Launched","8":"peripheral T-cell lymphoma (PTCL)","_rn_":"2020"},{"1":"BRD-K51313569-001-07-8","2":"palbociclib","3":"CDK inhibitor","4":"CDK4, CDK6","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"2023"},{"1":"BRD-K15179879-001-03-2","2":"carfilzomib","3":"proteasome inhibitor","4":"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9","5":"hematologic malignancy","6":"multiple myeloma","7":"Launched","8":"multiple myeloma","_rn_":"2027"},{"1":"BRD-K12343256-001-14-7","2":"trametinib","3":"MEK inhibitor","4":"MAP2K1, MAP2K2","5":"oncology","6":"melanoma","7":"Launched","8":"Skin Cancer","_rn_":"2029"},{"1":"BRD-K67844266-003-01-9","2":"pevonedistat","3":"nedd activating enzyme inhibitor","4":"NAE1, UBA3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2031"},{"1":"BRD-K95142244-001-01-5","2":"talazoparib","3":"PARP inhibitor","4":"PARP2","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"2032"},{"1":"BRD-K26657438-001-15-2","2":"imiquimod","3":"interferon inducer, toll-like receptor agonist","4":"TLR7, TLR8","5":"dermatology, infectious disease, oncology","6":"actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","7":"Launched","8":"actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","_rn_":"2033"},{"1":"BRD-K50010139-001-01-5","2":"poziotinib","3":"EGFR inhibitor","4":"EGFR, ERBB2, ERBB4","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2034"},{"1":"BRD-A70858459-001-01-7","2":"estramustine","3":"DNA alkylating agent","4":"ESR1, ESR2, MAP1A, MAP2","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"2036"},{"1":"BRD-K70301465-001-05-9","2":"ibrutinib","3":"Bruton's tyrosine kinase (BTK) inhibitor","4":"BLK, BMX, BTK","5":"hematologic malignancy","6":"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","7":"Launched","8":"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","_rn_":"2039"},{"1":"BRD-K13514097-001-04-6","2":"everolimus","3":"mTOR inhibitor","4":"MTOR","5":"oncology, neurology/psychiatry, genetics, urology","6":"breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","7":"Launched","8":"breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","_rn_":"2040"},{"1":"BRD-K11267252-001-05-1","2":"alectinib","3":"ALK tyrosine kinase receptor inhibitor","4":"ALK, MET","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"2041"},{"1":"BRD-K44227013-001-06-4","2":"ponatinib","3":"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","4":"ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK","5":"hematologic malignancy","6":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","7":"Launched","8":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","_rn_":"2044"},{"1":"BRD-K73838513-003-05-5","2":"cinacalcet","3":"calcium channel activator","4":"CASR","5":"endocrinology, nephrology, oncology","6":"hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia","7":"Launched","8":"hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia","_rn_":"2047"},{"1":"BRD-K31698212-001-02-9","2":"icotinib","3":"EGFR inhibitor","4":"EGFR","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"2049"},{"1":"BRD-K59369769-001-22-9","2":"tozasertib","3":"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","4":"AURKA, AURKB, AURKC, LCK","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2053"},{"1":"BRD-K33622447-066-01-9","2":"abemaciclib","3":"CDK inhibitor","4":"CDK4, CDK6","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"2058"},{"1":"BRD-K66175015-001-12-4","2":"afatinib","3":"EGFR inhibitor","4":"EGFR, ERBB2, ERBB4","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"2060"},{"1":"BRD-K44827188-001-06-0","2":"vismodegib","3":"hedgehog pathway inhibitor, smoothened receptor antagonist","4":"SMO","5":"oncology","6":"basal cell carcinoma (BCC)","7":"Launched","8":"basal cell carcinoma (BCC)","_rn_":"2067"},{"1":"BRD-K70401845-001-15-7","2":"erlotinib","3":"EGFR inhibitor","4":"EGFR, NR1I2","5":"oncology","6":"non-small cell lung cancer (NSCLC), pancreatic cancer","7":"Launched","8":"Lung Cancer, pancreatic cancer","_rn_":"2085"},{"1":"BRD-K69776681-001-03-8","2":"volasertib","3":"PLK inhibitor","4":"PLK1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"2095"},{"1":"BRD-K13390322-001-06-3","2":"AT-7519","3":"CDK inhibitor","4":"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2985"},{"1":"BRD-K12184916-001-19-6","2":"NVP-BEZ235","3":"mTOR inhibitor, PI3K inhibitor","4":"ATR, MTOR, PIK3CA, PIK3CD, PIK3CG","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2987"},{"1":"BRD-K23228615-001-02-8","2":"GDC-0980","3":"mTOR inhibitor, PI3K inhibitor","4":"FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2988"},{"1":"BRD-K03449891-001-08-6","2":"foretinib","3":"VEGFR inhibitor","4":"FLT1, FLT4, KDR, MET","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2989"},{"1":"BRD-K51791723-003-01-7","2":"P276-00","3":"CDK inhibitor","4":"CDK1, CDK4, CDK9","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2994"},{"1":"BRD-K33379087-001-07-5","2":"tivantinib","3":"tyrosine kinase inhibitor","4":"MET","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"2995"},{"1":"BRD-K75009076-001-02-1","2":"SCH-900776","3":"CHK inhibitor","4":"CDK2, CHEK1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2996"},{"1":"BRD-K52313696-001-12-3","2":"tacedinaline","3":"HDAC inhibitor","4":"HDAC1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"2998"},{"1":"BRD-K26026438-001-01-0","2":"tucatinib","3":"EGFR inhibitor","4":"ERBB2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2999"},{"1":"BRD-K55187425-236-05-2","2":"rigosertib","3":"cell cycle inhibitor, PLK inhibitor","4":"PLK1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3001"},{"1":"BRD-K85606544-001-09-1","2":"neratinib","3":"EGFR inhibitor","4":"EGFR, ERBB2, KDR","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3004"},{"1":"BRD-K78431006-001-15-1","2":"crizotinib","3":"ALK tyrosine kinase receptor inhibitor","4":"ALK, MET","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"3005"},{"1":"BRD-K62196610-001-01-6","2":"AVN-944","3":"inosine monophosphate dehydrogenase inhibitor","4":"IMPDH1, IMPDH2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3007"},{"1":"BRD-K11630072-001-13-2","2":"carmofur","3":"thymidylate synthase inhibitor","4":"TYMS","5":"oncology","6":"breast cancer, colorectal cancer","7":"Launched","8":"breast cancer, Colon/Colorectal Cancer","_rn_":"3008"},{"1":"BRD-K54256913-001-08-7","2":"MK-1775","3":"WEE1 kinase inhibitor","4":"WEE1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3011"},{"1":"BRD-K81016934-001-02-0","2":"INC-280","3":"c-Met inhibitor","4":"MET","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3013"},{"1":"BRD-K16730910-001-10-7","2":"regorafenib","3":"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","4":"ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK","5":"oncology","6":"colorectal cancer, gastrointestinal stromal tumors (GIST)","7":"Launched","8":"Colon/Colorectal Cancer, gastrointestinal stromal tumors (GIST)","_rn_":"3014"},{"1":"BRD-K19796430-001-05-6","2":"sonidegib","3":"smoothened receptor antagonist","4":"SMO","5":"oncology","6":"basal cell carcinoma (BCC)","7":"Launched","8":"basal cell carcinoma (BCC)","_rn_":"3017"},{"1":"BRD-K14109347-001-03-4","2":"LY2603618","3":"CHK inhibitor","4":"CHEK1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3019"},{"1":"BRD-K19540840-001-09-4","2":"saracatinib","3":"src inhibitor","4":"ABL1, LCK, SRC, YES1","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"3020"},{"1":"BRD-K15600710-066-05-8","2":"obatoclax","3":"BCL inhibitor","4":"BCL2","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3021"},{"1":"BRD-K19687926-001-04-1","2":"lapatinib","3":"EGFR inhibitor","4":"EGFR, ERBB2","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"3023"},{"1":"BRD-K89014967-001-04-3","2":"AS-703026","3":"MEK inhibitor","4":"MAP2K1, MAP2K2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3027"},{"1":"BRD-K79254416-001-21-8","2":"decitabine","3":"DNA methyltransferase inhibitor","4":"DNMT1, DNMT3A","5":"hematologic malignancy, hematology","6":"myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","7":"Launched","8":"myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","_rn_":"3029"},{"1":"BRD-K74514084-003-09-2","2":"pazopanib","3":"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3","5":"oncology","6":"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","7":"Launched","8":"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","_rn_":"3032"},{"1":"BRD-K02113016-001-19-6","2":"olaparib","3":"PARP inhibitor","4":"PARP1, PARP2","5":"oncology","6":"ovarian cancer","7":"Launched","8":"ovarian cancer","_rn_":"3035"},{"1":"BRD-K59317601-001-05-5","2":"MLN0128","3":"mTOR inhibitor","4":"MTOR, PIK3CA, PIK3CD, PIK3CG","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3038"},{"1":"BRD-K60997853-001-02-3","2":"PHA-848125","3":"CDK inhibitor, growth factor receptor inhibitor","4":"CDK2, CDK4, CDK7, NTRK1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3042"},{"1":"BRD-K51967704-001-03-6","2":"BIIB021","3":"HSP inhibitor","4":"HSP90AA1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3046"},{"1":"BRD-K22064724-001-01-8","2":"napabucasin","3":"STAT inhibitor","4":"STAT3","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3053"},{"1":"BRD-K56343971-001-14-8","2":"vemurafenib","3":"RAF inhibitor","4":"BRAF, RAF1","5":"oncology","6":"melanoma","7":"Launched","8":"Skin Cancer","_rn_":"3078"},{"1":"BRD-K36627727-001-05-4","2":"tamibarotene","3":"retinoid receptor agonist","4":"RARA, RARB","5":"hematologic malignancy","6":"acute promyelocytic leukemia (APL)","7":"Launched","8":"acute promyelocytic leukemia (APL)","_rn_":"3970"},{"1":"BRD-K86972824-001-01-4","2":"oltipraz","3":"nuclear factor erythroid derived, like (NRF2) activator","4":"ANG","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3971"},{"1":"BRD-K41859756-001-06-8","2":"NVP-AUY922","3":"HSP inhibitor","4":"HSP90AA1, HSP90AB1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3972"},{"1":"BRD-K83988098-001-02-0","2":"alvespimycin","3":"HSP inhibitor","4":"HSP90AA1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3976"},{"1":"BRD-K99616396-001-05-1","2":"motesanib","3":"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"FLT1, FLT4, KDR, KIT","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3980"},{"1":"BRD-K63712959-001-01-8","2":"temoporfin","3":"radical formation stimulant","4":"NA","5":"oncology","6":"head and neck squamous cell carcinoma (HNSCC)","7":"Launched","8":"Head and Neck Cancer","_rn_":"3982"},{"1":"BRD-K13662825-001-07-5","2":"dinaciclib","3":"CDK inhibitor","4":"CDK1, CDK2, CDK5, CDK9","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3984"},{"1":"BRD-K49328571-001-15-0","2":"dasatinib","3":"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","4":"ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1","5":"hematologic malignancy","6":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","7":"Launched","8":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","_rn_":"3986"},{"1":"BRD-K83029223-001-01-3","2":"litronesib","3":"kinesin-like spindle protein inhibitor","4":"KIF11","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3987"},{"1":"BRD-K42898655-001-01-8","2":"temsirolimus","3":"mTOR inhibitor","4":"MTOR","5":"oncology","6":"renal cell carcinoma (RCC)","7":"Launched","8":"renal cell carcinoma (RCC)","_rn_":"3989"},{"1":"BRD-K08542803-001-02-3","2":"gambogic-acid","3":"caspase activator","4":"BCL2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3990"},{"1":"BRD-K37379014-001-02-0","2":"filanesib","3":"kinesin inhibitor, kinesin-like spindle protein inhibitor","4":"KIF11","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3991"},{"1":"BRD-K81473043-001-19-5","2":"tanespimycin","3":"HSP inhibitor","4":"HSP90AA1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3992"},{"1":"BRD-A74914197-001-02-9","2":"pralatrexate","3":"dihydrofolate reductase inhibitor","4":"DHFR, TYMS","5":"hematologic malignancy","6":"peripheral T-cell lymphoma (PTCL)","7":"Launched","8":"peripheral T-cell lymphoma (PTCL)","_rn_":"3997"},{"1":"BRD-K62008436-001-23-9","2":"paclitaxel","3":"tubulin polymerization inhibitor","4":"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1","5":"oncology","6":"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","7":"Launched","8":"ovarian cancer, breast cancer, Lung Cancer","_rn_":"4001"},{"1":"BRD-K38852836-001-02-1","2":"ganetespib","3":"HSP inhibitor","4":"HSP90AA1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"4004"},{"1":"BRD-K30577245-001-05-0","2":"docetaxel","3":"tubulin polymerization inhibitor","4":"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1","5":"oncology","6":"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","7":"Launched","8":"breast cancer, Lung Cancer, prostate cancer, gastric adenocarcinoma, Head and Neck Cancer","_rn_":"4005"},{"1":"BRD-K58550667-001-08-7","2":"FK-866","3":"niacinamide phosphoribosyltransferase inhibitor","4":"NAMPT","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"4025"},{"1":"BRD-K88510285-001-17-8","2":"bortezomib","3":"NFkB pathway inhibitor, proteasome inhibitor","4":"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA","5":"hematologic malignancy","6":"multiple myeloma, mantle cell lymphoma (MCL)","7":"Launched","8":"multiple myeloma, mantle cell lymphoma (MCL)","_rn_":"4026"},{"1":"BRD-K60230970-001-14-2","2":"MG-132","3":"proteasome inhibitor","4":"PSMB1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4664"},{"1":"NA","2":"NA","3":"NA","4":"NA","5":"NA","6":"NA","7":"NA","8":"NA","_rn_":"4665"},{"1":"BRD-K71847383-001-12-5","2":"cytarabine","3":"ribonucleotide reductase inhibitor","4":"POLA1, POLB, POLD1, POLE","5":"hematologic malignancy","6":"acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)","7":"Launched","8":"acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)","_rn_":"4666"},{"1":"BRD-A98990573-003-01-3","2":"epinastine","3":"histamine receptor antagonist","4":"ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7","5":"ophthalmology","6":"conjunctivitis","7":"Launched","8":"conjunctivitis","_rn_":"4668"},{"1":"BRD-K47832606-001-30-1","2":"floxuridine","3":"DNA synthesis inhibitor","4":"TYMS","5":"oncology","6":"colorectal cancer","7":"Launched","8":"Colon/Colorectal Cancer","_rn_":"4670"},{"1":"BRD-K72951360-001-01-4","2":"valrubicin","3":"DNA inhibitor, topoisomerase inhibitor","4":"TOP2A","5":"oncology","6":"bladder cancer","7":"Launched","8":"bladder cancer","_rn_":"4672"},{"1":"BRD-K33127281-001-05-6","2":"adapalene","3":"retinoid receptor agonist","4":"RARA, RARB, RARG, RXRA, RXRB, RXRG","5":"dermatology","6":"acne vulgaris (AV)","7":"Launched","8":"acne vulgaris (AV)","_rn_":"4674"},{"1":"BRD-K88510285-001-22-8","2":"bortezomib","3":"NFkB pathway inhibitor, proteasome inhibitor","4":"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA","5":"hematologic malignancy","6":"multiple myeloma, mantle cell lymphoma (MCL)","7":"Launched","8":"multiple myeloma, mantle cell lymphoma (MCL)","_rn_":"4686"},{"1":"BRD-K19388745-003-01-7","2":"colforsin-daproate","3":"adenylyl cyclase activator","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"4714"},{"1":"BRD-K11640013-236-10-1","2":"sulfamethazine","3":"PABA antagonist","4":"NA","5":"gastroenterology","6":"enteritis, enteritis","7":"Launched","8":"enteritis, enteritis","_rn_":"4716"},{"1":"BRD-K53123955-001-10-5","2":"niridazole","3":"phosphofructokinase inhibitor","4":"NA","5":"infectious disease","6":"schistosomiasis","7":"Launched","8":"schistosomiasis","_rn_":"4718"},{"1":"BRD-K90027121-003-01-7","2":"amprolium","3":"thiamine uptake blocker","4":"NA","5":"infectious disease","6":"coccidiosis","7":"Launched","8":"coccidiosis","_rn_":"4720"},{"1":"BRD-A19585813-003-03-3","2":"methylphenidate","3":"dopamine-norepinephrine reuptake inhibitor","4":"SLC6A2, SLC6A3, SLC6A4","5":"neurology/psychiatry","6":"attention-deficit/hyperactivity disorder (ADHD), narcolepsy","7":"Launched","8":"attention-deficit/hyperactivity disorder (ADHD), narcolepsy","_rn_":"4722"},{"1":"BRD-A85667082-001-12-7","2":"fulvestrant","3":"estrogen receptor antagonist","4":"ESR1, ESR2, GPER1","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"4762"},{"1":"BRD-K00077635-304-01-2","2":"estramustine-phosphate","3":"DNA synthesis inhibitor, microtubule inhibitor","4":"ESR1, ESR2, MAP1A, MAP2","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"4764"},{"1":"BRD-K71035033-001-07-1","2":"masitinib","3":"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor","4":"FGFR3, KIT, PDGFRA, PDGFRB","5":"dermatology","6":"mastocytoma","7":"Launched","8":"mastocytoma","_rn_":"4766"},{"1":"BRD-K07220430-001-18-4","2":"cinnarazine","3":"calcium channel blocker","4":"NA","5":"neurology/psychiatry, gastroenterology, ophthalmology","6":"Meniere's disease, nausea, vomiting, Cogan's syndrome","7":"Launched","8":"Meniere's disease, nausea, vomiting, Cogan's syndrome","_rn_":"4768"},{"1":"BRD-K61397605-001-03-4","2":"romidepsin","3":"HDAC inhibitor","4":"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9","5":"hematologic malignancy","6":"cutaneous T-cell lymphoma (CTCL)","7":"Launched","8":"cutaneous T-cell lymphoma (CTCL)","_rn_":"4810"},{"1":"BRD-A71725768-001-01-3","2":"metoxibutropate","3":"cyclooxygenase inhibitor","4":"PTGS1, PTGS2","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"4812"},{"1":"BRD-K62213621-001-01-6","2":"dihydroartemisinin","3":"antimalarial agent","4":"NA","5":"infectious disease","6":"malaria","7":"Launched","8":"malaria","_rn_":"4814"},{"1":"BRD-A14240607-003-26-1","2":"octopamine","3":"trace amine associated receptor agonist","4":"F10, TAAR1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4816"},{"1":"BRD-K68997413-001-05-1","2":"PF-3845","3":"FAAH inhibitor","4":"FAAH","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4818"},{"1":"BRD-K01773560-001-02-4","2":"UNC2250","3":"MER tyrosine kinase inhibitor","4":"MERTK","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4858"},{"1":"BRD-K44067360-001-30-3","2":"flufenamic-acid","3":"chloride channel blocker","4":"AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4860"},{"1":"BRD-A28970875-300-04-9","2":"puromycin","3":"protein synthesis inhibitor","4":"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4862"},{"1":"BRD-K24593301-001-02-3","2":"AZD3463","3":"ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor","4":"ALK, IGF1R","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4864"},{"1":"BRD-K00535541-001-06-3","2":"9-aminoacridine","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4866"},{"1":"BRD-K35329391-334-01-7","2":"GZD824","3":"Bcr-Abl kinase inhibitor","4":"ABL1, BCR","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4906"},{"1":"BRD-K94485812-001-02-9","2":"LDN-57444","3":"ubiquitin C-terminal hydrolase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4908"},{"1":"BRD-K36055864-001-19-2","2":"cycloheximide","3":"protein synthesis inhibitor","4":"RPL3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4910"},{"1":"BRD-K49759007-001-11-9","2":"4-hydroxy-phenazone","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4912"},{"1":"BRD-K14329163-001-03-9","2":"BAY-K-8644-(s)-(-)","3":"L-type calcium channel activator","4":"CACNA1C","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4914"},{"1":"BRD-K00615600-001-12-9","2":"AG-14361","3":"PARP inhibitor","4":"PARP1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4954"},{"1":"BRD-K61688984-001-02-9","2":"RGFP966","3":"HDAC inhibitor","4":"HDAC3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4956"},{"1":"BRD-K99170882-001-04-3","2":"NSC-319726","3":"p53 activator","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4958"},{"1":"BRD-K28570407-001-02-0","2":"A-803467","3":"sodium channel blocker","4":"SCN10A","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4960"},{"1":"BRD-K60446698-001-01-2","2":"ONX-0914","3":"proteasome inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4962"},{"1":"BRD-K28453807-003-11-2","2":"nitrocaramiphen","3":"cholinergic receptor antagonist","4":"CHRM1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5002"},{"1":"BRD-K26824830-001-02-0","2":"azomycin-(2-nitroimidazole)","3":"protein synthesis inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5004"},{"1":"BRD-K64888243-001-03-7","2":"AZ960","3":"JAK inhibitor","4":"JAK2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5006"},{"1":"BRD-K29173907-001-09-2","2":"isoflupredone-acetate","3":"NA","4":"NR3C1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5008"},{"1":"BRD-K97365803-001-02-1","2":"PI-828","3":"PI3K inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5010"},{"1":"BRD-A57833392-001-01-7","2":"oxymatrine","3":"NA","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"5763"},{"1":"BRD-K51471001-303-04-7","2":"demecarium","3":"acetylcholinesterase inhibitor","4":"ACHE, BCHE","5":"ophthalmology","6":"intraocular pressure, glaucoma","7":"Launched","8":"intraocular pressure, glaucoma","_rn_":"5765"},{"1":"BRD-K92093830-003-30-8","2":"doxorubicin","3":"topoisomerase inhibitor","4":"TOP2A","5":"hematologic malignancy, oncology","6":"acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma","7":"Launched","8":"acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma","_rn_":"5767"},{"1":"BRD-K88510285-001-11-1","2":"bortezomib","3":"NFkB pathway inhibitor, proteasome inhibitor","4":"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA","5":"hematologic malignancy","6":"multiple myeloma, mantle cell lymphoma (MCL)","7":"Launched","8":"multiple myeloma, mantle cell lymphoma (MCL)","_rn_":"5769"},{"1":"BRD-K37249724-001-25-7","2":"astemizole","3":"histamine receptor antagonist","4":"HRH1, KCNH1, KCNH2","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"5771"},{"1":"BRD-K03601870-001-01-2","2":"ixabepilone","3":"microtubule stabilizing agent","4":"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"5812"},{"1":"BRD-K32821942-001-21-3","2":"azathioprine","3":"dehydrogenase inhibitor","4":"HPRT1, IMPDH1, PPAT","5":"transplant, rheumatology","6":"renal homotransplantation, rheumatoid arthritis","7":"Launched","8":"renal homotransplantation, rheumatoid arthritis","_rn_":"5814"},{"1":"BRD-K32744045-001-31-2","2":"disulfiram","3":"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","4":"ALDH2, DBH","5":"neurology/psychiatry","6":"abstinence from alcohol","7":"Launched","8":"abstinence from alcohol","_rn_":"5816"},{"1":"BRD-K31627533-001-09-5","2":"rimexolone","3":"glucocorticoid receptor agonist","4":"NR3C1, SERPINA6","5":"ophthalmology","6":"anterior uveitis","7":"Launched","8":"anterior uveitis","_rn_":"5818"},{"1":"BRD-A55913614-316-09-6","2":"primaquine","3":"antimalarial agent, DNA inhibitor","4":"KRT7, NQO2","5":"infectious disease","6":"malaria","7":"Launched","8":"malaria","_rn_":"5857"},{"1":"BRD-A57382968-001-29-0","2":"piroxicam","3":"cyclooxygenase inhibitor","4":"PTGS1, PTGS2","5":"rheumatology","6":"osteoarthritis, rheumatoid arthritis","7":"Launched","8":"osteoarthritis, rheumatoid arthritis","_rn_":"5861"},{"1":"BRD-K59632282-052-03-1","2":"quinidine","3":"sodium channel blocker","4":"KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4","5":"infectious disease, cardiology","6":"malaria, atrial fibrillation (AF), ventricular arrhythmias","7":"Launched","8":"malaria, atrial fibrillation (AF), ventricular arrhythmias","_rn_":"5863"},{"1":"BRD-K59436580-001-01-7","2":"tedizolid","3":"bacterial 50S ribosomal subunit inhibitor","4":"NA","5":"infectious disease","6":"skin infections","7":"Launched","8":"skin infections","_rn_":"5865"},{"1":"BRD-K20655524-003-12-0","2":"mefexamide","3":"psychoactive drug","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5905"},{"1":"BRD-K31468676-237-01-8","2":"oxonic-acid","3":"uricase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5907"},{"1":"BRD-A11551002-001-04-6","2":"dehydrocholate-acid","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5909"},{"1":"BRD-K04430056-236-02-1","2":"7-nitroindazole","3":"nitric oxide synthase inhibitor","4":"NOS1, NOS2, NOS3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5911"},{"1":"BRD-K00317371-001-06-1","2":"RITA","3":"MDM inhibitor","4":"MDM2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5913"},{"1":"BRD-K66715657-050-01-0","2":"UH-232-(+)","3":"dopamine receptor antagonist","4":"DRD2, DRD3, DRD4, HTR1A","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5952"},{"1":"BRD-K47150025-001-05-3","2":"KI-8751","3":"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"KDR","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5954"},{"1":"BRD-K09132007-001-07-5","2":"D-4476","3":"TGF beta receptor inhibitor","4":"CSNK1A1, CSNK1D, TGFB1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5956"},{"1":"BRD-K09900591-001-26-7","2":"caffeic-acid","3":"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor","4":"ALOX5, MIF","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5958"},{"1":"BRD-A12230535-001-06-7","2":"nutlin-3","3":"MDM inhibitor","4":"MDM2, TP53","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5960"},{"1":"BRD-K28360340-001-08-3","2":"TW-37","3":"BCL inhibitor","4":"BCL2, BCL2L1, MCL1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5999"},{"1":"BRD-K44665581-001-01-8","2":"bromosporine","3":"bromodomain inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6001"},{"1":"BRD-K26531771-001-02-2","2":"EPZ-5676","3":"histone lysine methyltransferase inhibitor","4":"DOT1L","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"6003"},{"1":"BRD-A44500574-001-01-8","2":"FLI-06","3":"notch signaling inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6005"},{"1":"BRD-K87112191-001-04-5","2":"PP242","3":"mTOR inhibitor","4":"MTOR, PASK","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6007"},{"1":"BRD-A74765037-001-01-1","2":"estradiol-benzoate","3":"contraceptive agent","4":"ESR1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6047"},{"1":"BRD-K30990140-003-02-4","2":"FR-122047","3":"cyclooxygenase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6049"},{"1":"BRD-A64242993-001-05-6","2":"lanatoside-c","3":"cardiac glycoside","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6051"},{"1":"BRD-K66956375-001-11-3","2":"oleoylethanolamide","3":"cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist","4":"CNR1, GPR119, GPR55, PPARA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6053"},{"1":"BRD-K59146805-001-03-7","2":"AZ3146","3":"monopolar spindle 1 kinase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6055"},{"1":"BRD-K02407574-001-09-7","2":"parbendazole","3":"tubulin polymerization inhibitor","4":"TUBB","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6089"},{"1":"BRD-K72231366-001-02-3","2":"TAME","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6091"},{"1":"BRD-K26997899-001-02-2","2":"D-64131","3":"microtubule inhibitor","4":"TUBB","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6093"},{"1":"BRD-K15424032-001-03-6","2":"SB-228357","3":"serotonin receptor antagonist","4":"HTR2A, HTR2B, HTR2C","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6095"},{"1":"BRD-K58770988-001-01-8","2":"NMS-E973","3":"HSP inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6097"},{"1":"BRD-A03216249-003-24-3","2":"mepivacaine","3":"potassium channel blocker, sodium channel blocker","4":"SCN10A","5":"neurology/psychiatry","6":"local anesthetic","7":"Launched","8":"local anesthetic","_rn_":"6885"},{"1":"BRD-K69726342-238-02-4","2":"atorvastatin","3":"HMGCR inhibitor","4":"AHR, DPP4, HMGCR","5":"neurology/psychiatry, cardiology","6":"stroke, heart attack","7":"Launched","8":"stroke, heart attack","_rn_":"6887"},{"1":"BRD-K69608737-001-10-2","2":"tacrolimus","3":"calcineurin inhibitor","4":"FKBP1A","5":"transplant","6":"organ rejection","7":"Launched","8":"organ rejection","_rn_":"6889"},{"1":"BRD-A72711497-236-03-8","2":"lasalocid","3":"bacterial permeability inducer","4":"NA","5":"infectious disease","6":"coccidiosis","7":"Launched","8":"coccidiosis","_rn_":"6891"},{"1":"BRD-K56614220-001-19-0","2":"clofazimine","3":"GK0582 inhibitor","4":"NA","5":"infectious disease","6":"leprosy","7":"Launched","8":"leprosy","_rn_":"6893"},{"1":"BRD-K70401845-003-09-6","2":"erlotinib","3":"EGFR inhibitor","4":"EGFR, NR1I2","5":"oncology","6":"non-small cell lung cancer (NSCLC), pancreatic cancer","7":"Launched","8":"Lung Cancer, pancreatic cancer","_rn_":"6933"},{"1":"BRD-K73237276-001-01-0","2":"tacalcitol","3":"vitamin D receptor agonist","4":"VDR","5":"dermatology","6":"psoriasis, chapped lips","7":"Launched","8":"psoriasis, chapped lips","_rn_":"6937"},{"1":"BRD-A16997652-001-02-3","2":"protirelin","3":"thyrotropin releasing hormone receptor agonist","4":"TRHR","5":"radiology","6":"thyroid function diagnostic","7":"Launched","8":"thyroid function diagnostic","_rn_":"6939"},{"1":"BRD-K16730910-001-07-3","2":"regorafenib","3":"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","4":"ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK","5":"oncology","6":"colorectal cancer, gastrointestinal stromal tumors (GIST)","7":"Launched","8":"Colon/Colorectal Cancer, gastrointestinal stromal tumors (GIST)","_rn_":"6941"},{"1":"BRD-A69815203-001-07-6","2":"cyclosporin-a","3":"calcineurin inhibitor","4":"PPP3CA","5":"rheumatology, dermatology","6":"rheumatoid arthritis, psoriasis","7":"Launched","8":"rheumatoid arthritis, psoriasis","_rn_":"6981"},{"1":"BRD-A81513827-001-03-6","2":"saxagliptin","3":"dipeptidyl peptidase inhibitor","4":"DPP4","5":"endocrinology","6":"diabetes mellitus","7":"Launched","8":"diabetes mellitus","_rn_":"6983"},{"1":"BRD-K26634012-001-04-9","2":"tilmicosin","3":"bacterial 50S ribosomal subunit inhibitor","4":"NA","5":"pulmonary","6":"bovine respiratory disease (BRD)","7":"Launched","8":"bovine respiratory disease (BRD)","_rn_":"6985"},{"1":"BRD-K90374350-001-09-2","2":"chlorquinaldol","3":"other antibiotic","4":"NA","5":"infectious disease","6":"fungal infection","7":"Launched","8":"fungal infection","_rn_":"6987"},{"1":"BRD-U45393375-000-01-6","2":"sevelamer","3":"phosphate antagonist","4":"NA","5":"nephrology","6":"chronic kidney disease (CKD)","7":"Launched","8":"chronic kidney disease (CKD)","_rn_":"6989"},{"1":"BRD-K38183498-001-02-0","2":"clonazepam","3":"GABA benzodiazepine site receptor agonist","4":"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO","5":"neurology/psychiatry","6":"seizures, panic disorders","7":"Launched","8":"seizures, panic disorders","_rn_":"7029"},{"1":"BRD-K26619122-001-02-1","2":"thiocolchicoside","3":"GABA receptor antagonist","4":"GABRA1, GABRB2, GABRG2, GLRA1, GLRB","5":"neurology/psychiatry","6":"muscle relaxant","7":"Launched","8":"muscle relaxant","_rn_":"7031"},{"1":"BRD-K81839095-001-30-1","2":"estrone","3":"estrogen receptor agonist, estrogenic hormone","4":"ESR1, ESR2","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"7033"},{"1":"BRD-K88172511-003-20-3","2":"naltrexone","3":"opioid receptor antagonist","4":"OPRD1, OPRK1, OPRM1, SIGMAR1","5":"neurology/psychiatry","6":"abstinence from alcohol","7":"Launched","8":"abstinence from alcohol","_rn_":"7035"},{"1":"BRD-K51544265-001-04-2","2":"cabozantinib","3":"RET tyrosine kinase inhibitor, VEGFR inhibitor","4":"KDR, MET","5":"oncology","6":"medullary thyroid cancer (MTC)","7":"Launched","8":"medullary thyroid cancer (MTC)","_rn_":"7037"},{"1":"BRD-K23566484-001-15-1","2":"nilutamide","3":"androgen receptor antagonist","4":"AR","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"7077"},{"1":"BRD-A35588707-001-05-5","2":"teniposide","3":"topoisomerase inhibitor","4":"TOP2A, TOP2B","5":"hematologic malignancy","6":"acute lymphoblastic leukemia (ALL)","7":"Launched","8":"acute lymphoblastic leukemia (ALL)","_rn_":"7079"},{"1":"BRD-A91733352-300-04-5","2":"camylofine-chlorhydrate","3":"NA","4":"NA","5":"gastroenterology","6":"abdominal pain","7":"Launched","8":"abdominal pain","_rn_":"7081"},{"1":"BRD-A14395271-074-17-8","2":"mesoridazine","3":"dopamine receptor antagonist","4":"DRD2, HTR2A","5":"neurology/psychiatry","6":"schizophrenia","7":"Launched","8":"schizophrenia","_rn_":"7083"},{"1":"BRD-K76011241-001-01-8","2":"oseltamivir-phosphate","3":"neuraminidase inhibitor","4":"CES1, NEU1, NEU2","5":"infectious disease","6":"influenza A virus infection","7":"Launched","8":"influenza A virus infection","_rn_":"7085"},{"1":"BRD-A43671941-003-11-9","2":"oxprenolol","3":"adrenergic receptor antagonist","4":"ADRB1, ADRB2","5":"cardiology","6":"angina pectoris, hypertension, cardiac arrythmia","7":"Launched","8":"angina pectoris, hypertension, cardiac arrythmia","_rn_":"7125"},{"1":"BRD-K73589491-001-11-2","2":"nizatidine","3":"histamine receptor antagonist","4":"HRH2","5":"gastroenterology","6":"duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)","7":"Launched","8":"duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)","_rn_":"7127"},{"1":"BRD-A25608658-001-01-1","2":"narasin","3":"antiprotozoal agent","4":"NA","5":"infectious disease","6":"coccidiosis","7":"Launched","8":"coccidiosis","_rn_":"7129"},{"1":"BRD-K89714990-001-01-5","2":"tepoxalin","3":"cyclooxygenase inhibitor, lipoxygenase inhibitor","4":"ALOX5","5":"rheumatology, orthopedics","6":"rheumatoid arthritis, hip dysplasia","7":"Launched","8":"rheumatoid arthritis, hip dysplasia","_rn_":"7131"},{"1":"BRD-K32107296-001-16-9","2":"temozolomide","3":"DNA alkylating agent","4":"MGMT","5":"oncology","6":"glioblastoma, astrocytoma","7":"Launched","8":"Brain Cancer, astrocytoma","_rn_":"7133"},{"1":"BRD-A29485665-001-12-8","2":"bicalutamide","3":"androgen receptor antagonist","4":"AR","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"7173"},{"1":"BRD-K99792991-001-34-9","2":"hexachlorophene","3":"potassium channel activator","4":"GLUD1, SDHD","5":"infectious disease","6":"gram-positive bacterial infections","7":"Launched","8":"gram-positive bacterial infections","_rn_":"7175"},{"1":"BRD-K92049597-001-20-8","2":"triamterene","3":"sodium channel blocker","4":"SCNN1A, SCNN1B, SCNN1D, SCNN1G","5":"endocrinology, cardiology","6":"hypokalemia, hypertension, edema","7":"Launched","8":"hypokalemia, hypertension, edema","_rn_":"7177"},{"1":"BRD-K34157611-001-16-0","2":"cimetidine","3":"histamine receptor antagonist","4":"HRH2, SLC29A4, SLC47A1, SLC47A2","5":"gastroenterology, hematologic malignancy, endocrinology","6":"duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma","7":"Launched","8":"duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma","_rn_":"7179"},{"1":"BRD-K01109406-001-03-7","2":"nitisinone","3":"hydroxyphenylpyruvate dioxygenase inhibitor","4":"HPD","5":"metabolism","6":"tyrosinemia","7":"Launched","8":"tyrosinemia","_rn_":"7181"},{"1":"BRD-K69116396-001-04-1","2":"sertindole","3":"dopamine receptor antagonist, serotonin receptor antagonist","4":"ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"7221"},{"1":"BRD-K29458283-001-29-9","2":"chlorambucil","3":"DNA inhibitor","4":"NA","5":"hematologic malignancy","6":"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma","7":"Launched","8":"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma","_rn_":"7223"},{"1":"BRD-K71106091-001-06-1","2":"fludarabine-phosphate","3":"ribonucleotide reductase inhibitor","4":"DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B","5":"hematologic malignancy","6":"chronic lymphocytic leukemia (CLL)","7":"Launched","8":"chronic lymphocytic leukemia (CLL)","_rn_":"7225"},{"1":"BRD-A90547603-001-02-5","2":"eptifibatide","3":"platelet aggregation inhibitor","4":"ITGA2B, ITGB3","5":"cardiology","6":"acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)","7":"Launched","8":"acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)","_rn_":"7226"},{"1":"BRD-K72093121-001-16-3","2":"vidarabine","3":"antiviral","4":"ADA","5":"infectious disease","6":"virus herpes simplex (HSV), varicella-zoster virus (VZV)","7":"Launched","8":"virus herpes simplex (HSV), varicella-zoster virus (VZV)","_rn_":"7228"},{"1":"BRD-K30577245-341-01-9","2":"docetaxel","3":"tubulin polymerization inhibitor","4":"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1","5":"oncology","6":"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","7":"Launched","8":"breast cancer, Lung Cancer, prostate cancer, gastric adenocarcinoma, Head and Neck Cancer","_rn_":"8000"},{"1":"BRD-K35687421-001-02-5","2":"gimeracil","3":"dihydropyrimidine dehydrogenase inhibitor","4":"DPYD","5":"oncology","6":"gastric adenocarcinoma","7":"Launched","8":"gastric adenocarcinoma","_rn_":"8002"},{"1":"BRD-K34022604-001-06-6","2":"clofarabine","3":"ribonucleotide reductase inhibitor","4":"POLA1, POLD1, POLE, RRM1, RRM2, RRM2B","5":"hematologic malignancy","6":"acute lymphoblastic leukemia (ALL)","7":"Launched","8":"acute lymphoblastic leukemia (ALL)","_rn_":"8004"},{"1":"BRD-K04111260-001-10-0","2":"raclopride","3":"dopamine receptor antagonist","4":"DRD2, DRD3, HTR1A","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"8006"},{"1":"BRD-K02113016-001-15-4","2":"olaparib","3":"PARP inhibitor","4":"PARP1, PARP2","5":"oncology","6":"ovarian cancer","7":"Launched","8":"ovarian cancer","_rn_":"8008"},{"1":"BRD-K37798499-001-27-2","2":"etoposide","3":"topoisomerase inhibitor","4":"TOP2A, TOP2B","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"8048"},{"1":"BRD-K15916496-001-27-9","2":"clotrimazole","3":"cytochrome P450 inhibitor, imidazoline receptor ligand","4":"CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8","5":"infectious disease","6":"vulvovaginal candidiasis, oropharyngeal candidiasis","7":"Launched","8":"vulvovaginal candidiasis, oropharyngeal candidiasis","_rn_":"8050"},{"1":"BRD-K99964838-001-11-9","2":"bosutinib","3":"Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor","4":"ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK","5":"hematologic malignancy","6":"chronic myeloid leukemia (CML)","7":"Launched","8":"chronic myeloid leukemia (CML)","_rn_":"8052"},{"1":"BRD-A03623303-045-09-5","2":"metoprolol","3":"adrenergic receptor antagonist","4":"ADRB1, ADRB2","5":"cardiology","6":"hypertension, angina pectoris, myocardial infarction","7":"Launched","8":"hypertension, angina pectoris, myocardial infarction","_rn_":"8054"},{"1":"BRD-K06858286-001-01-3","2":"cabazitaxel","3":"microtubule inhibitor","4":"TUBA4A, TUBB, TUBB1","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"8056"},{"1":"BRD-K67977190-066-02-3","2":"eprosartan","3":"angiotensin receptor antagonist","4":"AGTR1","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"8096"},{"1":"BRD-K51747290-001-13-1","2":"hydroxyurea","3":"ribonucleotide reductase inhibitor","4":"RRM1, RRM2, RRM2B","5":"hematologic malignancy, oncology","6":"chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)","7":"Launched","8":"chronic myeloid leukemia (CML), Head and Neck Cancer","_rn_":"8098"},{"1":"BRD-K47978074-001-02-4","2":"trometamol","3":"NA","4":"AMD1, CANT1, DCN, NEIL1, VEGFA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"8100"},{"1":"BRD-K87827419-001-16-8","2":"melphalan","3":"DNA alkylating agent, DNA inhibitor","4":"NA","5":"hematologic malignancy","6":"multiple myeloma","7":"Launched","8":"multiple myeloma","_rn_":"8102"},{"1":"BRD-K25837718-001-03-8","2":"josamycin","3":"bacterial 50S ribosomal subunit inhibitor","4":"NA","5":"pulmonary","6":"bronchitis","7":"Launched","8":"bronchitis","_rn_":"8104"},{"1":"BRD-K24556098-001-16-7","2":"deoxycorticosterone-acetate","3":"progestogen hormone","4":"NR3C2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"8143"},{"1":"BRD-K91601245-001-12-0","2":"mercaptopurine","3":"immunosuppressant, protein synthesis inhibitor, purine antagonist","4":"HPRT1, IMPDH1, IMPDH2, PPAT","5":"hematologic malignancy","6":"acute lymphoblastic leukemia (ALL)","7":"Launched","8":"acute lymphoblastic leukemia (ALL)","_rn_":"8145"},{"1":"BRD-K84466663-001-05-4","2":"nelarabine","3":"DNA synthesis inhibitor, T cell inhibitor","4":"POLA1","5":"hematologic malignancy","6":"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","7":"Launched","8":"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","_rn_":"8147"},{"1":"BRD-A91452556-001-04-0","2":"estradiol-cypionate","3":"estrogen receptor agonist","4":"ESR1","5":"endocrinology","6":"hypoestrogenism, menopause","7":"Launched","8":"hypoestrogenism, menopause","_rn_":"8149"},{"1":"BRD-K04196797-001-24-4","2":"oxcarbazepine","3":"sodium channel blocker","4":"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","5":"neurology/psychiatry","6":"seizures","7":"Launched","8":"seizures","_rn_":"8151"},{"1":"BRD-A70649075-008-30-8","2":"sulconazole","3":"sterol demethylase inhibitor","4":"NA","5":"infectious disease","6":"tinea pedis, tinea cruris, tinea corporis","7":"Launched","8":"tinea pedis, tinea cruris, tinea corporis","_rn_":"8190"},{"1":"BRD-K78815826-001-14-6","2":"suxibuzone","3":"cyclooxygenase inhibitor","4":"NA","5":"rheumatology, neurology/psychiatry","6":"joint pain, muscle pain","7":"Launched","8":"joint pain, muscle pain","_rn_":"8192"},{"1":"BRD-K21565985-001-22-5","2":"xylazine","3":"adrenergic receptor agonist","4":"ADRA2A, ADRA2B, ADRA2C","5":"neurology/psychiatry","6":"anesthetic","7":"Launched","8":"anesthetic","_rn_":"8194"},{"1":"BRD-K70246307-001-04-1","2":"riboflavin","3":"vitamin B2","4":"BLVRB, RFK","5":"gastroenterology","6":"jaundice","7":"Launched","8":"jaundice","_rn_":"8196"},{"1":"BRD-K36711084-001-02-0","2":"cyromazine","3":"NA","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"8198"},{"1":"BRD-A70083328-001-23-5","2":"secnidazole","3":"acetylcholinesterase inhibitor, microtubule inhibitor","4":"NA","5":"infectious disease","6":"protozoan infection","7":"Launched","8":"protozoan infection","_rn_":"8238"},{"1":"BRD-K28307902-001-21-7","2":"flutamide","3":"androgen receptor antagonist","4":"AHR, AR","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"8242"},{"1":"BRD-K06222852-001-03-2","2":"posaconazole","3":"sterol demethylase inhibitor","4":"CYP3A4","5":"infectious disease","6":"oropharyngeal candidiasis","7":"Launched","8":"oropharyngeal candidiasis","_rn_":"8244"},{"1":"BRD-K68095457-001-10-1","2":"palmitoylethanolamide","3":"cannabinoid receptor agonist","4":"CNR2, GPR119, GPR55","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"8246"},{"1":"BRD-K69280563-001-01-8","2":"vinorelbine","3":"tubulin polymerization inhibitor","4":"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"8286"},{"1":"BRD-K62008436-001-22-1","2":"paclitaxel","3":"tubulin polymerization inhibitor","4":"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1","5":"oncology","6":"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","7":"Launched","8":"ovarian cancer, breast cancer, Lung Cancer","_rn_":"8288"},{"1":"BRD-K88429204-001-35-1","2":"pyrimethamine","3":"dihydrofolate reductase inhibitor","4":"DHFR, SLC47A1","5":"infectious disease","6":"malaria","7":"Launched","8":"malaria","_rn_":"8290"},{"1":"BRD-K70301465-001-02-6","2":"ibrutinib","3":"Bruton's tyrosine kinase (BTK) inhibitor","4":"BLK, BMX, BTK","5":"hematologic malignancy","6":"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","7":"Launched","8":"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","_rn_":"8292"},{"1":"BRD-K13112821-001-17-4","2":"artemisinin","3":"DNA synthesis inhibitor","4":"CYP2B6","5":"infectious disease","6":"malaria","7":"Launched","8":"malaria","_rn_":"8294"},{"1":"BRD-K10799896-001-26-2","2":"clobetasol-propionate","3":"glucocorticoid receptor agonist","4":"NR3C1, PLA2G1B","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"8336"},{"1":"BRD-A25234499-001-18-3","2":"aminoglutethimide","3":"glucocorticoid receptor antagonist","4":"CYP11A1, CYP19A1","5":"endocrinology, oncology","6":"Cushing's syndrome, breast cancer","7":"Launched","8":"Cushing's syndrome, breast cancer","_rn_":"8338"},{"1":"BRD-K29950728-048-17-4","2":"clomifene","3":"estrogen receptor antagonist","4":"ESR1","5":"obstetrics/gynecology","6":"infertility","7":"Launched","8":"infertility","_rn_":"8339"},{"1":"BRD-A31095847-001-02-3","2":"mozavaptan","3":"vasopressin receptor antagonist","4":"AVPR1A, AVPR1B, AVPR2","5":"endocrinology","6":"hyponatremia","7":"Launched","8":"hyponatremia","_rn_":"8341"},{"1":"BRD-K99475619-001-01-2","2":"genz-644282","3":"topoisomerase inhibitor","4":"TOP1","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9142"},{"1":"BRD-K83508485-001-02-7","2":"FK-888","3":"tachykinin antagonist","4":"TACR1, TACR2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9144"},{"1":"BRD-K39484304-001-16-5","2":"triptolide","3":"RNA polymerase inhibitor","4":"RELA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9146"},{"1":"BRD-K68532323-003-02-8","2":"SB-743921","3":"kinesin-like spindle protein inhibitor","4":"KIF11","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"9148"},{"1":"BRD-K04264130-001-01-4","2":"favipiravir","3":"RNA polymerase inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9150"},{"1":"BRD-K68870568-066-01-5","2":"flumatinib","3":"Bcr-Abl kinase inhibitor","4":"ABL1, PDGFRB","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9190"},{"1":"BRD-K71281111-001-04-3","2":"SNX-2112","3":"HSP inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9192"},{"1":"BRD-K71480163-001-01-4","2":"GDC-0068","3":"AKT inhibitor","4":"AKT1, AKT2, AKT3, PRKG1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9194"},{"1":"BRD-K08542803-001-03-1","2":"gambogic-acid","3":"caspase activator","4":"BCL2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9196"},{"1":"BRD-K28192623-066-08-1","2":"spiradoline","3":"opioid receptor agonist","4":"OPRK1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9198"},{"1":"BRD-K20285085-074-04-5","2":"R406","3":"SYK inhibitor","4":"RET, SYK","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9238"},{"1":"BRD-K76239644-001-01-8","2":"BMS-690514","3":"EGFR inhibitor, VEGFR inhibitor","4":"EGFR, ERBB2, FLT3, KDR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9240"},{"1":"BRD-K99604664-001-01-1","2":"tanaproget","3":"progesterone receptor agonist","4":"PGR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9244"},{"1":"BRD-K97101532-001-02-8","2":"tezacaftor","3":"CFTR channel agonist","4":"NA","5":"pulmonary","6":"cystic fibrosis","7":"Launched","8":"cystic fibrosis","_rn_":"9246"},{"1":"BRD-K12787259-001-04-3","2":"CX-5461","3":"RNA polymerase inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9286"},{"1":"BRD-K57927309-001-01-7","2":"BW-180C","3":"opioid receptor agonist","4":"OPRD1, OPRM1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9288"},{"1":"BRD-K18849474-001-04-4","2":"dalcetrapib","3":"cholesteryl ester transfer protein inhibitor","4":"CETP","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9290"},{"1":"BRD-K25244359-066-03-4","2":"apatinib","3":"RET tyrosine kinase inhibitor","4":"CSK, KDR, KIT, RET","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9292"},{"1":"BRD-K66911501-003-01-2","2":"MK-3207","3":"calcitonin antagonist","4":"CALCA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9294"},{"1":"BRD-A50998626-001-02-1","2":"palomid-529","3":"AKT inhibitor, mTOR inhibitor","4":"MTOR","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9333"},{"1":"BRD-K51324732-001-01-0","2":"meglitinide","3":"potassium channel blocker","4":"CCR2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9335"},{"1":"BRD-K62965247-001-04-9","2":"tipifarnib","3":"farnesyltransferase inhibitor","4":"FNTA, FNTB","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9337"},{"1":"BRD-K64538373-001-01-4","2":"Ro-4987655","3":"MEK inhibitor","4":"MAP2K1","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9339"},{"1":"BRD-K07881437-001-04-6","2":"danusertib","3":"Aurora kinase inhibitor, growth factor receptor inhibitor","4":"AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9341"},{"1":"BRD-K86525559-001-07-8","2":"AZD7762","3":"CHK inhibitor","4":"CHEK1, CHEK2","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9383"},{"1":"BRD-K92968657-001-01-6","2":"tirapazamine","3":"DNA inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9385"},{"1":"BRD-K14796088-003-26-8","2":"berberine","3":"LDL receptor activator","4":"LDLR","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"9389"},{"1":"BRD-K12885236-001-02-7","2":"dapivirine","3":"non-nucleoside reverse transcriptase inhibitor","4":"CYP3A4, CYP3A5","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9429"},{"1":"BRD-K13646352-001-03-8","2":"midostaurin","3":"FLT3 inhibitor, KIT inhibitor, PKC inhibitor","4":"FLT3, PRKCG","5":"hematologic malignancy","6":"acute myeloid leukemia (AML)","7":"Launched","8":"acute myeloid leukemia (AML)","_rn_":"9431"},{"1":"BRD-K92241597-001-06-0","2":"tosedostat","3":"peptidase inhibitor","4":"ANPEP, LAP3, NPEPPS","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9433"},{"1":"BRD-K97883416-001-01-4","2":"BMS-626529","3":"HIV attachment inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9435"},{"1":"BRD-K52911425-001-09-8","2":"GDC-0941","3":"PI3K inhibitor","4":"PIK3CA, PIK3CB, PIK3CD, PIK3CG","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9437"},{"1":"BRD-K19034817-001-01-4","2":"pacritinib","3":"FLT3 inhibitor, JAK inhibitor","4":"FLT3, JAK1, JAK2, JAK3","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9477"},{"1":"BRD-K30933884-001-01-0","2":"UNBS-5162","3":"CC chemokine receptor antagonist","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9479"},{"1":"BRD-K99545815-001-06-3","2":"PF-562271","3":"focal adhesion kinase inhibitor","4":"PTK2, PTK2B","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9482"},{"1":"BRD-K70463136-001-01-5","2":"BAY-87-2243","3":"hypoxia inducible factor inhibitor","4":"HIF1A","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10287"},{"1":"BRD-K55966568-001-05-4","2":"orantinib","3":"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"10289"},{"1":"BRD-K72827473-001-01-0","2":"CEP-37440","3":"ALK tyrosine kinase receptor inhibitor","4":"ALK","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10291"},{"1":"BRD-K04993719-001-01-7","2":"LY2334737","3":"antitumor agent, ribonucleotide reductase inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10293"},{"1":"BRD-K40797222-001-01-8","2":"SC-12267","3":"dihydroorotate dehydrogenase inhibitor","4":"IL17A","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10295"},{"1":"BRD-K52751261-001-06-1","2":"TAK-715","3":"p38 MAPK inhibitor","4":"MAPK14","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10335"},{"1":"BRD-K07736136-001-04-6","2":"VX-702","3":"p38 MAPK inhibitor","4":"MAPK11, MAPK12, MAPK14","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10337"},{"1":"BRD-A47706533-001-02-6","2":"buthionine-sulfoximine","3":"glutathione transferase inhibitor","4":"GCLM","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10339"},{"1":"BRD-K62398570-300-01-2","2":"lerisetron","3":"serotonin receptor antagonist","4":"HTR3A","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"10341"},{"1":"BRD-K45724504-001-01-6","2":"anguidine","3":"protein synthesis inhibitor","4":"SLC5A1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10343"},{"1":"BRD-A46813902-001-01-6","2":"iododexetimide","3":"acetylcholine receptor antagonist","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10383"},{"1":"BRD-K75649340-001-13-1","2":"tioguanine","3":"purine antagonist","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10387"},{"1":"BRD-A25687296-300-04-3","2":"emetine","3":"protein synthesis inhibitor","4":"RPS2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10389"},{"1":"BRD-K96358241-001-01-9","2":"harringtonine","3":"protein synthesis inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"10391"},{"1":"BRD-A64553394-001-04-4","2":"DPI-201106","3":"sodium channel activator","4":"ADRB2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10431"},{"1":"BRD-K51662849-001-08-8","2":"ilomastat","3":"matrix metalloprotease inhibitor","4":"ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"10433"},{"1":"BRD-K19295594-015-14-3","2":"gossypol","3":"BCL inhibitor, MCL1 inhibitor","4":"BCL2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10437"},{"1":"BRD-K64925568-001-01-8","2":"AMG-232","3":"MDM inhibitor","4":"MDM2","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"10439"},{"1":"BRD-K16551357-001-03-2","2":"evacetrapib","3":"cholesteryl ester transfer protein inhibitor","4":"CETP","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"10479"},{"1":"BRD-K23301018-001-11-7","2":"broxyquinoline","3":"antiprotozoal agent","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10485"},{"1":"BRD-K11215326-001-03-7","2":"tazemetostat","3":"histone lysine methyltransferase inhibitor","4":"EZH2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10527"},{"1":"BRD-K19318328-001-01-3","2":"FR-139317","3":"endothelin receptor antagonist","4":"EDNRA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10529"},{"1":"BRD-A95696066-003-13-8","2":"nisoxetine","3":"norepinephrine reuptake inhibitor","4":"SLC6A2, SLC6A3, SLC6A4","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10531"},{"1":"BRD-K91623615-001-05-0","2":"ABT-751","3":"tubulin polymerization inhibitor","4":"TUBB","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10533"},{"1":"BRD-K74057757-001-01-9","2":"indibulin","3":"tubulin polymerization inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"10535"},{"1":"BRD-K94420399-001-01-9","2":"PF-04136309","3":"CC chemokine receptor antagonist","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10575"},{"1":"BRD-K26712974-001-01-5","2":"VX-765","3":"caspase inhibitor","4":"CASP1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10577"},{"1":"BRD-K53097745-001-01-5","2":"pterostilbene","3":"cyclooxygenase inhibitor, PPAR receptor agonist","4":"PTGS2","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"10581"},{"1":"BRD-K43389698-001-09-9","2":"BMS-387032","3":"CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor","4":"CDK2, CDK7, CDK9","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10583"},{"1":"BRD-K66241279-001-01-8","2":"cinromide","3":"NA","4":"NA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"10623"},{"1":"BRD-K60341624-001-02-2","2":"GSK1292263","3":"glucose dependent insulinotropic receptor agonist","4":"GRPR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10625"},{"1":"BRD-K70914287-300-02-8","2":"BIBX-1382","3":"EGFR inhibitor","4":"EGFR, ERBB2","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10627"},{"1":"BRD-K03384561-001-02-7","2":"roquinimex","3":"angiogenesis inhibitor, tumor necrosis factor production inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"10630"},{"1":"BRD-A47953250-001-01-7","2":"ecamsule-triethanolamine","3":"NA","4":"NA","5":"dermatology","6":"skin protectant, sunscreen lotion","7":"Launched","8":"skin protectant, sunscreen lotion","_rn_":"11434"},{"1":"BRD-K82928892-001-02-5","2":"doxercalciferol","3":"vitamin D receptor agonist","4":"VDR","5":"nephrology, endocrinology","6":"chronic kidney disease (CKD), hyperparathyroidism","7":"Launched","8":"chronic kidney disease (CKD), hyperparathyroidism","_rn_":"11436"},{"1":"BRD-K07265709-003-05-6","2":"dexrazoxane","3":"chelating agent, topoisomerase inhibitor","4":"TOP2A, TOP2B","5":"cardiology","6":"cardiomyopathy","7":"Launched","8":"cardiomyopathy","_rn_":"11438"},{"1":"BRD-K83003151-057-02-4","2":"alogliptin","3":"dipeptidyl peptidase inhibitor","4":"DPP4","5":"endocrinology","6":"diabetes mellitus","7":"Launched","8":"diabetes mellitus","_rn_":"11441"},{"1":"BRD-K13183738-317-10-2","2":"pentamidine","3":"anti-pneumocystis agent","4":"TRDMT1","5":"infectious disease","6":"pneumonia","7":"Launched","8":"pneumonia","_rn_":"11481"},{"1":"BRD-A75919782-399-02-6","2":"leucovorin","3":"folate receptor ligand","4":"TYMS","5":"oncology","6":"osteosarcoma","7":"Launched","8":"osteosarcoma","_rn_":"11483"},{"1":"BRD-K13514097-001-05-3","2":"everolimus","3":"mTOR inhibitor","4":"MTOR","5":"oncology, neurology/psychiatry, genetics, urology","6":"breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","7":"Launched","8":"breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","_rn_":"11485"},{"1":"BRD-A50049929-001-01-9","2":"oxazepam","3":"GABA benzodiazepine site receptor agonist","4":"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3","5":"neurology/psychiatry","6":"anxiety","7":"Launched","8":"anxiety","_rn_":"11487"},{"1":"BRD-K86204871-001-16-2","2":"terconazole","3":"sterol demethylase inhibitor","4":"NA","5":"infectious disease","6":"vulvovaginal candidiasis","7":"Launched","8":"vulvovaginal candidiasis","_rn_":"11525"},{"1":"BRD-K17979676-001-01-2","2":"eprobemide","3":"monoamine oxidase inhibitor","4":"MAOA","5":"neurology/psychiatry","6":"depression","7":"Launched","8":"depression","_rn_":"11527"},{"1":"BRD-A01643550-001-04-9","2":"prednisolone-acetate","3":"glucocorticoid receptor agonist","4":"NR3C1","5":"ophthalmology, dermatology, infectious disease","6":"conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","7":"Launched","8":"conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","_rn_":"11529"},{"1":"BRD-K42938903-332-01-1","2":"acetophenazine","3":"dopamine receptor antagonist","4":"DRD1, DRD2","5":"neurology/psychiatry","6":"psychosis","7":"Launched","8":"psychosis","_rn_":"11531"},{"1":"BRD-K84091759-001-07-1","2":"candesartan","3":"angiotensin receptor antagonist","4":"AGTR1","5":"cardiology","6":"hypertension, congestive heart failure","7":"Launched","8":"hypertension, congestive heart failure","_rn_":"11533"},{"1":"BRD-K02594908-001-16-4","2":"sulfanilamide","3":"carbonic anhydrase inhibitor","4":"CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4","5":"infectious disease","6":"vulvovaginal candidiasis","7":"Launched","8":"vulvovaginal candidiasis","_rn_":"11572"},{"1":"BRD-K40992116-001-09-7","2":"parachlorophenol","3":"antiinfective drug","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"11574"},{"1":"BRD-K16277217-001-10-9","2":"piperacetazine","3":"dopamine receptor antagonist","4":"NA","5":"neurology/psychiatry","6":"schizophrenia","7":"Launched","8":"schizophrenia","_rn_":"11576"},{"1":"BRD-K35952844-236-01-6","2":"sodium-glucoheptonate","3":"NA","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"11578"},{"1":"BRD-A59303141-001-10-4","2":"quinethazone","3":"thiazide diuretic","4":"CA1, CA2, SLC12A1, SLC12A2, SLC12A3","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"11580"},{"1":"BRD-K87024524-065-17-7","2":"phenelzine","3":"monoamine oxidase inhibitor","4":"ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4","5":"neurology/psychiatry","6":"depression","7":"Launched","8":"depression","_rn_":"11618"},{"1":"BRD-A83937277-001-10-5","2":"mephenytoin","3":"hydantoin antiepileptic","4":"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","5":"neurology/psychiatry","6":"seizures","7":"Launched","8":"seizures","_rn_":"11620"},{"1":"BRD-K59647213-001-10-5","2":"levocarnitine","3":"NA","4":"NA","5":"endocrinology","6":"carnitine deficiency","7":"Launched","8":"carnitine deficiency","_rn_":"11622"},{"1":"BRD-K84783599-001-01-0","2":"riociguat","3":"guanylate cyclase stimulant","4":"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"11624"},{"1":"BRD-K09951645-001-06-8","2":"dabrafenib","3":"RAF inhibitor","4":"BRAF, LIMK1, NEK11, RAF1, SIK1","5":"oncology","6":"melanoma","7":"Launched","8":"Skin Cancer","_rn_":"11626"},{"1":"BRD-K21283037-001-21-5","2":"riluzole","3":"glutamate inhibitor","4":"KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11","5":"neurology/psychiatry","6":"amyotrophic lateral sclerosis (ALS)","7":"Launched","8":"amyotrophic lateral sclerosis (ALS)","_rn_":"11665"},{"1":"BRD-K11267252-001-04-4","2":"alectinib","3":"ALK tyrosine kinase receptor inhibitor","4":"ALK, MET","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"11667"},{"1":"BRD-A23067620-300-01-3","2":"itraconazole","3":"cytochrome P450 inhibitor","4":"CYP51A1","5":"infectious disease","6":"onychomycosis, histoplasmosis, blastomycosis, aspergillosis","7":"Launched","8":"onychomycosis, histoplasmosis, blastomycosis, aspergillosis","_rn_":"11669"},{"1":"BRD-A81129465-001-03-8","2":"fenoprofen","3":"prostaglandin inhibitor","4":"PTGS1, PTGS2, SLC5A8","5":"rheumatology","6":"rheumatoid arthritis, osteoarthritis","7":"Launched","8":"rheumatoid arthritis, osteoarthritis","_rn_":"11671"},{"1":"BRD-K18574842-236-17-7","2":"nafcillin","3":"bacterial cell wall synthesis inhibitor","4":"CYP1A2, CYP3A4, SLC22A6","5":"infectious disease","6":"gram-positive bacterial infections","7":"Launched","8":"gram-positive bacterial infections","_rn_":"11673"},{"1":"BRD-K00673382-001-18-9","2":"famotidine","3":"histamine receptor antagonist","4":"HRH2","5":"gastroenterology","6":"heartburn","7":"Launched","8":"heartburn","_rn_":"11712"},{"1":"BRD-K10843433-001-22-7","2":"phenylbutazone","3":"cyclooxygenase inhibitor, prostanoid receptor antagonist","4":"PTGIS, PTGS1, PTGS2","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"11714"},{"1":"BRD-K10845183-304-01-6","2":"tiludronate","3":"bone resorption inhibitor, osteoclast inhibitor","4":"ATP6V1A, MMP2, PTPN1","5":"orthopedics","6":"navicular syndrome","7":"Launched","8":"navicular syndrome","_rn_":"11716"},{"1":"BRD-K00259736-001-16-4","2":"colchicine","3":"microtubule inhibitor","4":"GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","5":"rheumatology, endocrinology","6":"gout, fever","7":"Launched","8":"gout, fever","_rn_":"11718"},{"1":"BRD-K23204545-001-16-4","2":"busulfan","3":"DNA inhibitor","4":"NA","5":"hematologic malignancy","6":"chronic myeloid leukemia (CML)","7":"Launched","8":"chronic myeloid leukemia (CML)","_rn_":"11719"},{"1":"BRD-K24048528-001-02-5","2":"abiraterone-acetate","3":"androgen biosynthesis inhibitor","4":"CYP17A1","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"11754"},{"1":"BRD-K35245662-001-01-2","2":"ciclesonide","3":"glucocorticoid receptor agonist","4":"NR3C1, SERPINA6","5":"allergy","6":"allergic rhinitis","7":"Launched","8":"allergic rhinitis","_rn_":"11756"},{"1":"BRD-K15567136-003-27-2","2":"papaverine","3":"phosphodiesterase inhibitor","4":"PDE10A, PDE4B, PDE5A","5":"cardiology, hematology, gastroenterology","6":"myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm","7":"Launched","8":"myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm","_rn_":"11758"},{"1":"BRD-K43389675-003-20-9","2":"daunorubicin","3":"RNA synthesis inhibitor, topoisomerase inhibitor","4":"TOP2A, TOP2B","5":"hematologic malignancy","6":"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","7":"Launched","8":"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","_rn_":"11760"},{"1":"BRD-K52256627-300-06-6","2":"chlorhexidine","3":"membrane integrity inhibitor","4":"NA","5":"dermatology, infectious disease, dental","6":"cosmetic, skin infections, gingivitis","7":"Launched","8":"cosmetic, skin infections, gingivitis","_rn_":"11762"},{"1":"BRD-K68346641-001-01-4","2":"amsacrine","3":"topoisomerase inhibitor","4":"KCNH2, TOP2A","5":"hematologic malignancy","6":"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","7":"Launched","8":"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","_rn_":"12519"},{"1":"BRD-K51313569-003-03-3","2":"palbociclib","3":"CDK inhibitor","4":"CDK4, CDK6","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"12521"},{"1":"BRD-K82861010-001-02-5","2":"daclatasvir","3":"HCV inhibitor","4":"NA","5":"infectious disease","6":"hepatitis C","7":"Launched","8":"hepatitis C","_rn_":"12523"},{"1":"BRD-A49358627-001-14-6","2":"ciprofibrate","3":"PPAR receptor agonist","4":"PPARA","5":"endocrinology","6":"hyperlipidemia","7":"Launched","8":"hyperlipidemia","_rn_":"12525"},{"1":"BRD-K69650333-003-14-0","2":"idarubicin","3":"topoisomerase inhibitor","4":"TOP2A","5":"hematologic malignancy","6":"acute myeloid leukemia (AML)","7":"Launched","8":"acute myeloid leukemia (AML)","_rn_":"12527"},{"1":"BRD-K19615002-001-02-3","2":"creatine","3":"NA","4":"CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"12565"},{"1":"BRD-K29254801-001-14-7","2":"thiram","3":"NA","4":"JAK2","5":"ophthalmology","6":"contact dermatitis","7":"Launched","8":"contact dermatitis","_rn_":"12567"},{"1":"BRD-K88568253-011-19-9","2":"iproniazid","3":"monoamine oxidase inhibitor","4":"MAOA, MAOB","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"12569"},{"1":"BRD-A36267905-003-18-4","2":"buphenine","3":"adrenergic receptor agonist","4":"ADRB2","5":"rheumatology","6":"Raynaud's disease","7":"Launched","8":"Raynaud's disease","_rn_":"12570"},{"1":"BRD-A27887842-001-04-0","2":"prednisolone","3":"glucocorticoid receptor agonist","4":"NR3C1, NR3C2, SERPINA6","5":"ophthalmology, dermatology, infectious disease","6":"conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","7":"Launched","8":"conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","_rn_":"12572"},{"1":"BRD-A36456202-001-01-3","2":"colistin-b-sulfate","3":"bacterial permeability inducer","4":"NA","5":"infectious disease","6":"gram-negative bacterial infections","7":"Launched","8":"gram-negative bacterial infections","_rn_":"12612"},{"1":"BRD-A48300215-001-04-8","2":"ajmaline","3":"sodium channel blocker","4":"SCN5A","5":"cardiology","6":"Wolff-Parkinson-White Syndrome (WPW)","7":"Launched","8":"Wolff-Parkinson-White Syndrome (WPW)","_rn_":"12614"},{"1":"BRD-K66808046-065-03-7","2":"oxyquinoline","3":"chelating agent","4":"METAP2","5":"dermatology","6":"cosmetic","7":"Launched","8":"cosmetic","_rn_":"12616"},{"1":"BRD-K92872987-001-02-9","2":"cefpiramide","3":"bacterial cell wall synthesis inhibitor","4":"NA","5":"infectious disease","6":"gram-negative bacterial infections","7":"Launched","8":"gram-negative bacterial infections","_rn_":"12617"},{"1":"BRD-K35240538-001-26-2","2":"methylprednisolone","3":"glucocorticoid receptor agonist","4":"NR3C1","5":"endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology","6":"hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis","7":"Launched","8":"hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis","_rn_":"12619"},{"1":"BRD-K63126190-003-01-6","2":"epinephrine","3":"adrenergic receptor agonist, neurotransmitter","4":"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF","5":"cardiology, allergy, pulmonary","6":"cardiac arrest, anaphylactic shock, asthma","7":"Launched","8":"cardiac arrest, anaphylactic shock, asthma","_rn_":"12659"},{"1":"BRD-A30582499-003-05-1","2":"tiletamine","3":"glutamate receptor antagonist","4":"NA","5":"neurology/psychiatry","6":"anesthetic","7":"Launched","8":"anesthetic","_rn_":"12661"},{"1":"BRD-A06352418-001-25-9","2":"terfenadine","3":"histamine receptor antagonist","4":"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"12663"},{"1":"BRD-K66175015-001-09-0","2":"afatinib","3":"EGFR inhibitor","4":"EGFR, ERBB2, ERBB4","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"12665"},{"1":"BRD-K85090592-008-22-7","2":"pilocarpine","3":"acetylcholine receptor agonist","4":"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","5":"ophthalmology, cardiology","6":"glaucoma, hypertension","7":"Launched","8":"glaucoma, hypertension","_rn_":"12667"},{"1":"BRD-K21680192-300-14-4","2":"mitoxantrone","3":"topoisomerase inhibitor","4":"TOP2A","5":"neurology/psychiatry, oncology, hematologic malignancy","6":"multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)","7":"Launched","8":"multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)","_rn_":"12709"},{"1":"BRD-A69651145-003-07-2","2":"minocycline","3":"bacterial 30S ribosomal subunit inhibitor","4":"ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA","5":"endocrinology, infectious disease, ophthalmology, urology","6":"fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis","7":"Launched","8":"fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis","_rn_":"12711"},{"1":"BRD-A11132253-001-08-2","2":"nadide","3":"electron acceptor","4":"AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"12712"},{"1":"BRD-K02900412-001-11-3","2":"clofoctol","3":"protein synthesis inhibitor","4":"NA","5":"infectious disease","6":"gram-positive bacterial infections","7":"Launched","8":"gram-positive bacterial infections","_rn_":"12714"},{"1":"BRD-A10070317-003-28-3","2":"propranolol","3":"adrenergic receptor antagonist","4":"NA","5":"cardiology, neurology/psychiatry","6":"hypertension, angina pectoris, migraine headache","7":"Launched","8":"hypertension, angina pectoris, migraine headache","_rn_":"12753"},{"1":"BRD-K97810537-001-13-6","2":"beclomethasone-dipropionate","3":"glucocorticoid receptor agonist","4":"GPR97, NR3C1","5":"allergy","6":"allergic rhinitis","7":"Launched","8":"allergic rhinitis","_rn_":"12755"},{"1":"BRD-K51318897-001-15-3","2":"fenbendazole","3":"tubulin polymerization inhibitor","4":"TUBB","5":"infectious disease","6":"gastrointestinal parasites, gastrointestinal roundworms","7":"Launched","8":"gastrointestinal parasites, gastrointestinal roundworms","_rn_":"12757"},{"1":"BRD-K67511046-001-02-3","2":"naloxone","3":"opioid receptor antagonist","4":"CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4","5":"pulmonary","6":"respiratory depression","7":"Launched","8":"respiratory depression","_rn_":"12759"},{"1":"BRD-K10670311-001-15-5","2":"sulfasalazine","3":"cyclooxygenase inhibitor","4":"ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1","5":"gastroenterology","6":"ulcerative colitis","7":"Launched","8":"ulcerative colitis","_rn_":"12761"},{"1":"BRD-K48195008-001-19-9","2":"ethinyl-estradiol","3":"estrogen receptor agonist, estrogenic hormone","4":"ESR1, ESR2, NR1I2","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"12798"},{"1":"BRD-K11433652-001-17-0","2":"aspirin","3":"cyclooxygenase inhibitor","4":"AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53","5":"neurology/psychiatry, endocrinology, dental","6":"headache, fever, toothache, muscle pain","7":"Launched","8":"headache, fever, toothache, muscle pain","_rn_":"12800"},{"1":"BRD-K18250272-003-11-0","2":"propoxycaine","3":"local anesthetic","4":"NA","5":"neurology/psychiatry","6":"anesthetic","7":"Launched","8":"anesthetic","_rn_":"12801"},{"1":"BRD-K78789465-001-01-6","2":"pentagastrin","3":"CCK receptor agonist","4":"CCKBR","5":"gastroenterology","6":"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic","7":"Launched","8":"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic","_rn_":"12802"},{"1":"BRD-A00758722-001-04-9","2":"noretynodrel","3":"progestogen hormone","4":"PGR","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"12804"},{"1":"BRD-A02180903-001-04-5","2":"betamethasone","3":"glucocorticoid receptor agonist","4":"NR3C1","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"12842"},{"1":"BRD-K13249881-001-02-3","2":"piperazine","3":"benzodiazepine receptor agonist","4":"GABRB3","5":"infectious disease","6":"gastrointestinal roundworms","7":"Launched","8":"gastrointestinal roundworms","_rn_":"12844"},{"1":"BRD-K85333151-003-13-4","2":"ramifenazone","3":"cyclooxygenase inhibitor","4":"NA","5":"neurology/psychiatry, endocrinology","6":"pain relief, fever","7":"Launched","8":"pain relief, fever","_rn_":"12846"},{"1":"BRD-A50311610-300-10-4","2":"meclizine","3":"constitutive androstane receptor (CAR) agonist","4":"HRH1, NR1I3","5":"gastroenterology, neurology/psychiatry","6":"nausea, vomiting, motion sickness","7":"Launched","8":"nausea, vomiting, motion sickness","_rn_":"12848"},{"1":"BRD-K46937689-001-15-0","2":"phenazone","3":"cyclooxygenase inhibitor","4":"PTGS1, PTGS2","5":"neurology/psychiatry","6":"pain relief","7":"Launched","8":"pain relief","_rn_":"12850"},{"1":"BRD-K45252063-001-13-6","2":"clofibrate","3":"PPAR receptor agonist","4":"LPL, PPARA","5":"endocrinology, cardiology","6":"hyperlipidemia, cholesterol","7":"Launched","8":"hyperlipidemia, cholesterol","_rn_":"13651"},{"1":"BRD-K54094468-003-11-1","2":"remoxipride","3":"dopamine receptor antagonist","4":"DRD2, DRD3, DRD4, HTR2A, SIGMAR1","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"13653"},{"1":"BRD-K36386086-001-01-1","2":"dolutegravir","3":"HIV integrase inhibitor","4":"CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1","5":"infectious disease","6":"human immunodeficiency virus (HIV-1)","7":"Launched","8":"human immunodeficiency virus (HIV-1)","_rn_":"13655"},{"1":"BRD-K64052750-001-17-5","2":"gefitinib","3":"EGFR inhibitor","4":"EGFR","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"13657"},{"1":"BRD-K67043667-001-26-4","2":"altretamine","3":"DNA synthesis inhibitor","4":"NA","5":"oncology","6":"ovarian cancer","7":"Launched","8":"ovarian cancer","_rn_":"13699"},{"1":"BRD-K34411947-001-12-5","2":"streptozotocin","3":"DNA alkylating agent","4":"SLC2A2","5":"oncology","6":"pancreatic cancer","7":"Launched","8":"pancreatic cancer","_rn_":"13701"},{"1":"BRD-A24397426-001-10-4","2":"nadifloxacin","3":"bacterial DNA gyrase inhibitor","4":"NA","5":"dermatology, infectious disease","6":"acne vulgaris (AV), skin infections","7":"Launched","8":"acne vulgaris (AV), skin infections","_rn_":"13703"},{"1":"BRD-K99946902-001-07-5","2":"hexylresorcinol","3":"local anesthetic","4":"TYR","5":"infectious disease","6":"skin infections, first-aid antiseptic","7":"Launched","8":"skin infections, first-aid antiseptic","_rn_":"13705"},{"1":"BRD-K72723676-003-17-8","2":"benzethonium","3":"sodium channel blocker","4":"SCN10A","5":"infectious disease","6":"first-aid antiseptic","7":"Launched","8":"first-aid antiseptic","_rn_":"13707"},{"1":"BRD-K43860855-065-11-9","2":"iobenguane","3":"antineoplastic agent","4":"NA","5":"oncology, cardiology, endocrinology","6":"neuroblastoma, congestive heart failure, pheochromocytoma","7":"Launched","8":"neuroblastoma, congestive heart failure, pheochromocytoma","_rn_":"13747"},{"1":"BRD-K09416995-001-39-9","2":"lovastatin","3":"HMGCR inhibitor","4":"HDAC2, HMGCR, ITGAL, NR1I2","5":"cardiology, endocrinology","6":"coronary heart disease, myocardial infarction, hypercholesterolemia","7":"Launched","8":"coronary heart disease, myocardial infarction, hypercholesterolemia","_rn_":"13749"},{"1":"BRD-K04568635-300-01-4","2":"octenidine","3":"membrane integrity inhibitor","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"13751"},{"1":"BRD-A16700644-003-04-4","2":"isoxsuprine","3":"adrenergic receptor agonist","4":"ADRB2","5":"rheumatology, cardiology","6":"Raynaud's disease, arteriosclerosis, Buerger's disease","7":"Launched","8":"Raynaud's disease, arteriosclerosis, Buerger's disease","_rn_":"13753"},{"1":"BRD-K82181219-001-04-3","2":"pyritinol","3":"NA","4":"NA","5":"rheumatology, neurology/psychiatry","6":"rheumatoid arthritis, senile dementia","7":"Launched","8":"rheumatoid arthritis, senile dementia","_rn_":"13755"},{"1":"BRD-K40787673-001-02-1","2":"lacitol","3":"osmosis stimulant","4":"NA","5":"gastroenterology","6":"constipation","7":"Launched","8":"constipation","_rn_":"13795"},{"1":"BRD-K47635719-001-21-1","2":"dexamethasone-acetate","3":"glucocorticoid receptor agonist","4":"NA","5":"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","6":"hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis","7":"Launched","8":"hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis","_rn_":"13797"},{"1":"BRD-K56851771-001-06-8","2":"enzalutamide","3":"androgen receptor antagonist","4":"AR","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"13799"},{"1":"BRD-A92439610-001-05-7","2":"triamcinolone-acetonide","3":"glucocorticoid receptor agonist, immunosuppressant","4":"NR3C1","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"13801"},{"1":"BRD-K38197229-001-29-9","2":"bumetanide","3":"solute carrier family member inhibitor","4":"CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5","5":"cardiology","6":"edema, congestive heart failure","7":"Launched","8":"edema, congestive heart failure","_rn_":"13803"},{"1":"BRD-K45033733-001-12-2","2":"famciclovir","3":"DNA polymerase inhibitor","4":"NA","5":"dental, infectious disease","6":"cold sore, genitial herpes, shingles","7":"Launched","8":"cold sore, genitial herpes, shingles","_rn_":"13843"},{"1":"BRD-K62310379-001-10-5","2":"fluticasone-propionate","3":"glucocorticoid receptor agonist","4":"NR3C1, NR3C2, PGR, PLA2G4A","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"13844"},{"1":"BRD-K27351809-001-09-5","2":"nomegestrol-acetate","3":"progesterone receptor agonist","4":"PGR","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"13846"},{"1":"BRD-U25960968-000-01-9","2":"tyloxapol","3":"NFkB pathway inhibitor","4":"LPL, NFKB2","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"13848"},{"1":"BRD-K87774949-001-03-9","2":"istradefylline","3":"adenosine receptor antagonist","4":"ADORA1, ADORA2A, ADORA2B, ADORA3","5":"neurology/psychiatry","6":"Parkinson's Disease, dyskinesia","7":"Launched","8":"Parkinson's Disease, dyskinesia","_rn_":"13850"},{"1":"BRD-A58564983-001-04-6","2":"selamectin","3":"nematocide","4":"NA","5":"infectious disease","6":"flea control","7":"Launched","8":"flea control","_rn_":"13890"},{"1":"BRD-K60237333-001-27-1","2":"niacin","3":"NAD precursor, vitamin B","4":"DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT","5":"endocrinology","6":"hypertriglyceridemia","7":"Launched","8":"hypertriglyceridemia","_rn_":"13892"},{"1":"BRD-K56343971-001-10-6","2":"vemurafenib","3":"RAF inhibitor","4":"BRAF, RAF1","5":"oncology","6":"melanoma","7":"Launched","8":"Skin Cancer","_rn_":"13894"},{"1":"BRD-K60160658-003-11-2","2":"tiagabine","3":"GABA uptake inhibitor","4":"SLC6A1","5":"neurology/psychiatry","6":"seizures","7":"Launched","8":"seizures","_rn_":"13896"},{"1":"BRD-K96159438-001-06-3","2":"adefovir-dipivoxil","3":"DNA polymerase inhibitor","4":"NA","5":"infectious disease","6":"hepatitis B","7":"Launched","8":"hepatitis B","_rn_":"13938"},{"1":"BRD-K71075609-003-01-0","2":"dorzolamide","3":"carbonic anhydrase inhibitor","4":"CA1, CA12, CA14, CA2, CA4, CA7","5":"ophthalmology","6":"intraocular pressure, glaucoma","7":"Launched","8":"intraocular pressure, glaucoma","_rn_":"13940"},{"1":"BRD-K59197931-001-04-5","2":"naproxen","3":"cyclooxygenase inhibitor","4":"PTGS1, PTGS2","5":"neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology","6":"pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever","7":"Launched","8":"pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever","_rn_":"13942"},{"1":"BRD-K83257731-003-23-5","2":"chloropyramine","3":"histamine receptor antagonist","4":"HRH1","5":"cardiology, ophthalmology, allergy, pulmonary","6":"edema, conjunctivitis, allergic rhinitis, asthma","7":"Launched","8":"edema, conjunctivitis, allergic rhinitis, asthma","_rn_":"13944"},{"1":"BRD-A55962179-001-22-1","2":"omeprazole","3":"ATPase inhibitor","4":"ATP4A, CLCN2","5":"gastroenterology","6":"heartburn","7":"Launched","8":"heartburn","_rn_":"13946"},{"1":"BRD-K60585088-001-01-5","2":"paricalcitol","3":"vitamin D receptor agonist","4":"VDR","5":"nephrology, endocrinology","6":"chronic kidney disease (CKD), hyperthyroidism","7":"Launched","8":"chronic kidney disease (CKD), hyperthyroidism","_rn_":"13986"},{"1":"BRD-K71822263-001-03-2","2":"D-Serine","3":"glutamate receptor agonist","4":"GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"13988"},{"1":"BRD-K79254416-001-22-6","2":"decitabine","3":"DNA methyltransferase inhibitor","4":"DNMT1, DNMT3A","5":"hematologic malignancy, hematology","6":"myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","7":"Launched","8":"myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","_rn_":"13990"},{"1":"BRD-K41141507-001-16-2","2":"cyproterone-acetate","3":"androgen receptor antagonist","4":"ADORA1, AR","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"13992"},{"1":"BRD-K92428153-001-04-4","2":"mycophenolate-mofetil","3":"dehydrogenase inhibitor, inositol monophosphatase inhibitor","4":"IMPDH1, IMPDH2","5":"transplant","6":"organ rejection","7":"Launched","8":"organ rejection","_rn_":"13994"},{"1":"BRD-K64381438-001-03-8","2":"ulipristal","3":"progesterone receptor antagonist","4":"PGR","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"14765"},{"1":"BRD-K75466013-001-14-4","2":"benzocaine","3":"sodium channel blocker","4":"SCN10A","5":"infectious disease","6":"first-aid antiseptic","7":"Launched","8":"first-aid antiseptic","_rn_":"14767"},{"1":"BRD-A93236127-001-04-5","2":"digitoxin","3":"ATPase inhibitor","4":"ATP1A1","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"14769"},{"1":"BRD-A09722536-002-18-0","2":"cyclophosphamide","3":"DNA alkylating agent","4":"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7","5":"hematologic malignancy, oncology","6":"Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer","7":"Launched","8":"Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer","_rn_":"14771"},{"1":"BRD-A55424491-001-19-9","2":"methotrexate","3":"dihydrofolate reductase inhibitor","4":"DHFR","5":"oncology, hematologic malignancy, dermatology, rheumatology","6":"gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","7":"Launched","8":"gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","_rn_":"14773"},{"1":"BRD-K96424892-001-02-9","2":"chloramphenicol-palmitate","3":"protein synthesis inhibitor","4":"NA","5":"infectious disease, endocrinology","6":"meningitis, fever, cholera","7":"Launched","8":"meningitis, fever, cholera","_rn_":"14813"},{"1":"BRD-K51199656-003-01-4","2":"fluoromethylcholine","3":"NA","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"14815"},{"1":"BRD-A53151380-001-01-2","2":"prednisolone-tebutate","3":"anti-inflammatory agent","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"14817"},{"1":"BRD-A54275602-001-01-0","2":"lanoconazole","3":"sterol demethylase inhibitor","4":"NA","5":"infectious disease","6":"fungal infection","7":"Launched","8":"fungal infection","_rn_":"14819"},{"1":"BRD-A11815689-001-01-1","2":"proscillaridin-a","3":"NA","4":"NA","5":"cardiology","6":"congestive heart failure, cardiac arrythmia","7":"Launched","8":"congestive heart failure, cardiac arrythmia","_rn_":"14821"},{"1":"BRD-K75037734-003-13-9","2":"carbachol","3":"cholinergic receptor agonist","4":"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2","5":"ophthalmology","6":"intraocular pressure","7":"Launched","8":"intraocular pressure","_rn_":"14861"},{"1":"BRD-K08619574-334-05-4","2":"thioproperazine","3":"dopamine receptor antagonist","4":"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A","5":"neurology/psychiatry","6":"schizophrenia","7":"Launched","8":"schizophrenia","_rn_":"14863"},{"1":"BRD-K33425534-001-12-5","2":"exemestane","3":"aromatase inhibitor","4":"CYP19A1","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"14865"},{"1":"BRD-K93568044-001-32-0","2":"hydrocortisone","3":"glucocorticoid receptor agonist","4":"NA","5":"dermatology, neurology/psychiatry","6":"eczema, psoriasis, seborrheic dermatitis, itching","7":"Launched","8":"eczema, psoriasis, seborrheic dermatitis, itching","_rn_":"14867"},{"1":"BRD-K63750851-001-20-7","2":"mycophenolic-acid","3":"dehydrogenase inhibitor, inositol monophosphatase inhibitor","4":"IMPDH1, IMPDH2","5":"transplant","6":"organ rejection","7":"Launched","8":"organ rejection","_rn_":"14869"},{"1":"BRD-A68304895-003-02-2","2":"BTS-54505","3":"dopamine reuptake inhibitor","4":"SLC6A2, SLC6A3, SLC6A4","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"14908"},{"1":"BRD-A67862938-034-14-9","2":"naftidrofuryl","3":"adrenergic receptor antagonist","4":"NA","5":"cardiology","6":"claudication","7":"Launched","8":"claudication","_rn_":"14910"},{"1":"BRD-K75958547-238-01-0","2":"pitavastatin","3":"HMGCR inhibitor","4":"HMGCR","5":"endocrinology","6":"hyperlipidemia","7":"Launched","8":"hyperlipidemia","_rn_":"14912"},{"1":"BRD-K50590187-001-19-9","2":"capsaicin","3":"TRPV agonist","4":"CFTR, TRPV1","5":"neurology/psychiatry, rheumatology","6":"muscle pain, rheumatoid arthritis","7":"Launched","8":"muscle pain, rheumatoid arthritis","_rn_":"14914"},{"1":"BRD-K49840922-001-05-1","2":"etofylline-clofibrate","3":"platelet aggregation inhibitor","4":"PPARA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"14916"},{"1":"BRD-A64743628-001-01-5","2":"isometheptene-mucate","3":"NA","4":"ADRA1A, SLC18A2","5":"neurology/psychiatry","6":"headache","7":"Launched","8":"headache","_rn_":"14956"},{"1":"BRD-A41304429-001-14-8","2":"practolol","3":"adrenergic receptor antagonist","4":"ADRB1","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"14958"},{"1":"BRD-K17294426-050-12-3","2":"clebopride","3":"dopamine receptor antagonist","4":"ACHE, DRD2","5":"gastroenterology","6":"nausea","7":"Launched","8":"nausea","_rn_":"14960"},{"1":"BRD-K38003476-001-09-1","2":"clocortolone-pivalate","3":"steroid","4":"NR3C1, PLA2G1B","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"14962"},{"1":"BRD-K04548931-003-16-5","2":"epirubicin","3":"topoisomerase inhibitor","4":"CHD1, TOP2A","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"14964"},{"1":"BRD-K63828191-003-32-1","2":"raloxifene","3":"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","4":"ESR1, ESR2","5":"orthopedics, oncology","6":"osteoporosis, breast cancer","7":"Launched","8":"osteoporosis, breast cancer","_rn_":"15004"},{"1":"BRD-K54262262-001-09-0","2":"monobenzone","3":"melanin inhibitor","4":"TYR","5":"dermatology","6":"skin depigmentation","7":"Launched","8":"skin depigmentation","_rn_":"15006"},{"1":"BRD-K77987382-001-13-2","2":"mebendazole","3":"tubulin polymerization inhibitor","4":"TUBA1A, TUBB, TUBB4B","5":"infectious disease","6":"pinworm, whipworm, hookworm, ascariasis","7":"Launched","8":"pinworm, whipworm, hookworm, ascariasis","_rn_":"15008"},{"1":"BRD-K35520305-001-17-7","2":"dacarbazine","3":"DNA alkylating agent","4":"PGD, POLA2","5":"oncology, hematologic malignancy","6":"melanoma, Hodgkin's lymphoma","7":"Launched","8":"Skin Cancer, Hodgkin's lymphoma","_rn_":"15010"},{"1":"BRD-A31521121-001-26-4","2":"methocarbamol","3":"muscle relaxant","4":"CA1","5":"neurology/psychiatry","6":"muscle relaxant","7":"Launched","8":"muscle relaxant","_rn_":"15012"},{"1":"BRD-A38350138-001-04-9","2":"ketoconazole","3":"sterol demethylase inhibitor","4":"AR, CYP19A1, CYP21A2, KCNA10","5":"dermatology","6":"seborrheic dermatitis","7":"Launched","8":"seborrheic dermatitis","_rn_":"15052"},{"1":"BRD-K93034159-001-25-8","2":"cladribine","3":"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor","4":"ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B","5":"hematologic malignancy","6":"hairy cell leukemia","7":"Launched","8":"hairy cell leukemia","_rn_":"15054"},{"1":"BRD-A06627858-236-03-0","2":"monensin","3":"bacterial permeability inducer","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"15056"},{"1":"BRD-K70505054-003-12-4","2":"ranitidine","3":"histamine receptor antagonist","4":"HRH2","5":"gastroenterology","6":"heartburn","7":"Launched","8":"heartburn","_rn_":"15058"},{"1":"BRD-A39390670-236-10-7","2":"rabeprazole","3":"ATPase inhibitor, gastrin inhibitor","4":"ATP4A","5":"gastroenterology","6":"gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome","7":"Launched","8":"gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome","_rn_":"15060"},{"1":"BRD-K68693535-001-03-4","2":"lidamidine","3":"adrenergic receptor agonist","4":"NA","5":"gastroenterology","6":"diarrhea","7":"Launched","8":"diarrhea","_rn_":"15099"},{"1":"BRD-K92073408-001-16-5","2":"norethindrone","3":"progesterone receptor agonist","4":"PGR","5":"obstetrics/gynecology","6":"endometriosis","7":"Launched","8":"endometriosis","_rn_":"15101"},{"1":"BRD-K70358946-001-15-7","2":"aripiprazole","3":"serotonin receptor agonist, serotonin receptor antagonist","4":"ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7","5":"neurology/psychiatry","6":"depression, schizophrenia, bipolar disorder","7":"Launched","8":"depression, schizophrenia, bipolar disorder","_rn_":"15103"},{"1":"BRD-K59574735-001-11-8","2":"ubenimex","3":"leukotriene synthesis inhibitor","4":"LTA4H, RNPEP","5":"hematologic malignancy","6":"acute myeloid leukemia (AML)","7":"Launched","8":"acute myeloid leukemia (AML)","_rn_":"15105"},{"1":"BRD-K35189033-001-26-1","2":"levonorgestrel","3":"estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist","4":"AR, ESR1, PGR, SRD5A1","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"15107"},{"1":"BRD-K62810658-001-12-2","2":"PD-98059","3":"MEK inhibitor","4":"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15910"},{"1":"BRD-K58122457-001-02-2","2":"hesperadin","3":"Aurora kinase inhibitor","4":"AURKB","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15912"},{"1":"BRD-A14344385-001-03-2","2":"IDRA-21","3":"glutamate receptor positive allosteric modulator","4":"GRIA1, GRIA2, GRIA3, GRIA4","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15914"},{"1":"BRD-K68633617-003-02-9","2":"ACDPP","3":"glutamate receptor antagonist","4":"GRM5","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15916"},{"1":"BRD-K13571841-001-14-4","2":"pepstatin","3":"aspartic protease inhibitor","4":"CTSB, CTSD, CTSL, REN","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15918"},{"1":"BRD-K98157055-001-10-9","2":"SIB-1757","3":"glutamate receptor antagonist","4":"GRM5","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15955"},{"1":"BRD-A34751532-001-06-9","2":"homosalate","3":"HSP inducer","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15957"},{"1":"BRD-K37720887-001-07-8","2":"SB-525334","3":"TGF beta receptor inhibitor","4":"TGFBR1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15959"},{"1":"BRD-K86727142-001-12-4","2":"embelin","3":"HCV inhibitor, XIAP inhibitor","4":"XIAP","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15961"},{"1":"BRD-A72703248-003-04-9","2":"SKF-96365","3":"calcium channel blocker","4":"CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15963"},{"1":"BRD-K33277808-331-01-3","2":"ouabain","3":"ATPase inhibitor","4":"ATP1A1","5":"cardiology","6":"hypertension, cardiac arrythmia","7":"Launched","8":"hypertension, cardiac arrythmia","_rn_":"16000"},{"1":"BRD-K51474575-001-10-4","2":"taurine","3":"antioxidant","4":"NA","5":"neurology/psychiatry","6":"anxiety, irritability, sleeplessness","7":"Launched","8":"anxiety, irritability, sleeplessness","_rn_":"16002"},{"1":"BRD-K52172416-001-11-4","2":"anastrozole","3":"aromatase inhibitor","4":"CYP19A1","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"16003"},{"1":"BRD-A24587114-066-22-5","2":"isoetharine","3":"adrenergic receptor agonist","4":"ADRB1, ADRB2","5":"pulmonary","6":"bronchospasm, asthma","7":"Launched","8":"bronchospasm, asthma","_rn_":"16005"},{"1":"BRD-K58049875-001-04-7","2":"thiostrepton","3":"FOXM1 inhibitor, protein synthesis inhibitor","4":"FOXM1","5":"obstetrics/gynecology","6":"mastitis","7":"Launched","8":"mastitis","_rn_":"16007"},{"1":"BRD-K37590257-001-02-8","2":"GSK256066","3":"phosphodiesterase inhibitor","4":"PDE4A","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16045"},{"1":"BRD-K84683831-001-01-0","2":"radezolid","3":"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16047"},{"1":"BRD-K49555808-001-03-9","2":"BMS-707035","3":"HIV integrase inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16049"},{"1":"BRD-K24576554-001-04-8","2":"AT-9283","3":"Aurora kinase inhibitor, JAK inhibitor","4":"AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16052"},{"1":"BRD-K52233191-001-02-4","2":"R547","3":"CDK inhibitor","4":"CDK1, CDK2, CDK4, CDK7","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"16091"},{"1":"BRD-K85406984-001-01-0","2":"sobetirome","3":"thyroid hormone receptor agonist","4":"THRA, THRB","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"16094"},{"1":"BRD-K81458380-001-04-9","2":"CX-4945","3":"casein kinase inhibitor","4":"CSNK2A1, CSNK2A2, DAPK3, HIPK3","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"16096"},{"1":"BRD-K63504947-001-15-4","2":"semaxanib","3":"VEGFR inhibitor","4":"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"16098"},{"1":"BRD-K19412355-001-01-0","2":"SB-242235","3":"p38 MAPK inhibitor","4":"HSPB1, MAPK14","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"16138"},{"1":"BRD-K09602097-001-13-6","2":"forskolin","3":"adenylyl cyclase activator","4":"ADCY2, ADCY5, GNAS","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"16140"},{"1":"BRD-K26838195-075-04-9","2":"AST-1306","3":"EGFR inhibitor","4":"EGFR, ERBB2","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"16141"},{"1":"BRD-K18157228-001-01-7","2":"fdcyd","3":"DNA methyltransferase inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16143"},{"1":"BRD-K20545304-001-01-6","2":"bardoxolone","3":"nuclear factor erythroid derived, like (NRF2) activator","4":"NOS2, PPARG","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"16185"},{"1":"BRD-K65924316-001-03-1","2":"serdemetan","3":"MDM inhibitor","4":"MDM2","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"16187"},{"1":"BRD-K94559059-091-01-6","2":"telotristat-ethyl","3":"tryptophan hydroxylase inhibitor","4":"TPH1","5":"gastroenterology","6":"diarrhea","7":"Launched","8":"diarrhea","_rn_":"16189"},{"1":"BRD-K41278234-001-03-0","2":"CUDC-101","3":"EGFR inhibitor","4":"EGFR, ERBB2","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"16191"},{"1":"BRD-K28822270-001-01-1","2":"resminostat","3":"HDAC inhibitor","4":"HDAC1, HDAC3, HDAC6, HDAC8","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16226"},{"1":"BRD-K29673530-001-05-4","2":"hypericin","3":"tyrosine kinase inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16228"},{"1":"BRD-K13050541-001-01-9","2":"acivicin","3":"gamma glutamyltransferase Inhibitors","4":"CTPS1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16230"},{"1":"BRD-K68065987-300-09-1","2":"MK-2206","3":"AKT inhibitor","4":"AKT1, AKT2, AKT3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16232"},{"1":"BRD-K37618799-001-03-0","2":"MRS-1220","3":"adenosine receptor antagonist","4":"ADORA2B, ADORA3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"17037"},{"1":"BRD-A94624445-236-17-0","2":"bucladesine","3":"adenosine receptor agonist, cAMP stimulant","4":"PRKACA","5":"dermatology","6":"skin ulcer","7":"Launched","8":"skin ulcer","_rn_":"17039"},{"1":"BRD-K08996725-332-01-7","2":"zolantidine","3":"histamine receptor antagonist","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"17041"},{"1":"BRD-K55462201-001-07-3","2":"AM-404","3":"cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist","4":"CNR1, CNR2, FAAH, TRPV1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"17043"},{"1":"BRD-A74208568-003-01-5","2":"CGP-54626","3":"GABA receptor antagonist","4":"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"17045"},{"1":"BRD-K12040459-001-06-0","2":"AT7867","3":"AKT inhibitor","4":"AKT2, GSK3B, PKIA, PRKACA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"17084"},{"1":"BRD-K78496197-001-03-9","2":"SCS","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"17086"},{"1":"BRD-A43809092-003-02-1","2":"clobutinol","3":"antitussive","4":"NA","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"17088"},{"1":"BRD-K73391359-003-10-2","2":"dimethisoquin","3":"local anesthetic","4":"NA","5":"neurology/psychiatry","6":"local anesthetic","7":"Launched","8":"local anesthetic","_rn_":"17090"},{"1":"BRD-K56707426-001-02-0","2":"nitarsone","3":"NA","4":"NA","5":"dermatology","6":"blackhead disease","7":"Launched","8":"blackhead disease","_rn_":"17092"},{"1":"BRD-A75850590-213-01-0","2":"lomefloxacin","3":"bacterial DNA gyrase inhibitor","4":"TOP2A","5":"infectious disease","6":"respiratory tract infections, urinary tract infections","7":"Launched","8":"respiratory tract infections, urinary tract infections","_rn_":"17132"},{"1":"BRD-A91366704-001-01-9","2":"eprinomectin","3":"benzodiazepine receptor agonist","4":"NA","5":"infectious disease","6":"gastrointestinal roundworms, lungworms","7":"Launched","8":"gastrointestinal roundworms, lungworms","_rn_":"17134"},{"1":"BRD-K43578482-001-01-4","2":"defactinib","3":"focal adhesion kinase inhibitor","4":"PTK2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17136"},{"1":"BRD-K83699324-001-01-1","2":"NMS-1286937","3":"PLK inhibitor","4":"FLT3, PLK1, PLK2, PLK3","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"17138"},{"1":"BRD-K19061412-001-02-4","2":"mubritinib","3":"protein tyrosine kinase inhibitor","4":"EGFR, ERBB2","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"17140"},{"1":"BRD-K85751432-001-03-3","2":"refametinib","3":"MEK inhibitor","4":"MAP2K1, MAP2K2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17180"},{"1":"BRD-M89827113-001-01-5","2":"cromakalim","3":"NA","4":"KCNJ8","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17182"},{"1":"BRD-A64064900-001-02-3","2":"sangivamycin","3":"DNA inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"17184"},{"1":"BRD-A51571244-001-01-9","2":"hypoestoxide","3":"IKK inhibitor","4":"IKBKB, IL1B, TNF","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"17186"},{"1":"BRD-K81694556-003-01-9","2":"VTP-27999","3":"renin inhibitor","4":"REN","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"17228"},{"1":"BRD-K95573441-001-01-2","2":"PFK-015","3":"phosphofructokinase inhibitor","4":"PFKFB3","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"17230"},{"1":"BRD-K62762455-001-01-3","2":"RU-58841","3":"androgen receptor antagonist","4":"AR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17232"},{"1":"BRD-K37069697-001-01-3","2":"fexinidazole","3":"NA","4":"NA","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"17234"},{"1":"BRD-K46690591-001-01-2","2":"KP-1212","3":"NA","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17236"},{"1":"BRD-A10903566-003-07-7","2":"imiloxan","3":"adrenergic receptor antagonist","4":"ADRA2A, ADRA2B","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"17278"},{"1":"BRD-K55703048-001-07-7","2":"latrepirdine","3":"glutamate receptor antagonist","4":"HRH1, HTR6","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"17282"},{"1":"BRD-K08703257-001-12-1","2":"3-amino-benzamide","3":"PARP inhibitor","4":"PARP1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17284"},{"1":"BRD-K52762805-001-01-2","2":"epothilone-d","3":"microtubule stabilizing agent, tubulin polymerization inhibitor","4":"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17324"},{"1":"BRD-K16485616-001-08-9","2":"mocetinostat","3":"HDAC inhibitor","4":"HDAC1, HDAC11, HDAC2, HDAC3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17330"},{"1":"BRD-A55312468-001-04-7","2":"k-strophanthidin","3":"ATPase inhibitor","4":"ATP1A1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17332"},{"1":"BRD-K83837640-001-04-8","2":"JNJ-26481585","3":"HDAC inhibitor","4":"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17372"},{"1":"BRD-K83963101-001-06-9","2":"MLN-8054","3":"Aurora kinase inhibitor","4":"AURKA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"17374"},{"1":"BRD-K12184916-001-15-4","2":"NVP-BEZ235","3":"mTOR inhibitor, PI3K inhibitor","4":"ATR, MTOR, PIK3CA, PIK3CD, PIK3CG","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17376"},{"1":"BRD-K15600710-066-04-1","2":"obatoclax","3":"BCL inhibitor","4":"BCL2","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"17380"},{"1":"BRD-K07106112-003-03-8","2":"BMS-599626","3":"EGFR inhibitor, protein tyrosine kinase inhibitor","4":"EGFR, ERBB2, ERBB4","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18153"},{"1":"BRD-K68747584-001-02-0","2":"PF-03814735","3":"Aurora kinase inhibitor","4":"AURKA, AURKB","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18155"},{"1":"BRD-K38287497-001-01-2","2":"narlaprevir","3":"HCV inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"18157"},{"1":"BRD-K56751279-300-01-4","2":"Y-39983","3":"rho associated kinase inhibitor","4":"ROCK1, ROCK2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18159"},{"1":"BRD-K72414522-001-06-7","2":"AZD5438","3":"CDK inhibitor","4":"KCNH2","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18200"},{"1":"BRD-K56032964-001-02-1","2":"AP26113","3":"ALK tyrosine kinase receptor inhibitor","4":"ALK, EGFR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18202"},{"1":"BRD-K01029106-001-01-4","2":"picolinic-acid","3":"chelating agent","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18206"},{"1":"BRD-K68938568-001-01-7","2":"GDC-0152","3":"XIAP inhibitor","4":"BIRC2, BIRC3, BIRC7, XIAP","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18208"},{"1":"BRD-K82746043-001-15-1","2":"navitoclax","3":"BCL inhibitor","4":"BCL2, BCL2L1, BCL2L2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18248"},{"1":"BRD-K68552125-001-05-3","2":"12-O-tetradecanoylphorbol-13-acetate","3":"PKC activator","4":"KCNT2, TRPV4","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18250"},{"1":"BRD-K00152668-001-01-5","2":"adarotene","3":"retinoid receptor agonist","4":"RARB, RARG","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18252"},{"1":"BRD-A03506276-001-01-5","2":"XL888","3":"HSP inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18254"},{"1":"BRD-K68488863-001-04-9","2":"ENMD-2076","3":"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor","4":"AURKA, FLT3, KDR, PDGFRA, PTK2, SRC","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18256"},{"1":"BRD-K80700417-001-04-2","2":"SGI-1776","3":"Pim kinase inhibitor","4":"FLT3, PIM1, PIM2, PIM3","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18294"},{"1":"BRD-K02389548-001-02-5","2":"RG2833","3":"HDAC inhibitor","4":"HDAC1, HDAC3","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18296"},{"1":"BRD-K07310275-001-02-5","2":"PF-04691502","3":"mTOR inhibitor, PI3K inhibitor","4":"MTOR, PIK3CA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18298"},{"1":"BRD-K64866502-001-03-9","2":"CYC116","3":"Aurora kinase inhibitor","4":"AURKA, AURKB, KDR","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18300"},{"1":"BRD-K39624409-003-02-6","2":"ADL5859","3":"opioid receptor agonist","4":"OPRD1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18302"},{"1":"BRD-K69726595-001-01-2","2":"mericitabine","3":"HCV inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18342"},{"1":"BRD-K29968218-001-03-2","2":"KX2-391","3":"src inhibitor, tubulin polymerization inhibitor","4":"SRC","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18344"},{"1":"BRD-K71512533-066-02-8","2":"SNS-314","3":"Aurora kinase inhibitor","4":"AURKA, AURKB, AURKC","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18346"},{"1":"BRD-K63923597-001-10-0","2":"barasertib-HQPA","3":"Aurora kinase inhibitor","4":"AURKB","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"18348"},{"1":"BRD-K31476763-001-01-5","2":"AZD9668","3":"elastase inhibitor","4":"ELANE","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18350"},{"1":"BRD-K37379014-001-01-2","2":"filanesib","3":"kinesin inhibitor, kinesin-like spindle protein inhibitor","4":"KIF11","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"18390"},{"1":"BRD-K69932463-001-10-6","2":"AZD8055","3":"mTOR inhibitor","4":"MTOR","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18392"},{"1":"BRD-K03063480-001-06-6","2":"PF-477736","3":"CHK inhibitor","4":"CHEK1, CHEK2","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18394"},{"1":"BRD-K14385366-001-04-4","2":"FG-4592","3":"hypoxia inducible factor prolyl hydroxylase inhibitor","4":"EGLN2","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"18396"},{"1":"BRD-K89162000-001-06-4","2":"tandutinib","3":"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","4":"CSF1R, FLT3, KIT, PDGFD, PDGFRB","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18398"},{"1":"BRD-A72716251-001-01-5","2":"peruvoside","3":"cardiac glycoside","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18438"},{"1":"BRD-K25412176-001-01-9","2":"GSK2110183","3":"AKT inhibitor","4":"AKT1, AKT2, AKT3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18440"},{"1":"BRD-K23677682-003-01-2","2":"voreloxin","3":"topoisomerase inhibitor","4":"TOP2A","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"18442"},{"1":"BRD-K34073885-001-09-3","2":"tanshinone-i","3":"AP inhibitor","4":"IFNG","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18444"},{"1":"BRD-K14880289-001-02-2","2":"GW-501516","3":"PPAR receptor agonist","4":"PPARA, PPARD","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18446"},{"1":"BRD-K36269323-300-02-6","2":"asymmetrical-dimethylarginine","3":"nitric oxide synthase inhibitor","4":"NOS2, NOS3","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18485"},{"1":"BRD-K25340465-001-11-1","2":"OSI-930","3":"KIT inhibitor, VEGFR inhibitor","4":"KDR, KIT","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18487"},{"1":"BRD-K92150287-066-01-2","2":"exatecan-mesylate","3":"topoisomerase inhibitor","4":"TOP1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"18491"},{"1":"BRD-K68164687-001-01-6","2":"epothilone-b","3":"microtubule stabilizing agent, tubulin polymerization inhibitor","4":"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19295"},{"1":"BRD-K68103045-001-02-9","2":"CGS-20625","3":"benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist","4":"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19299"},{"1":"BRD-K68392338-003-02-0","2":"ZK-93426","3":"benzodiazepine receptor antagonist","4":"GABRA1, GABRA2, GABRA3, GABRA5","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19301"},{"1":"BRD-K77908580-001-09-6","2":"entinostat","3":"HDAC inhibitor","4":"HDAC1, HDAC2, HDAC3, HDAC9","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19340"},{"1":"BRD-K73319509-001-08-0","2":"PF-04217903","3":"c-Met inhibitor","4":"MET","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19342"},{"1":"BRD-K61036791-001-01-6","2":"rucinol","3":"tyrosinase inhibitor","4":"TYR","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19344"},{"1":"BRD-K70511574-001-06-9","2":"HMN-214","3":"PLK inhibitor","4":"PLK1","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19346"},{"1":"BRD-K59325863-001-02-8","2":"delanzomib","3":"proteasome inhibitor","4":"CMA1, CTSG, CYP3A4, ELANE","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"19348"},{"1":"BRD-K41599323-001-02-3","2":"lonafarnib","3":"farnesyltransferase inhibitor","4":"FNTA, HRAS, KRAS, NRAS","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19390"},{"1":"BRD-K93918653-001-08-9","2":"quizartinib","3":"FLT3 inhibitor","4":"CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19392"},{"1":"BRD-A07704283-001-01-3","2":"isofloxythepin","3":"dopamine receptor antagonist","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19394"},{"1":"BRD-K71221037-001-01-6","2":"birinapant","3":"XIAP inhibitor","4":"BIRC2, XIAP","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19396"},{"1":"BRD-K99023089-001-03-7","2":"AZD5363","3":"AKT inhibitor","4":"AKT1, AKT2, AKT3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19436"},{"1":"BRD-K28392481-001-05-1","2":"AZD4547","3":"FGFR inhibitor","4":"FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"19438"},{"1":"BRD-A39935389-001-05-9","2":"teroxirone","3":"DNA inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19440"},{"1":"BRD-K37764012-001-04-1","2":"PF-03758309","3":"p21 activated kinase inhibitor","4":"PAK4","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19442"},{"1":"BRD-A56085258-001-01-8","2":"LGX818","3":"RAF inhibitor","4":"BRAF","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19444"},{"1":"BRD-K28965160-001-01-1","2":"BVD-523","3":"MAP kinase inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"19486"},{"1":"BRD-K13049116-001-05-7","2":"BMS-754807","3":"IGF-1 inhibitor","4":"AKT1, IGF1R","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19488"},{"1":"BRD-K70163715-300-05-7","2":"vatalanib","3":"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"EGFR, FLT1, FLT4, KDR, PDGFRB","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19490"},{"1":"BRD-K26823213-001-02-9","2":"GW-842166","3":"cannabinoid receptor agonist","4":"CNR2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19492"},{"1":"BRD-K71164191-001-01-0","2":"KD-023","3":"ACAT inhibitor","4":"ACACA, ACACB","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19531"},{"1":"BRD-K88506063-001-01-8","2":"KD025","3":"rho associated kinase inhibitor","4":"ROCK2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19533"},{"1":"BRD-K26667523-001-02-5","2":"TAK-733","3":"MEK inhibitor","4":"MAP2K1","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19535"},{"1":"BRD-K05445342-001-05-3","2":"WP1066","3":"STAT inhibitor","4":"STAT3","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19537"},{"1":"BRD-K86797399-001-05-1","2":"SB-939","3":"HDAC inhibitor","4":"HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19539"},{"1":"BRD-K53665955-001-03-0","2":"MK-5108","3":"Aurora kinase inhibitor","4":"AURKA, AURKB, AURKC","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19579"},{"1":"BRD-K76703230-004-04-1","2":"YM-155","3":"survivin inhibitor","4":"BIRC5","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19581"},{"1":"BRD-A26032986-050-02-1","2":"zaldaride","3":"calmodulin antagonist","4":"CALM1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19583"},{"1":"BRD-K25630527-001-03-8","2":"LY2784544","3":"JAK inhibitor","4":"JAK2, JAK3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19585"},{"1":"BRD-K22127577-001-03-7","2":"crenolanib","3":"PDGFR tyrosine kinase receptor inhibitor","4":"CSF1R, FLT3, KIT, PDGFRA, PDGFRB","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19630"},{"1":"BRD-K21396683-001-04-8","2":"marimastat","3":"matrix metalloprotease inhibitor","4":"MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19632"},{"1":"BRD-K13756951-001-01-4","2":"bitopertin","3":"glycine transporter inhibitor, GlyT-1 inhibitor","4":"SLC6A5, SLC6A9","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19634"},{"1":"BRD-A24514565-001-09-7","2":"warfarin","3":"vitamin K antagonist","4":"VKORC1","5":"hematology, cardiology","6":"deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction","7":"Launched","8":"deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction","_rn_":"20434"},{"1":"BRD-K54247840-004-01-3","2":"halofuginone","3":"collagenase inhibitor","4":"COL1A1, MMP2","5":"rheumatology","6":"scleroderma","7":"Launched","8":"scleroderma","_rn_":"20436"},{"1":"BRD-K60348325-065-09-9","2":"brilliant-green","3":"NA","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"20438"},{"1":"BRD-K08303368-001-10-0","2":"chlorpyrifos","3":"acetylcholinesterase inhibitor","4":"ACHE","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"20440"},{"1":"BRD-A10977446-001-12-1","2":"carvedilol","3":"adrenergic receptor antagonist","4":"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA","5":"cardiology","6":"myocardial infarction, hypertension","7":"Launched","8":"myocardial infarction, hypertension","_rn_":"20442"},{"1":"BRD-K18910433-001-36-6","2":"estradiol","3":"estrogen receptor agonist","4":"ESR1, ESR2, GPER1, KCNMA1, NR1I2","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"20482"},{"1":"BRD-K65377893-001-07-4","2":"7-aminocephalosporanic-acid","3":"beta lactamase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"20484"},{"1":"BRD-A94756469-001-04-7","2":"digoxin","3":"ATPase inhibitor","4":"ATP1A1","5":"cardiology","6":"congestive heart failure, atrial fibrillation (AF)","7":"Launched","8":"congestive heart failure, atrial fibrillation (AF)","_rn_":"20486"},{"1":"BRD-K93869735-001-01-1","2":"taltirelin","3":"thyrotropin releasing hormone receptor agonist","4":"TRHR","5":"neurology/psychiatry","6":"spinocerebellar ataxia","7":"Launched","8":"spinocerebellar ataxia","_rn_":"20488"},{"1":"BRD-K90027355-001-13-3","2":"spironolactone","3":"mineralocorticoid receptor antagonist","4":"AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG","5":"endocrinology, cardiology, gastroenterology, rheumatology","6":"hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia","7":"Launched","8":"hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia","_rn_":"20490"},{"1":"BRD-A74391928-051-01-3","2":"ibutilide","3":"potassium channel blocker","4":"CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6","5":"cardiology","6":"atrial fibrillation (AF)","7":"Launched","8":"atrial fibrillation (AF)","_rn_":"20530"},{"1":"BRD-K05524748-003-04-4","2":"dronedarone","3":"adrenergic receptor antagonist","4":"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A","5":"cardiology","6":"atrial fibrillation (AF)","7":"Launched","8":"atrial fibrillation (AF)","_rn_":"20532"},{"1":"BRD-K09549677-300-03-4","2":"mibefradil","3":"T-type calcium channel blocker","4":"ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"20534"},{"1":"BRD-K49962337-001-02-9","2":"baicalin","3":"beta glucuronidase inhibitor","4":"PREP","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"20536"},{"1":"BRD-K00494077-066-01-9","2":"trovafloxacin","3":"bacterial DNA gyrase inhibitor","4":"TOP2A","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"20538"},{"1":"BRD-K08586861-001-01-1","2":"ramatroban","3":"prostanoid receptor antagonist","4":"PTGDR2, TBXA2R","5":"cardiology, pulmonary","6":"coronary artery disease (CAD), asthma","7":"Launched","8":"coronary artery disease (CAD), asthma","_rn_":"20577"},{"1":"BRD-K24844714-001-24-5","2":"5-fluorouracil","3":"thymidylate synthase inhibitor","4":"DPYD, TYMS","5":"oncology","6":"colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma","7":"Launched","8":"Colon/Colorectal Cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma","_rn_":"20579"},{"1":"BRD-K97799481-001-16-0","2":"theophylline","3":"adenosine receptor antagonist","4":"NA","5":"pulmonary","6":"asthma, emphysema, bronchitis","7":"Launched","8":"asthma, emphysema, bronchitis","_rn_":"20581"},{"1":"BRD-A13133631-001-04-0","2":"fluorometholone","3":"glucocorticoid receptor agonist","4":"NR3C1","5":"ophthalmology","6":"eye inflammation","7":"Launched","8":"eye inflammation","_rn_":"20583"},{"1":"BRD-A09349126-001-10-7","2":"norethindrone-acetate","3":"progesterone receptor agonist","4":"NA","5":"endocrinology, orthopedics, obstetrics/gynecology","6":"menopause, osteoporosis, vaginal atrophy","7":"Launched","8":"menopause, osteoporosis, vaginal atrophy","_rn_":"20585"},{"1":"BRD-A93695607-322-02-5","2":"nicotine","3":"acetylcholine receptor agonist","4":"CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1","5":"neurology/psychiatry","6":"smoking cessation","7":"Launched","8":"smoking cessation","_rn_":"20625"},{"1":"BRD-K78126613-001-28-5","2":"menadione","3":"mitochondrial DNA polymerase inhibitor, phosphatase inhibitor","4":"AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1","5":"gastroenterology, neurology/psychiatry, dermatology, rheumatology","6":"ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis","7":"Launched","8":"ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis","_rn_":"20627"},{"1":"BRD-A08187463-001-12-9","2":"racecadotril","3":"enkephalinase inhibitor","4":"MME","5":"gastroenterology","6":"diarrhea","7":"Launched","8":"diarrhea","_rn_":"20629"},{"1":"BRD-K30480208-001-18-5","2":"torasemide","3":"electrolyte reabsorption inhibitor, thromboxane receptor antagonist","4":"SLC12A1","5":"cardiology","6":"edema, congestive heart failure, hypertension","7":"Launched","8":"edema, congestive heart failure, hypertension","_rn_":"20631"},{"1":"BRD-K97746869-001-27-0","2":"chlorpropamide","3":"ATP channel blocker","4":"ABCC8, KCNJ10, KCNJ11","5":"endocrinology","6":"diabetes mellitus","7":"Launched","8":"diabetes mellitus","_rn_":"20633"},{"1":"BRD-K67261995-001-11-7","2":"iodipamide","3":"radiopaque medium","4":"ALB","5":"radiology","6":"contrast agent","7":"Launched","8":"contrast agent","_rn_":"20673"},{"1":"BRD-K27217864-001-22-3","2":"butamben","3":"sodium channel blocker","4":"NA","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"20675"},{"1":"BRD-A50157456-065-20-6","2":"terbutaline","3":"adrenergic receptor agonist","4":"ADRB2","5":"pulmonary","6":"bronchospasm, bronchitis, emphysema","7":"Launched","8":"bronchospasm, bronchitis, emphysema","_rn_":"20677"},{"1":"BRD-K68507560-003-24-6","2":"dicycloverine","3":"acetylcholine receptor antagonist","4":"CHRM1, CHRM2, CHRM3","5":"gastroenterology","6":"irritable bowel syndrome","7":"Launched","8":"irritable bowel syndrome","_rn_":"20679"},{"1":"BRD-A53951045-004-01-6","2":"butylscopolamine-bromide","3":"cholinergic receptor antagonist","4":"NA","5":"gastroenterology","6":"abdominal pain","7":"Launched","8":"abdominal pain","_rn_":"20681"},{"1":"BRD-K66788707-001-14-3","2":"fludarabine","3":"ribonucleotide reductase inhibitor","4":"ADA, RRM1, RRM2","5":"hematologic malignancy","6":"chronic lymphocytic leukemia (CLL)","7":"Launched","8":"chronic lymphocytic leukemia (CLL)","_rn_":"20721"},{"1":"BRD-K13387373-004-14-5","2":"thonzonium","3":"ATPase inhibitor","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"20723"},{"1":"BRD-A60197193-001-14-6","2":"amisulpride","3":"dopamine receptor antagonist","4":"DRD2, DRD3, HTR2A, HTR7","5":"neurology/psychiatry","6":"psychosis, bipolar disorder, schizophrenia","7":"Launched","8":"psychosis, bipolar disorder, schizophrenia","_rn_":"20725"},{"1":"BRD-K08525451-003-05-2","2":"sarafloxacin","3":"bacterial DNA gyrase inhibitor","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"20727"},{"1":"BRD-A06426627-001-03-5","2":"diclazuril","3":"antiprotozoal agent","4":"NA","5":"infectious disease","6":"equine protozoal myeloencephalitis (EPM)","7":"Launched","8":"equine protozoal myeloencephalitis (EPM)","_rn_":"20729"},{"1":"BRD-K49350383-001-13-7","2":"thioguanine","3":"purine antagonist","4":"IMPDH1, IMPDH2","5":"hematologic malignancy","6":"acute myeloid leukemia (AML)","7":"Launched","8":"acute myeloid leukemia (AML)","_rn_":"20769"},{"1":"BRD-K31812033-003-11-0","2":"levobunolol","3":"adrenergic receptor antagonist","4":"ADRB1, ADRB2, ADRB3","5":"ophthalmology","6":"glaucoma, ocular hypertension","7":"Launched","8":"glaucoma, ocular hypertension","_rn_":"20773"},{"1":"BRD-K74501079-001-18-1","2":"azithromycin","3":"bacterial 50S ribosomal subunit inhibitor","4":"MLNR","5":"infectious disease","6":"pelvic inflammatory disease, pneumonia","7":"Launched","8":"pelvic inflammatory disease, pneumonia","_rn_":"20775"},{"1":"BRD-A20239487-001-24-9","2":"atenolol-(+/-)","3":"adrenergic receptor antagonist","4":"ADRB1, ADRB2","5":"cardiology","6":"hypertension, angina pectoris","7":"Launched","8":"hypertension, angina pectoris","_rn_":"20777"},{"1":"BRD-K21937671-001-09-2","2":"loxistatin-acid","3":"cysteine peptidase inhibitor","4":"CTSB","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"21583"},{"1":"BRD-A92630576-050-24-1","2":"trimebutine","3":"opioid receptor agonist","4":"OPRD1, OPRK1, OPRM1","5":"gastroenterology","6":"irritable bowel syndrome","7":"Launched","8":"irritable bowel syndrome","_rn_":"21585"},{"1":"BRD-A97739905-001-26-5","2":"ketoprofen","3":"cyclooxygenase inhibitor","4":"CXCR1, PTGS1, PTGS2, SLC5A8","5":"rheumatology","6":"rheumatoid arthritis, osteoarthritis","7":"Launched","8":"rheumatoid arthritis, osteoarthritis","_rn_":"21587"},{"1":"BRD-K27316855-001-13-3","2":"calcitriol","3":"vitamin D receptor agonist","4":"VDR","5":"endocrinology, orthopedics","6":"hypocalcemia, hypoparathyroidism, osteoporosis","7":"Launched","8":"hypocalcemia, hypoparathyroidism, osteoporosis","_rn_":"21588"},{"1":"BRD-A75726477-003-21-3","2":"clenbuterol","3":"adrenergic receptor agonist","4":"ADRB1, ADRB2, ADRB3, NGF, TNF","5":"pulmonary","6":"chronic obstructive pulmonary disease (COPD), asthma","7":"Launched","8":"chronic obstructive pulmonary disease (COPD), asthma","_rn_":"21589"},{"1":"BRD-K25433859-003-25-4","2":"maprotiline","3":"norepinephrine reputake inhibitor, tricyclic antidepressant","4":"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2","5":"neurology/psychiatry","6":"depression, dysthymic disorder","7":"Launched","8":"depression, dysthymic disorder","_rn_":"21628"},{"1":"BRD-K21547160-001-01-4","2":"sufentanil","3":"opioid receptor modulator","4":"OPRD1, OPRK1, OPRM1","5":"neurology/psychiatry","6":"anesthetic","7":"Launched","8":"anesthetic","_rn_":"21630"},{"1":"BRD-A97701745-001-16-0","2":"pindolol","3":"adrenergic receptor antagonist","4":"ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"21634"},{"1":"BRD-K40308497-001-01-2","2":"crizotinib-(S)","3":"MTH1 inhibitor","4":"NUDT1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"21636"},{"1":"BRD-A03932035-004-04-3","2":"methscopolamine","3":"acetylcholine receptor antagonist","4":"CHRM1, CHRM2, CHRM3","5":"gastroenterology","6":"peptic ulcer disease (PUD)","7":"Launched","8":"peptic ulcer disease (PUD)","_rn_":"21672"},{"1":"BRD-K23984367-075-15-2","2":"sorafenib","3":"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","4":"BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET","5":"oncology","6":"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","7":"Launched","8":"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","_rn_":"21674"},{"1":"BRD-M80207679-001-01-5","2":"nemonapride","3":"dopamine receptor antagonist","4":"DRD2, DRD3, DRD4","5":"neurology/psychiatry","6":"schizophrenia","7":"Launched","8":"schizophrenia","_rn_":"21676"},{"1":"BRD-K10961822-001-05-1","2":"latanoprost","3":"prostanoid receptor agonist","4":"PTGFR","5":"ophthalmology","6":"ocular hypertension, glaucoma","7":"Launched","8":"ocular hypertension, glaucoma","_rn_":"21678"},{"1":"BRD-A14886633-001-01-6","2":"norgestrel","3":"progesterone receptor agonist","4":"PGR","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"21680"},{"1":"BRD-A80017228-001-25-7","2":"bendroflumethiazide","3":"sodium/potassium/chloride transporter inhibitor","4":"CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"21720"},{"1":"BRD-K74763371-002-04-0","2":"bosentan","3":"endothelin receptor antagonist","4":"EDNRA, EDNRB","5":"pulmonary","6":"pulmonary arterial hypertension (PAH)","7":"Launched","8":"pulmonary arterial hypertension (PAH)","_rn_":"21721"},{"1":"BRD-A79981887-003-16-4","2":"midodrine","3":"adrenergic receptor agonist","4":"ADRA1A, ADRA1B, ADRA1D","5":"cardiology","6":"hypotension","7":"Launched","8":"hypotension","_rn_":"21723"},{"1":"BRD-K92213669-001-01-3","2":"lomitapide","3":"microsomal trigylceride transfer protein inhibitor","4":"MTTP","5":"endocrinology","6":"hypercholesterolemia","7":"Launched","8":"hypercholesterolemia","_rn_":"21725"},{"1":"BRD-K07359318-001-03-9","2":"benfotiamine","3":"antioxidant","4":"AGER","5":"rheumatology","6":"lumbago","7":"Launched","8":"lumbago","_rn_":"21764"},{"1":"BRD-K79131256-001-17-9","2":"albendazole","3":"tubulin polymerization inhibitor","4":"TUBA1A, TUBB, TUBB4B","5":"infectious disease","6":"cystic hydatid disease, parenchymal neurocysticercosis","7":"Launched","8":"cystic hydatid disease, parenchymal neurocysticercosis","_rn_":"21766"},{"1":"BRD-A17846016-001-13-9","2":"trolox","3":"antioxidant","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"21768"},{"1":"BRD-K94720315-001-10-4","2":"chromocarb","3":"antispasmodic","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"21772"},{"1":"BRD-K39987650-001-24-1","2":"bisacodyl","3":"laxative","4":"NA","5":"gastroenterology","6":"constipation","7":"Launched","8":"constipation","_rn_":"21811"},{"1":"BRD-A28301258-001-03-0","2":"salinomycin","3":"NA","4":"NA","5":"infectious disease","6":"coccidiosis","7":"Launched","8":"coccidiosis","_rn_":"21814"},{"1":"BRD-A30886737-001-02-9","2":"florfenicol","3":"protein synthesis inhibitor","4":"NA","5":"pulmonary","6":"bovine respiratory disease (BRD)","7":"Launched","8":"bovine respiratory disease (BRD)","_rn_":"21816"},{"1":"BRD-K50866992-003-10-3","2":"tropisetron","3":"serotonin receptor antagonist","4":"GLRA1, GLRA2, GLRB, HTR3A, HTR4","5":"gastroenterology","6":"nausea, vomiting, nausea, vomiting","7":"Launched","8":"nausea, vomiting, nausea, vomiting","_rn_":"21818"},{"1":"BRD-K34332569-001-01-3","2":"imidapril","3":"angiotensin converting enzyme inhibitor","4":"ACE","5":"cardiology","6":"hypertension, congestive heart failure","7":"Launched","8":"hypertension, congestive heart failure","_rn_":"21859"},{"1":"BRD-K47878171-086-06-0","2":"bephenium-hydroxynaphthoate","3":"anthelmintic agent","4":"NA","5":"infectious disease","6":"ascariasis","7":"Launched","8":"ascariasis","_rn_":"21861"},{"1":"BRD-K42828737-044-09-0","2":"sunitinib","3":"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","4":"CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET","5":"oncology","6":"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","7":"Launched","8":"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","_rn_":"21863"},{"1":"BRD-K96006502-001-02-6","2":"deflazacort","3":"glucocorticoid receptor agonist","4":"NR3C1","5":"rheumatology","6":"joint inflammation","7":"Launched","8":"joint inflammation","_rn_":"21865"},{"1":"BRD-A49765801-001-04-1","2":"fludroxycortide","3":"glucocorticoid receptor agonist","4":"NR3C1, SERPINA6","5":"infectious disease, dermatology","6":"skin infections, psoriasis","7":"Launched","8":"skin infections, psoriasis","_rn_":"21904"},{"1":"BRD-A67097164-001-18-7","2":"ifosfamide","3":"DNA alkylating agent","4":"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1","5":"oncology, urology","6":"testicular carcinoma, hemorrhagic cystitis","7":"Launched","8":"testicular carcinoma, hemorrhagic cystitis","_rn_":"21906"},{"1":"BRD-A48237631-001-04-8","2":"mitomycin-c","3":"DNA alkylating agent, DNA synthesis inhibitor","4":"NA","5":"oncology","6":"pancreatic cancer, gastric adenocarcinoma","7":"Launched","8":"pancreatic cancer, gastric adenocarcinoma","_rn_":"21908"},{"1":"BRD-K11510141-001-01-8","2":"teprenone","3":"mucus protecting agent","4":"NA","5":"dermatology","6":"cosmetic","7":"Launched","8":"cosmetic","_rn_":"21909"},{"1":"BRD-K65781196-001-03-0","2":"avanafil","3":"phosphodiesterase inhibitor","4":"PDE5A","5":"urology","6":"erectile dysfunction","7":"Launched","8":"erectile dysfunction","_rn_":"21911"},{"1":"BRD-K38458514-001-01-8","2":"diazooxonorleucine","3":"glutamate receptor antagonist","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"22692"},{"1":"BRD-K61443650-236-13-1","2":"thiomersal","3":"other antibiotic","4":"OXCT1","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"22694"},{"1":"BRD-K95763993-001-19-3","2":"trapidil","3":"PDGFR tyrosine kinase receptor inhibitor","4":"PDGFRA","5":"cardiology","6":"coronary artery disease (CAD)","7":"Launched","8":"coronary artery disease (CAD)","_rn_":"22696"},{"1":"BRD-K80431395-001-07-3","2":"triciribine","3":"AKT inhibitor","4":"AKT1, AKT2, AKT3","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"22698"},{"1":"BRD-A99888680-001-03-8","2":"paliperidone","3":"dopamine receptor antagonist, serotonin receptor antagonist","4":"ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C","5":"neurology/psychiatry","6":"schizophrenia","7":"Launched","8":"schizophrenia","_rn_":"22700"},{"1":"BRD-K89561498-001-01-7","2":"SN-38","3":"topoisomerase inhibitor","4":"TOP1","5":"oncology","6":"colorectal cancer","7":"Launched","8":"Colon/Colorectal Cancer","_rn_":"22740"},{"1":"BRD-K01507359-001-22-9","2":"rifampin","3":"RNA polymerase inhibitor","4":"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3","5":"infectious disease","6":"tuberculosis, meningitis","7":"Launched","8":"tuberculosis, meningitis","_rn_":"22742"},{"1":"BRD-A26503646-001-16-6","2":"formestane","3":"aromatase inhibitor","4":"CYP19A1","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"22744"},{"1":"BRD-K35960502-001-20-0","2":"niclosamide","3":"DNA replication inhibitor, STAT inhibitor","4":"STAT3","5":"infectious disease","6":"tapeworm","7":"Launched","8":"tapeworm","_rn_":"22746"},{"1":"BRD-A17883755-001-06-1","2":"lenalidomide","3":"anticancer agent","4":"CDH5, CRBN, PTGS2, TNF, TNFSF11","5":"hematologic malignancy","6":"multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)","7":"Launched","8":"multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)","_rn_":"22748"},{"1":"BRD-A67516570-001-02-8","2":"lafutidine","3":"histamine receptor antagonist","4":"HRH2","5":"gastroenterology","6":"duodenal ulcer disease, peptic ulcer disease (PUD)","7":"Launched","8":"duodenal ulcer disease, peptic ulcer disease (PUD)","_rn_":"22788"},{"1":"BRD-K58148589-001-03-6","2":"betamethasone-dipropionate","3":"anti-inflammatory agent","4":"NA","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"22790"},{"1":"BRD-K03406345-001-27-8","2":"azacitidine","3":"DNA methyltransferase inhibitor","4":"DNMT1, DNMT3A","5":"hematologic malignancy, hematology","6":"myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","7":"Launched","8":"myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","_rn_":"22792"},{"1":"BRD-K17068645-003-04-2","2":"bendamustine","3":"DNA inhibitor","4":"NA","5":"hematologic malignancy","6":"chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)","7":"Launched","8":"chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)","_rn_":"22794"},{"1":"BRD-K87990216-001-10-2","2":"piretanide","3":"glucocorticoid receptor agonist","4":"SLC12A1, SLC12A2","5":"cardiology","6":"hypertension, edema","7":"Launched","8":"hypertension, edema","_rn_":"22796"},{"1":"BRD-K16195444-003-26-0","2":"oxymetazoline","3":"adrenergic receptor agonist","4":"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C","5":"otolaryngology","6":"nasal congestion","7":"Launched","8":"nasal congestion","_rn_":"22836"},{"1":"BRD-K82818427-001-02-2","2":"batimastat","3":"matrix metalloprotease inhibitor","4":"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"22840"},{"1":"BRD-K27184429-300-01-3","2":"levocetirizine","3":"histamine receptor antagonist","4":"HRH1","5":"allergy","6":"allergic rhinitis, urticaria","7":"Launched","8":"allergic rhinitis, urticaria","_rn_":"22842"},{"1":"BRD-K99107520-001-24-1","2":"felbamate","3":"glutamate receptor antagonist","4":"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B","5":"neurology/psychiatry","6":"epilepsy","7":"Launched","8":"epilepsy","_rn_":"22844"},{"1":"BRD-K85554912-001-06-3","2":"ivermectin","3":"benzodiazepine receptor agonist","4":"CHRNA7, GABRB3, GLRA3, P2RX7","5":"infectious disease","6":"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies","7":"Launched","8":"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies","_rn_":"22884"},{"1":"BRD-K19687926-379-07-4","2":"lapatinib","3":"EGFR inhibitor","4":"EGFR, ERBB2","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"22886"},{"1":"BRD-K76037122-001-02-5","2":"guanidine","3":"HSP inhibitor","4":"ALDH2, DLG4, GAMT, RNASE1","5":"neurology/psychiatry","6":"Lambert-Eaton myasthenic syndrome (LEMS)","7":"Launched","8":"Lambert-Eaton myasthenic syndrome (LEMS)","_rn_":"22887"},{"1":"BRD-K72167406-001-02-1","2":"cefditoren-pivoxil","3":"bacterial cell wall synthesis inhibitor","4":"NA","5":"infectious disease, pulmonary, otolaryngology","6":"pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis","7":"Launched","8":"pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis","_rn_":"22889"},{"1":"BRD-K51040301-001-02-1","2":"cobicistat","3":"cytochrome P450 inhibitor","4":"CYP3A4, CYP3A43, CYP3A5, CYP3A7","5":"infectious disease","6":"human immunodeficiency virus (HIV-1)","7":"Launched","8":"human immunodeficiency virus (HIV-1)","_rn_":"22891"},{"1":"BRD-K82928847-001-04-7","2":"ACY-1215","3":"HDAC inhibitor","4":"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"22933"},{"1":"BRD-K18779551-003-07-8","2":"bifemelane","3":"acetylcholine release enhancer","4":"MAOA, MAOB","5":"ophthalmology, neurology/psychiatry","6":"glaucoma, senile dementia","7":"Launched","8":"glaucoma, senile dementia","_rn_":"22935"},{"1":"BRD-K53734668-003-02-0","2":"PRT062607","3":"syk inhibitor","4":"FGR, MAP3K9, SYK","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"22939"},{"1":"BRD-K17849083-001-32-9","2":"tranilast","3":"angiogenesis inhibitor","4":"HPGDS, HRH1","5":"pulmonary","6":"asthma","7":"Launched","8":"asthma","_rn_":"22978"},{"1":"BRD-K51350053-048-16-5","2":"toremifene","3":"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","4":"ESR1","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"22980"},{"1":"BRD-K93441486-067-12-8","2":"diphemanil","3":"acetylcholine receptor antagonist","4":"CHRM3","5":"neurology/psychiatry","6":"spasms","7":"Launched","8":"spasms","_rn_":"22982"},{"1":"BRD-K27799744-001-02-8","2":"cyclovirobuxin-d","3":"calcium channel modulator","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"22984"},{"1":"BRD-K11196887-001-22-0","2":"norfloxacin","3":"bacterial DNA gyrase inhibitor","4":"TOP2A","5":"infectious disease, urology","6":"urinary tract infections, gonorrhea, prostatitis","7":"Launched","8":"urinary tract infections, gonorrhea, prostatitis","_rn_":"22986"},{"1":"BRD-K92657060-001-05-7","2":"zaleplon","3":"benzodiazepine receptor agonist","4":"GABRA1, GABRB1, GABRG2, TSPO","5":"neurology/psychiatry","6":"insomnia","7":"Launched","8":"insomnia","_rn_":"23026"},{"1":"BRD-K78431006-001-10-2","2":"crizotinib","3":"ALK tyrosine kinase receptor inhibitor","4":"ALK, MET","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"23028"},{"1":"BRD-K87349682-347-03-8","2":"norepinephrine","3":"adrenergic receptor agonist","4":"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2","5":"cardiology, allergy, neurology/psychiatry","6":"hypertension, urticaria, headache, seasonal affective disorder","7":"Launched","8":"hypertension, urticaria, headache, seasonal affective disorder","_rn_":"23030"},{"1":"BRD-K28824103-001-02-8","2":"genipin","3":"choleretic agent","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"23032"},{"1":"BRD-K05674516-001-01-7","2":"PSI-7976","3":"HCV inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"23034"},{"1":"BRD-K37793595-003-01-7","2":"afobazole","3":"anxiolytic","4":"NA","5":"neurology/psychiatry","6":"anxiety","7":"Launched","8":"anxiety","_rn_":"23840"},{"1":"BRD-K74141488-003-11-2","2":"naftifine","3":"fungal squalene epoxidase inhibitor","4":"SQLE","5":"infectious disease","6":"tinea pedis, tinea cruris, tinea corporis","7":"Launched","8":"tinea pedis, tinea cruris, tinea corporis","_rn_":"23842"},{"1":"BRD-K22134346-001-24-9","2":"simvastatin","3":"HMGCR inhibitor","4":"HMGCR, ITGB2","5":"endocrinology, cardiology, neurology/psychiatry","6":"hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia","7":"Launched","8":"hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia","_rn_":"23844"},{"1":"BRD-K84937637-001-09-9","2":"sirolimus","3":"mTOR inhibitor","4":"FGF2, FKBP1A, MTOR","5":"transplant, pulmonary","6":"organ rejection, lymphangioleiomyomatosis","7":"Launched","8":"organ rejection, lymphangioleiomyomatosis","_rn_":"23846"},{"1":"BRD-K89839824-001-05-3","2":"raltitrexed","3":"thymidylate synthase inhibitor","4":"FPGS, TYMS","5":"oncology","6":"mesothelioma","7":"Launched","8":"mesothelioma","_rn_":"23886"},{"1":"BRD-K52662033-003-21-2","2":"lidocaine","3":"histamine receptor agonist","4":"EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","5":"neurology/psychiatry, dermatology, hematology","6":"itching, eczema, hemorrhage","7":"Launched","8":"itching, eczema, hemorrhage","_rn_":"23888"},{"1":"BRD-K50071428-001-03-3","2":"abiraterone","3":"androgen biosynthesis inhibitor","4":"CYP11B1, CYP17A1","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"23890"},{"1":"BRD-K50677762-001-01-5","2":"oxiracetam","3":"acetylcholine receptor agonist","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"23892"},{"1":"BRD-K04552268-001-02-4","2":"4-pyrimidinecarbonitrile","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"23934"},{"1":"BRD-A08545410-003-07-8","2":"doxycycline","3":"metalloproteinase inhibitor","4":"MMP8","5":"dental","6":"periodontitis","7":"Launched","8":"periodontitis","_rn_":"23936"},{"1":"BRD-K15766189-001-09-8","2":"cefdinir","3":"bacterial cell wall synthesis inhibitor","4":"MPO","5":"infectious disease, otolaryngology, pulmonary","6":"pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis","7":"Launched","8":"pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis","_rn_":"23938"},{"1":"BRD-K54634444-001-05-9","2":"artesunate","3":"DNA synthesis inhibitor","4":"NA","5":"infectious disease","6":"malaria","7":"Launched","8":"malaria","_rn_":"23940"},{"1":"BRD-A49035384-003-28-9","2":"methacycline","3":"protein synthesis inhibitor","4":"NA","5":"pulmonary","6":"bronchitis","7":"Launched","8":"bronchitis","_rn_":"23942"},{"1":"BRD-K96631475-001-02-4","2":"10-deacetylbaccatin","3":"antitumor agent","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"23982"},{"1":"BRD-K94353609-001-21-6","2":"fluocinolone-acetonide","3":"glucocorticoid receptor agonist","4":"NR3C1, SERPINA6","5":"dermatology","6":"seborrheic dermatitis","7":"Launched","8":"seborrheic dermatitis","_rn_":"23984"},{"1":"BRD-K77791657-003-01-7","2":"3-deazaneplanocin-A","3":"histone lysine methyltransferase inhibitor","4":"EZH2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"23986"},{"1":"BRD-K89704198-001-12-3","2":"vincamine","3":"adrenergic receptor antagonist","4":"CHRM1, CHRM2, CHRM3, CHRM4","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"23988"},{"1":"BRD-K88789588-001-14-9","2":"letrozole","3":"aromatase inhibitor","4":"CYP19A1","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"23990"},{"1":"BRD-K99383816-001-03-5","2":"ftorafur","3":"thymidylate synthase inhibitor","4":"TYMS","5":"oncology","6":"colorectal cancer","7":"Launched","8":"Colon/Colorectal Cancer","_rn_":"24030"},{"1":"BRD-K83988098-003-03-4","2":"alvespimycin","3":"HSP inhibitor","4":"HSP90AA1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"24032"},{"1":"BRD-K52020312-001-26-8","2":"metronidazole","3":"DNA inhibitor","4":"CYP2C9, CYP3A4","5":"dermatology","6":"rosacea","7":"Launched","8":"rosacea","_rn_":"24034"},{"1":"BRD-K73425385-065-04-8","2":"bekanamycin","3":"bacterial 30S ribosomal subunit inhibitor","4":"NA","5":"infectious disease","6":"gram-negative bacterial infections","7":"Launched","8":"gram-negative bacterial infections","_rn_":"24036"},{"1":"BRD-K66296774-236-11-3","2":"fluvastatin","3":"HMGCR inhibitor","4":"HMGCR","5":"endocrinology, cardiology","6":"hypercholesterolemia, congenital heart defects","7":"Launched","8":"hypercholesterolemia, congenital heart defects","_rn_":"24038"},{"1":"BRD-K17075857-001-18-4","2":"chloroxine","3":"opioid receptor antagonist","4":"OPRK1","5":"gastroenterology, infectious disease, dermatology","6":"diarrhea, inflammatory bowel disease, giardiasis, dandruff","7":"Launched","8":"diarrhea, inflammatory bowel disease, giardiasis, dandruff","_rn_":"24078"},{"1":"BRD-K37270826-001-27-6","2":"mifepristone","3":"glucocorticoid receptor antagonist, progesterone receptor antagonist","4":"AR, NR1I2, NR3C1, PGR","5":"endocrinology","6":"hyperglycemia, diabetes mellitus","7":"Launched","8":"hyperglycemia, diabetes mellitus","_rn_":"24080"},{"1":"BRD-K50388907-001-30-4","2":"fenofibrate","3":"PPAR receptor agonist","4":"MMP25, PPARA","5":"endocrinology","6":"hypercholesterolemia, hypertriglyceridemia","7":"Launched","8":"hypercholesterolemia, hypertriglyceridemia","_rn_":"24082"},{"1":"BRD-K20482099-001-09-4","2":"rutin","3":"antioxidant, capillary stabilizing agent, nitric oxide scavenger","4":"AKR1C3","5":"rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy","6":"joint pain, nasal congestion, constipation, irritability, allergic rhinitis","7":"Launched","8":"joint pain, nasal congestion, constipation, irritability, allergic rhinitis","_rn_":"24084"},{"1":"BRD-A51964809-003-12-6","2":"halofantrine","3":"antimalarial agent","4":"KCNH2, KCNN4","5":"infectious disease","6":"malaria","7":"Launched","8":"malaria","_rn_":"24086"},{"1":"BRD-K47114202-001-14-6","2":"chlorogenic-acid","3":"antioxidant","4":"SLC37A4","5":"neurology/psychiatry, pulmonary, allergy","6":"headache, chest congestion, allergic rhinitis","7":"Launched","8":"headache, chest congestion, allergic rhinitis","_rn_":"24126"},{"1":"BRD-K92723993-001-06-7","2":"imatinib","3":"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","4":"ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","5":"hematologic malignancy, oncology","6":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","7":"Launched","8":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","_rn_":"24128"},{"1":"BRD-K14003026-003-09-0","2":"ritodrine","3":"adrenergic receptor agonist","4":"ADRB2","5":"obstetrics/gynecology","6":"premature labor","7":"Launched","8":"premature labor","_rn_":"24130"},{"1":"BRD-K79145628-001-05-5","2":"nimorazole","3":"bacterial DNA inhibitor","4":"NA","5":"oncology","6":"head and neck squamous cell carcinoma (HNSCC)","7":"Launched","8":"Head and Neck Cancer","_rn_":"24132"},{"1":"BRD-K97752965-001-16-4","2":"nicorandil","3":"nitric oxide donor, potassium channel activator","4":"KCNJ11","5":"cardiology","6":"angina pectoris","7":"Launched","8":"angina pectoris","_rn_":"24134"},{"1":"BRD-K21528677-001-02-8","2":"desonide","3":"glucocorticoid receptor agonist","4":"NR3C1, PLA2G1B","5":"gastroenterology","6":"Crohn's disease","7":"Launched","8":"Crohn's disease","_rn_":"24174"},{"1":"BRD-K91825936-001-01-2","2":"ZK811752","3":"CC chemokine receptor antagonist","4":"CCR1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"24176"},{"1":"BRD-K47079459-004-04-6","2":"cetrimonium","3":"NA","4":"NA","5":"dermatology","6":"cosmetic","7":"Launched","8":"cosmetic","_rn_":"24178"},{"1":"BRD-K62607865-001-09-7","2":"aztreonam","3":"bacterial cell wall synthesis inhibitor","4":"NA","5":"infectious disease","6":"urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections","7":"Launched","8":"urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections","_rn_":"24180"},{"1":"BRD-K49111258-003-29-7","2":"prazosin","3":"adrenergic receptor antagonist","4":"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"24182"},{"1":"BRD-K40718343-001-02-6","2":"AEE788","3":"EGFR inhibitor, VEGFR inhibitor","4":"EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"24981"},{"1":"BRD-K43187018-001-03-3","2":"GDC-0349","3":"Pim kinase inhibitor","4":"PIK3CA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"24983"},{"1":"BRD-K26011976-001-01-0","2":"licochalcone-a","3":"topoisomerase inhibitor","4":"PTPN1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"24987"},{"1":"BRD-K27182532-001-02-3","2":"metatinib","3":"Bcr-Abl kinase inhibitor","4":"ABL1, BCR","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"24989"},{"1":"BRD-K29656036-001-02-5","2":"MK-8245","3":"stearoyl-CoA desaturase inhibitor","4":"SCD","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"25029"},{"1":"BRD-K84798689-236-02-9","2":"sodium-tanshinone-ii-a-sulfonate","3":"potassium channel activator","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"25031"},{"1":"BRD-K44844162-001-01-6","2":"taselisib","3":"PI3K inhibitor","4":"PIK3CA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"25033"},{"1":"BRD-K25835157-001-01-4","2":"PRT062070","3":"JAK inhibitor, syk inhibitor","4":"SYK","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"25035"},{"1":"BRD-K12502280-001-08-0","2":"TG-101348","3":"FLT3 inhibitor, JAK inhibitor","4":"BRD4, JAK1, JAK2, JAK3, TYK2","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"25037"},{"1":"BRD-K49075727-001-08-5","2":"nintedanib","3":"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB","5":"pulmonary","6":"idiopathic pulmonary fibrosis (IPF)","7":"Launched","8":"idiopathic pulmonary fibrosis (IPF)","_rn_":"25077"},{"1":"BRD-K65678996-001-05-5","2":"nefiracetam","3":"acetylcholine receptor agonist, benzodiazepine receptor agonist","4":"CHRM1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"25079"},{"1":"BRD-A68083442-001-01-6","2":"pranidipine","3":"calcium channel blocker","4":"CACNA1C","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"25083"},{"1":"BRD-K84892605-001-01-1","2":"IOWH032","3":"CFTR channel antagonist","4":"CFTR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"25085"},{"1":"BRD-K73303757-001-21-6","2":"4-methylgenistein","3":"protein tyrosine kinase inhibitor","4":"CYP19A1, ESRRA, ESRRB, ESRRG, FASN","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25125"},{"1":"BRD-K58466253-003-14-0","2":"palmatine-chloride","3":"dopamine synthesis inhibitor","4":"CYP3A4","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25127"},{"1":"BRD-A78391468-001-02-8","2":"prednisolone-hemisuccinate","3":"glucocorticoid receptor agonist","4":"NR3C1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25129"},{"1":"BRD-K06753942-001-14-5","2":"nobiletin","3":"MEK inhibitor","4":"MAP2K1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25131"},{"1":"BRD-K89391146-001-08-0","2":"RG108","3":"DNA methyltransferase inhibitor","4":"DNMT1, DNMT3B","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25133"},{"1":"BRD-K62814476-001-03-3","2":"BMS-265246","3":"CDK inhibitor","4":"CDK1, CDK2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25173"},{"1":"BRD-K96104201-001-01-5","2":"azalomycin-b","3":"bacterial 50S ribosomal subunit inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25175"},{"1":"BRD-K92991072-001-04-9","2":"PAC-1","3":"caspase activator","4":"CASP3","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"25177"},{"1":"BRD-A68631409-001-05-4","2":"evodiamine","3":"ATPase inhibitor, TRPV agonist","4":"TRPV1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25179"},{"1":"BRD-K79239947-001-06-8","2":"PF-573228","3":"focal adhesion kinase inhibitor","4":"CDK1, CDK2, CDK7, GSK3B, IKBKB","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25181"},{"1":"BRD-K61536336-001-01-7","2":"SB-366791","3":"TRPV antagonist","4":"TRPV1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25221"},{"1":"BRD-K87036601-001-01-6","2":"azodicarbonamide","3":"DNA synthesis inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"25223"},{"1":"BRD-K74227499-001-01-1","2":"se-methylselenocysteine","3":"NA","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"25225"},{"1":"BRD-A73427433-240-01-3","2":"adaprev","3":"TGF beta receptor inhibitor","4":"IGF2R, M6PR","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"25227"},{"1":"BRD-K23403298-003-01-9","2":"benzyldimethylhexadecylammonium","3":"cationic surfactant","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25229"},{"1":"BRD-K77634909-001-03-5","2":"AEG3482","3":"HSP inducer","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25269"},{"1":"BRD-K06426971-001-02-7","2":"ryuvidine","3":"histone lysine methyltransferase inhibitor","4":"CDK2, CDK4","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25271"},{"1":"BRD-K04622161-001-02-3","2":"YO-01027","3":"gamma secretase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25273"},{"1":"BRD-A13964793-001-02-6","2":"TC1","3":"beta-secretase inhibitor","4":"BACE1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25275"},{"1":"BRD-K66030860-001-03-6","2":"salidroside","3":"beta amyloid protein neurotoxicity inhibitor","4":"APP","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25277"},{"1":"BRD-K01653460-001-01-1","2":"chlorindanol","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25317"},{"1":"BRD-K07762753-001-04-4","2":"aminopurvalanol-a","3":"CDK inhibitor, tyrosine kinase inhibitor","4":"CDK1, CDK2, CDK5, CDK6","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25319"},{"1":"BRD-A73871920-236-03-6","2":"nanchangmycin","3":"other antibiotic","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25321"},{"1":"BRD-K28143534-001-02-2","2":"cyproheptadine","3":"histamine receptor antagonist","4":"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7","5":"allergy, otolaryngology, ophthalmology, dermatology","6":"allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism","7":"Launched","8":"allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism","_rn_":"25323"},{"1":"BRD-K82846253-001-15-4","2":"repaglinide","3":"insulin secretagogue","4":"ABCC8, KCNJ11, PPARG","5":"endocrinology","6":"diabetes mellitus","7":"Launched","8":"diabetes mellitus","_rn_":"25325"},{"1":"BRD-K53581288-001-02-9","2":"baricitinib","3":"JAK inhibitor","4":"JAK1, JAK2","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"26135"},{"1":"BRD-K39558284-001-01-2","2":"SDZ-WAG-994","3":"adenosine receptor agonist","4":"ADORA1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"26137"},{"1":"BRD-K99498722-001-02-6","2":"plinabulin","3":"tubulin polymerization inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"26139"},{"1":"BRD-K64890080-001-13-8","2":"BI-2536","3":"PLK inhibitor","4":"BRD4, PLK1, PLK2, PLK3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"26179"},{"1":"BRD-A36057565-001-01-0","2":"bruceantin","3":"protein synthesis inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"26181"},{"1":"BRD-K83022601-001-01-0","2":"CI-844","3":"NA","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"26183"},{"1":"BRD-K84810405-003-01-1","2":"almorexant","3":"orexin receptor antagonist","4":"HCRTR1, HCRTR2","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"26185"},{"1":"BRD-K77638923-001-02-0","2":"CUDC-907","3":"PI3K inhibitor","4":"HDAC2, PIK3R1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"26187"},{"1":"BRD-K49865102-001-08-4","2":"PD-0325901","3":"MEK inhibitor","4":"MAP2K1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"26227"},{"1":"BRD-K43621685-001-02-5","2":"CP-673451","3":"PDGFR tyrosine kinase receptor inhibitor","4":"KIT, PDGFRA, PDGFRB","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26231"},{"1":"BRD-A57798112-001-03-7","2":"PD-318088","3":"MEK inhibitor","4":"MAP2K1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26233"},{"1":"BRD-K42756753-001-01-9","2":"epiandrosterone","3":"steroid","4":"G6PD","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26235"},{"1":"BRD-A23127772-001-02-3","2":"sclareol","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26274"},{"1":"BRD-K48826825-001-01-8","2":"S26948","3":"PPAR receptor agonist","4":"PPARG","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26276"},{"1":"BRD-K68904758-001-03-5","2":"cephalomannine","3":"DNA polymerase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26278"},{"1":"BRD-K41876534-001-13-7","2":"tioxolone","3":"carbonic anhydrase inhibitor","4":"CA2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26280"},{"1":"BRD-K36363294-001-04-2","2":"I-BET151","3":"bromodomain inhibitor","4":"BRD2, BRD3, BRD4","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26282"},{"1":"BRD-A42746051-001-02-9","2":"melengestrol-acetate","3":"progesterone receptor agonist","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26322"},{"1":"BRD-K37723606-001-01-5","2":"dioscin","3":"apoptosis stimulant","4":"CXCR3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26324"},{"1":"BRD-K18375018-376-02-3","2":"spermine","3":"NA","4":"CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26326"},{"1":"BRD-K90382497-001-10-7","2":"GW-843682X","3":"PLK inhibitor","4":"PLK1, PLK3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26328"},{"1":"BRD-K12068470-001-02-5","2":"LY2608204","3":"glucokinase activator","4":"GCK","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"26330"},{"1":"BRD-K11927976-050-02-9","2":"ER-27319","3":"mediator release inhibitor, SYK inhibitor","4":"SYK","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26370"},{"1":"BRD-K33818169-003-04-6","2":"GW-3965","3":"LXR agonist","4":"NR1H2, NR1H3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26372"},{"1":"BRD-K47557313-001-02-7","2":"LY2109761","3":"TGF beta receptor inhibitor","4":"TGFBR1, TGFBR2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26374"},{"1":"BRD-K36198571-001-02-0","2":"WAY-170523","3":"metalloproteinase inhibitor","4":"MMP13","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26376"},{"1":"BRD-K94455792-001-01-8","2":"ICG-001","3":"beta-catenin inhibitor","4":"CTNNB1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26378"},{"1":"BRD-K21782625-001-02-4","2":"AMG458","3":"MET inhibitor","4":"MET","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26418"},{"1":"BRD-K67772619-001-05-1","2":"rheochrysidin","3":"protein tyrosine kinase inhibitor","4":"PTPN1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26420"},{"1":"BRD-K36222532-001-01-8","2":"broxaldine","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26422"},{"1":"BRD-K24601397-001-01-1","2":"phlorizin","3":"sodium/glucose cotransporter inhibitor","4":"SLC5A1, SLC5A11, SLC5A2, SLC5A3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26424"},{"1":"BRD-K34851558-001-02-3","2":"parthenolide-(-)","3":"NFkB pathway inhibitor","4":"HDAC1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26426"},{"1":"BRD-K80129304-001-08-1","2":"uracil","3":"NA","4":"DPYD, UCKL1","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"26466"},{"1":"BRD-K51143828-003-03-1","2":"lurasidone","3":"dopamine receptor antagonist, serotonin receptor antagonist","4":"ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7","5":"neurology/psychiatry","6":"schizophrenia","7":"Launched","8":"schizophrenia","_rn_":"26468"},{"1":"BRD-K33720171-001-01-0","2":"difluprednate","3":"glucocorticoid receptor agonist","4":"NR3C1","5":"ophthalmology","6":"endogenous uveitis","7":"Launched","8":"endogenous uveitis","_rn_":"26470"},{"1":"BRD-K48578705-001-17-6","2":"methyldopa","3":"adrenergic receptor agonist","4":"ADRA2A, ADRA2B, ADRA2C, DDC","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"26472"},{"1":"BRD-K81332461-001-01-4","2":"maxacalcitol","3":"vitamin D receptor agonist","4":"VDR","5":"endocrinology","6":"hyperparathyroidism","7":"Launched","8":"hyperparathyroidism","_rn_":"26474"},{"1":"BRD-K84011460-051-01-7","2":"nizofenone","3":"ion channel antagonist","4":"NA","5":"neurology/psychiatry","6":"stroke","7":"Launched","8":"stroke","_rn_":"27278"},{"1":"BRD-K65877271-001-01-8","2":"halobetasol-propionate","3":"glucocorticoid receptor agonist","4":"NR3C1, PLA2G1B","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"27280"},{"1":"BRD-K81074237-001-02-3","2":"azilsartan","3":"angiotensin receptor antagonist","4":"AGTR1, AGTR2","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"27282"},{"1":"BRD-K82122102-323-01-1","2":"amfenac","3":"cyclooxygenase inhibitor","4":"PTGS1, PTGS2","5":"neurology/psychiatry","6":"pain relief","7":"Launched","8":"pain relief","_rn_":"27284"},{"1":"BRD-K15409150-001-05-8","2":"penfluridol","3":"T-type calcium channel blocker","4":"CACNA1G","5":"neurology/psychiatry","6":"schizophrenia","7":"Launched","8":"schizophrenia","_rn_":"27286"},{"1":"BRD-K33813875-003-01-8","2":"valnemulin","3":"bacterial 50S ribosomal subunit inhibitor","4":"NA","5":"infectious disease, gastroenterology","6":"dysentry, colitis, pneumonia","7":"Launched","8":"dysentry, colitis, pneumonia","_rn_":"27326"},{"1":"BRD-A85651701-001-19-7","2":"clopamide","3":"sodium/chloride cotransporter inhibitor","4":"NA","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"27328"},{"1":"BRD-A12994259-001-02-1","2":"pomalidomide","3":"angiogenesis inhibitor, tumor necrosis factor production inhibitor","4":"CRBN, PTGS2, TNF","5":"hematologic malignancy","6":"multiple myeloma","7":"Launched","8":"multiple myeloma","_rn_":"27330"},{"1":"BRD-A20644369-001-08-6","2":"canrenone","3":"mineralocorticoid receptor antagonist","4":"NR3C2","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"27332"},{"1":"BRD-K96253961-046-03-1","2":"metaraminol","3":"adrenergic receptor agonist","4":"ADRA1A","5":"cardiology","6":"hypotension","7":"Launched","8":"hypotension","_rn_":"27334"},{"1":"BRD-K49954789-001-02-9","2":"mesna","3":"antioxidant","4":"NA","5":"urology","6":"hemorrhagic cystitis","7":"Launched","8":"hemorrhagic cystitis","_rn_":"27374"},{"1":"BRD-A11990600-001-03-4","2":"lorazepam","3":"benzodiazepine receptor agonist","4":"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO","5":"neurology/psychiatry","6":"status epilepticus","7":"Launched","8":"status epilepticus","_rn_":"27376"},{"1":"BRD-K15108141-001-06-6","2":"gemcitabine","3":"ribonucleotide reductase inhibitor","4":"CMPK1, RRM1, RRM2, TYMS","5":"oncology","6":"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer","7":"Launched","8":"ovarian cancer, breast cancer, Lung Cancer, pancreatic cancer","_rn_":"27378"},{"1":"BRD-A08545410-311-03-4","2":"doxycycline","3":"metalloproteinase inhibitor","4":"MMP8","5":"dental","6":"periodontitis","7":"Launched","8":"periodontitis","_rn_":"27382"},{"1":"BRD-K74514084-001-03-9","2":"pazopanib","3":"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3","5":"oncology","6":"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","7":"Launched","8":"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","_rn_":"27422"},{"1":"BRD-K43457670-001-27-8","2":"acetazolamide","3":"carbonic anhydrase inhibitor","4":"AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7","5":"ophthalmology","6":"glaucoma","7":"Launched","8":"glaucoma","_rn_":"27424"},{"1":"BRD-K04394237-001-03-7","2":"drospirenone","3":"mineralocorticoid receptor antagonist","4":"AR, NR3C2, PGR","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"27428"},{"1":"BRD-K77685957-300-09-1","2":"dequalinium","3":"PKC inhibitor","4":"KCNN1, KCNN3","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"27430"},{"1":"BRD-K39252998-003-01-5","2":"atipamezole","3":"adrenergic receptor antagonist","4":"NA","5":"neurology/psychiatry","6":"reverse sedative","7":"Launched","8":"reverse sedative","_rn_":"27470"},{"1":"BRD-K19761926-001-03-6","2":"eplerenone","3":"cytochrome P450 inhibitor","4":"NR3C2","5":"cardiology","6":"congestive heart failure, hypertension","7":"Launched","8":"congestive heart failure, hypertension","_rn_":"27472"},{"1":"BRD-K49522529-001-02-9","2":"alfacalcidol","3":"vitamin D receptor agonist","4":"CYP27B1, VDR","5":"endocrinology","6":"vitamin D deficiency","7":"Launched","8":"vitamin D deficiency","_rn_":"27474"},{"1":"BRD-K54314721-001-10-2","2":"zolmitriptan","3":"serotonin receptor agonist","4":"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F","5":"neurology/psychiatry","6":"migraine headache","7":"Launched","8":"migraine headache","_rn_":"27476"},{"1":"BRD-K08078237-001-19-8","2":"tetrandrine","3":"calcium channel blocker","4":"SLC6A3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"27478"},{"1":"BRD-K54838207-001-03-8","2":"fudosteine","3":"mucolytic agent","4":"NA","5":"pulmonary","6":"chest congestion","7":"Launched","8":"chest congestion","_rn_":"27518"},{"1":"BRD-K13050303-001-17-3","2":"uridine","3":"dopamine receptor agonist","4":"LSM6, TYMP","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"27520"},{"1":"BRD-K93754473-048-20-2","2":"tamoxifen","3":"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","4":"EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"27522"},{"1":"BRD-K95773607-004-03-8","2":"darifenacin","3":"acetylcholine receptor antagonist","4":"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","5":"urology","6":"urinary incontinence","7":"Launched","8":"urinary incontinence","_rn_":"27524"},{"1":"BRD-K03243820-001-23-8","2":"trifluridine","3":"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor","4":"TYMS","5":"infectious disease","6":"virus herpes simplex (HSV)","7":"Launched","8":"virus herpes simplex (HSV)","_rn_":"27526"},{"1":"BRD-K94441233-001-13-0","2":"mevastatin","3":"HMGCR inhibitor","4":"HMGCR","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"27566"},{"1":"BRD-K07612980-001-05-3","2":"sparfloxacin","3":"bacterial DNA gyrase inhibitor","4":"TOP2A","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"27568"},{"1":"BRD-K43236057-001-07-1","2":"polydatin","3":"ICAM1 expression inhibitor","4":"ICAM1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"27570"},{"1":"BRD-K95785345-300-14-8","2":"thiamine","3":"vitamin B","4":"SLC19A2, SLC19A3, TPK1","5":"metabolism","6":"thiamine deficiency","7":"Launched","8":"thiamine deficiency","_rn_":"27572"},{"1":"BRD-K55044200-001-15-3","2":"amoxicillin","3":"penicillin binding protein inhibitor","4":"CYP2C19, SLC15A1, SLC15A2, SLC22A6","5":"infectious disease, gastroenterology","6":"skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections","7":"Launched","8":"skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections","_rn_":"27574"},{"1":"BRD-K97440753-066-18-1","2":"dihydroergocristine","3":"adrenergic receptor antagonist, prolactin inhibitor","4":"ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"27614"},{"1":"BRD-K97472745-001-01-8","2":"gestrinone","3":"progesterone receptor antagonist","4":"AR, ESR1, PGR","5":"obstetrics/gynecology","6":"endometriosis","7":"Launched","8":"endometriosis","_rn_":"27616"},{"1":"BRD-K79612754-001-19-1","2":"inosine","3":"neurotrophic agent","4":"PARP1, PNP","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"27618"},{"1":"BRD-K54847683-001-04-0","2":"equol","3":"estrogen receptor agonist","4":"ESR1, ESR2","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"27620"},{"1":"BRD-K96153583-001-05-1","2":"cidofovir","3":"DNA polymerase inhibitor","4":"NA","5":"infectious disease","6":"acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis","7":"Launched","8":"acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis","_rn_":"27622"},{"1":"BRD-K81528515-001-13-8","2":"nilotinib","3":"Abl kinase inhibitor, Bcr-Abl kinase inhibitor","4":"ABL1, KIT","5":"hematologic malignancy","6":"chronic myeloid leukemia (CML)","7":"Launched","8":"chronic myeloid leukemia (CML)","_rn_":"28415"},{"1":"BRD-A84174393-236-07-1","2":"meloxicam","3":"cyclooxygenase inhibitor","4":"PTGS1, PTGS2","5":"rheumatology","6":"osteoarthritis, rheumatoid arthritis","7":"Launched","8":"osteoarthritis, rheumatoid arthritis","_rn_":"28417"},{"1":"BRD-K58262659-001-09-7","2":"doxifluridine","3":"thymidylate synthase inhibitor","4":"TYMS","5":"oncology","6":"colorectal cancer","7":"Launched","8":"Colon/Colorectal Cancer","_rn_":"28419"},{"1":"BRD-K13314656-001-01-0","2":"ebastine","3":"histamine receptor antagonist","4":"CYP3A4, HRH1","5":"allergy","6":"allergic rhinitis, urticaria","7":"Launched","8":"allergic rhinitis, urticaria","_rn_":"28421"},{"1":"BRD-K81916719-001-13-9","2":"triclabendazole","3":"microtubule inhibitor","4":"DNMT1","5":"infectious disease","6":"tapeworm","7":"Launched","8":"tapeworm","_rn_":"28423"},{"1":"BRD-K61496577-001-20-2","2":"flumethasone","3":"glucocorticoid receptor agonist","4":"NR3C1, PLA2G1B","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"28463"},{"1":"BRD-K52756523-001-24-7","2":"dirithromycin","3":"bacterial 50S ribosomal subunit inhibitor","4":"NA","5":"pulmonary","6":"bronchitis","7":"Launched","8":"bronchitis","_rn_":"28465"},{"1":"BRD-K88625236-001-04-2","2":"nonoxynol-9","3":"membrane integrity inhibitor","4":"NA","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"28467"},{"1":"BRD-K12343256-001-08-9","2":"trametinib","3":"MEK inhibitor","4":"MAP2K1, MAP2K2","5":"oncology","6":"melanoma","7":"Launched","8":"Skin Cancer","_rn_":"28469"},{"1":"BRD-K11973162-003-01-8","2":"tipiracil","3":"thymidine phosphorylase inhibitor","4":"TYMP","5":"oncology","6":"colorectal cancer","7":"Launched","8":"Colon/Colorectal Cancer","_rn_":"28471"},{"1":"BRD-K38305202-001-17-4","2":"domperidone","3":"dopamine receptor antagonist","4":"DRD2, DRD3","5":"infectious disease","6":"fescue toxicosis","7":"Launched","8":"fescue toxicosis","_rn_":"28511"},{"1":"BRD-K76634210-001-14-7","2":"idoxuridine","3":"DNA directed DNA polymerase inhibitor","4":"NA","5":"infectious disease","6":"virus herpes simplex (HSV)","7":"Launched","8":"virus herpes simplex (HSV)","_rn_":"28513"},{"1":"BRD-A44090213-001-25-6","2":"indoprofen","3":"cyclooxygenase inhibitor, prostanoid receptor antagonist","4":"CXCR1, CXCR2, PTGS1, PTGS2","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"28515"},{"1":"BRD-K47869605-001-32-0","2":"podophyllotoxin","3":"microtubule inhibitor, tubulin polymerization inhibitor","4":"IGF1R, TOP2A, TUBA4A, TUBB","5":"infectious disease","6":"genital warts","7":"Launched","8":"genital warts","_rn_":"28517"},{"1":"BRD-K07572174-001-39-4","2":"curcumin","3":"cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor","4":"APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"28519"},{"1":"BRD-K23925186-001-02-8","2":"oridonin","3":"BCL inhibitor","4":"BCL2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"28559"},{"1":"BRD-K29582115-066-01-2","2":"ziprasidone","3":"dopamine receptor antagonist, serotonin receptor antagonist","4":"ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4","5":"neurology/psychiatry","6":"schizophrenia, bipolar disorder","7":"Launched","8":"schizophrenia, bipolar disorder","_rn_":"28561"},{"1":"BRD-K62779383-001-05-5","2":"cholecalciferol","3":"NA","4":"VDR","5":"endocrinology","6":"vitamin D deficiency","7":"Launched","8":"vitamin D deficiency","_rn_":"28563"},{"1":"BRD-K28542495-003-13-5","2":"benzydamine","3":"prostanoid receptor antagonist","4":"NA","5":"dental, otolaryngology","6":"mouth inflammation, throat inflammation","7":"Launched","8":"mouth inflammation, throat inflammation","_rn_":"28565"},{"1":"BRD-A88138582-001-04-8","2":"halcinonide","3":"glucocorticoid receptor agonist","4":"NR3C1","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"28567"},{"1":"BRD-K61717546-001-05-0","2":"fleroxacin","3":"topoisomerase inhibitor","4":"NA","5":"infectious disease, gastroenterology","6":"gonorrhea, enteritis, diarrhea, respiratory tract infections","7":"Launched","8":"gonorrhea, enteritis, diarrhea, respiratory tract infections","_rn_":"28607"},{"1":"BRD-A42699921-001-03-6","2":"teriflunomide","3":"dihydroorotate dehydrogenase inhibitor","4":"DHODH","5":"neurology/psychiatry","6":"multiple sclerosis","7":"Launched","8":"multiple sclerosis","_rn_":"28609"},{"1":"BRD-K93779381-001-01-9","2":"ingenol-mebutate","3":"PKC activator","4":"PRKCA, PRKCB, PRKCD, PRKCE, PRKCG","5":"dermatology","6":"actinic keratosis (AK)","7":"Launched","8":"actinic keratosis (AK)","_rn_":"28613"},{"1":"BRD-K01669786-001-02-2","2":"triapine","3":"ribonucleotide reductase inhibitor","4":"RRM1, RRM2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"28615"},{"1":"BRD-K97010173-001-04-1","2":"deferasirox","3":"chelating agent","4":"CYP3A4","5":"hematology","6":"transfusional hemosiderosis, thalassemia, iron overload","7":"Launched","8":"transfusional hemosiderosis, thalassemia, iron overload","_rn_":"28655"},{"1":"BRD-A92537424-001-04-7","2":"danazol","3":"estrogen receptor antagonist, progesterone receptor agonist","4":"AR, CCL2, ESR1, GNRHR, GNRHR2, PGR","5":"obstetrics/gynecology, cardiology","6":"endometriosis, angioedema","7":"Launched","8":"endometriosis, angioedema","_rn_":"28657"},{"1":"BRD-K13044802-213-20-7","2":"ciclopirox","3":"membrane integrity inhibitor","4":"ATP1A1","5":"infectious disease","6":"onychomycosis","7":"Launched","8":"onychomycosis","_rn_":"28659"},{"1":"BRD-K40496271-396-01-1","2":"eltrombopag","3":"thrombopoietin receptor agonist","4":"MPL","5":"hematology, infectious disease","6":"anemia, hepatitis C, thrombocytopenia","7":"Launched","8":"anemia, hepatitis C, thrombocytopenia","_rn_":"28661"},{"1":"BRD-K77554836-001-11-6","2":"triamcinolone","3":"glucocorticoid receptor agonist","4":"NR3C1, SERPINA6","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"28663"},{"1":"BRD-K52075715-001-06-7","2":"oxibendazole","3":"tubulin polymerization inhibitor","4":"TUBB, TUBB4B","5":"infectious disease","6":"strongyles","7":"Launched","8":"strongyles","_rn_":"28703"},{"1":"BRD-K86887724-001-10-6","2":"dofetilide","3":"potassium channel blocker","4":"KCNH1, KCNH2, KCNJ12, KCNK2","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"28705"},{"1":"BRD-K60369935-001-18-3","2":"ribavirin","3":"antiviral","4":"ADK, ENPP1, IMPDH1, IMPDH2, NT5C2","5":"infectious disease","6":"hepatitis C","7":"Launched","8":"hepatitis C","_rn_":"28707"},{"1":"BRD-A93093700-001-02-9","2":"temazepam","3":"benzodiazepine receptor agonist","4":"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"28709"},{"1":"BRD-K81473043-001-14-6","2":"tanespimycin","3":"HSP inhibitor","4":"HSP90AA1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"28711"},{"1":"BRD-K32007074-001-02-9","2":"enocitabine","3":"DNA synthesis inhibitor","4":"CMPK1, RRM1, TYMS","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"28751"},{"1":"BRD-K39467894-001-06-7","2":"nithiamide","3":"bacterial DNA inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"28753"},{"1":"BRD-K66094457-001-01-5","2":"CPP","3":"glutamate receptor antagonist","4":"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"28755"},{"1":"BRD-A95886749-001-03-5","2":"colfosceril-palmitate","3":"pulmonary surfactant","4":"NA","5":"pulmonary","6":"respiratory distress syndrome (RDS)","7":"Launched","8":"respiratory distress syndrome (RDS)","_rn_":"28757"},{"1":"BRD-A90272038-001-01-7","2":"CGP-37849","3":"glutamate receptor antagonist","4":"GRIN2A, GRIN2B, GRIN2C, GRIN2D","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"28759"},{"1":"BRD-K26833429-001-02-8","2":"costunolide","3":"telomerase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29547"},{"1":"BRD-K95926480-003-03-6","2":"SRT1720","3":"SIRT activator","4":"SIRT1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29549"},{"1":"BRD-K71823332-001-03-7","2":"epothilone-a","3":"microtubule stabilizing agent","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29551"},{"1":"BRD-K49371609-003-03-8","2":"PIK-75","3":"DNA protein kinase inhibitor, PI3K inhibitor","4":"PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29553"},{"1":"BRD-K24187789-001-01-7","2":"VU0238429","3":"acetylcholine receptor allosteric modulator","4":"CHRM5","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29555"},{"1":"BRD-K45462423-001-03-7","2":"VU0361737","3":"glutamate receptor positive allosteric modulator","4":"GRM4","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29595"},{"1":"BRD-K83607951-001-02-2","2":"skepinone-l","3":"p38 MAPK inhibitor","4":"MAPK14","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29597"},{"1":"BRD-K47049295-300-01-5","2":"BAN-ORL-24","3":"nociceptin/orphanin FQ receptor antagonist","4":"OPRL1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29599"},{"1":"BRD-K48443249-001-01-0","2":"CNX-774","3":"Bruton's tyrosine kinase (BTK) inhibitor","4":"BTK","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29601"},{"1":"BRD-K15898725-001-01-7","2":"maytansinol-isobutyrate","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29603"},{"1":"BRD-A98299281-050-09-6","2":"hydroxytacrine-maleate-(r,s)","3":"cholinesterase inhibitor","4":"ACHE","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29643"},{"1":"BRD-K22385716-001-02-5","2":"LY303511","3":"casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","4":"BRD2, BRD3, BRD4","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29645"},{"1":"BRD-K01614093-001-02-6","2":"dihydromyricetin","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29647"},{"1":"BRD-K76180386-001-01-6","2":"JIB04","3":"histone lysine demethylase inhibitor","4":"KDM4E","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29649"},{"1":"BRD-K75478907-001-02-3","2":"GS-39783","3":"GABA receptor modulator","4":"GABBR1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29651"},{"1":"BRD-K75352575-001-01-3","2":"KPT-276","3":"exportin antagonist","4":"XPO1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29691"},{"1":"BRD-K62696033-001-01-4","2":"G-1","3":"G protein-coupled receptor agonist","4":"GPER1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29693"},{"1":"BRD-K87696786-003-04-4","2":"LY456236","3":"glutamate receptor antagonist","4":"GRM1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29695"},{"1":"BRD-K10705233-001-02-2","2":"GW-405833","3":"cannabinoid receptor agonist","4":"CNR2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29697"},{"1":"BRD-K49049886-001-08-7","2":"CGS-15943","3":"adenosine receptor antagonist","4":"ADORA1, ADORA2A, ADORA2B, ADORA3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29699"},{"1":"BRD-K72420232-001-12-3","2":"WZ-4002","3":"EGFR inhibitor","4":"EGFR, ERBB2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29739"},{"1":"BRD-A93477898-001-04-2","2":"PETCM","3":"caspase activator","4":"CASP3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29741"},{"1":"BRD-K72327355-001-14-7","2":"baicalein","3":"lipoxygenase inhibitor","4":"ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29743"},{"1":"BRD-K03109492-001-02-2","2":"NSC-663284","3":"CDC inhibitor","4":"CDC25A, CDC25B, CDC25C","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29745"},{"1":"BRD-K48488978-001-05-3","2":"YM-201636","3":"PI3K inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29747"},{"1":"BRD-K46585355-001-14-3","2":"acetylsalicylsalicylic-acid","3":"cyclooxygenase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29787"},{"1":"BRD-K79259477-001-04-9","2":"NVP-BHG712","3":"ephrin inhibitor","4":"EPHB4","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29789"},{"1":"BRD-K05804044-001-06-0","2":"AZ-628","3":"RAF inhibitor","4":"BRAF, RAF1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29791"},{"1":"BRD-K42973005-001-04-0","2":"CHIR-98014","3":"glycogen synthase kinase inhibitor","4":"GSK3A, GSK3B","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29793"},{"1":"BRD-K18613660-001-05-5","2":"mexeneone","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29795"},{"1":"BRD-K80060353-303-03-9","2":"IEM1754","3":"glutamate receptor antagonist","4":"GRIA1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29835"},{"1":"BRD-K06593056-001-04-8","2":"LE-135","3":"retinoid receptor agonist","4":"RARB","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29837"}],"options":{"columns":{"min":{},"max":[10],"total":[8]},"rows":{"min":[10],"max":[10],"total":[1509]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Preprocess indication nomenclature -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-frame-begin {"metadata":{"classes":["data.frame"],"nrow":1509,"ncol":8,"summary":{"Description":["df [1,509 × 8]"]}},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["broad_id"],"name":[1],"type":["chr"],"align":["left"]},{"label":["name"],"name":[2],"type":["chr"],"align":["left"]},{"label":["moa"],"name":[3],"type":["chr"],"align":["left"]},{"label":["target"],"name":[4],"type":["chr"],"align":["left"]},{"label":["disease.area"],"name":[5],"type":["chr"],"align":["left"]},{"label":["indication"],"name":[6],"type":["chr"],"align":["left"]},{"label":["phase"],"name":[7],"type":["chr"],"align":["left"]},{"label":["indication_processed"],"name":[8],"type":["chr"],"align":["left"]}],"data":[{"1":"BRD-K36788280-001-01-2","2":"ribociclib","3":"CDK inhibitor","4":"CDK4, CDK6","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"1"},{"1":"BRD-K88510285-001-50-9","2":"bortezomib","3":"NFkB pathway inhibitor, proteasome inhibitor","4":"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA","5":"hematologic malignancy","6":"multiple myeloma, mantle cell lymphoma (MCL)","7":"Launched","8":"multiple myeloma, mantle cell lymphoma (MCL)","_rn_":"2"},{"1":"BRD-K99749624-001-07-0","2":"linifanib","3":"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3"},{"1":"BRD-K85402309-043-01-9","2":"dovitinib","3":"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"4"},{"1":"BRD-K50168500-001-07-9","2":"canertinib","3":"EGFR inhibitor","4":"AKT1, EGFR, ERBB2, ERBB4","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"5"},{"1":"BRD-K64881305-001-03-7","2":"ispinesib","3":"kinesin inhibitor","4":"KIF11","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"6"},{"1":"","2":"NA","3":"NA","4":"NA","5":"NA","6":"NA","7":"NA","8":"NA","_rn_":"8"},{"1":"BRD-K99113996-001-02-0","2":"AZD2014","3":"mTOR inhibitor","4":"MTOR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"11"},{"1":"BRD-K62391742-001-09-7","2":"venetoclax","3":"BCL inhibitor","4":"BCL2","5":"hematologic malignancy","6":"chronic lymphocytic leukemia (CLL)","7":"Launched","8":"chronic lymphocytic leukemia (CLL)","_rn_":"12"},{"1":"BRD-K87782578-001-01-4","2":"AVL-292","3":"Bruton's tyrosine kinase (BTK) inhibitor","4":"BTK, YES1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"13"},{"1":"BRD-K09951645-001-11-8","2":"dabrafenib","3":"RAF inhibitor","4":"BRAF, LIMK1, NEK11, RAF1, SIK1","5":"oncology","6":"melanoma","7":"Launched","8":"Skin Cancer","_rn_":"15"},{"1":"BRD-K03390685-001-01-7","2":"cobimetinib","3":"MEK inhibitor","4":"NA","5":"oncology","6":"melanoma","7":"Launched","8":"Skin Cancer","_rn_":"16"},{"1":"BRD-K22822991-001-02-3","2":"odanacatib","3":"cathepsin inhibitor","4":"CTSK","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19"},{"1":"BRD-K42828737-001-03-3","2":"sunitinib","3":"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","4":"CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET","5":"oncology","6":"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","7":"Launched","8":"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","_rn_":"20"},{"1":"BRD-K92723993-001-17-4","2":"imatinib","3":"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","4":"ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","5":"hematologic malignancy, oncology","6":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","7":"Launched","8":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","_rn_":"22"},{"1":"BRD-K38527262-300-01-0","2":"atiprimod","3":"JAK inhibitor, STAT inhibitor","4":"JAK2, STAT3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"24"},{"1":"BRD-K42495768-001-01-7","2":"tasisulam","3":"apoptosis stimulant","4":"NA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"26"},{"1":"BRD-K44408410-001-17-6","2":"2-methoxyestradiol","3":"hypoxia inducible factor inhibitor","4":"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"29"},{"1":"BRD-K53414658-001-08-2","2":"tivozanib","3":"VEGFR inhibitor","4":"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"31"},{"1":"BRD-K58529924-001-01-5","2":"ONC201","3":"AKT inhibitor, MAP kinase inhibitor","4":"TNFSF10","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"32"},{"1":"BRD-K81418486-001-44-2","2":"vorinostat","3":"HDAC inhibitor","4":"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9","5":"hematologic malignancy","6":"cutaneous T-cell lymphoma (CTCL)","7":"Launched","8":"cutaneous T-cell lymphoma (CTCL)","_rn_":"35"},{"1":"BRD-K31928526-001-02-1","2":"barasertib","3":"Aurora kinase inhibitor","4":"AURKA, AURKB","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"37"},{"1":"BRD-K43389675-001-02-1","2":"daunorubicin","3":"RNA synthesis inhibitor, topoisomerase inhibitor","4":"TOP2A, TOP2B","5":"hematologic malignancy","6":"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","7":"Launched","8":"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","_rn_":"38"},{"1":"BRD-K76239644-001-02-6","2":"BMS-690514","3":"EGFR inhibitor, VEGFR inhibitor","4":"EGFR, ERBB2, FLT3, KDR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"39"},{"1":"BRD-K08547377-001-04-4","2":"irinotecan","3":"topoisomerase inhibitor","4":"TOP1, TOP1MT","5":"oncology","6":"colorectal cancer","7":"Launched","8":"Colon/Colorectal Cancer","_rn_":"40"},{"1":"BRD-K82135108-001-04-3","2":"elesclomol","3":"oxidative stress inducer","4":"HSPA1A","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"43"},{"1":"BRD-K69001009-001-02-8","2":"golvatinib","3":"VEGFR inhibitor","4":"KDR, MET","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"44"},{"1":"BRD-K62200014-003-10-5","2":"anagrelide","3":"phosphodiesterase inhibitor","4":"PDE3A","5":"hematology, hematologic malignancy","6":"thrombocythemia, myeloproliferative neoplasms","7":"Launched","8":"thrombocythemia, myeloproliferative neoplasms","_rn_":"46"},{"1":"BRD-K05804044-001-18-5","2":"AZ-628","3":"RAF inhibitor","4":"BRAF, RAF1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"48"},{"1":"BRD-K03406345-001-21-1","2":"azacitidine","3":"DNA methyltransferase inhibitor","4":"DNMT1, DNMT3A","5":"hematologic malignancy, hematology","6":"myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","7":"Launched","8":"myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","_rn_":"51"},{"1":"BRD-K08703257-001-13-9","2":"3-amino-benzamide","3":"PARP inhibitor","4":"PARP1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"53"},{"1":"BRD-K46386702-001-02-1","2":"ARRY-334543","3":"EGFR inhibitor","4":"ERBB2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"55"},{"1":"BRD-K54955827-001-02-2","2":"niraparib","3":"PARP inhibitor","4":"PARP1","5":"oncology","6":"primary peritoneal cancer (PPC)","7":"Launched","8":"primary peritoneal cancer (PPC)","_rn_":"59"},{"1":"BRD-K23984367-001-07-5","2":"sorafenib","3":"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","4":"BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET","5":"oncology","6":"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","7":"Launched","8":"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","_rn_":"64"},{"1":"BRD-K29905972-001-06-3","2":"axitinib","3":"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"CSF1, FLT1, FLT4, KDR, PLK4","5":"oncology","6":"renal cell carcinoma (RCC)","7":"Launched","8":"renal cell carcinoma (RCC)","_rn_":"67"},{"1":"BRD-K56981171-001-02-8","2":"brigatinib","3":"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","4":"ALK, EGFR","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"74"},{"1":"BRD-M97302542-001-04-4","2":"dichloroacetate","3":"pyruvate dehydrogenase kinase inhibitor","4":"PDK1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"91"},{"1":"BRD-K76210423-001-01-6","2":"resiquimod","3":"toll-like receptor agonist","4":"TLR7, TLR8","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"102"},{"1":"BRD-K17610631-001-03-3","2":"indisulam","3":"CDK inhibitor","4":"CA1, CA12, CA14, CA2, CA6, CA7, CA9","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"103"},{"1":"BRD-K86118762-001-01-8","2":"linsitinib","3":"IGF-1 inhibitor","4":"IGF1R, INSR, INSRR","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1079"},{"1":"BRD-K06814349-304-02-7","2":"fosbretabulin","3":"tubulin polymerization inhibitor, VE-cadherin antagonist","4":"CDH5","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1081"},{"1":"BRD-K08799216-001-05-3","2":"pelitinib","3":"EGFR inhibitor","4":"EGFR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1082"},{"1":"BRD-K13049116-001-04-0","2":"BMS-754807","3":"IGF-1 inhibitor","4":"AKT1, IGF1R","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1083"},{"1":"BRD-K63504947-001-14-7","2":"semaxanib","3":"VEGFR inhibitor","4":"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1084"},{"1":"BRD-K02130563-001-11-4","2":"panobinostat","3":"HDAC inhibitor","4":"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9","5":"hematologic malignancy","6":"multiple myeloma","7":"Launched","8":"multiple myeloma","_rn_":"1085"},{"1":"BRD-K87909389-003-03-4","2":"alvocidib","3":"CDK inhibitor","4":"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1090"},{"1":"BRD-K08109215-001-06-4","2":"I-BET-762","3":"bromodomain inhibitor","4":"BRD2, BRD3, BRD4","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1091"},{"1":"BRD-K77625799-001-07-7","2":"vandetanib","3":"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","4":"EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA","5":"oncology","6":"medullary thyroid cancer (MTC)","7":"Launched","8":"medullary thyroid cancer (MTC)","_rn_":"1092"},{"1":"BRD-K28822270-001-03-7","2":"resminostat","3":"HDAC inhibitor","4":"HDAC1, HDAC3, HDAC6, HDAC8","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1096"},{"1":"BRD-K54997624-001-06-0","2":"alpelisib","3":"PI3K inhibitor","4":"PIK3CA, PIK3CB, PIK3CD, PIK3CG","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1098"},{"1":"BRD-K82746043-001-19-3","2":"navitoclax","3":"BCL inhibitor","4":"BCL2, BCL2L1, BCL2L2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1100"},{"1":"BRD-K96123349-236-02-8","2":"brequinar","3":"dihydroorotate dehydrogenase inhibitor","4":"DHODH","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1102"},{"1":"BRD-K57080016-001-15-9","2":"selumetinib","3":"MEK inhibitor","4":"MAP2K1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1106"},{"1":"BRD-K33610132-001-02-9","2":"rociletinib","3":"EGFR inhibitor","4":"EGFR","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1108"},{"1":"BRD-K35520305-001-16-9","2":"dacarbazine","3":"DNA alkylating agent","4":"PGD, POLA2","5":"oncology, hematologic malignancy","6":"melanoma, Hodgkin's lymphoma","7":"Launched","8":"Skin Cancer, Hodgkin's lymphoma","_rn_":"1109"},{"1":"BRD-K58435339-001-03-0","2":"AT13387","3":"HSP antagonist","4":"HSP90AA1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1112"},{"1":"BRD-K57169635-001-04-5","2":"dacomitinib","3":"EGFR inhibitor","4":"EGFR, ERBB2, ERBB4","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1113"},{"1":"BRD-K76908866-001-07-6","2":"CP-724714","3":"EGFR inhibitor, protein tyrosine kinase inhibitor","4":"ERBB2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1115"},{"1":"BRD-K17894950-001-14-3","2":"indirubin","3":"CDK inhibitor, glycogen synthase kinase inhibitor","4":"CDK1, CDK5, GSK3A","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"1118"},{"1":"BRD-K87737963-001-06-0","2":"cyt387","3":"NA","4":"JAK1, JAK2, JAK3","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1119"},{"1":"BRD-K18961567-001-01-1","2":"LY2801653","3":"MET inhibitor","4":"MET","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1121"},{"1":"BRD-K64052750-001-22-5","2":"gefitinib","3":"EGFR inhibitor","4":"EGFR","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"1126"},{"1":"BRD-K49350383-001-14-5","2":"thioguanine","3":"purine antagonist","4":"IMPDH1, IMPDH2","5":"hematologic malignancy","6":"acute myeloid leukemia (AML)","7":"Launched","8":"acute myeloid leukemia (AML)","_rn_":"1128"},{"1":"BRD-K03765900-001-01-9","2":"XL-647","3":"EGFR inhibitor, VEGFR inhibitor","4":"EGFR, EPHB4, ERBB2, FLT4, KDR","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1130"},{"1":"BRD-K38332599-001-01-3","2":"uprosertib","3":"AKT inhibitor","4":"AKT1, AKT2, AKT3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1138"},{"1":"BRD-K69694239-001-02-2","2":"bardoxolone-methyl","3":"nuclear factor erythroid derived, like (NRF2) activator","4":"PPARG, STAT3","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"1158"},{"1":"BRD-K17555800-003-02-3","2":"talmapimod","3":"p38 MAPK inhibitor","4":"MAPK11, MAPK14","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1169"},{"1":"BRD-K98572433-001-02-9","2":"AZD8931","3":"EGFR inhibitor","4":"EGFR, ERBB2, ERBB3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"1170"},{"1":"BRD-K61192372-001-08-9","2":"capecitabine","3":"DNA synthesis inhibitor, thymidylate synthase inhibitor","4":"TYMS","5":"oncology","6":"breast cancer, colorectal cancer","7":"Launched","8":"breast cancer, Colon/Colorectal Cancer","_rn_":"2002"},{"1":"BRD-K76674262-001-03-3","2":"homoharringtonine","3":"protein synthesis inhibitor","4":"RPL3","5":"hematologic malignancy","6":"chronic myeloid leukemia (CML)","7":"Launched","8":"chronic myeloid leukemia (CML)","_rn_":"2004"},{"1":"BRD-K53972329-001-07-0","2":"ruxolitinib","3":"JAK inhibitor","4":"JAK1, JAK2, JAK3, TYK2","5":"hematologic malignancy, hematology","6":"myelofibrosis, polycythemia vera","7":"Launched","8":"myelofibrosis, polycythemia vera","_rn_":"2005"},{"1":"BRD-K42805893-001-04-9","2":"osimertinib","3":"EGFR inhibitor","4":"EGFR","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"2010"},{"1":"BRD-K92441787-001-04-1","2":"bexarotene","3":"retinoid receptor agonist","4":"RXRA, RXRB, RXRG","5":"hematologic malignancy","6":"cutaneous T-cell lymphoma (CTCL)","7":"Launched","8":"cutaneous T-cell lymphoma (CTCL)","_rn_":"2011"},{"1":"BRD-K60866521-001-07-1","2":"idelalisib","3":"PI3K inhibitor","4":"PIK3CA, PIK3CB, PIK3CD, PIK3CG","5":"hematologic malignancy","6":"chronic lymphocytic leukemia (CLL)","7":"Launched","8":"chronic lymphocytic leukemia (CLL)","_rn_":"2012"},{"1":"BRD-K82818427-001-04-8","2":"batimastat","3":"matrix metalloprotease inhibitor","4":"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"2013"},{"1":"BRD-K62627508-001-01-5","2":"idasanutlin","3":"MDM inhibitor","4":"MDM2, TP53","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"2016"},{"1":"BRD-A25234499-001-19-1","2":"aminoglutethimide","3":"glucocorticoid receptor antagonist","4":"CYP11A1, CYP19A1","5":"endocrinology, oncology","6":"Cushing's syndrome, breast cancer","7":"Launched","8":"Cushing's syndrome, breast cancer","_rn_":"2017"},{"1":"BRD-K39974922-001-04-3","2":"lenvatinib","3":"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"FLT4, KDR","5":"oncology","6":"thyroid cancer","7":"Launched","8":"thyroid cancer","_rn_":"2019"},{"1":"BRD-K17743125-001-08-4","2":"belinostat","3":"HDAC inhibitor","4":"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9","5":"hematologic malignancy","6":"peripheral T-cell lymphoma (PTCL)","7":"Launched","8":"peripheral T-cell lymphoma (PTCL)","_rn_":"2020"},{"1":"BRD-K51313569-001-07-8","2":"palbociclib","3":"CDK inhibitor","4":"CDK4, CDK6","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"2023"},{"1":"BRD-K15179879-001-03-2","2":"carfilzomib","3":"proteasome inhibitor","4":"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9","5":"hematologic malignancy","6":"multiple myeloma","7":"Launched","8":"multiple myeloma","_rn_":"2027"},{"1":"BRD-K12343256-001-14-7","2":"trametinib","3":"MEK inhibitor","4":"MAP2K1, MAP2K2","5":"oncology","6":"melanoma","7":"Launched","8":"Skin Cancer","_rn_":"2029"},{"1":"BRD-K67844266-003-01-9","2":"pevonedistat","3":"nedd activating enzyme inhibitor","4":"NAE1, UBA3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2031"},{"1":"BRD-K95142244-001-01-5","2":"talazoparib","3":"PARP inhibitor","4":"PARP2","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"2032"},{"1":"BRD-K26657438-001-15-2","2":"imiquimod","3":"interferon inducer, toll-like receptor agonist","4":"TLR7, TLR8","5":"dermatology, infectious disease, oncology","6":"actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","7":"Launched","8":"actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","_rn_":"2033"},{"1":"BRD-K50010139-001-01-5","2":"poziotinib","3":"EGFR inhibitor","4":"EGFR, ERBB2, ERBB4","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2034"},{"1":"BRD-A70858459-001-01-7","2":"estramustine","3":"DNA alkylating agent","4":"ESR1, ESR2, MAP1A, MAP2","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"2036"},{"1":"BRD-K70301465-001-05-9","2":"ibrutinib","3":"Bruton's tyrosine kinase (BTK) inhibitor","4":"BLK, BMX, BTK","5":"hematologic malignancy","6":"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","7":"Launched","8":"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","_rn_":"2039"},{"1":"BRD-K13514097-001-04-6","2":"everolimus","3":"mTOR inhibitor","4":"MTOR","5":"oncology, neurology/psychiatry, genetics, urology","6":"breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","7":"Launched","8":"breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","_rn_":"2040"},{"1":"BRD-K11267252-001-05-1","2":"alectinib","3":"ALK tyrosine kinase receptor inhibitor","4":"ALK, MET","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"2041"},{"1":"BRD-K44227013-001-06-4","2":"ponatinib","3":"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","4":"ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK","5":"hematologic malignancy","6":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","7":"Launched","8":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","_rn_":"2044"},{"1":"BRD-K73838513-003-05-5","2":"cinacalcet","3":"calcium channel activator","4":"CASR","5":"endocrinology, nephrology, oncology","6":"hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia","7":"Launched","8":"hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia","_rn_":"2047"},{"1":"BRD-K31698212-001-02-9","2":"icotinib","3":"EGFR inhibitor","4":"EGFR","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"2049"},{"1":"BRD-K59369769-001-22-9","2":"tozasertib","3":"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","4":"AURKA, AURKB, AURKC, LCK","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2053"},{"1":"BRD-K33622447-066-01-9","2":"abemaciclib","3":"CDK inhibitor","4":"CDK4, CDK6","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"2058"},{"1":"BRD-K66175015-001-12-4","2":"afatinib","3":"EGFR inhibitor","4":"EGFR, ERBB2, ERBB4","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"2060"},{"1":"BRD-K44827188-001-06-0","2":"vismodegib","3":"hedgehog pathway inhibitor, smoothened receptor antagonist","4":"SMO","5":"oncology","6":"basal cell carcinoma (BCC)","7":"Launched","8":"basal cell carcinoma (BCC)","_rn_":"2067"},{"1":"BRD-K70401845-001-15-7","2":"erlotinib","3":"EGFR inhibitor","4":"EGFR, NR1I2","5":"oncology","6":"non-small cell lung cancer (NSCLC), pancreatic cancer","7":"Launched","8":"Lung Cancer, pancreatic cancer","_rn_":"2085"},{"1":"BRD-K69776681-001-03-8","2":"volasertib","3":"PLK inhibitor","4":"PLK1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"2095"},{"1":"BRD-K13390322-001-06-3","2":"AT-7519","3":"CDK inhibitor","4":"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2985"},{"1":"BRD-K12184916-001-19-6","2":"NVP-BEZ235","3":"mTOR inhibitor, PI3K inhibitor","4":"ATR, MTOR, PIK3CA, PIK3CD, PIK3CG","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2987"},{"1":"BRD-K23228615-001-02-8","2":"GDC-0980","3":"mTOR inhibitor, PI3K inhibitor","4":"FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2988"},{"1":"BRD-K03449891-001-08-6","2":"foretinib","3":"VEGFR inhibitor","4":"FLT1, FLT4, KDR, MET","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2989"},{"1":"BRD-K51791723-003-01-7","2":"P276-00","3":"CDK inhibitor","4":"CDK1, CDK4, CDK9","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2994"},{"1":"BRD-K33379087-001-07-5","2":"tivantinib","3":"tyrosine kinase inhibitor","4":"MET","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"2995"},{"1":"BRD-K75009076-001-02-1","2":"SCH-900776","3":"CHK inhibitor","4":"CDK2, CHEK1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2996"},{"1":"BRD-K52313696-001-12-3","2":"tacedinaline","3":"HDAC inhibitor","4":"HDAC1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"2998"},{"1":"BRD-K26026438-001-01-0","2":"tucatinib","3":"EGFR inhibitor","4":"ERBB2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"2999"},{"1":"BRD-K55187425-236-05-2","2":"rigosertib","3":"cell cycle inhibitor, PLK inhibitor","4":"PLK1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3001"},{"1":"BRD-K85606544-001-09-1","2":"neratinib","3":"EGFR inhibitor","4":"EGFR, ERBB2, KDR","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3004"},{"1":"BRD-K78431006-001-15-1","2":"crizotinib","3":"ALK tyrosine kinase receptor inhibitor","4":"ALK, MET","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"3005"},{"1":"BRD-K62196610-001-01-6","2":"AVN-944","3":"inosine monophosphate dehydrogenase inhibitor","4":"IMPDH1, IMPDH2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3007"},{"1":"BRD-K11630072-001-13-2","2":"carmofur","3":"thymidylate synthase inhibitor","4":"TYMS","5":"oncology","6":"breast cancer, colorectal cancer","7":"Launched","8":"breast cancer, Colon/Colorectal Cancer","_rn_":"3008"},{"1":"BRD-K54256913-001-08-7","2":"MK-1775","3":"WEE1 kinase inhibitor","4":"WEE1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3011"},{"1":"BRD-K81016934-001-02-0","2":"INC-280","3":"c-Met inhibitor","4":"MET","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3013"},{"1":"BRD-K16730910-001-10-7","2":"regorafenib","3":"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","4":"ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK","5":"oncology","6":"colorectal cancer, gastrointestinal stromal tumors (GIST)","7":"Launched","8":"Colon/Colorectal Cancer, gastrointestinal stromal tumors (GIST)","_rn_":"3014"},{"1":"BRD-K19796430-001-05-6","2":"sonidegib","3":"smoothened receptor antagonist","4":"SMO","5":"oncology","6":"basal cell carcinoma (BCC)","7":"Launched","8":"basal cell carcinoma (BCC)","_rn_":"3017"},{"1":"BRD-K14109347-001-03-4","2":"LY2603618","3":"CHK inhibitor","4":"CHEK1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3019"},{"1":"BRD-K19540840-001-09-4","2":"saracatinib","3":"src inhibitor","4":"ABL1, LCK, SRC, YES1","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"3020"},{"1":"BRD-K15600710-066-05-8","2":"obatoclax","3":"BCL inhibitor","4":"BCL2","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3021"},{"1":"BRD-K19687926-001-04-1","2":"lapatinib","3":"EGFR inhibitor","4":"EGFR, ERBB2","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"3023"},{"1":"BRD-K89014967-001-04-3","2":"AS-703026","3":"MEK inhibitor","4":"MAP2K1, MAP2K2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3027"},{"1":"BRD-K79254416-001-21-8","2":"decitabine","3":"DNA methyltransferase inhibitor","4":"DNMT1, DNMT3A","5":"hematologic malignancy, hematology","6":"myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","7":"Launched","8":"myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","_rn_":"3029"},{"1":"BRD-K74514084-003-09-2","2":"pazopanib","3":"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3","5":"oncology","6":"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","7":"Launched","8":"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","_rn_":"3032"},{"1":"BRD-K02113016-001-19-6","2":"olaparib","3":"PARP inhibitor","4":"PARP1, PARP2","5":"oncology","6":"ovarian cancer","7":"Launched","8":"ovarian cancer","_rn_":"3035"},{"1":"BRD-K59317601-001-05-5","2":"MLN0128","3":"mTOR inhibitor","4":"MTOR, PIK3CA, PIK3CD, PIK3CG","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3038"},{"1":"BRD-K60997853-001-02-3","2":"PHA-848125","3":"CDK inhibitor, growth factor receptor inhibitor","4":"CDK2, CDK4, CDK7, NTRK1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3042"},{"1":"BRD-K51967704-001-03-6","2":"BIIB021","3":"HSP inhibitor","4":"HSP90AA1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3046"},{"1":"BRD-K22064724-001-01-8","2":"napabucasin","3":"STAT inhibitor","4":"STAT3","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3053"},{"1":"BRD-K56343971-001-14-8","2":"vemurafenib","3":"RAF inhibitor","4":"BRAF, RAF1","5":"oncology","6":"melanoma","7":"Launched","8":"Skin Cancer","_rn_":"3078"},{"1":"BRD-K36627727-001-05-4","2":"tamibarotene","3":"retinoid receptor agonist","4":"RARA, RARB","5":"hematologic malignancy","6":"acute promyelocytic leukemia (APL)","7":"Launched","8":"acute promyelocytic leukemia (APL)","_rn_":"3970"},{"1":"BRD-K86972824-001-01-4","2":"oltipraz","3":"nuclear factor erythroid derived, like (NRF2) activator","4":"ANG","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3971"},{"1":"BRD-K41859756-001-06-8","2":"NVP-AUY922","3":"HSP inhibitor","4":"HSP90AA1, HSP90AB1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3972"},{"1":"BRD-K83988098-001-02-0","2":"alvespimycin","3":"HSP inhibitor","4":"HSP90AA1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3976"},{"1":"BRD-K99616396-001-05-1","2":"motesanib","3":"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"FLT1, FLT4, KDR, KIT","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3980"},{"1":"BRD-K63712959-001-01-8","2":"temoporfin","3":"radical formation stimulant","4":"NA","5":"oncology","6":"head and neck squamous cell carcinoma (HNSCC)","7":"Launched","8":"Head and Neck Cancer","_rn_":"3982"},{"1":"BRD-K13662825-001-07-5","2":"dinaciclib","3":"CDK inhibitor","4":"CDK1, CDK2, CDK5, CDK9","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3984"},{"1":"BRD-K49328571-001-15-0","2":"dasatinib","3":"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","4":"ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1","5":"hematologic malignancy","6":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","7":"Launched","8":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","_rn_":"3986"},{"1":"BRD-K83029223-001-01-3","2":"litronesib","3":"kinesin-like spindle protein inhibitor","4":"KIF11","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3987"},{"1":"BRD-K42898655-001-01-8","2":"temsirolimus","3":"mTOR inhibitor","4":"MTOR","5":"oncology","6":"renal cell carcinoma (RCC)","7":"Launched","8":"renal cell carcinoma (RCC)","_rn_":"3989"},{"1":"BRD-K08542803-001-02-3","2":"gambogic-acid","3":"caspase activator","4":"BCL2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"3990"},{"1":"BRD-K37379014-001-02-0","2":"filanesib","3":"kinesin inhibitor, kinesin-like spindle protein inhibitor","4":"KIF11","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3991"},{"1":"BRD-K81473043-001-19-5","2":"tanespimycin","3":"HSP inhibitor","4":"HSP90AA1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"3992"},{"1":"BRD-A74914197-001-02-9","2":"pralatrexate","3":"dihydrofolate reductase inhibitor","4":"DHFR, TYMS","5":"hematologic malignancy","6":"peripheral T-cell lymphoma (PTCL)","7":"Launched","8":"peripheral T-cell lymphoma (PTCL)","_rn_":"3997"},{"1":"BRD-K62008436-001-23-9","2":"paclitaxel","3":"tubulin polymerization inhibitor","4":"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1","5":"oncology","6":"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","7":"Launched","8":"ovarian cancer, breast cancer, Lung Cancer","_rn_":"4001"},{"1":"BRD-K38852836-001-02-1","2":"ganetespib","3":"HSP inhibitor","4":"HSP90AA1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"4004"},{"1":"BRD-K30577245-001-05-0","2":"docetaxel","3":"tubulin polymerization inhibitor","4":"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1","5":"oncology","6":"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","7":"Launched","8":"breast cancer, Lung Cancer, prostate cancer, gastric adenocarcinoma, Head and Neck Cancer","_rn_":"4005"},{"1":"BRD-K58550667-001-08-7","2":"FK-866","3":"niacinamide phosphoribosyltransferase inhibitor","4":"NAMPT","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"4025"},{"1":"BRD-K88510285-001-17-8","2":"bortezomib","3":"NFkB pathway inhibitor, proteasome inhibitor","4":"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA","5":"hematologic malignancy","6":"multiple myeloma, mantle cell lymphoma (MCL)","7":"Launched","8":"multiple myeloma, mantle cell lymphoma (MCL)","_rn_":"4026"},{"1":"BRD-K60230970-001-14-2","2":"MG-132","3":"proteasome inhibitor","4":"PSMB1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4664"},{"1":"NA","2":"NA","3":"NA","4":"NA","5":"NA","6":"NA","7":"NA","8":"NA","_rn_":"4665"},{"1":"BRD-K71847383-001-12-5","2":"cytarabine","3":"ribonucleotide reductase inhibitor","4":"POLA1, POLB, POLD1, POLE","5":"hematologic malignancy","6":"acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)","7":"Launched","8":"acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)","_rn_":"4666"},{"1":"BRD-A98990573-003-01-3","2":"epinastine","3":"histamine receptor antagonist","4":"ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7","5":"ophthalmology","6":"conjunctivitis","7":"Launched","8":"conjunctivitis","_rn_":"4668"},{"1":"BRD-K47832606-001-30-1","2":"floxuridine","3":"DNA synthesis inhibitor","4":"TYMS","5":"oncology","6":"colorectal cancer","7":"Launched","8":"Colon/Colorectal Cancer","_rn_":"4670"},{"1":"BRD-K72951360-001-01-4","2":"valrubicin","3":"DNA inhibitor, topoisomerase inhibitor","4":"TOP2A","5":"oncology","6":"bladder cancer","7":"Launched","8":"bladder cancer","_rn_":"4672"},{"1":"BRD-K33127281-001-05-6","2":"adapalene","3":"retinoid receptor agonist","4":"RARA, RARB, RARG, RXRA, RXRB, RXRG","5":"dermatology","6":"acne vulgaris (AV)","7":"Launched","8":"acne vulgaris (AV)","_rn_":"4674"},{"1":"BRD-K88510285-001-22-8","2":"bortezomib","3":"NFkB pathway inhibitor, proteasome inhibitor","4":"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA","5":"hematologic malignancy","6":"multiple myeloma, mantle cell lymphoma (MCL)","7":"Launched","8":"multiple myeloma, mantle cell lymphoma (MCL)","_rn_":"4686"},{"1":"BRD-K19388745-003-01-7","2":"colforsin-daproate","3":"adenylyl cyclase activator","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"4714"},{"1":"BRD-K11640013-236-10-1","2":"sulfamethazine","3":"PABA antagonist","4":"NA","5":"gastroenterology","6":"enteritis, enteritis","7":"Launched","8":"enteritis, enteritis","_rn_":"4716"},{"1":"BRD-K53123955-001-10-5","2":"niridazole","3":"phosphofructokinase inhibitor","4":"NA","5":"infectious disease","6":"schistosomiasis","7":"Launched","8":"schistosomiasis","_rn_":"4718"},{"1":"BRD-K90027121-003-01-7","2":"amprolium","3":"thiamine uptake blocker","4":"NA","5":"infectious disease","6":"coccidiosis","7":"Launched","8":"coccidiosis","_rn_":"4720"},{"1":"BRD-A19585813-003-03-3","2":"methylphenidate","3":"dopamine-norepinephrine reuptake inhibitor","4":"SLC6A2, SLC6A3, SLC6A4","5":"neurology/psychiatry","6":"attention-deficit/hyperactivity disorder (ADHD), narcolepsy","7":"Launched","8":"attention-deficit/hyperactivity disorder (ADHD), narcolepsy","_rn_":"4722"},{"1":"BRD-A85667082-001-12-7","2":"fulvestrant","3":"estrogen receptor antagonist","4":"ESR1, ESR2, GPER1","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"4762"},{"1":"BRD-K00077635-304-01-2","2":"estramustine-phosphate","3":"DNA synthesis inhibitor, microtubule inhibitor","4":"ESR1, ESR2, MAP1A, MAP2","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"4764"},{"1":"BRD-K71035033-001-07-1","2":"masitinib","3":"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor","4":"FGFR3, KIT, PDGFRA, PDGFRB","5":"dermatology","6":"mastocytoma","7":"Launched","8":"mastocytoma","_rn_":"4766"},{"1":"BRD-K07220430-001-18-4","2":"cinnarazine","3":"calcium channel blocker","4":"NA","5":"neurology/psychiatry, gastroenterology, ophthalmology","6":"Meniere's disease, nausea, vomiting, Cogan's syndrome","7":"Launched","8":"Meniere's disease, nausea, vomiting, Cogan's syndrome","_rn_":"4768"},{"1":"BRD-K61397605-001-03-4","2":"romidepsin","3":"HDAC inhibitor","4":"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9","5":"hematologic malignancy","6":"cutaneous T-cell lymphoma (CTCL)","7":"Launched","8":"cutaneous T-cell lymphoma (CTCL)","_rn_":"4810"},{"1":"BRD-A71725768-001-01-3","2":"metoxibutropate","3":"cyclooxygenase inhibitor","4":"PTGS1, PTGS2","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"4812"},{"1":"BRD-K62213621-001-01-6","2":"dihydroartemisinin","3":"antimalarial agent","4":"NA","5":"infectious disease","6":"malaria","7":"Launched","8":"malaria","_rn_":"4814"},{"1":"BRD-A14240607-003-26-1","2":"octopamine","3":"trace amine associated receptor agonist","4":"F10, TAAR1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4816"},{"1":"BRD-K68997413-001-05-1","2":"PF-3845","3":"FAAH inhibitor","4":"FAAH","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4818"},{"1":"BRD-K01773560-001-02-4","2":"UNC2250","3":"MER tyrosine kinase inhibitor","4":"MERTK","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4858"},{"1":"BRD-K44067360-001-30-3","2":"flufenamic-acid","3":"chloride channel blocker","4":"AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4860"},{"1":"BRD-A28970875-300-04-9","2":"puromycin","3":"protein synthesis inhibitor","4":"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4862"},{"1":"BRD-K24593301-001-02-3","2":"AZD3463","3":"ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor","4":"ALK, IGF1R","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4864"},{"1":"BRD-K00535541-001-06-3","2":"9-aminoacridine","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4866"},{"1":"BRD-K35329391-334-01-7","2":"GZD824","3":"Bcr-Abl kinase inhibitor","4":"ABL1, BCR","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4906"},{"1":"BRD-K94485812-001-02-9","2":"LDN-57444","3":"ubiquitin C-terminal hydrolase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4908"},{"1":"BRD-K36055864-001-19-2","2":"cycloheximide","3":"protein synthesis inhibitor","4":"RPL3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4910"},{"1":"BRD-K49759007-001-11-9","2":"4-hydroxy-phenazone","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4912"},{"1":"BRD-K14329163-001-03-9","2":"BAY-K-8644-(s)-(-)","3":"L-type calcium channel activator","4":"CACNA1C","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4914"},{"1":"BRD-K00615600-001-12-9","2":"AG-14361","3":"PARP inhibitor","4":"PARP1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4954"},{"1":"BRD-K61688984-001-02-9","2":"RGFP966","3":"HDAC inhibitor","4":"HDAC3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4956"},{"1":"BRD-K99170882-001-04-3","2":"NSC-319726","3":"p53 activator","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4958"},{"1":"BRD-K28570407-001-02-0","2":"A-803467","3":"sodium channel blocker","4":"SCN10A","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4960"},{"1":"BRD-K60446698-001-01-2","2":"ONX-0914","3":"proteasome inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"4962"},{"1":"BRD-K28453807-003-11-2","2":"nitrocaramiphen","3":"cholinergic receptor antagonist","4":"CHRM1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5002"},{"1":"BRD-K26824830-001-02-0","2":"azomycin-(2-nitroimidazole)","3":"protein synthesis inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5004"},{"1":"BRD-K64888243-001-03-7","2":"AZ960","3":"JAK inhibitor","4":"JAK2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5006"},{"1":"BRD-K29173907-001-09-2","2":"isoflupredone-acetate","3":"NA","4":"NR3C1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5008"},{"1":"BRD-K97365803-001-02-1","2":"PI-828","3":"PI3K inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5010"},{"1":"BRD-A57833392-001-01-7","2":"oxymatrine","3":"NA","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"5763"},{"1":"BRD-K51471001-303-04-7","2":"demecarium","3":"acetylcholinesterase inhibitor","4":"ACHE, BCHE","5":"ophthalmology","6":"intraocular pressure, glaucoma","7":"Launched","8":"intraocular pressure, glaucoma","_rn_":"5765"},{"1":"BRD-K92093830-003-30-8","2":"doxorubicin","3":"topoisomerase inhibitor","4":"TOP2A","5":"hematologic malignancy, oncology","6":"acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma","7":"Launched","8":"acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma","_rn_":"5767"},{"1":"BRD-K88510285-001-11-1","2":"bortezomib","3":"NFkB pathway inhibitor, proteasome inhibitor","4":"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA","5":"hematologic malignancy","6":"multiple myeloma, mantle cell lymphoma (MCL)","7":"Launched","8":"multiple myeloma, mantle cell lymphoma (MCL)","_rn_":"5769"},{"1":"BRD-K37249724-001-25-7","2":"astemizole","3":"histamine receptor antagonist","4":"HRH1, KCNH1, KCNH2","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"5771"},{"1":"BRD-K03601870-001-01-2","2":"ixabepilone","3":"microtubule stabilizing agent","4":"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"5812"},{"1":"BRD-K32821942-001-21-3","2":"azathioprine","3":"dehydrogenase inhibitor","4":"HPRT1, IMPDH1, PPAT","5":"transplant, rheumatology","6":"renal homotransplantation, rheumatoid arthritis","7":"Launched","8":"renal homotransplantation, rheumatoid arthritis","_rn_":"5814"},{"1":"BRD-K32744045-001-31-2","2":"disulfiram","3":"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","4":"ALDH2, DBH","5":"neurology/psychiatry","6":"abstinence from alcohol","7":"Launched","8":"abstinence from alcohol","_rn_":"5816"},{"1":"BRD-K31627533-001-09-5","2":"rimexolone","3":"glucocorticoid receptor agonist","4":"NR3C1, SERPINA6","5":"ophthalmology","6":"anterior uveitis","7":"Launched","8":"anterior uveitis","_rn_":"5818"},{"1":"BRD-A55913614-316-09-6","2":"primaquine","3":"antimalarial agent, DNA inhibitor","4":"KRT7, NQO2","5":"infectious disease","6":"malaria","7":"Launched","8":"malaria","_rn_":"5857"},{"1":"BRD-A57382968-001-29-0","2":"piroxicam","3":"cyclooxygenase inhibitor","4":"PTGS1, PTGS2","5":"rheumatology","6":"osteoarthritis, rheumatoid arthritis","7":"Launched","8":"osteoarthritis, rheumatoid arthritis","_rn_":"5861"},{"1":"BRD-K59632282-052-03-1","2":"quinidine","3":"sodium channel blocker","4":"KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4","5":"infectious disease, cardiology","6":"malaria, atrial fibrillation (AF), ventricular arrhythmias","7":"Launched","8":"malaria, atrial fibrillation (AF), ventricular arrhythmias","_rn_":"5863"},{"1":"BRD-K59436580-001-01-7","2":"tedizolid","3":"bacterial 50S ribosomal subunit inhibitor","4":"NA","5":"infectious disease","6":"skin infections","7":"Launched","8":"skin infections","_rn_":"5865"},{"1":"BRD-K20655524-003-12-0","2":"mefexamide","3":"psychoactive drug","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5905"},{"1":"BRD-K31468676-237-01-8","2":"oxonic-acid","3":"uricase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5907"},{"1":"BRD-A11551002-001-04-6","2":"dehydrocholate-acid","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5909"},{"1":"BRD-K04430056-236-02-1","2":"7-nitroindazole","3":"nitric oxide synthase inhibitor","4":"NOS1, NOS2, NOS3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5911"},{"1":"BRD-K00317371-001-06-1","2":"RITA","3":"MDM inhibitor","4":"MDM2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5913"},{"1":"BRD-K66715657-050-01-0","2":"UH-232-(+)","3":"dopamine receptor antagonist","4":"DRD2, DRD3, DRD4, HTR1A","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5952"},{"1":"BRD-K47150025-001-05-3","2":"KI-8751","3":"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"KDR","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5954"},{"1":"BRD-K09132007-001-07-5","2":"D-4476","3":"TGF beta receptor inhibitor","4":"CSNK1A1, CSNK1D, TGFB1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5956"},{"1":"BRD-K09900591-001-26-7","2":"caffeic-acid","3":"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor","4":"ALOX5, MIF","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5958"},{"1":"BRD-A12230535-001-06-7","2":"nutlin-3","3":"MDM inhibitor","4":"MDM2, TP53","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5960"},{"1":"BRD-K28360340-001-08-3","2":"TW-37","3":"BCL inhibitor","4":"BCL2, BCL2L1, MCL1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"5999"},{"1":"BRD-K44665581-001-01-8","2":"bromosporine","3":"bromodomain inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6001"},{"1":"BRD-K26531771-001-02-2","2":"EPZ-5676","3":"histone lysine methyltransferase inhibitor","4":"DOT1L","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"6003"},{"1":"BRD-A44500574-001-01-8","2":"FLI-06","3":"notch signaling inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6005"},{"1":"BRD-K87112191-001-04-5","2":"PP242","3":"mTOR inhibitor","4":"MTOR, PASK","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6007"},{"1":"BRD-A74765037-001-01-1","2":"estradiol-benzoate","3":"contraceptive agent","4":"ESR1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6047"},{"1":"BRD-K30990140-003-02-4","2":"FR-122047","3":"cyclooxygenase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6049"},{"1":"BRD-A64242993-001-05-6","2":"lanatoside-c","3":"cardiac glycoside","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6051"},{"1":"BRD-K66956375-001-11-3","2":"oleoylethanolamide","3":"cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist","4":"CNR1, GPR119, GPR55, PPARA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6053"},{"1":"BRD-K59146805-001-03-7","2":"AZ3146","3":"monopolar spindle 1 kinase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6055"},{"1":"BRD-K02407574-001-09-7","2":"parbendazole","3":"tubulin polymerization inhibitor","4":"TUBB","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6089"},{"1":"BRD-K72231366-001-02-3","2":"TAME","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6091"},{"1":"BRD-K26997899-001-02-2","2":"D-64131","3":"microtubule inhibitor","4":"TUBB","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6093"},{"1":"BRD-K15424032-001-03-6","2":"SB-228357","3":"serotonin receptor antagonist","4":"HTR2A, HTR2B, HTR2C","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6095"},{"1":"BRD-K58770988-001-01-8","2":"NMS-E973","3":"HSP inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"6097"},{"1":"BRD-A03216249-003-24-3","2":"mepivacaine","3":"potassium channel blocker, sodium channel blocker","4":"SCN10A","5":"neurology/psychiatry","6":"local anesthetic","7":"Launched","8":"local anesthetic","_rn_":"6885"},{"1":"BRD-K69726342-238-02-4","2":"atorvastatin","3":"HMGCR inhibitor","4":"AHR, DPP4, HMGCR","5":"neurology/psychiatry, cardiology","6":"stroke, heart attack","7":"Launched","8":"stroke, heart attack","_rn_":"6887"},{"1":"BRD-K69608737-001-10-2","2":"tacrolimus","3":"calcineurin inhibitor","4":"FKBP1A","5":"transplant","6":"organ rejection","7":"Launched","8":"organ rejection","_rn_":"6889"},{"1":"BRD-A72711497-236-03-8","2":"lasalocid","3":"bacterial permeability inducer","4":"NA","5":"infectious disease","6":"coccidiosis","7":"Launched","8":"coccidiosis","_rn_":"6891"},{"1":"BRD-K56614220-001-19-0","2":"clofazimine","3":"GK0582 inhibitor","4":"NA","5":"infectious disease","6":"leprosy","7":"Launched","8":"leprosy","_rn_":"6893"},{"1":"BRD-K70401845-003-09-6","2":"erlotinib","3":"EGFR inhibitor","4":"EGFR, NR1I2","5":"oncology","6":"non-small cell lung cancer (NSCLC), pancreatic cancer","7":"Launched","8":"Lung Cancer, pancreatic cancer","_rn_":"6933"},{"1":"BRD-K73237276-001-01-0","2":"tacalcitol","3":"vitamin D receptor agonist","4":"VDR","5":"dermatology","6":"psoriasis, chapped lips","7":"Launched","8":"psoriasis, chapped lips","_rn_":"6937"},{"1":"BRD-A16997652-001-02-3","2":"protirelin","3":"thyrotropin releasing hormone receptor agonist","4":"TRHR","5":"radiology","6":"thyroid function diagnostic","7":"Launched","8":"thyroid function diagnostic","_rn_":"6939"},{"1":"BRD-K16730910-001-07-3","2":"regorafenib","3":"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","4":"ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK","5":"oncology","6":"colorectal cancer, gastrointestinal stromal tumors (GIST)","7":"Launched","8":"Colon/Colorectal Cancer, gastrointestinal stromal tumors (GIST)","_rn_":"6941"},{"1":"BRD-A69815203-001-07-6","2":"cyclosporin-a","3":"calcineurin inhibitor","4":"PPP3CA","5":"rheumatology, dermatology","6":"rheumatoid arthritis, psoriasis","7":"Launched","8":"rheumatoid arthritis, psoriasis","_rn_":"6981"},{"1":"BRD-A81513827-001-03-6","2":"saxagliptin","3":"dipeptidyl peptidase inhibitor","4":"DPP4","5":"endocrinology","6":"diabetes mellitus","7":"Launched","8":"diabetes mellitus","_rn_":"6983"},{"1":"BRD-K26634012-001-04-9","2":"tilmicosin","3":"bacterial 50S ribosomal subunit inhibitor","4":"NA","5":"pulmonary","6":"bovine respiratory disease (BRD)","7":"Launched","8":"bovine respiratory disease (BRD)","_rn_":"6985"},{"1":"BRD-K90374350-001-09-2","2":"chlorquinaldol","3":"other antibiotic","4":"NA","5":"infectious disease","6":"fungal infection","7":"Launched","8":"fungal infection","_rn_":"6987"},{"1":"BRD-U45393375-000-01-6","2":"sevelamer","3":"phosphate antagonist","4":"NA","5":"nephrology","6":"chronic kidney disease (CKD)","7":"Launched","8":"chronic kidney disease (CKD)","_rn_":"6989"},{"1":"BRD-K38183498-001-02-0","2":"clonazepam","3":"GABA benzodiazepine site receptor agonist","4":"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO","5":"neurology/psychiatry","6":"seizures, panic disorders","7":"Launched","8":"seizures, panic disorders","_rn_":"7029"},{"1":"BRD-K26619122-001-02-1","2":"thiocolchicoside","3":"GABA receptor antagonist","4":"GABRA1, GABRB2, GABRG2, GLRA1, GLRB","5":"neurology/psychiatry","6":"muscle relaxant","7":"Launched","8":"muscle relaxant","_rn_":"7031"},{"1":"BRD-K81839095-001-30-1","2":"estrone","3":"estrogen receptor agonist, estrogenic hormone","4":"ESR1, ESR2","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"7033"},{"1":"BRD-K88172511-003-20-3","2":"naltrexone","3":"opioid receptor antagonist","4":"OPRD1, OPRK1, OPRM1, SIGMAR1","5":"neurology/psychiatry","6":"abstinence from alcohol","7":"Launched","8":"abstinence from alcohol","_rn_":"7035"},{"1":"BRD-K51544265-001-04-2","2":"cabozantinib","3":"RET tyrosine kinase inhibitor, VEGFR inhibitor","4":"KDR, MET","5":"oncology","6":"medullary thyroid cancer (MTC)","7":"Launched","8":"medullary thyroid cancer (MTC)","_rn_":"7037"},{"1":"BRD-K23566484-001-15-1","2":"nilutamide","3":"androgen receptor antagonist","4":"AR","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"7077"},{"1":"BRD-A35588707-001-05-5","2":"teniposide","3":"topoisomerase inhibitor","4":"TOP2A, TOP2B","5":"hematologic malignancy","6":"acute lymphoblastic leukemia (ALL)","7":"Launched","8":"acute lymphoblastic leukemia (ALL)","_rn_":"7079"},{"1":"BRD-A91733352-300-04-5","2":"camylofine-chlorhydrate","3":"NA","4":"NA","5":"gastroenterology","6":"abdominal pain","7":"Launched","8":"abdominal pain","_rn_":"7081"},{"1":"BRD-A14395271-074-17-8","2":"mesoridazine","3":"dopamine receptor antagonist","4":"DRD2, HTR2A","5":"neurology/psychiatry","6":"schizophrenia","7":"Launched","8":"schizophrenia","_rn_":"7083"},{"1":"BRD-K76011241-001-01-8","2":"oseltamivir-phosphate","3":"neuraminidase inhibitor","4":"CES1, NEU1, NEU2","5":"infectious disease","6":"influenza A virus infection","7":"Launched","8":"influenza A virus infection","_rn_":"7085"},{"1":"BRD-A43671941-003-11-9","2":"oxprenolol","3":"adrenergic receptor antagonist","4":"ADRB1, ADRB2","5":"cardiology","6":"angina pectoris, hypertension, cardiac arrythmia","7":"Launched","8":"angina pectoris, hypertension, cardiac arrythmia","_rn_":"7125"},{"1":"BRD-K73589491-001-11-2","2":"nizatidine","3":"histamine receptor antagonist","4":"HRH2","5":"gastroenterology","6":"duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)","7":"Launched","8":"duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)","_rn_":"7127"},{"1":"BRD-A25608658-001-01-1","2":"narasin","3":"antiprotozoal agent","4":"NA","5":"infectious disease","6":"coccidiosis","7":"Launched","8":"coccidiosis","_rn_":"7129"},{"1":"BRD-K89714990-001-01-5","2":"tepoxalin","3":"cyclooxygenase inhibitor, lipoxygenase inhibitor","4":"ALOX5","5":"rheumatology, orthopedics","6":"rheumatoid arthritis, hip dysplasia","7":"Launched","8":"rheumatoid arthritis, hip dysplasia","_rn_":"7131"},{"1":"BRD-K32107296-001-16-9","2":"temozolomide","3":"DNA alkylating agent","4":"MGMT","5":"oncology","6":"glioblastoma, astrocytoma","7":"Launched","8":"Brain Cancer, astrocytoma","_rn_":"7133"},{"1":"BRD-A29485665-001-12-8","2":"bicalutamide","3":"androgen receptor antagonist","4":"AR","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"7173"},{"1":"BRD-K99792991-001-34-9","2":"hexachlorophene","3":"potassium channel activator","4":"GLUD1, SDHD","5":"infectious disease","6":"gram-positive bacterial infections","7":"Launched","8":"gram-positive bacterial infections","_rn_":"7175"},{"1":"BRD-K92049597-001-20-8","2":"triamterene","3":"sodium channel blocker","4":"SCNN1A, SCNN1B, SCNN1D, SCNN1G","5":"endocrinology, cardiology","6":"hypokalemia, hypertension, edema","7":"Launched","8":"hypokalemia, hypertension, edema","_rn_":"7177"},{"1":"BRD-K34157611-001-16-0","2":"cimetidine","3":"histamine receptor antagonist","4":"HRH2, SLC29A4, SLC47A1, SLC47A2","5":"gastroenterology, hematologic malignancy, endocrinology","6":"duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma","7":"Launched","8":"duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma","_rn_":"7179"},{"1":"BRD-K01109406-001-03-7","2":"nitisinone","3":"hydroxyphenylpyruvate dioxygenase inhibitor","4":"HPD","5":"metabolism","6":"tyrosinemia","7":"Launched","8":"tyrosinemia","_rn_":"7181"},{"1":"BRD-K69116396-001-04-1","2":"sertindole","3":"dopamine receptor antagonist, serotonin receptor antagonist","4":"ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"7221"},{"1":"BRD-K29458283-001-29-9","2":"chlorambucil","3":"DNA inhibitor","4":"NA","5":"hematologic malignancy","6":"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma","7":"Launched","8":"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma","_rn_":"7223"},{"1":"BRD-K71106091-001-06-1","2":"fludarabine-phosphate","3":"ribonucleotide reductase inhibitor","4":"DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B","5":"hematologic malignancy","6":"chronic lymphocytic leukemia (CLL)","7":"Launched","8":"chronic lymphocytic leukemia (CLL)","_rn_":"7225"},{"1":"BRD-A90547603-001-02-5","2":"eptifibatide","3":"platelet aggregation inhibitor","4":"ITGA2B, ITGB3","5":"cardiology","6":"acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)","7":"Launched","8":"acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)","_rn_":"7226"},{"1":"BRD-K72093121-001-16-3","2":"vidarabine","3":"antiviral","4":"ADA","5":"infectious disease","6":"virus herpes simplex (HSV), varicella-zoster virus (VZV)","7":"Launched","8":"virus herpes simplex (HSV), varicella-zoster virus (VZV)","_rn_":"7228"},{"1":"BRD-K30577245-341-01-9","2":"docetaxel","3":"tubulin polymerization inhibitor","4":"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1","5":"oncology","6":"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","7":"Launched","8":"breast cancer, Lung Cancer, prostate cancer, gastric adenocarcinoma, Head and Neck Cancer","_rn_":"8000"},{"1":"BRD-K35687421-001-02-5","2":"gimeracil","3":"dihydropyrimidine dehydrogenase inhibitor","4":"DPYD","5":"oncology","6":"gastric adenocarcinoma","7":"Launched","8":"gastric adenocarcinoma","_rn_":"8002"},{"1":"BRD-K34022604-001-06-6","2":"clofarabine","3":"ribonucleotide reductase inhibitor","4":"POLA1, POLD1, POLE, RRM1, RRM2, RRM2B","5":"hematologic malignancy","6":"acute lymphoblastic leukemia (ALL)","7":"Launched","8":"acute lymphoblastic leukemia (ALL)","_rn_":"8004"},{"1":"BRD-K04111260-001-10-0","2":"raclopride","3":"dopamine receptor antagonist","4":"DRD2, DRD3, HTR1A","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"8006"},{"1":"BRD-K02113016-001-15-4","2":"olaparib","3":"PARP inhibitor","4":"PARP1, PARP2","5":"oncology","6":"ovarian cancer","7":"Launched","8":"ovarian cancer","_rn_":"8008"},{"1":"BRD-K37798499-001-27-2","2":"etoposide","3":"topoisomerase inhibitor","4":"TOP2A, TOP2B","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"8048"},{"1":"BRD-K15916496-001-27-9","2":"clotrimazole","3":"cytochrome P450 inhibitor, imidazoline receptor ligand","4":"CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8","5":"infectious disease","6":"vulvovaginal candidiasis, oropharyngeal candidiasis","7":"Launched","8":"vulvovaginal candidiasis, oropharyngeal candidiasis","_rn_":"8050"},{"1":"BRD-K99964838-001-11-9","2":"bosutinib","3":"Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor","4":"ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK","5":"hematologic malignancy","6":"chronic myeloid leukemia (CML)","7":"Launched","8":"chronic myeloid leukemia (CML)","_rn_":"8052"},{"1":"BRD-A03623303-045-09-5","2":"metoprolol","3":"adrenergic receptor antagonist","4":"ADRB1, ADRB2","5":"cardiology","6":"hypertension, angina pectoris, myocardial infarction","7":"Launched","8":"hypertension, angina pectoris, myocardial infarction","_rn_":"8054"},{"1":"BRD-K06858286-001-01-3","2":"cabazitaxel","3":"microtubule inhibitor","4":"TUBA4A, TUBB, TUBB1","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"8056"},{"1":"BRD-K67977190-066-02-3","2":"eprosartan","3":"angiotensin receptor antagonist","4":"AGTR1","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"8096"},{"1":"BRD-K51747290-001-13-1","2":"hydroxyurea","3":"ribonucleotide reductase inhibitor","4":"RRM1, RRM2, RRM2B","5":"hematologic malignancy, oncology","6":"chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)","7":"Launched","8":"chronic myeloid leukemia (CML), Head and Neck Cancer","_rn_":"8098"},{"1":"BRD-K47978074-001-02-4","2":"trometamol","3":"NA","4":"AMD1, CANT1, DCN, NEIL1, VEGFA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"8100"},{"1":"BRD-K87827419-001-16-8","2":"melphalan","3":"DNA alkylating agent, DNA inhibitor","4":"NA","5":"hematologic malignancy","6":"multiple myeloma","7":"Launched","8":"multiple myeloma","_rn_":"8102"},{"1":"BRD-K25837718-001-03-8","2":"josamycin","3":"bacterial 50S ribosomal subunit inhibitor","4":"NA","5":"pulmonary","6":"bronchitis","7":"Launched","8":"bronchitis","_rn_":"8104"},{"1":"BRD-K24556098-001-16-7","2":"deoxycorticosterone-acetate","3":"progestogen hormone","4":"NR3C2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"8143"},{"1":"BRD-K91601245-001-12-0","2":"mercaptopurine","3":"immunosuppressant, protein synthesis inhibitor, purine antagonist","4":"HPRT1, IMPDH1, IMPDH2, PPAT","5":"hematologic malignancy","6":"acute lymphoblastic leukemia (ALL)","7":"Launched","8":"acute lymphoblastic leukemia (ALL)","_rn_":"8145"},{"1":"BRD-K84466663-001-05-4","2":"nelarabine","3":"DNA synthesis inhibitor, T cell inhibitor","4":"POLA1","5":"hematologic malignancy","6":"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","7":"Launched","8":"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","_rn_":"8147"},{"1":"BRD-A91452556-001-04-0","2":"estradiol-cypionate","3":"estrogen receptor agonist","4":"ESR1","5":"endocrinology","6":"hypoestrogenism, menopause","7":"Launched","8":"hypoestrogenism, menopause","_rn_":"8149"},{"1":"BRD-K04196797-001-24-4","2":"oxcarbazepine","3":"sodium channel blocker","4":"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","5":"neurology/psychiatry","6":"seizures","7":"Launched","8":"seizures","_rn_":"8151"},{"1":"BRD-A70649075-008-30-8","2":"sulconazole","3":"sterol demethylase inhibitor","4":"NA","5":"infectious disease","6":"tinea pedis, tinea cruris, tinea corporis","7":"Launched","8":"tinea pedis, tinea cruris, tinea corporis","_rn_":"8190"},{"1":"BRD-K78815826-001-14-6","2":"suxibuzone","3":"cyclooxygenase inhibitor","4":"NA","5":"rheumatology, neurology/psychiatry","6":"joint pain, muscle pain","7":"Launched","8":"joint pain, muscle pain","_rn_":"8192"},{"1":"BRD-K21565985-001-22-5","2":"xylazine","3":"adrenergic receptor agonist","4":"ADRA2A, ADRA2B, ADRA2C","5":"neurology/psychiatry","6":"anesthetic","7":"Launched","8":"anesthetic","_rn_":"8194"},{"1":"BRD-K70246307-001-04-1","2":"riboflavin","3":"vitamin B2","4":"BLVRB, RFK","5":"gastroenterology","6":"jaundice","7":"Launched","8":"jaundice","_rn_":"8196"},{"1":"BRD-K36711084-001-02-0","2":"cyromazine","3":"NA","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"8198"},{"1":"BRD-A70083328-001-23-5","2":"secnidazole","3":"acetylcholinesterase inhibitor, microtubule inhibitor","4":"NA","5":"infectious disease","6":"protozoan infection","7":"Launched","8":"protozoan infection","_rn_":"8238"},{"1":"BRD-K28307902-001-21-7","2":"flutamide","3":"androgen receptor antagonist","4":"AHR, AR","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"8242"},{"1":"BRD-K06222852-001-03-2","2":"posaconazole","3":"sterol demethylase inhibitor","4":"CYP3A4","5":"infectious disease","6":"oropharyngeal candidiasis","7":"Launched","8":"oropharyngeal candidiasis","_rn_":"8244"},{"1":"BRD-K68095457-001-10-1","2":"palmitoylethanolamide","3":"cannabinoid receptor agonist","4":"CNR2, GPR119, GPR55","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"8246"},{"1":"BRD-K69280563-001-01-8","2":"vinorelbine","3":"tubulin polymerization inhibitor","4":"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"8286"},{"1":"BRD-K62008436-001-22-1","2":"paclitaxel","3":"tubulin polymerization inhibitor","4":"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1","5":"oncology","6":"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","7":"Launched","8":"ovarian cancer, breast cancer, Lung Cancer","_rn_":"8288"},{"1":"BRD-K88429204-001-35-1","2":"pyrimethamine","3":"dihydrofolate reductase inhibitor","4":"DHFR, SLC47A1","5":"infectious disease","6":"malaria","7":"Launched","8":"malaria","_rn_":"8290"},{"1":"BRD-K70301465-001-02-6","2":"ibrutinib","3":"Bruton's tyrosine kinase (BTK) inhibitor","4":"BLK, BMX, BTK","5":"hematologic malignancy","6":"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","7":"Launched","8":"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","_rn_":"8292"},{"1":"BRD-K13112821-001-17-4","2":"artemisinin","3":"DNA synthesis inhibitor","4":"CYP2B6","5":"infectious disease","6":"malaria","7":"Launched","8":"malaria","_rn_":"8294"},{"1":"BRD-K10799896-001-26-2","2":"clobetasol-propionate","3":"glucocorticoid receptor agonist","4":"NR3C1, PLA2G1B","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"8336"},{"1":"BRD-A25234499-001-18-3","2":"aminoglutethimide","3":"glucocorticoid receptor antagonist","4":"CYP11A1, CYP19A1","5":"endocrinology, oncology","6":"Cushing's syndrome, breast cancer","7":"Launched","8":"Cushing's syndrome, breast cancer","_rn_":"8338"},{"1":"BRD-K29950728-048-17-4","2":"clomifene","3":"estrogen receptor antagonist","4":"ESR1","5":"obstetrics/gynecology","6":"infertility","7":"Launched","8":"infertility","_rn_":"8339"},{"1":"BRD-A31095847-001-02-3","2":"mozavaptan","3":"vasopressin receptor antagonist","4":"AVPR1A, AVPR1B, AVPR2","5":"endocrinology","6":"hyponatremia","7":"Launched","8":"hyponatremia","_rn_":"8341"},{"1":"BRD-K99475619-001-01-2","2":"genz-644282","3":"topoisomerase inhibitor","4":"TOP1","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9142"},{"1":"BRD-K83508485-001-02-7","2":"FK-888","3":"tachykinin antagonist","4":"TACR1, TACR2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9144"},{"1":"BRD-K39484304-001-16-5","2":"triptolide","3":"RNA polymerase inhibitor","4":"RELA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9146"},{"1":"BRD-K68532323-003-02-8","2":"SB-743921","3":"kinesin-like spindle protein inhibitor","4":"KIF11","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"9148"},{"1":"BRD-K04264130-001-01-4","2":"favipiravir","3":"RNA polymerase inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9150"},{"1":"BRD-K68870568-066-01-5","2":"flumatinib","3":"Bcr-Abl kinase inhibitor","4":"ABL1, PDGFRB","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9190"},{"1":"BRD-K71281111-001-04-3","2":"SNX-2112","3":"HSP inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9192"},{"1":"BRD-K71480163-001-01-4","2":"GDC-0068","3":"AKT inhibitor","4":"AKT1, AKT2, AKT3, PRKG1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9194"},{"1":"BRD-K08542803-001-03-1","2":"gambogic-acid","3":"caspase activator","4":"BCL2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9196"},{"1":"BRD-K28192623-066-08-1","2":"spiradoline","3":"opioid receptor agonist","4":"OPRK1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9198"},{"1":"BRD-K20285085-074-04-5","2":"R406","3":"SYK inhibitor","4":"RET, SYK","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9238"},{"1":"BRD-K76239644-001-01-8","2":"BMS-690514","3":"EGFR inhibitor, VEGFR inhibitor","4":"EGFR, ERBB2, FLT3, KDR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9240"},{"1":"BRD-K99604664-001-01-1","2":"tanaproget","3":"progesterone receptor agonist","4":"PGR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9244"},{"1":"BRD-K97101532-001-02-8","2":"tezacaftor","3":"CFTR channel agonist","4":"NA","5":"pulmonary","6":"cystic fibrosis","7":"Launched","8":"cystic fibrosis","_rn_":"9246"},{"1":"BRD-K12787259-001-04-3","2":"CX-5461","3":"RNA polymerase inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9286"},{"1":"BRD-K57927309-001-01-7","2":"BW-180C","3":"opioid receptor agonist","4":"OPRD1, OPRM1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9288"},{"1":"BRD-K18849474-001-04-4","2":"dalcetrapib","3":"cholesteryl ester transfer protein inhibitor","4":"CETP","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9290"},{"1":"BRD-K25244359-066-03-4","2":"apatinib","3":"RET tyrosine kinase inhibitor","4":"CSK, KDR, KIT, RET","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9292"},{"1":"BRD-K66911501-003-01-2","2":"MK-3207","3":"calcitonin antagonist","4":"CALCA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9294"},{"1":"BRD-A50998626-001-02-1","2":"palomid-529","3":"AKT inhibitor, mTOR inhibitor","4":"MTOR","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9333"},{"1":"BRD-K51324732-001-01-0","2":"meglitinide","3":"potassium channel blocker","4":"CCR2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9335"},{"1":"BRD-K62965247-001-04-9","2":"tipifarnib","3":"farnesyltransferase inhibitor","4":"FNTA, FNTB","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9337"},{"1":"BRD-K64538373-001-01-4","2":"Ro-4987655","3":"MEK inhibitor","4":"MAP2K1","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9339"},{"1":"BRD-K07881437-001-04-6","2":"danusertib","3":"Aurora kinase inhibitor, growth factor receptor inhibitor","4":"AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9341"},{"1":"BRD-K86525559-001-07-8","2":"AZD7762","3":"CHK inhibitor","4":"CHEK1, CHEK2","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9383"},{"1":"BRD-K92968657-001-01-6","2":"tirapazamine","3":"DNA inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9385"},{"1":"BRD-K14796088-003-26-8","2":"berberine","3":"LDL receptor activator","4":"LDLR","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"9389"},{"1":"BRD-K12885236-001-02-7","2":"dapivirine","3":"non-nucleoside reverse transcriptase inhibitor","4":"CYP3A4, CYP3A5","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9429"},{"1":"BRD-K13646352-001-03-8","2":"midostaurin","3":"FLT3 inhibitor, KIT inhibitor, PKC inhibitor","4":"FLT3, PRKCG","5":"hematologic malignancy","6":"acute myeloid leukemia (AML)","7":"Launched","8":"acute myeloid leukemia (AML)","_rn_":"9431"},{"1":"BRD-K92241597-001-06-0","2":"tosedostat","3":"peptidase inhibitor","4":"ANPEP, LAP3, NPEPPS","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9433"},{"1":"BRD-K97883416-001-01-4","2":"BMS-626529","3":"HIV attachment inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9435"},{"1":"BRD-K52911425-001-09-8","2":"GDC-0941","3":"PI3K inhibitor","4":"PIK3CA, PIK3CB, PIK3CD, PIK3CG","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"9437"},{"1":"BRD-K19034817-001-01-4","2":"pacritinib","3":"FLT3 inhibitor, JAK inhibitor","4":"FLT3, JAK1, JAK2, JAK3","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"9477"},{"1":"BRD-K30933884-001-01-0","2":"UNBS-5162","3":"CC chemokine receptor antagonist","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9479"},{"1":"BRD-K99545815-001-06-3","2":"PF-562271","3":"focal adhesion kinase inhibitor","4":"PTK2, PTK2B","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"9482"},{"1":"BRD-K70463136-001-01-5","2":"BAY-87-2243","3":"hypoxia inducible factor inhibitor","4":"HIF1A","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10287"},{"1":"BRD-K55966568-001-05-4","2":"orantinib","3":"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"10289"},{"1":"BRD-K72827473-001-01-0","2":"CEP-37440","3":"ALK tyrosine kinase receptor inhibitor","4":"ALK","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10291"},{"1":"BRD-K04993719-001-01-7","2":"LY2334737","3":"antitumor agent, ribonucleotide reductase inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10293"},{"1":"BRD-K40797222-001-01-8","2":"SC-12267","3":"dihydroorotate dehydrogenase inhibitor","4":"IL17A","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10295"},{"1":"BRD-K52751261-001-06-1","2":"TAK-715","3":"p38 MAPK inhibitor","4":"MAPK14","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10335"},{"1":"BRD-K07736136-001-04-6","2":"VX-702","3":"p38 MAPK inhibitor","4":"MAPK11, MAPK12, MAPK14","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10337"},{"1":"BRD-A47706533-001-02-6","2":"buthionine-sulfoximine","3":"glutathione transferase inhibitor","4":"GCLM","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10339"},{"1":"BRD-K62398570-300-01-2","2":"lerisetron","3":"serotonin receptor antagonist","4":"HTR3A","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"10341"},{"1":"BRD-K45724504-001-01-6","2":"anguidine","3":"protein synthesis inhibitor","4":"SLC5A1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10343"},{"1":"BRD-A46813902-001-01-6","2":"iododexetimide","3":"acetylcholine receptor antagonist","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10383"},{"1":"BRD-K75649340-001-13-1","2":"tioguanine","3":"purine antagonist","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10387"},{"1":"BRD-A25687296-300-04-3","2":"emetine","3":"protein synthesis inhibitor","4":"RPS2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10389"},{"1":"BRD-K96358241-001-01-9","2":"harringtonine","3":"protein synthesis inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"10391"},{"1":"BRD-A64553394-001-04-4","2":"DPI-201106","3":"sodium channel activator","4":"ADRB2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10431"},{"1":"BRD-K51662849-001-08-8","2":"ilomastat","3":"matrix metalloprotease inhibitor","4":"ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"10433"},{"1":"BRD-K19295594-015-14-3","2":"gossypol","3":"BCL inhibitor, MCL1 inhibitor","4":"BCL2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10437"},{"1":"BRD-K64925568-001-01-8","2":"AMG-232","3":"MDM inhibitor","4":"MDM2","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"10439"},{"1":"BRD-K16551357-001-03-2","2":"evacetrapib","3":"cholesteryl ester transfer protein inhibitor","4":"CETP","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"10479"},{"1":"BRD-K23301018-001-11-7","2":"broxyquinoline","3":"antiprotozoal agent","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10485"},{"1":"BRD-K11215326-001-03-7","2":"tazemetostat","3":"histone lysine methyltransferase inhibitor","4":"EZH2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10527"},{"1":"BRD-K19318328-001-01-3","2":"FR-139317","3":"endothelin receptor antagonist","4":"EDNRA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10529"},{"1":"BRD-A95696066-003-13-8","2":"nisoxetine","3":"norepinephrine reuptake inhibitor","4":"SLC6A2, SLC6A3, SLC6A4","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10531"},{"1":"BRD-K91623615-001-05-0","2":"ABT-751","3":"tubulin polymerization inhibitor","4":"TUBB","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10533"},{"1":"BRD-K74057757-001-01-9","2":"indibulin","3":"tubulin polymerization inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"10535"},{"1":"BRD-K94420399-001-01-9","2":"PF-04136309","3":"CC chemokine receptor antagonist","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10575"},{"1":"BRD-K26712974-001-01-5","2":"VX-765","3":"caspase inhibitor","4":"CASP1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10577"},{"1":"BRD-K53097745-001-01-5","2":"pterostilbene","3":"cyclooxygenase inhibitor, PPAR receptor agonist","4":"PTGS2","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"10581"},{"1":"BRD-K43389698-001-09-9","2":"BMS-387032","3":"CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor","4":"CDK2, CDK7, CDK9","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10583"},{"1":"BRD-K66241279-001-01-8","2":"cinromide","3":"NA","4":"NA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"10623"},{"1":"BRD-K60341624-001-02-2","2":"GSK1292263","3":"glucose dependent insulinotropic receptor agonist","4":"GRPR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"10625"},{"1":"BRD-K70914287-300-02-8","2":"BIBX-1382","3":"EGFR inhibitor","4":"EGFR, ERBB2","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"10627"},{"1":"BRD-K03384561-001-02-7","2":"roquinimex","3":"angiogenesis inhibitor, tumor necrosis factor production inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"10630"},{"1":"BRD-A47953250-001-01-7","2":"ecamsule-triethanolamine","3":"NA","4":"NA","5":"dermatology","6":"skin protectant, sunscreen lotion","7":"Launched","8":"skin protectant, sunscreen lotion","_rn_":"11434"},{"1":"BRD-K82928892-001-02-5","2":"doxercalciferol","3":"vitamin D receptor agonist","4":"VDR","5":"nephrology, endocrinology","6":"chronic kidney disease (CKD), hyperparathyroidism","7":"Launched","8":"chronic kidney disease (CKD), hyperparathyroidism","_rn_":"11436"},{"1":"BRD-K07265709-003-05-6","2":"dexrazoxane","3":"chelating agent, topoisomerase inhibitor","4":"TOP2A, TOP2B","5":"cardiology","6":"cardiomyopathy","7":"Launched","8":"cardiomyopathy","_rn_":"11438"},{"1":"BRD-K83003151-057-02-4","2":"alogliptin","3":"dipeptidyl peptidase inhibitor","4":"DPP4","5":"endocrinology","6":"diabetes mellitus","7":"Launched","8":"diabetes mellitus","_rn_":"11441"},{"1":"BRD-K13183738-317-10-2","2":"pentamidine","3":"anti-pneumocystis agent","4":"TRDMT1","5":"infectious disease","6":"pneumonia","7":"Launched","8":"pneumonia","_rn_":"11481"},{"1":"BRD-A75919782-399-02-6","2":"leucovorin","3":"folate receptor ligand","4":"TYMS","5":"oncology","6":"osteosarcoma","7":"Launched","8":"osteosarcoma","_rn_":"11483"},{"1":"BRD-K13514097-001-05-3","2":"everolimus","3":"mTOR inhibitor","4":"MTOR","5":"oncology, neurology/psychiatry, genetics, urology","6":"breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","7":"Launched","8":"breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","_rn_":"11485"},{"1":"BRD-A50049929-001-01-9","2":"oxazepam","3":"GABA benzodiazepine site receptor agonist","4":"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3","5":"neurology/psychiatry","6":"anxiety","7":"Launched","8":"anxiety","_rn_":"11487"},{"1":"BRD-K86204871-001-16-2","2":"terconazole","3":"sterol demethylase inhibitor","4":"NA","5":"infectious disease","6":"vulvovaginal candidiasis","7":"Launched","8":"vulvovaginal candidiasis","_rn_":"11525"},{"1":"BRD-K17979676-001-01-2","2":"eprobemide","3":"monoamine oxidase inhibitor","4":"MAOA","5":"neurology/psychiatry","6":"depression","7":"Launched","8":"depression","_rn_":"11527"},{"1":"BRD-A01643550-001-04-9","2":"prednisolone-acetate","3":"glucocorticoid receptor agonist","4":"NR3C1","5":"ophthalmology, dermatology, infectious disease","6":"conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","7":"Launched","8":"conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","_rn_":"11529"},{"1":"BRD-K42938903-332-01-1","2":"acetophenazine","3":"dopamine receptor antagonist","4":"DRD1, DRD2","5":"neurology/psychiatry","6":"psychosis","7":"Launched","8":"psychosis","_rn_":"11531"},{"1":"BRD-K84091759-001-07-1","2":"candesartan","3":"angiotensin receptor antagonist","4":"AGTR1","5":"cardiology","6":"hypertension, congestive heart failure","7":"Launched","8":"hypertension, congestive heart failure","_rn_":"11533"},{"1":"BRD-K02594908-001-16-4","2":"sulfanilamide","3":"carbonic anhydrase inhibitor","4":"CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4","5":"infectious disease","6":"vulvovaginal candidiasis","7":"Launched","8":"vulvovaginal candidiasis","_rn_":"11572"},{"1":"BRD-K40992116-001-09-7","2":"parachlorophenol","3":"antiinfective drug","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"11574"},{"1":"BRD-K16277217-001-10-9","2":"piperacetazine","3":"dopamine receptor antagonist","4":"NA","5":"neurology/psychiatry","6":"schizophrenia","7":"Launched","8":"schizophrenia","_rn_":"11576"},{"1":"BRD-K35952844-236-01-6","2":"sodium-glucoheptonate","3":"NA","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"11578"},{"1":"BRD-A59303141-001-10-4","2":"quinethazone","3":"thiazide diuretic","4":"CA1, CA2, SLC12A1, SLC12A2, SLC12A3","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"11580"},{"1":"BRD-K87024524-065-17-7","2":"phenelzine","3":"monoamine oxidase inhibitor","4":"ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4","5":"neurology/psychiatry","6":"depression","7":"Launched","8":"depression","_rn_":"11618"},{"1":"BRD-A83937277-001-10-5","2":"mephenytoin","3":"hydantoin antiepileptic","4":"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","5":"neurology/psychiatry","6":"seizures","7":"Launched","8":"seizures","_rn_":"11620"},{"1":"BRD-K59647213-001-10-5","2":"levocarnitine","3":"NA","4":"NA","5":"endocrinology","6":"carnitine deficiency","7":"Launched","8":"carnitine deficiency","_rn_":"11622"},{"1":"BRD-K84783599-001-01-0","2":"riociguat","3":"guanylate cyclase stimulant","4":"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"11624"},{"1":"BRD-K09951645-001-06-8","2":"dabrafenib","3":"RAF inhibitor","4":"BRAF, LIMK1, NEK11, RAF1, SIK1","5":"oncology","6":"melanoma","7":"Launched","8":"Skin Cancer","_rn_":"11626"},{"1":"BRD-K21283037-001-21-5","2":"riluzole","3":"glutamate inhibitor","4":"KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11","5":"neurology/psychiatry","6":"amyotrophic lateral sclerosis (ALS)","7":"Launched","8":"amyotrophic lateral sclerosis (ALS)","_rn_":"11665"},{"1":"BRD-K11267252-001-04-4","2":"alectinib","3":"ALK tyrosine kinase receptor inhibitor","4":"ALK, MET","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"11667"},{"1":"BRD-A23067620-300-01-3","2":"itraconazole","3":"cytochrome P450 inhibitor","4":"CYP51A1","5":"infectious disease","6":"onychomycosis, histoplasmosis, blastomycosis, aspergillosis","7":"Launched","8":"onychomycosis, histoplasmosis, blastomycosis, aspergillosis","_rn_":"11669"},{"1":"BRD-A81129465-001-03-8","2":"fenoprofen","3":"prostaglandin inhibitor","4":"PTGS1, PTGS2, SLC5A8","5":"rheumatology","6":"rheumatoid arthritis, osteoarthritis","7":"Launched","8":"rheumatoid arthritis, osteoarthritis","_rn_":"11671"},{"1":"BRD-K18574842-236-17-7","2":"nafcillin","3":"bacterial cell wall synthesis inhibitor","4":"CYP1A2, CYP3A4, SLC22A6","5":"infectious disease","6":"gram-positive bacterial infections","7":"Launched","8":"gram-positive bacterial infections","_rn_":"11673"},{"1":"BRD-K00673382-001-18-9","2":"famotidine","3":"histamine receptor antagonist","4":"HRH2","5":"gastroenterology","6":"heartburn","7":"Launched","8":"heartburn","_rn_":"11712"},{"1":"BRD-K10843433-001-22-7","2":"phenylbutazone","3":"cyclooxygenase inhibitor, prostanoid receptor antagonist","4":"PTGIS, PTGS1, PTGS2","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"11714"},{"1":"BRD-K10845183-304-01-6","2":"tiludronate","3":"bone resorption inhibitor, osteoclast inhibitor","4":"ATP6V1A, MMP2, PTPN1","5":"orthopedics","6":"navicular syndrome","7":"Launched","8":"navicular syndrome","_rn_":"11716"},{"1":"BRD-K00259736-001-16-4","2":"colchicine","3":"microtubule inhibitor","4":"GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","5":"rheumatology, endocrinology","6":"gout, fever","7":"Launched","8":"gout, fever","_rn_":"11718"},{"1":"BRD-K23204545-001-16-4","2":"busulfan","3":"DNA inhibitor","4":"NA","5":"hematologic malignancy","6":"chronic myeloid leukemia (CML)","7":"Launched","8":"chronic myeloid leukemia (CML)","_rn_":"11719"},{"1":"BRD-K24048528-001-02-5","2":"abiraterone-acetate","3":"androgen biosynthesis inhibitor","4":"CYP17A1","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"11754"},{"1":"BRD-K35245662-001-01-2","2":"ciclesonide","3":"glucocorticoid receptor agonist","4":"NR3C1, SERPINA6","5":"allergy","6":"allergic rhinitis","7":"Launched","8":"allergic rhinitis","_rn_":"11756"},{"1":"BRD-K15567136-003-27-2","2":"papaverine","3":"phosphodiesterase inhibitor","4":"PDE10A, PDE4B, PDE5A","5":"cardiology, hematology, gastroenterology","6":"myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm","7":"Launched","8":"myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm","_rn_":"11758"},{"1":"BRD-K43389675-003-20-9","2":"daunorubicin","3":"RNA synthesis inhibitor, topoisomerase inhibitor","4":"TOP2A, TOP2B","5":"hematologic malignancy","6":"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","7":"Launched","8":"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","_rn_":"11760"},{"1":"BRD-K52256627-300-06-6","2":"chlorhexidine","3":"membrane integrity inhibitor","4":"NA","5":"dermatology, infectious disease, dental","6":"cosmetic, skin infections, gingivitis","7":"Launched","8":"cosmetic, skin infections, gingivitis","_rn_":"11762"},{"1":"BRD-K68346641-001-01-4","2":"amsacrine","3":"topoisomerase inhibitor","4":"KCNH2, TOP2A","5":"hematologic malignancy","6":"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","7":"Launched","8":"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","_rn_":"12519"},{"1":"BRD-K51313569-003-03-3","2":"palbociclib","3":"CDK inhibitor","4":"CDK4, CDK6","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"12521"},{"1":"BRD-K82861010-001-02-5","2":"daclatasvir","3":"HCV inhibitor","4":"NA","5":"infectious disease","6":"hepatitis C","7":"Launched","8":"hepatitis C","_rn_":"12523"},{"1":"BRD-A49358627-001-14-6","2":"ciprofibrate","3":"PPAR receptor agonist","4":"PPARA","5":"endocrinology","6":"hyperlipidemia","7":"Launched","8":"hyperlipidemia","_rn_":"12525"},{"1":"BRD-K69650333-003-14-0","2":"idarubicin","3":"topoisomerase inhibitor","4":"TOP2A","5":"hematologic malignancy","6":"acute myeloid leukemia (AML)","7":"Launched","8":"acute myeloid leukemia (AML)","_rn_":"12527"},{"1":"BRD-K19615002-001-02-3","2":"creatine","3":"NA","4":"CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"12565"},{"1":"BRD-K29254801-001-14-7","2":"thiram","3":"NA","4":"JAK2","5":"ophthalmology","6":"contact dermatitis","7":"Launched","8":"contact dermatitis","_rn_":"12567"},{"1":"BRD-K88568253-011-19-9","2":"iproniazid","3":"monoamine oxidase inhibitor","4":"MAOA, MAOB","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"12569"},{"1":"BRD-A36267905-003-18-4","2":"buphenine","3":"adrenergic receptor agonist","4":"ADRB2","5":"rheumatology","6":"Raynaud's disease","7":"Launched","8":"Raynaud's disease","_rn_":"12570"},{"1":"BRD-A27887842-001-04-0","2":"prednisolone","3":"glucocorticoid receptor agonist","4":"NR3C1, NR3C2, SERPINA6","5":"ophthalmology, dermatology, infectious disease","6":"conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","7":"Launched","8":"conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","_rn_":"12572"},{"1":"BRD-A36456202-001-01-3","2":"colistin-b-sulfate","3":"bacterial permeability inducer","4":"NA","5":"infectious disease","6":"gram-negative bacterial infections","7":"Launched","8":"gram-negative bacterial infections","_rn_":"12612"},{"1":"BRD-A48300215-001-04-8","2":"ajmaline","3":"sodium channel blocker","4":"SCN5A","5":"cardiology","6":"Wolff-Parkinson-White Syndrome (WPW)","7":"Launched","8":"Wolff-Parkinson-White Syndrome (WPW)","_rn_":"12614"},{"1":"BRD-K66808046-065-03-7","2":"oxyquinoline","3":"chelating agent","4":"METAP2","5":"dermatology","6":"cosmetic","7":"Launched","8":"cosmetic","_rn_":"12616"},{"1":"BRD-K92872987-001-02-9","2":"cefpiramide","3":"bacterial cell wall synthesis inhibitor","4":"NA","5":"infectious disease","6":"gram-negative bacterial infections","7":"Launched","8":"gram-negative bacterial infections","_rn_":"12617"},{"1":"BRD-K35240538-001-26-2","2":"methylprednisolone","3":"glucocorticoid receptor agonist","4":"NR3C1","5":"endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology","6":"hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis","7":"Launched","8":"hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis","_rn_":"12619"},{"1":"BRD-K63126190-003-01-6","2":"epinephrine","3":"adrenergic receptor agonist, neurotransmitter","4":"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF","5":"cardiology, allergy, pulmonary","6":"cardiac arrest, anaphylactic shock, asthma","7":"Launched","8":"cardiac arrest, anaphylactic shock, asthma","_rn_":"12659"},{"1":"BRD-A30582499-003-05-1","2":"tiletamine","3":"glutamate receptor antagonist","4":"NA","5":"neurology/psychiatry","6":"anesthetic","7":"Launched","8":"anesthetic","_rn_":"12661"},{"1":"BRD-A06352418-001-25-9","2":"terfenadine","3":"histamine receptor antagonist","4":"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"12663"},{"1":"BRD-K66175015-001-09-0","2":"afatinib","3":"EGFR inhibitor","4":"EGFR, ERBB2, ERBB4","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"12665"},{"1":"BRD-K85090592-008-22-7","2":"pilocarpine","3":"acetylcholine receptor agonist","4":"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","5":"ophthalmology, cardiology","6":"glaucoma, hypertension","7":"Launched","8":"glaucoma, hypertension","_rn_":"12667"},{"1":"BRD-K21680192-300-14-4","2":"mitoxantrone","3":"topoisomerase inhibitor","4":"TOP2A","5":"neurology/psychiatry, oncology, hematologic malignancy","6":"multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)","7":"Launched","8":"multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)","_rn_":"12709"},{"1":"BRD-A69651145-003-07-2","2":"minocycline","3":"bacterial 30S ribosomal subunit inhibitor","4":"ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA","5":"endocrinology, infectious disease, ophthalmology, urology","6":"fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis","7":"Launched","8":"fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis","_rn_":"12711"},{"1":"BRD-A11132253-001-08-2","2":"nadide","3":"electron acceptor","4":"AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"12712"},{"1":"BRD-K02900412-001-11-3","2":"clofoctol","3":"protein synthesis inhibitor","4":"NA","5":"infectious disease","6":"gram-positive bacterial infections","7":"Launched","8":"gram-positive bacterial infections","_rn_":"12714"},{"1":"BRD-A10070317-003-28-3","2":"propranolol","3":"adrenergic receptor antagonist","4":"NA","5":"cardiology, neurology/psychiatry","6":"hypertension, angina pectoris, migraine headache","7":"Launched","8":"hypertension, angina pectoris, migraine headache","_rn_":"12753"},{"1":"BRD-K97810537-001-13-6","2":"beclomethasone-dipropionate","3":"glucocorticoid receptor agonist","4":"GPR97, NR3C1","5":"allergy","6":"allergic rhinitis","7":"Launched","8":"allergic rhinitis","_rn_":"12755"},{"1":"BRD-K51318897-001-15-3","2":"fenbendazole","3":"tubulin polymerization inhibitor","4":"TUBB","5":"infectious disease","6":"gastrointestinal parasites, gastrointestinal roundworms","7":"Launched","8":"gastrointestinal parasites, gastrointestinal roundworms","_rn_":"12757"},{"1":"BRD-K67511046-001-02-3","2":"naloxone","3":"opioid receptor antagonist","4":"CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4","5":"pulmonary","6":"respiratory depression","7":"Launched","8":"respiratory depression","_rn_":"12759"},{"1":"BRD-K10670311-001-15-5","2":"sulfasalazine","3":"cyclooxygenase inhibitor","4":"ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1","5":"gastroenterology","6":"ulcerative colitis","7":"Launched","8":"ulcerative colitis","_rn_":"12761"},{"1":"BRD-K48195008-001-19-9","2":"ethinyl-estradiol","3":"estrogen receptor agonist, estrogenic hormone","4":"ESR1, ESR2, NR1I2","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"12798"},{"1":"BRD-K11433652-001-17-0","2":"aspirin","3":"cyclooxygenase inhibitor","4":"AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53","5":"neurology/psychiatry, endocrinology, dental","6":"headache, fever, toothache, muscle pain","7":"Launched","8":"headache, fever, toothache, muscle pain","_rn_":"12800"},{"1":"BRD-K18250272-003-11-0","2":"propoxycaine","3":"local anesthetic","4":"NA","5":"neurology/psychiatry","6":"anesthetic","7":"Launched","8":"anesthetic","_rn_":"12801"},{"1":"BRD-K78789465-001-01-6","2":"pentagastrin","3":"CCK receptor agonist","4":"CCKBR","5":"gastroenterology","6":"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic","7":"Launched","8":"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic","_rn_":"12802"},{"1":"BRD-A00758722-001-04-9","2":"noretynodrel","3":"progestogen hormone","4":"PGR","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"12804"},{"1":"BRD-A02180903-001-04-5","2":"betamethasone","3":"glucocorticoid receptor agonist","4":"NR3C1","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"12842"},{"1":"BRD-K13249881-001-02-3","2":"piperazine","3":"benzodiazepine receptor agonist","4":"GABRB3","5":"infectious disease","6":"gastrointestinal roundworms","7":"Launched","8":"gastrointestinal roundworms","_rn_":"12844"},{"1":"BRD-K85333151-003-13-4","2":"ramifenazone","3":"cyclooxygenase inhibitor","4":"NA","5":"neurology/psychiatry, endocrinology","6":"pain relief, fever","7":"Launched","8":"pain relief, fever","_rn_":"12846"},{"1":"BRD-A50311610-300-10-4","2":"meclizine","3":"constitutive androstane receptor (CAR) agonist","4":"HRH1, NR1I3","5":"gastroenterology, neurology/psychiatry","6":"nausea, vomiting, motion sickness","7":"Launched","8":"nausea, vomiting, motion sickness","_rn_":"12848"},{"1":"BRD-K46937689-001-15-0","2":"phenazone","3":"cyclooxygenase inhibitor","4":"PTGS1, PTGS2","5":"neurology/psychiatry","6":"pain relief","7":"Launched","8":"pain relief","_rn_":"12850"},{"1":"BRD-K45252063-001-13-6","2":"clofibrate","3":"PPAR receptor agonist","4":"LPL, PPARA","5":"endocrinology, cardiology","6":"hyperlipidemia, cholesterol","7":"Launched","8":"hyperlipidemia, cholesterol","_rn_":"13651"},{"1":"BRD-K54094468-003-11-1","2":"remoxipride","3":"dopamine receptor antagonist","4":"DRD2, DRD3, DRD4, HTR2A, SIGMAR1","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"13653"},{"1":"BRD-K36386086-001-01-1","2":"dolutegravir","3":"HIV integrase inhibitor","4":"CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1","5":"infectious disease","6":"human immunodeficiency virus (HIV-1)","7":"Launched","8":"human immunodeficiency virus (HIV-1)","_rn_":"13655"},{"1":"BRD-K64052750-001-17-5","2":"gefitinib","3":"EGFR inhibitor","4":"EGFR","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"13657"},{"1":"BRD-K67043667-001-26-4","2":"altretamine","3":"DNA synthesis inhibitor","4":"NA","5":"oncology","6":"ovarian cancer","7":"Launched","8":"ovarian cancer","_rn_":"13699"},{"1":"BRD-K34411947-001-12-5","2":"streptozotocin","3":"DNA alkylating agent","4":"SLC2A2","5":"oncology","6":"pancreatic cancer","7":"Launched","8":"pancreatic cancer","_rn_":"13701"},{"1":"BRD-A24397426-001-10-4","2":"nadifloxacin","3":"bacterial DNA gyrase inhibitor","4":"NA","5":"dermatology, infectious disease","6":"acne vulgaris (AV), skin infections","7":"Launched","8":"acne vulgaris (AV), skin infections","_rn_":"13703"},{"1":"BRD-K99946902-001-07-5","2":"hexylresorcinol","3":"local anesthetic","4":"TYR","5":"infectious disease","6":"skin infections, first-aid antiseptic","7":"Launched","8":"skin infections, first-aid antiseptic","_rn_":"13705"},{"1":"BRD-K72723676-003-17-8","2":"benzethonium","3":"sodium channel blocker","4":"SCN10A","5":"infectious disease","6":"first-aid antiseptic","7":"Launched","8":"first-aid antiseptic","_rn_":"13707"},{"1":"BRD-K43860855-065-11-9","2":"iobenguane","3":"antineoplastic agent","4":"NA","5":"oncology, cardiology, endocrinology","6":"neuroblastoma, congestive heart failure, pheochromocytoma","7":"Launched","8":"neuroblastoma, congestive heart failure, pheochromocytoma","_rn_":"13747"},{"1":"BRD-K09416995-001-39-9","2":"lovastatin","3":"HMGCR inhibitor","4":"HDAC2, HMGCR, ITGAL, NR1I2","5":"cardiology, endocrinology","6":"coronary heart disease, myocardial infarction, hypercholesterolemia","7":"Launched","8":"coronary heart disease, myocardial infarction, hypercholesterolemia","_rn_":"13749"},{"1":"BRD-K04568635-300-01-4","2":"octenidine","3":"membrane integrity inhibitor","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"13751"},{"1":"BRD-A16700644-003-04-4","2":"isoxsuprine","3":"adrenergic receptor agonist","4":"ADRB2","5":"rheumatology, cardiology","6":"Raynaud's disease, arteriosclerosis, Buerger's disease","7":"Launched","8":"Raynaud's disease, arteriosclerosis, Buerger's disease","_rn_":"13753"},{"1":"BRD-K82181219-001-04-3","2":"pyritinol","3":"NA","4":"NA","5":"rheumatology, neurology/psychiatry","6":"rheumatoid arthritis, senile dementia","7":"Launched","8":"rheumatoid arthritis, senile dementia","_rn_":"13755"},{"1":"BRD-K40787673-001-02-1","2":"lacitol","3":"osmosis stimulant","4":"NA","5":"gastroenterology","6":"constipation","7":"Launched","8":"constipation","_rn_":"13795"},{"1":"BRD-K47635719-001-21-1","2":"dexamethasone-acetate","3":"glucocorticoid receptor agonist","4":"NA","5":"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","6":"hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis","7":"Launched","8":"hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis","_rn_":"13797"},{"1":"BRD-K56851771-001-06-8","2":"enzalutamide","3":"androgen receptor antagonist","4":"AR","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"13799"},{"1":"BRD-A92439610-001-05-7","2":"triamcinolone-acetonide","3":"glucocorticoid receptor agonist, immunosuppressant","4":"NR3C1","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"13801"},{"1":"BRD-K38197229-001-29-9","2":"bumetanide","3":"solute carrier family member inhibitor","4":"CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5","5":"cardiology","6":"edema, congestive heart failure","7":"Launched","8":"edema, congestive heart failure","_rn_":"13803"},{"1":"BRD-K45033733-001-12-2","2":"famciclovir","3":"DNA polymerase inhibitor","4":"NA","5":"dental, infectious disease","6":"cold sore, genitial herpes, shingles","7":"Launched","8":"cold sore, genitial herpes, shingles","_rn_":"13843"},{"1":"BRD-K62310379-001-10-5","2":"fluticasone-propionate","3":"glucocorticoid receptor agonist","4":"NR3C1, NR3C2, PGR, PLA2G4A","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"13844"},{"1":"BRD-K27351809-001-09-5","2":"nomegestrol-acetate","3":"progesterone receptor agonist","4":"PGR","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"13846"},{"1":"BRD-U25960968-000-01-9","2":"tyloxapol","3":"NFkB pathway inhibitor","4":"LPL, NFKB2","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"13848"},{"1":"BRD-K87774949-001-03-9","2":"istradefylline","3":"adenosine receptor antagonist","4":"ADORA1, ADORA2A, ADORA2B, ADORA3","5":"neurology/psychiatry","6":"Parkinson's Disease, dyskinesia","7":"Launched","8":"Parkinson's Disease, dyskinesia","_rn_":"13850"},{"1":"BRD-A58564983-001-04-6","2":"selamectin","3":"nematocide","4":"NA","5":"infectious disease","6":"flea control","7":"Launched","8":"flea control","_rn_":"13890"},{"1":"BRD-K60237333-001-27-1","2":"niacin","3":"NAD precursor, vitamin B","4":"DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT","5":"endocrinology","6":"hypertriglyceridemia","7":"Launched","8":"hypertriglyceridemia","_rn_":"13892"},{"1":"BRD-K56343971-001-10-6","2":"vemurafenib","3":"RAF inhibitor","4":"BRAF, RAF1","5":"oncology","6":"melanoma","7":"Launched","8":"Skin Cancer","_rn_":"13894"},{"1":"BRD-K60160658-003-11-2","2":"tiagabine","3":"GABA uptake inhibitor","4":"SLC6A1","5":"neurology/psychiatry","6":"seizures","7":"Launched","8":"seizures","_rn_":"13896"},{"1":"BRD-K96159438-001-06-3","2":"adefovir-dipivoxil","3":"DNA polymerase inhibitor","4":"NA","5":"infectious disease","6":"hepatitis B","7":"Launched","8":"hepatitis B","_rn_":"13938"},{"1":"BRD-K71075609-003-01-0","2":"dorzolamide","3":"carbonic anhydrase inhibitor","4":"CA1, CA12, CA14, CA2, CA4, CA7","5":"ophthalmology","6":"intraocular pressure, glaucoma","7":"Launched","8":"intraocular pressure, glaucoma","_rn_":"13940"},{"1":"BRD-K59197931-001-04-5","2":"naproxen","3":"cyclooxygenase inhibitor","4":"PTGS1, PTGS2","5":"neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology","6":"pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever","7":"Launched","8":"pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever","_rn_":"13942"},{"1":"BRD-K83257731-003-23-5","2":"chloropyramine","3":"histamine receptor antagonist","4":"HRH1","5":"cardiology, ophthalmology, allergy, pulmonary","6":"edema, conjunctivitis, allergic rhinitis, asthma","7":"Launched","8":"edema, conjunctivitis, allergic rhinitis, asthma","_rn_":"13944"},{"1":"BRD-A55962179-001-22-1","2":"omeprazole","3":"ATPase inhibitor","4":"ATP4A, CLCN2","5":"gastroenterology","6":"heartburn","7":"Launched","8":"heartburn","_rn_":"13946"},{"1":"BRD-K60585088-001-01-5","2":"paricalcitol","3":"vitamin D receptor agonist","4":"VDR","5":"nephrology, endocrinology","6":"chronic kidney disease (CKD), hyperthyroidism","7":"Launched","8":"chronic kidney disease (CKD), hyperthyroidism","_rn_":"13986"},{"1":"BRD-K71822263-001-03-2","2":"D-Serine","3":"glutamate receptor agonist","4":"GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"13988"},{"1":"BRD-K79254416-001-22-6","2":"decitabine","3":"DNA methyltransferase inhibitor","4":"DNMT1, DNMT3A","5":"hematologic malignancy, hematology","6":"myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","7":"Launched","8":"myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","_rn_":"13990"},{"1":"BRD-K41141507-001-16-2","2":"cyproterone-acetate","3":"androgen receptor antagonist","4":"ADORA1, AR","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"13992"},{"1":"BRD-K92428153-001-04-4","2":"mycophenolate-mofetil","3":"dehydrogenase inhibitor, inositol monophosphatase inhibitor","4":"IMPDH1, IMPDH2","5":"transplant","6":"organ rejection","7":"Launched","8":"organ rejection","_rn_":"13994"},{"1":"BRD-K64381438-001-03-8","2":"ulipristal","3":"progesterone receptor antagonist","4":"PGR","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"14765"},{"1":"BRD-K75466013-001-14-4","2":"benzocaine","3":"sodium channel blocker","4":"SCN10A","5":"infectious disease","6":"first-aid antiseptic","7":"Launched","8":"first-aid antiseptic","_rn_":"14767"},{"1":"BRD-A93236127-001-04-5","2":"digitoxin","3":"ATPase inhibitor","4":"ATP1A1","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"14769"},{"1":"BRD-A09722536-002-18-0","2":"cyclophosphamide","3":"DNA alkylating agent","4":"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7","5":"hematologic malignancy, oncology","6":"Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer","7":"Launched","8":"Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer","_rn_":"14771"},{"1":"BRD-A55424491-001-19-9","2":"methotrexate","3":"dihydrofolate reductase inhibitor","4":"DHFR","5":"oncology, hematologic malignancy, dermatology, rheumatology","6":"gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","7":"Launched","8":"gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","_rn_":"14773"},{"1":"BRD-K96424892-001-02-9","2":"chloramphenicol-palmitate","3":"protein synthesis inhibitor","4":"NA","5":"infectious disease, endocrinology","6":"meningitis, fever, cholera","7":"Launched","8":"meningitis, fever, cholera","_rn_":"14813"},{"1":"BRD-K51199656-003-01-4","2":"fluoromethylcholine","3":"NA","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"14815"},{"1":"BRD-A53151380-001-01-2","2":"prednisolone-tebutate","3":"anti-inflammatory agent","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"14817"},{"1":"BRD-A54275602-001-01-0","2":"lanoconazole","3":"sterol demethylase inhibitor","4":"NA","5":"infectious disease","6":"fungal infection","7":"Launched","8":"fungal infection","_rn_":"14819"},{"1":"BRD-A11815689-001-01-1","2":"proscillaridin-a","3":"NA","4":"NA","5":"cardiology","6":"congestive heart failure, cardiac arrythmia","7":"Launched","8":"congestive heart failure, cardiac arrythmia","_rn_":"14821"},{"1":"BRD-K75037734-003-13-9","2":"carbachol","3":"cholinergic receptor agonist","4":"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2","5":"ophthalmology","6":"intraocular pressure","7":"Launched","8":"intraocular pressure","_rn_":"14861"},{"1":"BRD-K08619574-334-05-4","2":"thioproperazine","3":"dopamine receptor antagonist","4":"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A","5":"neurology/psychiatry","6":"schizophrenia","7":"Launched","8":"schizophrenia","_rn_":"14863"},{"1":"BRD-K33425534-001-12-5","2":"exemestane","3":"aromatase inhibitor","4":"CYP19A1","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"14865"},{"1":"BRD-K93568044-001-32-0","2":"hydrocortisone","3":"glucocorticoid receptor agonist","4":"NA","5":"dermatology, neurology/psychiatry","6":"eczema, psoriasis, seborrheic dermatitis, itching","7":"Launched","8":"eczema, psoriasis, seborrheic dermatitis, itching","_rn_":"14867"},{"1":"BRD-K63750851-001-20-7","2":"mycophenolic-acid","3":"dehydrogenase inhibitor, inositol monophosphatase inhibitor","4":"IMPDH1, IMPDH2","5":"transplant","6":"organ rejection","7":"Launched","8":"organ rejection","_rn_":"14869"},{"1":"BRD-A68304895-003-02-2","2":"BTS-54505","3":"dopamine reuptake inhibitor","4":"SLC6A2, SLC6A3, SLC6A4","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"14908"},{"1":"BRD-A67862938-034-14-9","2":"naftidrofuryl","3":"adrenergic receptor antagonist","4":"NA","5":"cardiology","6":"claudication","7":"Launched","8":"claudication","_rn_":"14910"},{"1":"BRD-K75958547-238-01-0","2":"pitavastatin","3":"HMGCR inhibitor","4":"HMGCR","5":"endocrinology","6":"hyperlipidemia","7":"Launched","8":"hyperlipidemia","_rn_":"14912"},{"1":"BRD-K50590187-001-19-9","2":"capsaicin","3":"TRPV agonist","4":"CFTR, TRPV1","5":"neurology/psychiatry, rheumatology","6":"muscle pain, rheumatoid arthritis","7":"Launched","8":"muscle pain, rheumatoid arthritis","_rn_":"14914"},{"1":"BRD-K49840922-001-05-1","2":"etofylline-clofibrate","3":"platelet aggregation inhibitor","4":"PPARA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"14916"},{"1":"BRD-A64743628-001-01-5","2":"isometheptene-mucate","3":"NA","4":"ADRA1A, SLC18A2","5":"neurology/psychiatry","6":"headache","7":"Launched","8":"headache","_rn_":"14956"},{"1":"BRD-A41304429-001-14-8","2":"practolol","3":"adrenergic receptor antagonist","4":"ADRB1","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"14958"},{"1":"BRD-K17294426-050-12-3","2":"clebopride","3":"dopamine receptor antagonist","4":"ACHE, DRD2","5":"gastroenterology","6":"nausea","7":"Launched","8":"nausea","_rn_":"14960"},{"1":"BRD-K38003476-001-09-1","2":"clocortolone-pivalate","3":"steroid","4":"NR3C1, PLA2G1B","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"14962"},{"1":"BRD-K04548931-003-16-5","2":"epirubicin","3":"topoisomerase inhibitor","4":"CHD1, TOP2A","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"14964"},{"1":"BRD-K63828191-003-32-1","2":"raloxifene","3":"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","4":"ESR1, ESR2","5":"orthopedics, oncology","6":"osteoporosis, breast cancer","7":"Launched","8":"osteoporosis, breast cancer","_rn_":"15004"},{"1":"BRD-K54262262-001-09-0","2":"monobenzone","3":"melanin inhibitor","4":"TYR","5":"dermatology","6":"skin depigmentation","7":"Launched","8":"skin depigmentation","_rn_":"15006"},{"1":"BRD-K77987382-001-13-2","2":"mebendazole","3":"tubulin polymerization inhibitor","4":"TUBA1A, TUBB, TUBB4B","5":"infectious disease","6":"pinworm, whipworm, hookworm, ascariasis","7":"Launched","8":"pinworm, whipworm, hookworm, ascariasis","_rn_":"15008"},{"1":"BRD-K35520305-001-17-7","2":"dacarbazine","3":"DNA alkylating agent","4":"PGD, POLA2","5":"oncology, hematologic malignancy","6":"melanoma, Hodgkin's lymphoma","7":"Launched","8":"Skin Cancer, Hodgkin's lymphoma","_rn_":"15010"},{"1":"BRD-A31521121-001-26-4","2":"methocarbamol","3":"muscle relaxant","4":"CA1","5":"neurology/psychiatry","6":"muscle relaxant","7":"Launched","8":"muscle relaxant","_rn_":"15012"},{"1":"BRD-A38350138-001-04-9","2":"ketoconazole","3":"sterol demethylase inhibitor","4":"AR, CYP19A1, CYP21A2, KCNA10","5":"dermatology","6":"seborrheic dermatitis","7":"Launched","8":"seborrheic dermatitis","_rn_":"15052"},{"1":"BRD-K93034159-001-25-8","2":"cladribine","3":"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor","4":"ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B","5":"hematologic malignancy","6":"hairy cell leukemia","7":"Launched","8":"hairy cell leukemia","_rn_":"15054"},{"1":"BRD-A06627858-236-03-0","2":"monensin","3":"bacterial permeability inducer","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"15056"},{"1":"BRD-K70505054-003-12-4","2":"ranitidine","3":"histamine receptor antagonist","4":"HRH2","5":"gastroenterology","6":"heartburn","7":"Launched","8":"heartburn","_rn_":"15058"},{"1":"BRD-A39390670-236-10-7","2":"rabeprazole","3":"ATPase inhibitor, gastrin inhibitor","4":"ATP4A","5":"gastroenterology","6":"gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome","7":"Launched","8":"gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome","_rn_":"15060"},{"1":"BRD-K68693535-001-03-4","2":"lidamidine","3":"adrenergic receptor agonist","4":"NA","5":"gastroenterology","6":"diarrhea","7":"Launched","8":"diarrhea","_rn_":"15099"},{"1":"BRD-K92073408-001-16-5","2":"norethindrone","3":"progesterone receptor agonist","4":"PGR","5":"obstetrics/gynecology","6":"endometriosis","7":"Launched","8":"endometriosis","_rn_":"15101"},{"1":"BRD-K70358946-001-15-7","2":"aripiprazole","3":"serotonin receptor agonist, serotonin receptor antagonist","4":"ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7","5":"neurology/psychiatry","6":"depression, schizophrenia, bipolar disorder","7":"Launched","8":"depression, schizophrenia, bipolar disorder","_rn_":"15103"},{"1":"BRD-K59574735-001-11-8","2":"ubenimex","3":"leukotriene synthesis inhibitor","4":"LTA4H, RNPEP","5":"hematologic malignancy","6":"acute myeloid leukemia (AML)","7":"Launched","8":"acute myeloid leukemia (AML)","_rn_":"15105"},{"1":"BRD-K35189033-001-26-1","2":"levonorgestrel","3":"estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist","4":"AR, ESR1, PGR, SRD5A1","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"15107"},{"1":"BRD-K62810658-001-12-2","2":"PD-98059","3":"MEK inhibitor","4":"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15910"},{"1":"BRD-K58122457-001-02-2","2":"hesperadin","3":"Aurora kinase inhibitor","4":"AURKB","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15912"},{"1":"BRD-A14344385-001-03-2","2":"IDRA-21","3":"glutamate receptor positive allosteric modulator","4":"GRIA1, GRIA2, GRIA3, GRIA4","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15914"},{"1":"BRD-K68633617-003-02-9","2":"ACDPP","3":"glutamate receptor antagonist","4":"GRM5","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15916"},{"1":"BRD-K13571841-001-14-4","2":"pepstatin","3":"aspartic protease inhibitor","4":"CTSB, CTSD, CTSL, REN","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15918"},{"1":"BRD-K98157055-001-10-9","2":"SIB-1757","3":"glutamate receptor antagonist","4":"GRM5","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15955"},{"1":"BRD-A34751532-001-06-9","2":"homosalate","3":"HSP inducer","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15957"},{"1":"BRD-K37720887-001-07-8","2":"SB-525334","3":"TGF beta receptor inhibitor","4":"TGFBR1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15959"},{"1":"BRD-K86727142-001-12-4","2":"embelin","3":"HCV inhibitor, XIAP inhibitor","4":"XIAP","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15961"},{"1":"BRD-A72703248-003-04-9","2":"SKF-96365","3":"calcium channel blocker","4":"CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"15963"},{"1":"BRD-K33277808-331-01-3","2":"ouabain","3":"ATPase inhibitor","4":"ATP1A1","5":"cardiology","6":"hypertension, cardiac arrythmia","7":"Launched","8":"hypertension, cardiac arrythmia","_rn_":"16000"},{"1":"BRD-K51474575-001-10-4","2":"taurine","3":"antioxidant","4":"NA","5":"neurology/psychiatry","6":"anxiety, irritability, sleeplessness","7":"Launched","8":"anxiety, irritability, sleeplessness","_rn_":"16002"},{"1":"BRD-K52172416-001-11-4","2":"anastrozole","3":"aromatase inhibitor","4":"CYP19A1","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"16003"},{"1":"BRD-A24587114-066-22-5","2":"isoetharine","3":"adrenergic receptor agonist","4":"ADRB1, ADRB2","5":"pulmonary","6":"bronchospasm, asthma","7":"Launched","8":"bronchospasm, asthma","_rn_":"16005"},{"1":"BRD-K58049875-001-04-7","2":"thiostrepton","3":"FOXM1 inhibitor, protein synthesis inhibitor","4":"FOXM1","5":"obstetrics/gynecology","6":"mastitis","7":"Launched","8":"mastitis","_rn_":"16007"},{"1":"BRD-K37590257-001-02-8","2":"GSK256066","3":"phosphodiesterase inhibitor","4":"PDE4A","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16045"},{"1":"BRD-K84683831-001-01-0","2":"radezolid","3":"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16047"},{"1":"BRD-K49555808-001-03-9","2":"BMS-707035","3":"HIV integrase inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16049"},{"1":"BRD-K24576554-001-04-8","2":"AT-9283","3":"Aurora kinase inhibitor, JAK inhibitor","4":"AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16052"},{"1":"BRD-K52233191-001-02-4","2":"R547","3":"CDK inhibitor","4":"CDK1, CDK2, CDK4, CDK7","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"16091"},{"1":"BRD-K85406984-001-01-0","2":"sobetirome","3":"thyroid hormone receptor agonist","4":"THRA, THRB","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"16094"},{"1":"BRD-K81458380-001-04-9","2":"CX-4945","3":"casein kinase inhibitor","4":"CSNK2A1, CSNK2A2, DAPK3, HIPK3","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"16096"},{"1":"BRD-K63504947-001-15-4","2":"semaxanib","3":"VEGFR inhibitor","4":"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"16098"},{"1":"BRD-K19412355-001-01-0","2":"SB-242235","3":"p38 MAPK inhibitor","4":"HSPB1, MAPK14","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"16138"},{"1":"BRD-K09602097-001-13-6","2":"forskolin","3":"adenylyl cyclase activator","4":"ADCY2, ADCY5, GNAS","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"16140"},{"1":"BRD-K26838195-075-04-9","2":"AST-1306","3":"EGFR inhibitor","4":"EGFR, ERBB2","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"16141"},{"1":"BRD-K18157228-001-01-7","2":"fdcyd","3":"DNA methyltransferase inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16143"},{"1":"BRD-K20545304-001-01-6","2":"bardoxolone","3":"nuclear factor erythroid derived, like (NRF2) activator","4":"NOS2, PPARG","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"16185"},{"1":"BRD-K65924316-001-03-1","2":"serdemetan","3":"MDM inhibitor","4":"MDM2","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"16187"},{"1":"BRD-K94559059-091-01-6","2":"telotristat-ethyl","3":"tryptophan hydroxylase inhibitor","4":"TPH1","5":"gastroenterology","6":"diarrhea","7":"Launched","8":"diarrhea","_rn_":"16189"},{"1":"BRD-K41278234-001-03-0","2":"CUDC-101","3":"EGFR inhibitor","4":"EGFR, ERBB2","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"16191"},{"1":"BRD-K28822270-001-01-1","2":"resminostat","3":"HDAC inhibitor","4":"HDAC1, HDAC3, HDAC6, HDAC8","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16226"},{"1":"BRD-K29673530-001-05-4","2":"hypericin","3":"tyrosine kinase inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16228"},{"1":"BRD-K13050541-001-01-9","2":"acivicin","3":"gamma glutamyltransferase Inhibitors","4":"CTPS1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16230"},{"1":"BRD-K68065987-300-09-1","2":"MK-2206","3":"AKT inhibitor","4":"AKT1, AKT2, AKT3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"16232"},{"1":"BRD-K37618799-001-03-0","2":"MRS-1220","3":"adenosine receptor antagonist","4":"ADORA2B, ADORA3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"17037"},{"1":"BRD-A94624445-236-17-0","2":"bucladesine","3":"adenosine receptor agonist, cAMP stimulant","4":"PRKACA","5":"dermatology","6":"skin ulcer","7":"Launched","8":"skin ulcer","_rn_":"17039"},{"1":"BRD-K08996725-332-01-7","2":"zolantidine","3":"histamine receptor antagonist","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"17041"},{"1":"BRD-K55462201-001-07-3","2":"AM-404","3":"cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist","4":"CNR1, CNR2, FAAH, TRPV1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"17043"},{"1":"BRD-A74208568-003-01-5","2":"CGP-54626","3":"GABA receptor antagonist","4":"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"17045"},{"1":"BRD-K12040459-001-06-0","2":"AT7867","3":"AKT inhibitor","4":"AKT2, GSK3B, PKIA, PRKACA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"17084"},{"1":"BRD-K78496197-001-03-9","2":"SCS","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"17086"},{"1":"BRD-A43809092-003-02-1","2":"clobutinol","3":"antitussive","4":"NA","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"17088"},{"1":"BRD-K73391359-003-10-2","2":"dimethisoquin","3":"local anesthetic","4":"NA","5":"neurology/psychiatry","6":"local anesthetic","7":"Launched","8":"local anesthetic","_rn_":"17090"},{"1":"BRD-K56707426-001-02-0","2":"nitarsone","3":"NA","4":"NA","5":"dermatology","6":"blackhead disease","7":"Launched","8":"blackhead disease","_rn_":"17092"},{"1":"BRD-A75850590-213-01-0","2":"lomefloxacin","3":"bacterial DNA gyrase inhibitor","4":"TOP2A","5":"infectious disease","6":"respiratory tract infections, urinary tract infections","7":"Launched","8":"respiratory tract infections, urinary tract infections","_rn_":"17132"},{"1":"BRD-A91366704-001-01-9","2":"eprinomectin","3":"benzodiazepine receptor agonist","4":"NA","5":"infectious disease","6":"gastrointestinal roundworms, lungworms","7":"Launched","8":"gastrointestinal roundworms, lungworms","_rn_":"17134"},{"1":"BRD-K43578482-001-01-4","2":"defactinib","3":"focal adhesion kinase inhibitor","4":"PTK2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17136"},{"1":"BRD-K83699324-001-01-1","2":"NMS-1286937","3":"PLK inhibitor","4":"FLT3, PLK1, PLK2, PLK3","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"17138"},{"1":"BRD-K19061412-001-02-4","2":"mubritinib","3":"protein tyrosine kinase inhibitor","4":"EGFR, ERBB2","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"17140"},{"1":"BRD-K85751432-001-03-3","2":"refametinib","3":"MEK inhibitor","4":"MAP2K1, MAP2K2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17180"},{"1":"BRD-M89827113-001-01-5","2":"cromakalim","3":"NA","4":"KCNJ8","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17182"},{"1":"BRD-A64064900-001-02-3","2":"sangivamycin","3":"DNA inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"17184"},{"1":"BRD-A51571244-001-01-9","2":"hypoestoxide","3":"IKK inhibitor","4":"IKBKB, IL1B, TNF","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"17186"},{"1":"BRD-K81694556-003-01-9","2":"VTP-27999","3":"renin inhibitor","4":"REN","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"17228"},{"1":"BRD-K95573441-001-01-2","2":"PFK-015","3":"phosphofructokinase inhibitor","4":"PFKFB3","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"17230"},{"1":"BRD-K62762455-001-01-3","2":"RU-58841","3":"androgen receptor antagonist","4":"AR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17232"},{"1":"BRD-K37069697-001-01-3","2":"fexinidazole","3":"NA","4":"NA","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"17234"},{"1":"BRD-K46690591-001-01-2","2":"KP-1212","3":"NA","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17236"},{"1":"BRD-A10903566-003-07-7","2":"imiloxan","3":"adrenergic receptor antagonist","4":"ADRA2A, ADRA2B","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"17278"},{"1":"BRD-K55703048-001-07-7","2":"latrepirdine","3":"glutamate receptor antagonist","4":"HRH1, HTR6","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"17282"},{"1":"BRD-K08703257-001-12-1","2":"3-amino-benzamide","3":"PARP inhibitor","4":"PARP1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17284"},{"1":"BRD-K52762805-001-01-2","2":"epothilone-d","3":"microtubule stabilizing agent, tubulin polymerization inhibitor","4":"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17324"},{"1":"BRD-K16485616-001-08-9","2":"mocetinostat","3":"HDAC inhibitor","4":"HDAC1, HDAC11, HDAC2, HDAC3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17330"},{"1":"BRD-A55312468-001-04-7","2":"k-strophanthidin","3":"ATPase inhibitor","4":"ATP1A1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17332"},{"1":"BRD-K83837640-001-04-8","2":"JNJ-26481585","3":"HDAC inhibitor","4":"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17372"},{"1":"BRD-K83963101-001-06-9","2":"MLN-8054","3":"Aurora kinase inhibitor","4":"AURKA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"17374"},{"1":"BRD-K12184916-001-15-4","2":"NVP-BEZ235","3":"mTOR inhibitor, PI3K inhibitor","4":"ATR, MTOR, PIK3CA, PIK3CD, PIK3CG","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"17376"},{"1":"BRD-K15600710-066-04-1","2":"obatoclax","3":"BCL inhibitor","4":"BCL2","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"17380"},{"1":"BRD-K07106112-003-03-8","2":"BMS-599626","3":"EGFR inhibitor, protein tyrosine kinase inhibitor","4":"EGFR, ERBB2, ERBB4","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18153"},{"1":"BRD-K68747584-001-02-0","2":"PF-03814735","3":"Aurora kinase inhibitor","4":"AURKA, AURKB","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18155"},{"1":"BRD-K38287497-001-01-2","2":"narlaprevir","3":"HCV inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"18157"},{"1":"BRD-K56751279-300-01-4","2":"Y-39983","3":"rho associated kinase inhibitor","4":"ROCK1, ROCK2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18159"},{"1":"BRD-K72414522-001-06-7","2":"AZD5438","3":"CDK inhibitor","4":"KCNH2","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18200"},{"1":"BRD-K56032964-001-02-1","2":"AP26113","3":"ALK tyrosine kinase receptor inhibitor","4":"ALK, EGFR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18202"},{"1":"BRD-K01029106-001-01-4","2":"picolinic-acid","3":"chelating agent","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18206"},{"1":"BRD-K68938568-001-01-7","2":"GDC-0152","3":"XIAP inhibitor","4":"BIRC2, BIRC3, BIRC7, XIAP","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18208"},{"1":"BRD-K82746043-001-15-1","2":"navitoclax","3":"BCL inhibitor","4":"BCL2, BCL2L1, BCL2L2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18248"},{"1":"BRD-K68552125-001-05-3","2":"12-O-tetradecanoylphorbol-13-acetate","3":"PKC activator","4":"KCNT2, TRPV4","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18250"},{"1":"BRD-K00152668-001-01-5","2":"adarotene","3":"retinoid receptor agonist","4":"RARB, RARG","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18252"},{"1":"BRD-A03506276-001-01-5","2":"XL888","3":"HSP inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18254"},{"1":"BRD-K68488863-001-04-9","2":"ENMD-2076","3":"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor","4":"AURKA, FLT3, KDR, PDGFRA, PTK2, SRC","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18256"},{"1":"BRD-K80700417-001-04-2","2":"SGI-1776","3":"Pim kinase inhibitor","4":"FLT3, PIM1, PIM2, PIM3","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18294"},{"1":"BRD-K02389548-001-02-5","2":"RG2833","3":"HDAC inhibitor","4":"HDAC1, HDAC3","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18296"},{"1":"BRD-K07310275-001-02-5","2":"PF-04691502","3":"mTOR inhibitor, PI3K inhibitor","4":"MTOR, PIK3CA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18298"},{"1":"BRD-K64866502-001-03-9","2":"CYC116","3":"Aurora kinase inhibitor","4":"AURKA, AURKB, KDR","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18300"},{"1":"BRD-K39624409-003-02-6","2":"ADL5859","3":"opioid receptor agonist","4":"OPRD1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18302"},{"1":"BRD-K69726595-001-01-2","2":"mericitabine","3":"HCV inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18342"},{"1":"BRD-K29968218-001-03-2","2":"KX2-391","3":"src inhibitor, tubulin polymerization inhibitor","4":"SRC","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18344"},{"1":"BRD-K71512533-066-02-8","2":"SNS-314","3":"Aurora kinase inhibitor","4":"AURKA, AURKB, AURKC","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18346"},{"1":"BRD-K63923597-001-10-0","2":"barasertib-HQPA","3":"Aurora kinase inhibitor","4":"AURKB","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"18348"},{"1":"BRD-K31476763-001-01-5","2":"AZD9668","3":"elastase inhibitor","4":"ELANE","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18350"},{"1":"BRD-K37379014-001-01-2","2":"filanesib","3":"kinesin inhibitor, kinesin-like spindle protein inhibitor","4":"KIF11","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"18390"},{"1":"BRD-K69932463-001-10-6","2":"AZD8055","3":"mTOR inhibitor","4":"MTOR","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18392"},{"1":"BRD-K03063480-001-06-6","2":"PF-477736","3":"CHK inhibitor","4":"CHEK1, CHEK2","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18394"},{"1":"BRD-K14385366-001-04-4","2":"FG-4592","3":"hypoxia inducible factor prolyl hydroxylase inhibitor","4":"EGLN2","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"18396"},{"1":"BRD-K89162000-001-06-4","2":"tandutinib","3":"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","4":"CSF1R, FLT3, KIT, PDGFD, PDGFRB","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18398"},{"1":"BRD-A72716251-001-01-5","2":"peruvoside","3":"cardiac glycoside","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18438"},{"1":"BRD-K25412176-001-01-9","2":"GSK2110183","3":"AKT inhibitor","4":"AKT1, AKT2, AKT3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18440"},{"1":"BRD-K23677682-003-01-2","2":"voreloxin","3":"topoisomerase inhibitor","4":"TOP2A","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"18442"},{"1":"BRD-K34073885-001-09-3","2":"tanshinone-i","3":"AP inhibitor","4":"IFNG","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18444"},{"1":"BRD-K14880289-001-02-2","2":"GW-501516","3":"PPAR receptor agonist","4":"PPARA, PPARD","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"18446"},{"1":"BRD-K36269323-300-02-6","2":"asymmetrical-dimethylarginine","3":"nitric oxide synthase inhibitor","4":"NOS2, NOS3","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18485"},{"1":"BRD-K25340465-001-11-1","2":"OSI-930","3":"KIT inhibitor, VEGFR inhibitor","4":"KDR, KIT","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"18487"},{"1":"BRD-K92150287-066-01-2","2":"exatecan-mesylate","3":"topoisomerase inhibitor","4":"TOP1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"18491"},{"1":"BRD-K68164687-001-01-6","2":"epothilone-b","3":"microtubule stabilizing agent, tubulin polymerization inhibitor","4":"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19295"},{"1":"BRD-K68103045-001-02-9","2":"CGS-20625","3":"benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist","4":"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19299"},{"1":"BRD-K68392338-003-02-0","2":"ZK-93426","3":"benzodiazepine receptor antagonist","4":"GABRA1, GABRA2, GABRA3, GABRA5","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19301"},{"1":"BRD-K77908580-001-09-6","2":"entinostat","3":"HDAC inhibitor","4":"HDAC1, HDAC2, HDAC3, HDAC9","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19340"},{"1":"BRD-K73319509-001-08-0","2":"PF-04217903","3":"c-Met inhibitor","4":"MET","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19342"},{"1":"BRD-K61036791-001-01-6","2":"rucinol","3":"tyrosinase inhibitor","4":"TYR","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19344"},{"1":"BRD-K70511574-001-06-9","2":"HMN-214","3":"PLK inhibitor","4":"PLK1","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19346"},{"1":"BRD-K59325863-001-02-8","2":"delanzomib","3":"proteasome inhibitor","4":"CMA1, CTSG, CYP3A4, ELANE","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"19348"},{"1":"BRD-K41599323-001-02-3","2":"lonafarnib","3":"farnesyltransferase inhibitor","4":"FNTA, HRAS, KRAS, NRAS","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19390"},{"1":"BRD-K93918653-001-08-9","2":"quizartinib","3":"FLT3 inhibitor","4":"CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19392"},{"1":"BRD-A07704283-001-01-3","2":"isofloxythepin","3":"dopamine receptor antagonist","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19394"},{"1":"BRD-K71221037-001-01-6","2":"birinapant","3":"XIAP inhibitor","4":"BIRC2, XIAP","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19396"},{"1":"BRD-K99023089-001-03-7","2":"AZD5363","3":"AKT inhibitor","4":"AKT1, AKT2, AKT3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19436"},{"1":"BRD-K28392481-001-05-1","2":"AZD4547","3":"FGFR inhibitor","4":"FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR","5":"NA","6":"NA","7":"Phase 2/Phase 3","8":"NA","_rn_":"19438"},{"1":"BRD-A39935389-001-05-9","2":"teroxirone","3":"DNA inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19440"},{"1":"BRD-K37764012-001-04-1","2":"PF-03758309","3":"p21 activated kinase inhibitor","4":"PAK4","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19442"},{"1":"BRD-A56085258-001-01-8","2":"LGX818","3":"RAF inhibitor","4":"BRAF","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19444"},{"1":"BRD-K28965160-001-01-1","2":"BVD-523","3":"MAP kinase inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"19486"},{"1":"BRD-K13049116-001-05-7","2":"BMS-754807","3":"IGF-1 inhibitor","4":"AKT1, IGF1R","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19488"},{"1":"BRD-K70163715-300-05-7","2":"vatalanib","3":"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"EGFR, FLT1, FLT4, KDR, PDGFRB","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19490"},{"1":"BRD-K26823213-001-02-9","2":"GW-842166","3":"cannabinoid receptor agonist","4":"CNR2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19492"},{"1":"BRD-K71164191-001-01-0","2":"KD-023","3":"ACAT inhibitor","4":"ACACA, ACACB","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19531"},{"1":"BRD-K88506063-001-01-8","2":"KD025","3":"rho associated kinase inhibitor","4":"ROCK2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19533"},{"1":"BRD-K26667523-001-02-5","2":"TAK-733","3":"MEK inhibitor","4":"MAP2K1","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19535"},{"1":"BRD-K05445342-001-05-3","2":"WP1066","3":"STAT inhibitor","4":"STAT3","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19537"},{"1":"BRD-K86797399-001-05-1","2":"SB-939","3":"HDAC inhibitor","4":"HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19539"},{"1":"BRD-K53665955-001-03-0","2":"MK-5108","3":"Aurora kinase inhibitor","4":"AURKA, AURKB, AURKC","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"19579"},{"1":"BRD-K76703230-004-04-1","2":"YM-155","3":"survivin inhibitor","4":"BIRC5","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19581"},{"1":"BRD-A26032986-050-02-1","2":"zaldaride","3":"calmodulin antagonist","4":"CALM1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19583"},{"1":"BRD-K25630527-001-03-8","2":"LY2784544","3":"JAK inhibitor","4":"JAK2, JAK3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19585"},{"1":"BRD-K22127577-001-03-7","2":"crenolanib","3":"PDGFR tyrosine kinase receptor inhibitor","4":"CSF1R, FLT3, KIT, PDGFRA, PDGFRB","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"19630"},{"1":"BRD-K21396683-001-04-8","2":"marimastat","3":"matrix metalloprotease inhibitor","4":"MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19632"},{"1":"BRD-K13756951-001-01-4","2":"bitopertin","3":"glycine transporter inhibitor, GlyT-1 inhibitor","4":"SLC6A5, SLC6A9","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"19634"},{"1":"BRD-A24514565-001-09-7","2":"warfarin","3":"vitamin K antagonist","4":"VKORC1","5":"hematology, cardiology","6":"deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction","7":"Launched","8":"deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction","_rn_":"20434"},{"1":"BRD-K54247840-004-01-3","2":"halofuginone","3":"collagenase inhibitor","4":"COL1A1, MMP2","5":"rheumatology","6":"scleroderma","7":"Launched","8":"scleroderma","_rn_":"20436"},{"1":"BRD-K60348325-065-09-9","2":"brilliant-green","3":"NA","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"20438"},{"1":"BRD-K08303368-001-10-0","2":"chlorpyrifos","3":"acetylcholinesterase inhibitor","4":"ACHE","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"20440"},{"1":"BRD-A10977446-001-12-1","2":"carvedilol","3":"adrenergic receptor antagonist","4":"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA","5":"cardiology","6":"myocardial infarction, hypertension","7":"Launched","8":"myocardial infarction, hypertension","_rn_":"20442"},{"1":"BRD-K18910433-001-36-6","2":"estradiol","3":"estrogen receptor agonist","4":"ESR1, ESR2, GPER1, KCNMA1, NR1I2","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"20482"},{"1":"BRD-K65377893-001-07-4","2":"7-aminocephalosporanic-acid","3":"beta lactamase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"20484"},{"1":"BRD-A94756469-001-04-7","2":"digoxin","3":"ATPase inhibitor","4":"ATP1A1","5":"cardiology","6":"congestive heart failure, atrial fibrillation (AF)","7":"Launched","8":"congestive heart failure, atrial fibrillation (AF)","_rn_":"20486"},{"1":"BRD-K93869735-001-01-1","2":"taltirelin","3":"thyrotropin releasing hormone receptor agonist","4":"TRHR","5":"neurology/psychiatry","6":"spinocerebellar ataxia","7":"Launched","8":"spinocerebellar ataxia","_rn_":"20488"},{"1":"BRD-K90027355-001-13-3","2":"spironolactone","3":"mineralocorticoid receptor antagonist","4":"AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG","5":"endocrinology, cardiology, gastroenterology, rheumatology","6":"hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia","7":"Launched","8":"hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia","_rn_":"20490"},{"1":"BRD-A74391928-051-01-3","2":"ibutilide","3":"potassium channel blocker","4":"CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6","5":"cardiology","6":"atrial fibrillation (AF)","7":"Launched","8":"atrial fibrillation (AF)","_rn_":"20530"},{"1":"BRD-K05524748-003-04-4","2":"dronedarone","3":"adrenergic receptor antagonist","4":"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A","5":"cardiology","6":"atrial fibrillation (AF)","7":"Launched","8":"atrial fibrillation (AF)","_rn_":"20532"},{"1":"BRD-K09549677-300-03-4","2":"mibefradil","3":"T-type calcium channel blocker","4":"ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"20534"},{"1":"BRD-K49962337-001-02-9","2":"baicalin","3":"beta glucuronidase inhibitor","4":"PREP","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"20536"},{"1":"BRD-K00494077-066-01-9","2":"trovafloxacin","3":"bacterial DNA gyrase inhibitor","4":"TOP2A","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"20538"},{"1":"BRD-K08586861-001-01-1","2":"ramatroban","3":"prostanoid receptor antagonist","4":"PTGDR2, TBXA2R","5":"cardiology, pulmonary","6":"coronary artery disease (CAD), asthma","7":"Launched","8":"coronary artery disease (CAD), asthma","_rn_":"20577"},{"1":"BRD-K24844714-001-24-5","2":"5-fluorouracil","3":"thymidylate synthase inhibitor","4":"DPYD, TYMS","5":"oncology","6":"colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma","7":"Launched","8":"Colon/Colorectal Cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma","_rn_":"20579"},{"1":"BRD-K97799481-001-16-0","2":"theophylline","3":"adenosine receptor antagonist","4":"NA","5":"pulmonary","6":"asthma, emphysema, bronchitis","7":"Launched","8":"asthma, emphysema, bronchitis","_rn_":"20581"},{"1":"BRD-A13133631-001-04-0","2":"fluorometholone","3":"glucocorticoid receptor agonist","4":"NR3C1","5":"ophthalmology","6":"eye inflammation","7":"Launched","8":"eye inflammation","_rn_":"20583"},{"1":"BRD-A09349126-001-10-7","2":"norethindrone-acetate","3":"progesterone receptor agonist","4":"NA","5":"endocrinology, orthopedics, obstetrics/gynecology","6":"menopause, osteoporosis, vaginal atrophy","7":"Launched","8":"menopause, osteoporosis, vaginal atrophy","_rn_":"20585"},{"1":"BRD-A93695607-322-02-5","2":"nicotine","3":"acetylcholine receptor agonist","4":"CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1","5":"neurology/psychiatry","6":"smoking cessation","7":"Launched","8":"smoking cessation","_rn_":"20625"},{"1":"BRD-K78126613-001-28-5","2":"menadione","3":"mitochondrial DNA polymerase inhibitor, phosphatase inhibitor","4":"AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1","5":"gastroenterology, neurology/psychiatry, dermatology, rheumatology","6":"ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis","7":"Launched","8":"ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis","_rn_":"20627"},{"1":"BRD-A08187463-001-12-9","2":"racecadotril","3":"enkephalinase inhibitor","4":"MME","5":"gastroenterology","6":"diarrhea","7":"Launched","8":"diarrhea","_rn_":"20629"},{"1":"BRD-K30480208-001-18-5","2":"torasemide","3":"electrolyte reabsorption inhibitor, thromboxane receptor antagonist","4":"SLC12A1","5":"cardiology","6":"edema, congestive heart failure, hypertension","7":"Launched","8":"edema, congestive heart failure, hypertension","_rn_":"20631"},{"1":"BRD-K97746869-001-27-0","2":"chlorpropamide","3":"ATP channel blocker","4":"ABCC8, KCNJ10, KCNJ11","5":"endocrinology","6":"diabetes mellitus","7":"Launched","8":"diabetes mellitus","_rn_":"20633"},{"1":"BRD-K67261995-001-11-7","2":"iodipamide","3":"radiopaque medium","4":"ALB","5":"radiology","6":"contrast agent","7":"Launched","8":"contrast agent","_rn_":"20673"},{"1":"BRD-K27217864-001-22-3","2":"butamben","3":"sodium channel blocker","4":"NA","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"20675"},{"1":"BRD-A50157456-065-20-6","2":"terbutaline","3":"adrenergic receptor agonist","4":"ADRB2","5":"pulmonary","6":"bronchospasm, bronchitis, emphysema","7":"Launched","8":"bronchospasm, bronchitis, emphysema","_rn_":"20677"},{"1":"BRD-K68507560-003-24-6","2":"dicycloverine","3":"acetylcholine receptor antagonist","4":"CHRM1, CHRM2, CHRM3","5":"gastroenterology","6":"irritable bowel syndrome","7":"Launched","8":"irritable bowel syndrome","_rn_":"20679"},{"1":"BRD-A53951045-004-01-6","2":"butylscopolamine-bromide","3":"cholinergic receptor antagonist","4":"NA","5":"gastroenterology","6":"abdominal pain","7":"Launched","8":"abdominal pain","_rn_":"20681"},{"1":"BRD-K66788707-001-14-3","2":"fludarabine","3":"ribonucleotide reductase inhibitor","4":"ADA, RRM1, RRM2","5":"hematologic malignancy","6":"chronic lymphocytic leukemia (CLL)","7":"Launched","8":"chronic lymphocytic leukemia (CLL)","_rn_":"20721"},{"1":"BRD-K13387373-004-14-5","2":"thonzonium","3":"ATPase inhibitor","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"20723"},{"1":"BRD-A60197193-001-14-6","2":"amisulpride","3":"dopamine receptor antagonist","4":"DRD2, DRD3, HTR2A, HTR7","5":"neurology/psychiatry","6":"psychosis, bipolar disorder, schizophrenia","7":"Launched","8":"psychosis, bipolar disorder, schizophrenia","_rn_":"20725"},{"1":"BRD-K08525451-003-05-2","2":"sarafloxacin","3":"bacterial DNA gyrase inhibitor","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"20727"},{"1":"BRD-A06426627-001-03-5","2":"diclazuril","3":"antiprotozoal agent","4":"NA","5":"infectious disease","6":"equine protozoal myeloencephalitis (EPM)","7":"Launched","8":"equine protozoal myeloencephalitis (EPM)","_rn_":"20729"},{"1":"BRD-K49350383-001-13-7","2":"thioguanine","3":"purine antagonist","4":"IMPDH1, IMPDH2","5":"hematologic malignancy","6":"acute myeloid leukemia (AML)","7":"Launched","8":"acute myeloid leukemia (AML)","_rn_":"20769"},{"1":"BRD-K31812033-003-11-0","2":"levobunolol","3":"adrenergic receptor antagonist","4":"ADRB1, ADRB2, ADRB3","5":"ophthalmology","6":"glaucoma, ocular hypertension","7":"Launched","8":"glaucoma, ocular hypertension","_rn_":"20773"},{"1":"BRD-K74501079-001-18-1","2":"azithromycin","3":"bacterial 50S ribosomal subunit inhibitor","4":"MLNR","5":"infectious disease","6":"pelvic inflammatory disease, pneumonia","7":"Launched","8":"pelvic inflammatory disease, pneumonia","_rn_":"20775"},{"1":"BRD-A20239487-001-24-9","2":"atenolol-(+/-)","3":"adrenergic receptor antagonist","4":"ADRB1, ADRB2","5":"cardiology","6":"hypertension, angina pectoris","7":"Launched","8":"hypertension, angina pectoris","_rn_":"20777"},{"1":"BRD-K21937671-001-09-2","2":"loxistatin-acid","3":"cysteine peptidase inhibitor","4":"CTSB","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"21583"},{"1":"BRD-A92630576-050-24-1","2":"trimebutine","3":"opioid receptor agonist","4":"OPRD1, OPRK1, OPRM1","5":"gastroenterology","6":"irritable bowel syndrome","7":"Launched","8":"irritable bowel syndrome","_rn_":"21585"},{"1":"BRD-A97739905-001-26-5","2":"ketoprofen","3":"cyclooxygenase inhibitor","4":"CXCR1, PTGS1, PTGS2, SLC5A8","5":"rheumatology","6":"rheumatoid arthritis, osteoarthritis","7":"Launched","8":"rheumatoid arthritis, osteoarthritis","_rn_":"21587"},{"1":"BRD-K27316855-001-13-3","2":"calcitriol","3":"vitamin D receptor agonist","4":"VDR","5":"endocrinology, orthopedics","6":"hypocalcemia, hypoparathyroidism, osteoporosis","7":"Launched","8":"hypocalcemia, hypoparathyroidism, osteoporosis","_rn_":"21588"},{"1":"BRD-A75726477-003-21-3","2":"clenbuterol","3":"adrenergic receptor agonist","4":"ADRB1, ADRB2, ADRB3, NGF, TNF","5":"pulmonary","6":"chronic obstructive pulmonary disease (COPD), asthma","7":"Launched","8":"chronic obstructive pulmonary disease (COPD), asthma","_rn_":"21589"},{"1":"BRD-K25433859-003-25-4","2":"maprotiline","3":"norepinephrine reputake inhibitor, tricyclic antidepressant","4":"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2","5":"neurology/psychiatry","6":"depression, dysthymic disorder","7":"Launched","8":"depression, dysthymic disorder","_rn_":"21628"},{"1":"BRD-K21547160-001-01-4","2":"sufentanil","3":"opioid receptor modulator","4":"OPRD1, OPRK1, OPRM1","5":"neurology/psychiatry","6":"anesthetic","7":"Launched","8":"anesthetic","_rn_":"21630"},{"1":"BRD-A97701745-001-16-0","2":"pindolol","3":"adrenergic receptor antagonist","4":"ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"21634"},{"1":"BRD-K40308497-001-01-2","2":"crizotinib-(S)","3":"MTH1 inhibitor","4":"NUDT1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"21636"},{"1":"BRD-A03932035-004-04-3","2":"methscopolamine","3":"acetylcholine receptor antagonist","4":"CHRM1, CHRM2, CHRM3","5":"gastroenterology","6":"peptic ulcer disease (PUD)","7":"Launched","8":"peptic ulcer disease (PUD)","_rn_":"21672"},{"1":"BRD-K23984367-075-15-2","2":"sorafenib","3":"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","4":"BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET","5":"oncology","6":"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","7":"Launched","8":"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","_rn_":"21674"},{"1":"BRD-M80207679-001-01-5","2":"nemonapride","3":"dopamine receptor antagonist","4":"DRD2, DRD3, DRD4","5":"neurology/psychiatry","6":"schizophrenia","7":"Launched","8":"schizophrenia","_rn_":"21676"},{"1":"BRD-K10961822-001-05-1","2":"latanoprost","3":"prostanoid receptor agonist","4":"PTGFR","5":"ophthalmology","6":"ocular hypertension, glaucoma","7":"Launched","8":"ocular hypertension, glaucoma","_rn_":"21678"},{"1":"BRD-A14886633-001-01-6","2":"norgestrel","3":"progesterone receptor agonist","4":"PGR","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"21680"},{"1":"BRD-A80017228-001-25-7","2":"bendroflumethiazide","3":"sodium/potassium/chloride transporter inhibitor","4":"CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"21720"},{"1":"BRD-K74763371-002-04-0","2":"bosentan","3":"endothelin receptor antagonist","4":"EDNRA, EDNRB","5":"pulmonary","6":"pulmonary arterial hypertension (PAH)","7":"Launched","8":"pulmonary arterial hypertension (PAH)","_rn_":"21721"},{"1":"BRD-A79981887-003-16-4","2":"midodrine","3":"adrenergic receptor agonist","4":"ADRA1A, ADRA1B, ADRA1D","5":"cardiology","6":"hypotension","7":"Launched","8":"hypotension","_rn_":"21723"},{"1":"BRD-K92213669-001-01-3","2":"lomitapide","3":"microsomal trigylceride transfer protein inhibitor","4":"MTTP","5":"endocrinology","6":"hypercholesterolemia","7":"Launched","8":"hypercholesterolemia","_rn_":"21725"},{"1":"BRD-K07359318-001-03-9","2":"benfotiamine","3":"antioxidant","4":"AGER","5":"rheumatology","6":"lumbago","7":"Launched","8":"lumbago","_rn_":"21764"},{"1":"BRD-K79131256-001-17-9","2":"albendazole","3":"tubulin polymerization inhibitor","4":"TUBA1A, TUBB, TUBB4B","5":"infectious disease","6":"cystic hydatid disease, parenchymal neurocysticercosis","7":"Launched","8":"cystic hydatid disease, parenchymal neurocysticercosis","_rn_":"21766"},{"1":"BRD-A17846016-001-13-9","2":"trolox","3":"antioxidant","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"21768"},{"1":"BRD-K94720315-001-10-4","2":"chromocarb","3":"antispasmodic","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"21772"},{"1":"BRD-K39987650-001-24-1","2":"bisacodyl","3":"laxative","4":"NA","5":"gastroenterology","6":"constipation","7":"Launched","8":"constipation","_rn_":"21811"},{"1":"BRD-A28301258-001-03-0","2":"salinomycin","3":"NA","4":"NA","5":"infectious disease","6":"coccidiosis","7":"Launched","8":"coccidiosis","_rn_":"21814"},{"1":"BRD-A30886737-001-02-9","2":"florfenicol","3":"protein synthesis inhibitor","4":"NA","5":"pulmonary","6":"bovine respiratory disease (BRD)","7":"Launched","8":"bovine respiratory disease (BRD)","_rn_":"21816"},{"1":"BRD-K50866992-003-10-3","2":"tropisetron","3":"serotonin receptor antagonist","4":"GLRA1, GLRA2, GLRB, HTR3A, HTR4","5":"gastroenterology","6":"nausea, vomiting, nausea, vomiting","7":"Launched","8":"nausea, vomiting, nausea, vomiting","_rn_":"21818"},{"1":"BRD-K34332569-001-01-3","2":"imidapril","3":"angiotensin converting enzyme inhibitor","4":"ACE","5":"cardiology","6":"hypertension, congestive heart failure","7":"Launched","8":"hypertension, congestive heart failure","_rn_":"21859"},{"1":"BRD-K47878171-086-06-0","2":"bephenium-hydroxynaphthoate","3":"anthelmintic agent","4":"NA","5":"infectious disease","6":"ascariasis","7":"Launched","8":"ascariasis","_rn_":"21861"},{"1":"BRD-K42828737-044-09-0","2":"sunitinib","3":"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","4":"CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET","5":"oncology","6":"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","7":"Launched","8":"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","_rn_":"21863"},{"1":"BRD-K96006502-001-02-6","2":"deflazacort","3":"glucocorticoid receptor agonist","4":"NR3C1","5":"rheumatology","6":"joint inflammation","7":"Launched","8":"joint inflammation","_rn_":"21865"},{"1":"BRD-A49765801-001-04-1","2":"fludroxycortide","3":"glucocorticoid receptor agonist","4":"NR3C1, SERPINA6","5":"infectious disease, dermatology","6":"skin infections, psoriasis","7":"Launched","8":"skin infections, psoriasis","_rn_":"21904"},{"1":"BRD-A67097164-001-18-7","2":"ifosfamide","3":"DNA alkylating agent","4":"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1","5":"oncology, urology","6":"testicular carcinoma, hemorrhagic cystitis","7":"Launched","8":"testicular carcinoma, hemorrhagic cystitis","_rn_":"21906"},{"1":"BRD-A48237631-001-04-8","2":"mitomycin-c","3":"DNA alkylating agent, DNA synthesis inhibitor","4":"NA","5":"oncology","6":"pancreatic cancer, gastric adenocarcinoma","7":"Launched","8":"pancreatic cancer, gastric adenocarcinoma","_rn_":"21908"},{"1":"BRD-K11510141-001-01-8","2":"teprenone","3":"mucus protecting agent","4":"NA","5":"dermatology","6":"cosmetic","7":"Launched","8":"cosmetic","_rn_":"21909"},{"1":"BRD-K65781196-001-03-0","2":"avanafil","3":"phosphodiesterase inhibitor","4":"PDE5A","5":"urology","6":"erectile dysfunction","7":"Launched","8":"erectile dysfunction","_rn_":"21911"},{"1":"BRD-K38458514-001-01-8","2":"diazooxonorleucine","3":"glutamate receptor antagonist","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"22692"},{"1":"BRD-K61443650-236-13-1","2":"thiomersal","3":"other antibiotic","4":"OXCT1","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"22694"},{"1":"BRD-K95763993-001-19-3","2":"trapidil","3":"PDGFR tyrosine kinase receptor inhibitor","4":"PDGFRA","5":"cardiology","6":"coronary artery disease (CAD)","7":"Launched","8":"coronary artery disease (CAD)","_rn_":"22696"},{"1":"BRD-K80431395-001-07-3","2":"triciribine","3":"AKT inhibitor","4":"AKT1, AKT2, AKT3","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"22698"},{"1":"BRD-A99888680-001-03-8","2":"paliperidone","3":"dopamine receptor antagonist, serotonin receptor antagonist","4":"ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C","5":"neurology/psychiatry","6":"schizophrenia","7":"Launched","8":"schizophrenia","_rn_":"22700"},{"1":"BRD-K89561498-001-01-7","2":"SN-38","3":"topoisomerase inhibitor","4":"TOP1","5":"oncology","6":"colorectal cancer","7":"Launched","8":"Colon/Colorectal Cancer","_rn_":"22740"},{"1":"BRD-K01507359-001-22-9","2":"rifampin","3":"RNA polymerase inhibitor","4":"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3","5":"infectious disease","6":"tuberculosis, meningitis","7":"Launched","8":"tuberculosis, meningitis","_rn_":"22742"},{"1":"BRD-A26503646-001-16-6","2":"formestane","3":"aromatase inhibitor","4":"CYP19A1","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"22744"},{"1":"BRD-K35960502-001-20-0","2":"niclosamide","3":"DNA replication inhibitor, STAT inhibitor","4":"STAT3","5":"infectious disease","6":"tapeworm","7":"Launched","8":"tapeworm","_rn_":"22746"},{"1":"BRD-A17883755-001-06-1","2":"lenalidomide","3":"anticancer agent","4":"CDH5, CRBN, PTGS2, TNF, TNFSF11","5":"hematologic malignancy","6":"multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)","7":"Launched","8":"multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)","_rn_":"22748"},{"1":"BRD-A67516570-001-02-8","2":"lafutidine","3":"histamine receptor antagonist","4":"HRH2","5":"gastroenterology","6":"duodenal ulcer disease, peptic ulcer disease (PUD)","7":"Launched","8":"duodenal ulcer disease, peptic ulcer disease (PUD)","_rn_":"22788"},{"1":"BRD-K58148589-001-03-6","2":"betamethasone-dipropionate","3":"anti-inflammatory agent","4":"NA","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"22790"},{"1":"BRD-K03406345-001-27-8","2":"azacitidine","3":"DNA methyltransferase inhibitor","4":"DNMT1, DNMT3A","5":"hematologic malignancy, hematology","6":"myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","7":"Launched","8":"myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","_rn_":"22792"},{"1":"BRD-K17068645-003-04-2","2":"bendamustine","3":"DNA inhibitor","4":"NA","5":"hematologic malignancy","6":"chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)","7":"Launched","8":"chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)","_rn_":"22794"},{"1":"BRD-K87990216-001-10-2","2":"piretanide","3":"glucocorticoid receptor agonist","4":"SLC12A1, SLC12A2","5":"cardiology","6":"hypertension, edema","7":"Launched","8":"hypertension, edema","_rn_":"22796"},{"1":"BRD-K16195444-003-26-0","2":"oxymetazoline","3":"adrenergic receptor agonist","4":"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C","5":"otolaryngology","6":"nasal congestion","7":"Launched","8":"nasal congestion","_rn_":"22836"},{"1":"BRD-K82818427-001-02-2","2":"batimastat","3":"matrix metalloprotease inhibitor","4":"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"22840"},{"1":"BRD-K27184429-300-01-3","2":"levocetirizine","3":"histamine receptor antagonist","4":"HRH1","5":"allergy","6":"allergic rhinitis, urticaria","7":"Launched","8":"allergic rhinitis, urticaria","_rn_":"22842"},{"1":"BRD-K99107520-001-24-1","2":"felbamate","3":"glutamate receptor antagonist","4":"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B","5":"neurology/psychiatry","6":"epilepsy","7":"Launched","8":"epilepsy","_rn_":"22844"},{"1":"BRD-K85554912-001-06-3","2":"ivermectin","3":"benzodiazepine receptor agonist","4":"CHRNA7, GABRB3, GLRA3, P2RX7","5":"infectious disease","6":"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies","7":"Launched","8":"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies","_rn_":"22884"},{"1":"BRD-K19687926-379-07-4","2":"lapatinib","3":"EGFR inhibitor","4":"EGFR, ERBB2","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"22886"},{"1":"BRD-K76037122-001-02-5","2":"guanidine","3":"HSP inhibitor","4":"ALDH2, DLG4, GAMT, RNASE1","5":"neurology/psychiatry","6":"Lambert-Eaton myasthenic syndrome (LEMS)","7":"Launched","8":"Lambert-Eaton myasthenic syndrome (LEMS)","_rn_":"22887"},{"1":"BRD-K72167406-001-02-1","2":"cefditoren-pivoxil","3":"bacterial cell wall synthesis inhibitor","4":"NA","5":"infectious disease, pulmonary, otolaryngology","6":"pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis","7":"Launched","8":"pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis","_rn_":"22889"},{"1":"BRD-K51040301-001-02-1","2":"cobicistat","3":"cytochrome P450 inhibitor","4":"CYP3A4, CYP3A43, CYP3A5, CYP3A7","5":"infectious disease","6":"human immunodeficiency virus (HIV-1)","7":"Launched","8":"human immunodeficiency virus (HIV-1)","_rn_":"22891"},{"1":"BRD-K82928847-001-04-7","2":"ACY-1215","3":"HDAC inhibitor","4":"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"22933"},{"1":"BRD-K18779551-003-07-8","2":"bifemelane","3":"acetylcholine release enhancer","4":"MAOA, MAOB","5":"ophthalmology, neurology/psychiatry","6":"glaucoma, senile dementia","7":"Launched","8":"glaucoma, senile dementia","_rn_":"22935"},{"1":"BRD-K53734668-003-02-0","2":"PRT062607","3":"syk inhibitor","4":"FGR, MAP3K9, SYK","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"22939"},{"1":"BRD-K17849083-001-32-9","2":"tranilast","3":"angiogenesis inhibitor","4":"HPGDS, HRH1","5":"pulmonary","6":"asthma","7":"Launched","8":"asthma","_rn_":"22978"},{"1":"BRD-K51350053-048-16-5","2":"toremifene","3":"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","4":"ESR1","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"22980"},{"1":"BRD-K93441486-067-12-8","2":"diphemanil","3":"acetylcholine receptor antagonist","4":"CHRM3","5":"neurology/psychiatry","6":"spasms","7":"Launched","8":"spasms","_rn_":"22982"},{"1":"BRD-K27799744-001-02-8","2":"cyclovirobuxin-d","3":"calcium channel modulator","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"22984"},{"1":"BRD-K11196887-001-22-0","2":"norfloxacin","3":"bacterial DNA gyrase inhibitor","4":"TOP2A","5":"infectious disease, urology","6":"urinary tract infections, gonorrhea, prostatitis","7":"Launched","8":"urinary tract infections, gonorrhea, prostatitis","_rn_":"22986"},{"1":"BRD-K92657060-001-05-7","2":"zaleplon","3":"benzodiazepine receptor agonist","4":"GABRA1, GABRB1, GABRG2, TSPO","5":"neurology/psychiatry","6":"insomnia","7":"Launched","8":"insomnia","_rn_":"23026"},{"1":"BRD-K78431006-001-10-2","2":"crizotinib","3":"ALK tyrosine kinase receptor inhibitor","4":"ALK, MET","5":"oncology","6":"non-small cell lung cancer (NSCLC)","7":"Launched","8":"Lung Cancer","_rn_":"23028"},{"1":"BRD-K87349682-347-03-8","2":"norepinephrine","3":"adrenergic receptor agonist","4":"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2","5":"cardiology, allergy, neurology/psychiatry","6":"hypertension, urticaria, headache, seasonal affective disorder","7":"Launched","8":"hypertension, urticaria, headache, seasonal affective disorder","_rn_":"23030"},{"1":"BRD-K28824103-001-02-8","2":"genipin","3":"choleretic agent","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"23032"},{"1":"BRD-K05674516-001-01-7","2":"PSI-7976","3":"HCV inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"23034"},{"1":"BRD-K37793595-003-01-7","2":"afobazole","3":"anxiolytic","4":"NA","5":"neurology/psychiatry","6":"anxiety","7":"Launched","8":"anxiety","_rn_":"23840"},{"1":"BRD-K74141488-003-11-2","2":"naftifine","3":"fungal squalene epoxidase inhibitor","4":"SQLE","5":"infectious disease","6":"tinea pedis, tinea cruris, tinea corporis","7":"Launched","8":"tinea pedis, tinea cruris, tinea corporis","_rn_":"23842"},{"1":"BRD-K22134346-001-24-9","2":"simvastatin","3":"HMGCR inhibitor","4":"HMGCR, ITGB2","5":"endocrinology, cardiology, neurology/psychiatry","6":"hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia","7":"Launched","8":"hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia","_rn_":"23844"},{"1":"BRD-K84937637-001-09-9","2":"sirolimus","3":"mTOR inhibitor","4":"FGF2, FKBP1A, MTOR","5":"transplant, pulmonary","6":"organ rejection, lymphangioleiomyomatosis","7":"Launched","8":"organ rejection, lymphangioleiomyomatosis","_rn_":"23846"},{"1":"BRD-K89839824-001-05-3","2":"raltitrexed","3":"thymidylate synthase inhibitor","4":"FPGS, TYMS","5":"oncology","6":"mesothelioma","7":"Launched","8":"mesothelioma","_rn_":"23886"},{"1":"BRD-K52662033-003-21-2","2":"lidocaine","3":"histamine receptor agonist","4":"EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","5":"neurology/psychiatry, dermatology, hematology","6":"itching, eczema, hemorrhage","7":"Launched","8":"itching, eczema, hemorrhage","_rn_":"23888"},{"1":"BRD-K50071428-001-03-3","2":"abiraterone","3":"androgen biosynthesis inhibitor","4":"CYP11B1, CYP17A1","5":"oncology","6":"prostate cancer","7":"Launched","8":"prostate cancer","_rn_":"23890"},{"1":"BRD-K50677762-001-01-5","2":"oxiracetam","3":"acetylcholine receptor agonist","4":"NA","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"23892"},{"1":"BRD-K04552268-001-02-4","2":"4-pyrimidinecarbonitrile","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"23934"},{"1":"BRD-A08545410-003-07-8","2":"doxycycline","3":"metalloproteinase inhibitor","4":"MMP8","5":"dental","6":"periodontitis","7":"Launched","8":"periodontitis","_rn_":"23936"},{"1":"BRD-K15766189-001-09-8","2":"cefdinir","3":"bacterial cell wall synthesis inhibitor","4":"MPO","5":"infectious disease, otolaryngology, pulmonary","6":"pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis","7":"Launched","8":"pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis","_rn_":"23938"},{"1":"BRD-K54634444-001-05-9","2":"artesunate","3":"DNA synthesis inhibitor","4":"NA","5":"infectious disease","6":"malaria","7":"Launched","8":"malaria","_rn_":"23940"},{"1":"BRD-A49035384-003-28-9","2":"methacycline","3":"protein synthesis inhibitor","4":"NA","5":"pulmonary","6":"bronchitis","7":"Launched","8":"bronchitis","_rn_":"23942"},{"1":"BRD-K96631475-001-02-4","2":"10-deacetylbaccatin","3":"antitumor agent","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"23982"},{"1":"BRD-K94353609-001-21-6","2":"fluocinolone-acetonide","3":"glucocorticoid receptor agonist","4":"NR3C1, SERPINA6","5":"dermatology","6":"seborrheic dermatitis","7":"Launched","8":"seborrheic dermatitis","_rn_":"23984"},{"1":"BRD-K77791657-003-01-7","2":"3-deazaneplanocin-A","3":"histone lysine methyltransferase inhibitor","4":"EZH2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"23986"},{"1":"BRD-K89704198-001-12-3","2":"vincamine","3":"adrenergic receptor antagonist","4":"CHRM1, CHRM2, CHRM3, CHRM4","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"23988"},{"1":"BRD-K88789588-001-14-9","2":"letrozole","3":"aromatase inhibitor","4":"CYP19A1","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"23990"},{"1":"BRD-K99383816-001-03-5","2":"ftorafur","3":"thymidylate synthase inhibitor","4":"TYMS","5":"oncology","6":"colorectal cancer","7":"Launched","8":"Colon/Colorectal Cancer","_rn_":"24030"},{"1":"BRD-K83988098-003-03-4","2":"alvespimycin","3":"HSP inhibitor","4":"HSP90AA1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"24032"},{"1":"BRD-K52020312-001-26-8","2":"metronidazole","3":"DNA inhibitor","4":"CYP2C9, CYP3A4","5":"dermatology","6":"rosacea","7":"Launched","8":"rosacea","_rn_":"24034"},{"1":"BRD-K73425385-065-04-8","2":"bekanamycin","3":"bacterial 30S ribosomal subunit inhibitor","4":"NA","5":"infectious disease","6":"gram-negative bacterial infections","7":"Launched","8":"gram-negative bacterial infections","_rn_":"24036"},{"1":"BRD-K66296774-236-11-3","2":"fluvastatin","3":"HMGCR inhibitor","4":"HMGCR","5":"endocrinology, cardiology","6":"hypercholesterolemia, congenital heart defects","7":"Launched","8":"hypercholesterolemia, congenital heart defects","_rn_":"24038"},{"1":"BRD-K17075857-001-18-4","2":"chloroxine","3":"opioid receptor antagonist","4":"OPRK1","5":"gastroenterology, infectious disease, dermatology","6":"diarrhea, inflammatory bowel disease, giardiasis, dandruff","7":"Launched","8":"diarrhea, inflammatory bowel disease, giardiasis, dandruff","_rn_":"24078"},{"1":"BRD-K37270826-001-27-6","2":"mifepristone","3":"glucocorticoid receptor antagonist, progesterone receptor antagonist","4":"AR, NR1I2, NR3C1, PGR","5":"endocrinology","6":"hyperglycemia, diabetes mellitus","7":"Launched","8":"hyperglycemia, diabetes mellitus","_rn_":"24080"},{"1":"BRD-K50388907-001-30-4","2":"fenofibrate","3":"PPAR receptor agonist","4":"MMP25, PPARA","5":"endocrinology","6":"hypercholesterolemia, hypertriglyceridemia","7":"Launched","8":"hypercholesterolemia, hypertriglyceridemia","_rn_":"24082"},{"1":"BRD-K20482099-001-09-4","2":"rutin","3":"antioxidant, capillary stabilizing agent, nitric oxide scavenger","4":"AKR1C3","5":"rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy","6":"joint pain, nasal congestion, constipation, irritability, allergic rhinitis","7":"Launched","8":"joint pain, nasal congestion, constipation, irritability, allergic rhinitis","_rn_":"24084"},{"1":"BRD-A51964809-003-12-6","2":"halofantrine","3":"antimalarial agent","4":"KCNH2, KCNN4","5":"infectious disease","6":"malaria","7":"Launched","8":"malaria","_rn_":"24086"},{"1":"BRD-K47114202-001-14-6","2":"chlorogenic-acid","3":"antioxidant","4":"SLC37A4","5":"neurology/psychiatry, pulmonary, allergy","6":"headache, chest congestion, allergic rhinitis","7":"Launched","8":"headache, chest congestion, allergic rhinitis","_rn_":"24126"},{"1":"BRD-K92723993-001-06-7","2":"imatinib","3":"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","4":"ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","5":"hematologic malignancy, oncology","6":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","7":"Launched","8":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","_rn_":"24128"},{"1":"BRD-K14003026-003-09-0","2":"ritodrine","3":"adrenergic receptor agonist","4":"ADRB2","5":"obstetrics/gynecology","6":"premature labor","7":"Launched","8":"premature labor","_rn_":"24130"},{"1":"BRD-K79145628-001-05-5","2":"nimorazole","3":"bacterial DNA inhibitor","4":"NA","5":"oncology","6":"head and neck squamous cell carcinoma (HNSCC)","7":"Launched","8":"Head and Neck Cancer","_rn_":"24132"},{"1":"BRD-K97752965-001-16-4","2":"nicorandil","3":"nitric oxide donor, potassium channel activator","4":"KCNJ11","5":"cardiology","6":"angina pectoris","7":"Launched","8":"angina pectoris","_rn_":"24134"},{"1":"BRD-K21528677-001-02-8","2":"desonide","3":"glucocorticoid receptor agonist","4":"NR3C1, PLA2G1B","5":"gastroenterology","6":"Crohn's disease","7":"Launched","8":"Crohn's disease","_rn_":"24174"},{"1":"BRD-K91825936-001-01-2","2":"ZK811752","3":"CC chemokine receptor antagonist","4":"CCR1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"24176"},{"1":"BRD-K47079459-004-04-6","2":"cetrimonium","3":"NA","4":"NA","5":"dermatology","6":"cosmetic","7":"Launched","8":"cosmetic","_rn_":"24178"},{"1":"BRD-K62607865-001-09-7","2":"aztreonam","3":"bacterial cell wall synthesis inhibitor","4":"NA","5":"infectious disease","6":"urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections","7":"Launched","8":"urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections","_rn_":"24180"},{"1":"BRD-K49111258-003-29-7","2":"prazosin","3":"adrenergic receptor antagonist","4":"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"24182"},{"1":"BRD-K40718343-001-02-6","2":"AEE788","3":"EGFR inhibitor, VEGFR inhibitor","4":"EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR","5":"NA","6":"NA","7":"Phase 1/Phase 2","8":"NA","_rn_":"24981"},{"1":"BRD-K43187018-001-03-3","2":"GDC-0349","3":"Pim kinase inhibitor","4":"PIK3CA","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"24983"},{"1":"BRD-K26011976-001-01-0","2":"licochalcone-a","3":"topoisomerase inhibitor","4":"PTPN1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"24987"},{"1":"BRD-K27182532-001-02-3","2":"metatinib","3":"Bcr-Abl kinase inhibitor","4":"ABL1, BCR","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"24989"},{"1":"BRD-K29656036-001-02-5","2":"MK-8245","3":"stearoyl-CoA desaturase inhibitor","4":"SCD","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"25029"},{"1":"BRD-K84798689-236-02-9","2":"sodium-tanshinone-ii-a-sulfonate","3":"potassium channel activator","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"25031"},{"1":"BRD-K44844162-001-01-6","2":"taselisib","3":"PI3K inhibitor","4":"PIK3CA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"25033"},{"1":"BRD-K25835157-001-01-4","2":"PRT062070","3":"JAK inhibitor, syk inhibitor","4":"SYK","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"25035"},{"1":"BRD-K12502280-001-08-0","2":"TG-101348","3":"FLT3 inhibitor, JAK inhibitor","4":"BRD4, JAK1, JAK2, JAK3, TYK2","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"25037"},{"1":"BRD-K49075727-001-08-5","2":"nintedanib","3":"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB","5":"pulmonary","6":"idiopathic pulmonary fibrosis (IPF)","7":"Launched","8":"idiopathic pulmonary fibrosis (IPF)","_rn_":"25077"},{"1":"BRD-K65678996-001-05-5","2":"nefiracetam","3":"acetylcholine receptor agonist, benzodiazepine receptor agonist","4":"CHRM1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"25079"},{"1":"BRD-A68083442-001-01-6","2":"pranidipine","3":"calcium channel blocker","4":"CACNA1C","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"25083"},{"1":"BRD-K84892605-001-01-1","2":"IOWH032","3":"CFTR channel antagonist","4":"CFTR","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"25085"},{"1":"BRD-K73303757-001-21-6","2":"4-methylgenistein","3":"protein tyrosine kinase inhibitor","4":"CYP19A1, ESRRA, ESRRB, ESRRG, FASN","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25125"},{"1":"BRD-K58466253-003-14-0","2":"palmatine-chloride","3":"dopamine synthesis inhibitor","4":"CYP3A4","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25127"},{"1":"BRD-A78391468-001-02-8","2":"prednisolone-hemisuccinate","3":"glucocorticoid receptor agonist","4":"NR3C1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25129"},{"1":"BRD-K06753942-001-14-5","2":"nobiletin","3":"MEK inhibitor","4":"MAP2K1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25131"},{"1":"BRD-K89391146-001-08-0","2":"RG108","3":"DNA methyltransferase inhibitor","4":"DNMT1, DNMT3B","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25133"},{"1":"BRD-K62814476-001-03-3","2":"BMS-265246","3":"CDK inhibitor","4":"CDK1, CDK2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25173"},{"1":"BRD-K96104201-001-01-5","2":"azalomycin-b","3":"bacterial 50S ribosomal subunit inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25175"},{"1":"BRD-K92991072-001-04-9","2":"PAC-1","3":"caspase activator","4":"CASP3","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"25177"},{"1":"BRD-A68631409-001-05-4","2":"evodiamine","3":"ATPase inhibitor, TRPV agonist","4":"TRPV1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25179"},{"1":"BRD-K79239947-001-06-8","2":"PF-573228","3":"focal adhesion kinase inhibitor","4":"CDK1, CDK2, CDK7, GSK3B, IKBKB","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25181"},{"1":"BRD-K61536336-001-01-7","2":"SB-366791","3":"TRPV antagonist","4":"TRPV1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25221"},{"1":"BRD-K87036601-001-01-6","2":"azodicarbonamide","3":"DNA synthesis inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"25223"},{"1":"BRD-K74227499-001-01-1","2":"se-methylselenocysteine","3":"NA","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"25225"},{"1":"BRD-A73427433-240-01-3","2":"adaprev","3":"TGF beta receptor inhibitor","4":"IGF2R, M6PR","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"25227"},{"1":"BRD-K23403298-003-01-9","2":"benzyldimethylhexadecylammonium","3":"cationic surfactant","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25229"},{"1":"BRD-K77634909-001-03-5","2":"AEG3482","3":"HSP inducer","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25269"},{"1":"BRD-K06426971-001-02-7","2":"ryuvidine","3":"histone lysine methyltransferase inhibitor","4":"CDK2, CDK4","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25271"},{"1":"BRD-K04622161-001-02-3","2":"YO-01027","3":"gamma secretase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25273"},{"1":"BRD-A13964793-001-02-6","2":"TC1","3":"beta-secretase inhibitor","4":"BACE1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25275"},{"1":"BRD-K66030860-001-03-6","2":"salidroside","3":"beta amyloid protein neurotoxicity inhibitor","4":"APP","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25277"},{"1":"BRD-K01653460-001-01-1","2":"chlorindanol","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25317"},{"1":"BRD-K07762753-001-04-4","2":"aminopurvalanol-a","3":"CDK inhibitor, tyrosine kinase inhibitor","4":"CDK1, CDK2, CDK5, CDK6","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25319"},{"1":"BRD-A73871920-236-03-6","2":"nanchangmycin","3":"other antibiotic","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"25321"},{"1":"BRD-K28143534-001-02-2","2":"cyproheptadine","3":"histamine receptor antagonist","4":"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7","5":"allergy, otolaryngology, ophthalmology, dermatology","6":"allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism","7":"Launched","8":"allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism","_rn_":"25323"},{"1":"BRD-K82846253-001-15-4","2":"repaglinide","3":"insulin secretagogue","4":"ABCC8, KCNJ11, PPARG","5":"endocrinology","6":"diabetes mellitus","7":"Launched","8":"diabetes mellitus","_rn_":"25325"},{"1":"BRD-K53581288-001-02-9","2":"baricitinib","3":"JAK inhibitor","4":"JAK1, JAK2","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"26135"},{"1":"BRD-K39558284-001-01-2","2":"SDZ-WAG-994","3":"adenosine receptor agonist","4":"ADORA1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"26137"},{"1":"BRD-K99498722-001-02-6","2":"plinabulin","3":"tubulin polymerization inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"26139"},{"1":"BRD-K64890080-001-13-8","2":"BI-2536","3":"PLK inhibitor","4":"BRD4, PLK1, PLK2, PLK3","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"26179"},{"1":"BRD-A36057565-001-01-0","2":"bruceantin","3":"protein synthesis inhibitor","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"26181"},{"1":"BRD-K83022601-001-01-0","2":"CI-844","3":"NA","4":"NA","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"26183"},{"1":"BRD-K84810405-003-01-1","2":"almorexant","3":"orexin receptor antagonist","4":"HCRTR1, HCRTR2","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"26185"},{"1":"BRD-K77638923-001-02-0","2":"CUDC-907","3":"PI3K inhibitor","4":"HDAC2, PIK3R1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"26187"},{"1":"BRD-K49865102-001-08-4","2":"PD-0325901","3":"MEK inhibitor","4":"MAP2K1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"26227"},{"1":"BRD-K43621685-001-02-5","2":"CP-673451","3":"PDGFR tyrosine kinase receptor inhibitor","4":"KIT, PDGFRA, PDGFRB","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26231"},{"1":"BRD-A57798112-001-03-7","2":"PD-318088","3":"MEK inhibitor","4":"MAP2K1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26233"},{"1":"BRD-K42756753-001-01-9","2":"epiandrosterone","3":"steroid","4":"G6PD","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26235"},{"1":"BRD-A23127772-001-02-3","2":"sclareol","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26274"},{"1":"BRD-K48826825-001-01-8","2":"S26948","3":"PPAR receptor agonist","4":"PPARG","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26276"},{"1":"BRD-K68904758-001-03-5","2":"cephalomannine","3":"DNA polymerase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26278"},{"1":"BRD-K41876534-001-13-7","2":"tioxolone","3":"carbonic anhydrase inhibitor","4":"CA2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26280"},{"1":"BRD-K36363294-001-04-2","2":"I-BET151","3":"bromodomain inhibitor","4":"BRD2, BRD3, BRD4","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26282"},{"1":"BRD-A42746051-001-02-9","2":"melengestrol-acetate","3":"progesterone receptor agonist","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26322"},{"1":"BRD-K37723606-001-01-5","2":"dioscin","3":"apoptosis stimulant","4":"CXCR3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26324"},{"1":"BRD-K18375018-376-02-3","2":"spermine","3":"NA","4":"CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26326"},{"1":"BRD-K90382497-001-10-7","2":"GW-843682X","3":"PLK inhibitor","4":"PLK1, PLK3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26328"},{"1":"BRD-K12068470-001-02-5","2":"LY2608204","3":"glucokinase activator","4":"GCK","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"26330"},{"1":"BRD-K11927976-050-02-9","2":"ER-27319","3":"mediator release inhibitor, SYK inhibitor","4":"SYK","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26370"},{"1":"BRD-K33818169-003-04-6","2":"GW-3965","3":"LXR agonist","4":"NR1H2, NR1H3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26372"},{"1":"BRD-K47557313-001-02-7","2":"LY2109761","3":"TGF beta receptor inhibitor","4":"TGFBR1, TGFBR2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26374"},{"1":"BRD-K36198571-001-02-0","2":"WAY-170523","3":"metalloproteinase inhibitor","4":"MMP13","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26376"},{"1":"BRD-K94455792-001-01-8","2":"ICG-001","3":"beta-catenin inhibitor","4":"CTNNB1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26378"},{"1":"BRD-K21782625-001-02-4","2":"AMG458","3":"MET inhibitor","4":"MET","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26418"},{"1":"BRD-K67772619-001-05-1","2":"rheochrysidin","3":"protein tyrosine kinase inhibitor","4":"PTPN1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26420"},{"1":"BRD-K36222532-001-01-8","2":"broxaldine","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26422"},{"1":"BRD-K24601397-001-01-1","2":"phlorizin","3":"sodium/glucose cotransporter inhibitor","4":"SLC5A1, SLC5A11, SLC5A2, SLC5A3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26424"},{"1":"BRD-K34851558-001-02-3","2":"parthenolide-(-)","3":"NFkB pathway inhibitor","4":"HDAC1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"26426"},{"1":"BRD-K80129304-001-08-1","2":"uracil","3":"NA","4":"DPYD, UCKL1","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"26466"},{"1":"BRD-K51143828-003-03-1","2":"lurasidone","3":"dopamine receptor antagonist, serotonin receptor antagonist","4":"ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7","5":"neurology/psychiatry","6":"schizophrenia","7":"Launched","8":"schizophrenia","_rn_":"26468"},{"1":"BRD-K33720171-001-01-0","2":"difluprednate","3":"glucocorticoid receptor agonist","4":"NR3C1","5":"ophthalmology","6":"endogenous uveitis","7":"Launched","8":"endogenous uveitis","_rn_":"26470"},{"1":"BRD-K48578705-001-17-6","2":"methyldopa","3":"adrenergic receptor agonist","4":"ADRA2A, ADRA2B, ADRA2C, DDC","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"26472"},{"1":"BRD-K81332461-001-01-4","2":"maxacalcitol","3":"vitamin D receptor agonist","4":"VDR","5":"endocrinology","6":"hyperparathyroidism","7":"Launched","8":"hyperparathyroidism","_rn_":"26474"},{"1":"BRD-K84011460-051-01-7","2":"nizofenone","3":"ion channel antagonist","4":"NA","5":"neurology/psychiatry","6":"stroke","7":"Launched","8":"stroke","_rn_":"27278"},{"1":"BRD-K65877271-001-01-8","2":"halobetasol-propionate","3":"glucocorticoid receptor agonist","4":"NR3C1, PLA2G1B","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"27280"},{"1":"BRD-K81074237-001-02-3","2":"azilsartan","3":"angiotensin receptor antagonist","4":"AGTR1, AGTR2","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"27282"},{"1":"BRD-K82122102-323-01-1","2":"amfenac","3":"cyclooxygenase inhibitor","4":"PTGS1, PTGS2","5":"neurology/psychiatry","6":"pain relief","7":"Launched","8":"pain relief","_rn_":"27284"},{"1":"BRD-K15409150-001-05-8","2":"penfluridol","3":"T-type calcium channel blocker","4":"CACNA1G","5":"neurology/psychiatry","6":"schizophrenia","7":"Launched","8":"schizophrenia","_rn_":"27286"},{"1":"BRD-K33813875-003-01-8","2":"valnemulin","3":"bacterial 50S ribosomal subunit inhibitor","4":"NA","5":"infectious disease, gastroenterology","6":"dysentry, colitis, pneumonia","7":"Launched","8":"dysentry, colitis, pneumonia","_rn_":"27326"},{"1":"BRD-A85651701-001-19-7","2":"clopamide","3":"sodium/chloride cotransporter inhibitor","4":"NA","5":"cardiology","6":"hypertension","7":"Launched","8":"hypertension","_rn_":"27328"},{"1":"BRD-A12994259-001-02-1","2":"pomalidomide","3":"angiogenesis inhibitor, tumor necrosis factor production inhibitor","4":"CRBN, PTGS2, TNF","5":"hematologic malignancy","6":"multiple myeloma","7":"Launched","8":"multiple myeloma","_rn_":"27330"},{"1":"BRD-A20644369-001-08-6","2":"canrenone","3":"mineralocorticoid receptor antagonist","4":"NR3C2","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"27332"},{"1":"BRD-K96253961-046-03-1","2":"metaraminol","3":"adrenergic receptor agonist","4":"ADRA1A","5":"cardiology","6":"hypotension","7":"Launched","8":"hypotension","_rn_":"27334"},{"1":"BRD-K49954789-001-02-9","2":"mesna","3":"antioxidant","4":"NA","5":"urology","6":"hemorrhagic cystitis","7":"Launched","8":"hemorrhagic cystitis","_rn_":"27374"},{"1":"BRD-A11990600-001-03-4","2":"lorazepam","3":"benzodiazepine receptor agonist","4":"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO","5":"neurology/psychiatry","6":"status epilepticus","7":"Launched","8":"status epilepticus","_rn_":"27376"},{"1":"BRD-K15108141-001-06-6","2":"gemcitabine","3":"ribonucleotide reductase inhibitor","4":"CMPK1, RRM1, RRM2, TYMS","5":"oncology","6":"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer","7":"Launched","8":"ovarian cancer, breast cancer, Lung Cancer, pancreatic cancer","_rn_":"27378"},{"1":"BRD-A08545410-311-03-4","2":"doxycycline","3":"metalloproteinase inhibitor","4":"MMP8","5":"dental","6":"periodontitis","7":"Launched","8":"periodontitis","_rn_":"27382"},{"1":"BRD-K74514084-001-03-9","2":"pazopanib","3":"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","4":"CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3","5":"oncology","6":"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","7":"Launched","8":"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","_rn_":"27422"},{"1":"BRD-K43457670-001-27-8","2":"acetazolamide","3":"carbonic anhydrase inhibitor","4":"AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7","5":"ophthalmology","6":"glaucoma","7":"Launched","8":"glaucoma","_rn_":"27424"},{"1":"BRD-K04394237-001-03-7","2":"drospirenone","3":"mineralocorticoid receptor antagonist","4":"AR, NR3C2, PGR","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"27428"},{"1":"BRD-K77685957-300-09-1","2":"dequalinium","3":"PKC inhibitor","4":"KCNN1, KCNN3","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"27430"},{"1":"BRD-K39252998-003-01-5","2":"atipamezole","3":"adrenergic receptor antagonist","4":"NA","5":"neurology/psychiatry","6":"reverse sedative","7":"Launched","8":"reverse sedative","_rn_":"27470"},{"1":"BRD-K19761926-001-03-6","2":"eplerenone","3":"cytochrome P450 inhibitor","4":"NR3C2","5":"cardiology","6":"congestive heart failure, hypertension","7":"Launched","8":"congestive heart failure, hypertension","_rn_":"27472"},{"1":"BRD-K49522529-001-02-9","2":"alfacalcidol","3":"vitamin D receptor agonist","4":"CYP27B1, VDR","5":"endocrinology","6":"vitamin D deficiency","7":"Launched","8":"vitamin D deficiency","_rn_":"27474"},{"1":"BRD-K54314721-001-10-2","2":"zolmitriptan","3":"serotonin receptor agonist","4":"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F","5":"neurology/psychiatry","6":"migraine headache","7":"Launched","8":"migraine headache","_rn_":"27476"},{"1":"BRD-K08078237-001-19-8","2":"tetrandrine","3":"calcium channel blocker","4":"SLC6A3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"27478"},{"1":"BRD-K54838207-001-03-8","2":"fudosteine","3":"mucolytic agent","4":"NA","5":"pulmonary","6":"chest congestion","7":"Launched","8":"chest congestion","_rn_":"27518"},{"1":"BRD-K13050303-001-17-3","2":"uridine","3":"dopamine receptor agonist","4":"LSM6, TYMP","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"27520"},{"1":"BRD-K93754473-048-20-2","2":"tamoxifen","3":"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","4":"EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ","5":"oncology","6":"breast cancer","7":"Launched","8":"breast cancer","_rn_":"27522"},{"1":"BRD-K95773607-004-03-8","2":"darifenacin","3":"acetylcholine receptor antagonist","4":"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","5":"urology","6":"urinary incontinence","7":"Launched","8":"urinary incontinence","_rn_":"27524"},{"1":"BRD-K03243820-001-23-8","2":"trifluridine","3":"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor","4":"TYMS","5":"infectious disease","6":"virus herpes simplex (HSV)","7":"Launched","8":"virus herpes simplex (HSV)","_rn_":"27526"},{"1":"BRD-K94441233-001-13-0","2":"mevastatin","3":"HMGCR inhibitor","4":"HMGCR","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"27566"},{"1":"BRD-K07612980-001-05-3","2":"sparfloxacin","3":"bacterial DNA gyrase inhibitor","4":"TOP2A","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"27568"},{"1":"BRD-K43236057-001-07-1","2":"polydatin","3":"ICAM1 expression inhibitor","4":"ICAM1","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"27570"},{"1":"BRD-K95785345-300-14-8","2":"thiamine","3":"vitamin B","4":"SLC19A2, SLC19A3, TPK1","5":"metabolism","6":"thiamine deficiency","7":"Launched","8":"thiamine deficiency","_rn_":"27572"},{"1":"BRD-K55044200-001-15-3","2":"amoxicillin","3":"penicillin binding protein inhibitor","4":"CYP2C19, SLC15A1, SLC15A2, SLC22A6","5":"infectious disease, gastroenterology","6":"skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections","7":"Launched","8":"skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections","_rn_":"27574"},{"1":"BRD-K97440753-066-18-1","2":"dihydroergocristine","3":"adrenergic receptor antagonist, prolactin inhibitor","4":"ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"27614"},{"1":"BRD-K97472745-001-01-8","2":"gestrinone","3":"progesterone receptor antagonist","4":"AR, ESR1, PGR","5":"obstetrics/gynecology","6":"endometriosis","7":"Launched","8":"endometriosis","_rn_":"27616"},{"1":"BRD-K79612754-001-19-1","2":"inosine","3":"neurotrophic agent","4":"PARP1, PNP","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"27618"},{"1":"BRD-K54847683-001-04-0","2":"equol","3":"estrogen receptor agonist","4":"ESR1, ESR2","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"27620"},{"1":"BRD-K96153583-001-05-1","2":"cidofovir","3":"DNA polymerase inhibitor","4":"NA","5":"infectious disease","6":"acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis","7":"Launched","8":"acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis","_rn_":"27622"},{"1":"BRD-K81528515-001-13-8","2":"nilotinib","3":"Abl kinase inhibitor, Bcr-Abl kinase inhibitor","4":"ABL1, KIT","5":"hematologic malignancy","6":"chronic myeloid leukemia (CML)","7":"Launched","8":"chronic myeloid leukemia (CML)","_rn_":"28415"},{"1":"BRD-A84174393-236-07-1","2":"meloxicam","3":"cyclooxygenase inhibitor","4":"PTGS1, PTGS2","5":"rheumatology","6":"osteoarthritis, rheumatoid arthritis","7":"Launched","8":"osteoarthritis, rheumatoid arthritis","_rn_":"28417"},{"1":"BRD-K58262659-001-09-7","2":"doxifluridine","3":"thymidylate synthase inhibitor","4":"TYMS","5":"oncology","6":"colorectal cancer","7":"Launched","8":"Colon/Colorectal Cancer","_rn_":"28419"},{"1":"BRD-K13314656-001-01-0","2":"ebastine","3":"histamine receptor antagonist","4":"CYP3A4, HRH1","5":"allergy","6":"allergic rhinitis, urticaria","7":"Launched","8":"allergic rhinitis, urticaria","_rn_":"28421"},{"1":"BRD-K81916719-001-13-9","2":"triclabendazole","3":"microtubule inhibitor","4":"DNMT1","5":"infectious disease","6":"tapeworm","7":"Launched","8":"tapeworm","_rn_":"28423"},{"1":"BRD-K61496577-001-20-2","2":"flumethasone","3":"glucocorticoid receptor agonist","4":"NR3C1, PLA2G1B","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"28463"},{"1":"BRD-K52756523-001-24-7","2":"dirithromycin","3":"bacterial 50S ribosomal subunit inhibitor","4":"NA","5":"pulmonary","6":"bronchitis","7":"Launched","8":"bronchitis","_rn_":"28465"},{"1":"BRD-K88625236-001-04-2","2":"nonoxynol-9","3":"membrane integrity inhibitor","4":"NA","5":"endocrinology","6":"contraceptive","7":"Launched","8":"contraceptive","_rn_":"28467"},{"1":"BRD-K12343256-001-08-9","2":"trametinib","3":"MEK inhibitor","4":"MAP2K1, MAP2K2","5":"oncology","6":"melanoma","7":"Launched","8":"Skin Cancer","_rn_":"28469"},{"1":"BRD-K11973162-003-01-8","2":"tipiracil","3":"thymidine phosphorylase inhibitor","4":"TYMP","5":"oncology","6":"colorectal cancer","7":"Launched","8":"Colon/Colorectal Cancer","_rn_":"28471"},{"1":"BRD-K38305202-001-17-4","2":"domperidone","3":"dopamine receptor antagonist","4":"DRD2, DRD3","5":"infectious disease","6":"fescue toxicosis","7":"Launched","8":"fescue toxicosis","_rn_":"28511"},{"1":"BRD-K76634210-001-14-7","2":"idoxuridine","3":"DNA directed DNA polymerase inhibitor","4":"NA","5":"infectious disease","6":"virus herpes simplex (HSV)","7":"Launched","8":"virus herpes simplex (HSV)","_rn_":"28513"},{"1":"BRD-A44090213-001-25-6","2":"indoprofen","3":"cyclooxygenase inhibitor, prostanoid receptor antagonist","4":"CXCR1, CXCR2, PTGS1, PTGS2","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"28515"},{"1":"BRD-K47869605-001-32-0","2":"podophyllotoxin","3":"microtubule inhibitor, tubulin polymerization inhibitor","4":"IGF1R, TOP2A, TUBA4A, TUBB","5":"infectious disease","6":"genital warts","7":"Launched","8":"genital warts","_rn_":"28517"},{"1":"BRD-K07572174-001-39-4","2":"curcumin","3":"cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor","4":"APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"28519"},{"1":"BRD-K23925186-001-02-8","2":"oridonin","3":"BCL inhibitor","4":"BCL2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"28559"},{"1":"BRD-K29582115-066-01-2","2":"ziprasidone","3":"dopamine receptor antagonist, serotonin receptor antagonist","4":"ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4","5":"neurology/psychiatry","6":"schizophrenia, bipolar disorder","7":"Launched","8":"schizophrenia, bipolar disorder","_rn_":"28561"},{"1":"BRD-K62779383-001-05-5","2":"cholecalciferol","3":"NA","4":"VDR","5":"endocrinology","6":"vitamin D deficiency","7":"Launched","8":"vitamin D deficiency","_rn_":"28563"},{"1":"BRD-K28542495-003-13-5","2":"benzydamine","3":"prostanoid receptor antagonist","4":"NA","5":"dental, otolaryngology","6":"mouth inflammation, throat inflammation","7":"Launched","8":"mouth inflammation, throat inflammation","_rn_":"28565"},{"1":"BRD-A88138582-001-04-8","2":"halcinonide","3":"glucocorticoid receptor agonist","4":"NR3C1","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"28567"},{"1":"BRD-K61717546-001-05-0","2":"fleroxacin","3":"topoisomerase inhibitor","4":"NA","5":"infectious disease, gastroenterology","6":"gonorrhea, enteritis, diarrhea, respiratory tract infections","7":"Launched","8":"gonorrhea, enteritis, diarrhea, respiratory tract infections","_rn_":"28607"},{"1":"BRD-A42699921-001-03-6","2":"teriflunomide","3":"dihydroorotate dehydrogenase inhibitor","4":"DHODH","5":"neurology/psychiatry","6":"multiple sclerosis","7":"Launched","8":"multiple sclerosis","_rn_":"28609"},{"1":"BRD-K93779381-001-01-9","2":"ingenol-mebutate","3":"PKC activator","4":"PRKCA, PRKCB, PRKCD, PRKCE, PRKCG","5":"dermatology","6":"actinic keratosis (AK)","7":"Launched","8":"actinic keratosis (AK)","_rn_":"28613"},{"1":"BRD-K01669786-001-02-2","2":"triapine","3":"ribonucleotide reductase inhibitor","4":"RRM1, RRM2","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"28615"},{"1":"BRD-K97010173-001-04-1","2":"deferasirox","3":"chelating agent","4":"CYP3A4","5":"hematology","6":"transfusional hemosiderosis, thalassemia, iron overload","7":"Launched","8":"transfusional hemosiderosis, thalassemia, iron overload","_rn_":"28655"},{"1":"BRD-A92537424-001-04-7","2":"danazol","3":"estrogen receptor antagonist, progesterone receptor agonist","4":"AR, CCL2, ESR1, GNRHR, GNRHR2, PGR","5":"obstetrics/gynecology, cardiology","6":"endometriosis, angioedema","7":"Launched","8":"endometriosis, angioedema","_rn_":"28657"},{"1":"BRD-K13044802-213-20-7","2":"ciclopirox","3":"membrane integrity inhibitor","4":"ATP1A1","5":"infectious disease","6":"onychomycosis","7":"Launched","8":"onychomycosis","_rn_":"28659"},{"1":"BRD-K40496271-396-01-1","2":"eltrombopag","3":"thrombopoietin receptor agonist","4":"MPL","5":"hematology, infectious disease","6":"anemia, hepatitis C, thrombocytopenia","7":"Launched","8":"anemia, hepatitis C, thrombocytopenia","_rn_":"28661"},{"1":"BRD-K77554836-001-11-6","2":"triamcinolone","3":"glucocorticoid receptor agonist","4":"NR3C1, SERPINA6","5":"dermatology","6":"corticosteroid-responsive dermatoses","7":"Launched","8":"corticosteroid-responsive dermatoses","_rn_":"28663"},{"1":"BRD-K52075715-001-06-7","2":"oxibendazole","3":"tubulin polymerization inhibitor","4":"TUBB, TUBB4B","5":"infectious disease","6":"strongyles","7":"Launched","8":"strongyles","_rn_":"28703"},{"1":"BRD-K86887724-001-10-6","2":"dofetilide","3":"potassium channel blocker","4":"KCNH1, KCNH2, KCNJ12, KCNK2","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"28705"},{"1":"BRD-K60369935-001-18-3","2":"ribavirin","3":"antiviral","4":"ADK, ENPP1, IMPDH1, IMPDH2, NT5C2","5":"infectious disease","6":"hepatitis C","7":"Launched","8":"hepatitis C","_rn_":"28707"},{"1":"BRD-A93093700-001-02-9","2":"temazepam","3":"benzodiazepine receptor agonist","4":"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO","5":"NA","6":"NA","7":"Withdrawn","8":"NA","_rn_":"28709"},{"1":"BRD-K81473043-001-14-6","2":"tanespimycin","3":"HSP inhibitor","4":"HSP90AA1","5":"NA","6":"NA","7":"Phase 3","8":"NA","_rn_":"28711"},{"1":"BRD-K32007074-001-02-9","2":"enocitabine","3":"DNA synthesis inhibitor","4":"CMPK1, RRM1, TYMS","5":"NA","6":"NA","7":"Launched","8":"NA","_rn_":"28751"},{"1":"BRD-K39467894-001-06-7","2":"nithiamide","3":"bacterial DNA inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"28753"},{"1":"BRD-K66094457-001-01-5","2":"CPP","3":"glutamate receptor antagonist","4":"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D","5":"NA","6":"NA","7":"Phase 2","8":"NA","_rn_":"28755"},{"1":"BRD-A95886749-001-03-5","2":"colfosceril-palmitate","3":"pulmonary surfactant","4":"NA","5":"pulmonary","6":"respiratory distress syndrome (RDS)","7":"Launched","8":"respiratory distress syndrome (RDS)","_rn_":"28757"},{"1":"BRD-A90272038-001-01-7","2":"CGP-37849","3":"glutamate receptor antagonist","4":"GRIN2A, GRIN2B, GRIN2C, GRIN2D","5":"NA","6":"NA","7":"Phase 1","8":"NA","_rn_":"28759"},{"1":"BRD-K26833429-001-02-8","2":"costunolide","3":"telomerase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29547"},{"1":"BRD-K95926480-003-03-6","2":"SRT1720","3":"SIRT activator","4":"SIRT1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29549"},{"1":"BRD-K71823332-001-03-7","2":"epothilone-a","3":"microtubule stabilizing agent","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29551"},{"1":"BRD-K49371609-003-03-8","2":"PIK-75","3":"DNA protein kinase inhibitor, PI3K inhibitor","4":"PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29553"},{"1":"BRD-K24187789-001-01-7","2":"VU0238429","3":"acetylcholine receptor allosteric modulator","4":"CHRM5","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29555"},{"1":"BRD-K45462423-001-03-7","2":"VU0361737","3":"glutamate receptor positive allosteric modulator","4":"GRM4","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29595"},{"1":"BRD-K83607951-001-02-2","2":"skepinone-l","3":"p38 MAPK inhibitor","4":"MAPK14","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29597"},{"1":"BRD-K47049295-300-01-5","2":"BAN-ORL-24","3":"nociceptin/orphanin FQ receptor antagonist","4":"OPRL1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29599"},{"1":"BRD-K48443249-001-01-0","2":"CNX-774","3":"Bruton's tyrosine kinase (BTK) inhibitor","4":"BTK","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29601"},{"1":"BRD-K15898725-001-01-7","2":"maytansinol-isobutyrate","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29603"},{"1":"BRD-A98299281-050-09-6","2":"hydroxytacrine-maleate-(r,s)","3":"cholinesterase inhibitor","4":"ACHE","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29643"},{"1":"BRD-K22385716-001-02-5","2":"LY303511","3":"casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","4":"BRD2, BRD3, BRD4","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29645"},{"1":"BRD-K01614093-001-02-6","2":"dihydromyricetin","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29647"},{"1":"BRD-K76180386-001-01-6","2":"JIB04","3":"histone lysine demethylase inhibitor","4":"KDM4E","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29649"},{"1":"BRD-K75478907-001-02-3","2":"GS-39783","3":"GABA receptor modulator","4":"GABBR1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29651"},{"1":"BRD-K75352575-001-01-3","2":"KPT-276","3":"exportin antagonist","4":"XPO1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29691"},{"1":"BRD-K62696033-001-01-4","2":"G-1","3":"G protein-coupled receptor agonist","4":"GPER1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29693"},{"1":"BRD-K87696786-003-04-4","2":"LY456236","3":"glutamate receptor antagonist","4":"GRM1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29695"},{"1":"BRD-K10705233-001-02-2","2":"GW-405833","3":"cannabinoid receptor agonist","4":"CNR2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29697"},{"1":"BRD-K49049886-001-08-7","2":"CGS-15943","3":"adenosine receptor antagonist","4":"ADORA1, ADORA2A, ADORA2B, ADORA3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29699"},{"1":"BRD-K72420232-001-12-3","2":"WZ-4002","3":"EGFR inhibitor","4":"EGFR, ERBB2","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29739"},{"1":"BRD-A93477898-001-04-2","2":"PETCM","3":"caspase activator","4":"CASP3","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29741"},{"1":"BRD-K72327355-001-14-7","2":"baicalein","3":"lipoxygenase inhibitor","4":"ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29743"},{"1":"BRD-K03109492-001-02-2","2":"NSC-663284","3":"CDC inhibitor","4":"CDC25A, CDC25B, CDC25C","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29745"},{"1":"BRD-K48488978-001-05-3","2":"YM-201636","3":"PI3K inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29747"},{"1":"BRD-K46585355-001-14-3","2":"acetylsalicylsalicylic-acid","3":"cyclooxygenase inhibitor","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29787"},{"1":"BRD-K79259477-001-04-9","2":"NVP-BHG712","3":"ephrin inhibitor","4":"EPHB4","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29789"},{"1":"BRD-K05804044-001-06-0","2":"AZ-628","3":"RAF inhibitor","4":"BRAF, RAF1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29791"},{"1":"BRD-K42973005-001-04-0","2":"CHIR-98014","3":"glycogen synthase kinase inhibitor","4":"GSK3A, GSK3B","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29793"},{"1":"BRD-K18613660-001-05-5","2":"mexeneone","3":"NA","4":"NA","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29795"},{"1":"BRD-K80060353-303-03-9","2":"IEM1754","3":"glutamate receptor antagonist","4":"GRIA1","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29835"},{"1":"BRD-K06593056-001-04-8","2":"LE-135","3":"retinoid receptor agonist","4":"RARB","5":"NA","6":"NA","7":"Preclinical","8":"NA","_rn_":"29837"}],"options":{"columns":{"min":{},"max":[10],"total":[8]},"rows":{"min":[10],"max":[10],"total":[1509]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Extract drugs that is approved for each indication -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZHJ1Z3NfYXBwcm92ZWRfZm9yX2VhY2hfaW5kaWNhdGlvbnNcblxuYGBgIn0= -->
<pre class="r"><code>drugs_approved_for_each_indications
</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code>$`Brain Cancer`
[1] &quot;temozolomide&quot; &quot;carmustine&quot;  

$`Colon/Colorectal Cancer`
 [1] &quot;irinotecan&quot;     &quot;capecitabine&quot;   &quot;carmofur&quot;       &quot;regorafenib&quot;    &quot;floxuridine&quot;    &quot;5-fluorouracil&quot; &quot;SN-38&quot;          &quot;ftorafur&quot;       &quot;doxifluridine&quot;  &quot;tipiracil&quot;     
[11] &quot;oxaliplatin&quot;   

$`Esophageal Cancer`
character(0)

$`Head and Neck Cancer`
[1] &quot;temoporfin&quot;  &quot;docetaxel&quot;   &quot;hydroxyurea&quot; &quot;nimorazole&quot; 

$`Lung Cancer`
 [1] &quot;brigatinib&quot;          &quot;gefitinib&quot;           &quot;osimertinib&quot;         &quot;alectinib&quot;           &quot;icotinib&quot;            &quot;afatinib&quot;            &quot;erlotinib&quot;           &quot;crizotinib&quot;         
 [9] &quot;paclitaxel&quot;          &quot;docetaxel&quot;           &quot;etoposide&quot;           &quot;vinorelbine&quot;         &quot;gemcitabine&quot;         &quot;etoposide-phosphate&quot; &quot;topotecan&quot;           &quot;vindesine&quot;          

$`Ovarian Cancer`
[1] &quot;olaparib&quot;         &quot;paclitaxel&quot;       &quot;doxorubicin&quot;      &quot;altretamine&quot;      &quot;cyclophosphamide&quot; &quot;gemcitabine&quot;      &quot;cisplatin&quot;        &quot;carboplatin&quot;     

$`Pancreatic Cancer`
[1] &quot;erlotinib&quot;      &quot;streptozotocin&quot; &quot;5-fluorouracil&quot; &quot;mitomycin-c&quot;    &quot;gemcitabine&quot;   

$`Skin Cancer`
[1] &quot;dabrafenib&quot;  &quot;cobimetinib&quot; &quot;dacarbazine&quot; &quot;trametinib&quot;  &quot;vemurafenib&quot; &quot;vindesine&quot;  </code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Step 0: Compute the DSKT in each indication -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuaXMubmEoRFNLVF9zY29yZVssMV0pXG5cbmBgYCJ9 -->
<pre class="r"><code>is.na(DSKT_score[,1])
</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiIFsxXSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSAgVFJVRSAgVFJVRSBGQUxTRSBGQUxTRSAgVFJVRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRSBGQUxTRVxuWzMyXSBGQUxTRSBGQUxTRSBGQUxTRSAgVFJVRSBGQUxTRSBGQUxTRSAgVFJVRSBGQUxTRSAgVFJVRSBGQUxTRSAgVFJVRSBGQUxTRSBGQUxTRSBGQUxTRVxuIn0= -->
<pre><code> [1] FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE  TRUE  TRUE FALSE FALSE  TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
[32] FALSE FALSE FALSE  TRUE FALSE FALSE  TRUE FALSE  TRUE FALSE  TRUE FALSE FALSE FALSE</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Step 1: For a given drug, approved indication rank based on DSKT -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxucmVzcGVjdGl2ZUFQUENhbl9DVF9hcHBEcnVnc1xuXG5gYGAifQ== -->
<pre class="r"><code>respectiveAPPCan_CT_appDrugs
</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code>$temozolomide
[1] &quot;Brain Cancer&quot;

$carmustine
[1] &quot;Brain Cancer&quot;

$irinotecan
[1] &quot;Colon/Colorectal Cancer&quot;

$capecitabine
[1] &quot;Colon/Colorectal Cancer&quot;

$carmofur
[1] &quot;Colon/Colorectal Cancer&quot;

$regorafenib
[1] &quot;Colon/Colorectal Cancer&quot;

$floxuridine
[1] &quot;Colon/Colorectal Cancer&quot;

$`5-fluorouracil`
[1] &quot;Colon/Colorectal Cancer&quot; &quot;Pancreatic Cancer&quot;      

$`SN-38`
[1] &quot;Colon/Colorectal Cancer&quot;

$ftorafur
[1] &quot;Colon/Colorectal Cancer&quot;

$doxifluridine
[1] &quot;Colon/Colorectal Cancer&quot;

$tipiracil
[1] &quot;Colon/Colorectal Cancer&quot;

$oxaliplatin
[1] &quot;Colon/Colorectal Cancer&quot;

$temoporfin
[1] &quot;Head and Neck Cancer&quot;

$docetaxel
[1] &quot;Head and Neck Cancer&quot; &quot;Lung Cancer&quot;         

$hydroxyurea
[1] &quot;Head and Neck Cancer&quot;

$nimorazole
[1] &quot;Head and Neck Cancer&quot;

$brigatinib
[1] &quot;Lung Cancer&quot;

$gefitinib
[1] &quot;Lung Cancer&quot;

$osimertinib
[1] &quot;Lung Cancer&quot;

$alectinib
[1] &quot;Lung Cancer&quot;

$icotinib
[1] &quot;Lung Cancer&quot;

$afatinib
[1] &quot;Lung Cancer&quot;

$erlotinib
[1] &quot;Lung Cancer&quot;       &quot;Pancreatic Cancer&quot;

$crizotinib
[1] &quot;Lung Cancer&quot;

$paclitaxel
[1] &quot;Lung Cancer&quot;    &quot;Ovarian Cancer&quot;

$etoposide
[1] &quot;Lung Cancer&quot;

$vinorelbine
[1] &quot;Lung Cancer&quot;

$gemcitabine
[1] &quot;Lung Cancer&quot;       &quot;Ovarian Cancer&quot;    &quot;Pancreatic Cancer&quot;

$`etoposide-phosphate`
[1] &quot;Lung Cancer&quot;

$topotecan
[1] &quot;Lung Cancer&quot;

$vindesine
[1] &quot;Lung Cancer&quot; &quot;Skin Cancer&quot;

$olaparib
[1] &quot;Ovarian Cancer&quot;

$doxorubicin
[1] &quot;Ovarian Cancer&quot;

$altretamine
[1] &quot;Ovarian Cancer&quot;

$cyclophosphamide
[1] &quot;Ovarian Cancer&quot;

$cisplatin
[1] &quot;Ovarian Cancer&quot;

$carboplatin
[1] &quot;Ovarian Cancer&quot;

$streptozotocin
[1] &quot;Pancreatic Cancer&quot;

$`mitomycin-c`
[1] &quot;Pancreatic Cancer&quot;

$dabrafenib
[1] &quot;Skin Cancer&quot;

$cobimetinib
[1] &quot;Skin Cancer&quot;

$dacarbazine
[1] &quot;Skin Cancer&quot;

$trametinib
[1] &quot;Skin Cancer&quot;

$vemurafenib
[1] &quot;Skin Cancer&quot;</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Compute Approved vs non-approved indications DKST score -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-frame-begin {"metadata":{"classes":["data.frame"],"nrow":45,"ncol":8,"summary":{"Description":["df [45 × 8]"]}},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["drugname"],"name":[1],"type":["chr"],"align":["left"]},{"label":["Target"],"name":[2],"type":["chr"],"align":["left"]},{"label":["drugID"],"name":[3],"type":["chr"],"align":["left"]},{"label":["CT_Rank_basedon_DKST"],"name":[4],"type":["dbl"],"align":["right"]},{"label":["drug_category"],"name":[5],"type":["fctr"],"align":["left"]},{"label":["is.inhibitor"],"name":[6],"type":["lgl"],"align":["right"]},{"label":["moa"],"name":[7],"type":["fctr"],"align":["left"]},{"label":["approvedCan_DKST"],"name":[8],"type":["dbl"],"align":["right"]}],"data":[{"1":"temozolomide","2":"MGMT","3":"K32107296","4":"4.0","5":"chemo","6":"FALSE","7":"DNA alkylating agent","8":"0.047037586"},{"1":"carmustine","2":"GSR","3":"K36234266","4":"6.0","5":"chemo","6":"TRUE","7":"DNA alkylating agent, DNA inhibitor","8":"-0.156892703"},{"1":"irinotecan","2":"TOP1","3":"K08547377","4":"2.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","8":"0.159101572"},{"1":"capecitabine","2":"TYMS","3":"K61192372","4":"7.0","5":"chemo","6":"TRUE","7":"DNA synthesis inhibitor, thymidylate synthase inhibitor","8":"-0.182854867"},{"1":"carmofur","2":"TYMS","3":"K11630072","4":"5.0","5":"targeted cancer","6":"TRUE","7":"thymidylate synthase inhibitor","8":"0.220947912"},{"1":"regorafenib","2":"MAPK11","3":"K16730910","4":"8.0","5":"targeted cancer","6":"TRUE","7":"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","8":"-0.332763971"},{"1":"floxuridine","2":"TYMS","3":"K47832606","4":"4.0","5":"chemo","6":"TRUE","7":"DNA synthesis inhibitor","8":"0.251170442"},{"1":"5-fluorouracil","2":"TYMS","3":"K24844714","4":"5.5","5":"chemo","6":"TRUE","7":"thymidylate synthase inhibitor","8":"0.017486127"},{"1":"SN-38","2":"TOP1","3":"K89561498","4":"1.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","8":"0.557037060"},{"1":"ftorafur","2":"TYMS","3":"K99383816","4":"5.0","5":"targeted cancer","6":"TRUE","7":"thymidylate synthase inhibitor","8":"0.126116880"},{"1":"doxifluridine","2":"TYMS","3":"K58262659","4":"4.0","5":"targeted cancer","6":"TRUE","7":"thymidylate synthase inhibitor","8":"0.126519116"},{"1":"tipiracil","2":"TYMP","3":"K11973162","4":"2.0","5":"targeted cancer","6":"TRUE","7":"thymidine phosphorylase inhibitor","8":"0.153348205"},{"1":"oxaliplatin","2":"NA","3":"K78960041","4":"2.0","5":"chemo","6":"TRUE","7":"DNA inhibitor","8":"NA"},{"1":"temoporfin","2":"NA","3":"K63712959","4":"4.0","5":"targeted cancer","6":"FALSE","7":"radical formation stimulant","8":"NA"},{"1":"docetaxel","2":"NR1I2","3":"K30577245","4":"4.5","5":"chemo","6":"TRUE","7":"tubulin polymerization inhibitor","8":"0.115922643"},{"1":"hydroxyurea","2":"RRM1","3":"K51747290","4":"7.0","5":"chemo","6":"TRUE","7":"ribonucleotide reductase inhibitor","8":"-0.006466037"},{"1":"nimorazole","2":"NA","3":"K79145628","4":"4.0","5":"targeted cancer","6":"TRUE","7":"bacterial DNA inhibitor","8":"NA"},{"1":"brigatinib","2":"EGFR","3":"K56981171","4":"2.0","5":"targeted cancer","6":"TRUE","7":"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","8":"0.216416342"},{"1":"gefitinib","2":"EGFR","3":"K64052750","4":"8.0","5":"targeted cancer","6":"TRUE","7":"EGFR inhibitor","8":"-0.054870340"},{"1":"osimertinib","2":"EGFR","3":"K42805893","4":"6.0","5":"targeted cancer","6":"TRUE","7":"EGFR inhibitor","8":"0.171879507"},{"1":"alectinib","2":"ALK","3":"K11267252","4":"4.0","5":"targeted cancer","6":"TRUE","7":"ALK tyrosine kinase receptor inhibitor","8":"0.006838924"},{"1":"icotinib","2":"EGFR","3":"K31698212","4":"6.0","5":"targeted cancer","6":"TRUE","7":"EGFR inhibitor","8":"0.118439326"},{"1":"afatinib","2":"EGFR","3":"K66175015","4":"7.0","5":"targeted cancer","6":"TRUE","7":"EGFR inhibitor","8":"0.074616384"},{"1":"erlotinib","2":"EGFR","3":"K70401845","4":"3.5","5":"targeted cancer","6":"TRUE","7":"EGFR inhibitor","8":"0.326851713"},{"1":"crizotinib","2":"MET","3":"K78431006","4":"1.0","5":"targeted cancer","6":"TRUE","7":"ALK tyrosine kinase receptor inhibitor","8":"0.323726259"},{"1":"paclitaxel","2":"NR1I2","3":"K62008436","4":"2.5","5":"chemo","6":"TRUE","7":"tubulin polymerization inhibitor","8":"0.141669969"},{"1":"etoposide","2":"TOP2A","3":"K37798499","4":"6.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","8":"-0.010123618"},{"1":"vinorelbine","2":"TUBA1B","3":"K69280563","4":"5.0","5":"chemo","6":"TRUE","7":"tubulin polymerization inhibitor","8":"0.102888138"},{"1":"gemcitabine","2":"CMPK1","3":"K15108141","4":"6.0","5":"chemo","6":"TRUE","7":"ribonucleotide reductase inhibitor","8":"-0.084269127"},{"1":"etoposide-phosphate","2":"TOP2A","3":"K72533376","4":"4.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","8":"0.072396767"},{"1":"topotecan","2":"TOP1","3":"K55696337","4":"1.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","8":"0.327376952"},{"1":"vindesine","2":"TUBB","3":"K59753975","4":"3.0","5":"chemo","6":"TRUE","7":"tubulin polymerization inhibitor","8":"0.153900885"},{"1":"olaparib","2":"PARP1","3":"K02113016","4":"7.0","5":"targeted cancer","6":"TRUE","7":"PARP inhibitor","8":"-0.192824258"},{"1":"doxorubicin","2":"TOP2A","3":"K92093830","4":"7.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","8":"-0.028650040"},{"1":"altretamine","2":"NA","3":"K67043667","4":"6.0","5":"chemo","6":"TRUE","7":"DNA synthesis inhibitor","8":"NA"},{"1":"cyclophosphamide","2":"CYP2C19","3":"A09722536","4":"3.0","5":"chemo","6":"FALSE","7":"DNA alkylating agent","8":"0.358704823"},{"1":"cisplatin","2":"XIAP","3":"K69172251","4":"6.0","5":"chemo","6":"TRUE","7":"DNA alkylating agent, DNA synthesis inhibitor","8":"-0.020766854"},{"1":"carboplatin","2":"NA","3":"K90947825","4":"6.0","5":"chemo","6":"TRUE","7":"DNA alkylating agent, DNA inhibitor","8":"NA"},{"1":"streptozotocin","2":"SLC2A2","3":"K34411947","4":"7.0","5":"chemo","6":"FALSE","7":"DNA alkylating agent","8":"-0.269406787"},{"1":"mitomycin-c","2":"NA","3":"A48237631","4":"7.0","5":"chemo","6":"TRUE","7":"DNA alkylating agent, DNA synthesis inhibitor","8":"NA"},{"1":"dabrafenib","2":"BRAF","3":"K09951645","4":"1.0","5":"targeted cancer","6":"TRUE","7":"RAF inhibitor","8":"0.393270078"},{"1":"cobimetinib","2":"NA","3":"K03390685","4":"8.0","5":"targeted cancer","6":"TRUE","7":"MEK inhibitor","8":"NA"},{"1":"dacarbazine","2":"POLA2","3":"K35520305","4":"7.0","5":"chemo","6":"FALSE","7":"DNA alkylating agent","8":"-0.238573586"},{"1":"trametinib","2":"MAP2K1","3":"K12343256","4":"2.0","5":"targeted cancer","6":"TRUE","7":"MEK inhibitor","8":"0.255406122"},{"1":"vemurafenib","2":"BRAF","3":"K56343971","4":"1.0","5":"targeted cancer","6":"TRUE","7":"RAF inhibitor","8":"0.435861422"}],"options":{"columns":{"min":{},"max":[10],"total":[8]},"rows":{"min":[10],"max":[10],"total":[45]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Compute various drugs properties to identify the subset we are interested in -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-frame-begin {"metadata":{"classes":["data.frame"],"nrow":1,"ncol":8,"summary":{"Description":["df [1 × 8]"]}},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["drugname"],"name":[1],"type":["chr"],"align":["left"]},{"label":["Target"],"name":[2],"type":["chr"],"align":["left"]},{"label":["drugID"],"name":[3],"type":["chr"],"align":["left"]},{"label":["CT_Rank_basedon_DKST"],"name":[4],"type":["dbl"],"align":["right"]},{"label":["drug_category"],"name":[5],"type":["fctr"],"align":["left"]},{"label":["is.inhibitor"],"name":[6],"type":["lgl"],"align":["right"]},{"label":["moa"],"name":[7],"type":["fctr"],"align":["left"]},{"label":["approvedCan_DKST"],"name":[8],"type":["dbl"],"align":["right"]}],"data":[{"1":"vinorelbine","2":"TUBA1B","3":"K69280563","4":"5","5":"chemo","6":"TRUE","7":"tubulin polymerization inhibitor","8":"0.1028881","_rn_":"28"}],"options":{"columns":{"min":{},"max":[10],"total":[8]},"rows":{"min":[10],"max":[10],"total":[1]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Compare the DKST score in app vs non-approved indications -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubWVhbih1bmxpc3QoYXBwcm92ZWRDYW5fREtTVFtpbnRlcmVzdGVkRHJ1Z3NdKSkvXG4gIG1lYW4odW5saXN0KE5PTmFwcHJvdmVkQ2FuX0RLU1RbaW50ZXJlc3RlZERydWdzXSkpXG5cbmBgYCJ9 -->
<pre class="r"><code>mean(unlist(approvedCan_DKST[interestedDrugs]))/
  mean(unlist(NONapprovedCan_DKST[interestedDrugs]))
</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDAuNjQyMTIxNlxuIn0= -->
<pre><code>[1] 0.6421216</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Compute an AUC power. -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-frame-begin {"metadata":{"classes":["data.frame"],"nrow":34,"ncol":7,"summary":{"Description":["df [34 × 7]"]}},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["drugname"],"name":[1],"type":["chr"],"align":["left"]},{"label":["Target"],"name":[2],"type":["chr"],"align":["left"]},{"label":["drugID"],"name":[3],"type":["chr"],"align":["left"]},{"label":["CT_Rank_basedon_DKST"],"name":[4],"type":["dbl"],"align":["right"]},{"label":["drug_category"],"name":[5],"type":["fctr"],"align":["left"]},{"label":["is.inhibitor"],"name":[6],"type":["lgl"],"align":["right"]},{"label":["moa"],"name":[7],"type":["fctr"],"align":["left"]}],"data":[{"1":"carmustine","2":"GSR","3":"K36234266","4":"6.0","5":"chemo","6":"TRUE","7":"DNA alkylating agent, DNA inhibitor","_rn_":"2"},{"1":"irinotecan","2":"TOP1","3":"K08547377","4":"2.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","_rn_":"3"},{"1":"capecitabine","2":"TYMS","3":"K61192372","4":"7.0","5":"chemo","6":"TRUE","7":"DNA synthesis inhibitor, thymidylate synthase inhibitor","_rn_":"4"},{"1":"carmofur","2":"TYMS","3":"K11630072","4":"5.0","5":"targeted cancer","6":"TRUE","7":"thymidylate synthase inhibitor","_rn_":"5"},{"1":"regorafenib","2":"MAPK11","3":"K16730910","4":"8.0","5":"targeted cancer","6":"TRUE","7":"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","_rn_":"6"},{"1":"floxuridine","2":"TYMS","3":"K47832606","4":"4.0","5":"chemo","6":"TRUE","7":"DNA synthesis inhibitor","_rn_":"7"},{"1":"5-fluorouracil","2":"TYMS","3":"K24844714","4":"5.5","5":"chemo","6":"TRUE","7":"thymidylate synthase inhibitor","_rn_":"8"},{"1":"SN-38","2":"TOP1","3":"K89561498","4":"1.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","_rn_":"9"},{"1":"ftorafur","2":"TYMS","3":"K99383816","4":"5.0","5":"targeted cancer","6":"TRUE","7":"thymidylate synthase inhibitor","_rn_":"10"},{"1":"doxifluridine","2":"TYMS","3":"K58262659","4":"4.0","5":"targeted cancer","6":"TRUE","7":"thymidylate synthase inhibitor","_rn_":"11"},{"1":"tipiracil","2":"TYMP","3":"K11973162","4":"2.0","5":"targeted cancer","6":"TRUE","7":"thymidine phosphorylase inhibitor","_rn_":"12"},{"1":"docetaxel","2":"NR1I2","3":"K30577245","4":"4.5","5":"chemo","6":"TRUE","7":"tubulin polymerization inhibitor","_rn_":"15"},{"1":"hydroxyurea","2":"RRM1","3":"K51747290","4":"7.0","5":"chemo","6":"TRUE","7":"ribonucleotide reductase inhibitor","_rn_":"16"},{"1":"brigatinib","2":"EGFR","3":"K56981171","4":"2.0","5":"targeted cancer","6":"TRUE","7":"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","_rn_":"18"},{"1":"gefitinib","2":"EGFR","3":"K64052750","4":"8.0","5":"targeted cancer","6":"TRUE","7":"EGFR inhibitor","_rn_":"19"},{"1":"osimertinib","2":"EGFR","3":"K42805893","4":"6.0","5":"targeted cancer","6":"TRUE","7":"EGFR inhibitor","_rn_":"20"},{"1":"alectinib","2":"ALK","3":"K11267252","4":"4.0","5":"targeted cancer","6":"TRUE","7":"ALK tyrosine kinase receptor inhibitor","_rn_":"21"},{"1":"icotinib","2":"EGFR","3":"K31698212","4":"6.0","5":"targeted cancer","6":"TRUE","7":"EGFR inhibitor","_rn_":"22"},{"1":"afatinib","2":"EGFR","3":"K66175015","4":"7.0","5":"targeted cancer","6":"TRUE","7":"EGFR inhibitor","_rn_":"23"},{"1":"erlotinib","2":"EGFR","3":"K70401845","4":"3.5","5":"targeted cancer","6":"TRUE","7":"EGFR inhibitor","_rn_":"24"},{"1":"crizotinib","2":"MET","3":"K78431006","4":"1.0","5":"targeted cancer","6":"TRUE","7":"ALK tyrosine kinase receptor inhibitor","_rn_":"25"},{"1":"paclitaxel","2":"NR1I2","3":"K62008436","4":"2.5","5":"chemo","6":"TRUE","7":"tubulin polymerization inhibitor","_rn_":"26"},{"1":"etoposide","2":"TOP2A","3":"K37798499","4":"6.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","_rn_":"27"},{"1":"vinorelbine","2":"TUBA1B","3":"K69280563","4":"5.0","5":"chemo","6":"TRUE","7":"tubulin polymerization inhibitor","_rn_":"28"},{"1":"gemcitabine","2":"CMPK1","3":"K15108141","4":"6.0","5":"chemo","6":"TRUE","7":"ribonucleotide reductase inhibitor","_rn_":"29"},{"1":"etoposide-phosphate","2":"TOP2A","3":"K72533376","4":"4.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","_rn_":"30"},{"1":"topotecan","2":"TOP1","3":"K55696337","4":"1.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","_rn_":"31"},{"1":"vindesine","2":"TUBB","3":"K59753975","4":"3.0","5":"chemo","6":"TRUE","7":"tubulin polymerization inhibitor","_rn_":"32"},{"1":"olaparib","2":"PARP1","3":"K02113016","4":"7.0","5":"targeted cancer","6":"TRUE","7":"PARP inhibitor","_rn_":"33"},{"1":"doxorubicin","2":"TOP2A","3":"K92093830","4":"7.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","_rn_":"34"},{"1":"cisplatin","2":"XIAP","3":"K69172251","4":"6.0","5":"chemo","6":"TRUE","7":"DNA alkylating agent, DNA synthesis inhibitor","_rn_":"37"},{"1":"dabrafenib","2":"BRAF","3":"K09951645","4":"1.0","5":"targeted cancer","6":"TRUE","7":"RAF inhibitor","_rn_":"41"},{"1":"trametinib","2":"MAP2K1","3":"K12343256","4":"2.0","5":"targeted cancer","6":"TRUE","7":"MEK inhibitor","_rn_":"44"},{"1":"vemurafenib","2":"BRAF","3":"K56343971","4":"1.0","5":"targeted cancer","6":"TRUE","7":"RAF inhibitor","_rn_":"45"}],"options":{"columns":{"min":{},"max":[10],"total":[7]},"rows":{"min":[10],"max":[10],"total":[34]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Create a boxPlot showing DKST in approved vs non-approved cancer types -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-frame-begin {"metadata":{"classes":["data.frame"],"nrow":34,"ncol":7,"summary":{"Description":["df [34 × 7]"]}},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["drugname"],"name":[1],"type":["chr"],"align":["left"]},{"label":["Target"],"name":[2],"type":["chr"],"align":["left"]},{"label":["drugID"],"name":[3],"type":["chr"],"align":["left"]},{"label":["CT_Rank_basedon_DKST"],"name":[4],"type":["dbl"],"align":["right"]},{"label":["drug_category"],"name":[5],"type":["fctr"],"align":["left"]},{"label":["is.inhibitor"],"name":[6],"type":["lgl"],"align":["right"]},{"label":["moa"],"name":[7],"type":["fctr"],"align":["left"]}],"data":[{"1":"carmustine","2":"GSR","3":"K36234266","4":"6.0","5":"chemo","6":"TRUE","7":"DNA alkylating agent, DNA inhibitor","_rn_":"2"},{"1":"irinotecan","2":"TOP1","3":"K08547377","4":"2.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","_rn_":"3"},{"1":"capecitabine","2":"TYMS","3":"K61192372","4":"7.0","5":"chemo","6":"TRUE","7":"DNA synthesis inhibitor, thymidylate synthase inhibitor","_rn_":"4"},{"1":"carmofur","2":"TYMS","3":"K11630072","4":"5.0","5":"targeted cancer","6":"TRUE","7":"thymidylate synthase inhibitor","_rn_":"5"},{"1":"regorafenib","2":"MAPK11","3":"K16730910","4":"8.0","5":"targeted cancer","6":"TRUE","7":"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","_rn_":"6"},{"1":"floxuridine","2":"TYMS","3":"K47832606","4":"4.0","5":"chemo","6":"TRUE","7":"DNA synthesis inhibitor","_rn_":"7"},{"1":"5-fluorouracil","2":"TYMS","3":"K24844714","4":"5.5","5":"chemo","6":"TRUE","7":"thymidylate synthase inhibitor","_rn_":"8"},{"1":"SN-38","2":"TOP1","3":"K89561498","4":"1.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","_rn_":"9"},{"1":"ftorafur","2":"TYMS","3":"K99383816","4":"5.0","5":"targeted cancer","6":"TRUE","7":"thymidylate synthase inhibitor","_rn_":"10"},{"1":"doxifluridine","2":"TYMS","3":"K58262659","4":"4.0","5":"targeted cancer","6":"TRUE","7":"thymidylate synthase inhibitor","_rn_":"11"},{"1":"tipiracil","2":"TYMP","3":"K11973162","4":"2.0","5":"targeted cancer","6":"TRUE","7":"thymidine phosphorylase inhibitor","_rn_":"12"},{"1":"docetaxel","2":"NR1I2","3":"K30577245","4":"4.5","5":"chemo","6":"TRUE","7":"tubulin polymerization inhibitor","_rn_":"15"},{"1":"hydroxyurea","2":"RRM1","3":"K51747290","4":"7.0","5":"chemo","6":"TRUE","7":"ribonucleotide reductase inhibitor","_rn_":"16"},{"1":"brigatinib","2":"EGFR","3":"K56981171","4":"2.0","5":"targeted cancer","6":"TRUE","7":"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","_rn_":"18"},{"1":"gefitinib","2":"EGFR","3":"K64052750","4":"8.0","5":"targeted cancer","6":"TRUE","7":"EGFR inhibitor","_rn_":"19"},{"1":"osimertinib","2":"EGFR","3":"K42805893","4":"6.0","5":"targeted cancer","6":"TRUE","7":"EGFR inhibitor","_rn_":"20"},{"1":"alectinib","2":"ALK","3":"K11267252","4":"4.0","5":"targeted cancer","6":"TRUE","7":"ALK tyrosine kinase receptor inhibitor","_rn_":"21"},{"1":"icotinib","2":"EGFR","3":"K31698212","4":"6.0","5":"targeted cancer","6":"TRUE","7":"EGFR inhibitor","_rn_":"22"},{"1":"afatinib","2":"EGFR","3":"K66175015","4":"7.0","5":"targeted cancer","6":"TRUE","7":"EGFR inhibitor","_rn_":"23"},{"1":"erlotinib","2":"EGFR","3":"K70401845","4":"3.5","5":"targeted cancer","6":"TRUE","7":"EGFR inhibitor","_rn_":"24"},{"1":"crizotinib","2":"MET","3":"K78431006","4":"1.0","5":"targeted cancer","6":"TRUE","7":"ALK tyrosine kinase receptor inhibitor","_rn_":"25"},{"1":"paclitaxel","2":"NR1I2","3":"K62008436","4":"2.5","5":"chemo","6":"TRUE","7":"tubulin polymerization inhibitor","_rn_":"26"},{"1":"etoposide","2":"TOP2A","3":"K37798499","4":"6.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","_rn_":"27"},{"1":"vinorelbine","2":"TUBA1B","3":"K69280563","4":"5.0","5":"chemo","6":"TRUE","7":"tubulin polymerization inhibitor","_rn_":"28"},{"1":"gemcitabine","2":"CMPK1","3":"K15108141","4":"6.0","5":"chemo","6":"TRUE","7":"ribonucleotide reductase inhibitor","_rn_":"29"},{"1":"etoposide-phosphate","2":"TOP2A","3":"K72533376","4":"4.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","_rn_":"30"},{"1":"topotecan","2":"TOP1","3":"K55696337","4":"1.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","_rn_":"31"},{"1":"vindesine","2":"TUBB","3":"K59753975","4":"3.0","5":"chemo","6":"TRUE","7":"tubulin polymerization inhibitor","_rn_":"32"},{"1":"olaparib","2":"PARP1","3":"K02113016","4":"7.0","5":"targeted cancer","6":"TRUE","7":"PARP inhibitor","_rn_":"33"},{"1":"doxorubicin","2":"TOP2A","3":"K92093830","4":"7.0","5":"chemo","6":"TRUE","7":"topoisomerase inhibitor","_rn_":"34"},{"1":"cisplatin","2":"XIAP","3":"K69172251","4":"6.0","5":"chemo","6":"TRUE","7":"DNA alkylating agent, DNA synthesis inhibitor","_rn_":"37"},{"1":"dabrafenib","2":"BRAF","3":"K09951645","4":"1.0","5":"targeted cancer","6":"TRUE","7":"RAF inhibitor","_rn_":"41"},{"1":"trametinib","2":"MAP2K1","3":"K12343256","4":"2.0","5":"targeted cancer","6":"TRUE","7":"MEK inhibitor","_rn_":"44"},{"1":"vemurafenib","2":"BRAF","3":"K56343971","4":"1.0","5":"targeted cancer","6":"TRUE","7":"RAF inhibitor","_rn_":"45"}],"options":{"columns":{"min":{},"max":[10],"total":[7]},"rows":{"min":[10],"max":[10],"total":[34]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Plot AUC stratification power of DSKT score distribution  -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>Figure4I &lt;- ggroc(ROC_ofInterest_list)+ 
  theme_bw(base_size = 15) + 
  theme(legend.title = element_blank(), 
        legend.position = c(0.6, 0.2),
        legend.text = element_text(size=15),
        text = element_text(size=15),
        legend.spacing.y = unit(0, &#39;cm&#39;)) +
  geom_segment(aes(x = 1, xend = 0, y = 0, yend = 1), color=&quot;grey&quot;, linetype=&quot;dashed&quot;)+
  labs(title=&quot;&quot;, x=&quot;Specificity&quot;, y=&quot;Sensitivity&quot;)+
  guides(color = guide_legend(byrow = TRUE))
Figure4I</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuRFNLVF9zY29yZV9UYXJnZXRlZCA8LSBEU0tUX3Njb3JlW0NUX2FwcERydWdzJGRydWduYW1lW2ludGVyZXN0ZWREcnVnc10sXVxuRmlndXJlNEogPC0gSGVhdG1hcChEU0tUX3Njb3JlX1RhcmdldGVkLCBuYW1lID0gJ0RLUyBTY29yZScpXG5gYGAifQ== -->
<pre class="r"><code>DSKT_score_Targeted &lt;- DSKT_score[CT_appDrugs$drugname[interestedDrugs],]
Figure4J &lt;- Heatmap(DSKT_score_Targeted, name = &#39;DKS Score&#39;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Put the above three Figures Together -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>Figure4J_grob &lt;- grid.grabExpr(draw(Figure4J))
Figure4Part2= grid.arrange(Figure4H,Figure4I, Figure4J_grob,
                            layout_matrix=rbind(c(1, 2, 2, 3, 3, 3))
                        )
ggsave(Figure4Part2, filename = &#39;/Users/sinhas8/Project_TrueTarget/Results/Figure4Part2.pdf&#39;, width = 15)
ggsave(Figure4Part2, filename = &#39;/Users/sinhas8/Project_TrueTarget/Results/Figure4Part2.png&#39;, width = 15)
ggsave(Figure4Part2, filename = &#39;/Users/sinhas8/Project_TrueTarget/Results/Figure4Part2.png&#39;, width = 15)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- Test what is the DKST based rank distribution overall and in various groups -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>CT_appDrugs$drug_category=onTarget$drugCategory$drug_category[match(CT_appDrugs$drugname, onTarget$drugCategory$name)]
CT_appDrugs$is.inhibitor=onTarget$drugCategory$is.inhibitor[match(CT_appDrugs$drugname, onTarget$drugCategory$name)]
CT_appDrugs$moa=onTarget$drugCategory$moa[match(CT_appDrugs$drugname, onTarget$drugCategory$name)]
onTarget$drugCategory
CT_appDrugs_noNA &lt;- CT_appDrugs[!is.na(CT_appDrugs$Target),]
CT_appDrugs_noNA=CT_appDrugs_noNA[CT_appDrugs_noNA$is.inhibitor,]</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>mean(CT_appDrugs_noNA$CT_Rank_basedon_DKST)
aggregate(CT_Rank_basedon_DKST~drug_category, CT_appDrugs_noNA, mean)
score_per_moa=aggregate(CT_Rank_basedon_DKST~moa, CT_appDrugs_noNA, mean )
score_per_moa[order(score_per_moa$CT_Rank_basedon_DKST, decreasing = F),]
score_per_moa[match(names(head(sort(table(as.character(CT_appDrugs_noNA$moa)), decreasing = T), 8)), score_per_moa$moa),]
aggregate(CT_Rank_basedon_DKST~is.inhibitor, CT_appDrugs_noNA, mean)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>Add a new chunk by clicking the <em>Insert Chunk</em> button on the
toolbar or by pressing <em>Cmd+Option+I</em>.</p>
<p>When you save the notebook, an HTML file containing the code and
output will be saved alongside it (click the <em>Preview</em> button or
press <em>Cmd+Shift+K</em> to preview the HTML file).</p>
<p>The preview shows you a rendered HTML copy of the contents of the
editor. Consequently, unlike <em>Knit</em>, <em>Preview</em> does not
run any R code chunks. Instead, the output of the chunk when it was last
run in the editor is displayed.</p>
<p>onTarget$drugCategory</p>
<!-- rnb-text-end -->

<div id="rmd-source-code">---
title: "R Notebook"
output: html_notebook
---

This is an [R Markdown](http://rmarkdown.rstudio.com) Notebook. When you execute code within the notebook, the results appear beneath the code. 

Try executing this chunk by clicking the *Run* button within the chunk or by placing your cursor inside it and pressing *Cmd+Shift+Enter*. 
<!-- "Drug's specificity to its known target" (DSKT score) -->
<!-- Find if DSKT Score can explain the cancer types where the drug is approved -->
<!-- Scripts and data needed -->
```{r}
knitr::knit('/Users/sinhas8/Project_TrueTarget/Tools_github/3.Tools/Step0B_Data_and_Libraries.Rmd')
knitr::knit('/Users/sinhas8/Project_TrueTarget/Tools_github/3.Tools/Step0_Write_Functions.Rmd')
```


<!-- Provide query drug -->
```{r}
Query_Drug='erlotinib'
```
<!-- Note 1: Please write a script to provide all the synonyms of a given Query_Drug -->
<!-- Check if the drug is in our screens and if yes, please provide drugID -->
```{r}
Query_DrugID=match_stripall(Query_Drug, onTarget$drugCategory$name)
Query_DrugID_knownInfo=onTarget$drugCategory[Query_DrugID,]
Query_DrugID_knownInfo=apply(Query_DrugID_knownInfo, 2, function(x) x)
Query_DrugID_broadID=Query_DrugID_knownInfo['broad_id_trimmed']
Query_DrugID_matched=which(drugBroadID %in% Query_DrugID_broadID)[1]
if(is.na(Query_DrugID)){ print('Not in our screens')
} else{ print('It is present in our screens') }
if(is.na(Query_DrugID_matched)){ print('Present in shallow screens only(one dosage)')
} else{ print('Present in our deep screens(multiple dosages)') }

# Information gathered about drug
Query_Drug; Query_DrugID; Query_DrugID_broadID; Query_DrugID_matched; Query_DrugID_knownInfo
```

<!-- Step 0: Find Lineages with greater than 20 cell lines -->
```{r}
matched_Lineages=onTarget$annotation_20Q4$lineage[match(matched_cellLines, onTarget$annotation_20Q4$DepMap_ID)]
matched_primary_disease=onTarget$annotation_20Q4$primary_disease[
  match(matched_cellLines, onTarget$annotation_20Q4$DepMap_ID)]
matched_primary_disease_freq=table(as.character(matched_primary_disease))
primary_diseaseWD_greaterThan_20_cellLines=names(which(matched_primary_disease_freq>=20))
paste(primary_diseaseWD_greaterThan_20_cellLines,';',
      matched_primary_disease_freq[which(matched_primary_disease_freq>=20)], sep = '')
```
<!-- Step 1: Function to compute Primary-target profile in lineages with greater than 20 cell lines -->
```{r}
Find_cancer_specific_targetProfile <- function(
    infunc_cancerType_of_interest=primary_diseaseWD_greaterThan_20_cellLines[1],
    infunc_drugBroadID=Query_DrugID_broadID){
  # Lineage of Interest is denoted with LOI
  cellLines_LOI= matched_cellLines[matched_primary_disease %in% infunc_cancerType_of_interest]
  drug_matched_subsettedLOI=drug_matched[infunc_drugBroadID,cellLines_LOI]
  avana_matched_subsettedLOI=avana_matched[,cellLines_LOI]
  avana_matched_subsettedLOI=avana_matched_subsettedLOI[,!is.na(drug_matched_subsettedLOI)]
  drug_matched_subsettedLOI=na.omit(drug_matched_subsettedLOI)
  Primarytarget_profile=apply(avana_matched_subsettedLOI, 1, function(x)
    unlist(cor.test_trimmed_v0(x, drug_matched_subsettedLOI))
    )
}
```
<!-- Step 2: Call Function and preprocess results -->
```{r}
PrimaryTarget_Profile_inDiff_CanTypes=mclapply(primary_diseaseWD_greaterThan_20_cellLines, function(x)
  Find_cancer_specific_targetProfile(infunc_cancerType_of_interest=x,
                                     infunc_drugBroadID=Query_DrugID_broadID),
  mc.cores = detectCores()
  )
PrimaryTarget_Profile_inDiff_CanTypes_prep=lapply(PrimaryTarget_Profile_inDiff_CanTypes, t)
names(PrimaryTarget_Profile_inDiff_CanTypes_prep)=primary_diseaseWD_greaterThan_20_cellLines
```
<!-- See if drug specificity to its Target is more in approved cancer types vs non-aproved ones -->
```{r}
Query_Target='EGFR'
sapply(PrimaryTarget_Profile_inDiff_CanTypes_prep, function(x) x[Query_Target,2])
```
<!-- Identify all the drugs for our seven cancer types of interest -->
```{r}
secondary.screen.replicate.treatment.info=read.csv('/Users/sinhas8/Project_TrueTarget/Data/secondary-screen-replicate-treatment-info_with_Indication.csv')
drug_CLinicalInfo=secondary.screen.replicate.treatment.info[,c('broad_id','name', 'moa','target','disease.area','indication', 'phase') ]
drug_CLinicalInfo=unique(drug_CLinicalInfo)
saveRDS(drug_CLinicalInfo, '/Users/sinhas8/Project_TrueTarget/Data/drug_CLinicalInfo.RDS')
sort(table(drug_CLinicalInfo$disease.area), decreasing = T)
```

<!-- Preprocess indication nomenclature -->
```{r}
#Change 1: 'non-small cell lung cancer \\(NSCLC\\)' *to* 'Lung Cancer'
drug_CLinicalInfo$indication_processed=gsub('non-small cell lung cancer \\(NSCLC\\)','Lung Cancer',drug_CLinicalInfo$indication)
#Change 2: 'glioblastoma' to 'Brain Cancer'
drug_CLinicalInfo$indication_processed=gsub('glioblastoma','Brain Cancer',drug_CLinicalInfo$indication_processed)
drug_CLinicalInfo$indication_processed=gsub('colorectal cancer','Colon/Colorectal Cancer',drug_CLinicalInfo$indication_processed)
drug_CLinicalInfo$indication_processed=gsub('head and neck squamous cell carcinoma \\(HNSCC\\)', 'Head and Neck Cancer',drug_CLinicalInfo$indication_processed)
drug_CLinicalInfo$indication_processed=gsub('melanoma','Skin Cancer',drug_CLinicalInfo$indication_processed)
```
<!-- Extract drugs that is approved for each indication -->
```{r}
drugs_approved_for_each_indications=lapply(primary_diseaseWD_greaterThan_20_cellLines, function(x) 
  unique(drug_CLinicalInfo$name[grep(x,drug_CLinicalInfo$indication_processed, ignore.case = T)]) )
names(drugs_approved_for_each_indications)=primary_diseaseWD_greaterThan_20_cellLines
```
<!-- Step 0: Compute the DSKT in each indication -->
```{r, fig.height=8}
drugs_approved_for_each_indications_unlisted=unique(unlist(drugs_approved_for_each_indications))
CT_appDrugs=data.frame(drugname=KnownTarget_predictions$drugName[match(drugs_approved_for_each_indications_unlisted, KnownTarget_predictions$drugName)],
           Target=KnownTarget_predictions$MaxTargetName[match(drugs_approved_for_each_indications_unlisted, KnownTarget_predictions$drugName)],
           drugID=KnownTarget_predictions$drugBroadID[match(drugs_approved_for_each_indications_unlisted, KnownTarget_predictions$drugName)])

#Cancer Specific Target profile
PriTarget_in_diffCanType_list=lapply(CT_appDrugs$drugID, function(y)
  mclapply(primary_diseaseWD_greaterThan_20_cellLines, function(x)
  Find_cancer_specific_targetProfile(infunc_cancerType_of_interest=x,
                                     infunc_drugBroadID=y),
  mc.cores = detectCores()
  ))

PriTarget_in_diffCanType_list=lapply(PriTarget_in_diffCanType_list, function(x) lapply(x, t))
PriTarget_in_diffCanType_list_cor=lapply(PriTarget_in_diffCanType_list, function(x) sapply(x, function(y) y[,2] ))
# DSKT_score stands for Drug Specificity to its known Target
DSKT_score=data.frame(do.call(rbind, lapply(1:nrow(CT_appDrugs), function(x)
  err_handle(PriTarget_in_diffCanType_list_cor[[x]][CT_appDrugs$Target[x],])
  )))
colnames(DSKT_score)=primary_diseaseWD_greaterThan_20_cellLines
rownames(DSKT_score)=CT_appDrugs$drugname
DSKT_score_rank=t(apply(-DSKT_score, 1, rank))
apply(DSKT_score_rank, 1, mean)
DSKT_score_rank[1,]
CT_appDrugs_wdSpecificity=data.frame(CT_appDrugs, DSKT_score)
Heatmap(na.omit(DSKT_score))
```
<!-- Step 1: For a given drug, approved indication rank based on DSKT -->
```{r}
# err_handle_nonNA <- function(x){ tryCatch(x, error=function(e){'Error'}) }
respectiveAPPCan_CT_appDrugs <- lapply(CT_appDrugs$drugname, function(y) names(unlist(sapply(drugs_approved_for_each_indications, function(x) grep(y, x) ))) )
names(respectiveAPPCan_CT_appDrugs) <- CT_appDrugs$drugname
respectiveAPPCan_CT_appDrugs[[27]]='Lung Cancer'
```

<!-- Compute Approved vs non-approved indications DKST score -->
```{r}
#DKST based rank for approved cancers
approvedCan_rank_based_on_DKST=lapply(1:length(respectiveAPPCan_CT_appDrugs),
       function(x) 
         unlist(DSKT_score_rank[x, respectiveAPPCan_CT_appDrugs[[x]] ]) )
CT_appDrugs$CT_Rank_basedon_DKST=sapply(approvedCan_rank_based_on_DKST, mean)
#DKST based rank for NONapproved cancers
NONapprovedCan_rank_based_on_DKST=lapply(1:length(respectiveAPPCan_CT_appDrugs),
       function(x) 
         unlist(DSKT_score_rank[x, colnames(DSKT_score_rank) %!in% respectiveAPPCan_CT_appDrugs[[x]] ]) )

#DKST score for approved cancers
approvedCan_DKST=lapply(1:length(respectiveAPPCan_CT_appDrugs),
       function(x) 
         unlist(DSKT_score[x, respectiveAPPCan_CT_appDrugs[[x]] ]) )
CT_appDrugs$approvedCan_DKST=sapply(approvedCan_DKST, mean)

#DKST score for NONapproved cancers
NONapprovedCan_DKST=lapply(1:length(respectiveAPPCan_CT_appDrugs),
       function(x) 
         unlist(DSKT_score[x, colnames(DSKT_score) %!in% respectiveAPPCan_CT_appDrugs[[x]] ]) )
```
<!-- Compute various drugs properties to identify the subset we are interested in -->
```{r}
#remove drugs with NAs
remove_NAs_score=!is.na(DSKT_score[,1])
CT_appDrugs
target_overall_rank=KnownTarget_predictions$PredictedRank[match(CT_appDrugs$drugname, KnownTarget_predictions$drugName)]
DeepTarget_able2Predict_target=target_overall_rank<100
remove_egfr_inhibitors <- CT_appDrugs$moa!='EGFR inhibitor'
interestedDrugs = which(
  CT_appDrugs$is.inhibitor &
    CT_appDrugs$drug_category=='targeted cancer' &
    remove_NAs_score &
    DeepTarget_able2Predict_target &
   remove_egfr_inhibitors
)
ChemointerestedDrugs = which(
  CT_appDrugs$is.inhibitor &
    CT_appDrugs$drug_category!='targeted cancer' &
    remove_NAs_score &
    DeepTarget_able2Predict_target &
   remove_egfr_inhibitors
)
CT_appDrugs[interestedDrugs,]
# Identify the subset of drugs "CT_appDrugs" whose target is predicted correctly
```
<!-- Compare the DKST score in app vs non-approved indications -->
```{r}
mean(unlist(approvedCan_rank_based_on_DKST[interestedDrugs]))
wilcox.test(unlist(NONapprovedCan_rank_based_on_DKST[interestedDrugs]),
            unlist(approvedCan_rank_based_on_DKST[interestedDrugs]), alternative = 'g')$p.value
wilcox.test(unlist(NONapprovedCan_DKST[interestedDrugs]),
            unlist(approvedCan_DKST[interestedDrugs]), alternative = 'l')$p.value
mean(unlist(approvedCan_DKST[interestedDrugs]))/
  mean(unlist(NONapprovedCan_DKST[interestedDrugs]))
```
<!-- Compute an AUC power. -->
```{r}
dfforROC=rbind(data.frame(DSKT=unlist(approvedCan_DKST[interestedDrugs]), category='Approved'),
               data.frame(DSKT=unlist(NONapprovedCan_DKST[interestedDrugs]), category='NoTApproved'))
ChemodfforROC=rbind(data.frame(DSKT=unlist(approvedCan_DKST[ChemointerestedDrugs]), category='Approved'),
               data.frame(DSKT=unlist(NONapprovedCan_DKST[ChemointerestedDrugs]), category='NoTApproved'))
ROC_ofInterest_list=list(Targeted=roc(dfforROC$category, dfforROC$DSKT),
                         Chemo=roc(ChemodfforROC$category, ChemodfforROC$DSKT))
names(ROC_ofInterest_list)=c('Targeted=0.93',
                  'Chemo=0.57')
```
<!-- Create a boxPlot showing DKST in approved vs non-approved cancer types -->
```{r}
dfforROC$category <- factor(dfforROC$category)
levels(dfforROC$category)[2]='Not Approved'
Figure4H <- ggplot(dfforROC, aes(y=DSKT,
                                 x=str_wrap(category, 5)))+
  geom_boxplot()+
  stat_compare_means(method = 'wilcox', label = 'p')+
  theme_bw(base_size = 15)+
  labs(x='Approval Status', y='Cancer Specific DKS Score')
Figure4H
```
<!-- Plot AUC stratification power of DSKT score distribution  -->
```{r}
Figure4I <- ggroc(ROC_ofInterest_list)+ 
  theme_bw(base_size = 15) + 
  theme(legend.title = element_blank(), 
        legend.position = c(0.6, 0.2),
        legend.text = element_text(size=15),
        text = element_text(size=15),
        legend.spacing.y = unit(0, 'cm')) +
  geom_segment(aes(x = 1, xend = 0, y = 0, yend = 1), color="grey", linetype="dashed")+
  labs(title="", x="Specificity", y="Sensitivity")+
  guides(color = guide_legend(byrow = TRUE))
Figure4I
```

```{r}
DSKT_score_Targeted <- DSKT_score[CT_appDrugs$drugname[interestedDrugs],]
Figure4J <- Heatmap(DSKT_score_Targeted, name = 'DKS Score')
```
<!-- Put the above three Figures Together -->
```{r}
Figure4J_grob <- grid.grabExpr(draw(Figure4J))
Figure4Part2= grid.arrange(Figure4H,Figure4I, Figure4J_grob,
                            layout_matrix=rbind(c(1, 2, 2, 3, 3, 3))
                        )
ggsave(Figure4Part2, filename = '/Users/sinhas8/Project_TrueTarget/Results/Figure4Part2.pdf', width = 15)
ggsave(Figure4Part2, filename = '/Users/sinhas8/Project_TrueTarget/Results/Figure4Part2.png', width = 15)
ggsave(Figure4Part2, filename = '/Users/sinhas8/Project_TrueTarget/Results/Figure4Part2.png', width = 15)
```


<!-- Test what is the DKST based rank distribution overall and in various groups -->
```{r}
CT_appDrugs$drug_category=onTarget$drugCategory$drug_category[match(CT_appDrugs$drugname, onTarget$drugCategory$name)]
CT_appDrugs$is.inhibitor=onTarget$drugCategory$is.inhibitor[match(CT_appDrugs$drugname, onTarget$drugCategory$name)]
CT_appDrugs$moa=onTarget$drugCategory$moa[match(CT_appDrugs$drugname, onTarget$drugCategory$name)]
onTarget$drugCategory
CT_appDrugs_noNA <- CT_appDrugs[!is.na(CT_appDrugs$Target),]
CT_appDrugs_noNA=CT_appDrugs_noNA[CT_appDrugs_noNA$is.inhibitor,]
```
```{r}
mean(CT_appDrugs_noNA$CT_Rank_basedon_DKST)
aggregate(CT_Rank_basedon_DKST~drug_category, CT_appDrugs_noNA, mean)
score_per_moa=aggregate(CT_Rank_basedon_DKST~moa, CT_appDrugs_noNA, mean )
score_per_moa[order(score_per_moa$CT_Rank_basedon_DKST, decreasing = F),]
score_per_moa[match(names(head(sort(table(as.character(CT_appDrugs_noNA$moa)), decreasing = T), 8)), score_per_moa$moa),]
aggregate(CT_Rank_basedon_DKST~is.inhibitor, CT_appDrugs_noNA, mean)
```


Add a new chunk by clicking the *Insert Chunk* button on the toolbar or by pressing *Cmd+Option+I*.

When you save the notebook, an HTML file containing the code and output will be saved alongside it (click the *Preview* button or press *Cmd+Shift+K* to preview the HTML file). 

The preview shows you a rendered HTML copy of the contents of the editor. Consequently, unlike *Knit*, *Preview* does not run any R code chunks. Instead, the output of the chunk when it was last run in the editor is displayed.

onTarget$drugCategory</div>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});

$(document).ready(function () {
  $('.knitsql-table').addClass('kable-table');
  var container = $('.kable-table');
  container.each(function() {

    // move the caption out of the table
    var table = $(this).children('table');
    var caption = table.children('caption').detach();
    caption.insertBefore($(this)).css('display', 'inherit');
  });
});

</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->
<script>
$(document).ready(function () {
  window.initializeSourceEmbed("step9_highSpecificity_inApprovedCancerTypes.Rmd");
  window.initializeCodeFolding("show" === "show");
});
</script>


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
